assay_description,canonical_smiles,document_chembl_id,relation,standard_relation,standard_type,standard_units,standard_value,type,units,value,SMILES,year
Inhibitory concentration against cyclin-dependent kinase 2,COc1ccc(Nc2ccnc(Nc3ccc(OCC(O)CN(C)C)cc3)n2)cc1,CHEMBL1136192,=,=,IC50,nM,36000.0,IC50,uM,36.0,COc1ccc(Nc2ccnc(Nc3ccc(OCC(O)CN(C)C)cc3)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3ccc(O)c(Br)c3)ccc12)C1CC1,CHEMBL1136207,=,=,IC50,nM,2.0,IC50,nM,2.0,O=C(Nc1n[nH]c2nc(-c3ccc(O)c(Br)c3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3nccs3)c(Br)cc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3nccs3)c(Br)cc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3nccs3)c(Br)cc12)C1CCCC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3nccs3)c(Br)cc12)C1CCCC1,2003.0
Inhibition of Cyclin-dependent kinase 2,CC(C)C(CO)Nc1nc(NCc2cccc(O)c2)c2ncn(C(C)C)c2n1,CHEMBL1133758,=,=,IC50,nM,30.0,IC50,uM,0.03,CC(C)C(CO)Nc1nc(NCc2cccc(O)c2)c2ncn(C(C)C)c2n1,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2ncc(Br)c(N(CCCC(F)(F)F)c3ccccc3)n2)cc1,CHEMBL1136192,=,=,IC50,nM,200.0,IC50,uM,0.2,CN(C)CC(O)COc1ccc(Nc2ncc(Br)c(N(CCCC(F)(F)F)c3ccccc3)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2cc(-c3ccc[nH]3)ccc12)C1CC1,CHEMBL1136207,=,=,IC50,nM,497.0,IC50,nM,497.0,O=C(Nc1n[nH]c2cc(-c3ccc[nH]3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3cccs3)c(Br)cc12)C1CCCC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3cccs3)c(Br)cc12)C1CCCC1,2003.0
Inhibition of Cyclin-dependent kinase 2,CC(C)n1cnc2c(NCc3ccccc3)nc(NCCO)nc21,CHEMBL1133758,=,=,IC50,nM,8000.0,IC50,uM,8.0,CC(C)n1cnc2c(NCc3ccccc3)nc(NCCO)nc21,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1,CHEMBL1136192,=,=,IC50,nM,1000.0,IC50,uM,1.0,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,Cc1ccc(Cl)c(Nc2cc(Nc3ccc(OCC(O)CN(C)C)cc3)ncn2)c1,CHEMBL1136192,=,=,IC50,nM,22000.0,IC50,uM,22.0,Cc1ccc(Cl)c(Nc2cc(Nc3ccc(OCC(O)CN(C)C)cc3)ncn2)c1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(N(Cc3ccccc3)c3cc(Cl)ccc3Cl)n2)cc1,CHEMBL1136192,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN(C)CC(O)COc1ccc(Nc2nccc(N(Cc3ccccc3)c3cc(Cl)ccc3Cl)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1,CHEMBL1136192,>,>,IC50,nM,100000.0,IC50,uM,100.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1[nH]nc2cc(-c3ccc(O)nc3)ccc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1[nH]nc2cc(-c3ccc(O)nc3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3cccs3)c(Br)cc12)C1CC1,CHEMBL1136207,=,=,IC50,nM,639.0,IC50,nM,639.0,O=C(Nc1n[nH]c2nc(-c3cccs3)c(Br)cc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3C#N)n2)cc1,CHEMBL1136192,=,=,IC50,nM,4000.0,IC50,uM,4.0,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3C#N)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3Br)ncn2)cc1,CHEMBL1136192,=,=,IC50,nM,28000.0,IC50,uM,28.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3Br)ncn2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,Cc1ccc(F)c(Nc2cc(Nc3ccc(OCC(O)CN(C)C)cc3)ncn2)c1,CHEMBL1136192,=,=,IC50,nM,81000.0,IC50,uM,81.0,Cc1ccc(F)c(Nc2cc(Nc3ccc(OCC(O)CN(C)C)cc3)ncn2)c1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2cc(-c3ccc(O)cc3)ccc12)C1CC1,CHEMBL1136207,=,=,IC50,nM,5.0,IC50,nM,5.0,O=C(Nc1n[nH]c2cc(-c3ccc(O)cc3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2cc(-c3cccc(F)c3)ccc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2cc(-c3cccc(F)c3)ccc12)C1CC1,2003.0
Inhibition of Cyclin-dependent kinase 2 (No Data),CC(C)C(CO)Nc1nc(NCc2ccccc2O)c2ncn(C(C)C)c2n1,CHEMBL1133758,,,IC50,nM,,IC50,uM,,CC(C)C(CO)Nc1nc(NCc2ccccc2O)c2ncn(C(C)C)c2n1,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2cc(-c3ccco3)ccc12)C1CC1,CHEMBL1136207,=,=,IC50,nM,631.0,IC50,nM,631.0,O=C(Nc1n[nH]c2cc(-c3ccco3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(-c3ccccc3)cc12)C1CC1,CHEMBL1136207,=,=,IC50,nM,5.0,IC50,nM,5.0,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(-c3ccccc3)cc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1,2003.0
Inhibition of Cyclin-dependent kinase 2,CC(C)n1cnc2c(NC3CCCC3)nc(NCCCO)nc21,CHEMBL1133758,=,=,IC50,nM,900.0,IC50,uM,0.9,CC(C)n1cnc2c(NC3CCCC3)nc(NCCCO)nc21,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1,2003.0
Inhibition of Cyclin-dependent kinase 2,CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21,CHEMBL1133758,=,=,IC50,nM,800.0,IC50,uM,0.8,CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(N(CCC#N)c3cc(Cl)ccc3Cl)n2)cc1,CHEMBL1136192,=,=,IC50,nM,3000.0,IC50,uM,3.0,CN(C)CC(O)COc1ccc(Nc2nccc(N(CCC#N)c3cc(Cl)ccc3Cl)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,Cc1cnc(Nc2ccc(OCC(O)CN(C)C)cc2)nc1Nc1ccccc1,CHEMBL1136192,=,=,IC50,nM,8000.0,IC50,uM,8.0,Cc1cnc(Nc2ccc(OCC(O)CN(C)C)cc2)nc1Nc1ccccc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2cc(-c3ccsc3)ccc12)C1CC1,CHEMBL1136207,=,=,IC50,nM,484.0,IC50,nM,484.0,O=C(Nc1n[nH]c2cc(-c3ccsc3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,Cc1ccc(Nc2ccnc(Nc3ccc(OCC(O)CN(C)C)cc3)n2)cc1,CHEMBL1136192,=,=,IC50,nM,26000.0,IC50,uM,26.0,Cc1ccc(Nc2ccnc(Nc3ccc(OCC(O)CN(C)C)cc3)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3F)ncn2)cc1,CHEMBL1136192,>,>,IC50,nM,100000.0,IC50,uM,100.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3F)ncn2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1,2003.0
Inhibition of Cyclin-dependent kinase 2,CC(C)n1cnc2c(N)nc(NCCCO)nc21,CHEMBL1133758,=,=,IC50,nM,2400.0,IC50,uM,2.4,CC(C)n1cnc2c(N)nc(NCCCO)nc21,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(N(CCCC(F)(F)F)c3cc(Cl)ccc3Cl)n2)cc1,CHEMBL1136192,=,=,IC50,nM,12000.0,IC50,uM,12.0,CN(C)CC(O)COc1ccc(Nc2nccc(N(CCCC(F)(F)F)c3cc(Cl)ccc3Cl)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CCN1CCN(CCCC(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1,CHEMBL1136207,=,=,IC50,nM,60.0,IC50,nM,60.0,CCN1CCN(CCCC(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1[nH]nc2cc(-c3ccc4ncccc4c3)ccc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1[nH]nc2cc(-c3ccc4ncccc4c3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3ccc(O)c(Cl)c3)ccc12)C1CC1,CHEMBL1136207,=,=,IC50,nM,2.0,IC50,nM,2.0,O=C(Nc1n[nH]c2nc(-c3ccc(O)c(Cl)c3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,COc1ccccc1Nc1cc(Nc2ccc(OCC(O)CN(C)C)cc2)ncn1,CHEMBL1136192,=,=,IC50,nM,85000.0,IC50,uM,85.0,COc1ccccc1Nc1cc(Nc2ccc(OCC(O)CN(C)C)cc2)ncn1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2cc(Nc3cc(Cl)ccc3Cl)ncn2)cc1,CHEMBL1136192,=,=,IC50,nM,22000.0,IC50,uM,22.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3cc(Cl)ccc3Cl)ncn2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(N(CC#N)c3cc(Cl)ccc3Cl)n2)cc1,CHEMBL1136192,=,=,IC50,nM,700.0,IC50,uM,0.7,CN(C)CC(O)COc1ccc(Nc2nccc(N(CC#N)c3cc(Cl)ccc3Cl)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2ncc(Cl)c(Nc3ccccc3)n2)cc1,CHEMBL1136192,=,=,IC50,nM,500.0,IC50,uM,0.5,CN(C)CC(O)COc1ccc(Nc2ncc(Cl)c(Nc3ccccc3)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1,CHEMBL1136207,=,=,IC50,nM,62.0,IC50,nM,62.0,O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3Cl)ncn2)cc1,CHEMBL1136192,=,=,IC50,nM,95000.0,IC50,uM,95.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3Cl)ncn2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2cc(-c3ccoc3)ccc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2cc(-c3ccoc3)ccc12)C1CC1,2003.0
Inhibition of Cyclin-dependent kinase 2,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,CHEMBL1133758,=,=,IC50,nM,1200.0,IC50,uM,1.2,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3Cl)n2)cc1,CHEMBL1136192,=,=,IC50,nM,6000.0,IC50,uM,6.0,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3Cl)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,C#CCN(c1ccnc(Nc2ccc(OCC(O)CN(C)C)cc2)n1)c1cc(Cl)ccc1Cl,CHEMBL1136192,=,=,IC50,nM,2000.0,IC50,uM,2.0,C#CCN(c1ccnc(Nc2ccc(OCC(O)CN(C)C)cc2)n1)c1cc(Cl)ccc1Cl,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1[nH]nc2cc(-c3ccc(F)c(F)c3)ccc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1[nH]nc2cc(-c3ccc(F)c(F)c3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1[nH]nc2cc(-c3cccc(F)c3F)ccc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1[nH]nc2cc(-c3cccc(F)c3F)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,Cc1ccc(Nc2cc(Nc3ccc(OCC(O)CN(C)C)cc3)ncn2)cc1,CHEMBL1136192,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1ccc(Nc2cc(Nc3ccc(OCC(O)CN(C)C)cc3)ncn2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,Cc1ccc(Cl)c(Nc2ccnc(Nc3ccc(OCC(O)CN(C)C)cc3)n2)c1,CHEMBL1136192,=,=,IC50,nM,5000.0,IC50,uM,5.0,Cc1ccc(Cl)c(Nc2ccnc(Nc3ccc(OCC(O)CN(C)C)cc3)n2)c1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2ncc(F)c(Nc3ccccc3)n2)cc1,CHEMBL1136192,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN(C)CC(O)COc1ccc(Nc2ncc(F)c(Nc3ccccc3)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1,CHEMBL1136207,=,=,IC50,nM,5.0,IC50,nM,5.0,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1,2003.0
Inhibition of Cyclin-dependent kinase 2,CC(C)n1cnc2c(NCc3ccccc3)nc(NC[C@@H](C)O)nc21,CHEMBL1133758,=,=,IC50,nM,200.0,IC50,uM,0.2,CC(C)n1cnc2c(NCc3ccccc3)nc(NC[C@@H](C)O)nc21,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3F)n2)cc1,CHEMBL1136192,=,=,IC50,nM,7000.0,IC50,uM,7.0,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3F)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3Br)n2)cc1,CHEMBL1136192,=,=,IC50,nM,7000.0,IC50,uM,7.0,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3Br)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cccc(Cl)c3)n2)cc1,CHEMBL1136192,=,=,IC50,nM,5000.0,IC50,uM,5.0,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cccc(Cl)c3)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2cc(-c3ccc4[nH]ccc4c3)ccc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2cc(-c3ccc4[nH]ccc4c3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,COc1ccccc1Nc1ccnc(Nc2ccc(OCC(O)CN(C)C)cc2)n1,CHEMBL1136192,=,=,IC50,nM,15000.0,IC50,uM,15.0,COc1ccccc1Nc1ccnc(Nc2ccc(OCC(O)CN(C)C)cc2)n1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,COc1ccc(Nc2cc(Nc3ccc(OCC(O)CN(C)C)cc3)ncn2)cc1,CHEMBL1136192,>,>,IC50,nM,100000.0,IC50,uM,100.0,COc1ccc(Nc2cc(Nc3ccc(OCC(O)CN(C)C)cc3)ncn2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3ccccc3)c(Br)cc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3ccccc3)c(Br)cc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2cc(-c3cccs3)ccc12)C1CC1,CHEMBL1136207,=,=,IC50,nM,341.0,IC50,nM,341.0,O=C(Nc1n[nH]c2cc(-c3cccs3)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CCN(Cc2ccccc2)C1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CCN(Cc2ccccc2)C1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccc(Cl)cc3)n2)cc1,CHEMBL1136192,=,=,IC50,nM,18000.0,IC50,uM,18.0,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccc(Cl)cc3)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,Cc1ccc(F)c(Nc2ccnc(Nc3ccc(OCC(O)CN(C)C)cc3)n2)c1,CHEMBL1136192,=,=,IC50,nM,2000.0,IC50,uM,2.0,Cc1ccc(F)c(Nc2ccnc(Nc3ccc(OCC(O)CN(C)C)cc3)n2)c1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(C(F)(F)F)ccc3F)n2)cc1,CHEMBL1136192,=,=,IC50,nM,1000.0,IC50,uM,1.0,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(C(F)(F)F)ccc3F)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2cc(Nc3cc(C(F)(F)F)ccc3F)ncn2)cc1,CHEMBL1136192,=,=,IC50,nM,35000.0,IC50,uM,35.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3cc(C(F)(F)F)ccc3F)ncn2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1[nH]nc2cc(-c3ccccc3F)ccc12)C1CC1,CHEMBL1136207,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1[nH]nc2cc(-c3ccccc3F)ccc12)C1CC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1,CHEMBL1136192,=,=,IC50,nM,34000.0,IC50,uM,34.0,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2ncc(Br)c(Nc3ccccc3)n2)cc1,CHEMBL1136192,=,=,IC50,nM,300.0,IC50,uM,0.3,CN(C)CC(O)COc1ccc(Nc2ncc(Br)c(Nc3ccccc3)n2)cc1,2003.0
Inhibition of Cyclin-dependent kinase 2,CC(C)n1cnc2c(NCc3ccccc3)ncnc21,CHEMBL1133758,=,=,IC50,nM,4500.0,IC50,uM,4.5,CC(C)n1cnc2c(NCc3ccccc3)ncnc21,2000.0
Inhibition of Cyclin-dependent kinase 2,CC(C)n1cnc2c(NC34CC5CC(CC(C5)C3)C4)nc(NCCCO)nc21,CHEMBL1133758,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC(C)n1cnc2c(NC34CC5CC(CC(C5)C3)C4)nc(NCCCO)nc21,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccc(Cl)cc3)ncn2)cc1,CHEMBL1136192,>,>,IC50,nM,100000.0,IC50,uM,100.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccc(Cl)cc3)ncn2)cc1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)ccc12)C1CC1,CHEMBL1136207,=,=,IC50,nM,13.0,IC50,nM,13.0,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)ccc12)C1CC1,2003.0
Percentage A2780 cells in G1 after 24 hr r at 20 nM (IC50),CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,58.0,Cell cycle,nM,58.0,CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,2002.0
Percentage A2780 cells in S-phase after 24 hr r at 20 nM (IC50),CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,11.0,Cell cycle,nM,11.0,CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,2002.0
Percentage A2780 cells in G2/M after 24 hr r at 20 nM (IC50),CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,29.0,Cell cycle,nM,29.0,CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,2002.0
Percentage A2780 cells in sub-G1 after 24 hr r at 20 nM (IC50),CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,2.0,Cell cycle,nM,2.0,CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,2002.0
Apoptotic A2780 cells after 24 hr r at 20 nM (IC50),CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,6.0,Cell cycle,nM,6.0,CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,2002.0
Percentage A2780 cells in G1 after 24 hr r at 295 nM (IC90),CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,62.0,Cell cycle,nM,62.0,CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,2002.0
Percentage A2780 cells in S-phase after 24 hr r at 295 nM (IC90),CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,6.0,Cell cycle,nM,6.0,CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,2002.0
Percentage A2780 cells in G2/M after 24 hr r at 295 nM (IC90),CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,25.0,Cell cycle,nM,25.0,CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,2002.0
Percentage A2780 cells in sub-G1 after 24 hr r at 295 nM (IC90),CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,7.0,Cell cycle,nM,7.0,CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,2002.0
Apoptotic A2780 cells after 24 hr r at 295 nM (IC90),CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,16.0,Cell cycle,nM,16.0,CCc1cnc(CSc2cnc(NC(C)=O)s2)o1,2002.0
Percentage A2780 cells in G1 after 24 hr r at 5 nM (IC50),CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,71.0,Cell cycle,nM,71.0,CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,2002.0
Percentage A2780 cells in S-phase after 24 hr r at 5 nM (IC50),CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,7.0,Cell cycle,nM,7.0,CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,2002.0
Percentage A2780 cells in G2/M after 24 hr r at 5 nM (IC50),CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,20.0,Cell cycle,nM,20.0,CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,2002.0
Percentage A2780 cells in sub-G1 after 24 hr r at 5 nM (IC50),CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,2.0,Cell cycle,nM,2.0,CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,2002.0
Apoptotic A2780 cells after 24 hr r at 5 nM (IC50),CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,4.0,Cell cycle,nM,4.0,CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,2002.0
Percentage A2780 cells in G1 after 24 hr r at 29 nM (IC90),CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,50.0,Cell cycle,nM,50.0,CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,2002.0
Percentage A2780 cells in S-phase after 24 hr r at 29 nM (IC90),CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,7.0,Cell cycle,nM,7.0,CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,2002.0
Percentage A2780 cells in G2/M after 24 hr r at 29 nM (IC90),CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,18.0,Cell cycle,nM,18.0,CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,2002.0
Percentage A2780 cells in sub-G1 after 24 hr r at 2 nM (IC90),CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,25.0,Cell cycle,nM,25.0,CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,2002.0
Apoptotic A2780 cells after 24 hr r at 29 nM (IC90),CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,CHEMBL1135763,=,=,Cell cycle,nM,69.0,Cell cycle,nM,69.0,CCc1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,2002.0
Percentage A2780 cells in G1 after 24 hr r at 330 nM (IC50),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1135763,=,=,Cell cycle,nM,60.0,Cell cycle,nM,60.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2002.0
Percentage A2780 cells in S-phase after 24 hr r at 330 nM (IC50),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1135763,=,=,Cell cycle,nM,16.0,Cell cycle,nM,16.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2002.0
Percentage A2780 cells in G2/M after 24 hr r at 330 nM (IC50),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1135763,=,=,Cell cycle,nM,23.0,Cell cycle,nM,23.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2002.0
Percentage A2780 cells in sb-G1 after 24 hr r at 330 nM (IC50),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1135763,=,=,Cell cycle,nM,1.0,Cell cycle,nM,1.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2002.0
Apoptotic A2780 cells after 24 hr r at 330 nM (IC50),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1135763,=,=,Cell cycle,nM,1.0,Cell cycle,nM,1.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2002.0
Percentage A2780 cells in G1 after 24 hr r at 2980 nM (IC90),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1135763,=,=,Cell cycle,nM,61.0,Cell cycle,nM,61.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2002.0
Percentage A2780 cells in S-phase after 24 hr r at 2980 nM (IC90),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1135763,=,=,Cell cycle,nM,12.0,Cell cycle,nM,12.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2002.0
Percentage A2780 cells in G2/M after 24 hr r at 2980 nM (IC90),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1135763,=,=,Cell cycle,nM,25.0,Cell cycle,nM,25.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2002.0
Percentage A2780 cells in sub-G1 after 24 hr r at 2980 nM (IC90),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1135763,=,=,Cell cycle,nM,2.0,Cell cycle,nM,2.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2002.0
Apoptotic A2780 cells after 24 hr r at 2980 nM (IC90),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1135763,=,=,Cell cycle,nM,9.0,Cell cycle,nM,9.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2002.0
Inhibition of Cyclin-Dependent Kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1,CHEMBL1148343,=,=,IC50,nM,30.0,IC50,uM,0.03,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),CNc1nccc(-c2sc(C)nc2C)n1,CHEMBL1149116,>,>,Ki,nM,20000.0,Ki,uM,20.0,CNc1nccc(-c2sc(C)nc2C)n1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3ccc(O)cc3)n2)s1,CHEMBL1149116,=,=,Ki,nM,140.0,Ki,uM,0.14,Cc1nc(C)c(-c2ccnc(Nc3ccc(O)cc3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(N)n2)s1,CHEMBL1149116,=,=,Ki,nM,6500.0,Ki,uM,6.5,Cc1nc(C)c(-c2ccnc(N)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3ccccc3F)n2)s1,CHEMBL1149116,=,=,Ki,nM,1200.0,Ki,uM,1.2,Cc1nc(C)c(-c2ccnc(Nc3ccccc3F)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),CNc1nc(C)c(-c2ccnc(Nc3cccc(O)c3)n2)s1,CHEMBL1149116,=,=,Ki,nM,110.0,Ki,uM,0.11,CNc1nc(C)c(-c2ccnc(Nc3cccc(O)c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3cccc(C#N)c3)n2)s1,CHEMBL1149116,=,=,Ki,nM,300.0,Ki,uM,0.3,Cc1nc(C)c(-c2ccnc(Nc3cccc(C#N)c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3cccc(N)c3)n2)s1,CHEMBL1149116,=,=,Ki,nM,400.0,Ki,uM,0.4,Cc1nc(C)c(-c2ccnc(Nc3cccc(N)c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3ccc(N(C)C)c(Cl)c3)n2)s1,CHEMBL1149116,=,=,Ki,nM,100.0,Ki,uM,0.1,Cc1nc(C)c(-c2ccnc(Nc3ccc(N(C)C)c(Cl)c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(N)sc1-c1ccnc(Nc2ccc(O)cc2)n1,CHEMBL1149116,=,=,Ki,nM,30.0,Ki,uM,0.03,Cc1nc(N)sc1-c1ccnc(Nc2ccc(O)cc2)n1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3cccc(O)c3)n2)s1,CHEMBL1149116,=,=,Ki,nM,60.0,Ki,uM,0.06,Cc1nc(C)c(-c2ccnc(Nc3cccc(O)c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3ccc(N(C)C)cc3)n2)s1,CHEMBL1149116,=,=,Ki,nM,220.0,Ki,uM,0.22,Cc1nc(C)c(-c2ccnc(Nc3ccc(N(C)C)cc3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,CHEMBL1149116,=,=,Ki,nM,2.0,Ki,uM,0.002,Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(N)sc1-c1ccnc(Nc2ccc(N(C)C)cc2)n1,CHEMBL1149116,=,=,Ki,nM,700.0,Ki,uM,0.7,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N(C)C)cc2)n1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3ccccc3Cl)n2)s1,CHEMBL1149116,>,>,Ki,nM,20000.0,Ki,uM,20.0,Cc1nc(C)c(-c2ccnc(Nc3ccccc3Cl)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),CCNc1nc(C)c(-c2ccnc(Nc3cccc(O)c3)n2)s1,CHEMBL1149116,>,>,Ki,nM,10000.0,Ki,uM,10.0,CCNc1nc(C)c(-c2ccnc(Nc3cccc(O)c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),CNc1nc(C)c(-c2ccnc(Nc3cccc([N+](=O)[O-])c3)n2)s1,CHEMBL1149116,=,=,Ki,nM,800.0,Ki,uM,0.8,CNc1nc(C)c(-c2ccnc(Nc3cccc([N+](=O)[O-])c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3ccccc3)n2)s1,CHEMBL1149116,=,=,Ki,nM,80.0,Ki,uM,0.08,Cc1nc(C)c(-c2ccnc(Nc3ccccc3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),CNc1nc(C)c(-c2ccnc(Nc3ccc(O)cc3)n2)s1,CHEMBL1149116,=,=,Ki,nM,70.0,Ki,uM,0.07,CNc1nc(C)c(-c2ccnc(Nc3ccc(O)cc3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3ccc(N(C)C)c([N+](=O)[O-])c3)n2)s1,CHEMBL1149116,=,=,Ki,nM,20.0,Ki,uM,0.02,Cc1nc(C)c(-c2ccnc(Nc3ccc(N(C)C)c([N+](=O)[O-])c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(N(C)c3cccc([N+](=O)[O-])c3)n2)s1,CHEMBL1149116,>,>,Ki,nM,20000.0,Ki,uM,20.0,Cc1nc(C)c(-c2ccnc(N(C)c3cccc([N+](=O)[O-])c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)s1,CHEMBL1149116,>,>,Ki,nM,20000.0,Ki,uM,20.0,Cc1nc(C)c(-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3ccc(C(F)(F)F)cc3)n2)s1,CHEMBL1149116,=,=,Ki,nM,290.0,Ki,uM,0.29,Cc1nc(C)c(-c2ccnc(Nc3ccc(C(F)(F)F)cc3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3cccc(F)c3)n2)s1,CHEMBL1149116,=,=,Ki,nM,100.0,Ki,uM,0.1,Cc1nc(C)c(-c2ccnc(Nc3cccc(F)c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(N(C)C)n2)s1,CHEMBL1149116,>,>,Ki,nM,20000.0,Ki,uM,20.0,Cc1nc(C)c(-c2ccnc(N(C)C)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(N(C)C)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,CHEMBL1149116,=,=,Ki,nM,60.0,Ki,uM,0.06,Cc1nc(N(C)C)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3ccc(Cl)cc3)n2)s1,CHEMBL1149116,=,=,Ki,nM,2500.0,Ki,uM,2.5,Cc1nc(C)c(-c2ccnc(Nc3ccc(Cl)cc3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(-c2ccccn2)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,CHEMBL1149116,>,>,Ki,nM,20000.0,Ki,uM,20.0,Cc1nc(-c2ccccn2)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3ccc([N+](=O)[O-])cc3)n2)s1,CHEMBL1149116,=,=,Ki,nM,4100.0,Ki,uM,4.1,Cc1nc(C)c(-c2ccnc(Nc3ccc([N+](=O)[O-])cc3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3ccccc3C(F)(F)F)n2)s1,CHEMBL1149116,>,>,Ki,nM,20000.0,Ki,uM,20.0,Cc1nc(C)c(-c2ccnc(Nc3ccccc3C(F)(F)F)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3ccc(F)cc3)n2)s1,CHEMBL1149116,=,=,Ki,nM,40.0,Ki,uM,0.04,Cc1nc(C)c(-c2ccnc(Nc3ccc(F)cc3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),C=CCNc1nc(C)c(-c2ccnc(Nc3cccc([N+](=O)[O-])c3)n2)s1,CHEMBL1149116,=,=,Ki,nM,160.0,Ki,uM,0.16,C=CCNc1nc(C)c(-c2ccnc(Nc3cccc([N+](=O)[O-])c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3cccc(Cl)c3)n2)s1,CHEMBL1149116,=,=,Ki,nM,670.0,Ki,uM,0.67,Cc1nc(C)c(-c2ccnc(Nc3cccc(Cl)c3)n2)s1,2004.0
Inhibitory activity against human CDK2 (Cyclin dependent kinase 2),Cc1nc(C)c(-c2ccnc(Nc3cccc([N+](=O)[O-])c3)n2)s1,CHEMBL1149116,=,=,Ki,nM,110.0,Ki,uM,0.11,Cc1nc(C)c(-c2ccnc(Nc3cccc([N+](=O)[O-])c3)n2)s1,2004.0
Inhibition of Cyclin-dependent kinase 2 (CDK2) at ATP concentration <Km,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1,CHEMBL1135889,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1,2002.0
Inhibition of Cyclin-dependent kinase 2 (CDK2) at ATP concentration <Km,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1.Cl,CHEMBL1135889,>,>,IC50,nM,20000.0,IC50,uM,20.0,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1.Cl,2002.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,Cc1ccc(N(CC#N)c2cc(Nc3ccc(OCC(O)CN(C)C)cc3)ncn2)c(Br)c1,CHEMBL1136191,=,=,IC50,nM,3000.0,IC50,uM,3.0,Cc1ccc(N(CC#N)c2cc(Nc3ccc(OCC(O)CN(C)C)cc3)ncn2)c(Br)c1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccc(F)cc3F)ncn2)cc1,CHEMBL1136191,=,=,IC50,nM,93000.0,IC50,uM,93.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccc(F)cc3F)ncn2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3F)ncn2)cc1,CHEMBL1136191,>,>,IC50,nM,100000.0,IC50,uM,100.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3F)ncn2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)CC(O)COc1ccc(Nc2cc(N(CC#N)c3cc(Cl)ccc3Cl)ncn2)cc1,CHEMBL1136191,=,=,IC50,nM,1000.0,IC50,uM,1.0,CN(C)CC(O)COc1ccc(Nc2cc(N(CC#N)c3cc(Cl)ccc3Cl)ncn2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)CC(O)COc1ccc(Nc2cc(N(CCC#N)c3cc(Cl)ccc3Cl)ncn2)cc1,CHEMBL1136191,=,=,IC50,nM,5000.0,IC50,uM,5.0,CN(C)CC(O)COc1ccc(Nc2cc(N(CCC#N)c3cc(Cl)ccc3Cl)ncn2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,Cc1ccccc1Nc1cc(Nc2ccc(OCC(O)CN(C)C)cc2)ncn1,CHEMBL1136191,=,=,IC50,nM,39000.0,IC50,uM,39.0,Cc1ccccc1Nc1cc(Nc2ccc(OCC(O)CN(C)C)cc2)ncn1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)CC(O)COc1ccc(Nc2cc(Nc3cc(Cl)ccc3Cl)ncn2)cc1,CHEMBL1136191,=,=,IC50,nM,22000.0,IC50,uM,22.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3cc(Cl)ccc3Cl)ncn2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,COc1ccccc1Nc1cc(Nc2ccc(OCC(O)CN(C)C)cc2)ncn1,CHEMBL1136191,=,=,IC50,nM,85000.0,IC50,uM,85.0,COc1ccccc1Nc1cc(Nc2ccc(OCC(O)CN(C)C)cc2)ncn1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)CC(O)COc1ccc(Nc2cc(N(Cc3ccccc3)c3cc(Cl)ccc3Cl)ncn2)cc1,CHEMBL1136191,>,>,IC50,nM,100000.0,IC50,uM,100.0,CN(C)CC(O)COc1ccc(Nc2cc(N(Cc3ccccc3)c3cc(Cl)ccc3Cl)ncn2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,C#CCN(c1cc(Nc2ccc(OCC(O)CN(C)C)cc2)ncn1)c1cc(Cl)ccc1Cl,CHEMBL1136191,=,=,IC50,nM,19000.0,IC50,uM,19.0,C#CCN(c1cc(Nc2ccc(OCC(O)CN(C)C)cc2)ncn1)c1cc(Cl)ccc1Cl,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1,CHEMBL1136191,>,>,IC50,nM,100000.0,IC50,uM,100.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3Br)ncn2)cc1,CHEMBL1136191,=,=,IC50,nM,28000.0,IC50,uM,28.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3Br)ncn2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)CC(O)COc1ccc(Nc2cc(Nc3cc(C(F)(F)F)ccc3F)ncn2)cc1,CHEMBL1136191,=,=,IC50,nM,35000.0,IC50,uM,35.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3cc(C(F)(F)F)ccc3F)ncn2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CC(C)c1ccccc1Nc1cc(Nc2ccc(OCC(O)CN(C)C)cc2)ncn1,CHEMBL1136191,=,=,IC50,nM,24000.0,IC50,uM,24.0,CC(C)c1ccccc1Nc1cc(Nc2ccc(OCC(O)CN(C)C)cc2)ncn1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)CC(O)COc1ccc(Nc2cc(Nc3c(F)cccc3F)ncn2)cc1,CHEMBL1136191,=,=,IC50,nM,38000.0,IC50,uM,38.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3c(F)cccc3F)ncn2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3Cl)ncn2)cc1,CHEMBL1136191,=,=,IC50,nM,95000.0,IC50,uM,95.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3Cl)ncn2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3[N+](=O)[O-])ncn2)cc1,CHEMBL1136191,=,=,IC50,nM,25000.0,IC50,uM,25.0,CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccccc3[N+](=O)[O-])ncn2)cc1,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21,CHEMBL1137075,=,=,IC50,nM,360.0,IC50,nM,360.0,C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc(S(N)(=O)=O)cc2)C3=O)CC1,CHEMBL1137075,=,=,IC50,nM,30.0,IC50,nM,30.0,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc(S(N)(=O)=O)cc2)C3=O)CC1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),COc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,54.0,IC50,nM,54.0,COc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),COc1ccc2[nH]c(O)c(/N=N/c3ccccc3)c2c1,CHEMBL1137075,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1ccc2[nH]c(O)c(/N=N/c3ccccc3)c2c1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,CHEMBL1137075,=,=,IC50,nM,9.7,IC50,nM,9.7,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),Oc1[nH]c2ccccc2c1/N=N/c1ccccc1,CHEMBL1137075,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Oc1[nH]c2ccccc2c1/N=N/c1ccccc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),Oc1[nH]c2ccc(Br)cc2c1/N=N/c1ccccc1,CHEMBL1137075,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Oc1[nH]c2ccc(Br)cc2c1/N=N/c1ccccc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc([N+](=O)[O-])cc2)C3=O)CC1,CHEMBL1137075,=,=,IC50,nM,310.0,IC50,nM,310.0,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc([N+](=O)[O-])cc2)C3=O)CC1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCc2ccccc2)cc1,CHEMBL1137075,=,=,IC50,nM,5.6,IC50,nM,5.6,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCc2ccccc2)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCO)cc1,CHEMBL1137075,=,=,IC50,nM,4.7,IC50,nM,4.7,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCO)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(Cl)cc21,CHEMBL1137075,=,=,IC50,nM,22.0,IC50,nM,22.0,C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(Cl)cc21,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,2.1,IC50,nM,2.1,COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),CN(C)S(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1137075,=,=,IC50,nM,4.6,IC50,nM,4.6,CN(C)S(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,310.0,IC50,nM,310.0,CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2)C3=O)CC1,CHEMBL1137075,=,=,IC50,nM,1280.0,IC50,nM,1280.0,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2)C3=O)CC1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),Cc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,13.0,IC50,nM,13.0,Cc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),Cc1cccc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1137075,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cccc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),Cc1cc(Cl)cc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1137075,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(Cl)cc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),CNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1137075,=,=,IC50,nM,5.6,IC50,nM,5.6,CNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccc2)cc1,CHEMBL1137075,=,=,IC50,nM,4.3,IC50,nM,4.3,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccc2)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cc(CO)ccc32)cc1,CHEMBL1137075,=,=,IC50,nM,61.0,IC50,nM,61.0,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cc(CO)ccc32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1137075,=,=,IC50,nM,2.8,IC50,nM,2.8,NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cccc(CO)c32)cc1,CHEMBL1137075,=,=,IC50,nM,54.0,IC50,nM,54.0,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cccc(CO)c32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),Cc1c([N+](=O)[O-])ccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,4.6,IC50,nM,4.6,Cc1c([N+](=O)[O-])ccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1,CHEMBL1137075,=,=,IC50,nM,690.0,IC50,nM,690.0,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2Cl)C3=O)CC1,CHEMBL1137075,=,=,IC50,nM,3970.0,IC50,nM,3970.0,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2Cl)C3=O)CC1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2 (CDK2),CC(=O)NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1137075,=,=,IC50,nM,75.0,IC50,nM,75.0,CC(=O)NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2cccc(C3CCNCC3)c2/C1=C/c1[nH]cc2c1CCNC2=O,CHEMBL1136528,=,=,IC50,nM,49.0,IC50,uM,0.049,O=C1Nc2cccc(C3CCNCC3)c2/C1=C/c1[nH]cc2c1CCNC2=O,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,CC(=O)OCCCOc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(=O)OCCCOc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,CS(=O)(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,16.0,IC50,nM,16.0,CS(=O)(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,COc1ccc2c(c1)/C(=C/c1[nH]cc3c1CCOC3=O)C(=O)N2,CHEMBL1136528,=,=,IC50,nM,40.0,IC50,uM,0.04,COc1ccc2c(c1)/C(=C/c1[nH]cc3c1CCOC3=O)C(=O)N2,2003.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1[nH]cc2c1CCNC2=O,CHEMBL1136528,=,=,IC50,nM,5700.0,IC50,uM,5.7,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1[nH]cc2c1CCNC2=O,2003.0
Inhibitory activity against Cyclin-dependent kinase 2,NS(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]cc3c1CCOC3=O)C(=O)N2,CHEMBL1136528,=,=,IC50,nM,12.0,IC50,uM,0.012,NS(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]cc3c1CCOC3=O)C(=O)N2,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,CC(=O)NCCNc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,127.0,IC50,nM,127.0,CC(=O)NCCNc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccc(O)cc4)c32)cc1,CHEMBL1137075,=,=,IC50,nM,12.0,IC50,nM,12.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccc(O)cc4)c32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(-c4cc[nH]n4)c32)cc1,CHEMBL1137075,=,=,IC50,nM,19.0,IC50,nM,19.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(-c4cc[nH]n4)c32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1,CHEMBL1137075,=,=,IC50,nM,2.3,IC50,nM,2.3,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]cc3c1CCOC3=O)C(=O)N2,CHEMBL1136528,=,=,IC50,nM,4.0,IC50,uM,0.004,CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]cc3c1CCOC3=O)C(=O)N2,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,NCCOc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,12.0,IC50,nM,12.0,NCCOc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,Cc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,376.0,IC50,nM,376.0,Cc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,NC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,4.5,IC50,nM,4.5,NC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]cc3c1CCNC3=O)C(=O)N2,CHEMBL1136528,=,=,IC50,nM,9.0,IC50,uM,0.009,CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]cc3c1CCNC3=O)C(=O)N2,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc([N+](=O)[O-])c32)cc1,CHEMBL1137075,=,=,IC50,nM,2400.0,IC50,nM,2400.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc([N+](=O)[O-])c32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1,CHEMBL1137075,=,=,IC50,nM,8.9,IC50,nM,8.9,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1[nH]cc2c1CCOC2=O,CHEMBL1136528,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1[nH]cc2c1CCOC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(O)cc32)cc1,CHEMBL1137075,=,=,IC50,nM,10.0,IC50,nM,10.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(O)cc32)cc1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2ccc(Cl)cc2/C1=C/c1[nH]cc2c1CCOC2=O,CHEMBL1136528,=,=,IC50,nM,88.0,IC50,uM,0.088,O=C1Nc2ccc(Cl)cc2/C1=C/c1[nH]cc2c1CCOC2=O,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,O=C1Nc2ccc(F)c3c(OCCCO)cc(-c4ccc[nH]4)c1c23,CHEMBL1136123,=,=,IC50,nM,18.0,IC50,nM,18.0,O=C1Nc2ccc(F)c3c(OCCCO)cc(-c4ccc[nH]4)c1c23,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,COc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,18.0,IC50,nM,18.0,COc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,CC(C)Cc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,124.0,IC50,nM,124.0,CC(C)Cc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1,CHEMBL1137075,=,=,IC50,nM,43.0,IC50,nM,43.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1,2004.0
In vitro inhibition of Cyclin-dependent kinase 2,O=C1Nc2ccc(F)c3c(NCCO)cc(-c4ccc[nH]4)c1c23,CHEMBL1136123,=,=,IC50,nM,54.0,IC50,nM,54.0,O=C1Nc2ccc(F)c3c(NCCO)cc(-c4ccc[nH]4)c1c23,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,CC(C)(C)OC(=O)NCCNc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,5500.0,IC50,nM,5500.0,CC(C)(C)OC(=O)NCCNc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,NCCSc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,3.0,IC50,nM,3.0,NCCSc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,46.0,IC50,nM,46.0,Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2cccc(C3CCNCC3)c2/C1=C/c1[nH]cc2c1CCOC2=O,CHEMBL1136528,=,=,IC50,nM,9.0,IC50,uM,0.009,O=C1Nc2cccc(C3CCNCC3)c2/C1=C/c1[nH]cc2c1CCOC2=O,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,CCN(CC)CCNc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,294.0,IC50,nM,294.0,CCN(CC)CCNc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,CCc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,72.0,IC50,nM,72.0,CCc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1,CHEMBL1137075,=,=,IC50,nM,60.0,IC50,nM,60.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1,2004.0
In vitro inhibition of Cyclin-dependent kinase 2,O=C1Nc2ccc(F)c3c(SCCO)cc(-c4ccc[nH]4)c1c23,CHEMBL1136123,=,=,IC50,nM,14.0,IC50,nM,14.0,O=C1Nc2ccc(F)c3c(SCCO)cc(-c4ccc[nH]4)c1c23,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,O=C1Nc2ccc(F)c3c(S[C@H]4CCNC4)cc(-c4ccc[nH]4)c1c23,CHEMBL1136123,=,=,IC50,nM,5.0,IC50,nM,5.0,O=C1Nc2ccc(F)c3c(S[C@H]4CCNC4)cc(-c4ccc[nH]4)c1c23,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,CC(C)Oc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,3.4,IC50,nM,3.4,CC(C)Oc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)cc1,CHEMBL1137075,=,=,IC50,nM,43.0,IC50,nM,43.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)cc1,2004.0
In vitro inhibition of Cyclin-dependent kinase 2,NCC[S+]([O-])c1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,28.0,IC50,nM,28.0,NCC[S+]([O-])c1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,NCCS(=O)(=O)c1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,23.0,IC50,nM,23.0,NCCS(=O)(=O)c1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
Inhibitory activity against Cyclin-dependent kinase 2,CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]cc3c1CCNC3=O)C(=O)N2,CHEMBL1136528,=,=,IC50,nM,68.0,IC50,uM,0.068,CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]cc3c1CCNC3=O)C(=O)N2,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,1.5,IC50,nM,1.5,CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2,CHEMBL1136528,=,=,IC50,nM,110.0,IC50,uM,0.11,COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,N#CCCc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,5.0,IC50,nM,5.0,N#CCCc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(I)cc32)cc1,CHEMBL1137075,=,=,IC50,nM,11.0,IC50,nM,11.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(I)cc32)cc1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,Cc1cccc2c1/C(=C/c1[nH]cc3c1CCOC3=O)C(=O)N2,CHEMBL1136528,=,=,IC50,nM,270.0,IC50,uM,0.27,Cc1cccc2c1/C(=C/c1[nH]cc3c1CCOC3=O)C(=O)N2,2003.0
Inhibitory activity against Cyclin-dependent kinase 2,COc1ccc2c(c1)NC(=O)/C2=C\c1[nH]cc2c1CCOC2=O,CHEMBL1136528,=,=,IC50,nM,1500.0,IC50,uM,1.5,COc1ccc2c(c1)NC(=O)/C2=C\c1[nH]cc2c1CCOC2=O,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,NCCNc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,12.0,IC50,nM,12.0,NCCNc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccccc32)cc1,CHEMBL1137075,=,=,IC50,nM,120.0,IC50,nM,120.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccccc32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,NC(=O)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,>,>,IC50,nM,1000.0,IC50,nM,1000.0,NC(=O)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2ccc(C(=O)O)cc2/C1=C/c1[nH]cc2c1CCOC2=O,CHEMBL1136528,=,=,IC50,nM,4.0,IC50,uM,0.004,O=C1Nc2ccc(C(=O)O)cc2/C1=C/c1[nH]cc2c1CCOC2=O,2003.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2ccc(Br)cc2/C1=C/c1[nH]cc2c1CCOC2=O,CHEMBL1136528,=,=,IC50,nM,190.0,IC50,uM,0.19,O=C1Nc2ccc(Br)cc2/C1=C/c1[nH]cc2c1CCOC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(/N=N/c2c(O)[nH]c3cccc(I)c23)cc1,CHEMBL1137075,=,=,IC50,nM,4.6,IC50,nM,4.6,NS(=O)(=O)c1ccc(/N=N/c2c(O)[nH]c3cccc(I)c23)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,CC(C)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,2.5,IC50,nM,2.5,CC(C)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,Nc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,74.0,IC50,nM,74.0,Nc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1,CHEMBL1137075,=,=,IC50,nM,21.0,IC50,nM,21.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Br)ccc32)cc1,CHEMBL1137075,=,=,IC50,nM,43.0,IC50,nM,43.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Br)ccc32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(F)cc32)cc1,CHEMBL1137075,=,=,IC50,nM,34.0,IC50,nM,34.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(F)cc32)cc1,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,CN(C)C(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,17.0,IC50,nM,17.0,CN(C)C(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,COc1ccc2c(c1)/C(=C/c1[nH]cc3c1CCNC3=O)C(=O)N2,CHEMBL1136528,=,=,IC50,nM,250.0,IC50,uM,0.25,COc1ccc2c(c1)/C(=C/c1[nH]cc3c1CCNC3=O)C(=O)N2,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,O=C1Nc2ccc(F)c3ccc(-c4ccc[nH]4)c1c23,CHEMBL1136123,=,=,IC50,nM,204.0,IC50,nM,204.0,O=C1Nc2ccc(F)c3ccc(-c4ccc[nH]4)c1c23,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,NCCCc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,7.0,IC50,nM,7.0,NCCCc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
Inhibitory activity against Cyclin-dependent kinase 2,CC(C)NS(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]cc3c1CCOC3=O)C(=O)N2,CHEMBL1136528,=,=,IC50,nM,64.0,IC50,uM,0.064,CC(C)NS(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]cc3c1CCOC3=O)C(=O)N2,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,CCOc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,77.0,IC50,nM,77.0,CCOc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,O=C1Nc2ccc(F)c3c(OCCO)cc(-c4ccc[nH]4)c1c23,CHEMBL1136123,=,=,IC50,nM,62.0,IC50,nM,62.0,O=C1Nc2ccc(F)c3c(OCCO)cc(-c4ccc[nH]4)c1c23,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,CCOc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,93.0,IC50,nM,93.0,CCOc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4cccnc4)cc32)cc1,CHEMBL1137075,=,=,IC50,nM,2.1,IC50,nM,2.1,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4cccnc4)cc32)cc1,2004.0
In vitro inhibition of Cyclin-dependent kinase 2,O=C1Nc2ccc(F)c3c(SC[C@@H]4CCCN4)cc(-c4ccc[nH]4)c1c23,CHEMBL1136123,=,=,IC50,nM,18.0,IC50,nM,18.0,O=C1Nc2ccc(F)c3c(SC[C@@H]4CCCN4)cc(-c4ccc[nH]4)c1c23,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,CCc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,7.9,IC50,nM,7.9,CCc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2ccc(C(=O)O)cc2/C1=C/c1[nH]cc2c1CCNC2=O,CHEMBL1136528,=,=,IC50,nM,68.0,IC50,uM,0.068,O=C1Nc2ccc(C(=O)O)cc2/C1=C/c1[nH]cc2c1CCNC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,CC(C)Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,1.2,IC50,nM,1.2,CC(C)Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1137075,=,=,IC50,nM,75.0,IC50,nM,75.0,CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]cc3c1CCOC3=O)C(=O)N2,CHEMBL1136528,=,=,IC50,nM,33.0,IC50,uM,0.033,CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]cc3c1CCOC3=O)C(=O)N2,2003.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2ccc(Br)cc2/C1=C/c1[nH]cc2c1CCNC2=O,CHEMBL1136528,=,=,IC50,nM,530.0,IC50,uM,0.53,O=C1Nc2ccc(Br)cc2/C1=C/c1[nH]cc2c1CCNC2=O,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,O=C1Nc2ccc(F)c3c(S(=O)(=O)CCO)cc(-c4ccc[nH]4)c1c23,CHEMBL1136123,=,=,IC50,nM,15.0,IC50,nM,15.0,O=C1Nc2ccc(F)c3c(S(=O)(=O)CCO)cc(-c4ccc[nH]4)c1c23,2003.0
Inhibition of cyclin dependent kinase 2,CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1,CHEMBL1135866,=,=,IC50,nM,3300.0,IC50,uM,3.3,CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1,2002.0
Evaluated for inhibition of human cyclin dependent kinase 2,CCc1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1137075,=,=,IC50,nM,21.0,IC50,nM,21.0,CCc1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2cccc(CCO)c2/C1=C/c1[nH]cc2c1CCOC2=O,CHEMBL1136528,=,=,IC50,nM,30.0,IC50,uM,0.03,O=C1Nc2cccc(CCO)c2/C1=C/c1[nH]cc2c1CCOC2=O,2003.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2cccc(CCO)c2/C1=C/c1[nH]cc2c1CCNC2=O,CHEMBL1136528,=,=,IC50,nM,340.0,IC50,uM,0.34,O=C1Nc2cccc(CCO)c2/C1=C/c1[nH]cc2c1CCNC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(Oc4ccccc4)c32)cc1,CHEMBL1137075,=,=,IC50,nM,13.0,IC50,nM,13.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(Oc4ccccc4)c32)cc1,2004.0
In vitro inhibition of Cyclin-dependent kinase 2,NCCCNc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,48.0,IC50,nM,48.0,NCCCNc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
In vitro inhibition of Cyclin-dependent kinase 2,CC(C)(N)CNc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,CHEMBL1136123,=,=,IC50,nM,65.0,IC50,nM,65.0,CC(C)(N)CNc1cc(-c2ccc[nH]2)c2c3c(ccc(F)c13)NC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc([N+](=O)[O-])cc32)cc1,CHEMBL1137075,=,=,IC50,nM,15.0,IC50,nM,15.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc([N+](=O)[O-])cc32)cc1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2ccc(F)cc2/C1=C/c1[nH]cc2c1CCOC2=O,CHEMBL1136528,=,=,IC50,nM,82.0,IC50,uM,0.082,O=C1Nc2ccc(F)cc2/C1=C/c1[nH]cc2c1CCOC2=O,2003.0
Inhibitory activity against Cyclin-dependent kinase 2,O=C1Nc2ccc(F)cc2/C1=C/c1[nH]cc2c1CCNC2=O,CHEMBL1136528,=,=,IC50,nM,300.0,IC50,uM,0.3,O=C1Nc2ccc(F)cc2/C1=C/c1[nH]cc2c1CCNC2=O,2003.0
Evaluated for inhibition of human cyclin dependent kinase 2,COc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1137075,=,=,IC50,nM,12.0,IC50,nM,12.0,COc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2004.0
Evaluated for inhibition of human cyclin dependent kinase 2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Oc4ccccc4)ccc32)cc1,CHEMBL1137075,>,>,IC50,nM,10000.0,IC50,nM,10000.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Oc4ccccc4)ccc32)cc1,2004.0
Inhibition of CDK2 kinase,Cc1cccc(Cl)c1NC(=O)c1cnc(NC(=O)C2CC2)s1,CHEMBL1136358,>,>,IC50,nM,25000.0,IC50,uM,25.0,Cc1cccc(Cl)c1NC(=O)c1cnc(NC(=O)C2CC2)s1,2003.0
Selectivity against CDK2 kinase,Cc1cccc(Cl)c1NC(=O)c1cnc(NC(=O)C2CC2)s1,CHEMBL1136358,>,>,Fold selectivity,,700.0,Fold selectivity,,700.0,Cc1cccc(Cl)c1NC(=O)c1cnc(NC(=O)C2CC2)s1,2003.0
Inhibition of cyclin A activated Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2Cl)C3=O)CC1,CHEMBL1135924,=,=,IC50,nM,3970.0,IC50,uM,3.97,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2Cl)C3=O)CC1,2002.0
Inhibition of cyclin A activated Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H](O)C1,CHEMBL1135924,=,=,IC50,nM,220.0,IC50,uM,0.22,CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H](O)C1,2002.0
Inhibition of cyclin A activated Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc(S(N)(=O)=O)cc2)C3=O)CC1,CHEMBL1135924,=,=,IC50,nM,30.0,IC50,uM,0.03,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc(S(N)(=O)=O)cc2)C3=O)CC1,2002.0
Inhibition of cyclin A activated Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc(N4CCN(C)CC4)cc2)C3=O)CC1,CHEMBL1135924,=,=,IC50,nM,2980.0,IC50,uM,2.98,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc(N4CCN(C)CC4)cc2)C3=O)CC1,2002.0
Inhibition of cyclin A activated Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2)C3=O)CC1,CHEMBL1135924,=,=,IC50,nM,1280.0,IC50,uM,1.28,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2)C3=O)CC1,2002.0
Inhibition of cyclin A activated Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc([N+](=O)[O-])cc2)C3=O)CC1,CHEMBL1135924,=,=,IC50,nM,310.0,IC50,uM,0.31,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc([N+](=O)[O-])cc2)C3=O)CC1,2002.0
Inhibitory concentration against cyclin-dependent kinase 2,CNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,CHEMBL1147565,<,<,IC50,nM,3.0,IC50,uM,0.003,CNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,2004.0
Binding affinity towards cyclin dependent kinase-2 was determined,CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1,CHEMBL1136434,=,=,cKi,nM,540.0,cKi,nM,540.0,CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1,2003.0
Selectivity ratio between CDK-2 to GSK-3,CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1,CHEMBL1136434,=,=,Ratio,,2842.0,Ratio,,2842.0,CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1,2003.0
Binding affinity towards cyclin dependent kinase-2 was determined,O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1,CHEMBL1136434,=,=,cKi,nM,5.0,cKi,nM,5.0,O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1,2003.0
Selectivity ratio between CDK-2 to GSK-3,O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1,CHEMBL1136434,=,=,Ratio,,62.0,Ratio,,62.0,O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A),CCOc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1,CHEMBL1133408,>,>,IC50,nM,200000.0,IC50,uM,200.0,CCOc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,CHEMBL1147565,<,<,IC50,nM,3.0,IC50,uM,0.003,c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,2004.0
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A),Cc1nc2c(s1)C(=O)C=C(Nc1ccc(F)cc1)C2=O,CHEMBL1133408,>,>,IC50,nM,200000.0,IC50,uM,200.0,Cc1nc2c(s1)C(=O)C=C(Nc1ccc(F)cc1)C2=O,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccc(Sc5ccccc5)cn34)n2)cc1,CHEMBL1147565,=,=,IC50,nM,16.0,IC50,uM,0.016,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccc(Sc5ccccc5)cn34)n2)cc1,2004.0
Inhibitory concentration against cyclin-dependent kinase 2,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,CHEMBL1147565,=,=,IC50,nM,12.0,IC50,uM,0.012,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,2004.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,CHEMBL1147565,=,=,IC50,nM,5.0,IC50,uM,0.005,CN(C)CCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,2004.0
Inhibitory concentration against cyclin-dependent kinase 2,Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(Cl)cc2)n1,CHEMBL1147565,=,=,IC50,nM,620.0,IC50,uM,0.62,Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(Cl)cc2)n1,2004.0
Inhibitory concentration against cyclin-dependent kinase 2,COCCNS(=O)(=O)c1ccc(Nc2ncc(Cl)c(-c3cnc4ccccn34)n2)cc1,CHEMBL1147565,<,<,IC50,nM,3.0,IC50,uM,0.003,COCCNS(=O)(=O)c1ccc(Nc2ncc(Cl)c(-c3cnc4ccccn34)n2)cc1,2004.0
Inhibitory concentration against cyclin-dependent kinase 2,Cc1nc2ccccn2c1-c1ccnc(Nc2cccc(Cl)c2)n1,CHEMBL1147565,=,=,IC50,nM,150.0,IC50,uM,0.15,Cc1nc2ccccn2c1-c1ccnc(Nc2cccc(Cl)c2)n1,2004.0
Inhibitory concentration against cyclin-dependent kinase 2,NS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,CHEMBL1147565,<,<,IC50,nM,3.0,IC50,uM,0.003,NS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,2004.0
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A),Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,CHEMBL1133408,=,=,IC50,nM,7000.0,IC50,uM,7.0,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,Cc1nc2ccccn2c1-c1ccnc(Nc2ccccc2Cl)n1,CHEMBL1147565,=,=,IC50,nM,8800.0,IC50,uM,8.8,Cc1nc2ccccn2c1-c1ccnc(Nc2ccccc2Cl)n1,2004.0
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A) (Not tested),,CHEMBL1133408,,,IC50,nM,,IC50,uM,,,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,CCSc1ccc2ncc(-c3ccnc(Nc4ccc(S(=O)(=O)NCCOC)cc4)n3)n2c1,CHEMBL1147565,<,<,IC50,nM,3.0,IC50,uM,0.003,CCSc1ccc2ncc(-c3ccnc(Nc4ccc(S(=O)(=O)NCCOC)cc4)n3)n2c1,2004.0
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A),Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1,CHEMBL1133408,>,>,IC50,nM,200000.0,IC50,uM,200.0,Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1,2000.0
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A),CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL1133408,=,=,IC50,nM,600.0,IC50,uM,0.6,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,Cc1nc2ccccn2c1-c1ccnc(Nc2ccccc2)n1,CHEMBL1147565,=,=,IC50,nM,210.0,IC50,uM,0.21,Cc1nc2ccccn2c1-c1ccnc(Nc2ccccc2)n1,2004.0
Binding affinity towards cyclin dependent kinase-2 was determined,CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3ccccc3)cc12,CHEMBL1136434,=,=,cKi,nM,1695.0,cKi,nM,1695.0,CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3ccccc3)cc12,2003.0
Selectivity ratio between CDK-2 to GSK-3,CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3ccccc3)cc12,CHEMBL1136434,=,=,Ratio,,678.0,Ratio,,678.0,CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3ccccc3)cc12,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A),Cc1nc2c(s1)C(=O)C=C(Nc1ccccc1)C2=O,CHEMBL1133408,>,>,IC50,nM,200000.0,IC50,uM,200.0,Cc1nc2c(s1)C(=O)C=C(Nc1ccccc1)C2=O,2000.0
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A),Cc1nc2c(s1)C(=O)C=C(Nc1ccc(I)cc1)C2=O,CHEMBL1133408,>,>,IC50,nM,200000.0,IC50,uM,200.0,Cc1nc2c(s1)C(=O)C=C(Nc1ccc(I)cc1)C2=O,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,Clc1cccc(Nc2nccc(-n3cnc4ccccc43)n2)c1,CHEMBL1147565,=,=,IC50,nM,680.0,IC50,uM,0.68,Clc1cccc(Nc2nccc(-n3cnc4ccccc43)n2)c1,2004.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,CHEMBL1147565,<,<,IC50,nM,3.0,IC50,uM,0.003,CN(C)CCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,2004.0
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A),Cc1nc2c(s1)C(=O)C=C(Nc1ccc(O)cc1)C2=O,CHEMBL1133408,>,>,IC50,nM,200000.0,IC50,uM,200.0,Cc1nc2c(s1)C(=O)C=C(Nc1ccc(O)cc1)C2=O,2000.0
Inhibition of Cyclin-dependent kinase 2,C[C@H](O)CNc1cc(-c2[nH]c3cccnc3c2-c2ccc(F)cc2)ccn1,CHEMBL1145138,>,>,IC50,nM,25000.0,IC50,uM,25.0,C[C@H](O)CNc1cc(-c2[nH]c3cccnc3c2-c2ccc(F)cc2)ccn1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,COCCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,CHEMBL1147565,=,=,IC50,nM,4.0,IC50,uM,0.004,COCCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,2004.0
Inhibitory concentration against cyclin-dependent kinase 2,Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(S(N)(=O)=O)cc2)n1,CHEMBL1147565,=,=,IC50,nM,38.0,IC50,uM,0.038,Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(S(N)(=O)=O)cc2)n1,2004.0
Inhibitory concentration against cyclin-dependent kinase 2,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccc(Br)cn34)n2)cc1,CHEMBL1147565,<,<,IC50,nM,3.0,IC50,uM,0.003,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccc(Br)cn34)n2)cc1,2004.0
Binding affinity towards cyclin dependent kinase-2 was determined,O=C(Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12)C1CCCC1,CHEMBL1136434,=,=,cKi,nM,5.0,cKi,nM,5.0,O=C(Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12)C1CCCC1,2003.0
Selectivity ratio between CDK-2 to GSK-3,O=C(Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12)C1CCCC1,CHEMBL1136434,=,=,Ratio,,45.0,Ratio,,45.0,O=C(Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12)C1CCCC1,2003.0
Inhibitory concentration against cyclin-dependent kinase 2,CN(C)CCCN(C)S(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,CHEMBL1147565,=,=,IC50,nM,5.0,IC50,uM,0.005,CN(C)CCCN(C)S(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,2004.0
Inhibitory concentration against cyclin-dependent kinase 2,COCCNS(=O)(=O)c1ccc(Nc2ncc(Sc3ccccc3)c(-c3cnc4ccccn34)n2)cc1,CHEMBL1147565,>,>,IC50,nM,10000.0,IC50,uM,10.0,COCCNS(=O)(=O)c1ccc(Nc2ncc(Sc3ccccc3)c(-c3cnc4ccccn34)n2)cc1,2004.0
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A),Cc1nc2c(s1)C(=O)C=C(Nc1ccc(Br)cc1)C2=O,CHEMBL1133408,>,>,IC50,nM,200000.0,IC50,uM,200.0,Cc1nc2c(s1)C(=O)C=C(Nc1ccc(Br)cc1)C2=O,2000.0
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A),COc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1,CHEMBL1133408,>,>,IC50,nM,200000.0,IC50,uM,200.0,COc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1,2000.0
Binding affinity towards cyclin dependent kinase-2 was determined,CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1,CHEMBL1136434,=,=,cKi,nM,450.0,cKi,nM,450.0,CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1,2003.0
Selectivity ratio between CDK-2 to GSK-3,CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1,CHEMBL1136434,=,=,Ratio,,474.0,Ratio,,474.0,CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A),Cc1nc2c(s1)C(=O)C=C(Nc1ccc(Cl)cc1)C2=O,CHEMBL1133408,>,>,IC50,nM,200000.0,IC50,uM,200.0,Cc1nc2c(s1)C(=O)C=C(Nc1ccc(Cl)cc1)C2=O,2000.0
Inhibitory concentration against cyclin-dependent kinase 2,Clc1cccc(Nc2nccc(-c3cnc4ccccn34)n2)c1,CHEMBL1147565,=,=,IC50,nM,5.0,IC50,uM,0.005,Clc1cccc(Nc2nccc(-c3cnc4ccccn34)n2)c1,2004.0
Inhibitory concentration against cyclin-dependent kinase 2,COCCNS(=O)(=O)c1ccc(Nc2ncc(Br)c(-c3cnc4ccccn34)n2)cc1,CHEMBL1147565,<,<,IC50,nM,3.0,IC50,uM,0.003,COCCNS(=O)(=O)c1ccc(Nc2ncc(Br)c(-c3cnc4ccccn34)n2)cc1,2004.0
Inhibitory concentration against cyclin-dependent kinase 2,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccc(C#N)cn34)n2)cc1,CHEMBL1147565,<,<,IC50,nM,3.0,IC50,uM,0.003,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccc(C#N)cn34)n2)cc1,2004.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,CHEMBL1136209,=,=,IC50,nM,4.0,IC50,nM,4.0,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,2003.0
"Selectivity for cyclin-dependent kinase 2, CDK2",N[C@H]1CC[C@H](Nc2nc(Nc3ccc(P(=O)(O)CP(=O)(O)O)cc3)c3ncn(C4CCCC4)c3n2)CC1,CHEMBL1136209,=,=,Selectivity,,10.0,Selectivity,,10.0,N[C@H]1CC[C@H](Nc2nc(Nc3ccc(P(=O)(O)CP(=O)(O)O)cc3)c3ncn(C4CCCC4)c3n2)CC1,2003.0
Inhibition of Cyclin-dependent kinase 2,CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1,CHEMBL1134080,>,>,IC50,nM,8000.0,IC50,uM,8.0,CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1,2001.0
Inhibition of Cyclin-dependent kinase 2,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,CHEMBL1133170,=,=,IC50,nM,250000.0,IC50,uM,250.0,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,2000.0
Inhibition of Cyclin-dependent kinase 2,Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(S(N)(=O)=O)cc2)n1,CHEMBL1136202,<,<,IC50,nM,3.0,IC50,uM,0.003,Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(S(N)(=O)=O)cc2)n1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),Cc1cc(C)nc(Sc2cc(=O)c3c(O)cc(O)c(C4CCN(C)CC4O)c3o2)n1,CHEMBL1136795,=,=,IC50,nM,40400.0,IC50,uM,40.4,Cc1cc(C)nc(Sc2cc(=O)c3c(O)cc(O)c(C4CCN(C)CC4O)c3o2)n1,2003.0
Inhibition of Cyclin-dependent kinase 2,Cc1nc2ccccn2c1-c1ccnc(NC(=O)C(F)(F)F)n1,CHEMBL1136202,=,=,IC50,nM,95000.0,IC50,uM,95.0,Cc1nc2ccccn2c1-c1ccnc(NC(=O)C(F)(F)F)n1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc(S(N)(=O)=O)cc2)C3=O)CC1,CHEMBL1136795,=,=,IC50,nM,30.0,IC50,uM,0.03,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc(S(N)(=O)=O)cc2)C3=O)CC1,2003.0
Inhibition of Cyclin-dependent kinase 2,Cc1nc2ccccn2c1-c1ccnc(NC(=O)Nc2ccccc2)n1,CHEMBL1136202,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1nc2ccccn2c1-c1ccnc(NC(=O)Nc2ccccc2)n1,2003.0
Inhibition of Cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1,CHEMBL1136202,=,=,IC50,nM,32000.0,IC50,uM,32.0,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1,2003.0
Inhibition of Cyclin-dependent kinase 2,Cc1nc2ccccn2c1-c1ccnc(Nc2ccccc2)n1,CHEMBL1136202,=,=,IC50,nM,36.0,IC50,uM,0.036,Cc1nc2ccccn2c1-c1ccnc(Nc2ccccc2)n1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c(=O)cc(Sc4ccccc4)oc23)C(O)C1,CHEMBL1136795,=,=,IC50,nM,6590.0,IC50,uM,6.59,CN1CCC(c2c(O)cc(O)c3c(=O)cc(Sc4ccccc4)oc23)C(O)C1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c(=O)cc(Sc4ccccc4Cl)oc23)C(O)C1,CHEMBL1136795,=,=,IC50,nM,2100.0,IC50,uM,2.1,CN1CCC(c2c(O)cc(O)c3c(=O)cc(Sc4ccccc4Cl)oc23)C(O)C1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c(=O)cc(SC(C)(C)C)oc23)C(O)C1,CHEMBL1136795,=,=,IC50,nM,1070.0,IC50,uM,1.07,CN1CCC(c2c(O)cc(O)c3c(=O)cc(SC(C)(C)C)oc23)C(O)C1,2003.0
Inhibition of Cyclin-dependent kinase 2,Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(OCC(O)CN(C)C)cc2)n1,CHEMBL1136202,=,=,IC50,nM,32.0,IC50,uM,0.032,Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(OCC(O)CN(C)C)cc2)n1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),CCSc1cc(=O)c2c(O)cc(O)c(C3CCN(C)CC3O)c2o1,CHEMBL1136795,=,=,IC50,nM,3930.0,IC50,uM,3.93,CCSc1cc(=O)c2c(O)cc(O)c(C3CCN(C)CC3O)c2o1,2003.0
Inhibition of Cyclin-dependent kinase 2,CC(=O)Nc1nccc(-c2c(C)nc3ccccn23)n1,CHEMBL1136202,=,=,IC50,nM,2900.0,IC50,uM,2.9,CC(=O)Nc1nccc(-c2c(C)nc3ccccn23)n1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2)C3=O)CC1,CHEMBL1136795,=,=,IC50,nM,1280.0,IC50,uM,1.28,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2)C3=O)CC1,2003.0
Inhibition of Cyclin-dependent kinase 2,Cc1nc2ccccn2c1-c1ccnc(N)n1,CHEMBL1136202,=,=,IC50,nM,4000.0,IC50,uM,4.0,Cc1nc2ccccn2c1-c1ccnc(N)n1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c(=O)cc(Oc4ccccc4Cl)oc23)C(O)C1,CHEMBL1136795,=,=,IC50,nM,2110.0,IC50,uM,2.11,CN1CCC(c2c(O)cc(O)c3c(=O)cc(Oc4ccccc4Cl)oc23)C(O)C1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc([N+](=O)[O-])cc2)C3=O)CC1,CHEMBL1136795,=,=,IC50,nM,310.0,IC50,uM,0.31,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccc([N+](=O)[O-])cc2)C3=O)CC1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2Cl)C3=O)CC1,CHEMBL1136795,=,=,IC50,nM,3970.0,IC50,uM,3.97,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2Cl)C3=O)CC1,2003.0
Inhibition of Cyclin-dependent kinase 2,Cc1ccc(F)c(Nc2ccnc(Nc3ccc(S(N)(=O)=O)cc3)n2)c1,CHEMBL1136202,=,=,IC50,nM,6.0,IC50,uM,0.006,Cc1ccc(F)c(Nc2ccnc(Nc3ccc(S(N)(=O)=O)cc3)n2)c1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,Nc1cccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)c1,CHEMBL1136197,=,=,IC50,nM,166.0,IC50,nM,166.0,Nc1cccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)c1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1,CHEMBL1136197,=,=,IC50,nM,9.1,IC50,nM,9.1,NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CN(C)c1ccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)cc1,CHEMBL1136197,>,>,IC50,nM,2000.0,IC50,nM,2000.0,CN(C)c1ccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,Nc1ccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)cc1,CHEMBL1136197,=,=,IC50,nM,0.34,IC50,nM,0.34,Nc1ccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,COc1cccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)c1,CHEMBL1136197,=,=,IC50,nM,24.5,IC50,nM,24.5,COc1cccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)c1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(Br)cc3)[nH]n2)cc1,CHEMBL1136197,=,=,IC50,nM,10.0,IC50,nM,10.0,NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(Br)cc3)[nH]n2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(N4CCOCC4)c3)[nH]n2)cc1,CHEMBL1136197,=,=,IC50,nM,490.0,IC50,nM,490.0,NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(N4CCOCC4)c3)[nH]n2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(NS(=O)(=O)c4ccccc4)c3)[nH]n2)cc1,CHEMBL1136197,=,=,IC50,nM,10.7,IC50,nM,10.7,NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(NS(=O)(=O)c4ccccc4)c3)[nH]n2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(Br)c3)[nH]n2)cc1,CHEMBL1136197,=,=,IC50,nM,23.4,IC50,nM,23.4,NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(Br)c3)[nH]n2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,COc1ccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)cc1F,CHEMBL1136197,=,=,IC50,nM,407.0,IC50,nM,407.0,COc1ccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)cc1F,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CS(=O)(=O)Nc1ccc(Nc2cc(-c3cccc(Br)c3)[nH]n2)cc1,CHEMBL1136197,=,=,IC50,nM,602.0,IC50,nM,602.0,CS(=O)(=O)Nc1ccc(Nc2cc(-c3cccc(Br)c3)[nH]n2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1,CHEMBL1136197,=,=,IC50,nM,17.4,IC50,nM,17.4,NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1,CHEMBL1136197,=,=,IC50,nM,12.6,IC50,nM,12.6,NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,CS(=O)(=O)Nc1cccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)c1,CHEMBL1136197,=,=,IC50,nM,10.7,IC50,nM,10.7,CS(=O)(=O)Nc1cccc(-c2cc(Nc3ccc(S(N)(=O)=O)cc3)[nH]n2)c1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1,CHEMBL1136197,=,=,IC50,nM,871.0,IC50,nM,871.0,NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,NS(=O)(=O)c1ccc(Nc2cc(-c3ccc([N+](=O)[O-])cc3)[nH]n2)cc1,CHEMBL1136197,=,=,IC50,nM,0.33,IC50,nM,0.33,NS(=O)(=O)c1ccc(Nc2cc(-c3ccc([N+](=O)[O-])cc3)[nH]n2)cc1,2003.0
In vitro inhibition of Cyclin-dependent kinase 2 was determined.,NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)[nH]n2)cc1,CHEMBL1136197,=,=,IC50,nM,61.6,IC50,nM,61.6,NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)[nH]n2)cc1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCn1cc2c2cccnc21,CHEMBL1145082,=,=,IC50,nM,2439.0,IC50,uM,2.439,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCn1cc2c2cccnc21,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCn1cc2c2cccnc21,CHEMBL1145082,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCn1cc2c2cccnc21,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCn1cc2c2ccccc21,CHEMBL1145082,=,=,IC50,nM,992.0,IC50,uM,0.992,O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCOCCOCCOCCn1cc2c2ccccc21,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCOCCn1cc2c2cccnc21,CHEMBL1145082,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCOCCn1cc2c2cccnc21,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2) at 12.5 uM ATP,Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1,CHEMBL1136212,=,=,IC50,nM,2200.0,IC50,uM,2.2,Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2) at 12.5 uM ATP,NC(=O)c1ccc(Nc2nc(N)c(N=O)c(OCC3CCCCC3)n2)cc1,CHEMBL1136212,=,=,IC50,nM,34.0,IC50,uM,0.034,NC(=O)c1ccc(Nc2nc(N)c(N=O)c(OCC3CCCCC3)n2)cc1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2) at 12.5 uM ATP,NC(=O)c1ccc(Nc2nc(N)cc(OCC3CCCCC3)n2)cc1,CHEMBL1136212,=,=,IC50,nM,59000.0,IC50,uM,59.0,NC(=O)c1ccc(Nc2nc(N)cc(OCC3CCCCC3)n2)cc1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2) at 12.5 uM ATP,CSc1ccc(Nc2nc(N)c(N=O)c(OCC3CCCCC3)n2)cc1,CHEMBL1136212,=,=,IC50,nM,120.0,IC50,uM,0.12,CSc1ccc(Nc2nc(N)c(N=O)c(OCC3CCCCC3)n2)cc1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2) at 12.5 uM ATP,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc(OCC2CCCCC2)c1N=O,CHEMBL1136212,=,=,IC50,nM,1.1,IC50,uM,0.0011,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc(OCC2CCCCC2)c1N=O,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2) at 12.5 uM ATP,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1136212,=,=,IC50,nM,5.4,IC50,uM,0.0054,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2) at 12.5 uM ATP,Nc1nc(OCC2CCCCC2)c2nc[nH]c2n1,CHEMBL1136212,=,=,IC50,nM,17000.0,IC50,uM,17.0,Nc1nc(OCC2CCCCC2)c2nc[nH]c2n1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2) at 12.5 uM ATP,Nc1cc(OCC2CCCCC2)nc(Nc2ccc(S(N)(=O)=O)cc2)n1,CHEMBL1136212,=,=,IC50,nM,2900.0,IC50,uM,2.9,Nc1cc(OCC2CCCCC2)nc(Nc2ccc(S(N)(=O)=O)cc2)n1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2) at 12.5 uM ATP,Nc1nc(Nc2cccc(Br)c2)nc(OCC2CCCCC2)c1N=O,CHEMBL1136212,=,=,IC50,nM,500.0,IC50,uM,0.5,Nc1nc(Nc2cccc(Br)c2)nc(OCC2CCCCC2)c1N=O,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2) at 12.5 uM ATP,COc1ccc(Nc2nc(N)c(N=O)c(OCC3CCCCC3)n2)cc1,CHEMBL1136212,=,=,IC50,nM,220.0,IC50,uM,0.22,COc1ccc(Nc2nc(N)c(N=O)c(OCC3CCCCC3)n2)cc1,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),O=C1Nc2ccccc2/C1=C1/Nc2ccccc2C1=O,CHEMBL1146605,=,=,IC50,nM,2200.0,IC50,uM,2.2,O=C1Nc2ccccc2/C1=C1/Nc2ccccc2C1=O,2003.0
Inhibition of Cyclin-dependent kinase 2 (CDK2),O=C1/C(=C2\Nc3ccccc3C2=O)Nc2ccccc21,CHEMBL1146605,=,=,IC50,nM,70000.0,IC50,uM,70.0,O=C1/C(=C2\Nc3ccccc3C2=O)Nc2ccccc21,2003.0
Inhibition of Cyclin-dependent kinase 2,O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1[C@H]1CC[C@@H]3O1,CHEMBL1146650,=,=,IC50,nM,540.0,IC50,uM,0.54,O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1[C@H]1CC[C@@H]3O1,2004.0
Inhibition of Cyclin-dependent kinase 2 enzyme from starfish oocytes,Nc1cc(OCC2CCCCC2)nc(N)n1,CHEMBL1133452,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1cc(OCC2CCCCC2)nc(N)n1,2000.0
Inhibition of Cyclin-dependent kinase 2 enzyme from starfish oocytes,Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1,CHEMBL1133452,=,=,Ki,nM,1300.0,Ki,uM,1.3,Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1,2000.0
Inhibition of Cyclin-dependent kinase 2 enzyme from starfish oocytes,Nc1nc(OCC2CCCCC2)c2nc[nH]c2n1,CHEMBL1133452,=,=,Ki,nM,12000.0,Ki,uM,12.0,Nc1nc(OCC2CCCCC2)c2nc[nH]c2n1,2000.0
Inhibition of Cyclin-dependent kinase 2 enzyme from starfish oocytes,c1nc(OCC2CCCCC2)c2nc[nH]c2n1,CHEMBL1133452,=,=,IC50,nM,13000.0,IC50,uM,13.0,c1nc(OCC2CCCCC2)c2nc[nH]c2n1,2000.0
Inhibition of Cyclin-dependent kinase 2 enzyme from starfish oocytes,Cn1cnc2c(OCC3CCCCC3)nc(N)nc21,CHEMBL1133452,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cn1cnc2c(OCC3CCCCC3)nc(N)nc21,2000.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCc2ccccc2)cc1,CHEMBL1134300,=,=,IC50,nM,5.6,IC50,nM,5.6,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCc2ccccc2)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1,CHEMBL1134300,=,=,IC50,nM,560.0,IC50,nM,560.0,CNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(/N=N/c2c(O)[nH]c3cccc(I)c23)cc1,CHEMBL1134300,=,=,IC50,nM,4.6,IC50,nM,4.6,NS(=O)(=O)c1ccc(/N=N/c2c(O)[nH]c3cccc(I)c23)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,8.9,IC50,nM,8.9,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccccc32)cc1,CHEMBL1134300,=,=,IC50,nM,120.0,IC50,nM,120.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccccc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,2.5,IC50,nM,2.5,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,CHEMBL1134300,=,=,IC50,nM,9.7,IC50,nM,9.7,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CNS(=O)(=O)Cc1ccc(N/N=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,5.7,IC50,nM,5.7,CNS(=O)(=O)Cc1ccc(N/N=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CCc1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1134300,=,=,IC50,nM,21.0,IC50,nM,21.0,CCc1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),COCCOCCOCCOCCN(C)S(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,1.0,IC50,nM,1.0,COCCOCCOCCOCCN(C)S(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),Cc1c([N+](=O)[O-])ccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,4.6,IC50,nM,4.6,Cc1c([N+](=O)[O-])ccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1,CHEMBL1134300,=,=,IC50,nM,690.0,IC50,nM,690.0,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,43.0,IC50,nM,43.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(Oc4ccccc4)c32)cc1,CHEMBL1134300,=,=,IC50,nM,13.0,IC50,nM,13.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(Oc4ccccc4)c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,25.0,IC50,nM,25.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccc(O)cc4)c32)cc1,CHEMBL1134300,=,=,IC50,nM,12.0,IC50,nM,12.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccc(O)cc4)c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CC(C)CC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,1.9,IC50,nM,1.9,CC(C)CC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4cccnc4)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,2.1,IC50,nM,2.1,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4cccnc4)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Br)ccc32)cc1,CHEMBL1134300,=,=,IC50,nM,43.0,IC50,nM,43.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Br)ccc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]ncc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,13.0,IC50,nM,13.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]ncc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)N[n+]2ccc3ccccc3c2)cc1,CHEMBL1134300,=,=,IC50,nM,9.5,IC50,nM,9.5,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)N[n+]2ccc3ccccc3c2)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CN(C)CCNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1,CHEMBL1134300,=,=,IC50,nM,1000.0,IC50,nM,1000.0,CN(C)CCNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cccc(CO)c32)cc1,CHEMBL1134300,=,=,IC50,nM,54.0,IC50,nM,54.0,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cccc(CO)c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,46.0,IC50,nM,46.0,Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),COc1cccc(OC)c1CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,1.7,IC50,nM,1.7,COc1cccc(OC)c1CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(/C=C/c4ccc(O)cc4)c32)cc1,CHEMBL1134300,=,=,IC50,nM,9.3,IC50,nM,9.3,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(/C=C/c4ccc(O)cc4)c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CN(C)C(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,17.0,IC50,nM,17.0,CN(C)C(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CN(C)S(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,4.6,IC50,nM,4.6,CN(C)S(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCc2c[nH]cn2)cc1,CHEMBL1134300,=,=,IC50,nM,3.6,IC50,nM,3.6,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCc2c[nH]cn2)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc([N+](=O)[O-])c32)cc1,CHEMBL1134300,=,=,IC50,nM,2400.0,IC50,nM,2400.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc([N+](=O)[O-])c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncccc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,1.5,IC50,nM,1.5,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncccc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccc2)cc1,CHEMBL1134300,=,=,IC50,nM,4.3,IC50,nM,4.3,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccc2)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(O)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,10.0,IC50,nM,10.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(O)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(=O)(=O)O)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,15.0,IC50,nM,15.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(=O)(=O)O)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cc(CO)ccc32)cc1,CHEMBL1134300,=,=,IC50,nM,61.0,IC50,nM,61.0,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cc(CO)ccc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,5.6,IC50,nM,5.6,CNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,5.7,IC50,nM,5.7,CS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(CS(=O)(=O)NCCO)cc1,CHEMBL1134300,=,=,IC50,nM,13.0,IC50,nM,13.0,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(CS(=O)(=O)NCCO)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CCOC(=O)c1cccc2c1/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,8.9,IC50,nM,8.9,CCOC(=O)c1cccc2c1/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,1.6,IC50,nM,1.6,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCOCCO)cc1,CHEMBL1134300,=,=,IC50,nM,0.54,IC50,nM,0.54,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCOCCO)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CS(=O)(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,16.0,IC50,nM,16.0,CS(=O)(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1134300,=,=,IC50,nM,75.0,IC50,nM,75.0,CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),O=C1Nc2ccc(-c3cnco3)cc2/C1=C/Nc1ccc2c(c1)CS(=O)(=O)C2,CHEMBL1134300,=,=,IC50,nM,8.9,IC50,nM,8.9,O=C1Nc2ccc(-c3cnco3)cc2/C1=C/Nc1ccc2c(c1)CS(=O)(=O)C2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1,CHEMBL1134300,=,=,IC50,nM,21.0,IC50,nM,21.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),O=C1Nc2ccccc2/C1=C/Nc1ccc(S(=O)(=O)Nc2nccs2)cc1,CHEMBL1134300,=,=,IC50,nM,1000.0,IC50,nM,1000.0,O=C1Nc2ccccc2/C1=C/Nc1ccc(S(=O)(=O)Nc2nccs2)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(Cl)cc21,CHEMBL1134300,=,=,IC50,nM,22.0,IC50,nM,22.0,C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(Cl)cc21,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),Nc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,74.0,IC50,nM,74.0,Nc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CCc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,7.9,IC50,nM,7.9,CCc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),Cc1cc(C)c2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(C)c2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CNS(=O)(=O)Cc1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,26.0,IC50,nM,26.0,CNS(=O)(=O)Cc1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,2.3,IC50,nM,2.3,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NC(=O)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,>,>,IC50,nM,1000.0,IC50,nM,1000.0,NC(=O)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),COc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,12.0,IC50,nM,12.0,COc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]nnc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,9.5,IC50,nM,9.5,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]nnc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CC(C)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,2.5,IC50,nM,2.5,CC(C)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(-c4cc[nH]n4)c32)cc1,CHEMBL1134300,=,=,IC50,nM,19.0,IC50,nM,19.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(-c4cc[nH]n4)c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),Cc1cccc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1134300,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cccc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]nc(Cl)c4c32)cc1,CHEMBL1134300,=,=,IC50,nM,2.2,IC50,nM,2.2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]nc(Cl)c4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,310.0,IC50,nM,310.0,CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),N=C(N)NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1,CHEMBL1134300,=,=,IC50,nM,660.0,IC50,nM,660.0,N=C(N)NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(I)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,11.0,IC50,nM,11.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(I)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,12.0,IC50,nM,12.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,2.8,IC50,nM,2.8,NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CS(=O)(=O)Cc1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,50.0,IC50,nM,50.0,CS(=O)(=O)Cc1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CC(C)(C)c1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1134300,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CC(C)(C)c1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCO)cc1,CHEMBL1134300,=,=,IC50,nM,4.7,IC50,nM,4.7,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCO)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),Cc1cccc(C)c1NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,281.0,IC50,nM,281.0,Cc1cccc(C)c1NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)Cc1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,7.5,IC50,nM,7.5,NS(=O)(=O)Cc1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibition of Cyclin-dependent kinase 2,CCN(CC)C/C=C/c1nc(O)c2c(ccc3nc(Nc4c(Cl)cccc4Cl)n(C)c32)c1C,CHEMBL1136753,>,>,IC50,nM,1000.0,IC50,uM,1.0,CCN(CC)C/C=C/c1nc(O)c2c(ccc3nc(Nc4c(Cl)cccc4Cl)n(C)c32)c1C,2003.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,60.0,IC50,nM,60.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CC(C)Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,1.2,IC50,nM,1.2,CC(C)Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(F)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,34.0,IC50,nM,34.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(F)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,43.0,IC50,nM,43.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,2.1,IC50,nM,2.1,COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CN(c1ccccn1)S(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,5.6,IC50,nM,5.6,CN(c1ccccn1)S(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CC(=O)NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,75.0,IC50,nM,75.0,CC(=O)NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,1.5,IC50,nM,1.5,CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,3.0,IC50,nM,3.0,CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),Cc1cc(Cl)cc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1134300,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(Cl)cc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc2c(c1)CS(=O)(=O)C2,CHEMBL1134300,=,=,IC50,nM,14.0,IC50,nM,14.0,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc2c(c1)CS(=O)(=O)C2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21,CHEMBL1134300,=,=,IC50,nM,360.0,IC50,nM,360.0,C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc([N+](=O)[O-])cc32)cc1,CHEMBL1134300,=,=,IC50,nM,15.0,IC50,nM,15.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc([N+](=O)[O-])cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),COc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,54.0,IC50,nM,54.0,COc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc(C(=O)O)cc32)cc1,CHEMBL1134300,=,=,IC50,nM,28.0,IC50,nM,28.0,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc(C(=O)O)cc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(-c3cnco3)cc21,CHEMBL1134300,=,=,IC50,nM,2.0,IC50,nM,2.0,C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(-c3cnco3)cc21,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,4.5,IC50,nM,4.5,NC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,7.1,IC50,nM,7.1,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Oc4ccccc4)ccc32)cc1,CHEMBL1134300,>,>,IC50,nM,10000.0,IC50,nM,10000.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Oc4ccccc4)ccc32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),Cc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,13.0,IC50,nM,13.0,Cc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),N=C(N)NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,3.3,IC50,nM,3.3,N=C(N)NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CCOc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,93.0,IC50,nM,93.0,CCOc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CC(C)Oc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,3.4,IC50,nM,3.4,CC(C)Oc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1134300,=,=,IC50,nM,6.8,IC50,nM,6.8,CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2001.0
Inhibitory activity against human cyclin-dependent kinase 2 (CDK2),COCCOCCOCCOCCNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1134300,=,=,IC50,nM,4.5,IC50,nM,4.5,COCCOCCOCCOCCNS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2001.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Fc1ccc2c(c1)[nH]c1c(-c3ccccc3)nccc12,CHEMBL1135277,=,=,Inhibition,%,57.0,Inhibition,%,57.0,Fc1ccc2c(c1)[nH]c1c(-c3ccccc3)nccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1cc(OCC(=O)OCc3ccccc3)ccc12,CHEMBL1135277,=,=,Inhibition,%,57.0,Inhibition,%,57.0,Cc1nccc2c1[nH]c1cc(OCC(=O)OCc3ccccc3)ccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Fc1ccc2c(c1)[nH]c1c(-c3ccccc3F)nccc12,CHEMBL1135277,=,=,Inhibition,%,55.0,Inhibition,%,55.0,Fc1ccc2c(c1)[nH]c1c(-c3ccccc3F)nccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Clc1ccccc1-c1[nH]ccc2c3ccccc3nc1-2,CHEMBL1135277,=,=,Inhibition,%,69.0,Inhibition,%,69.0,Clc1ccccc1-c1[nH]ccc2c3ccccc3nc1-2,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Clc1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1,CHEMBL1135277,=,=,Inhibition,%,48.0,Inhibition,%,48.0,Clc1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,N#Cc1ccccc1-c1[nH]ccc2c3ccccc3nc1-2,CHEMBL1135277,=,=,Inhibition,%,8.0,Inhibition,%,8.0,N#Cc1ccccc1-c1[nH]ccc2c3ccccc3nc1-2,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1ccc(-c2[nH]ccc3c4ccccc4nc2-3)c(C)c1,CHEMBL1135277,=,=,Inhibition,%,5.0,Inhibition,%,5.0,Cc1ccc(-c2[nH]ccc3c4ccccc4nc2-3)c(C)c1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,CCCc1ncc(N)c2c1[nH]c1ccccc12,CHEMBL1135277,=,=,Inhibition,%,22.0,Inhibition,%,22.0,CCCc1ncc(N)c2c1[nH]c1ccccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,O=[N+]([O-])c1ccc(Cl)c(-c2[nH]ccc3c4ccccc4nc2-3)c1,CHEMBL1135277,=,=,Inhibition,%,70.0,Inhibition,%,70.0,O=[N+]([O-])c1ccc(Cl)c(-c2[nH]ccc3c4ccccc4nc2-3)c1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,CC(=O)OCCOc1ccc2c(c1)[nH]c1c(C)nccc12,CHEMBL1135277,=,=,Inhibition,%,23.0,Inhibition,%,23.0,CC(=O)OCCOc1ccc2c(c1)[nH]c1c(C)nccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Fc1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1,CHEMBL1135277,=,=,Inhibition,%,20.0,Inhibition,%,20.0,Fc1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,O=[N+]([O-])c1ccccc1-c1[nH]ccc2c3ccccc3nc1-2,CHEMBL1135277,=,=,Inhibition,%,43.0,Inhibition,%,43.0,O=[N+]([O-])c1ccccc1-c1[nH]ccc2c3ccccc3nc1-2,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,CCOc1ccc2c(c1)[nH]c1c(C)nccc12,CHEMBL1135277,=,=,Inhibition,%,43.0,Inhibition,%,43.0,CCOc1ccc2c(c1)[nH]c1c(C)nccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,COc1ccc2c3c([nH]c2c1)C(C)=NCC3,CHEMBL1135277,=,=,Inhibition,%,10.0,Inhibition,%,10.0,COc1ccc2c3c([nH]c2c1)C(C)=NCC3,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1ccc2c(c1)[nH]c1c(-c3ccccc3F)nccc12,CHEMBL1135277,=,=,Inhibition,%,36.0,Inhibition,%,36.0,Cc1ccc2c(c1)[nH]c1c(-c3ccccc3F)nccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,COC(=O)Cc1nccc2c1[nH]c1ccccc12,CHEMBL1135277,=,=,Inhibition,%,11.0,Inhibition,%,11.0,COC(=O)Cc1nccc2c1[nH]c1ccccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,COc1ccc2[nH]c3c(C(=O)O)nccc3c2c1,CHEMBL1135277,=,=,Inhibition,%,12.0,Inhibition,%,12.0,COc1ccc2[nH]c3c(C(=O)O)nccc3c2c1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,CC(C)(C)c1[nH]ccc2c3ccccc3nc1-2,CHEMBL1135277,=,=,Inhibition,%,50.0,Inhibition,%,50.0,CC(C)(C)c1[nH]ccc2c3ccccc3nc1-2,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Brc1ccccc1-c1[nH]ccc2c3ccccc3nc1-2,CHEMBL1135277,=,=,Inhibition,%,10.0,Inhibition,%,10.0,Brc1ccccc1-c1[nH]ccc2c3ccccc3nc1-2,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Fc1ccc(-c2[nH]ccc3c4ccccc4nc2-3)c(F)c1,CHEMBL1135277,=,=,Inhibition,%,56.0,Inhibition,%,56.0,Fc1ccc(-c2[nH]ccc3c4ccccc4nc2-3)c(F)c1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,CCc1nccc2c1[nH]c1cc(F)ccc12,CHEMBL1135277,=,=,Inhibition,%,54.0,Inhibition,%,54.0,CCc1nccc2c1[nH]c1cc(F)ccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,COc1ccc2[nH]c3c(C)nccc3c2c1,CHEMBL1135277,=,=,Inhibition,%,2.0,Inhibition,%,2.0,COc1ccc2[nH]c3c(C)nccc3c2c1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1cc(OCC(N)=O)ccc12,CHEMBL1135277,=,=,Inhibition,%,15.0,Inhibition,%,15.0,Cc1nccc2c1[nH]c1cc(OCC(N)=O)ccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,c1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1,CHEMBL1135277,=,=,Inhibition,%,13.0,Inhibition,%,13.0,c1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Clc1cccc(-c2[nH]ccc3c4ccccc4nc2-3)c1,CHEMBL1135277,=,=,Inhibition,%,32.0,Inhibition,%,32.0,Clc1cccc(-c2[nH]ccc3c4ccccc4nc2-3)c1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,O=[N+]([O-])c1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1,CHEMBL1135277,=,=,Inhibition,%,31.0,Inhibition,%,31.0,O=[N+]([O-])c1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1cc(OCCN3C(=O)c4ccccc4C3=O)ccc12,CHEMBL1135277,=,=,Inhibition,%,8.0,Inhibition,%,8.0,Cc1nccc2c1[nH]c1cc(OCCN3C(=O)c4ccccc4C3=O)ccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1ccc2[nH]c3c(C)nccc3c2c1,CHEMBL1135277,=,=,Inhibition,%,15.0,Inhibition,%,15.0,Cc1ccc2[nH]c3c(C)nccc3c2c1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,CC1=NCCc2c1[nH]c1cc(O)ccc21,CHEMBL1135277,=,=,Inhibition,%,13.0,Inhibition,%,13.0,CC1=NCCc2c1[nH]c1cc(O)ccc21,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1ccc(F)cc12,CHEMBL1135277,=,=,Inhibition,%,46.0,Inhibition,%,46.0,Cc1nccc2c1[nH]c1ccc(F)cc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1[nH]cnc1-c1[nH]ccc2c3ccc(F)cc3nc1-2,CHEMBL1135277,=,=,Inhibition,%,51.0,Inhibition,%,51.0,Cc1[nH]cnc1-c1[nH]ccc2c3ccc(F)cc3nc1-2,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1[nH]cnc1-c1[nH]ccc2c3ccccc3nc1-2,CHEMBL1135277,=,=,Inhibition,%,89.0,Inhibition,%,89.0,Cc1[nH]cnc1-c1[nH]ccc2c3ccccc3nc1-2,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1cc(OCCO)ccc12,CHEMBL1135277,=,=,Inhibition,%,4.0,Inhibition,%,4.0,Cc1nccc2c1[nH]c1cc(OCCO)ccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,CCCCOc1ccc2c(c1)[nH]c1c(C)nccc12,CHEMBL1135277,=,=,Inhibition,%,50.0,Inhibition,%,50.0,CCCCOc1ccc2c(c1)[nH]c1c(C)nccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,O=[N+]([O-])c1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1Cl,CHEMBL1135277,=,=,Inhibition,%,4.0,Inhibition,%,4.0,O=[N+]([O-])c1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1Cl,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1cccc(C)c12,CHEMBL1135277,=,=,Inhibition,%,30.0,Inhibition,%,30.0,Cc1nccc2c1[nH]c1cccc(C)c12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1cccc(F)c12,CHEMBL1135277,=,=,Inhibition,%,55.0,Inhibition,%,55.0,Cc1nccc2c1[nH]c1cccc(F)c12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1cc(F)ccc12,CHEMBL1135277,=,=,Inhibition,%,65.0,Inhibition,%,65.0,Cc1nccc2c1[nH]c1cc(F)ccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,CCCc1nccc2c1[nH]c1ccccc12,CHEMBL1135277,=,=,Inhibition,%,43.0,Inhibition,%,43.0,CCCc1nccc2c1[nH]c1ccccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Fc1cccc(-c2[nH]ccc3c4ccccc4nc2-3)c1,CHEMBL1135277,=,=,Inhibition,%,6.0,Inhibition,%,6.0,Fc1cccc(-c2[nH]ccc3c4ccccc4nc2-3)c1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,COc1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1,CHEMBL1135277,=,=,Inhibition,%,6.0,Inhibition,%,6.0,COc1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,N#Cc1cccc(-c2[nH]ccc3c4ccccc4nc2-3)c1,CHEMBL1135277,=,=,Inhibition,%,31.0,Inhibition,%,31.0,N#Cc1cccc(-c2[nH]ccc3c4ccccc4nc2-3)c1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,CCCNC(=O)Oc1ccc2c(c1)[nH]c1c(C)nccc12,CHEMBL1135277,=,=,Inhibition,%,61.0,Inhibition,%,61.0,CCCNC(=O)Oc1ccc2c(c1)[nH]c1c(C)nccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,c1ccc2c(c1)[nH]c1c(-c3c[nH]cn3)nccc12,CHEMBL1135277,=,=,Inhibition,%,30.0,Inhibition,%,30.0,c1ccc2c(c1)[nH]c1c(-c3c[nH]cn3)nccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,c1ccc2c(c1)[nH]c1cnccc12,CHEMBL1135277,=,=,Inhibition,%,37.0,Inhibition,%,37.0,c1ccc2c(c1)[nH]c1cnccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,COc1ccc2c(c1)[nH]c1c(C)nccc12,CHEMBL1135277,=,=,Inhibition,%,62.0,Inhibition,%,62.0,COc1ccc2c(c1)[nH]c1c(C)nccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,O=[N+]([O-])c1cccc(-c2[nH]ccc3c4ccccc4nc2-3)c1,CHEMBL1135277,=,=,Inhibition,%,19.0,Inhibition,%,19.0,O=[N+]([O-])c1cccc(-c2[nH]ccc3c4ccccc4nc2-3)c1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,FC(F)(F)c1[nH]ccc2c3ccccc3nc1-2,CHEMBL1135277,=,=,Inhibition,%,39.0,Inhibition,%,39.0,FC(F)(F)c1[nH]ccc2c3ccccc3nc1-2,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1cc(OCCOC(=O)c3ccccc3)ccc12,CHEMBL1135277,=,=,Inhibition,%,13.0,Inhibition,%,13.0,Cc1nccc2c1[nH]c1cc(OCCOC(=O)c3ccccc3)ccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1ccccc12,CHEMBL1135277,=,=,Inhibition,%,47.0,Inhibition,%,47.0,Cc1nccc2c1[nH]c1ccccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,CC(C)c1nccc2c1[nH]c1ccccc12,CHEMBL1135277,=,=,Inhibition,%,44.0,Inhibition,%,44.0,CC(C)c1nccc2c1[nH]c1ccccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Fc1ccccc1-c1[nH]ccc2c3ccccc3nc1-2,CHEMBL1135277,=,=,Inhibition,%,64.0,Inhibition,%,64.0,Fc1ccccc1-c1[nH]ccc2c3ccccc3nc1-2,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,COc1cccc(-c2[nH]ccc3c4ccccc4nc2-3)c1,CHEMBL1135277,=,=,Inhibition,%,5.0,Inhibition,%,5.0,COc1cccc(-c2[nH]ccc3c4ccccc4nc2-3)c1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1ccc2c(c1)[nH]c1c(C)nccc12,CHEMBL1135277,=,=,Inhibition,%,23.0,Inhibition,%,23.0,Cc1ccc2c(c1)[nH]c1c(C)nccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1cc(OC(=O)NC3CCCCC3)ccc12,CHEMBL1135277,=,=,Inhibition,%,53.0,Inhibition,%,53.0,Cc1nccc2c1[nH]c1cc(OC(=O)NC3CCCCC3)ccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1cc(Oc3ncc(C(F)(F)F)cc3Cl)ccc12,CHEMBL1135277,=,=,Inhibition,%,10.0,Inhibition,%,10.0,Cc1nccc2c1[nH]c1cc(Oc3ncc(C(F)(F)F)cc3Cl)ccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,N#Cc1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1,CHEMBL1135277,=,=,Inhibition,%,29.0,Inhibition,%,29.0,N#Cc1ccc(-c2[nH]ccc3c4ccccc4nc2-3)cc1,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,CCCc1nccc2c1[nH]c1cc(F)ccc12,CHEMBL1135277,=,=,Inhibition,%,60.0,Inhibition,%,60.0,CCCc1nccc2c1[nH]c1cc(F)ccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1ccc(OC(=O)c3ccccc3)cc12,CHEMBL1135277,=,=,Inhibition,%,2.0,Inhibition,%,2.0,Cc1nccc2c1[nH]c1ccc(OC(=O)c3ccccc3)cc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1nccc2c1[nH]c1cc(OCCC3(C)OCC(C)(C)CO3)ccc12,CHEMBL1135277,=,=,Inhibition,%,27.0,Inhibition,%,27.0,Cc1nccc2c1[nH]c1cc(OCCC3(C)OCC(C)(C)CO3)ccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,Cc1[nH]ccc2c1[nH]c1cc(=O)ccc12,CHEMBL1135277,=,=,Inhibition,%,69.0,Inhibition,%,69.0,Cc1[nH]ccc2c1[nH]c1cc(=O)ccc12,2002.0
Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM,CCOC(COc1ccc2c(c1)[nH]c1c(C)nccc12)OCC,CHEMBL1135277,=,=,Inhibition,%,1.0,Inhibition,%,1.0,CCOC(COc1ccc2c(c1)[nH]c1c(C)nccc12)OCC,2002.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(C#N)cnn23)cc1,CHEMBL1141971,=,=,IC50,nM,7.0,IC50,uM,0.007,CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(C#N)cnn23)cc1,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(Cl)cnn23)cc1,CHEMBL1141971,=,=,IC50,nM,8.0,IC50,uM,0.008,CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(Cl)cnn23)cc1,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(Br)cnn23)cc1,CHEMBL1141971,=,=,IC50,nM,10.0,IC50,uM,0.01,CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(Br)cnn23)cc1,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),CCN[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)N(C)C)cc3)n3ncc(C(C)C)c3n2)CC1,CHEMBL1141971,=,=,IC50,nM,61.0,IC50,uM,0.061,CCN[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)N(C)C)cc3)n3ncc(C(C)C)c3n2)CC1,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),CCN(CC)[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)N(C)C)cc3)n3ncc(C(C)C)c3n2)CC1,CHEMBL1141971,=,=,IC50,nM,92.0,IC50,uM,0.092,CCN(CC)[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)N(C)C)cc3)n3ncc(C(C)C)c3n2)CC1,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),CC(C)c1cnn2c(Nc3ccc(S(=O)(=O)N(C)C)cc3)cc(O[C@H]3CC[C@H](N)CC3)nc12,CHEMBL1141971,=,=,IC50,nM,17.0,IC50,uM,0.017,CC(C)c1cnn2c(Nc3ccc(S(=O)(=O)N(C)C)cc3)cc(O[C@H]3CC[C@H](N)CC3)nc12,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),CC(C)c1cnn2c(Nc3ccc(S(=O)(=O)N(C)C)cc3)cc(NC3CCCC(N)C3)nc12,CHEMBL1141971,=,=,IC50,nM,2100.0,IC50,uM,2.1,CC(C)c1cnn2c(Nc3ccc(S(=O)(=O)N(C)C)cc3)cc(NC3CCCC(N)C3)nc12,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),CC(C)COc1cc(Nc2ccc(S(=O)(=O)N(C)C)cc2)n2ncc(C(C)C)c2n1,CHEMBL1141971,=,=,IC50,nM,1200.0,IC50,uM,1.2,CC(C)COc1cc(Nc2ccc(S(=O)(=O)N(C)C)cc2)n2ncc(C(C)C)c2n1,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),CC(C)COc1cc(Nc2ccc(S(C)(=O)=O)cc2)n2ncc(C(C)C)c2n1,CHEMBL1141971,=,=,IC50,nM,1200.0,IC50,uM,1.2,CC(C)COc1cc(Nc2ccc(S(C)(=O)=O)cc2)n2ncc(C(C)C)c2n1,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(Br)cnn23)cc1Cl,CHEMBL1141971,=,=,IC50,nM,2.0,IC50,uM,0.002,CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(Br)cnn23)cc1Cl,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),N[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)c4cccs4)cc3)n3ncc(Cl)c3n2)CC1,CHEMBL1141971,=,=,IC50,nM,11.0,IC50,uM,0.011,N[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)c4cccs4)cc3)n3ncc(Cl)c3n2)CC1,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),N[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)c4ccccc4)cc3)n3ncc(Br)c3n2)CC1,CHEMBL1141971,=,=,IC50,nM,16.0,IC50,uM,0.016,N[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)c4ccccc4)cc3)n3ncc(Br)c3n2)CC1,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),CC(C)c1cnn2c(Nc3ccc(S(=O)(=O)N(C)C)cc3)cc(N[C@H]3CC[C@H](N)CC3)nc12,CHEMBL1141971,=,=,IC50,nM,59.0,IC50,uM,0.059,CC(C)c1cnn2c(Nc3ccc(S(=O)(=O)N(C)C)cc3)cc(N[C@H]3CC[C@H](N)CC3)nc12,2005.0
Inhibitory concentration for Cyclin-dependent kinase 2 was determined in the presence of 100 um ATP (Km 50 uM),CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(C4CCCC4)cnn23)cc1,CHEMBL1141971,=,=,IC50,nM,4.0,IC50,uM,0.004,CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3c(C4CCCC4)cnn23)cc1,2005.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccc(F)cc3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccc(F)cc3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccc(F)c(F)c4)n3)c(-c3ccc(F)cc3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccc(F)c(F)c4)n3)c(-c3ccc(F)cc3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(F)cc3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(F)cc3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccc(Cl)c(C(F)(F)F)c4)n3)c(-c3ccc(F)cc3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccc(Cl)c(C(F)(F)F)c4)n3)c(-c3ccc(F)cc3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,c1ccc(Nc2nccc(-c3c(C4CC4)nn4ncccc34)n2)cc1,CHEMBL1138749,=,=,Ki,nM,3980.0,Ki,uM,3.98,c1ccc(Nc2nccc(-c3c(C4CC4)nn4ncccc34)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1ccc(Nc2nccc(-c3c(C4CC4)nn4ncccc34)n2)cc1F,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Fc1ccc(Nc2nccc(-c3c(C4CC4)nn4ncccc34)n2)cc1F,2004.0
Binding affinity for human cyclin-dependent kinase 2,c1ccc(Nc2nccc(-c3c(C4CCCCC4)nn4ncccc34)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,c1ccc(Nc2nccc(-c3c(C4CCCCC4)nn4ncccc34)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1ccc(Nc2nccc(-c3c(C4CCCCC4)nn4ncccc34)n2)cc1F,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Fc1ccc(Nc2nccc(-c3c(C4CCCCC4)nn4ncccc34)n2)cc1F,2004.0
Binding affinity for human cyclin-dependent kinase 2,COCCOc1cnn2ncc(-c3ccnc(Nc4cccc(OC)c4)n3)c2c1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,COCCOc1cnn2ncc(-c3ccnc(Nc4cccc(OC)c4)n3)c2c1,2004.0
Inhibition of cyclin-dependent kinase 2,CCCCCC(=O)Nc1ncnc2oc(-c3ccc(OC)cc3)cc12,CHEMBL1137112,>,>,IC50,nM,19000.0,IC50,uM,19.0,CCCCCC(=O)Nc1ncnc2oc(-c3ccc(OC)cc3)cc12,2004.0
Inhibition of cyclin-dependent kinase 2,COc1ccc(-c2cc3c(NC(=O)CCSC)ncnc3o2)cc1,CHEMBL1137112,>,>,IC50,nM,20000.0,IC50,uM,20.0,COc1ccc(-c2cc3c(NC(=O)CCSC)ncnc3o2)cc1,2004.0
Inhibition of cyclin-dependent kinase 2,COc1ccc(-c2cc3c(NC(=O)C(C)C)ncnc3o2)cc1,CHEMBL1137112,>,>,IC50,nM,21000.0,IC50,uM,21.0,COc1ccc(-c2cc3c(NC(=O)C(C)C)ncnc3o2)cc1,2004.0
Inhibition of cyclin-dependent kinase 2,COc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1,CHEMBL1137112,>,>,IC50,nM,20000.0,IC50,uM,20.0,COc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1,2004.0
Inhibition of cyclin-dependent kinase 2,COc1ccc(-c2cc3c(NC(=O)C4CCCC4)ncnc3o2)cc1,CHEMBL1137112,>,>,IC50,nM,19000.0,IC50,uM,19.0,COc1ccc(-c2cc3c(NC(=O)C4CCCC4)ncnc3o2)cc1,2004.0
Inhibition of cyclin-dependent kinase 2,COc1ccc(-c2cc3c(NC(=O)CC4CCCC4)ncnc3o2)cc1,CHEMBL1137112,>,>,IC50,nM,19000.0,IC50,uM,19.0,COc1ccc(-c2cc3c(NC(=O)CC4CCCC4)ncnc3o2)cc1,2004.0
Inhibition of cyclin-dependent kinase 2,COc1ccc(-c2cc3c(NC(=O)C4CCCCC4)ncnc3o2)cc1,CHEMBL1137112,>,>,IC50,nM,20000.0,IC50,uM,20.0,COc1ccc(-c2cc3c(NC(=O)C4CCCCC4)ncnc3o2)cc1,2004.0
Inhibition of cyclin-dependent kinase 2,COc1ccc(-c2cc3c(NC(=O)N4CCOCC4)ncnc3o2)cc1,CHEMBL1137112,>,>,IC50,nM,20000.0,IC50,uM,20.0,COc1ccc(-c2cc3c(NC(=O)N4CCOCC4)ncnc3o2)cc1,2004.0
Inhibition of cyclin-dependent kinase 2,COc1ccc(-c2cc3c(NC(=O)N4CCCC4)ncnc3o2)cc1,CHEMBL1137112,>,>,IC50,nM,21000.0,IC50,uM,21.0,COc1ccc(-c2cc3c(NC(=O)N4CCCC4)ncnc3o2)cc1,2004.0
Inhibition of cyclin-dependent kinase 2,COc1ccc(-c2cc3c(NC(=O)c4cccc(F)c4)ncnc3o2)cc1,CHEMBL1137112,>,>,IC50,nM,21000.0,IC50,uM,21.0,COc1ccc(-c2cc3c(NC(=O)c4cccc(F)c4)ncnc3o2)cc1,2004.0
Inhibition of cyclin-dependent kinase 2,COc1ccc(-c2cc3c(NC(=O)c4ccco4)ncnc3o2)cc1,CHEMBL1137112,>,>,IC50,nM,20000.0,IC50,uM,20.0,COc1ccc(-c2cc3c(NC(=O)c4ccco4)ncnc3o2)cc1,2004.0
Inhibition of cyclin-dependent kinase 2,O=C(Nc1ncnc2oc(-c3ccccc3)cc12)C1CC1,CHEMBL1137112,>,>,IC50,nM,21000.0,IC50,uM,21.0,O=C(Nc1ncnc2oc(-c3ccccc3)cc12)C1CC1,2004.0
Inhibition of cyclin-dependent kinase 2,O=C(Nc1ncnc2oc(-c3ccc(Cl)cc3)cc12)C1CC1,CHEMBL1137112,>,>,IC50,nM,20000.0,IC50,uM,20.0,O=C(Nc1ncnc2oc(-c3ccc(Cl)cc3)cc12)C1CC1,2004.0
Inhibition of cyclin-dependent kinase 2,Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1,CHEMBL1137112,>,>,IC50,nM,21000.0,IC50,uM,21.0,Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1,2004.0
Inhibition of cyclin-dependent kinase 2,O=C(Nc1ncnc2oc(-c3ccc(F)cc3)cc12)C1CC1,CHEMBL1137112,>,>,IC50,nM,19000.0,IC50,uM,19.0,O=C(Nc1ncnc2oc(-c3ccc(F)cc3)cc12)C1CC1,2004.0
Inhibition of cyclin-dependent kinase 2,O=C(Nc1ncnc2oc(-c3cccnc3)cc12)C1CC1,CHEMBL1137112,=,=,IC50,nM,440.0,IC50,uM,0.44,O=C(Nc1ncnc2oc(-c3cccnc3)cc12)C1CC1,2004.0
Inhibition of cyclin-dependent kinase 2,O=C(Nc1ncnc2oc(-c3ccccc3)cc12)C1CCCC1,CHEMBL1137112,>,>,IC50,nM,19000.0,IC50,uM,19.0,O=C(Nc1ncnc2oc(-c3ccccc3)cc12)C1CCCC1,2004.0
Inhibition of cyclin-dependent kinase 2,O=C(Nc1ncnc2oc(-c3ccc(Cl)cc3)cc12)C1CCCC1,CHEMBL1137112,>,>,IC50,nM,20000.0,IC50,uM,20.0,O=C(Nc1ncnc2oc(-c3ccc(Cl)cc3)cc12)C1CCCC1,2004.0
Inhibition of cyclin-dependent kinase 2,Cc1ccc(-c2cc3c(NC(=O)C4CCCC4)ncnc3o2)cc1,CHEMBL1137112,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1ccc(-c2cc3c(NC(=O)C4CCCC4)ncnc3o2)cc1,2004.0
Inhibition of cyclin-dependent kinase 2,O=C(Nc1ncnc2oc(-c3ccc(F)cc3)cc12)C1CCCC1,CHEMBL1137112,>,>,IC50,nM,19000.0,IC50,uM,19.0,O=C(Nc1ncnc2oc(-c3ccc(F)cc3)cc12)C1CCCC1,2004.0
Inhibition of cyclin-dependent kinase 2,O=C(Nc1ncnc2oc(-c3cccnc3)cc12)C1CCCC1,CHEMBL1137112,=,=,IC50,nM,450.0,IC50,uM,0.45,O=C(Nc1ncnc2oc(-c3cccnc3)cc12)C1CCCC1,2004.0
Inhibition of Cyclin dependent kinase 2,Cc1[nH]c(C(N)=O)c(C)c1-c1ccnc(Nc2ccc(F)cc2)n1,CHEMBL1137157,=,=,Ki,nM,80.0,Ki,uM,0.08,Cc1[nH]c(C(N)=O)c(C)c1-c1ccnc(Nc2ccc(F)cc2)n1,2004.0
Inhibition of Cyclin dependent kinase 2,Cc1[nH]c([N+](=O)[O-])c(C)c1-c1ccnc(Nc2ccc(F)cc2)n1,CHEMBL1137157,=,=,Ki,nM,30.0,Ki,uM,0.03,Cc1[nH]c([N+](=O)[O-])c(C)c1-c1ccnc(Nc2ccc(F)cc2)n1,2004.0
Inhibition of Cyclin dependent kinase 2,Cc1[nH]c(Cl)c(C)c1-c1ccnc(Nc2ccc(F)cc2)n1,CHEMBL1137157,=,=,Ki,nM,360.0,Ki,uM,0.36,Cc1[nH]c(Cl)c(C)c1-c1ccnc(Nc2ccc(F)cc2)n1,2004.0
Inhibition of Cyclin dependent kinase 2,Cc1[nH]c(Br)c(C)c1-c1ccnc(Nc2ccc(F)cc2)n1,CHEMBL1137157,=,=,Ki,nM,270.0,Ki,uM,0.27,Cc1[nH]c(Br)c(C)c1-c1ccnc(Nc2ccc(F)cc2)n1,2004.0
Inhibition of Cyclin dependent kinase 2,Cc1c[nH]c(C)c1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,CHEMBL1137157,=,=,Ki,nM,50.0,Ki,uM,0.05,Cc1c[nH]c(C)c1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,2004.0
Inhibition of Cyclin dependent kinase 2,Cc1[nH]c(C#N)c(C)c1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,CHEMBL1137157,=,=,Ki,nM,140.0,Ki,uM,0.14,Cc1[nH]c(C#N)c(C)c1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,2004.0
Inhibition of Cyclin dependent kinase 2,Cc1ccc(Nc2nccc(-c3c(C)[nH]c(C#N)c3C)n2)cc1[N+](=O)[O-],CHEMBL1137157,=,=,Ki,nM,50.0,Ki,uM,0.05,Cc1ccc(Nc2nccc(-c3c(C)[nH]c(C#N)c3C)n2)cc1[N+](=O)[O-],2004.0
Inhibition of Cyclin dependent kinase 2,Cc1[nH]c(C#N)c(C)c1-c1ccnc(Nc2ccc(O)cc2)n1,CHEMBL1137157,=,=,Ki,nM,50.0,Ki,uM,0.05,Cc1[nH]c(C#N)c(C)c1-c1ccnc(Nc2ccc(O)cc2)n1,2004.0
Inhibition of Cyclin dependent kinase 2,Cc1[nH]c(C#N)c(C)c1-c1ccnc(Nc2cccc(O)c2)n1,CHEMBL1137157,=,=,Ki,nM,30.0,Ki,uM,0.03,Cc1[nH]c(C#N)c(C)c1-c1ccnc(Nc2cccc(O)c2)n1,2004.0
Inhibition of Cyclin dependent kinase 2,Cc1ccc(Nc2nccc(-c3c(C)[nH]c(C#N)c3C)n2)cc1O,CHEMBL1137157,=,=,Ki,nM,130.0,Ki,uM,0.13,Cc1ccc(Nc2nccc(-c3c(C)[nH]c(C#N)c3C)n2)cc1O,2004.0
Inhibition of Cyclin dependent kinase 2,Cc1cc(Nc2nccc(-c3c(C)[nH]c(C#N)c3C)n2)ccc1F,CHEMBL1137157,=,=,Ki,nM,90.0,Ki,uM,0.09,Cc1cc(Nc2nccc(-c3c(C)[nH]c(C#N)c3C)n2)ccc1F,2004.0
Inhibition of Cyclin dependent kinase 2,Cc1[nH]c(C#N)c(C)c1-c1ccnc(Nc2ccc(F)cc2)n1,CHEMBL1137157,=,=,Ki,nM,100.0,Ki,uM,0.1,Cc1[nH]c(C#N)c(C)c1-c1ccnc(Nc2ccc(F)cc2)n1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1c(F)cccc1F,CHEMBL1138729,=,=,IC50,nM,122.0,IC50,nM,122.0,Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1c(F)cccc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3ccccc3)cn2c1C(=O)c1c(F)cccc1F,CHEMBL1138729,=,=,IC50,nM,1927.0,IC50,nM,1927.0,Nc1nc2ccc(C(=O)c3ccccc3)cn2c1C(=O)c1c(F)cccc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3ccccc3Cl)cn2c1C(=O)c1c(F)cccc1F,CHEMBL1138729,=,=,IC50,nM,428.0,IC50,nM,428.0,Nc1nc2ccc(C(=O)c3ccccc3Cl)cn2c1C(=O)c1c(F)cccc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3ccccc3C(F)(F)F)cn2c1C(=O)c1c(F)cccc1F,CHEMBL1138729,=,=,IC50,nM,1068.0,IC50,nM,1068.0,Nc1nc2ccc(C(=O)c3ccccc3C(F)(F)F)cn2c1C(=O)c1c(F)cccc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Cc1ccccc1C(=O)c1ccc2nc(N)c(C(=O)c3c(F)cccc3F)n2c1,CHEMBL1138729,=,=,IC50,nM,1294.0,IC50,nM,1294.0,Cc1ccccc1C(=O)c1ccc2nc(N)c(C(=O)c3c(F)cccc3F)n2c1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),COc1ccccc1C(=O)c1ccc2nc(N)c(C(=O)c3c(F)cccc3F)n2c1,CHEMBL1138729,=,=,IC50,nM,603.0,IC50,nM,603.0,COc1ccccc1C(=O)c1ccc2nc(N)c(C(=O)c3c(F)cccc3F)n2c1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3ccccc3OC(F)(F)F)cn2c1C(=O)c1c(F)cccc1F,CHEMBL1138729,=,=,IC50,nM,2171.0,IC50,nM,2171.0,Nc1nc2ccc(C(=O)c3ccccc3OC(F)(F)F)cn2c1C(=O)c1c(F)cccc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(Cl)cccc3Cl)cn2c1C(=O)c1c(F)cccc1F,CHEMBL1138729,=,=,IC50,nM,53.0,IC50,nM,53.0,Nc1nc2ccc(C(=O)c3c(Cl)cccc3Cl)cn2c1C(=O)c1c(F)cccc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(F)cccc3Cl)cn2c1C(=O)c1c(F)cccc1F,CHEMBL1138729,=,=,IC50,nM,33.0,IC50,nM,33.0,Nc1nc2ccc(C(=O)c3c(F)cccc3Cl)cn2c1C(=O)c1c(F)cccc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),C=C(c1ccc2nc(N)c(C(=O)c3c(F)cccc3F)n2c1)c1c(F)cccc1F,CHEMBL1138729,=,=,IC50,nM,63.0,IC50,nM,63.0,C=C(c1ccc2nc(N)c(C(=O)c3c(F)cccc3F)n2c1)c1c(F)cccc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),N#C/C=C(/c1ccc2nc(N)c(C(=O)c3c(F)cccc3F)n2c1)c1c(F)cccc1F,CHEMBL1138729,=,=,IC50,nM,160.0,IC50,nM,160.0,N#C/C=C(/c1ccc2nc(N)c(C(=O)c3c(F)cccc3F)n2c1)c1c(F)cccc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),N#C/C=C(\c1ccc2nc(N)c(C(=O)c3c(F)cccc3F)n2c1)c1c(F)cccc1F,CHEMBL1138729,=,=,IC50,nM,896.0,IC50,nM,896.0,N#C/C=C(\c1ccc2nc(N)c(C(=O)c3c(F)cccc3F)n2c1)c1c(F)cccc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(/C(=C/c3nn[nH]n3)c3c(F)cccc3F)cn2c1C(=O)c1c(F)cccc1F,CHEMBL1138729,=,=,IC50,nM,1691.0,IC50,nM,1691.0,Nc1nc2ccc(/C(=C/c3nn[nH]n3)c3c(F)cccc3F)cn2c1C(=O)c1c(F)cccc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1ccccc1,CHEMBL1138729,=,=,IC50,nM,324.0,IC50,nM,324.0,Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1ccccc1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),COc1ccccc1C(=O)c1c(N)nc2ccc(C(=O)c3c(F)cccc3F)cn12,CHEMBL1138729,=,=,IC50,nM,68.0,IC50,nM,68.0,COc1ccccc1C(=O)c1c(N)nc2ccc(C(=O)c3c(F)cccc3F)cn12,2004.0
Inhibitory activity against Cyclin-dependent kinase 2,Cc1cc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)nc(C)n1,CHEMBL1138725,>,>,IC50,nM,25000.0,IC50,uM,25.0,Cc1cc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)nc(C)n1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1c(F)cccc1Cl,CHEMBL1138729,=,=,IC50,nM,102.0,IC50,nM,102.0,Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1c(F)cccc1Cl,2004.0
Inhibition of human Cyclin-dependent kinase 2,CC(C)OC(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)C1,CHEMBL1138659,=,=,IC50,nM,3400.0,IC50,uM,3.4,CC(C)OC(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)C1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),COc1cc(F)c(C(=O)c2c(N)nc3ccc(C(=O)c4c(F)cccc4F)cn23)c(F)c1,CHEMBL1138729,=,=,IC50,nM,91.0,IC50,nM,91.0,COc1cc(F)c(C(=O)c2c(N)nc3ccc(C(=O)c4c(F)cccc4F)cn23)c(F)c1,2004.0
Inhibition of human Cyclin-dependent kinase 2,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCCCC1)CC2,CHEMBL1138659,=,=,IC50,nM,5400.0,IC50,uM,5.4,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCCCC1)CC2,2004.0
Inhibition of human Cyclin-dependent kinase 2,Cc1cc2c3c(c1)c(C1=C(c4cnc5ccccn45)C(=O)NC1=O)cn3CCN(C(=O)N1CCCCC1)C2,CHEMBL1138659,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1cc2c3c(c1)c(C1=C(c4cnc5ccccn45)C(=O)NC1=O)cn3CCN(C(=O)N1CCCCC1)C2,2004.0
Inhibition of human Cyclin-dependent kinase 2,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2,CHEMBL1138659,=,=,IC50,nM,5300.0,IC50,uM,5.3,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2,2004.0
Inhibition of human Cyclin-dependent kinase 2,CN(C)C(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)C1,CHEMBL1138659,=,=,IC50,nM,2100.0,IC50,uM,2.1,CN(C)C(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)C1,2004.0
Inhibition of human Cyclin-dependent kinase 2,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2,CHEMBL1138659,=,=,IC50,nM,2800.0,IC50,uM,2.8,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=S)c1ccccc1,CHEMBL1138729,=,=,IC50,nM,214.0,IC50,nM,214.0,Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=S)c1ccccc1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=S)c1c(F)cccc1F,CHEMBL1138729,=,=,IC50,nM,26.0,IC50,nM,26.0,Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=S)c1c(F)cccc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),COc1cc(F)c(C(=S)c2c(N)nc3ccc(C(=O)c4c(F)cccc4F)cn23)c(F)c1,CHEMBL1138729,=,=,IC50,nM,29.0,IC50,nM,29.0,COc1cc(F)c(C(=S)c2c(N)nc3ccc(C(=O)c4c(F)cccc4F)cn23)c(F)c1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(Cl)cccc3Cl)cn2c1C(=O)c1c(F)cc(O)cc1F,CHEMBL1138729,=,=,IC50,nM,52.0,IC50,nM,52.0,Nc1nc2ccc(C(=O)c3c(Cl)cccc3Cl)cn2c1C(=O)c1c(F)cc(O)cc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),CN(C)CCOc1cc(F)c(C(=O)c2c(N)nc3ccc(C(=O)c4c(Cl)cccc4Cl)cn23)c(F)c1,CHEMBL1138729,=,=,IC50,nM,984.0,IC50,nM,984.0,CN(C)CCOc1cc(F)c(C(=O)c2c(N)nc3ccc(C(=O)c4c(Cl)cccc4Cl)cn23)c(F)c1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),CN1CCN(CCOc2cc(F)c(C(=O)c3c(N)nc4ccc(C(=O)c5c(Cl)cccc5Cl)cn34)c(F)c2)CC1,CHEMBL1138729,=,=,IC50,nM,812.0,IC50,nM,812.0,CN1CCN(CCOc2cc(F)c(C(=O)c3c(N)nc4ccc(C(=O)c5c(Cl)cccc5Cl)cn34)c(F)c2)CC1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(Cl)cccc3Cl)cn2c1C(=O)c1c(F)cc(C(=O)O)cc1F,CHEMBL1138729,=,=,IC50,nM,95.0,IC50,nM,95.0,Nc1nc2ccc(C(=O)c3c(Cl)cccc3Cl)cn2c1C(=O)c1c(F)cc(C(=O)O)cc1F,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),COc1cccc(OC)c1C(=S)c1c(N)nc2ccc(C(=O)c3c(F)cccc3F)cn12,CHEMBL1138729,=,=,IC50,nM,462.0,IC50,nM,462.0,COc1cccc(OC)c1C(=S)c1c(N)nc2ccc(C(=O)c3c(F)cccc3F)cn12,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),NC(=O)c1cc(F)c(C(=O)c2c(N)nc3ccc(C(=O)c4c(Cl)cccc4Cl)cn23)c(F)c1,CHEMBL1138729,=,=,IC50,nM,46.0,IC50,nM,46.0,NC(=O)c1cc(F)c(C(=O)c2c(N)nc3ccc(C(=O)c4c(Cl)cccc4Cl)cn23)c(F)c1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1cccs1,CHEMBL1138729,=,=,IC50,nM,547.0,IC50,nM,547.0,Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1cccs1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1ccc(Cl)cc1,CHEMBL1138729,=,=,IC50,nM,1711.0,IC50,nM,1711.0,Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1ccc(Cl)cc1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1ccncc1,CHEMBL1138729,=,=,IC50,nM,2538.0,IC50,nM,2538.0,Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1ccncc1,2004.0
Inhibitory activity against Cyclin-dependent kinase 2 (CDK2),Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1c(Cl)cccc1Cl,CHEMBL1138729,=,=,IC50,nM,121.0,IC50,nM,121.0,Nc1nc2ccc(C(=O)c3c(F)cccc3F)cn2c1C(=O)c1c(Cl)cccc1Cl,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccc(F)c(F)c4)n3)c(-c3ccccc3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccc(F)c(F)c4)n3)c(-c3ccccc3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccc(Cl)c(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccc(Cl)c(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccccc3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccccc3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3cccc(C(F)(F)F)c3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3cccc(C(F)(F)F)c3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccc(F)c(F)c4)n3)c(-c3cccc(C(F)(F)F)c3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccc(F)c(F)c4)n3)c(-c3cccc(C(F)(F)F)c3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccc(Cl)c(C(F)(F)F)c4)n3)c(-c3cccc(C(F)(F)F)c3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccc(Cl)c(C(F)(F)F)c4)n3)c(-c3cccc(C(F)(F)F)c3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3cccc(C(F)(F)F)c3)nn2n1,CHEMBL1138749,=,=,Ki,nM,5000.0,Ki,uM,5.0,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3cccc(C(F)(F)F)c3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1138749,=,=,Ki,nM,5.0,Ki,uM,0.005,c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,CN(c1ccccc1)c1nccc(-c2cnn3ncccc23)n1,CHEMBL1138749,=,=,Ki,nM,19900.0,Ki,uM,19.9,CN(c1ccccc1)c1nccc(-c2cnn3ncccc23)n1,2004.0
Binding affinity for human cyclin-dependent kinase 2; ND= Not determined,Cc1ccccc1Nc1nccc(-c2cnn3ncccc23)n1,CHEMBL1138749,,,Ki,nM,,Ki,uM,,Cc1ccccc1Nc1nccc(-c2cnn3ncccc23)n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,CHEMBL1138749,=,=,Ki,nM,2.0,Ki,uM,0.002,COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,N#Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1138749,=,=,Ki,nM,1.0,Ki,uM,0.001,N#Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,O=[N+]([O-])c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1138749,=,=,Ki,nM,20.0,Ki,uM,0.02,O=[N+]([O-])c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1138749,=,=,Ki,nM,10.0,Ki,uM,0.01,CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,CCC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1138749,=,=,Ki,nM,150.0,Ki,uM,0.15,CCC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,CC(C)(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1138749,=,=,Ki,nM,150.0,Ki,uM,0.15,CC(C)(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1OC,CHEMBL1138749,=,=,Ki,nM,50.0,Ki,uM,0.05,COc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1OC,2004.0
Binding affinity for human cyclin-dependent kinase 2,c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCO5)n3)c2c1,CHEMBL1138749,=,=,Ki,nM,10.0,Ki,uM,0.01,c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCO5)n3)c2c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1,CHEMBL1138749,=,=,Ki,nM,6.0,Ki,uM,0.006,c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1F,CHEMBL1138749,=,=,Ki,nM,2.0,Ki,uM,0.002,Fc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1F,2004.0
Binding affinity for human cyclin-dependent kinase 2,c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCCO5)n3)c2c1,CHEMBL1138749,=,=,Ki,nM,6.0,Ki,uM,0.006,c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCCO5)n3)c2c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Clc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1Cl,CHEMBL1138749,=,=,Ki,nM,1.0,Ki,uM,0.001,Clc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1Cl,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1cc(Nc2nccc(-c3cnn4ncccc34)n2)ccc1Cl,CHEMBL1138749,=,=,Ki,nM,10.0,Ki,uM,0.01,FC(F)(F)c1cc(Nc2nccc(-c3cnn4ncccc34)n2)ccc1Cl,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1,CHEMBL1138749,=,=,Ki,nM,10.0,Ki,uM,0.01,COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(C(F)(F)F)c1,CHEMBL1138749,=,=,Ki,nM,10.0,Ki,uM,0.01,COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(C(F)(F)F)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1cc(Br)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,CHEMBL1138749,=,=,Ki,nM,10.0,Ki,uM,0.01,FC(F)(F)c1cc(Br)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1cc(F)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,CHEMBL1138749,=,=,Ki,nM,1.0,Ki,uM,0.001,Fc1cc(F)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Clc1cc(Cl)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,CHEMBL1138749,=,=,Ki,nM,310.0,Ki,uM,0.31,Clc1cc(Cl)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1cc(C)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,CHEMBL1138749,=,=,Ki,nM,3.0,Ki,uM,0.003,Cc1cc(C)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Oc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,CHEMBL1138749,=,=,Ki,nM,8.0,Ki,uM,0.008,Oc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,CHEMBL1138749,=,=,Ki,nM,160.0,Ki,uM,0.16,COc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,CHEMBL1138749,=,=,Ki,nM,1990.0,Ki,uM,1.99,CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,CCCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,CHEMBL1138749,=,=,Ki,nM,1260.0,Ki,uM,1.26,CCCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1cccc(Nc2nccc(-c3cnn4nc(OC)ccc34)n2)c1,CHEMBL1138749,=,=,Ki,nM,60.0,Ki,uM,0.06,COc1cccc(Nc2nccc(-c3cnn4nc(OC)ccc34)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1,CHEMBL1138749,=,=,Ki,nM,190.0,Ki,uM,0.19,COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1ccc2c(-c3ccnc(Nc4ccc(C#N)cc4)n3)cnn2n1,CHEMBL1138749,=,=,Ki,nM,500.0,Ki,uM,0.5,COc1ccc2c(-c3ccnc(Nc4ccc(C#N)cc4)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1ccc2c(-c3ccnc(Nc4ccc([N+](=O)[O-])cc4)n3)cnn2n1,CHEMBL1138749,=,=,Ki,nM,20.0,Ki,uM,0.02,COc1ccc2c(-c3ccnc(Nc4ccc([N+](=O)[O-])cc4)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1cc(Nc2nccc(-c3cnn4nc(OC)ccc34)n2)cc(OC)c1,CHEMBL1138749,=,=,Ki,nM,190.0,Ki,uM,0.19,COc1cc(Nc2nccc(-c3cnn4nc(OC)ccc34)n2)cc(OC)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1cc(Nc2nccc(-c3cnn4nc(OC)ccc34)n2)cc(C(F)(F)F)c1,CHEMBL1138749,=,=,Ki,nM,790.0,Ki,uM,0.79,COc1cc(Nc2nccc(-c3cnn4nc(OC)ccc34)n2)cc(C(F)(F)F)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1ccc2c(-c3ccnc(Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)cnn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,COc1ccc2c(-c3ccnc(Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)cnn2n1,CHEMBL1138749,=,=,Ki,nM,100.0,Ki,uM,0.1,COc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,CHEMBL1138749,=,=,Ki,nM,50.0,Ki,uM,0.05,Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccc(C(F)(F)F)cc4)n3)cnn2n1,CHEMBL1138749,=,=,Ki,nM,190.0,Ki,uM,0.19,Cc1ccc2c(-c3ccnc(Nc4ccc(C(F)(F)F)cc4)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1cc(Nc2nccc(-c3cnn4nc(C)ccc34)n2)cc(C(F)(F)F)c1,CHEMBL1138749,=,=,Ki,nM,20.0,Ki,uM,0.02,COc1cc(Nc2nccc(-c3cnn4nc(C)ccc34)n2)cc(C(F)(F)F)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)cnn2n1,CHEMBL1138749,=,=,Ki,nM,6.0,Ki,uM,0.006,Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)cnn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1,CHEMBL1138749,=,=,Ki,nM,2500.0,Ki,uM,2.5,FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,c1ccc(-c2ccc3c(-c4ccnc(Nc5ccc6c(c5)OCCO6)n4)cnn3n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,c1ccc(-c2ccc3c(-c4ccnc(Nc5ccc6c(c5)OCCO6)n4)cnn3n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,c1ccc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)cc1,CHEMBL1138749,=,=,Ki,nM,3980.0,Ki,uM,3.98,c1ccc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1cccc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)c1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,FC(F)(F)c1cccc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1ccc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)cc1F,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Fc1ccc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)cc1F,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1cc(F)cc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)c1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Fc1cc(F)cc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1cc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)ccc1Cl,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,FC(F)(F)c1cc(Nc2nccc(-c3c(-c4ccccc4)nn4ncccc34)n2)ccc1Cl,2004.0
Binding affinity for human cyclin-dependent kinase 2,c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)c1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1ccc(Nc2nccc(-c3c(-c4cccc(C(F)(F)F)c4)nn4ncccc34)n2)cc1F,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Fc1ccc(Nc2nccc(-c3c(-c4cccc(C(F)(F)F)c4)nn4ncccc34)n2)cc1F,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)c1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1cccc(Nc2nccc(-c3c(-c4ccc(Cl)cc4)nn4ncccc34)n2)c1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,FC(F)(F)c1cccc(Nc2nccc(-c3c(-c4ccc(Cl)cc4)nn4ncccc34)n2)c1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Fc1ccc(Nc2nccc(-c3c(-c4ccc(Cl)cc4)nn4ncccc34)n2)cc1F,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Fc1ccc(Nc2nccc(-c3c(-c4ccc(Cl)cc4)nn4ncccc34)n2)cc1F,2004.0
Binding affinity for human cyclin-dependent kinase 2,FC(F)(F)c1cc(Nc2nccc(-c3c(-c4ccc(Cl)cc4)nn4ncccc34)n2)ccc1Cl,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,FC(F)(F)c1cc(Nc2nccc(-c3c(-c4ccc(Cl)cc4)nn4ncccc34)n2)ccc1Cl,2004.0
Binding affinity for human cyclin-dependent kinase 2,Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccccc3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccccc3)nn2n1,2004.0
Binding affinity for human cyclin-dependent kinase 2,Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1,CHEMBL1138749,>,>,Ki,nM,19950.0,Ki,uM,19.95,Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1,2004.0
Inhibitory concentration against selected kinase CDK2,CCn1c(-c2nonc2N)nc2cnccc21,CHEMBL1139578,=,=,IC50,nM,169.0,IC50,nM,169.0,CCn1c(-c2nonc2N)nc2cnccc21,2005.0
Percent inhibition against CDK2 at 10 uM using 100 uM ATP,CCn1c(-c2nonc2N)nc2cnccc21,CHEMBL1139578,=,=,Inhibition,%,84.0,Inhibition,%,84.0,CCn1c(-c2nonc2N)nc2cnccc21,2005.0
Inhibitory concentration against selected kinase CDK2,CCn1c(-c2nonc2N)nc2cncc(CNC3CCNCC3)c21,CHEMBL1139578,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CCn1c(-c2nonc2N)nc2cncc(CNC3CCNCC3)c21,2005.0
Inhibition of Cyclin-dependent kinase 2,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,CHEMBL1144417,=,=,IC50,nM,10.0,IC50,uM,0.01,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,2005.0
Inhibition of Cyclin-dependent kinase 2,Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(OCC(O)CN(C)C)cc2)n1,CHEMBL1144417,=,=,IC50,nM,10.0,IC50,uM,0.01,Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(OCC(O)CN(C)C)cc2)n1,2005.0
Inhibition of Cyclin-dependent kinase 2,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1,CHEMBL1144417,=,=,IC50,nM,1000.0,IC50,uM,1.0,CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1,2005.0
Inhibition of Cyclin-dependent kinase 2,O=C1NC2C=CC=CC2/C1=C/Nc1ccc(S(=O)(=O)Nc2nccs2)cc1,CHEMBL1144417,=,=,IC50,nM,1000.0,IC50,uM,1.0,O=C1NC2C=CC=CC2/C1=C/Nc1ccc(S(=O)(=O)Nc2nccs2)cc1,2005.0
Inhibition of human cyclin-dependent kinase 2,CONC(=O)c1cc(Nc2ncnn3cc(NC(=O)OCCCS(C)(=O)=O)c(C(C)C)c23)c(F)cc1F,CHEMBL1144449,>,>,IC50,nM,50000.0,IC50,uM,50.0,CONC(=O)c1cc(Nc2ncnn3cc(NC(=O)OCCCS(C)(=O)=O)c(C(C)C)c23)c(F)cc1F,2005.0
Inhibition of human cyclin-dependent kinase 2,CONC(=O)c1cc(Nc2ncnn3cc(NC(=O)OCC4CCCO4)c(C(C)C)c23)c(F)cc1F,CHEMBL1144449,>,>,IC50,nM,50000.0,IC50,uM,50.0,CONC(=O)c1cc(Nc2ncnn3cc(NC(=O)OCC4CCCO4)c(C(C)C)c23)c(F)cc1F,2005.0
Inhibition of human cyclin-dependent kinase 2,CONC(=O)c1cc(Nc2ncnn3cc(-c4nnc(C)o4)c(C(C)C)c23)c(F)cc1F,CHEMBL1144449,>,>,IC50,nM,50000.0,IC50,uM,50.0,CONC(=O)c1cc(Nc2ncnn3cc(-c4nnc(C)o4)c(C(C)C)c23)c(F)cc1F,2005.0
Inhibition of human cyclin-dependent kinase 2,CONC(=O)c1cc(Nc2ncnn3cc(-c4nnc(C(F)F)o4)c(C(C)C)c23)c(F)cc1F,CHEMBL1144449,>,>,IC50,nM,50000.0,IC50,uM,50.0,CONC(=O)c1cc(Nc2ncnn3cc(-c4nnc(C(F)F)o4)c(C(C)C)c23)c(F)cc1F,2005.0
Inhibition of human cyclin-dependent kinase 2,CONC(=O)c1cc(Nc2ncnn3cc(-c4nnc(C(F)(F)S(C)(=O)=O)o4)c(C(C)C)c23)c(F)cc1F,CHEMBL1144449,>,>,IC50,nM,50000.0,IC50,uM,50.0,CONC(=O)c1cc(Nc2ncnn3cc(-c4nnc(C(F)(F)S(C)(=O)=O)o4)c(C(C)C)c23)c(F)cc1F,2005.0
Inhibition of cyclin-dependent kinase 2,O=C(Nc1ccc(Cl)c(COc2cccnc2)c1)c1cc(F)cc(N2CCOCC2)c1,CHEMBL1141173,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(Nc1ccc(Cl)c(COc2cccnc2)c1)c1cc(F)cc(N2CCOCC2)c1,2005.0
Binding affinity for cyclin-dependent kinase 2,Nc1cncc(Cl)n1,CHEMBL1141172,=,=,Affinity,uM,350.0,Affinity,uM,350.0,Nc1cncc(Cl)n1,2005.0
Selectivity for Cyclin-dependent kinase 2 by scintillation proximity assay,CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccn4)c3)o2)c1,CHEMBL1142709,=,=,Selectivity,uM,1.7,Selectivity,uM,1.7,CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccn4)c3)o2)c1,2005.0
Selectivity for Cyclin-dependent kinase 2 by scintillation proximity assay; No data,CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1,CHEMBL1142709,,,Selectivity,,,Selectivity,uM,,CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1,2005.0
Selectivity for Cyclin-dependent kinase 2 by scintillation proximity assay; No data,CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4Cl)c3)o2)c1,CHEMBL1142709,,,Selectivity,,,Selectivity,uM,,CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4Cl)c3)o2)c1,2005.0
In vitro inhibitory concentration against cyclin-dependent kinase 2,CN(C)S(=O)(=O)c1ccc(Nc2ccc(C(=O)c3c(F)cccc3F)c(N)n2)cc1,CHEMBL1144370,=,=,IC50,nM,500.0,IC50,uM,0.5,CN(C)S(=O)(=O)c1ccc(Nc2ccc(C(=O)c3c(F)cccc3F)c(N)n2)cc1,2005.0
In vitro inhibitory concentration against cyclin-dependent kinase 2,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)ccc1C(=O)c1c(F)cccc1F,CHEMBL1144370,=,=,IC50,nM,180.0,IC50,uM,0.18,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)ccc1C(=O)c1c(F)cccc1F,2005.0
In vitro inhibitory concentration against cyclin-dependent kinase 2,CCCCOc1cc(Nc2ccc(S(N)(=O)=O)cc2)nc(N)c1C(=O)c1c(F)cccc1F,CHEMBL1144370,=,=,IC50,nM,84.0,IC50,uM,0.084,CCCCOc1cc(Nc2ccc(S(N)(=O)=O)cc2)nc(N)c1C(=O)c1c(F)cccc1F,2005.0
Inhibitory concentration against CDK2,Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc(NC2CCCC2)c1C#N,CHEMBL1141103,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc(NC2CCCC2)c1C#N,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,CHEMBL1144455,,,Kd,,,Kd,,,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,CHEMBL1144455,,,Kd,,,Kd,,,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,CHEMBL1144455,,,Kd,,,Kd,,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,CHEMBL1144455,,,Kd,,,Kd,,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,CHEMBL1144455,,,Kd,,,Kd,,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,CHEMBL1144455,,,Kd,,,Kd,,,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,CHEMBL1144455,,,Kd,,,Kd,,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL1144455,=,=,Kd,nM,2900.0,Kd,uM,2.9,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1144455,=,=,Kd,nM,200.0,Kd,uM,0.2,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1144455,=,=,Kd,nM,8.1,Kd,uM,0.0081,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1144455,,,Kd,,,Kd,,,Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1144455,,,Kd,,,Kd,,,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,CHEMBL1144455,,,Kd,,,Kd,,,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,CHEMBL1144455,,,Kd,,,Kd,,,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,Oc1c2ccccc2c2c3c(cccc13)N=N2,CHEMBL1144455,=,=,Kd,nM,3200.0,Kd,uM,3.2,Oc1c2ccccc2c2c3c(cccc13)N=N2,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CHEMBL1144455,,,Kd,,,Kd,,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,CHEMBL1144455,,,Kd,,,Kd,,,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,CHEMBL1144455,,,Kd,,,Kd,,,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,CHEMBL1144455,,,Kd,,,Kd,,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,2005.0
Average Binding Constant for CDK2; NA=Not Active at 10 uM,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,CHEMBL1144455,,,Kd,,,Kd,,,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,2005.0
Inhibitory activity against CDK2,COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2,CHEMBL1140423,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2,2005.0
Inhibitory activity against CDK2,NC1=NONC1N1N=NC(C(=O)N/N=C/c2ccncc2)C1CN1CCCCC1,CHEMBL1141936,=,=,IC50,nM,96000.0,IC50,uM,96.0,NC1=NONC1N1N=NC(C(=O)N/N=C/c2ccncc2)C1CN1CCCCC1,2005.0
Inhibitory activity against CDK2,NC1=NONC1N1N=NC(c2n[nH]c(-c3ccncc3)n2)C1CN1CCCCC1,CHEMBL1141936,>,>,IC50,nM,250000.0,IC50,uM,250.0,NC1=NONC1N1N=NC(c2n[nH]c(-c3ccncc3)n2)C1CN1CCCCC1,2005.0
Inhibition of CDK2 at 10 uM,CN1C(=O)C(C(=O)Nc2nncs2)c2cc3occc3cc21,CHEMBL1147762,=,=,Inhibition,%,2.0,Inhibition,%,2.0,CN1C(=O)C(C(=O)Nc2nncs2)c2cc3occc3cc21,2006.0
Inhibitory activity against CDK2,COc1cc2c(Nc3ncc(CC(=O)Nc4cccc(F)c4)s3)ncnc2cc1OCCCN1CCC(CO)CC1,CHEMBL1149372,=,=,IC50,nM,62000.0,IC50,uM,62.0,COc1cc2c(Nc3ncc(CC(=O)Nc4cccc(F)c4)s3)ncnc2cc1OCCCN1CCC(CO)CC1,2006.0
Inhibition of CDK2 using 100 uM ATP,Brc1cccc(-c2cc(NCc3ccncc3)n3nccc3n2)c1,CHEMBL1138980,=,=,IC50,nM,1800.0,IC50,uM,1.8,Brc1cccc(-c2cc(NCc3ccncc3)n3nccc3n2)c1,2006.0
Inhibition of CDK2 using 100 uM ATP,N[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)c4ccccc4)cc3)n3ncnc3n2)CC1,CHEMBL1138980,=,=,IC50,nM,260.0,IC50,uM,0.26,N[C@H]1CC[C@H](Nc2cc(Nc3ccc(S(=O)(=O)c4ccccc4)cc3)n3ncnc3n2)CC1,2006.0
Inhibition of CDK2 using 100 uM ATP,CS(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3ncnn23)cc1,CHEMBL1138980,=,=,IC50,nM,250.0,IC50,uM,0.25,CS(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3ncnn23)cc1,2006.0
Inhibition of CDK2 using 100 uM ATP,CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3ncnn23)cc1,CHEMBL1138980,=,=,IC50,nM,120.0,IC50,uM,0.12,CN(C)S(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3ncnn23)cc1,2006.0
Inhibition of CDK2 using 100 uM ATP,NS(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3ncnn23)cc1,CHEMBL1138980,=,=,IC50,nM,270.0,IC50,uM,0.27,NS(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3ncnn23)cc1,2006.0
Inhibition of CDK2 using 100 uM ATP,CCN(CC)c1cc(Nc2ccc(S(N)(=O)=O)cc2)n2ncnc2n1,CHEMBL1138980,=,=,IC50,nM,400.0,IC50,uM,0.4,CCN(CC)c1cc(Nc2ccc(S(N)(=O)=O)cc2)n2ncnc2n1,2006.0
Inhibition of CDK2 using 100 uM ATP,NS(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](O)CC3)nc3ncnn23)cc1,CHEMBL1138980,=,=,IC50,nM,7400.0,IC50,uM,7.4,NS(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](O)CC3)nc3ncnn23)cc1,2006.0
Inhibition of CDK2 using 100 uM ATP,NS(=O)(=O)c1ccc(Nc2cc(NC3CCCCC3)nc3ncnn23)cc1,CHEMBL1138980,=,=,IC50,nM,730.0,IC50,uM,0.73,NS(=O)(=O)c1ccc(Nc2cc(NC3CCCCC3)nc3ncnn23)cc1,2006.0
Inhibition of CDK2 using 100 uM ATP,NS(=O)(=O)c1ccc(Nc2cc(OC3CCCCC3)nc3ncnn23)cc1,CHEMBL1138980,=,=,IC50,nM,350.0,IC50,uM,0.35,NS(=O)(=O)c1ccc(Nc2cc(OC3CCCCC3)nc3ncnn23)cc1,2006.0
Inhibition of CDK2 using 100 uM ATP,NS(=O)(=O)c1ccc(Nc2cc(OCC3CCCCC3)nc3ncnn23)cc1,CHEMBL1138980,=,=,IC50,nM,11000.0,IC50,uM,11.0,NS(=O)(=O)c1ccc(Nc2cc(OCC3CCCCC3)nc3ncnn23)cc1,2006.0
Inhibition of CDK2 using 100 uM ATP,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1138980,=,=,IC50,nM,80.0,IC50,nM,80.0,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Inhibition of CDK2 using 100 uM ATP,Brc1cccc(-c2cc(NCc3ccncc3)n3ncnc3n2)c1,CHEMBL1138980,=,=,IC50,nM,26000.0,IC50,uM,26.0,Brc1cccc(-c2cc(NCc3ccncc3)n3ncnc3n2)c1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Cl)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Cl)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Cc3ccccc3)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Cc3ccccc3)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Oc3ccccc3)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Oc3ccccc3)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(-c3ccccc3)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(-c3ccccc3)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Br)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Br)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(NCc2ccc3c(c2)OCO3)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(NCc2ccc3c(c2)OCO3)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cc1ccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)c(F)c1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cc1ccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)c(F)c1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Cl)c(C(F)(F)F)c2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Cl)c(C(F)(F)F)c2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,COc1ccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)cc1OC,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,COc1ccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)cc1OC,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Cl)c(Cl)c2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Cl)c(Cl)c2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cc1ccccc1Nc1nnc(-c2c(NCc3ccncc3)ncn2C)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cc1ccccc1Nc1nnc(-c2c(NCc3ccncc3)ncn2C)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,COc1ccccc1Nc1nnc(-c2c(NCc3ccncc3)ncn2C)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,COc1ccccc1Nc1nnc(-c2c(NCc3ccncc3)ncn2C)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,COc1cccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)c1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,COc1cccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)c1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cc1cccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)c1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cc1cccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)c1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2cccc(OC(F)(F)F)c2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2cccc(OC(F)(F)F)c2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(C(F)(F)F)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(C(F)(F)F)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(OC(F)(F)F)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(OC(F)(F)F)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(OC(F)(F)Cl)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(OC(F)(F)Cl)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,CC(C)c1ccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)cc1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,CC(C)c1ccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)cc1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(C(C)(C)C)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(C(C)(C)C)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2cccc3ncccc23)c1-c1nnc(Nc2ccc(Cl)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2cccc3ncccc23)c1-c1nnc(Nc2ccc(Cl)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccc3ccccc3n2)c1-c1nnc(Nc2ccc(Cl)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccc3ccccc3n2)c1-c1nnc(Nc2ccc(Cl)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccc3[nH]ncc3c2)c1-c1nnc(Nc2ccc(Cl)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccc3[nH]ncc3c2)c1-c1nnc(Nc2ccc(Cl)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccc(F)c(F)c2)c1-c1nnc(Nc2ccc(Cl)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccc(F)c(F)c2)c1-c1nnc(Nc2ccc(Cl)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCCc2ccc3c(c2)OCO3)c1-c1nnc(Nc2ccc(Cl)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCCc2ccc3c(c2)OCO3)c1-c1nnc(Nc2ccc(Cl)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2ccccn2)c1-c1nnc(Nc2ccc(Cl)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2ccccn2)c1-c1nnc(Nc2ccc(Cl)cc2)o1,2006.0
Protective index against Cdk2 at 10 uM by HTRF method,Cn1cnc(NCc2cccnc2)c1-c1nnc(Nc2ccc(Cl)cc2)o1,CHEMBL1139649,<,<,Activity,%,30.0,Activity,%,30.0,Cn1cnc(NCc2cccnc2)c1-c1nnc(Nc2ccc(Cl)cc2)o1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,c1ccc(-c2ccc(Nc3nnc(-c4cccnc4CCc4ccncc4)o3)cc2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,c1ccc(-c2ccc(Nc3nnc(-c4cccnc4CCc4ccncc4)o3)cc2)cc1,2006.0
Inhibition of CDK2 at 10 uM,c1cnc(CCc2ccncc2)c(-c2nnc(NCc3ccc4c(c3)OCO4)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,c1cnc(CCc2ccncc2)c(-c2nnc(NCc3ccc4c(c3)OCO4)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,Cc1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1C(F)(F)F,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,Cc1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1C(F)(F)F,2006.0
Inhibition of CDK2 at 10 uM,COc1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1OC,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,COc1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1OC,2006.0
Inhibition of CDK2 at 10 uM,Clc1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1Cl,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,Clc1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1Cl,2006.0
Inhibition of CDK2 at 10 uM,Cc1ccccc1Nc1nnc(-c2cccnc2CCc2ccncc2)o1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,Cc1ccccc1Nc1nnc(-c2cccnc2CCc2ccncc2)o1,2006.0
Inhibition of CDK2 at 10 uM,COc1ccccc1Nc1nnc(-c2cccnc2CCc2ccncc2)o1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,COc1ccccc1Nc1nnc(-c2cccnc2CCc2ccncc2)o1,2006.0
Inhibition of CDK2 at 10 uM,COc1cccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,COc1cccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,Cc1cccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,Cc1cccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)Oc1cccc(Nc2nnc(-c3cnccc3CCc3ccncc3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)Oc1cccc(Nc2nnc(-c3cnccc3CCc3ccncc3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)Oc1cccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)Oc1cccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)Oc1cccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)Oc1cccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1ccc(Nc2nnc(-c3cnccc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1ccc(Nc2nnc(-c3cnccc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)Oc1ccc(Nc2nnc(-c3cnccc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)Oc1ccc(Nc2nnc(-c3cnccc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(Cl)Oc1ccc(Nc2nnc(-c3cnccc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(Cl)Oc1ccc(Nc2nnc(-c3cnccc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1ccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1ccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)Oc1ccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)Oc1ccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(Cl)Oc1ccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(Cl)Oc1ccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)Oc1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)Oc1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(Cl)Oc1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(Cl)Oc1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,CC(C)(C)c1ccc(Nc2nnc(-c3cc4ccccc4nc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,CC(C)(C)c1ccc(Nc2nnc(-c3cc4ccccc4nc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,CC(C)(C)c1ccc(Nc2nnc(-c3cnccc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,CC(C)(C)c1ccc(Nc2nnc(-c3cnccc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,CC(C)c1ccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,CC(C)c1ccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,CC(C)(C)c1ccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,CC(C)(C)c1ccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,CC(C)c1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,CC(C)c1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,CC(C)(C)c1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,CC(C)(C)c1ccc(Nc2nnc(-c3cccnc3CCc3ccncc3)o2)cc1,2006.0
Inhibition of CDK2 at 10 uM,c1ccc2ncc(Nc3nnc(-c4cc5ccccc5nc4CCc4ccncc4)o3)cc2c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,c1ccc2ncc(Nc3nnc(-c4cc5ccccc5nc4CCc4ccncc4)o3)cc2c1,2006.0
Inhibition of CDK2 at 10 uM,c1cnc(CCc2ccncc2)c(-c2nnc(Nc3cnc4ccccc4c3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,c1cnc(CCc2ccncc2)c(-c2nnc(Nc3cnc4ccccc4c3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCc3cccc4ncccc34)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCc3cccc4ncccc34)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCc3ccc4ccccc4n3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCc3ccc4ccccc4n3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCc3ccc4[nH]ncc4c3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCc3ccc4[nH]ncc4c3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1cccc(Nc2nnc(-c3ccncc3CCCc3ccc4c(c3)OCO4)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1cccc(Nc2nnc(-c3ccncc3CCCc3ccc4c(c3)OCO4)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,Fc1ccc(CCc2ncccc2-c2nnc(Nc3cccc(C(F)(F)F)c3)o2)cc1F,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,Fc1ccc(CCc2ncccc2-c2nnc(Nc3cccc(C(F)(F)F)c3)o2)cc1F,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCCc3ccc4c(c3)OCO4)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCCc3ccc4c(c3)OCO4)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCc3ccccn3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCc3ccccn3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCc3cccnc3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1cccc(Nc2nnc(-c3cccnc3CCc3cccnc3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1cccc(Nc2nnc(-c3cc4ccccc4nc3CCc3ccncc3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1cccc(Nc2nnc(-c3cc4ccccc4nc3CCc3ccncc3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1cccc(Nc2nnc(-c3cnccc3CCc3ccncc3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1cccc(Nc2nnc(-c3cnccc3CCc3ccncc3)o2)c1,2006.0
Inhibition of CDK2 at 10 uM,FC(F)(F)c1cccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)c1,CHEMBL1146931,>,>,PI,%,30.0,PI,%,30.0,FC(F)(F)c1cccc(Nc2nnc(-c3ccncc3CCc3ccncc3)o2)c1,2006.0
Inhibition of CDK2,CCOc1nc(NC(C)=O)cc(N)c1C#N,CHEMBL1148638,>,>,Ki,nM,8600.0,Ki,nM,8600.0,CCOc1nc(NC(C)=O)cc(N)c1C#N,2006.0
Inhibition of CDK2,CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl,CHEMBL1148638,>,>,Ki,nM,8600.0,Ki,nM,8600.0,CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl,2006.0
Inhibition of CDK2,COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1,CHEMBL1148638,>,>,Ki,nM,8600.0,Ki,nM,8600.0,COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1,2006.0
Inhibition of CDK2,CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N,CHEMBL1148638,>,>,Ki,nM,8600.0,Ki,nM,8600.0,CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N,2006.0
Inhibition of CDK2,CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N,CHEMBL1148638,=,=,Ki,nM,820.0,Ki,nM,820.0,CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N,2006.0
Inhibition of CDK2,CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1,CHEMBL1148638,=,=,Ki,nM,1300.0,Ki,nM,1300.0,CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1,2006.0
Inhibition of Cdk2,COc1cc(C)c(Sc2cnc(NC(=O)c3ccc(CNC(C)C(C)(C)C)cc3)s2)cc1C(=O)N1CCN(C(C)=O)CC1,CHEMBL1138957,=,=,IC50,nM,29000.0,IC50,uM,29.0,COc1cc(C)c(Sc2cnc(NC(=O)c3ccc(CNC(C)C(C)(C)C)cc3)s2)cc1C(=O)N1CCN(C(C)=O)CC1,2006.0
Inhibition of CDK2,Cc1cc(-c2cnc(Nc3cnc(CN4CCN(C)CC4)cn3)s2)nc(OC2CCCCC2)n1,CHEMBL1137419,=,=,IC50,nM,1700.0,IC50,nM,1700.0,Cc1cc(-c2cnc(Nc3cnc(CN4CCN(C)CC4)cn3)s2)nc(OC2CCCCC2)n1,2006.0
Inhibition of CDK2,Cc1cc(-c2cnc(Nc3ccccn3)s2)nc(OC2CCCCC2)n1,CHEMBL1137419,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1cc(-c2cnc(Nc3ccccn3)s2)nc(OC2CCCCC2)n1,2006.0
Inhibition of CDK2,Cc1cnc(OC2CCCCC2)nc1-c1cnc(Nc2ccccn2)s1,CHEMBL1137419,=,=,IC50,nM,270.0,IC50,nM,270.0,Cc1cnc(OC2CCCCC2)nc1-c1cnc(Nc2ccccn2)s1,2006.0
Inhibition of CDK2,c1ccc(Nc2ncc(-c3ccnc(OC4CCCCC4)n3)s2)nc1,CHEMBL1137419,=,=,IC50,nM,14.0,IC50,nM,14.0,c1ccc(Nc2ncc(-c3ccnc(OC4CCCCC4)n3)s2)nc1,2006.0
Inhibition of CDK2,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,CHEMBL1138960,=,=,IC50,nM,2.0,IC50,nM,2.0,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,2006.0
Inhibition of CDK2,Nc1nc(Nc2ccc(S(=O)(=O)NC(=O)[C@H](N)CO)cc2)nn1C(=O)c1c(F)cccc1F,CHEMBL1138960,=,=,IC50,nM,140.0,IC50,uM,0.14,Nc1nc(Nc2ccc(S(=O)(=O)NC(=O)[C@H](N)CO)cc2)nn1C(=O)c1c(F)cccc1F,2006.0
Inhibition of CDK2,CCOC(=O)CCC(=O)NS(=O)(=O)c1ccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)cc1,CHEMBL1138960,=,=,IC50,nM,62.0,IC50,uM,0.062,CCOC(=O)CCC(=O)NS(=O)(=O)c1ccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)cc1,2006.0
Inhibition of CDK2,COCCOCC(=O)NS(=O)(=O)c1ccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)cc1,CHEMBL1138960,=,=,IC50,nM,247.0,IC50,uM,0.247,COCCOCC(=O)NS(=O)(=O)c1ccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)cc1,2006.0
Inhibition of CDK2,NCC(=O)NS(=O)(=O)c1ccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)cc1,CHEMBL1138960,=,=,IC50,nM,120.0,IC50,uM,0.12,NCC(=O)NS(=O)(=O)c1ccc(Nc2nc(N)n(C(=O)c3c(F)cccc3F)n2)cc1,2006.0
Inhibition of CDK2,CN1CCN(CCC(=O)NS(=O)(=O)c2ccc(Nc3nc(N)n(C(=O)c4c(F)cccc4F)n3)cc2)CC1,CHEMBL1138960,=,=,IC50,nM,266.0,IC50,uM,0.266,CN1CCN(CCC(=O)NS(=O)(=O)c2ccc(Nc3nc(N)n(C(=O)c4c(F)cccc4F)n3)cc2)CC1,2006.0
Inhibition of CDK2,Nc1nc(Nc2ccc(S(=O)(=O)NC(=O)CCC(=O)O)cc2)nn1C(=O)c1c(F)cccc1F,CHEMBL1138960,=,=,IC50,nM,71.0,IC50,uM,0.071,Nc1nc(Nc2ccc(S(=O)(=O)NC(=O)CCC(=O)O)cc2)nn1C(=O)c1c(F)cccc1F,2006.0
Inhibition of CDK2,Nc1nc(Nc2ccc(S(=O)(=O)NC(=O)CCN3CCOCC3)cc2)nn1C(=O)c1c(F)cccc1F,CHEMBL1138960,=,=,IC50,nM,118.0,IC50,uM,0.118,Nc1nc(Nc2ccc(S(=O)(=O)NC(=O)CCN3CCOCC3)cc2)nn1C(=O)c1c(F)cccc1F,2006.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12,CHEMBL1137422,=,=,Ki,nM,46.0,Ki,nM,46.0,Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12,2006.0
Inhibition of CDK2,CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl,CHEMBL1138045,>,>,Ki,nM,8600.0,Ki,uM,8.6,CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl,2006.0
Inhibition of CDK2,O=C(NC1CC1)c1cc(NCc2cnc(Nc3ccccn3)s2)c(F)cc1F,CHEMBL1138058,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(NC1CC1)c1cc(NCc2cnc(Nc3ccccn3)s2)c(F)cc1F,2006.0
Inhibition of CDK2,COc1ccc(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)cc1OC,CHEMBL1138058,=,=,IC50,nM,50.0,IC50,nM,50.0,COc1ccc(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)cc1OC,2006.0
Inhibition of CDK2,COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3cc(OC)c(OCCCN4CCN(C)CC4)c(OC)c3)n2)c(OC)c1,CHEMBL1145338,>,>,IC50,nM,40000.0,IC50,uM,40.0,COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3cc(OC)c(OCCCN4CCN(C)CC4)c(OC)c3)n2)c(OC)c1,2006.0
Inhibition of CDK2,NC(=O)c1ccc(Nc2nc(N)c(N=O)c(OCC3CCCCC3)n2)cc1,CHEMBL1146006,=,=,Ki,nM,2400.0,Ki,uM,2.4,NC(=O)c1ccc(Nc2nc(N)c(N=O)c(OCC3CCCCC3)n2)cc1,2006.0
Inhibition of CDK2,Nc1nc(OCC2CCCCC2)c2nc[nH]c2n1,CHEMBL1146006,=,=,Ki,nM,1200.0,Ki,uM,1.2,Nc1nc(OCC2CCCCC2)c2nc[nH]c2n1,2006.0
Inhibition of CDK2,CC(C)c1nnc2ccc(-c3ocnc3-c3ccc(F)cc3Cl)cn12,CHEMBL1145312,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(C)c1nnc2ccc(-c3ocnc3-c3ccc(F)cc3Cl)cn12,2006.0
Inhibition of CDK2,CC(C)c1nnc2ccc(-c3ocnc3-c3cc(F)c(F)cc3F)cn12,CHEMBL1145312,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(C)c1nnc2ccc(-c3ocnc3-c3cc(F)c(F)cc3F)cn12,2006.0
Inhibition of CDK2,CCNc1nnc2ccc(-c3ocnc3-c3ccc(F)cc3)cn12,CHEMBL1145312,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCNc1nnc2ccc(-c3ocnc3-c3ccc(F)cc3)cn12,2006.0
Inhibition of CDK2,CC(C)(C)c1nnc2ccc(-c3ocnc3-c3ccc(F)cc3F)cn12,CHEMBL1145312,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(C)(C)c1nnc2ccc(-c3ocnc3-c3ccc(F)cc3F)cn12,2006.0
Inhibition of CDK2,CC(C)(C)c1nnc2ccc(-c3ocnc3-c3cc(F)c(F)cc3F)cn12,CHEMBL1145312,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(C)(C)c1nnc2ccc(-c3ocnc3-c3cc(F)c(F)cc3F)cn12,2006.0
Inhibition of CDK2,CC(C)c1nnc2ccc(-c3c[nH]nc3-c3cc(F)ccc3F)cn12,CHEMBL1145312,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(C)c1nnc2ccc(-c3c[nH]nc3-c3cc(F)ccc3F)cn12,2006.0
Inhibition of CDK2,CC(C)c1nnc2ccc(-c3ocnc3-c3ccccc3)cn12,CHEMBL1145312,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(C)c1nnc2ccc(-c3ocnc3-c3ccccc3)cn12,2006.0
Ratio of IC50 for CDK4 to CDK2/CycA3,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1149496,=,=,Ratio IC50,,200.0,Ratio IC50,,200.0,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Ratio of IC50 for CDK2 F82H/L83V/H84D/K89T mutant/CycA3 to CDK2/CycA3,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1149496,=,=,Ratio IC50,,15.0,Ratio IC50,,15.0,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Ratio of IC50 for CDK2 F82H/L83V/H84D mutant/CycA3 to CDK2/CycA3,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1149496,=,=,Ratio IC50,,13.0,Ratio IC50,,13.0,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Ratio of IC50 for CDK2 F82H mutant/CycA3 to CDK2/CycA3,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1149496,=,=,Ratio IC50,,4.0,Ratio IC50,,4.0,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Ratio of IC50 for CDK2 L83V/H84D mutant/CycA3 to CDK2/CycA3,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1149496,=,=,Ratio IC50,,3.0,Ratio IC50,,3.0,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Ratio of IC50 for CDK2 K89T mutant/CycA3 to CDK2/CycA3,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1149496,=,=,Ratio IC50,,1.0,Ratio IC50,,1.0,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Inhibition of CDK2 F82H/L83V/H84D/K89T mutant/CycA3,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1149496,=,=,IC50,nM,120.0,IC50,nM,120.0,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Inhibition of CDK2 F82H/L83V/H84D mutant/CycA3,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1149496,=,=,IC50,nM,103.0,IC50,nM,103.0,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Inhibition of CDK2 F82H mutant/CycA3,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1149496,=,=,IC50,nM,33000.0,IC50,uM,33.0,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Inhibition of CDK2 L83V/H84D mutant/CycA3,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1149496,=,=,IC50,nM,21000.0,IC50,uM,21.0,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Inhibition of CDK2 K89T mutant/CycA3,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1149496,=,=,IC50,nM,8.9,IC50,nM,8.9,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Inhibition of CDK2/CycA3,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1149496,=,=,IC50,nM,8.1,IC50,nM,8.1,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2006.0
Inhibition of CDK2 K89T mutant/CycA3,Cc1ccc(Cl)c(N(CC#N)c2cc(Nc3ccc(OC[C@@H](O)CN(C)C)cc3)ncn2)c1,CHEMBL1149496,=,=,IC50,nM,140.0,IC50,uM,0.14,Cc1ccc(Cl)c(N(CC#N)c2cc(Nc3ccc(OC[C@@H](O)CN(C)C)cc3)ncn2)c1,2006.0
Inhibition of CDK2 F82H/L83V/H84D mutant/CycA3,Cc1ccc(Cl)c(N(CC#N)c2cc(Nc3ccc(OC[C@@H](O)CN(C)C)cc3)ncn2)c1,CHEMBL1149496,=,=,IC50,nM,7300.0,IC50,uM,7.3,Cc1ccc(Cl)c(N(CC#N)c2cc(Nc3ccc(OC[C@@H](O)CN(C)C)cc3)ncn2)c1,2006.0
Inhibition of CDK2 F82H/L83V/H84D/K89T mutant/CycA3,Cc1ccc(Cl)c(N(CC#N)c2cc(Nc3ccc(OC[C@@H](O)CN(C)C)cc3)ncn2)c1,CHEMBL1149496,=,=,IC50,nM,640.0,IC50,uM,0.64,Cc1ccc(Cl)c(N(CC#N)c2cc(Nc3ccc(OC[C@@H](O)CN(C)C)cc3)ncn2)c1,2006.0
Inhibition of CDK2 L83V/H84D mutant/CycA3,Cc1ccc(Cl)c(N(CC#N)c2cc(Nc3ccc(OC[C@@H](O)CN(C)C)cc3)ncn2)c1,CHEMBL1149496,,,IC50,,,IC50,,,Cc1ccc(Cl)c(N(CC#N)c2cc(Nc3ccc(OC[C@@H](O)CN(C)C)cc3)ncn2)c1,2006.0
Inhibition of CDK2 F82H mutant/CycA3,Cc1ccc(Cl)c(N(CC#N)c2cc(Nc3ccc(OC[C@@H](O)CN(C)C)cc3)ncn2)c1,CHEMBL1149496,,,IC50,,,IC50,,,Cc1ccc(Cl)c(N(CC#N)c2cc(Nc3ccc(OC[C@@H](O)CN(C)C)cc3)ncn2)c1,2006.0
Inhibition of CDK2/CycA3,Cc1ccc(Cl)c(N(CC#N)c2cc(Nc3ccc(OC[C@@H](O)CN(C)C)cc3)ncn2)c1,CHEMBL1149496,=,=,IC50,nM,2600.0,IC50,uM,2.6,Cc1ccc(Cl)c(N(CC#N)c2cc(Nc3ccc(OC[C@@H](O)CN(C)C)cc3)ncn2)c1,2006.0
Inhibition of CDK2,O=C(Nc1cc(CN[C@H]2Cc3ccc(Cl)cc3C2)n[nH]1)Nc1cccc2c1[C@@H]1CCCN1C2=O,CHEMBL1149510,=,=,IC50,nM,440.0,IC50,nM,440.0,O=C(Nc1cc(CN[C@H]2Cc3ccc(Cl)cc3C2)n[nH]1)Nc1cccc2c1[C@@H]1CCCN1C2=O,2006.0
Inhibition of CDK2,O=C(Nc1ccccn1)Nc1cccc2c1[C@H]1CCCN1C2=O,CHEMBL1149510,=,=,IC50,nM,80.0,IC50,nM,80.0,O=C(Nc1ccccn1)Nc1cccc2c1[C@H]1CCCN1C2=O,2006.0
Inhibition of CDK2,C[C@@H]1C[C@H]2CN1CCn1nc3c(cccc3c1O)-c1nc3c(cccc3nc1O)O2,CHEMBL1149510,=,=,IC50,nM,3.4,IC50,nM,3.4,C[C@@H]1C[C@H]2CN1CCn1nc3c(cccc3c1O)-c1nc3c(cccc3nc1O)O2,2006.0
Inhibition of CDK2/Cyclin E,COc1cccc(C(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2N)c1,CHEMBL1137323,>,>,Ki,nM,10000.0,Ki,uM,10.0,COc1cccc(C(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2N)c1,2006.0
Inhibition of CDK2/Cyclin E,COc1ccccc1C(=O)c1cnc(Nc2ccc(N3CCN(C)CC3)cc2)nc1N,CHEMBL1137323,=,=,Ki,nM,5141.0,Ki,uM,5.141,COc1ccccc1C(=O)c1cnc(Nc2ccc(N3CCN(C)CC3)cc2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,Cc1ccccc1C(=O)c1cnc(Nc2ccc(N3CCN(C)CC3)cc2)nc1N,CHEMBL1137323,>,>,Ki,nM,10000.0,Ki,uM,10.0,Cc1ccccc1C(=O)c1cnc(Nc2ccc(N3CCN(C)CC3)cc2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,CN1CCN(c2ccc(Nc3ncc(C(=O)c4ccccc4C(F)(F)F)c(N)n3)cc2)CC1,CHEMBL1137323,>,>,Ki,nM,10000.0,Ki,uM,10.0,CN1CCN(c2ccc(Nc3ncc(C(=O)c4ccccc4C(F)(F)F)c(N)n3)cc2)CC1,2006.0
Inhibition of CDK2/Cyclin E,CN1CCN(c2ccc(Nc3ncc(C(=O)c4cccc(C(F)(F)F)c4)c(N)n3)cc2)CC1,CHEMBL1137323,>,>,Ki,nM,10000.0,Ki,uM,10.0,CN1CCN(c2ccc(Nc3ncc(C(=O)c4cccc(C(F)(F)F)c4)c(N)n3)cc2)CC1,2006.0
Inhibition of CDK2/Cyclin E,CN1CCN(c2ccc(Nc3ncc(C(=O)c4cccc(F)c4)c(N)n3)cc2)CC1,CHEMBL1137323,>,>,Ki,nM,10000.0,Ki,uM,10.0,CN1CCN(c2ccc(Nc3ncc(C(=O)c4cccc(F)c4)c(N)n3)cc2)CC1,2006.0
Inhibition of CDK2/Cyclin E,COc1c(C(=O)c2cnc(NC3CCN(S(C)(=O)=O)CC3)nc2N)cc(F)c(F)c1F,CHEMBL1137323,=,=,Ki,nM,495.0,Ki,uM,0.495,COc1c(C(=O)c2cnc(NC3CCN(S(C)(=O)=O)CC3)nc2N)cc(F)c(F)c1F,2006.0
Inhibition of CDK2/Cyclin E,COc1cc(F)c(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,CHEMBL1137323,=,=,Ki,nM,2.0,Ki,uM,0.002,COc1cc(F)c(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,COc1cc(F)c(F)cc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,CHEMBL1137323,=,=,Ki,nM,6.0,Ki,uM,0.006,COc1cc(F)c(F)cc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,CHEMBL1137323,=,=,Ki,nM,3.0,Ki,uM,0.003,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,CS(=O)(=O)N1CCC(Nc2ncc(C(=O)c3c(F)cccc3F)c(N)n2)CC1,CHEMBL1137323,=,=,Ki,nM,15.0,Ki,uM,0.015,CS(=O)(=O)N1CCC(Nc2ncc(C(=O)c3c(F)cccc3F)c(N)n2)CC1,2006.0
Inhibition of CDK2/Cyclin E,COc1cccc(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,CHEMBL1137323,=,=,Ki,nM,13.0,Ki,uM,0.013,COc1cccc(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,COc1ccc(Cl)cc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,CHEMBL1137323,=,=,Ki,nM,451.0,Ki,uM,0.451,COc1ccc(Cl)cc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,COc1ccc(F)cc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,CHEMBL1137323,=,=,Ki,nM,7.0,Ki,uM,0.007,COc1ccc(F)cc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,COc1cc(F)ccc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,CHEMBL1137323,=,=,Ki,nM,84.0,Ki,uM,0.084,COc1cc(F)ccc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,CCOc1ccccc1C(=O)c1cnc(NC2CCN(C(C)=O)CC2)nc1N,CHEMBL1137323,=,=,Ki,nM,2030.0,Ki,uM,2.03,CCOc1ccccc1C(=O)c1cnc(NC2CCN(C(C)=O)CC2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,CCOC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3C)c(N)n2)CC1,CHEMBL1137323,=,=,Ki,nM,2166.0,Ki,uM,2.166,CCOC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3C)c(N)n2)CC1,2006.0
Inhibition of CDK2/Cyclin E,CCOC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3F)c(N)n2)CC1,CHEMBL1137323,=,=,Ki,nM,3137.0,Ki,uM,3.137,CCOC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3F)c(N)n2)CC1,2006.0
Inhibition of CDK2/Cyclin E,CCS(=O)(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3OC)c(N)n2)CC1,CHEMBL1137323,=,=,Ki,nM,51.0,Ki,uM,0.051,CCS(=O)(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3OC)c(N)n2)CC1,2006.0
Inhibition of CDK2/Cyclin E,COc1ccccc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,CHEMBL1137323,=,=,Ki,nM,24.0,Ki,uM,0.024,COc1ccccc1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,CCCC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3OC)c(N)n2)CC1,CHEMBL1137323,=,=,Ki,nM,886.0,Ki,uM,0.886,CCCC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3OC)c(N)n2)CC1,2006.0
Inhibition of CDK2/Cyclin E,COc1ccccc1C(=O)c1cnc(NC2CCN(C(C)=O)CC2)nc1N,CHEMBL1137323,=,=,Ki,nM,327.0,Ki,uM,0.327,COc1ccccc1C(=O)c1cnc(NC2CCN(C(C)=O)CC2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,CCOC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3OC)c(N)n2)CC1,CHEMBL1137323,=,=,Ki,nM,597.0,Ki,uM,0.597,CCOC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3OC)c(N)n2)CC1,2006.0
Inhibition of CDK2/Cyclin E,CCNC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3OC)c(N)n2)CC1,CHEMBL1137323,=,=,Ki,nM,1756.0,Ki,uM,1.756,CCNC(=O)N1CCC(Nc2ncc(C(=O)c3ccccc3OC)c(N)n2)CC1,2006.0
Inhibition of CDK2/Cyclin E,COc1ccccc1C(=O)c1cnc(NC2CCN(C)CC2)nc1N,CHEMBL1137323,>,>,Ki,nM,10000.0,Ki,uM,10.0,COc1ccccc1C(=O)c1cnc(NC2CCN(C)CC2)nc1N,2006.0
Inhibition of CDK2/Cyclin E,COc1ccccc1C(=O)c1cnc(NC2CCNCC2)nc1N,CHEMBL1137323,=,=,Ki,nM,6266.0,Ki,uM,6.266,COc1ccccc1C(=O)c1cnc(NC2CCNCC2)nc1N,2006.0
Inhibition of Cdk2,Cc1cc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)nc(C)n1,CHEMBL1137331,>,>,IC50,nM,25000.0,IC50,nM,25000.0,Cc1cc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)nc(C)n1,2006.0
Inhibition of Cdk2,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,CHEMBL1137331,>,>,IC50,nM,5000.0,IC50,nM,5000.0,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,2006.0
Inhibition of CDK2 by SPA,Clc1ccc2c(c1Nc1ncnc3cc(OCCCN4CCCC4)cc(OC4CCOCC4)c13)OCO2,CHEMBL1137334,>,>,IC50,nM,10000.0,IC50,uM,10.0,Clc1ccc2c(c1Nc1ncnc3cc(OCCCN4CCCC4)cc(OC4CCOCC4)c13)OCO2,2006.0
Inhibition of CDK2 by SPA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,CHEMBL1137334,=,=,IC50,nM,10000.0,IC50,uM,10.0,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,2006.0
Inhibition of CDK2/cyclin A,CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1,CHEMBL1137365,=,=,IC50,nM,462.0,IC50,uM,0.462,CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1,2006.0
Inhibition of human recombinant CDK2,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,CHEMBL1147984,>,>,Ki,nM,10000.0,Ki,uM,10.0,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,2007.0
Inhibition of CDK2 kinase activity assessed as decrease in histone H1 phosphorylation in LNCaP cells at 50 nM after 72 hrs by Western blot analysis,C[C@H]1[C@@H](CC(CNc2ccccc2)C[C@H]2O[C@@H]3O[C@@]4(C)CC[C@H]5[C@H](C)CC[C@@H]([C@H]2C)[C@@]35OO4)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,CHEMBL1138226,,,Activity,,,Activity,,,C[C@H]1[C@@H](CC(CNc2ccccc2)C[C@H]2O[C@@H]3O[C@@]4(C)CC[C@H]5[C@H](C)CC[C@@H]([C@H]2C)[C@@]35OO4)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,2006.0
Inhibition of CDK2 kinase activity assessed as decrease in histone H1 phosphorylation in LNCaP cells at 50 nM after 72 hrs by Western blot analysis,CCOP(=O)(OCC)OCC(C[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3)C[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3,CHEMBL1138226,,,Activity,,,Activity,,,CCOP(=O)(OCC)OCC(C[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3)C[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3,2006.0
Inhibition of CDK2 kinase activity assessed as decrease in histone H1 phosphorylation in LNCaP cells at 50 nM after 72 hrs by Western blot analysis,C[C@H]1[C@@H](CC(COP(=O)(Oc2ccccc2)Oc2ccccc2)C[C@H]2O[C@@H]3O[C@@]4(C)CC[C@H]5[C@H](C)CC[C@@H]([C@H]2C)[C@@]35OO4)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,CHEMBL1138226,,,Activity,,,Activity,,,C[C@H]1[C@@H](CC(COP(=O)(Oc2ccccc2)Oc2ccccc2)C[C@H]2O[C@@H]3O[C@@]4(C)CC[C@H]5[C@H](C)CC[C@@H]([C@H]2C)[C@@]35OO4)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,2006.0
Inhibition of CDK2,COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC,CHEMBL1146152,=,=,IC50,nM,1584.89,Log IC50,,-5.8,COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC,2006.0
Inhibition of CDK2 at 1 uM,O=C1NCc2c3c(c4[nH]c5ccccc5c4c21)Cc1ccccc1-3,CHEMBL1141396,<,<,Inhibition,%,30.0,Inhibition,%,30.0,O=C1NCc2c3c(c4[nH]c5ccccc5c4c21)Cc1ccccc1-3,2007.0
Inhibition of CDK2 at 1 uM,O=C1NCc2c1c1c3ccccc3sc1c1[nH]c3ccccc3c21,CHEMBL1141396,<,<,Inhibition,%,30.0,Inhibition,%,30.0,O=C1NCc2c1c1c3ccccc3sc1c1[nH]c3ccccc3c21,2007.0
Inhibition of CDK2 at 1 uM,O=C1NCc2c1c1c(c3[nH]c4ccccc4c23)Cc2ccccc2-1,CHEMBL1141396,<,<,Inhibition,%,30.0,Inhibition,%,30.0,O=C1NCc2c1c1c(c3[nH]c4ccccc4c23)Cc2ccccc2-1,2007.0
Inhibition of CDK2 at 1 uM,O=C1NCc2c3c(c4[nH]c5ccccc5c4c21)CCc1ccccc1-3,CHEMBL1141396,<,<,Inhibition,%,30.0,Inhibition,%,30.0,O=C1NCc2c3c(c4[nH]c5ccccc5c4c21)CCc1ccccc1-3,2007.0
Inhibition of CDK2 at 1 uM,O=C1NC(=O)c2c1c1c(c3[nH]c4ccccc4c23)CCc2ccccc2-1,CHEMBL1141396,<,<,Inhibition,%,30.0,Inhibition,%,30.0,O=C1NC(=O)c2c1c1c(c3[nH]c4ccccc4c23)CCc2ccccc2-1,2007.0
Inhibition of CDK2,O=C(N[C@H](CO)c1ccc(F)c(Cl)c1)c1cc(-c2n[nH]cc2-c2cccc(Cl)c2)c[nH]1,CHEMBL1142871,>,>,Ki,nM,4000.0,Ki,uM,4.0,O=C(N[C@H](CO)c1ccc(F)c(Cl)c1)c1cc(-c2n[nH]cc2-c2cccc(Cl)c2)c[nH]1,2007.0
Inhibition of Cdk2,CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2,CHEMBL1142994,>,>,Ki,nM,10000.0,Ki,uM,10.0,CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2,2007.0
Inhibition of Cdk2,N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2,CHEMBL1142994,=,=,Ki,nM,5760.0,Ki,uM,5.76,N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2,2007.0
Inhibition of Cdk2,N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2,CHEMBL1142994,>,>,Ki,nM,10000.0,Ki,uM,10.0,N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2,2007.0
Inhibition of CDK2,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,CHEMBL1149291,>,>,IC50,nM,5000.0,IC50,nM,5000.0,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,2004.0
Inhibition of CDK2,C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br,CHEMBL1144565,>,>,IC50,nM,500000.0,IC50,uM,500.0,C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br,2007.0
Inhibition of CDK2 at 100 uM,O=C1Nc2c(Br)cc(Br)cc2C1=O,CHEMBL1144554,=,=,Inhibition,%,44.0,Inhibition,%,44.0,O=C1Nc2c(Br)cc(Br)cc2C1=O,2007.0
Inhibition at CDK2,NC(=O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1,CHEMBL1143787,=,=,IC50,nM,2700.0,IC50,uM,2.7,NC(=O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1,2007.0
Inhibition of CDK2,Cc1cc(Nc2ncnc3cnc(N4CCOCC4)cc23)ccc1Oc1ccc(C(=O)NCC(C)(C)C)cc1,CHEMBL1144645,>,>,Activity,uM,10.0,Activity,uM,10.0,Cc1cc(Nc2ncnc3cnc(N4CCOCC4)cc23)ccc1Oc1ccc(C(=O)NCC(C)(C)C)cc1,2007.0
Inhibition of CDK2,NC1=NC(=O)/C(=C/c2ccc3ncccc3c2)S1,CHEMBL1147195,=,=,Ki,nM,2000.0,Ki,uM,2.0,NC1=NC(=O)/C(=C/c2ccc3ncccc3c2)S1,2007.0
Inhibition of CDK2,O=C1N=C(N[C@@H]2C[C@H]2c2ccccc2)S/C1=C\c1ccc2ncccc2c1,CHEMBL1147195,>,>,Ki,nM,2000.0,Ki,uM,2.0,O=C1N=C(N[C@@H]2C[C@H]2c2ccccc2)S/C1=C\c1ccc2ncccc2c1,2007.0
Inhibition of CDK2,O=C1N=C(NCc2cccs2)S/C1=C\c1ccc2ncccc2c1,CHEMBL1147195,=,=,Ki,nM,340.0,Ki,uM,0.34,O=C1N=C(NCc2cccs2)S/C1=C\c1ccc2ncccc2c1,2007.0
Inhibition of CDK2,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,CHEMBL1148833,=,=,IC50,nM,40000.0,IC50,uM,40.0,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,2007.0
Inhibition of CDK2,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2ccccc12,CHEMBL1148833,=,=,IC50,nM,4000.0,IC50,uM,4.0,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2ccccc12,2007.0
Inhibition of CDK2,O=c1cc(-c2ccc(O)c(O)c2)oc2ccccc12,CHEMBL1148833,>,>,IC50,nM,500000.0,IC50,uM,500.0,O=c1cc(-c2ccc(O)c(O)c2)oc2ccccc12,2007.0
Inhibition of CDK2,O=c1cc(-c2ccc(O)c(O)c2)oc2c(O)c(O)ccc12,CHEMBL1148833,>,>,IC50,nM,500000.0,IC50,uM,500.0,O=c1cc(-c2ccc(O)c(O)c2)oc2c(O)c(O)ccc12,2007.0
Inhibition of CDK2,O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,CHEMBL1148833,=,=,IC50,nM,20000.0,IC50,uM,20.0,O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,2007.0
Inhibition of CDK2,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)ccc12,CHEMBL1148833,=,=,IC50,nM,5000.0,IC50,uM,5.0,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)ccc12,2007.0
Inhibition of CDK2,Cc1cc(N2C(=O)CN(C)C2=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,56.0,IC50,uM,0.056,Cc1cc(N2C(=O)CN(C)C2=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2C(=O)CNC2=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,4000.0,IC50,uM,4.0,Cc1cc(N2C(=O)CNC2=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2C(=O)CCCC2=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,4400.0,IC50,uM,4.4,Cc1cc(N2C(=O)CCCC2=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2C(=O)CCC2=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,1500.0,IC50,uM,1.5,Cc1cc(N2C(=O)CCC2=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2CCCC2=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,1600.0,IC50,uM,1.6,Cc1cc(N2CCCC2=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2CCN(C)CC2)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,640.0,IC50,uM,0.64,Cc1cc(N2CCN(C)CC2)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2CCCCC2)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,2600.0,IC50,uM,2.6,Cc1cc(N2CCCCC2)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2CCCC2)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,3000.0,IC50,uM,3.0,Cc1cc(N2CCCC2)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,CCN(CC)c1cc(C)cc2c(=O)c(O)c(-c3ccc(O)c(O)c3)oc12,CHEMBL1148833,=,=,IC50,nM,1600.0,IC50,uM,1.6,CCN(CC)c1cc(C)cc2c(=O)c(O)c(-c3ccc(O)c(O)c3)oc12,2007.0
Inhibition of CDK2,Cc1cc(N)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,630.0,IC50,uM,0.63,Cc1cc(N)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(C(F)(F)F)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,1700.0,IC50,uM,1.7,Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(C(F)(F)F)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(C#N)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,1400.0,IC50,uM,1.4,Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(C#N)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(Br)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,75.0,IC50,uM,0.075,Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(Br)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(Cl)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,190.0,IC50,uM,0.19,Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(Cl)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)cc3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,250.0,IC50,uM,0.25,Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)cc3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,CHEMBL1148833,=,=,IC50,nM,87.0,IC50,uM,0.087,Cc1cc(N2CCCS2(=O)=O)c2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1,2007.0
Inhibition of CDK2,N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2,CHEMBL1148840,<,>,IC50,nM,10000.0,pIC50,,5.0,N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2,2007.0
Inhibition of CDK2,N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1,CHEMBL1148840,<,>,IC50,nM,10000.0,pIC50,,5.0,N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1ccccn1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1ccccn1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1nnnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1nnnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,CC(C)(C)c1ccc(NC(=O)c2nnnn2CCc2ccncc2)cc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,CC(C)(C)c1ccc(NC(=O)c2nnnn2CCc2ccncc2)cc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(OC(F)(F)F)cc1)c1nnnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(OC(F)(F)F)cc1)c1nnnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(C(F)(F)F)cc1)c1nnnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(C(F)(F)F)cc1)c1nnnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)cc1)c1nnnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)cc1)c1nnnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1nc2ccccc2n1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1nc2ccccc2n1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(OC(F)(F)F)cc1)c1nc2ccccc2n1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(OC(F)(F)F)cc1)c1nc2ccccc2n1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)cc1)c1nc2ccccc2n1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)cc1)c1nc2ccccc2n1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1nccn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1nccn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,CC(C)(C)c1ccc(NC(=O)c2nccn2CCc2ccncc2)cc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,CC(C)(C)c1ccc(NC(=O)c2nccn2CCc2ccncc2)cc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(OC(F)(F)F)cc1)c1nccn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(OC(F)(F)F)cc1)c1nccn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(C(F)(F)F)cc1)c1nccn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(C(F)(F)F)cc1)c1nccn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)cc1)c1nccn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)cc1)c1nccn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(OC(F)(F)F)cc1)c1cc2ccccc2n1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(OC(F)(F)F)cc1)c1cc2ccccc2n1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)cc1)c1cc2ccccc2n1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)cc1)c1cc2ccccc2n1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,Cc1nn(CCc2ccncc2)c(C(=O)Nc2ccc(OC(F)(F)F)cc2)c1C,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,Cc1nn(CCc2ccncc2)c(C(=O)Nc2ccc(OC(F)(F)F)cc2)c1C,2007.0
Inhibition of Cdk2 at 10 uM,Cc1nn(CCc2ccncc2)c(C(=O)Nc2ccc(Cl)cc2)c1C,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,Cc1nn(CCc2ccncc2)c(C(=O)Nc2ccc(Cl)cc2)c1C,2007.0
Inhibition of Cdk2 at 10 uM,Cc1cc(C(=O)Nc2ccc(OC(F)(F)F)cc2)n(CCc2ccncc2)n1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,Cc1cc(C(=O)Nc2ccc(OC(F)(F)F)cc2)n(CCc2ccncc2)n1,2007.0
Inhibition of Cdk2 at 10 uM,Cc1cc(C(=O)Nc2ccc(Cl)cc2)n(CCc2ccncc2)n1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,Cc1cc(C(=O)Nc2ccc(Cl)cc2)n(CCc2ccncc2)n1,2007.0
Inhibition of Cdk2 at 10 uM,COc1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1OC,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,COc1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1OC,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)c(Cl)c1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)c(Cl)c1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc2cn[nH]c2c1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc2cn[nH]c2c1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc2[nH]ncc2c1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc2[nH]ncc2c1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1cnc2ccccc2c1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1cnc2ccccc2c1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(OCc2ccccc2)cc1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(OCc2ccccc2)cc1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Oc2ccccc2)cc1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Oc2ccccc2)cc1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(-c2ccccc2)cc1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(-c2ccccc2)cc1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,CC(C)c1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,CC(C)c1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1,2007.0
Inhibition of Cdk2 at 10 uM,CC(C)(C)c1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,CC(C)(C)c1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1cccc(OC(F)(F)Cl)c1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1cccc(OC(F)(F)Cl)c1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1cccc(OC(F)(F)F)c1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1cccc(OC(F)(F)F)c1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(OC(F)(F)F)cc1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(OC(F)(F)F)cc1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,CCc1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,CCc1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(C(F)(F)F)cc1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(C(F)(F)F)cc1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1c[nH]cn1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1c[nH]cn1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1noc2ccccc12,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1noc2ccccc12,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1cnoc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1cnoc1,2007.0
Inhibition of Cdk2 at 10 uM,COc1ccc(CCn2nccc2C(=O)Nc2ccc(Cl)cc2)cc1OC,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,COc1ccc(CCn2nccc2C(=O)Nc2ccc(Cl)cc2)cc1OC,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1ccc(F)c(F)c1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1ccc(F)c(F)c1,2007.0
Inhibition of Cdk2 at 10 uM,CC1C=C2OCOC2=C(CCn2nccc2C(=O)Nc2ccc(Cl)cc2)C1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,CC1C=C2OCOC2=C(CCn2nccc2C(=O)Nc2ccc(Cl)cc2)C1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1ccncc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1ccncc1,2007.0
Inhibition of Cdk2 at 10 uM,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1cccnc1,CHEMBL1148870,>,>,Activity,%,30.0,Activity,%,30.0,O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1cccnc1,2007.0
Inhibition of CDK2 at 10 uM,CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1cccs1)n2CCCN,CHEMBL1148883,=,=,Inhibition,%,7.0,Inhibition,%,7.0,CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1cccs1)n2CCCN,2007.0
Inhibition of CDK2,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(N)(=O)=O)cc3)o2)S1,CHEMBL1149560,=,=,IC50,nM,180.0,IC50,uM,0.18,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(N)(=O)=O)cc3)o2)S1,2007.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)cc1,CHEMBL1149560,=,=,IC50,nM,27000.0,IC50,uM,27.0,NS(=O)(=O)c1ccc(-c2ccc(/C=C3\SC(=O)NC3=O)o2)cc1,2007.0
Inhibition of CDK2,C/C(=C1/SC(=N)NC1=O)c1ccc(-c2ccc(S(N)(=O)=O)cc2)o1,CHEMBL1149560,=,=,IC50,nM,30.0,IC50,uM,0.03,C/C(=C1/SC(=N)NC1=O)c1ccc(-c2ccc(S(N)(=O)=O)cc2)o1,2007.0
Inhibition of CDK2,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(N)(=O)=O)c(Cl)c3)o2)S1,CHEMBL1149560,=,=,IC50,nM,570.0,IC50,uM,0.57,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(N)(=O)=O)c(Cl)c3)o2)S1,2007.0
Inhibition of CDK2,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(N)(=O)=O)c(C(F)(F)F)c3)o2)S1,CHEMBL1149560,=,=,IC50,nM,610.0,IC50,uM,0.61,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(N)(=O)=O)c(C(F)(F)F)c3)o2)S1,2007.0
Inhibition of CDK2,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(C(N)=O)cc3)o2)S1,CHEMBL1149560,=,=,IC50,nM,9300.0,IC50,uM,9.3,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(C(N)=O)cc3)o2)S1,2007.0
Inhibition of CDK2,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(=O)(=O)N4CCOCC4)cc3)o2)S1,CHEMBL1149560,=,=,IC50,nM,150000.0,IC50,uM,150.0,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(=O)(=O)N4CCOCC4)cc3)o2)S1,2007.0
Inhibition of CDK2,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(=O)(=O)N4CCNCC4)cc3)o2)S1,CHEMBL1149560,=,=,IC50,nM,2900.0,IC50,uM,2.9,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(=O)(=O)N4CCNCC4)cc3)o2)S1,2007.0
Inhibition of CDK2,CN(C)CCNS(=O)(=O)c1ccc(-c2ccc(/C=C3\SC(=N)NC3=O)o2)cc1,CHEMBL1149560,=,=,IC50,nM,570.0,IC50,uM,0.57,CN(C)CCNS(=O)(=O)c1ccc(-c2ccc(/C=C3\SC(=N)NC3=O)o2)cc1,2007.0
Inhibition of CDK2,CNS(=O)(=O)c1ccc(-c2ccc(/C=C3\SC(=N)NC3=O)o2)cc1,CHEMBL1149560,=,=,IC50,nM,120.0,IC50,uM,0.12,CNS(=O)(=O)c1ccc(-c2ccc(/C=C3\SC(=N)NC3=O)o2)cc1,2007.0
Inhibition of CDK2,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(C(=O)O)cc3)o2)S1,CHEMBL1149560,=,=,IC50,nM,47000.0,IC50,uM,47.0,N=C1NC(=O)/C(=C/c2ccc(-c3ccc(C(=O)O)cc3)o2)S1,2007.0
Inhibition of CDK2,N=C1NC(=O)/C(=C/c2ccc(-c3ccccc3[N+](=O)[O-])o2)S1,CHEMBL1149560,=,=,IC50,nM,19000.0,IC50,uM,19.0,N=C1NC(=O)/C(=C/c2ccc(-c3ccccc3[N+](=O)[O-])o2)S1,2007.0
Inhibition of CDK2/cyclin A at 1 uM,O=C1NC(=O)c2c1c1c3cc(Cl)ccc3[nH]c1c1cccn21,CHEMBL1149629,=,=,Inhibition,%,69.0,Inhibition,%,69.0,O=C1NC(=O)c2c1c1c3cc(Cl)ccc3[nH]c1c1cccn21,2007.0
Inhibition of CDK2/cyclin A at 1 uM,O=C1NC(=O)c2c1c1c3cc(Br)ccc3[nH]c1c1cccn21,CHEMBL1149629,=,=,Inhibition,%,88.0,Inhibition,%,88.0,O=C1NC(=O)c2c1c1c3cc(Br)ccc3[nH]c1c1cccn21,2007.0
Inhibition of CDK2,COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1,CHEMBL1137478,>,>,IC50,nM,30000.0,IC50,nM,30000.0,COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1,2007.0
Inhibition of CDK2 at 1 uM,CC(C)NCc1ccc(Nc2cc(-c3ccc(-c4ccc(O)cc4O)cc3)[nH]n2)cc1,CHEMBL1137531,=,=,Inhibition,%,31.0,Inhibition,%,31.0,CC(C)NCc1ccc(Nc2cc(-c3ccc(-c4ccc(O)cc4O)cc3)[nH]n2)cc1,2007.0
Inhibition of CDK2,Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12,CHEMBL1138370,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12,2007.0
Inhibition of CDK2,Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12,CHEMBL1138370,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12,2007.0
Inhibition of human CDK2,Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12,CHEMBL1139135,=,=,IC50,nM,17782.79,Log IC50,,-4.75,Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC(Nc2ncc(C#N)c(-c3c[nH]c4cc(F)ccc34)n2)CC1,CHEMBL1139954,=,=,IC50,nM,412.0,IC50,nM,412.0,CCNC(=O)N1CCC(Nc2ncc(C#N)c(-c3c[nH]c4cc(F)ccc34)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC(Nc2nccc(-c3c(-c4ccccc4)[nH]c4ccccc34)n2)CC1,CHEMBL1139954,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CCNC(=O)N1CCC(Nc2nccc(-c3c(-c4ccccc4)[nH]c4ccccc34)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC(Nc2nccc(-c3c(C(C)C)[nH]c4ccccc34)n2)CC1,CHEMBL1139954,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CCNC(=O)N1CCC(Nc2nccc(-c3c(C(C)C)[nH]c4ccccc34)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CC1CCN(NC(=O)N2CCC(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)CC2)CC1,CHEMBL1139954,=,=,IC50,nM,6652.0,IC50,nM,6652.0,CC1CCN(NC(=O)N2CCC(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)CC2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CC1CCN(C(=O)N2CCC(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)CC2)CC1,CHEMBL1139954,=,=,IC50,nM,1895.0,IC50,nM,1895.0,CC1CCN(C(=O)N2CCC(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)CC2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CN(C)CC(=O)N1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)CC1,CHEMBL1139954,=,=,IC50,nM,1126.0,IC50,nM,1126.0,CN(C)CC(=O)N1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CNCC(=O)N1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)CC1,CHEMBL1139954,=,=,IC50,nM,2672.0,IC50,nM,2672.0,CNCC(=O)N1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CC(=O)NCC(=O)N1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)CC1,CHEMBL1139954,=,=,IC50,nM,551.0,IC50,nM,551.0,CC(=O)NCC(=O)N1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CN1CCN(C(=O)N2CCC(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)CC2)CC1,CHEMBL1139954,=,=,IC50,nM,5281.0,IC50,nM,5281.0,CN1CCN(C(=O)N2CCC(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)CC2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CN(C)C(=O)N1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)CC1,CHEMBL1139954,=,=,IC50,nM,4358.0,IC50,nM,4358.0,CN(C)C(=O)N1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CNC(=O)CN1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)CC1,CHEMBL1139954,=,=,IC50,nM,123.0,IC50,nM,123.0,CNC(=O)CN1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CNC(=O)CN1CCC[C@@H](Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)C1,CHEMBL1139954,=,=,IC50,nM,612.0,IC50,nM,612.0,CNC(=O)CN1CCC[C@@H](Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)C1,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC[C@@H](Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)C1,CHEMBL1139954,=,=,IC50,nM,1264.0,IC50,nM,1264.0,CCNC(=O)N1CCC[C@@H](Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)C1,2007.0
Inhibition of CDK2 by IMAP technology,CNC(=O)CN1CCC[C@H](Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)C1,CHEMBL1139954,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CNC(=O)CN1CCC[C@H](Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)C1,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC[C@H](Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)C1,CHEMBL1139954,=,=,IC50,nM,555.0,IC50,nM,555.0,CCNC(=O)N1CCC[C@H](Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)C1,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)C1,CHEMBL1139954,=,=,IC50,nM,2483.0,IC50,nM,2483.0,CCNC(=O)N1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)C1,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC(Nc2nccc(-n3ccc4ccccc43)n2)CC1,CHEMBL1139954,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CCNC(=O)N1CCC(Nc2nccc(-n3ccc4ccccc43)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC(Nc2nccc(-c3cnc4ccccn34)n2)CC1,CHEMBL1139954,=,=,IC50,nM,4219.0,IC50,nM,4219.0,CCNC(=O)N1CCC(Nc2nccc(-c3cnc4ccccn34)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC(Nc2ncc(Cl)c(-n3ccc4ccccc43)n2)CC1,CHEMBL1139954,=,=,IC50,nM,4443.0,IC50,nM,4443.0,CCNC(=O)N1CCC(Nc2ncc(Cl)c(-n3ccc4ccccc43)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC(Nc2ncc(Cl)c(-c3cnc4ccccn34)n2)CC1,CHEMBL1139954,=,=,IC50,nM,605.0,IC50,nM,605.0,CCNC(=O)N1CCC(Nc2ncc(Cl)c(-c3cnc4ccccn34)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC(Nc2nccc(-c3c[nH]c4ccccc34)n2)CC1,CHEMBL1139954,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CCNC(=O)N1CCC(Nc2nccc(-c3c[nH]c4ccccc34)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC(Nc2ncc(C)c(-c3c[nH]c4ccccc34)n2)CC1,CHEMBL1139954,,,Activity,,,Activity,,,CCNC(=O)N1CCC(Nc2ncc(C)c(-c3c[nH]c4ccccc34)n2)CC1,2007.0
Inhibition of CDK2 by IMAP technology,CCNC(=O)N1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)CC1,CHEMBL1139954,=,=,IC50,nM,1517.0,IC50,nM,1517.0,CCNC(=O)N1CCC(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)CC1,2007.0
Inhibition of CDK2,N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2,CHEMBL1140564,=,=,Ki,nM,3088.0,Ki,uM,3.088,N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2,2007.0
Inhibition of CDK2,CC(=O)N1CCN(C(=O)c2cc(Sc3cnc(Nc4cccc(Br)n4)s3)ccc2C)CC1,CHEMBL1140800,=,=,IC50,nM,490.0,IC50,uM,0.49,CC(=O)N1CCN(C(=O)c2cc(Sc3cnc(Nc4cccc(Br)n4)s3)ccc2C)CC1,2008.0
Inhibition of CDK2,Cc1ccc(Sc2cnc(Nc3cccc(Br)n3)s2)cc1C(=O)N1CCN(C(=O)[C@@H](C)N)CC1,CHEMBL1140800,=,=,IC50,nM,230.0,IC50,uM,0.23,Cc1ccc(Sc2cnc(Nc3cccc(Br)n3)s2)cc1C(=O)N1CCN(C(=O)[C@@H](C)N)CC1,2008.0
Inhibition of CDK2,Cc1ccc(Sc2cnc(Nc3cccc(Br)n3)s2)cc1C(=O)N1CCN(C(=O)[C@H](C)N)CC1,CHEMBL1140800,=,=,IC50,nM,520.0,IC50,uM,0.52,Cc1ccc(Sc2cnc(Nc3cccc(Br)n3)s2)cc1C(=O)N1CCN(C(=O)[C@H](C)N)CC1,2008.0
Inhibition of CDK2,Cc1ccc(Sc2cnc(Nc3cccc(Br)n3)s2)cc1C(=O)N1CCN(C(=O)CN)CC1,CHEMBL1140800,=,=,IC50,nM,540.0,IC50,uM,0.54,Cc1ccc(Sc2cnc(Nc3cccc(Br)n3)s2)cc1C(=O)N1CCN(C(=O)CN)CC1,2008.0
Inhibition of CDK2,CNCCN(C)C(=O)c1cc(Sc2cnc(Nc3cccc(Br)n3)s2)ccc1C,CHEMBL1140800,=,=,IC50,nM,180.0,IC50,uM,0.18,CNCCN(C)C(=O)c1cc(Sc2cnc(Nc3cccc(Br)n3)s2)ccc1C,2008.0
Binding affinity to human CDK2,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(O)cc(O)c12,CHEMBL1140807,,,Activity,,,Activity,,,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(O)cc(O)c12,2008.0
Inhibition of CDK2,CCN(CC)CCOc1ccc(Nc2cc(NC(=O)Nc3c(Cl)cccc3Cl)ncn2)cc1,CHEMBL1141507,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCN(CC)CCOc1ccc(Nc2cc(NC(=O)Nc3c(Cl)cccc3Cl)ncn2)cc1,2008.0
Inhibition of CDK2,NC1CCN(Cc2ccn3ncnc(Oc4ccc(NC(=O)NC(=O)Cc5ccc(F)cc5)cc4F)c23)CC1,CHEMBL1141528,>,>,IC50,nM,5000.0,IC50,uM,5.0,NC1CCN(Cc2ccn3ncnc(Oc4ccc(NC(=O)NC(=O)Cc5ccc(F)cc5)cc4F)c23)CC1,2008.0
Inhibition of CDK2,O=C(Cc1ccccc1)Nc1n[nH]c2ccc([N+](=O)[O-])cc12,CHEMBL1141545,=,=,IC50,nM,2000.0,IC50,uM,2.0,O=C(Cc1ccccc1)Nc1n[nH]c2ccc([N+](=O)[O-])cc12,2008.0
Inhibition of CDK2,O=C(Cc1ccc(-c2ccncc2)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,30.0,IC50,uM,0.03,O=C(Cc1ccc(-c2ccncc2)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1ccc(-c2ccccc2)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,14.0,IC50,uM,0.014,O=C(Cc1ccc(-c2ccccc2)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1ccc2ccccc2c1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,9.0,IC50,uM,0.009,O=C(Cc1ccc2ccccc2c1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1cccc2ccccc12)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,20.0,IC50,uM,0.02,O=C(Cc1cccc2ccccc12)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,CS(=O)(=O)c1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1,CHEMBL1141545,=,=,IC50,nM,22.0,IC50,uM,0.022,CS(=O)(=O)c1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1,2008.0
Inhibition of CDK2,CSc1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1,CHEMBL1141545,=,=,IC50,nM,10.0,IC50,uM,0.01,CSc1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1,2008.0
Inhibition of CDK2,O=C(Cc1ccc(N2CCCCC2)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,30.0,IC50,uM,0.03,O=C(Cc1ccc(N2CCCCC2)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,CCN(CC)c1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1,CHEMBL1141545,=,=,IC50,nM,40.0,IC50,uM,0.04,CCN(CC)c1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1,2008.0
Inhibition of CDK2,CN(C)c1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1,CHEMBL1141545,=,=,IC50,nM,10.0,IC50,uM,0.01,CN(C)c1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1,2008.0
Inhibition of CDK2,Nc1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1,CHEMBL1141545,=,=,IC50,nM,16.0,IC50,uM,0.016,Nc1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1,2008.0
Inhibition of CDK2,O=C(Cc1ccc(O)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,9.0,IC50,uM,0.009,O=C(Cc1ccc(O)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,Cc1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1,CHEMBL1141545,=,=,IC50,nM,7.0,IC50,uM,0.007,Cc1ccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)cc1,2008.0
Inhibition of CDK2,Cc1cccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)c1,CHEMBL1141545,=,=,IC50,nM,10.0,IC50,uM,0.01,Cc1cccc(CC(=O)Nc2n[nH]c3ccc(N4CCCS4(=O)=O)cc23)c1,2008.0
Inhibition of CDK2,O=C(Cc1ccc(Br)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,7.0,IC50,uM,0.007,O=C(Cc1ccc(Br)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1cccc(Br)c1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,7.0,IC50,uM,0.007,O=C(Cc1cccc(Br)c1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1ccc(Cl)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,10.0,IC50,uM,0.01,O=C(Cc1ccc(Cl)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1cccc(Cl)c1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,10.0,IC50,uM,0.01,O=C(Cc1cccc(Cl)c1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1ccccc1Cl)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,24.0,IC50,uM,0.024,O=C(Cc1ccccc1Cl)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1ccc(F)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,20.0,IC50,uM,0.02,O=C(Cc1ccc(F)cc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1cccc(F)c1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,10.0,IC50,uM,0.01,O=C(Cc1cccc(F)c1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1ccccc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,CHEMBL1141545,=,=,IC50,nM,36.0,IC50,uM,0.036,O=C(Cc1ccccc1)Nc1n[nH]c2ccc(N3CCCS3(=O)=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1ccccc1)Nc1n[nH]c2ccc(N3C(=O)CNC3=O)cc12,CHEMBL1141545,=,=,IC50,nM,2000.0,IC50,uM,2.0,O=C(Cc1ccccc1)Nc1n[nH]c2ccc(N3C(=O)CNC3=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1ccccc1)Nc1n[nH]c2ccc(N3CCCCC3=O)cc12,CHEMBL1141545,=,=,IC50,nM,7100.0,IC50,uM,7.1,O=C(Cc1ccccc1)Nc1n[nH]c2ccc(N3CCCCC3=O)cc12,2008.0
Inhibition of CDK2,O=C(Cc1ccccc1)Nc1n[nH]c2ccc(N3CCCC3=O)cc12,CHEMBL1141545,=,=,IC50,nM,170.0,IC50,uM,0.17,O=C(Cc1ccccc1)Nc1n[nH]c2ccc(N3CCCC3=O)cc12,2008.0
Inhibition of CDK2,CCCCN(CCCC)c1ccc2[nH]nc(NC(=O)Cc3ccccc3)c2c1,CHEMBL1141545,>,>,IC50,nM,100000.0,IC50,uM,100.0,CCCCN(CCCC)c1ccc2[nH]nc(NC(=O)Cc3ccccc3)c2c1,2008.0
Inhibition of CDK2,CCCN(CCC)c1ccc2[nH]nc(NC(=O)Cc3ccccc3)c2c1,CHEMBL1141545,=,=,IC50,nM,1800.0,IC50,uM,1.8,CCCN(CCC)c1ccc2[nH]nc(NC(=O)Cc3ccccc3)c2c1,2008.0
Inhibition of CDK2,CCN(CC)c1ccc2[nH]nc(NC(=O)Cc3ccccc3)c2c1,CHEMBL1141545,=,=,IC50,nM,200.0,IC50,uM,0.2,CCN(CC)c1ccc2[nH]nc(NC(=O)Cc3ccccc3)c2c1,2008.0
Inhibition of CDK2,CCNc1ccc2[nH]nc(NC(=O)Cc3ccccc3)c2c1,CHEMBL1141545,=,=,IC50,nM,500.0,IC50,uM,0.5,CCNc1ccc2[nH]nc(NC(=O)Cc3ccccc3)c2c1,2008.0
Inhibition of CDK2,COc1cccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)c1,CHEMBL1143258,<,<,IC50,nM,16000.0,IC50,uM,16.0,COc1cccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)c1,2008.0
Inhibition of CDK2,NC(=O)c1c(NC(=O)CN2C(=O)CCC2=O)sc2c1CCC2,CHEMBL1143196,<,<,IC50,nM,10000.0,IC50,uM,10.0,NC(=O)c1c(NC(=O)CN2C(=O)CCC2=O)sc2c1CCC2,2008.0
Inhibition of CDK2 by FRET assay,NC(=O)c1c(NC(=O)CN2C(=O)CCC2=O)sc2c1CCC2,CHEMBL1143196,=,=,IC50,nM,7500.0,IC50,uM,7.5,NC(=O)c1c(NC(=O)CN2C(=O)CCC2=O)sc2c1CCC2,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,60.0,IC50,nM,60.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncccc4c32)cc1,CHEMBL1143196,=,=,IC50,nM,1.5,IC50,nM,1.5,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncccc4c32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1,CHEMBL1143196,=,=,IC50,nM,1.6,IC50,nM,1.6,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1143196,=,=,IC50,nM,2.8,IC50,nM,2.8,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncsc4c32)cc1,CHEMBL1143196,=,=,IC50,nM,7.1,IC50,nM,7.1,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncsc4c32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]nnc4c32)cc1,CHEMBL1143196,=,=,IC50,nM,9.5,IC50,nM,9.5,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]nnc4c32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]nc(Cl)c4c32)cc1,CHEMBL1143196,=,=,IC50,nM,2.2,IC50,nM,2.2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]nc(Cl)c4c32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]ncc4c32)cc1,CHEMBL1143196,=,=,IC50,nM,13.0,IC50,nM,13.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4[nH]ncc4c32)cc1,2008.0
Inhibition of CDK2,Cc1c([N+](=O)[O-])ccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,4.6,IC50,nM,4.6,Cc1c([N+](=O)[O-])ccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,COc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,54.0,IC50,nM,54.0,COc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,Cc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,13.0,IC50,nM,13.0,Cc1ccc2c(c1Cl)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cc(CO)ccc32)cc1,CHEMBL1143196,=,=,IC50,nM,61.0,IC50,nM,61.0,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cc(CO)ccc32)cc1,2008.0
Inhibition of CDK2,CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1143196,=,=,IC50,nM,75.0,IC50,nM,75.0,CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1,2008.0
Inhibition of CDK2,CCc1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1143196,=,=,IC50,nM,21.0,IC50,nM,21.0,CCc1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Br)ccc32)cc1,CHEMBL1143196,=,=,IC50,nM,43.0,IC50,nM,43.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Br)ccc32)cc1,2008.0
Inhibition of CDK2,COc1cccc(OC)c1CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,1.7,IC50,nM,1.7,COc1cccc(OC)c1CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,6.8,IC50,nM,6.8,CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4cccnc4)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,2.1,IC50,nM,2.1,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4cccnc4)cc32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,8.9,IC50,nM,8.9,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,25.0,IC50,nM,25.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,12.0,IC50,nM,12.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1,2008.0
Inhibition of CDK2,CN(C)C(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,17.0,IC50,nM,17.0,CN(C)C(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,NC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,4.5,IC50,nM,4.5,NC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,CC(C)CC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,1.9,IC50,nM,1.9,CC(C)CC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,3.0,IC50,nM,3.0,CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,2.1,IC50,nM,2.1,COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc(C(=O)O)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,28.0,IC50,nM,28.0,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc(C(=O)O)cc32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(=O)(=O)O)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,15.0,IC50,nM,15.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(=O)(=O)O)cc32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,43.0,IC50,nM,43.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)cc1,2008.0
Inhibition of CDK2,CS(=O)(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,16.0,IC50,nM,16.0,CS(=O)(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,310.0,IC50,nM,310.0,CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,Nc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,74.0,IC50,nM,74.0,Nc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc([N+](=O)[O-])cc32)cc1,CHEMBL1143196,=,=,IC50,nM,15.0,IC50,nM,15.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc([N+](=O)[O-])cc32)cc1,2008.0
Inhibition of CDK2,COc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,12.0,IC50,nM,12.0,COc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(O)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,10.0,IC50,nM,10.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(O)cc32)cc1,2008.0
Inhibition of CDK2,Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,46.0,IC50,nM,46.0,Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(I)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,11.0,IC50,nM,11.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(I)cc32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(F)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,34.0,IC50,nM,34.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(F)cc32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc([N+](=O)[O-])c32)cc1,CHEMBL1143196,=,=,IC50,nM,2400.0,IC50,nM,2400.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc([N+](=O)[O-])c32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cccc(CO)c32)cc1,CHEMBL1143196,=,=,IC50,nM,54.0,IC50,nM,54.0,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3cccc(CO)c32)cc1,2008.0
Inhibition of CDK2,CCOC(=O)c1cccc2c1/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,8.9,IC50,nM,8.9,CCOC(=O)c1cccc2c1/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(-c4cc[nH]n4)c32)cc1,CHEMBL1143196,=,=,IC50,nM,19.0,IC50,nM,19.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(-c4cc[nH]n4)c32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccc(O)cc4)c32)cc1,CHEMBL1143196,=,=,IC50,nM,12.0,IC50,nM,12.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccc(O)cc4)c32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(/C=C/c4ccc(O)cc4)c32)cc1,CHEMBL1143196,=,=,IC50,nM,9.3,IC50,nM,9.3,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(/C=C/c4ccc(O)cc4)c32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(OCCc4ccncc4)c32)cc1,CHEMBL1143196,=,=,IC50,nM,21.0,IC50,nM,21.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(OCCc4ccncc4)c32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(Oc4ccccc4)c32)cc1,CHEMBL1143196,=,=,IC50,nM,13.0,IC50,nM,13.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(Oc4ccccc4)c32)cc1,2008.0
Inhibition of CDK2,CC(C)Oc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,3.4,IC50,nM,3.4,CC(C)Oc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,CCOc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,93.0,IC50,nM,93.0,CCOc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,1.5,IC50,nM,1.5,CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,CC(C)Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,1.2,IC50,nM,1.2,CC(C)Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,CC(C)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,2.5,IC50,nM,2.5,CC(C)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,CCc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,=,=,IC50,nM,7.9,IC50,nM,7.9,CCc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(/N=N/c2c(O)[nH]c3cccc(I)c23)cc1,CHEMBL1143196,=,=,IC50,nM,4.6,IC50,nM,4.6,NS(=O)(=O)c1ccc(/N=N/c2c(O)[nH]c3cccc(I)c23)cc1,2008.0
Inhibition of CDK2,C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(-c3cnco3)cc21,CHEMBL1143196,=,=,IC50,nM,2.0,IC50,nM,2.0,C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(-c3cnco3)cc21,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,2.5,IC50,nM,2.5,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,2.3,IC50,nM,2.3,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1,2008.0
Inhibition of CDK2,C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(Cl)cc21,CHEMBL1143196,=,=,IC50,nM,22.0,IC50,nM,22.0,C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccc(Cl)cc21,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1,CHEMBL1143196,=,=,IC50,nM,43.0,IC50,nM,43.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1,2008.0
Inhibition of CDK2,C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21,CHEMBL1143196,=,=,IC50,nM,360.0,IC50,nM,360.0,C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1,CHEMBL1143196,=,=,IC50,nM,690.0,IC50,nM,690.0,NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccccc32)cc1,CHEMBL1143196,=,=,IC50,nM,120.0,IC50,nM,120.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccccc32)cc1,2008.0
Inhibition of CDK2,NC(=O)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,>,>,IC50,nM,1000.0,IC50,nM,1000.0,NC(=O)c1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,Cc1cc(Cl)cc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1143196,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1cc(Cl)cc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1,2008.0
Inhibition of CDK2,Cc1cc(C)c2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,CHEMBL1143196,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1cc(C)c2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2,2008.0
Inhibition of CDK2,Cc1cccc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1143196,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1cccc2c1NC(=O)/C2=C\Nc1ccc(S(N)(=O)=O)cc1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Oc4ccccc4)ccc32)cc1,CHEMBL1143196,>,>,IC50,nM,1000.0,IC50,nM,1000.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cc(Oc4ccccc4)ccc32)cc1,2008.0
Inhibition of CDK2,CC(C)(C)c1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1143196,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(C)(C)c1ccc2c(c1)NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1,2008.0
Inhibition of CDK2 at 10 uM,Nc1ncnc2oc(-c3cccnc3)c(-c3ccc(NS(=O)(=O)c4ccccc4)cc3)c12,CHEMBL1142374,=,=,Inhibition,%,27.0,Inhibition,%,27.0,Nc1ncnc2oc(-c3cccnc3)c(-c3ccc(NS(=O)(=O)c4ccccc4)cc3)c12,2008.0
Inhibition of Cdk2,COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1,CHEMBL1145498,>,>,IC50,nM,100000.0,IC50,nM,100000.0,COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1,2007.0
Inhibition of Cdk2,COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2,CHEMBL1145498,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2,2007.0
Inhibition of Cdk2,CC(C)n1cnc2c(NCc3ccccc3O)nc(NCCCO)nc21,CHEMBL1145498,=,=,IC50,nM,80.0,IC50,nM,80.0,CC(C)n1cnc2c(NCc3ccccc3O)nc(NCCCO)nc21,2007.0
Inhibition of Cdk2,COc1cc2ncnc(Nc3cccc(O)c3)c2cc1OC,CHEMBL1145498,=,=,IC50,nM,1000.0,IC50,nM,1000.0,COc1cc2ncnc(Nc3cccc(O)c3)c2cc1OC,2007.0
Inhibition of human CDK2,NC(=O)c1c(NC(=O)C2CC2)sc2c1CCCC2,CHEMBL1147038,,,Activity,,,Activity,,,NC(=O)c1c(NC(=O)C2CC2)sc2c1CCCC2,2007.0
Inhibition of CDK2 at 20 uM,CN(C)CCOc1ccc2c(-c3c(-c4ccccn4)nn4c3CCC4)ccnc2c1,CHEMBL1144852,<,<,Inhibition,%,50.0,Inhibition,%,50.0,CN(C)CCOc1ccc2c(-c3c(-c4ccccn4)nn4c3CCC4)ccnc2c1,2008.0
Inhibition of CDK2 at 20 uM,c1ccc(-c2nn3c(c2-c2ccnc4cc(OCCN5CCOCC5)ccc24)CCC3)nc1,CHEMBL1144852,<,<,Inhibition,%,50.0,Inhibition,%,50.0,c1ccc(-c2nn3c(c2-c2ccnc4cc(OCCN5CCOCC5)ccc24)CCC3)nc1,2008.0
Inhibition of Cdk2,Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1,CHEMBL1144728,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1,2008.0
Inhibition of CDK2,CS(=O)(=O)c1cccc(Nc2nccc(Nc3c(Cl)ccc4c3OCO4)n2)c1,CHEMBL1145633,=,=,IC50,nM,17600.0,IC50,uM,17.6,CS(=O)(=O)c1cccc(Nc2nccc(Nc3c(Cl)ccc4c3OCO4)n2)c1,2008.0
Inhibition of human CDK2/cyclinA at 1 uM,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1,CHEMBL1156453,=,=,Inhibition,%,50.0,INH,%,50.0,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1,2007.0
Inhibition of human CDK2/cyclinE at 1 uM,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1,CHEMBL1156453,=,=,Inhibition,%,44.0,INH,%,44.0,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1,2007.0
Inhibition of Cdk2/cyclin A,OCCn1cnc2c(NCc3ccccc3)nc(NCc3ccc(Br)cc3)nc21,CHEMBL1149915,=,=,IC50,nM,20000.0,IC50,uM,20.0,OCCn1cnc2c(NCc3ccccc3)nc(NCc3ccc(Br)cc3)nc21,2008.0
Binding affinity to CDK2,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL1156625,=,=,IC50,nM,100.0,IC50,uM,0.1,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2008.0
Binding affinity to CDK2,O=C(/C=C/c1ccc(O)c(O)c1)c1ccc(O)cc1O,CHEMBL1156625,=,=,Kd,nM,100000.0,Kd,uM,100.0,O=C(/C=C/c1ccc(O)c(O)c1)c1ccc(O)cc1O,2008.0
Inhibition of CDK2/cyclin E,O=C(Nc1ccc(Oc2ccnc3[nH]ccc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,CHEMBL1157356,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1ccc(Oc2ccnc3[nH]ccc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(-c3ccccc3)cc12)C1CC1,CHEMBL1156672,=,=,IC50,nM,5.0,IC50,nM,5.0,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(-c3ccccc3)cc12)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2nc(-c3cccs3)c(Br)cc12)C1CC1,CHEMBL1156672,=,=,IC50,nM,639.0,IC50,nM,639.0,O=C(Nc1n[nH]c2nc(-c3cccs3)c(Br)cc12)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2cc(-c3ccsc3)ccc12)C1CC1,CHEMBL1156672,=,=,IC50,nM,484.0,IC50,nM,484.0,O=C(Nc1n[nH]c2cc(-c3ccsc3)ccc12)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2cc(-c3cccs3)ccc12)C1CC1,CHEMBL1156672,=,=,IC50,nM,341.0,IC50,nM,341.0,O=C(Nc1n[nH]c2cc(-c3cccs3)ccc12)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2cc(-c3ccco3)ccc12)C1CC1,CHEMBL1156672,=,=,IC50,nM,631.0,IC50,nM,631.0,O=C(Nc1n[nH]c2cc(-c3ccco3)ccc12)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2cc(-c3ccc[nH]3)ccc12)C1CC1,CHEMBL1156672,=,=,IC50,nM,497.0,IC50,nM,497.0,O=C(Nc1n[nH]c2cc(-c3ccc[nH]3)ccc12)C1CC1,2008.0
Inhibition of CDK2,O=C(NC1=NNC2=CC=CC21)C1CC1,CHEMBL1156672,=,=,IC50,nM,5.0,IC50,nM,5.0,O=C(NC1=NNC2=CC=CC21)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2nc(-c3ccc(O)c(Br)c3)ccc12)C1CC1,CHEMBL1156672,=,=,IC50,nM,2.0,IC50,nM,2.0,O=C(Nc1n[nH]c2nc(-c3ccc(O)c(Br)c3)ccc12)C1CC1,2008.0
Inhibition of CDK2,CCN1CCN(CCCC(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1,CHEMBL1156672,=,=,IC50,nM,60.0,IC50,nM,60.0,CCN1CCN(CCCC(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2nc(-c3ccccc3)c(Br)cc12)C1CC1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3ccccc3)c(Br)cc12)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1,CHEMBL1156672,=,=,IC50,nM,5.0,IC50,nM,5.0,O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CCN(Cc2ccccc2)C1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CCN(Cc2ccccc2)C1,2008.0
Inhibition of CDK2,CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2nc(-c3nccs3)c(Br)cc12)C1CCCC1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3nccs3)c(Br)cc12)C1CCCC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2nc(-c3nccs3)c(Br)cc12)C1CC1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3nccs3)c(Br)cc12)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2nc(-c3cccs3)c(Br)cc12)C1CCCC1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2nc(-c3cccs3)c(Br)cc12)C1CCCC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2cc(-c3ccoc3)ccc12)C1CC1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2cc(-c3ccoc3)ccc12)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2cc(-c3cccc(F)c3)ccc12)C1CC1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2cc(-c3cccc(F)c3)ccc12)C1CC1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2cc(-c3ccc4[nH]ccc4c3)ccc12)C1CC1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2cc(-c3ccc4[nH]ccc4c3)ccc12)C1CC1,2008.0
Inhibition of CDK2,O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1,CHEMBL1156672,>,>,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1,2008.0
Inhibition of CDK2/CyclinA,Cc1cccc(C)c1/C=C/n1cnc2c(Nc3ccc(P(C)(C)=O)cc3)ncnc21,CHEMBL1139396,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1cccc(C)c1/C=C/n1cnc2c(Nc3ccc(P(C)(C)=O)cc3)ncnc21,2008.0
Inhibition of CDK2/cyclinA assessed as residual enzyme activity at 1 uM,Cc1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2Cl)s1,CHEMBL1139407,=,=,Activity,%,95.0,Activity,%,95.0,Cc1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2Cl)s1,2008.0
Inhibition of CDK2/cyclin A at 10 uM,O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCCc1nnn[nH]1,CHEMBL1156685,=,=,Inhibition,%,27.0,INH,%,27.0,O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCCc1nnn[nH]1,2008.0
Inhibition of CDK2/cyclin A at 10 uM,CS(=O)(=O)NC(=O)CCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O,CHEMBL1156685,=,=,Inhibition,%,54.0,INH,%,54.0,CS(=O)(=O)NC(=O)CCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O,2008.0
Inhibition of CDK2/cyclin A at 10 uM,CN(C)CCNC(=O)CCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O,CHEMBL1156685,=,=,Inhibition,%,48.0,INH,%,48.0,CN(C)CCNC(=O)CCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O,2008.0
Inhibition of CDK2/cyclin A at 10 uM,CNCCCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O,CHEMBL1156685,=,=,Inhibition,%,10.0,INH,%,10.0,CNCCCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O,2008.0
Inhibition of CDK2/cyclin A at 10 uM,CNCCCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4)cc21)C(=O)NC3=O,CHEMBL1156685,=,=,Inhibition,%,14.0,INH,%,14.0,CNCCCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4)cc21)C(=O)NC3=O,2008.0
Inhibition of CDK2/cyclin A at 10 uM,O=C1NC(=O)c2c1c(-c1c(Cl)cccc1Cl)cc1c2c2cc(O)ccc2n1CCCO,CHEMBL1156685,=,=,Inhibition,%,4.0,INH,%,4.0,O=C1NC(=O)c2c1c(-c1c(Cl)cccc1Cl)cc1c2c2cc(O)ccc2n1CCCO,2008.0
Inhibition of CDK2/cyclin A at 10 uM,O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCCO,CHEMBL1156685,=,=,Inhibition,%,38.0,INH,%,38.0,O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCCO,2008.0
Inhibition of CDK2/cyclin A at 10 uM,O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21,CHEMBL1156685,=,=,Inhibition,%,38.0,INH,%,38.0,O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21,2008.0
Inhibition of CDK2 at 30 uM,CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(C(F)(F)F)cc3)c2)n1,CHEMBL1156556,,,Activity,,,Activity,,,CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(C(F)(F)F)cc3)c2)n1,2008.0
Inhibition of CDK2 at 5 uM,O=C1NC(=O)/C(=C/c2cccc(C(F)(F)F)c2)S1,CHEMBL1139352,=,=,Inhibition,%,0.0,INH,%,0.0,O=C1NC(=O)/C(=C/c2cccc(C(F)(F)F)c2)S1,2009.0
Inhibition of CDK2 at 5 uM,CCCOc1ccc(/C=C2\SC(=O)NC2=O)cc1,CHEMBL1139352,=,=,Inhibition,%,-2.0,INH,%,-2.0,CCCOc1ccc(/C=C2\SC(=O)NC2=O)cc1,2009.0
Inhibition of Cdk2A,Nc1nccc(-c2cc3c([nH]2)[C@@H](CCF)CNC3=O)n1,CHEMBL1139384,=,=,IC50,nM,138.0,IC50,uM,0.138,Nc1nccc(-c2cc3c([nH]2)[C@@H](CCF)CNC3=O)n1,2009.0
Inhibition of CDK2/Cyclin A,c1ccc2[nH]c(-c3cc[nH]n3)nc2c1,CHEMBL1139387,=,=,IC50,nM,28000.0,IC50,uM,28.0,c1ccc2[nH]c(-c3cc[nH]n3)nc2c1,2009.0
Inhibition of CDK2/Cyclin A,CC(=O)Nc1c[nH]nc1-c1nc2ccccc2[nH]1,CHEMBL1139387,=,=,IC50,nM,990.0,IC50,uM,0.99,CC(=O)Nc1c[nH]nc1-c1nc2ccccc2[nH]1,2009.0
Inhibition of CDK2/Cyclin A,O=C(Nc1c[nH]nc1-c1nc2ccccc2[nH]1)c1ccccc1,CHEMBL1139387,=,=,IC50,nM,52.0,IC50,uM,0.052,O=C(Nc1c[nH]nc1-c1nc2ccccc2[nH]1)c1ccccc1,2009.0
Inhibition of CDK2/Cyclin A,O=C(Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1)c1ccccc1,CHEMBL1139387,=,=,IC50,nM,140.0,IC50,uM,0.14,O=C(Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1)c1ccccc1,2009.0
Inhibition of CDK2/Cyclin A,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)c1ccc(F)cc1,CHEMBL1139387,=,=,IC50,nM,530.0,IC50,uM,0.53,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)c1ccc(F)cc1,2009.0
Inhibition of CDK2/Cyclin A,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,CHEMBL1139387,,,IC50,,,IC50,,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,2009.0
Inhibition of CDK2/Cyclin A,O=C(Nc1ccccc1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,CHEMBL1139387,=,=,IC50,nM,1800.0,IC50,uM,1.8,O=C(Nc1ccccc1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,2009.0
Inhibition of CDK2/Cyclin A,O=C(Nc1ccccc1F)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,CHEMBL1139387,=,=,IC50,nM,230.0,IC50,uM,0.23,O=C(Nc1ccccc1F)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,2009.0
Inhibition of CDK2/Cyclin A,O=C(Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1)Nc1c(F)cccc1F,CHEMBL1139387,=,=,IC50,nM,160.0,IC50,uM,0.16,O=C(Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1)Nc1c(F)cccc1F,2009.0
Inhibition of CDK2/Cyclin A,O=C(Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1)NC1CCCCC1,CHEMBL1139387,=,=,IC50,nM,1200.0,IC50,uM,1.2,O=C(Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1)NC1CCCCC1,2009.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cccnc1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,CHEMBL1139387,=,=,IC50,nM,160.0,IC50,uM,0.16,O=C(Nc1cccnc1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,2009.0
Inhibition of CDK2/Cyclin A,O=C(Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1)NC1CCOCC1,CHEMBL1139387,,,IC50,,,IC50,,,O=C(Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1)NC1CCOCC1,2009.0
Inhibition of CDK2,Cc1nnc(-c2ccc(-c3cc(NC(=O)c4ccc(CN5CCN(C)CC5)cc4)ccc3C)c(C)c2)o1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1nnc(-c2ccc(-c3cc(NC(=O)c4ccc(CN5CCN(C)CC5)cc4)ccc3C)c(C)c2)o1,2008.0
Inhibition of CDK2,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1-c1ccc2ccncc2c1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1-c1ccc2ccncc2c1,2008.0
Inhibition of CDK2,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1-c1ccc2c(N)noc2c1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1-c1ccc2c(N)noc2c1,2008.0
Inhibition of CDK2,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1-c1ccc(-c2csc(N)n2)cc1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1-c1ccc(-c2csc(N)n2)cc1,2008.0
Inhibition of human CDK2 by HTRF assay,c1cnn2ncc(-c3ccnc(NC4CC4)n3)c2c1,CHEMBL1143431,=,=,IC50,nM,120.0,IC50,uM,0.12,c1cnn2ncc(-c3ccnc(NC4CC4)n3)c2c1,2008.0
Inhibition of human CDK2 by HTRF assay,FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1,CHEMBL1143431,=,=,IC50,nM,1000.0,IC50,uM,1.0,FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1,2008.0
Inhibition of human CDK2 by HTRF assay,Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1143431,=,=,IC50,nM,1000.0,IC50,uM,1.0,Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1,2008.0
Inhibition of human CDK2 by HTRF assay,c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1143431,=,=,IC50,nM,8.0,IC50,uM,0.008,c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2008.0
Inhibition of human CDK2 by HTRF assay,CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1,CHEMBL1143431,=,=,IC50,nM,4.0,IC50,uM,0.004,CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1,2008.0
Inhibition of human CDK2 by HTRF assay,CCN(CC)Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,CHEMBL1143431,=,=,IC50,nM,50.0,IC50,uM,0.05,CCN(CC)Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,2008.0
Inhibition of human CDK2 by HTRF assay,O=[N+]([O-])c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1143431,=,=,IC50,nM,3.0,IC50,uM,0.003,O=[N+]([O-])c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2008.0
Inhibition of human CDK2 by HTRF assay,O=[N+]([O-])c1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,CHEMBL1143431,=,=,IC50,nM,0.3,IC50,uM,0.0003,O=[N+]([O-])c1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,2008.0
Inhibition of human CDK2 by HTRF assay,N#Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1143431,=,=,IC50,nM,2.0,IC50,uM,0.002,N#Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2008.0
Inhibition of human CDK2 by HTRF assay,N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,CHEMBL1143431,=,=,IC50,nM,2.0,IC50,uM,0.002,N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,2008.0
Inhibition of human CDK2 by HTRF assay,c1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(-c2cocn2)c1,CHEMBL1143431,=,=,IC50,nM,3.0,IC50,uM,0.003,c1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(-c2cocn2)c1,2008.0
Inhibition of human CDK2 by HTRF assay,NC(=O)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1143431,=,=,IC50,nM,16.0,IC50,uM,0.016,NC(=O)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2008.0
Inhibition of human CDK2 by HTRF assay,O=C(O)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1143431,=,=,IC50,nM,40.0,IC50,uM,0.04,O=C(O)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2008.0
Inhibition of human CDK2 by HTRF assay,CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL1143431,=,=,IC50,nM,40.0,IC50,uM,0.04,CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2008.0
Inhibition of human CDK2 by HTRF assay,CCN(CC)CCNC(=O)c1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,CHEMBL1143431,=,=,IC50,nM,40.0,IC50,uM,0.04,CCN(CC)CCNC(=O)c1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,2008.0
Inhibition of human CDK2 by HTRF assay,CN1CCN(c2ccc(Nc3nccc(-c4cnn5nc(-c6ccc(F)cc6)ccc45)n3)cc2)CC1,CHEMBL1143431,>,>,IC50,nM,25000.0,IC50,uM,25.0,CN1CCN(c2ccc(Nc3nccc(-c4cnn5nc(-c6ccc(F)cc6)ccc45)n3)cc2)CC1,2008.0
Inhibition of human CDK2 by HTRF assay,CC(C)Oc1ccc2c(-c3ccnc(Nc4ccc(N5CCN(C)CC5)cc4)n3)cnn2n1,CHEMBL1143431,=,=,IC50,nM,230.0,IC50,uM,0.23,CC(C)Oc1ccc2c(-c3ccnc(Nc4ccc(N5CCN(C)CC5)cc4)n3)cnn2n1,2008.0
Inhibition of human CDK2 by HTRF assay,CN(C)CC(O)COc1ccc(Nc2nccc(-c3cnn4nc(N5CCOCC5)ccc34)n2)cc1,CHEMBL1143431,=,=,IC50,nM,450.0,IC50,uM,0.45,CN(C)CC(O)COc1ccc(Nc2nccc(-c3cnn4nc(N5CCOCC5)ccc34)n2)cc1,2008.0
Inhibition of human CDK2 by HTRF assay,CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2)CC1,CHEMBL1143431,=,=,IC50,nM,100.0,IC50,uM,0.1,CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2)CC1,2008.0
Inhibition of CDK2/cyclin A by IMAP florescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,CHEMBL1143434,=,=,IC50,nM,38.0,IC50,uM,0.038,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,2008.0
Inhibition of CDK2/cyclin A by IMAP florescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(NCC3CCNCC3)s2)o1,CHEMBL1143434,=,=,IC50,nM,229.0,IC50,uM,0.229,CC(C)(C)c1cnc(CSc2cnc(NCC3CCNCC3)s2)o1,2008.0
Inhibition of CDK2/cyclin A by IMAP florescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(NCC3CCCCC3)s2)o1,CHEMBL1143434,=,=,IC50,nM,168.0,IC50,uM,0.168,CC(C)(C)c1cnc(CSc2cnc(NCC3CCCCC3)s2)o1,2008.0
Inhibition of CDK2/cyclin A by IMAP florescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(N[C@H]3CC[C@H](N)CC3)s2)o1,CHEMBL1143434,=,=,IC50,nM,20.0,IC50,uM,0.02,CC(C)(C)c1cnc(CSc2cnc(N[C@H]3CC[C@H](N)CC3)s2)o1,2008.0
Inhibition of CDK2/cyclin A by IMAP florescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(N[C@H]3CC[C@@H](N)CC3)s2)o1,CHEMBL1143434,=,=,IC50,nM,503.0,IC50,uM,0.503,CC(C)(C)c1cnc(CSc2cnc(N[C@H]3CC[C@@H](N)CC3)s2)o1,2008.0
Inhibition of CDK2/cyclin A by IMAP florescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(N[C@H]3CC[C@H](O)CC3)s2)o1,CHEMBL1143434,=,=,IC50,nM,7.0,IC50,uM,0.007,CC(C)(C)c1cnc(CSc2cnc(N[C@H]3CC[C@H](O)CC3)s2)o1,2008.0
Inhibition of CDK2/cyclin A by IMAP florescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(NC3CCCC(N)C3)s2)o1,CHEMBL1143434,=,=,IC50,nM,158.0,IC50,uM,0.158,CC(C)(C)c1cnc(CSc2cnc(NC3CCCC(N)C3)s2)o1,2008.0
Inhibition of CDK2/cyclin A by IMAP florescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(NC3CCCC(O)C3)s2)o1,CHEMBL1143434,=,=,IC50,nM,28.0,IC50,uM,0.028,CC(C)(C)c1cnc(CSc2cnc(NC3CCCC(O)C3)s2)o1,2008.0
Inhibition of CDK2/cyclin A by IMAP florescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(NC3CCCCC3)s2)o1,CHEMBL1143434,=,=,IC50,nM,9.0,IC50,uM,0.009,CC(C)(C)c1cnc(CSc2cnc(NC3CCCCC3)s2)o1,2008.0
Inhibition of CDK2/cyclin A by IMAP florescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(NC3CCNCC3)s2)o1,CHEMBL1143434,=,=,IC50,nM,538.0,IC50,uM,0.538,CC(C)(C)c1cnc(CSc2cnc(NC3CCNCC3)s2)o1,2008.0
Inhibition of CDK2/cyclin A by IMAP florescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(N)s2)o1,CHEMBL1143434,=,=,IC50,nM,690.0,IC50,uM,0.69,CC(C)(C)c1cnc(CSc2cnc(N)s2)o1,2008.0
Inhibition of CDK2/CyclinA,Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1,CHEMBL1152233,>,>,IC50,nM,10000.0,IC50,uM,10.0,Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1,2008.0
Inhibition of CDK2,Cc1ccc(C(=O)Nc2cccc(N3CCOCC3)c2)cc1-c1ccc2c(C3CCNCC3)noc2c1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1ccc(C(=O)Nc2cccc(N3CCOCC3)c2)cc1-c1ccc2c(C3CCNCC3)noc2c1,2008.0
Inhibition of CDK2,Cc1nnc(-c2ccc(-c3cc(C(=O)Nc4cccc(N5CCOCC5)c4)ccc3C)c(C)c2)o1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1nnc(-c2ccc(-c3cc(C(=O)Nc4cccc(N5CCOCC5)c4)ccc3C)c(C)c2)o1,2008.0
Inhibition of CDK2,Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc2c(C3CCNCC3)noc2c1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc2c(C3CCNCC3)noc2c1,2008.0
Inhibition of CDK2,Cc1nnc(-c2ccc(-c3cc(NC(=O)c4ccnc(N5CCCC5)c4)ccc3C)c(C)c2)o1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1nnc(-c2ccc(-c3cc(NC(=O)c4ccnc(N5CCCC5)c4)ccc3C)c(C)c2)o1,2008.0
Inhibition of CDK2,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(C3CCNCC3)noc2c1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(C3CCNCC3)noc2c1,2008.0
Inhibition of CDK2,Cc1nnc(-c2ccc(-c3cc(C(=O)NC4CC4)ccc3C)c(C)c2)o1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1nnc(-c2ccc(-c3cc(C(=O)NC4CC4)ccc3C)c(C)c2)o1,2008.0
Inhibition of CDK2,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(=O)n(CC3CC3)nnc2c1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(=O)n(CC3CC3)nnc2c1,2008.0
Inhibition of CDK2,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2ccncc2c1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2ccncc2c1,2008.0
Inhibition of CDK2,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1,CHEMBL1141712,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1,2008.0
Inhibition of Cdk2 at 10 uM,Clc1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,Clc1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,Clc1cccc(-n2cc(-c3ccccc3NCc3c[nH]cn3)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,Clc1cccc(-n2cc(-c3ccccc3NCc3c[nH]cn3)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3ccnc4ccccc34)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3ccnc4ccccc34)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,Clc1cccc(-n2cc(-c3ccccc3NCc3ccnc4ccccc34)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,Clc1cccc(-n2cc(-c3ccccc3NCc3ccnc4ccccc34)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3ccc4c(c3)OCO4)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3ccc4c(c3)OCO4)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,Clc1cccc(-n2cc(-c3ccccc3NCc3ccc4c(c3)OCO4)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,Clc1cccc(-n2cc(-c3ccccc3NCc3ccc4c(c3)OCO4)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,Fc1ccc(CNc2ccccc2-c2cn(-c3cccc(Cl)c3)nn2)cc1F,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,Fc1ccc(CNc2ccccc2-c2cn(-c3cccc(Cl)c3)nn2)cc1F,2009.0
Inhibition of Cdk2 at 10 uM,Cc1cc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)ccc1C(F)(F)F,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,Cc1cc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)ccc1C(F)(F)F,2009.0
Inhibition of Cdk2 at 10 uM,Cc1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1C(F)(F)F,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,Cc1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1C(F)(F)F,2009.0
Inhibition of Cdk2 at 10 uM,Clc1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1Cl,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,Clc1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1Cl,2009.0
Inhibition of Cdk2 at 10 uM,FC(F)(F)c1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1Cl,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,FC(F)(F)c1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1Cl,2009.0
Inhibition of Cdk2 at 10 uM,FC(F)(F)c1cc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)ccc1Cl,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,FC(F)(F)c1cc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)ccc1Cl,2009.0
Inhibition of Cdk2 at 10 uM,c1ccc(-c2cn(-c3ccc4[nH]ncc4c3)nn2)c(NCc2ccncc2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,c1ccc(-c2cn(-c3ccc4[nH]ncc4c3)nn2)c(NCc2ccncc2)c1,2009.0
Inhibition of Cdk2 at 10 uM,c1ccc(-c2cn(-c3ccc4ccccc4n3)nn2)c(NCc2ccncc2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,c1ccc(-c2cn(-c3ccc4ccccc4n3)nn2)c(NCc2ccncc2)c1,2009.0
Inhibition of Cdk2 at 10 uM,CC(C)(C)c1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,CC(C)(C)c1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1,2009.0
Inhibition of Cdk2 at 10 uM,CC(C)(C)c1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,CC(C)(C)c1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,CC(C)c1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,CC(C)c1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,FC(F)(F)Oc1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,FC(F)(F)Oc1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1,2009.0
Inhibition of Cdk2 at 10 uM,FC(F)(F)c1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,FC(F)(F)c1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1,2009.0
Inhibition of Cdk2 at 10 uM,Clc1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,Clc1ccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)cc1,2009.0
Inhibition of Cdk2 at 10 uM,FC(F)(F)Oc1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,FC(F)(F)Oc1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3ccccn3)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3ccccn3)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3cccnc3)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3cccnc3)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,FC(F)(F)c1cccc(-n2cc(-c3ccccc3NCc3ccncc3)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,Clc1cccc(-n2cc(-c3ccccc3NCc3ccccn3)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,Clc1cccc(-n2cc(-c3ccccc3NCc3ccccn3)nn2)c1,2009.0
Inhibition of Cdk2 at 10 uM,Clc1cccc(-n2cc(-c3ccccc3NCc3cccnc3)nn2)c1,CHEMBL1153264,<,<,Inhibition,%,30.0,INH,%,30.0,Clc1cccc(-n2cc(-c3ccccc3NCc3cccnc3)nn2)c1,2009.0
Inhibition of CDK2 by virtual HTS assay,O=C(NC(=S)Nc1ccc(O)c(-c2nc3ccccc3s2)c1)c1ccc([N+](=O)[O-])cc1,CHEMBL1153282,=,=,IC50,nM,700.0,IC50,uM,0.7,O=C(NC(=S)Nc1ccc(O)c(-c2nc3ccccc3s2)c1)c1ccc([N+](=O)[O-])cc1,2009.0
Inhibition of CDK2 at 10 uM,CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1,CHEMBL1153342,>,>,Inhibition,%,50.0,INH,%,50.0,CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1,2009.0
Inhibition of Cdk2,CNc1nc2oc(-c3ccccc3)nc2c2c1ncn2C,CHEMBL1153345,=,=,IC50,nM,16000.0,IC50,uM,16.0,CNc1nc2oc(-c3ccccc3)nc2c2c1ncn2C,2009.0
Inhibition of Cdk2,CNc1nc2c(nc(-c3ccccc3)n2C)c2c1ncn2C,CHEMBL1153345,=,=,IC50,nM,23000.0,IC50,uM,23.0,CNc1nc2c(nc(-c3ccccc3)n2C)c2c1ncn2C,2009.0
Inhibition of Cdk2,CNc1nc2sc(-c3cccc(CNC(C)=O)c3)nc2c2c1ncn2C,CHEMBL1153345,=,=,IC50,nM,31000.0,IC50,uM,31.0,CNc1nc2sc(-c3cccc(CNC(C)=O)c3)nc2c2c1ncn2C,2009.0
Inhibition of Cdk2/cyclinA,O=C1N=C(NCc2ccccc2)S/C1=C\c1c[nH]c2ncccc12,CHEMBL1137791,<,<,IC50,nM,50.0,IC50,nM,50.0,O=C1N=C(NCc2ccccc2)S/C1=C\c1c[nH]c2ncccc12,2009.0
Inhibition of CDK2/cyclin A up to 100 uM,CN(C)c1ncnc2c1ncn2CC(=O)c1c[nH]c2ccccc12,CHEMBL1137681,,,Inhibition,%,,INH,,,CN(C)c1ncnc2c1ncn2CC(=O)c1c[nH]c2ccccc12,2009.0
Inhibition of CDK2/cyclin A up to 100 uM,COc1ncnc2ncn(CC(=O)c3ccccc3)c12,CHEMBL1137681,,,Inhibition,%,,INH,,,COc1ncnc2ncn(CC(=O)c3ccccc3)c12,2009.0
Inhibition of CDK2/cyclin A up to 100 uM,COc1ncnc2c1ncn2CC(=O)c1ccccc1,CHEMBL1137681,,,Inhibition,%,,INH,,,COc1ncnc2c1ncn2CC(=O)c1ccccc1,2009.0
Inhibition of CDK2/cyclin A up to 100 uM,Nc1ncnc2c1ncn2CC(=O)c1cccnc1,CHEMBL1137681,,,Inhibition,%,,INH,,,Nc1ncnc2c1ncn2CC(=O)c1cccnc1,2009.0
Inhibition of CDK2/cyclin A up to 100 uM,Nc1ncnc2c1ncn2CC(=O)c1ccccn1,CHEMBL1137681,,,Inhibition,%,,INH,,,Nc1ncnc2c1ncn2CC(=O)c1ccccn1,2009.0
Inhibition of CDK2/cyclin A up to 100 uM,Nc1ncnc2ncn(CC(=O)c3ccccc3)c12,CHEMBL1137681,,,Inhibition,%,,INH,,,Nc1ncnc2ncn(CC(=O)c3ccccc3)c12,2009.0
Inhibition of CDK2/cyclin A up to 100 uM,Nc1ncnc2c1ncn2CC(=O)c1ccccc1,CHEMBL1137681,,,Inhibition,%,,INH,,,Nc1ncnc2c1ncn2CC(=O)c1ccccc1,2009.0
Inhibition of CDK2/cyclin A up to 100 uM,Nc1ncnc2ncn(CC(=O)c3c[nH]c4ccccc34)c12,CHEMBL1137681,,,Inhibition,%,,INH,,,Nc1ncnc2ncn(CC(=O)c3c[nH]c4ccccc34)c12,2009.0
Inhibition of CDK2/cyclin A up to 100 uM,Nc1ncnc2c1ncn2CC(=O)c1c[nH]c2ccccc12,CHEMBL1137681,,,Inhibition,%,,INH,,,Nc1ncnc2c1ncn2CC(=O)c1c[nH]c2ccccc12,2009.0
Inhibition of CDK2/cyclin A at 10 uM,Nc1ncnc2ncn(CC(=O)c3c[nH]c4ccccc34)c12,CHEMBL1137681,,,Inhibition,%,,INH,,,Nc1ncnc2ncn(CC(=O)c3c[nH]c4ccccc34)c12,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(N(C)c2cc(N3CCN(C(=O)Cc4c[nH]c5ccccc45)CC3)ncn2)c1,CHEMBL1150387,=,=,Inhibition,%,10.0,INH,%,10.0,Cc1cccc(N(C)c2cc(N3CCN(C(=O)Cc4c[nH]c5ccccc45)CC3)ncn2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,CN(C)CC(C)(C)CNC(=O)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1,CHEMBL1150387,=,=,Inhibition,%,24.0,INH,%,24.0,CN(C)CC(C)(C)CNC(=O)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Nc1nc(N2CCOCC2)cc(N2CCC(C(=O)NCCc3ccc(O)cc3)CC2)n1,CHEMBL1150387,=,=,Inhibition,%,5.0,INH,%,5.0,Nc1nc(N2CCOCC2)cc(N2CCC(C(=O)NCCc3ccc(O)cc3)CC2)n1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,O=C(NCCc1ccc(O)cc1)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1,CHEMBL1150387,=,=,Inhibition,%,8.0,INH,%,8.0,O=C(NCCc1ccc(O)cc1)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,O=C(c1nc(SCc2ccc(Cl)cc2)n2ccccc12)N1CCN(c2cc(Nc3cccc(Br)c3)ncn2)CC1,CHEMBL1150387,=,=,Inhibition,%,5.0,INH,%,5.0,O=C(c1nc(SCc2ccc(Cl)cc2)n2ccccc12)N1CCN(c2cc(Nc3cccc(Br)c3)ncn2)CC1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Nc1nc(Nc2ccc3ncsc3c2)cc(N2CCC[C@H]2C(=O)N[C@@H](CO)c2ccccc2)n1,CHEMBL1150387,=,=,Inhibition,%,1.0,INH,%,1.0,Nc1nc(Nc2ccc3ncsc3c2)cc(N2CCC[C@H]2C(=O)N[C@@H](CO)c2ccccc2)n1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Nc1nc(Nc2ccc3ncsc3c2)cc(N2CCC[C@H]2C(=O)NCCc2cccc(I)c2)n1,CHEMBL1150387,=,=,Inhibition,%,5.0,INH,%,5.0,Nc1nc(Nc2ccc3ncsc3c2)cc(N2CCC[C@H]2C(=O)NCCc2cccc(I)c2)n1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,O=C(NC1Cc2ccccc2C1)c1cccc(Nc2ccnc(N3CCN(c4ccccc4)CC3)n2)c1,CHEMBL1150387,=,=,Inhibition,%,2.0,INH,%,2.0,O=C(NC1Cc2ccccc2C1)c1cccc(Nc2ccnc(N3CCN(c4ccccc4)CC3)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCc4ccc(N(C)C)cc4)c3)ncn2)c1,CHEMBL1150387,=,=,Inhibition,%,1.0,INH,%,1.0,Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCc4ccc(N(C)C)cc4)c3)ncn2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(N(C)c2cc(Nc3ccc(CC(=O)Nc4ccc5ncsc5c4)cc3)ncn2)c1,CHEMBL1150387,=,=,Inhibition,%,4.0,INH,%,4.0,Cc1cccc(N(C)c2cc(Nc3ccc(CC(=O)Nc4ccc5ncsc5c4)cc3)ncn2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,COc1ccc(NC(=O)Cc2ccc(Nc3cc(N(C)c4cccc(C)c4)ncn3)cc2)cn1,CHEMBL1150387,=,=,Inhibition,%,6.0,INH,%,6.0,COc1ccc(NC(=O)Cc2ccc(Nc3cc(N(C)c4cccc(C)c4)ncn3)cc2)cn1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(Nc2nccc(Nc3cccc(C(=O)NCc4ccc(N(C)C)cc4)c3)n2)c1,CHEMBL1150387,=,=,Inhibition,%,1.0,INH,%,1.0,Cc1cccc(Nc2nccc(Nc3cccc(C(=O)NCc4ccc(N(C)C)cc4)c3)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,O=C(NCc1cccnc1)c1cccc(-c2ccc(Nc3ccc4ncsc4c3)nn2)c1,CHEMBL1150387,=,=,Inhibition,%,0.0,INH,%,0.0,O=C(NCc1cccnc1)c1cccc(-c2ccc(Nc3ccc4ncsc4c3)nn2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N4CCCC5CCCCC54)c3)ncn2)c1,CHEMBL1150387,=,=,Inhibition,%,4.0,INH,%,4.0,Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N4CCCC5CCCCC54)c3)ncn2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,COc1cccc(Nc2cc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)nc(N)n2)c1,CHEMBL1150387,=,=,Inhibition,%,1.0,INH,%,1.0,COc1cccc(Nc2cc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)nc(N)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(Nc2nccc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)n2)c1,CHEMBL1150387,=,=,Inhibition,%,28.0,INH,%,28.0,Cc1cccc(Nc2nccc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,O=C(CN1CCN(c2ncnc3c2CN(Cc2ccccc2)CC3)CC1)Nc1cc(F)ccc1F,CHEMBL1150387,=,=,Inhibition,%,9.0,INH,%,9.0,O=C(CN1CCN(c2ncnc3c2CN(Cc2ccccc2)CC3)CC1)Nc1cc(F)ccc1F,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,O=C(NCc1ccncc1)c1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1,CHEMBL1150387,=,=,Inhibition,%,15.0,INH,%,15.0,O=C(NCc1ccncc1)c1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(Nc2cc(Nc3cccc(C(=O)N(CC(C)O)CC(C)O)c3)ncn2)c1,CHEMBL1150387,=,=,Inhibition,%,3.0,INH,%,3.0,Cc1cccc(Nc2cc(Nc3cccc(C(=O)N(CC(C)O)CC(C)O)c3)ncn2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCCCn4ccnc4)c3)ncn2)c1,CHEMBL1150387,=,=,Inhibition,%,12.0,INH,%,12.0,Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCCCn4ccnc4)c3)ncn2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)ncn2)c1,CHEMBL1150387,=,=,Inhibition,%,21.0,INH,%,21.0,Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)ncn2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,CC(=O)N1CCN(C(=O)c2cccc(Nc3cc(N(C)c4cccc(C)c4)ncn3)c2)CC1,CHEMBL1150387,=,=,Inhibition,%,9.0,INH,%,9.0,CC(=O)N1CCN(C(=O)c2cccc(Nc3cc(N(C)c4cccc(C)c4)ncn3)c2)CC1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCc4ccncc4)c3)ncn2)c1,CHEMBL1150387,=,=,Inhibition,%,20.0,INH,%,20.0,Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCc4ccncc4)c3)ncn2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,CN(CCc1ccccn1)C(=O)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1,CHEMBL1150387,=,=,Inhibition,%,12.0,INH,%,12.0,CN(CCc1ccccn1)C(=O)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,COc1cccc(Nc2cc(Nc3cccc(C(=O)NCCCn4ccnc4)c3)nc(N)n2)c1,CHEMBL1150387,=,=,Inhibition,%,2.0,INH,%,2.0,COc1cccc(Nc2cc(Nc3cccc(C(=O)NCCCn4ccnc4)c3)nc(N)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,COC[C@@H]1CCCN1C(=O)[C@@H]1CCCN1c1cc(Nc2cccc(OC)c2)nc(N)n1,CHEMBL1150387,=,=,Inhibition,%,7.0,INH,%,7.0,COC[C@@H]1CCCN1C(=O)[C@@H]1CCCN1c1cc(Nc2cccc(OC)c2)nc(N)n1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,COc1cccc(Nc2cc(N3CCC[C@H]3C(=O)NCCN3CCCCC3)nc(N)n2)c1,CHEMBL1150387,=,=,Inhibition,%,12.0,INH,%,12.0,COc1cccc(Nc2cc(N3CCC[C@H]3C(=O)NCCN3CCCCC3)nc(N)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,O=C(COc1ccccc1)N1CCN(c2nccc(Nc3ccc4ncsc4c3)n2)CC1,CHEMBL1150387,=,=,Inhibition,%,8.0,INH,%,8.0,O=C(COc1ccccc1)N1CCN(c2nccc(Nc3ccc4ncsc4c3)n2)CC1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,O=C(NC[C@@H]1CCCO1)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1,CHEMBL1150387,=,=,Inhibition,%,38.0,INH,%,38.0,O=C(NC[C@@H]1CCCO1)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Clc1ccc2sc(CN3CCN(c4ncnc5c4CN(Cc4ccccc4)CC5)CC3)cc2c1,CHEMBL1150387,=,=,Inhibition,%,16.0,INH,%,16.0,Clc1ccc2sc(CN3CCN(c4ncnc5c4CN(Cc4ccccc4)CC5)CC3)cc2c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Nc1nc(Nc2ccccc2)cc(N2CCC(C(=O)NCCc3ccccn3)CC2)n1,CHEMBL1150387,=,=,Inhibition,%,17.0,INH,%,17.0,Nc1nc(Nc2ccccc2)cc(N2CCC(C(=O)NCCc3ccccn3)CC2)n1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,CC(=O)CCCCC(=O)N1CCN(c2nccc(Oc3cccc(C)c3)n2)CC1,CHEMBL1150387,=,=,Inhibition,%,10.0,INH,%,10.0,CC(=O)CCCCC(=O)N1CCN(c2nccc(Oc3cccc(C)c3)n2)CC1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,COc1ccc(-c2noc(CN3CCN(c4cc(Nc5cccc(O)c5)ncn4)CC3)n2)cc1,CHEMBL1150387,=,=,Inhibition,%,6.0,INH,%,6.0,COc1ccc(-c2noc(CN3CCN(c4cc(Nc5cccc(O)c5)ncn4)CC3)n2)cc1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(Oc2ccnc(N3CCN(CC(=O)Nc4cccc5c4CCCC5)CC3)n2)c1,CHEMBL1150387,=,=,Inhibition,%,4.0,INH,%,4.0,Cc1cccc(Oc2ccnc(N3CCN(CC(=O)Nc4cccc5c4CCCC5)CC3)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(N(C)c2cc(N3CCN(CC(=O)Nc4nc(-c5ccccc5)cs4)CC3)ncn2)c1,CHEMBL1150387,=,=,Inhibition,%,2.0,INH,%,2.0,Cc1cccc(N(C)c2cc(N3CCN(CC(=O)Nc4nc(-c5ccccc5)cs4)CC3)ncn2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Nc1nc(Nc2ccc(C(=O)NCCc3ccncc3)cc2)cc(N2CCOCC2)n1,CHEMBL1150387,=,=,Inhibition,%,2.0,INH,%,2.0,Nc1nc(Nc2ccc(C(=O)NCCc3ccncc3)cc2)cc(N2CCOCC2)n1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(Nc2nccc3c2CN(C(=O)c2cc(C)n(C)c2C)CC3)c1,CHEMBL1150387,=,=,Inhibition,%,8.0,INH,%,8.0,Cc1cccc(Nc2nccc3c2CN(C(=O)c2cc(C)n(C)c2C)CC3)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cc(C(=O)N2CCN(c3ncnc4c3CN(Cc3ccccc3)CC4)CC2)c(C)n1C,CHEMBL1150387,=,=,Inhibition,%,3.0,INH,%,3.0,Cc1cc(C(=O)N2CCN(c3ncnc4c3CN(Cc3ccccc3)CC4)CC2)c(C)n1C,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Nc1nc(N2CCOCC2)cc(N2CCC(C(=O)NCc3cccs3)CC2)n1,CHEMBL1150387,=,=,Inhibition,%,14.0,INH,%,14.0,Nc1nc(N2CCOCC2)cc(N2CCC(C(=O)NCc3cccs3)CC2)n1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,COc1cccc(Nc2cc(N3CCC[C@H]3C(=O)NCCc3ccc(O)cc3)nc(N)n2)c1,CHEMBL1150387,=,=,Inhibition,%,3.0,INH,%,3.0,COc1cccc(Nc2cc(N3CCC[C@H]3C(=O)NCCc3ccc(O)cc3)nc(N)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(Oc2ccnc(N3CCC[C@H]3C(=O)NCc3cccnc3)n2)c1,CHEMBL1150387,=,=,Inhibition,%,8.0,INH,%,8.0,Cc1cccc(Oc2ccnc(N3CCC[C@H]3C(=O)NCc3cccnc3)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,COC(=O)C(CO)NC(=O)[C@@H]1CCCN1c1nccc(Oc2cccc(C)c2)n1,CHEMBL1150387,=,=,Inhibition,%,6.0,INH,%,6.0,COC(=O)C(CO)NC(=O)[C@@H]1CCCN1c1nccc(Oc2cccc(C)c2)n1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(Oc2ccnc(N3CCN(C(=O)c4c(C)noc4C)CC3)n2)c1,CHEMBL1150387,=,=,Inhibition,%,2.0,INH,%,2.0,Cc1cccc(Oc2ccnc(N3CCN(C(=O)c4c(C)noc4C)CC3)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,CN(C)CC(C)(C)CNC(=O)C1CCN(c2cc(N3CCOCC3)nc(N)n2)CC1,CHEMBL1150387,=,=,Inhibition,%,8.0,INH,%,8.0,CN(C)CC(C)(C)CNC(=O)C1CCN(c2cc(N3CCOCC3)nc(N)n2)CC1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(Oc2ccnc(N3CCC[C@H]3C(=O)NCCCn3ccnc3)n2)c1,CHEMBL1150387,=,=,Inhibition,%,3.0,INH,%,3.0,Cc1cccc(Oc2ccnc(N3CCC[C@H]3C(=O)NCCCn3ccnc3)n2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,O=C(c1nc(SCc2ccc(Cl)cc2)n2ccccc12)N1CCN(c2ncnc3c2CN(Cc2ccccc2)CC3)CC1,CHEMBL1150387,=,=,Inhibition,%,0.0,INH,%,0.0,O=C(c1nc(SCc2ccc(Cl)cc2)n2ccccc12)N1CCN(c2ncnc3c2CN(Cc2ccccc2)CC3)CC1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,CN(C)c1ccc(C(=O)N2CCN(c3ncnc4c3CN(Cc3ccccc3)CC4)CC2)c2ccccc12,CHEMBL1150387,=,=,Inhibition,%,5.0,INH,%,5.0,CN(C)c1ccc(C(=O)N2CCN(c3ncnc4c3CN(Cc3ccccc3)CC4)CC2)c2ccccc12,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(Nc2ncnc3c2CN(C(=O)c2ccc(N(C)C)c4ccccc24)CC3)c1,CHEMBL1150387,=,=,Inhibition,%,24.0,INH,%,24.0,Cc1cccc(Nc2ncnc3c2CN(C(=O)c2ccc(N(C)C)c4ccccc24)CC3)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,COC[C@@H]1CCCN1C(=O)C1CCCN1c1cc(Nc2cccc(Br)c2)ncn1,CHEMBL1150387,=,=,Inhibition,%,4.0,INH,%,4.0,COC[C@@H]1CCCN1C(=O)C1CCCN1c1cc(Nc2cccc(Br)c2)ncn1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,COC[C@@H]1CCCN1C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1,CHEMBL1150387,=,=,Inhibition,%,0.0,INH,%,0.0,COC[C@@H]1CCCN1C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,CN(C)CC(C)(C)CNC(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1,CHEMBL1150387,=,=,Inhibition,%,9.0,INH,%,9.0,CN(C)CC(C)(C)CNC(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,O=C(C1CCN(c2nccc(Nc3ccccc3)n2)CC1)N1CC[C@@H](O)C1,CHEMBL1150387,=,=,Inhibition,%,5.0,INH,%,5.0,O=C(C1CCN(c2nccc(Nc3ccccc3)n2)CC1)N1CC[C@@H](O)C1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N(CC(C)C)CC(C)C)c3)ncn2)c1,CHEMBL1150387,=,=,Inhibition,%,6.0,INH,%,6.0,Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N(CC(C)C)CC(C)C)c3)ncn2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,CN(CCc1ccccn1)C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1,CHEMBL1150387,=,=,Inhibition,%,5.0,INH,%,5.0,CN(CCc1ccccn1)C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,CN(CCCn1ccnc1)C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1,CHEMBL1150387,=,=,Inhibition,%,24.0,INH,%,24.0,CN(CCCn1ccnc1)C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1cccc(CN2CCN(c3cc(N(C)c4cccc(C)c4)ncn3)CC2)c1,CHEMBL1150387,=,=,Inhibition,%,0.0,INH,%,0.0,Cc1cccc(CN2CCN(c3cc(N(C)c4cccc(C)c4)ncn3)CC2)c1,2008.0
Inhibition of CDK2 at 10 uM by HTRF assay relative to control,Cc1ccc(CN2CCN(c3nccc(C(C#N)c4ccccn4)n3)CC2)cc1,CHEMBL1150387,=,=,Inhibition,%,7.0,INH,%,7.0,Cc1ccc(CN2CCN(c3nccc(C(C#N)c4ccccn4)n3)CC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccccc43)cc2)CC1,CHEMBL1150411,>,>,IC50,nM,28000.0,IC50,uM,28.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccccc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(C#Cc5ccccc5)cc43)cc2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(C#Cc5ccccc5)cc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccc(C=O)cc5)cc43)cc2)CC1,CHEMBL1150411,=,=,IC50,nM,7700.0,IC50,uM,7.7,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccc(C=O)cc5)cc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccsc5)cc43)cc2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccsc5)cc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)cc2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccco5)cc43)cc2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccco5)cc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccccc5)cc43)cc2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccccc5)cc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(N5CCCCC5)cc43)cc2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(N5CCCCC5)cc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CC(=O)Nc1ccc2c(c1)/C(=C/Nc1ccc(N3CCN(C)CC3)cc1)C(=O)NC2=O,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CC(=O)Nc1ccc2c(c1)/C(=C/Nc1ccc(N3CCN(C)CC3)cc1)C(=O)NC2=O,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-n5cccc5)cc43)cc2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-n5cccc5)cc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(C(=O)N(C)C)cc43)cc2)CC1,CHEMBL1150411,=,=,IC50,nM,47000.0,IC50,uM,47.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(C(=O)N(C)C)cc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(I)cc43)cc2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(I)cc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc([N+](=O)[O-])cc43)cc2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc([N+](=O)[O-])cc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(Br)cc43)cc2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(Br)cc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4cc(Br)ccc43)cc2)CC1,CHEMBL1150411,=,=,IC50,nM,47000.0,IC50,uM,47.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4cc(Br)ccc43)cc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccccc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,=,=,IC50,nM,19600.0,IC50,uM,19.6,O=C1NC(=O)c2ccccc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccccc2/C1=C/Nc1ccc(CN2CCOCC2)cc1,CHEMBL1150411,=,=,IC50,nM,21000.0,IC50,uM,21.0,O=C1NC(=O)c2ccccc2/C1=C/Nc1ccc(CN2CCOCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccccc2/C1=C/Nc1ccc(N2CCOCC2)cc1,CHEMBL1150411,>,>,IC50,nM,29000.0,IC50,uM,29.0,O=C1NC(=O)c2ccccc2/C1=C/Nc1ccc(N2CCOCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(Br)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(Br)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2cnc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)cn2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2cnc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)cn2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ncc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)cn2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ncc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)cn2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)cc2F)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)cc2F)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)nn2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)nn2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)cn2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)cn2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)nc2)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(-c5ccoc5)cc43)nc2)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,C[C@@H]1CN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(I)cc43)cc2)[C@@H](C)CN1C,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,C[C@@H]1CN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(I)cc43)cc2)[C@@H](C)CN1C,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CC1CN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(I)cc43)cc2)CCN1C,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CC1CN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(I)cc43)cc2)CCN1C,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,C[C@@H]1CN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(I)cc43)cc2)C[C@H](C)N1C,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,C[C@@H]1CN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(I)cc43)cc2)C[C@H](C)N1C,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,C[C@@H]1CN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(I)cc43)cc2)C[C@H](C)N1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,C[C@@H]1CN(c2ccc(N/C=C3\C(=O)NC(=O)c4ccc(I)cc43)cc2)C[C@H](C)N1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CC2CC1CN2c1ccc(N/C=C2\C(=O)NC(=O)c3ccc(I)cc32)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CC2CC1CN2c1ccc(N/C=C2\C(=O)NC(=O)c3ccc(I)cc32)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,N#Cc1ccc2c(c1)/C(=C/Nc1ccc(CN3CCCCC3)cc1)C(=O)NC2=O,CHEMBL1150411,=,=,IC50,nM,26500.0,IC50,uM,26.5,N#Cc1ccc2c(c1)/C(=C/Nc1ccc(CN3CCCCC3)cc1)C(=O)NC2=O,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(-c3ccc(Oc4ccccc4)cc3)cc2/C1=C\Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(-c3ccc(Oc4ccccc4)cc3)cc2/C1=C\Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,COc1ccc(-c2ccc3c(c2)/C(=C/Nc2ccc(CN4CCCCC4)cc2)C(=O)NC3=O)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc(-c2ccc3c(c2)/C(=C/Nc2ccc(CN4CCCCC4)cc2)C(=O)NC3=O)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,COc1cccc(-c2ccc3c(c2)/C(=C/Nc2ccc(CN4CCCCC4)cc2)C(=O)NC3=O)c1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1cccc(-c2ccc3c(c2)/C(=C/Nc2ccc(CN4CCCCC4)cc2)C(=O)NC3=O)c1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(-c3ccc(O)cc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(-c3ccc(O)cc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(-c3cccc(O)c3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(-c3cccc(O)c3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(-c3ccc(Cl)cc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(-c3ccc(Cl)cc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(-c3ccc(F)cc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(-c3ccc(F)cc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(-c3ccsc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(-c3ccsc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(-c3cccnc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(-c3cccnc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(-c3ccoc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(-c3ccoc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(-c3ccccc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(-c3ccccc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(Nc3ccccc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(Nc3ccccc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN1CCN(c2ccc3c(c2)/C(=C/Nc2ccc(CN4CCCCC4)cc2)C(=O)NC3=O)CC1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN1CCN(c2ccc3c(c2)/C(=C/Nc2ccc(CN4CCCCC4)cc2)C(=O)NC3=O)CC1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(N3CCOCC3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(N3CCOCC3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(N3CCCCC3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(N3CCCCC3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CC(=O)Nc1ccc2c(c1)/C(=C/Nc1ccc(CN3CCCCC3)cc1)C(=O)NC2=O,CHEMBL1150411,=,=,IC50,nM,8100.0,IC50,uM,8.1,CC(=O)Nc1ccc2c(c1)/C(=C/Nc1ccc(CN3CCCCC3)cc1)C(=O)NC2=O,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(-n3cccc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(-n3cccc3)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,CN(C)C(=O)c1ccc2c(c1)/C(=C/Nc1ccc(CN3CCCCC3)cc1)C(=O)NC2=O,CHEMBL1150411,=,=,IC50,nM,39800.0,IC50,uM,39.8,CN(C)C(=O)c1ccc2c(c1)/C(=C/Nc1ccc(CN3CCCCC3)cc1)C(=O)NC2=O,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(I)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,=,=,IC50,nM,20400.0,IC50,uM,20.4,O=C1NC(=O)c2ccc(I)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc([N+](=O)[O-])cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc([N+](=O)[O-])cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,COc1ccc2c(c1)/C(=C/Nc1ccc(CN3CCCCC3)cc1)C(=O)NC2=O,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc2c(c1)/C(=C/Nc1ccc(CN3CCCCC3)cc1)C(=O)NC2=O,2008.0
Inhibition of CDK2/cyclin E expressed in Sf9 cells-baculovirus system assessed as retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(Cl)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,CHEMBL1150411,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(Cl)cc2/C1=C/Nc1ccc(CN2CCCCC2)cc1,2008.0
Inhibition of CDK2 at 1 uM relative to control,Cc1ccn(-c2cccc(C(F)(F)F)c2)c(=O)c1-c1ccc2nc(N)ncc2c1,CHEMBL1150317,=,=,Inhibition,%,50.0,INH,%,50.0,Cc1ccn(-c2cccc(C(F)(F)F)c2)c(=O)c1-c1ccc2nc(N)ncc2c1,2008.0
Inhibition of CDK2/Cyclin A at 1 uM relative to control,COc1ccc(/C=N/Nc2[nH]nc(C)c2C(=O)Nc2cccc(NC(C)=O)c2)cc1,CHEMBL1140919,=,=,Inhibition,%,48.0,INH,%,48.0,COc1ccc(/C=N/Nc2[nH]nc(C)c2C(=O)Nc2cccc(NC(C)=O)c2)cc1,2009.0
Inhibition of CDK2,Cc1cc(C)cc(Nc2nccc(-c3nc(C)c(C(=O)N[C@H](C)CO)s3)n2)c1,CHEMBL1152268,>,>,Ki,nM,3330.0,Ki,uM,3.33,Cc1cc(C)cc(Nc2nccc(-c3nc(C)c(C(=O)N[C@H](C)CO)s3)n2)c1,2008.0
Inhibition of CDK2,Cc1cc(C)cc(Nc2nccc(-c3nc(C)c(C(=O)N[C@@H](C)CO)s3)n2)c1,CHEMBL1152268,>,>,Ki,nM,3330.0,Ki,uM,3.33,Cc1cc(C)cc(Nc2nccc(-c3nc(C)c(C(=O)N[C@@H](C)CO)s3)n2)c1,2008.0
Inhibition of CDK2,OCCCOc1cc(Nc2nccc(-c3nccs3)n2)cc(C(F)(F)F)c1,CHEMBL1152268,>,>,Ki,nM,5000.0,Ki,uM,5.0,OCCCOc1cc(Nc2nccc(-c3nccs3)n2)cc(C(F)(F)F)c1,2008.0
Inhibition of CDK2,Oc1cc(Nc2nccc(-c3nccs3)n2)cc(C(F)(F)F)c1,CHEMBL1152268,=,=,Ki,nM,1652.0,Ki,uM,1.652,Oc1cc(Nc2nccc(-c3nccs3)n2)cc(C(F)(F)F)c1,2008.0
Inhibition of CDK2,Cc1cc(Nc2nccc(-c3nc(CO)cs3)n2)cc(C(F)(F)F)c1,CHEMBL1152268,=,=,Ki,nM,1500.0,Ki,uM,1.5,Cc1cc(Nc2nccc(-c3nc(CO)cs3)n2)cc(C(F)(F)F)c1,2008.0
Inhibition of CDK2,COc1cc(Nc2nccc(-c3ncc(C)s3)n2)cc(C(F)(F)F)c1,CHEMBL1152268,>,>,Ki,nM,2500.0,Ki,uM,2.5,COc1cc(Nc2nccc(-c3ncc(C)s3)n2)cc(C(F)(F)F)c1,2008.0
Inhibition of CDK2,OCc1csc(-c2ccnc(Nc3cc(O)cc(C(F)(F)F)c3)n2)n1,CHEMBL1152268,=,=,Ki,nM,1500.0,Ki,uM,1.5,OCc1csc(-c2ccnc(Nc3cc(O)cc(C(F)(F)F)c3)n2)n1,2008.0
Inhibition of CDK2,COc1cc(Nc2nccc(-c3nc(CO)cs3)n2)cc(C(F)(F)F)c1,CHEMBL1152268,>,>,Ki,nM,2500.0,Ki,uM,2.5,COc1cc(Nc2nccc(-c3nc(CO)cs3)n2)cc(C(F)(F)F)c1,2008.0
Inhibition of CDK2,Cc1cc(Nc2nccc(-c3nc(C)c(CCO)s3)n2)cc(C(F)(F)F)c1,CHEMBL1152268,>,>,Ki,nM,2500.0,Ki,uM,2.5,Cc1cc(Nc2nccc(-c3nc(C)c(CCO)s3)n2)cc(C(F)(F)F)c1,2008.0
Inhibition of CDK2,Cc1cc(C)cc(Nc2nccc(-c3nc(C)c(CCO)s3)n2)c1,CHEMBL1152268,>,>,Ki,nM,2270.0,Ki,uM,2.27,Cc1cc(C)cc(Nc2nccc(-c3nc(C)c(CCO)s3)n2)c1,2008.0
Inhibition of CDK2,Cc1cc(C)cc(Nc2nccc(-c3nc(CO)cs3)n2)c1,CHEMBL1152268,=,=,Ki,nM,2400.0,Ki,uM,2.4,Cc1cc(C)cc(Nc2nccc(-c3nc(CO)cs3)n2)c1,2008.0
Inhibition of CDK2,Cc1cc(C)cc(Nc2nccc(-c3ncc(CO)s3)n2)c1,CHEMBL1152268,>,>,Ki,nM,2500.0,Ki,uM,2.5,Cc1cc(C)cc(Nc2nccc(-c3ncc(CO)s3)n2)c1,2008.0
Inhibition of CDK2,Cc1cc(C)cc(Nc2nccc(-c3nc(C)cs3)n2)c1,CHEMBL1152268,=,=,Ki,nM,100.0,Ki,uM,0.1,Cc1cc(C)cc(Nc2nccc(-c3nc(C)cs3)n2)c1,2008.0
Inhibition of CDK2,Cc1cc(C)cc(Nc2nccc(-c3ncc(C)s3)n2)c1,CHEMBL1152268,=,=,Ki,nM,1100.0,Ki,uM,1.1,Cc1cc(C)cc(Nc2nccc(-c3ncc(C)s3)n2)c1,2008.0
Inhibition of CDK2,Cc1ccc(C)c(Nc2nccc(-c3nccs3)n2)c1,CHEMBL1152268,>,>,Ki,nM,5000.0,Ki,uM,5.0,Cc1ccc(C)c(Nc2nccc(-c3nccs3)n2)c1,2008.0
Inhibition of CDK2,Cc1cccc(Nc2nccc(-c3nccs3)n2)c1,CHEMBL1152268,=,=,Ki,nM,2452.0,Ki,uM,2.452,Cc1cccc(Nc2nccc(-c3nccs3)n2)c1,2008.0
Inhibition of CDK2,COc1cc(Nc2nccc(-c3nccs3)n2)cc(OC)c1,CHEMBL1152268,>,>,Ki,nM,5000.0,Ki,uM,5.0,COc1cc(Nc2nccc(-c3nccs3)n2)cc(OC)c1,2008.0
Inhibition of CDK2,Cc1cc(Nc2nccc(-c3nccs3)n2)cc(C(F)(F)F)c1,CHEMBL1152268,>,>,Ki,nM,5000.0,Ki,uM,5.0,Cc1cc(Nc2nccc(-c3nccs3)n2)cc(C(F)(F)F)c1,2008.0
Inhibition of CDK2,COc1cc(Nc2nccc(-c3nccs3)n2)cc(C(F)(F)F)c1,CHEMBL1152268,>,>,Ki,nM,5000.0,Ki,uM,5.0,COc1cc(Nc2nccc(-c3nccs3)n2)cc(C(F)(F)F)c1,2008.0
Inhibition of CDK2,Cc1cc(C)cc(Nc2nccc(-c3nccs3)n2)c1,CHEMBL1152268,>,>,Ki,nM,5000.0,Ki,uM,5.0,Cc1cc(C)cc(Nc2nccc(-c3nccs3)n2)c1,2008.0
Inhibition of CDK2/cyclin A,COc1cc(Nc2ncc3c(C)nc(-c4ccccc4)n3n2)cc(OC)c1OC,CHEMBL1152258,=,=,IC50,nM,230.0,IC50,uM,0.23,COc1cc(Nc2ncc3c(C)nc(-c4ccccc4)n3n2)cc(OC)c1OC,2008.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccn(-c2ccoc2)c(=O)c1,CHEMBL1153424,=,=,IC50,nM,2600.0,IC50,uM,2.6,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccn(-c2ccoc2)c(=O)c1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccn(-c2ccccc2)c(=O)c1,CHEMBL1153424,=,=,IC50,nM,41500.0,IC50,uM,41.5,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccn(-c2ccccc2)c(=O)c1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(Br)cc2/C1=C/NCc1cc[nH]c(=O)c1,CHEMBL1153424,=,=,IC50,nM,2700.0,IC50,uM,2.7,O=C1NC(=O)c2ccc(Br)cc2/C1=C/NCc1cc[nH]c(=O)c1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1coc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1=O,CHEMBL1153424,=,=,IC50,nM,16900.0,IC50,uM,16.9,COc1coc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1=O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1cc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)ccn1,CHEMBL1153424,=,=,IC50,nM,6100.0,IC50,uM,6.1,COc1cc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)ccn1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(C3CCCC3)cc2/C1=C/NCc1cc(O)c(-c2ccoc2)cn1,CHEMBL1153424,=,=,IC50,nM,1300.0,IC50,uM,1.3,O=C1NC(=O)c2ccc(C3CCCC3)cc2/C1=C/NCc1cc(O)c(-c2ccoc2)cn1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,CC(C)(C)c1ccc2c(c1)/C(=C/NCc1cc(O)c(-c3ccoc3)cn1)C(=O)NC2=O,CHEMBL1153424,=,=,IC50,nM,1900.0,IC50,uM,1.9,CC(C)(C)c1ccc2c(c1)/C(=C/NCc1cc(O)c(-c3ccoc3)cn1)C(=O)NC2=O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1cc(O)c(-c2ccoc2)cn1,CHEMBL1153424,=,=,IC50,nM,2300.0,IC50,uM,2.3,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1cc(O)c(-c2ccoc2)cn1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,CC(C)(C)c1ccc2c(c1)/C(=C/NCc1cc(O)c(-c3ccccc3)cn1)C(=O)NC2=O,CHEMBL1153424,=,=,IC50,nM,2600.0,IC50,uM,2.6,CC(C)(C)c1ccc2c(c1)/C(=C/NCc1cc(O)c(-c3ccccc3)cn1)C(=O)NC2=O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,CCCOc1cnc(CN/C=C2\C(=O)NC(=O)c3ccc(C4CCCC4)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,1200.0,IC50,uM,1.2,CCCOc1cnc(CN/C=C2\C(=O)NC(=O)c3ccc(C4CCCC4)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,CCCOc1cnc(CN/C=C2\C(=O)NC(=O)c3ccc(C(C)(C)C)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,960.0,IC50,uM,0.96,CCCOc1cnc(CN/C=C2\C(=O)NC(=O)c3ccc(C(C)(C)C)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,CCCOc1cnc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,1600.0,IC50,uM,1.6,CCCOc1cnc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1cnc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,500.0,IC50,uM,0.5,COc1cnc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,CCCOc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)nc1O,CHEMBL1153424,=,=,IC50,nM,700.0,IC50,uM,0.7,CCCOc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)nc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1cnc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)nc1O,CHEMBL1153424,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1cnc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)nc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,CCCOc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,2600.0,IC50,uM,2.6,CCCOc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2ccncc2)c(O)c1,CHEMBL1153424,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2ccncc2)c(O)c1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2cccnc2)c(O)c1,CHEMBL1153424,=,=,IC50,nM,3600.0,IC50,uM,3.6,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2cccnc2)c(O)c1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2ccccn2)c(O)c1,CHEMBL1153424,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2ccccn2)c(O)c1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2ccoc2)c(O)c1,CHEMBL1153424,=,=,IC50,nM,4700.0,IC50,uM,4.7,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2ccoc2)c(O)c1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2ccco2)c(O)c1,CHEMBL1153424,=,=,IC50,nM,8400.0,IC50,uM,8.4,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2ccco2)c(O)c1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2ccccc2)c(O)c1,CHEMBL1153424,=,=,IC50,nM,15100.0,IC50,uM,15.1,O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2ccccc2)c(O)c1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,Cc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,13600.0,IC50,uM,13.6,Cc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,Nc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,6700.0,IC50,uM,6.7,Nc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1cc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc(O)c1OC,CHEMBL1153424,<,<,IC50,nM,50000.0,IC50,uM,50.0,COc1cc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc(O)c1OC,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,CCOc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,45500.0,IC50,uM,45.5,CCOc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COCCOc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,CHEMBL1153424,<,<,IC50,nM,50000.0,IC50,uM,50.0,COCCOc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,CCCOc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,CHEMBL1153424,<,<,IC50,nM,34500.0,IC50,uM,34.5,CCCOc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccc(Br)cc2/C1=C/NCc1ccc(O)c(O)c1,CHEMBL1153424,<,<,IC50,nM,50000.0,IC50,uM,50.0,O=C1NC(=O)c2ccc(Br)cc2/C1=C/NCc1ccc(O)c(O)c1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc(CN(C)/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,44400.0,IC50,uM,44.4,COc1ccc(CN(C)/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc(C(C)N/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,CHEMBL1153424,<,<,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc(C(C)N/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(-c4ccccc4)cc32)cc1O,CHEMBL1153424,<,<,IC50,nM,25900.0,IC50,uM,25.9,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(-c4ccccc4)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(-c4ccoc4)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,1100.0,IC50,uM,1.1,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(-c4ccoc4)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(-c4ccsc4)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,18300.0,IC50,uM,18.3,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(-c4ccsc4)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(-n4cccc4)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,3100.0,IC50,uM,3.1,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(-n4cccc4)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc2c(c1)/C(=C/NCc1ccc(OC)c(O)c1)C(=O)NC2=O,CHEMBL1153424,=,=,IC50,nM,2900.0,IC50,uM,2.9,COc1ccc2c(c1)/C(=C/NCc1ccc(OC)c(O)c1)C(=O)NC2=O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,870.0,IC50,uM,0.87,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(I)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,CHEMBL1153424,<,<,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(Br)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc(CN/C=C2\C(=O)NC(=O)c3cccc(Br)c32)cc1O,CHEMBL1153424,=,=,IC50,nM,3100.0,IC50,uM,3.1,COc1ccc(CN/C=C2\C(=O)NC(=O)c3cccc(Br)c32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(Cl)cc32)cc1O,CHEMBL1153424,<,<,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(Cl)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(F)cc32)cc1O,CHEMBL1153424,=,=,IC50,nM,6600.0,IC50,uM,6.6,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccc(F)cc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccccc32)cc1O,CHEMBL1153424,=,=,IC50,nM,6900.0,IC50,uM,6.9,COc1ccc(CN/C=C2\C(=O)NC(=O)c3ccccc32)cc1O,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccccc2/C1=C/NCc1cccc(O)c1,CHEMBL1153424,=,=,IC50,nM,16900.0,IC50,uM,16.9,O=C1NC(=O)c2ccccc2/C1=C/NCc1cccc(O)c1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccccc2/C1=C/NCc1ccc(O)cc1,CHEMBL1153424,=,=,IC50,nM,17300.0,IC50,uM,17.3,O=C1NC(=O)c2ccccc2/C1=C/NCc1ccc(O)cc1,2009.0
Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation,O=C1NC(=O)c2ccccc2/C1=C/NCc1ccc(O)c(O)c1,CHEMBL1153424,=,=,IC50,nM,12500.0,IC50,uM,12.5,O=C1NC(=O)c2ccccc2/C1=C/NCc1ccc(O)c(O)c1,2009.0
Inhibition of CDK2/Cyclin E,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2ccccc21,CHEMBL1153825,=,=,IC50,nM,1410.0,IC50,nM,1410.0,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2ccccc21,2009.0
Inhibition of CDK2/Cyclin E,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(F)ccc21,CHEMBL1153825,=,=,IC50,nM,237.0,IC50,nM,237.0,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(F)ccc21,2009.0
Inhibition of CDK2/Cyclin E,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(F)c(Cl)cc21,CHEMBL1153825,=,=,IC50,nM,11700.0,IC50,nM,11700.0,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(F)c(Cl)cc21,2009.0
Inhibition of CDK2/Cyclin E,COc1cccc2c(C3=C(c4cn(C)c5cc(Cl)c(F)cc45)C(=O)NC3=O)coc12,CHEMBL1153825,=,=,IC50,nM,99000.0,IC50,nM,99000.0,COc1cccc2c(C3=C(c4cn(C)c5cc(Cl)c(F)cc45)C(=O)NC3=O)coc12,2009.0
Inhibition of CDK2/Cyclin E,COc1cccc2c(C3=C(c4cn(C)c5ccc(Br)cc45)C(=O)NC3=O)coc12,CHEMBL1153825,=,=,IC50,nM,1160.0,IC50,nM,1160.0,COc1cccc2c(C3=C(c4cn(C)c5ccc(Br)cc45)C(=O)NC3=O)coc12,2009.0
Inhibition of CDK2/Cyclin E,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(Br)ccc21,CHEMBL1153825,=,=,IC50,nM,337.0,IC50,nM,337.0,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(Br)ccc21,2009.0
Inhibition of CDK2/Cyclin E,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc(Cl)ccc21,CHEMBL1153825,=,=,IC50,nM,1840.0,IC50,nM,1840.0,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc(Cl)ccc21,2009.0
Inhibition of CDK2/Cyclin E,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(I)ccc21,CHEMBL1153825,=,=,IC50,nM,1070.0,IC50,nM,1070.0,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(I)ccc21,2009.0
Inhibition of CDK2/Cyclin E,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(C3CC3)ccc21,CHEMBL1153825,=,=,IC50,nM,32000.0,IC50,nM,32000.0,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cc(C3CC3)ccc21,2009.0
Inhibition of CDK2/Cyclin E,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cccc(CO)c21,CHEMBL1153825,=,=,IC50,nM,149.0,IC50,nM,149.0,Cn1cc(C2=C(c3coc4ccccc34)C(=O)NC2=O)c2cccc(CO)c21,2009.0
Inhibition of CDK2/Cyclin E,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cccc(CO)c21,CHEMBL1153825,=,=,IC50,nM,27.0,IC50,nM,27.0,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cccc(CO)c21,2009.0
Inhibition of CDK2/Cyclin E,COCc1cccc2c(C3=C(c4coc5ccccc45)C(=O)NC3=O)cn(C)c12,CHEMBL1153825,=,=,IC50,nM,3880.0,IC50,nM,3880.0,COCc1cccc2c(C3=C(c4coc5ccccc45)C(=O)NC3=O)cn(C)c12,2009.0
Inhibition of CDK2/Cyclin E,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1153825,=,=,IC50,nM,3.8,IC50,nM,3.8,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009.0
Inhibition of CDK2/cyclin A at 1 uM,C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O,CHEMBL1153413,=,=,Inhibition,%,0.0,INH,%,0.0,C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O,2009.0
Inhibition of CDK2/Cyclin A,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(F)c(Cl)cc21,CHEMBL1153825,=,=,IC50,nM,10600.0,IC50,uM,10.6,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(F)c(Cl)cc21,2009.0
Inhibition of CDK2/Cyclin A,COc1cccc2c(C3=C(c4cn(C)c5cc(Cl)c(F)cc45)C(=O)NC3=O)coc12,CHEMBL1153825,=,=,IC50,nM,27200.0,IC50,uM,27.2,COc1cccc2c(C3=C(c4cn(C)c5cc(Cl)c(F)cc45)C(=O)NC3=O)coc12,2009.0
Inhibition of CDK2/Cyclin A,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(Br)ccc21,CHEMBL1153825,=,=,IC50,nM,550.0,IC50,uM,0.55,Cn1cc(C2=C(c3coc4cc(CO)ccc34)C(=O)NC2=O)c2cc(Br)ccc21,2009.0
Inhibition of CDK2/Cyclin A,COCc1cccc2c(C3=C(c4coc5ccccc45)C(=O)NC3=O)cn(C)c12,CHEMBL1153825,=,=,IC50,nM,4090.0,IC50,uM,4.09,COCc1cccc2c(C3=C(c4coc5ccccc45)C(=O)NC3=O)cn(C)c12,2009.0
Inhibition of CDK2/Cyclin A,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1153825,=,=,IC50,nM,1.4,IC50,uM,0.0014,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009.0
Inhibition of CDK2/Cyclin A,COc1cccc2c(C3=C(c4cn(C)c5cc(I)c(F)cc45)C(=O)NC3=O)coc12,CHEMBL1153825,>,>,IC50,nM,50000.0,IC50,nM,50000.0,COc1cccc2c(C3=C(c4cn(C)c5cc(I)c(F)cc45)C(=O)NC3=O)coc12,2009.0
Inhibition of CDK2/Cyclin E,COc1cccc2c(C3=C(c4cn(C)c5cc(I)c(F)cc45)C(=O)NC3=O)coc12,CHEMBL1153825,>,>,IC50,nM,50000.0,IC50,nM,50000.0,COc1cccc2c(C3=C(c4cn(C)c5cc(I)c(F)cc45)C(=O)NC3=O)coc12,2009.0
Inhibition of human cdk2/cyclin A,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,CHEMBL1153829,=,=,IC50,nM,70.0,IC50,nM,70.0,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,1998.0
Inhibition of human cdk2/cyclin E,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,CHEMBL1153829,=,=,IC50,nM,35.0,IC50,nM,35.0,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,1998.0
Inhibition of human cdk2/cyclin A,CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(=O)O)c(Cl)c2)c2ncn(C(C)C)c2n1,CHEMBL1153829,=,=,IC50,nM,6.0,IC50,nM,6.0,CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(=O)O)c(Cl)c2)c2ncn(C(C)C)c2n1,1998.0
Inhibition of human cdk2/cyclin E,CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(=O)O)c(Cl)c2)c2ncn(C(C)C)c2n1,CHEMBL1153829,=,=,IC50,nM,9.0,IC50,nM,9.0,CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(=O)O)c(Cl)c2)c2ncn(C(C)C)c2n1,1998.0
Inhibition of CDK2,Nc1cncc(Cl)n1,CHEMBL1157388,=,=,IC50,nM,350000.0,IC50,uM,350.0,Nc1cncc(Cl)n1,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(Nc2cncc(Cl)n2)cc1,CHEMBL1157388,=,=,IC50,nM,9100.0,IC50,uM,9.1,NS(=O)(=O)c1ccc(Nc2cncc(Cl)n2)cc1,2008.0
Inhibition of recombinant CDK2/CycA,Cc1cc(O)cc2oc(=O)c3c(O)cc(O)cc3c12,CHEMBL1157406,=,=,IC50,ug.mL-1,3.3,IC50,10'-6g/ml,3.3,Cc1cc(O)cc2oc(=O)c3c(O)cc(O)cc3c12,2008.0
Inhibition of recombinant CDK2/CycA,COc1cc(O)c2c(=O)oc3c(O)c(O)cc(C)c3c2c1,CHEMBL1157406,=,=,IC50,ug.mL-1,2.4,IC50,10'-6g/ml,2.4,COc1cc(O)c2c(=O)oc3c(O)c(O)cc(C)c3c2c1,2008.0
Inhibition of recombinant CDK2/CycA,COc1cc(O)c2c(=O)oc3cc(O)cc(C)c3c2c1,CHEMBL1157406,=,=,IC50,ug.mL-1,3.6,IC50,10'-6g/ml,3.6,COc1cc(O)c2c(=O)oc3cc(O)cc(C)c3c2c1,2008.0
Inhibition of recombinant CDK2/CycA,Cc1cc(O)cc2oc(=O)c3c(O)cc(OS(=O)(=O)O)cc3c12,CHEMBL1157406,=,=,IC50,ug.mL-1,0.84,IC50,10'-7g/ml,8.4,Cc1cc(O)cc2oc(=O)c3c(O)cc(OS(=O)(=O)O)cc3c12,2008.0
Inhibition of recombinant CDK2/CycA,COc1cc(O)c(C(=O)O)c(-c2cc(O)c(O)cc2C)c1,CHEMBL1157406,>,>,IC50,ug.mL-1,10.0,IC50,10'-5g/ml,1.0,COc1cc(O)c(C(=O)O)c(-c2cc(O)c(O)cc2C)c1,2008.0
Inhibition of recombinant CDK2/CycA,O=C1C[C@H](O)[C@@H]2c3c(ccc(O)c31)-c1ccc(O)c3c1[C@@]2(O)CCC3=O,CHEMBL1157406,>,>,IC50,ug.mL-1,10.0,IC50,10'-5g/ml,1.0,O=C1C[C@H](O)[C@@H]2c3c(ccc(O)c31)-c1ccc(O)c3c1[C@@]2(O)CCC3=O,2008.0
Inhibition of recombinant CDK2/CycA,COc1cc(O)c(C(=O)O)c(C2=C(C)C[C@@H](O)C2=O)c1,CHEMBL1157406,>,>,IC50,ug.mL-1,10.0,IC50,10'-5g/ml,1.0,COc1cc(O)c(C(=O)O)c(C2=C(C)C[C@@H](O)C2=O)c1,2008.0
Inhibition of recombinant CDK2/CycA,COc1cc(O)c2c(c1)C1(OC2=O)C(C)=CC(=O)C1O,CHEMBL1157406,>,>,IC50,ug.mL-1,10.0,IC50,10'-5g/ml,1.0,COc1cc(O)c2c(c1)C1(OC2=O)C(C)=CC(=O)C1O,2008.0
Inhibition of recombinant CDK2/CycA,COc1cc(O)c2c(c1)-c1cc(O)c(O)cc1COC2=O,CHEMBL1157406,>,>,IC50,ug.mL-1,10.0,IC50,10'-5g/ml,1.0,COc1cc(O)c2c(c1)-c1cc(O)c(O)cc1COC2=O,2008.0
Inhibition of recombinant CDK2/CycA,Cc1cc(O)c(O)cc1-c1cc(O)cc(O)c1C(=O)O,CHEMBL1157406,>,>,IC50,ug.mL-1,10.0,IC50,10'-5g/ml,1.0,Cc1cc(O)c(O)cc1-c1cc(O)cc(O)c1C(=O)O,2008.0
Inhibition of human recombinant CDK2/cyclin A,COc1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,CHEMBL1157465,=,=,IC50,nM,6900.0,IC50,uM,6.9,COc1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,2008.0
Inhibition of human recombinant CDK2/cyclin A,COc1cc(C2=C(c3cn(C)c4ccccc34)C(=O)NC2)cc(OC)c1OC,CHEMBL1157465,=,=,IC50,nM,42000.0,IC50,uM,42.0,COc1cc(C2=C(c3cn(C)c4ccccc34)C(=O)NC2)cc(OC)c1OC,2008.0
Inhibition of human recombinant CDK2/cyclin A,COc1cc(C2=C(c3cn(COc4ccccc4)c4ccccc34)CNC2=O)cc(OC)c1OC,CHEMBL1157465,=,=,IC50,nM,20000.0,IC50,uM,20.0,COc1cc(C2=C(c3cn(COc4ccccc4)c4ccccc34)CNC2=O)cc(OC)c1OC,2008.0
Inhibition of human recombinant CDK2/cyclin A,COc1cc(C2=C(c3cn(COC(C)(C)C)c4ccccc34)CNC2=O)cc(OC)c1OC,CHEMBL1157465,=,=,IC50,nM,23000.0,IC50,uM,23.0,COc1cc(C2=C(c3cn(COC(C)(C)C)c4ccccc34)CNC2=O)cc(OC)c1OC,2008.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,CHEMBL1142453,=,=,IC50,nM,2.0,IC50,uM,0.002,NS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,2008.0
Inhibition of CDK2,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,CHEMBL1142453,<,<,IC50,nM,12.0,IC50,uM,0.012,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,2008.0
Inhibition of CDK2,CNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4cccnn34)n2)cc1,CHEMBL1142453,<,<,IC50,nM,3.0,IC50,uM,0.003,CNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4cccnn34)n2)cc1,2008.0
Inhibition of CDK2,CN(C)CCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4cccnn34)n2)cc1,CHEMBL1142453,=,=,IC50,nM,8.0,IC50,uM,0.008,CN(C)CCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4cccnn34)n2)cc1,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(S(N)(=O)=O)cc3)n2)n1C,CHEMBL1142453,=,=,IC50,nM,11.0,IC50,uM,0.011,Cc1ncc(-c2ccnc(Nc3ccc(S(N)(=O)=O)cc3)n2)n1C,2008.0
Inhibition of CDK2,CNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C)n2)cc1,CHEMBL1142453,<,<,IC50,nM,3.0,IC50,uM,0.003,CNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C)n2)cc1,2008.0
Inhibition of CDK2,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C)n2)cc1,CHEMBL1142453,=,=,IC50,nM,8.0,IC50,uM,0.008,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C)n2)cc1,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)NCCCOC(C)C)cc3)n2)n1C,CHEMBL1142453,=,=,IC50,nM,6.0,IC50,uM,0.006,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)NCCCOC(C)C)cc3)n2)n1C,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)NCCN(C)C)cc3)n2)n1C,CHEMBL1142453,=,=,IC50,nM,25.0,IC50,uM,0.025,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)NCCN(C)C)cc3)n2)n1C,2008.0
Inhibition of CDK2,COCCN(C)S(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C)n2)cc1,CHEMBL1142453,=,=,IC50,nM,400.0,IC50,uM,0.4,COCCN(C)S(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C)n2)cc1,2008.0
Inhibition of CDK2,CCn1c(-c2ccnc(Nc3ccc(S(=O)(=O)NCCOC)cc3)n2)cnc1C,CHEMBL1142453,=,=,IC50,nM,4.0,IC50,uM,0.004,CCn1c(-c2ccnc(Nc3ccc(S(=O)(=O)NCCOC)cc3)n2)cnc1C,2008.0
Inhibition of CDK2,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1,CHEMBL1142453,=,=,IC50,nM,1.0,IC50,uM,0.001,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1,2008.0
Inhibition of CDK2,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C3CCCC3)n2)cc1,CHEMBL1142453,<,<,IC50,nM,3.0,IC50,uM,0.003,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C3CCCC3)n2)cc1,2008.0
Inhibition of CDK2,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3CC(C)C)n2)cc1,CHEMBL1142453,=,=,IC50,nM,15.0,IC50,uM,0.015,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3CC(C)C)n2)cc1,2008.0
Inhibition of CDK2,COCCN(C)S(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C3CC3)n2)cc1,CHEMBL1142453,=,=,IC50,nM,83.0,IC50,uM,0.083,COCCN(C)S(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C3CC3)n2)cc1,2008.0
Inhibition of CDK2,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3c(C)nc(C)n3C)n2)cc1,CHEMBL1142453,=,=,IC50,nM,68.0,IC50,uM,0.068,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3c(C)nc(C)n3C)n2)cc1,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)CCCN(C)C)cc3)n2)n1C,CHEMBL1142453,=,=,IC50,nM,295.0,IC50,uM,0.295,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)CCCN(C)C)cc3)n2)n1C,2008.0
Inhibition of CDK2,CCn1c(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)cnc1C,CHEMBL1142453,=,=,IC50,nM,23.0,IC50,uM,0.023,CCn1c(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)cnc1C,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,CHEMBL1142453,=,=,IC50,nM,6.0,IC50,uM,0.006,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,CCCS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1,CHEMBL1142453,=,=,IC50,nM,8.0,IC50,uM,0.008,CCCS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)Cc4ccccc4)cc3)n2)n1C(C)C,CHEMBL1142453,=,=,IC50,nM,19.0,IC50,uM,0.019,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)Cc4ccccc4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,COCCS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1,CHEMBL1142453,=,=,IC50,nM,14.0,IC50,uM,0.014,COCCS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)CC4CCCO4)cc3)n2)n1C(C)C,CHEMBL1142453,=,=,IC50,nM,13.0,IC50,uM,0.013,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)CC4CCCO4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)CCCN(C)C)cc3)n2)n1C(C)C,CHEMBL1142453,=,=,IC50,nM,36.0,IC50,uM,0.036,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)CCCN(C)C)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)CCCN4CCOCC4)cc3)n2)n1C(C)C,CHEMBL1142453,=,=,IC50,nM,33.0,IC50,uM,0.033,Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)CCCN4CCOCC4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2 at 3 uM,CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1,CHEMBL1142492,<,<,Inhibition,%,10.0,INH,%,10.0,CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1,CHEMBL1151712,,,Activity,,,Activity,,,NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2,CHEMBL1151712,,,Activity,,,Activity,,,N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,CHEMBL1151712,=,=,Activity,%,26.2,Activity,%,26.2,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1,CHEMBL1151712,=,=,Activity,%,0.9,Activity,%,0.9,N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O,CHEMBL1151712,,,Activity,,,Activity,,,NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2,CHEMBL1151712,=,=,Activity,%,28.3,Activity,%,28.3,CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,CHEMBL1151712,,,Activity,,,Activity,,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,2008.0
Inhibition of Cdk2,CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21,CHEMBL1144228,>,>,Ki,nM,8570.0,Ki,uM,8.57,CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21,2008.0
Inhibition of human recombinant CDK2/cyclin A expressed in baculovirus-infected insect cells,CC[C@H](CO)Nc1nc(NCc2ccccc2)n2ncc(C(C)C)c2n1,CHEMBL1143353,=,=,IC50,nM,40.0,IC50,uM,0.04,CC[C@H](CO)Nc1nc(NCc2ccccc2)n2ncc(C(C)C)c2n1,2009.0
Inhibition of human recombinant CDK2/cyclin A expressed in baculovirus-infected insect cells,CC(C)c1cnn2c(NCc3ccc(Cl)cc3)nc(N[C@@H](CO)C(C)C)nc12,CHEMBL1143353,=,=,IC50,nM,60.0,IC50,uM,0.06,CC(C)c1cnn2c(NCc3ccc(Cl)cc3)nc(N[C@@H](CO)C(C)C)nc12,2009.0
Inhibition of human recombinant CDK2/cyclin A expressed in baculovirus-infected insect cells,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,CHEMBL1143353,=,=,IC50,nM,70.0,IC50,uM,0.07,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,2009.0
Inhibition of human recombinant CDK2/cyclin A expressed in baculovirus-infected insect cells,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL1143353,=,=,IC50,nM,220.0,IC50,uM,0.22,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2009.0
Inhibition of human recombinant CDK2/cyclin A expressed in baculovirus-infected insect cells,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncc(C(C)C)n2n1,CHEMBL1143353,=,=,IC50,nM,220.0,IC50,uM,0.22,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncc(C(C)C)n2n1,2009.0
Inhibition of human recombinant CDK2/cyclin A expressed in baculovirus-infected insect cells,CC[C@@H](CO)Nc1nc(NCc2ccccc2)n2ncc(C(C)C)c2n1,CHEMBL1143353,,,IC50,,,IC50,,,CC[C@@H](CO)Nc1nc(NCc2ccccc2)n2ncc(C(C)C)c2n1,2009.0
Inhibition of CDK2/Cyclin B,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,CHEMBL1140982,=,=,IC50,nM,7000.0,IC50,uM,7.0,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,2009.0
Inhibition of CDK2/Cyclin E,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,CHEMBL1140982,=,=,IC50,nM,7000.0,IC50,uM,7.0,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,2009.0
Inhibition of CDK2 in human HeLa cells by immunoprecipitation kinase assay,C=CC1CC2(O)CC3(O)CCC=CC3C2(O)C1(O)CCC,CHEMBL1141027,,,Activity,,,Activity,,,C=CC1CC2(O)CC3(O)CCC=CC3C2(O)C1(O)CCC,2009.0
Inhibition of CDK2/Cyclin A,Cc1cc(NC(=O)c2ccccc2)n[nH]1,CHEMBL1140962,=,=,IC50,nM,1500.0,IC50,nM,1500.0,Cc1cc(NC(=O)c2ccccc2)n[nH]1,2008.0
Inhibition of CDK2/Cyclin A,CCCC(=O)Nc1cc(C)[nH]n1,CHEMBL1140962,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CCCC(=O)Nc1cc(C)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,CCCC(=O)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,=,=,IC50,nM,224.0,IC50,nM,224.0,CCCC(=O)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)n[nH]1)c1ccccc1,CHEMBL1140962,=,=,IC50,nM,290.0,IC50,nM,290.0,O=C(Nc1cc(C2CC2)n[nH]1)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1ccc(Br)cc1,CHEMBL1140962,=,=,IC50,nM,34.0,IC50,nM,34.0,O=C(Nc1cc(C2CC2)[nH]n1)c1ccc(Br)cc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1ccc(Cl)cc1,CHEMBL1140962,=,=,IC50,nM,85.0,IC50,nM,85.0,O=C(Nc1cc(C2CC2)[nH]n1)c1ccc(Cl)cc1,2008.0
Inhibition of CDK2/Cyclin A,COc1ccc(C(=O)Nc2cc(C3CC3)[nH]n2)cc1,CHEMBL1140962,=,=,IC50,nM,705.0,IC50,nM,705.0,COc1ccc(C(=O)Nc2cc(C3CC3)[nH]n2)cc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(O)c1ccc(C(=O)Nc2cc(C3CC3)[nH]n2)cc1,CHEMBL1140962,=,=,IC50,nM,165.0,IC50,nM,165.0,O=C(O)c1ccc(C(=O)Nc2cc(C3CC3)[nH]n2)cc1,2008.0
Inhibition of CDK2/Cyclin A,NC(=O)c1ccc(C(=O)Nc2cc(C3CC3)[nH]n2)cc1,CHEMBL1140962,=,=,IC50,nM,68.0,IC50,nM,68.0,NC(=O)c1ccc(C(=O)Nc2cc(C3CC3)[nH]n2)cc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1cccc(Br)c1,CHEMBL1140962,=,=,IC50,nM,990.0,IC50,nM,990.0,O=C(Nc1cc(C2CC2)[nH]n1)c1cccc(Br)c1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1cccc(Cl)c1,CHEMBL1140962,=,=,IC50,nM,1000.0,IC50,nM,1000.0,O=C(Nc1cc(C2CC2)[nH]n1)c1cccc(Cl)c1,2008.0
Inhibition of CDK2/Cyclin A,COc1cccc(C(=O)Nc2cc(C3CC3)[nH]n2)c1,CHEMBL1140962,=,=,IC50,nM,600.0,IC50,nM,600.0,COc1cccc(C(=O)Nc2cc(C3CC3)[nH]n2)c1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1cccc(C(F)(F)F)c1,CHEMBL1140962,=,=,IC50,nM,500.0,IC50,nM,500.0,O=C(Nc1cc(C2CC2)[nH]n1)c1cccc(C(F)(F)F)c1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1ccccc1Br,CHEMBL1140962,=,=,IC50,nM,1500.0,IC50,nM,1500.0,O=C(Nc1cc(C2CC2)[nH]n1)c1ccccc1Br,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1ccccc1Cl,CHEMBL1140962,=,=,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Nc1cc(C2CC2)[nH]n1)c1ccccc1Cl,2008.0
Inhibition of CDK2/Cyclin A,COc1ccccc1C(=O)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1ccccc1C(=O)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1c(Cl)cccc1Cl,CHEMBL1140962,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Nc1cc(C2CC2)[nH]n1)c1c(Cl)cccc1Cl,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1ccc(Cl)c(Cl)c1,CHEMBL1140962,=,=,IC50,nM,83.0,IC50,nM,83.0,O=C(Nc1cc(C2CC2)[nH]n1)c1ccc(Cl)c(Cl)c1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CCC2)[nH]n1)c1ccc(Br)cc1,CHEMBL1140962,=,=,IC50,nM,90.0,IC50,nM,90.0,O=C(Nc1cc(C2CCC2)[nH]n1)c1ccc(Br)cc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CCCC2)[nH]n1)c1ccc(Br)cc1,CHEMBL1140962,=,=,IC50,nM,50.0,IC50,nM,50.0,O=C(Nc1cc(C2CCCC2)[nH]n1)c1ccc(Br)cc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CCCCC2)[nH]n1)c1ccc(Br)cc1,CHEMBL1140962,=,=,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Nc1cc(C2CCCCC2)[nH]n1)c1ccc(Br)cc1,2008.0
Inhibition of CDK2/Cyclin A,Cc1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,CHEMBL1140962,=,=,IC50,nM,6000.0,IC50,nM,6000.0,Cc1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,2008.0
Inhibition of CDK2/Cyclin A,CCc1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,CHEMBL1140962,=,=,IC50,nM,630.0,IC50,nM,630.0,CCc1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,2008.0
Inhibition of CDK2/Cyclin A,CCCc1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,CHEMBL1140962,=,=,IC50,nM,650.0,IC50,nM,650.0,CCCc1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,2008.0
Inhibition of CDK2/Cyclin A,CC(C)c1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,CHEMBL1140962,=,=,IC50,nM,200.0,IC50,nM,200.0,CC(C)c1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,2008.0
Inhibition of CDK2/Cyclin A,CC(C)(C)c1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,CHEMBL1140962,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CC(C)(C)c1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(-c2ccccc2)[nH]n1)c1ccc(Br)cc1,CHEMBL1140962,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Nc1cc(-c2ccccc2)[nH]n1)c1ccc(Br)cc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(Cc2ccccc2)[nH]n1)c1ccc(Br)cc1,CHEMBL1140962,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(Nc1cc(Cc2ccccc2)[nH]n1)c1ccc(Br)cc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Cc1ccccc1)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,=,=,IC50,nM,48.0,IC50,nM,48.0,O=C(Cc1ccccc1)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,NC(=O)c1ccc(CC(=O)Nc2cc(C3CC3)[nH]n2)cc1,CHEMBL1140962,=,=,IC50,nM,74.0,IC50,nM,74.0,NC(=O)c1ccc(CC(=O)Nc2cc(C3CC3)[nH]n2)cc1,2008.0
Inhibition of CDK2/Cyclin A,COc1cccc(CC(=O)Nc2cc(C3CC3)[nH]n2)c1,CHEMBL1140962,=,=,IC50,nM,29.0,IC50,nM,29.0,COc1cccc(CC(=O)Nc2cc(C3CC3)[nH]n2)c1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Cc1ccc(OC(F)(F)F)cc1)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,=,=,IC50,nM,67.0,IC50,nM,67.0,O=C(Cc1ccc(OC(F)(F)F)cc1)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Cc1ccc(-c2ccccc2)cc1)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,=,=,IC50,nM,56.0,IC50,nM,56.0,O=C(Cc1ccc(-c2ccccc2)cc1)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Cc1ccc(-c2ccccc2)c(F)c1)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,=,=,IC50,nM,4.0,IC50,nM,4.0,O=C(Cc1ccc(-c2ccccc2)c(F)c1)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,Cc1cc(CC(=O)Nc2cc(C3CC3)[nH]n2)ccc1-c1ccccc1,CHEMBL1140962,=,=,IC50,nM,9.0,IC50,nM,9.0,Cc1cc(CC(=O)Nc2cc(C3CC3)[nH]n2)ccc1-c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Cc1ccc(Cc2cccs2)cc1)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,=,=,IC50,nM,3.0,IC50,nM,3.0,O=C(Cc1ccc(Cc2cccs2)cc1)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,CO[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,CHEMBL1140962,=,=,IC50,nM,2000.0,IC50,nM,2000.0,CO[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,CO[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,CHEMBL1140962,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CO[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,N[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,CHEMBL1140962,=,=,IC50,nM,960.0,IC50,nM,960.0,N[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)C(=O)c1ccccc1,CHEMBL1140962,=,=,IC50,nM,2600.0,IC50,nM,2600.0,O=C(Nc1cc(C2CC2)[nH]n1)C(=O)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,CHEMBL1140962,=,=,IC50,nM,84.0,IC50,nM,84.0,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,CHEMBL1140962,=,=,IC50,nM,6000.0,IC50,nM,6000.0,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCCC2=O)cc1,CHEMBL1140962,=,=,IC50,nM,2500.0,IC50,nM,2500.0,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCCC2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCCC2=O)cc1,CHEMBL1140962,=,=,IC50,nM,37.0,IC50,nM,37.0,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCCC2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2Cc3ccccc3C2=O)cc1,CHEMBL1140962,=,=,IC50,nM,170.0,IC50,nM,170.0,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2Cc3ccccc3C2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2Cc3ccccc3C2=O)cc1,CHEMBL1140962,=,=,IC50,nM,2.0,IC50,nM,2.0,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2Cc3ccccc3C2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCNC2=O)cc1,CHEMBL1140962,=,=,IC50,nM,455.0,IC50,nM,455.0,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCNC2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCNC2=O)cc1,CHEMBL1140962,=,=,IC50,nM,2.0,IC50,nM,2.0,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCNC2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCN(C)C2=O)cc1,CHEMBL1140962,=,=,IC50,nM,8500.0,IC50,nM,8500.0,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCN(C)C2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCN(C)C2=O)cc1,CHEMBL1140962,=,=,IC50,nM,17.0,IC50,nM,17.0,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCN(C)C2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCOC2=O)cc1,CHEMBL1140962,=,=,IC50,nM,2500.0,IC50,nM,2500.0,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCOC2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCOC2=O)cc1,CHEMBL1140962,=,=,IC50,nM,20.0,IC50,nM,20.0,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCOC2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCCC2)cc1,CHEMBL1140962,=,=,IC50,nM,80.0,IC50,nM,80.0,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCCC2)cc1,2008.0
Inhibition of CDK2/Cyclin A,Cc1cc(NC(=O)c2ccccc2)n[nH]1,CHEMBL1140962,=,=,IC50,nM,1499.68,pIC50,,5.824,Cc1cc(NC(=O)c2ccccc2)n[nH]1,2008.0
Inhibition of CDK2/Cyclin A,CCCC(=O)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,=,=,IC50,nM,223.87,pIC50,,6.65,CCCC(=O)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)n[nH]1)c1ccccc1,CHEMBL1140962,=,=,IC50,nM,289.73,pIC50,,6.538,O=C(Nc1cc(C2CC2)n[nH]1)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1ccc(Br)cc1,CHEMBL1140962,=,=,IC50,nM,33.96,pIC50,,7.469,O=C(Nc1cc(C2CC2)[nH]n1)c1ccc(Br)cc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1ccc(Cl)cc1,CHEMBL1140962,=,=,IC50,nM,84.92,pIC50,,7.071,O=C(Nc1cc(C2CC2)[nH]n1)c1ccc(Cl)cc1,2008.0
Inhibition of CDK2/Cyclin A,COc1ccc(C(=O)Nc2cc(C3CC3)[nH]n2)cc1,CHEMBL1140962,=,=,IC50,nM,704.69,pIC50,,6.152,COc1ccc(C(=O)Nc2cc(C3CC3)[nH]n2)cc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(O)c1ccc(C(=O)Nc2cc(C3CC3)[nH]n2)cc1,CHEMBL1140962,=,=,IC50,nM,164.82,pIC50,,6.783,O=C(O)c1ccc(C(=O)Nc2cc(C3CC3)[nH]n2)cc1,2008.0
Inhibition of CDK2/Cyclin A,NC(=O)c1ccc(C(=O)Nc2cc(C3CC3)[nH]n2)cc1,CHEMBL1140962,=,=,IC50,nM,68.08,pIC50,,7.167,NC(=O)c1ccc(C(=O)Nc2cc(C3CC3)[nH]n2)cc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1cccc(Br)c1,CHEMBL1140962,=,=,IC50,nM,990.83,pIC50,,6.004,O=C(Nc1cc(C2CC2)[nH]n1)c1cccc(Br)c1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1cccc(Cl)c1,CHEMBL1140962,=,=,IC50,nM,1000.0,pIC50,,6.0,O=C(Nc1cc(C2CC2)[nH]n1)c1cccc(Cl)c1,2008.0
Inhibition of CDK2/Cyclin A,COc1cccc(C(=O)Nc2cc(C3CC3)[nH]n2)c1,CHEMBL1140962,=,=,IC50,nM,599.79,pIC50,,6.222,COc1cccc(C(=O)Nc2cc(C3CC3)[nH]n2)c1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1cccc(C(F)(F)F)c1,CHEMBL1140962,=,=,IC50,nM,500.03,pIC50,,6.301,O=C(Nc1cc(C2CC2)[nH]n1)c1cccc(C(F)(F)F)c1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1ccccc1Br,CHEMBL1140962,=,=,IC50,nM,1499.68,pIC50,,5.824,O=C(Nc1cc(C2CC2)[nH]n1)c1ccccc1Br,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1ccccc1Cl,CHEMBL1140962,=,=,IC50,nM,1000.0,pIC50,,6.0,O=C(Nc1cc(C2CC2)[nH]n1)c1ccccc1Cl,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)c1ccc(Cl)c(Cl)c1,CHEMBL1140962,=,=,IC50,nM,82.99,pIC50,,7.081,O=C(Nc1cc(C2CC2)[nH]n1)c1ccc(Cl)c(Cl)c1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CCC2)[nH]n1)c1ccc(Br)cc1,CHEMBL1140962,=,=,IC50,nM,89.95,pIC50,,7.046,O=C(Nc1cc(C2CCC2)[nH]n1)c1ccc(Br)cc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CCCC2)[nH]n1)c1ccc(Br)cc1,CHEMBL1140962,=,=,IC50,nM,50.0,pIC50,,7.301,O=C(Nc1cc(C2CCCC2)[nH]n1)c1ccc(Br)cc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CCCCC2)[nH]n1)c1ccc(Br)cc1,CHEMBL1140962,=,=,IC50,nM,1000.0,pIC50,,6.0,O=C(Nc1cc(C2CCCCC2)[nH]n1)c1ccc(Br)cc1,2008.0
Inhibition of CDK2/Cyclin A,Cc1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,CHEMBL1140962,=,=,IC50,nM,5997.91,pIC50,,5.222,Cc1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,2008.0
Inhibition of CDK2/Cyclin A,CCc1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,CHEMBL1140962,=,=,IC50,nM,629.51,pIC50,,6.201,CCc1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,2008.0
Inhibition of CDK2/Cyclin A,CCCc1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,CHEMBL1140962,=,=,IC50,nM,650.13,pIC50,,6.187,CCCc1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,2008.0
Inhibition of CDK2/Cyclin A,CC(C)c1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,CHEMBL1140962,=,=,IC50,nM,199.99,pIC50,,6.699,CC(C)c1cc(NC(=O)c2ccc(Br)cc2)n[nH]1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Cc1ccccc1)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,=,=,IC50,nM,47.97,pIC50,,7.319,O=C(Cc1ccccc1)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,NC(=O)c1ccc(CC(=O)Nc2cc(C3CC3)[nH]n2)cc1,CHEMBL1140962,=,=,IC50,nM,73.96,pIC50,,7.131,NC(=O)c1ccc(CC(=O)Nc2cc(C3CC3)[nH]n2)cc1,2008.0
Inhibition of CDK2/Cyclin A,COc1cccc(CC(=O)Nc2cc(C3CC3)[nH]n2)c1,CHEMBL1140962,=,=,IC50,nM,28.97,pIC50,,7.538,COc1cccc(CC(=O)Nc2cc(C3CC3)[nH]n2)c1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Cc1ccc(OC(F)(F)F)cc1)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,=,=,IC50,nM,66.99,pIC50,,7.174,O=C(Cc1ccc(OC(F)(F)F)cc1)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Cc1ccc(-c2ccccc2)cc1)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,=,=,IC50,nM,55.98,pIC50,,7.252,O=C(Cc1ccc(-c2ccccc2)cc1)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Cc1ccc(-c2ccccc2)c(F)c1)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,=,=,IC50,nM,3.999,pIC50,,8.398,O=C(Cc1ccc(-c2ccccc2)c(F)c1)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,Cc1cc(CC(=O)Nc2cc(C3CC3)[nH]n2)ccc1-c1ccccc1,CHEMBL1140962,=,=,IC50,nM,8.995,pIC50,,8.046,Cc1cc(CC(=O)Nc2cc(C3CC3)[nH]n2)ccc1-c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Cc1ccc(Cc2cccs2)cc1)Nc1cc(C2CC2)[nH]n1,CHEMBL1140962,=,=,IC50,nM,2.999,pIC50,,8.523,O=C(Cc1ccc(Cc2cccs2)cc1)Nc1cc(C2CC2)[nH]n1,2008.0
Inhibition of CDK2/Cyclin A,CO[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,CHEMBL1140962,=,=,IC50,nM,1999.86,pIC50,,5.699,CO[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,N[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,CHEMBL1140962,=,=,IC50,nM,959.4,pIC50,,6.018,N[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,O=C(Nc1cc(C2CC2)[nH]n1)C(=O)c1ccccc1,CHEMBL1140962,=,=,IC50,nM,2600.16,pIC50,,5.585,O=C(Nc1cc(C2CC2)[nH]n1)C(=O)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,CHEMBL1140962,=,=,IC50,nM,83.95,pIC50,,7.076,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,CHEMBL1140962,=,=,IC50,nM,5997.91,pIC50,,5.222,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCCC2=O)cc1,CHEMBL1140962,=,=,IC50,nM,2500.35,pIC50,,5.602,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCCC2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCCC2=O)cc1,CHEMBL1140962,=,=,IC50,nM,36.98,pIC50,,7.432,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCCC2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2Cc3ccccc3C2=O)cc1,CHEMBL1140962,=,=,IC50,nM,169.82,pIC50,,6.77,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2Cc3ccccc3C2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2Cc3ccccc3C2=O)cc1,CHEMBL1140962,=,=,IC50,nM,2.0,pIC50,,8.699,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2Cc3ccccc3C2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCNC2=O)cc1,CHEMBL1140962,=,=,IC50,nM,454.99,pIC50,,6.342,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCNC2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCNC2=O)cc1,CHEMBL1140962,=,=,IC50,nM,2.0,pIC50,,8.699,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCNC2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCN(C)C2=O)cc1,CHEMBL1140962,=,=,IC50,nM,8491.8,pIC50,,5.071,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCN(C)C2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCN(C)C2=O)cc1,CHEMBL1140962,=,=,IC50,nM,16.98,pIC50,,7.77,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCN(C)C2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCOC2=O)cc1,CHEMBL1140962,=,=,IC50,nM,2500.35,pIC50,,5.602,C[C@@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCOC2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCOC2=O)cc1,CHEMBL1140962,=,=,IC50,nM,20.0,pIC50,,7.699,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCOC2=O)cc1,2008.0
Inhibition of CDK2/Cyclin A,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCCC2)cc1,CHEMBL1140962,=,=,IC50,nM,79.98,pIC50,,7.097,C[C@H](C(=O)Nc1cc(C2CC2)[nH]n1)c1ccc(N2CCCC2)cc1,2008.0
Inhibition of human CDK2,COc1cc(O)ccc1-c1ccc2c(-c3nc4c(N5CCN(C)CC5)cccc4[nH]3)n[nH]c2c1,CHEMBL1143269,=,=,IC50,nM,102.0,IC50,nM,102.0,COc1cc(O)ccc1-c1ccc2c(-c3nc4c(N5CCN(C)CC5)cccc4[nH]3)n[nH]c2c1,2009.0
Inhibition of human CDK2,COc1cc(-c2ccc3c(-c4nc5c(N6CCN(C)CC6)cccc5[nH]4)n[nH]c3c2)ccc1O,CHEMBL1143269,=,=,IC50,nM,4.1,IC50,nM,4.1,COc1cc(-c2ccc3c(-c4nc5c(N6CCN(C)CC6)cccc5[nH]4)n[nH]c3c2)ccc1O,2009.0
Inhibition of human CDK2,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6ccc(O)cc6)ccc45)nc23)CC1,CHEMBL1143269,=,=,IC50,nM,13.3,IC50,nM,13.3,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6ccc(O)cc6)ccc45)nc23)CC1,2009.0
Inhibition of human CDK2,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6ccc(CO)cc6)ccc45)nc23)CC1,CHEMBL1143269,=,=,IC50,nM,21500.0,IC50,nM,21500.0,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6ccc(CO)cc6)ccc45)nc23)CC1,2009.0
Inhibition of human CDK2,COc1ccc(-c2ccc3c(-c4nc5c(N6CCN(C)CC6)cccc5[nH]4)n[nH]c3c2)c(OC)c1,CHEMBL1143269,=,=,IC50,nM,10000.0,IC50,nM,10000.0,COc1ccc(-c2ccc3c(-c4nc5c(N6CCN(C)CC6)cccc5[nH]4)n[nH]c3c2)c(OC)c1,2009.0
Inhibition of human CDK2,COc1ccccc1-c1ccc2c(-c3nc4c(N5CCN(C)CC5)cccc4[nH]3)n[nH]c2c1,CHEMBL1143269,=,=,IC50,nM,10000.0,IC50,nM,10000.0,COc1ccccc1-c1ccc2c(-c3nc4c(N5CCN(C)CC5)cccc4[nH]3)n[nH]c2c1,2009.0
Inhibition of human CDK2,COc1cc(F)ccc1-c1ccc2c(-c3nc4c(N5CCN(C)CC5)cccc4[nH]3)n[nH]c2c1,CHEMBL1143269,=,=,IC50,nM,10000.0,IC50,nM,10000.0,COc1cc(F)ccc1-c1ccc2c(-c3nc4c(N5CCN(C)CC5)cccc4[nH]3)n[nH]c2c1,2009.0
Inhibition of human CDK2,CN1CCN(c2cccc3nc(-c4n[nH]c5cc(-c6ccc(N)cc6)ccc45)[nH]c23)CC1,CHEMBL1143269,=,=,IC50,nM,1040.0,IC50,nM,1040.0,CN1CCN(c2cccc3nc(-c4n[nH]c5cc(-c6ccc(N)cc6)ccc45)[nH]c23)CC1,2009.0
Inhibition of human CDK2,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6cccc(N)c6)ccc45)nc23)CC1,CHEMBL1143269,=,=,IC50,nM,6100.0,IC50,nM,6100.0,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6cccc(N)c6)ccc45)nc23)CC1,2009.0
Inhibition of human CDK2,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6ccc(N)c(F)c6)ccc45)nc23)CC1,CHEMBL1143269,=,=,IC50,nM,1730.0,IC50,nM,1730.0,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6ccc(N)c(F)c6)ccc45)nc23)CC1,2009.0
Inhibition of human CDK2,COc1cc(-c2ccc3c(-c4nc5c(N6CCN(C)CC6)cccc5[nH]4)n[nH]c3c2)ccc1N,CHEMBL1143269,=,=,IC50,nM,247.0,IC50,nM,247.0,COc1cc(-c2ccc3c(-c4nc5c(N6CCN(C)CC6)cccc5[nH]4)n[nH]c3c2)ccc1N,2009.0
Inhibition of human CDK2,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6ccc(CN)cc6)ccc45)nc23)CC1,CHEMBL1143269,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6ccc(CN)cc6)ccc45)nc23)CC1,2009.0
Inhibition of human CDK2,CC(=O)Nc1ccc(-c2ccc3c(-c4nc5c(N6CCN(C)CC6)cccc5[nH]4)n[nH]c3c2)cc1,CHEMBL1143269,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CC(=O)Nc1ccc(-c2ccc3c(-c4nc5c(N6CCN(C)CC6)cccc5[nH]4)n[nH]c3c2)cc1,2009.0
Inhibition of human CDK2,CNc1ccc(-c2ccc3c(-c4nc5c(N6CCN(C)CC6)cccc5[nH]4)n[nH]c3c2)cc1,CHEMBL1143269,=,=,IC50,nM,109000.0,IC50,nM,109000.0,CNc1ccc(-c2ccc3c(-c4nc5c(N6CCN(C)CC6)cccc5[nH]4)n[nH]c3c2)cc1,2009.0
Inhibition of human CDK2,COc1cc(N)ccc1-c1ccc2c(-c3nc4c(N5CCN(C)CC5)cccc4[nH]3)n[nH]c2c1,CHEMBL1143269,=,=,IC50,nM,10000.0,IC50,nM,10000.0,COc1cc(N)ccc1-c1ccc2c(-c3nc4c(N5CCN(C)CC5)cccc4[nH]3)n[nH]c2c1,2009.0
Inhibition of human CDK2,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6ccc(C(=O)O)cc6)ccc45)nc23)CC1,CHEMBL1143269,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6ccc(C(=O)O)cc6)ccc45)nc23)CC1,2009.0
Inhibition of human CDK2,CC(=O)c1ccc(-c2ccc3c(-c4nc5c(N6CCN(C)CC6)cccc5[nH]4)n[nH]c3c2)cc1,CHEMBL1143269,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CC(=O)c1ccc(-c2ccc3c(-c4nc5c(N6CCN(C)CC6)cccc5[nH]4)n[nH]c3c2)cc1,2009.0
Inhibition of human CDK2,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6ccc7[nH]ccc7c6)ccc45)nc23)CC1,CHEMBL1143269,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(-c6ccc7[nH]ccc7c6)ccc45)nc23)CC1,2009.0
Inhibition of human CDK2,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(C6=CC7=CC=CNC7C=C6)ccc45)nc23)CC1,CHEMBL1143269,=,=,IC50,nM,10000.0,IC50,nM,10000.0,CN1CCN(c2cccc3[nH]c(-c4n[nH]c5cc(C6=CC7=CC=CNC7C=C6)ccc45)nc23)CC1,2009.0
Inhibition of human CDK2,O=C(NC1CC1)c1n[nH]c2cc(-c3ccc(O)cc3)c(Br)cc12,CHEMBL1143269,=,=,IC50,nM,5.0,IC50,nM,5.0,O=C(NC1CC1)c1n[nH]c2cc(-c3ccc(O)cc3)c(Br)cc12,2009.0
Inhibition of Cdk2,Nc1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2Cl)cc1Cl,CHEMBL1143270,>,>,IC50,nM,30000.0,IC50,uM,30.0,Nc1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2Cl)cc1Cl,2009.0
Inhibition of CDK2/cyclinA,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1138507,=,=,IC50,nM,0.36,IC50,uM,0.00036,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009.0
Inhibition of CDK2/cyclinA,COc1ccc(NC(=S)N/N=C2\C(=O)Nc3ccccc32)cc1,CHEMBL1138507,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc(NC(=S)N/N=C2\C(=O)Nc3ccccc32)cc1,2009.0
Inhibition of human CDK2/cyclin E at 1 uM assessed as residual enzyme activity,O=C(Nc1ccccc1Cl)c1ccc(Nc2nc(Nc3ccc(O)cc3)ncc2F)cc1,CHEMBL1138512,=,=,Activity,%,44.0,Activity,%,44.0,O=C(Nc1ccccc1Cl)c1ccc(Nc2nc(Nc3ccc(O)cc3)ncc2F)cc1,2009.0
Inhibition of CDK2/cyclin A at 1 uM,CC(=O)N1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1,CHEMBL1138512,=,=,Inhibition,%,15.0,INH,%,15.0,CC(=O)N1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1,2009.0
Inhibition of CDK2/cyclin A,O=C(Nc1ccccc1Cl)c1ccc(Nc2nc(Nc3ccc(O)cc3)ncc2F)cc1,CHEMBL1138512,=,=,IC50,nM,3200.0,IC50,uM,3.2,O=C(Nc1ccccc1Cl)c1ccc(Nc2nc(Nc3ccc(O)cc3)ncc2F)cc1,2009.0
Inhibition of CDK2/cyclin A,CC(=O)N1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1,CHEMBL1138512,>,>,IC50,nM,16000.0,IC50,uM,16.0,CC(=O)N1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1,2009.0
Inhibition of CDK2/cyclin A,CCN1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1,CHEMBL1138512,>,>,IC50,nM,16000.0,IC50,uM,16.0,CCN1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1,2009.0
Inhibition of CDK2/cyclin A,O=C(NC1CC1)c1ccc(Nc2nc(Nc3ccc(O)cc3)ncc2F)cc1,CHEMBL1138512,,,IC50,,,IC50,,,O=C(NC1CC1)c1ccc(Nc2nc(Nc3ccc(O)cc3)ncc2F)cc1,2009.0
Inhibition of CDK2/cyclin A,O=C(Nc1ccc(Nc2nc(Nc3ccc(O)cc3)ncc2F)cc1)c1ccccc1Cl,CHEMBL1138512,,,IC50,,,IC50,,,O=C(Nc1ccc(Nc2nc(Nc3ccc(O)cc3)ncc2F)cc1)c1ccccc1Cl,2009.0
Inhibition of CDK2/cyclin A,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,CHEMBL1138512,,,IC50,,,IC50,,,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,2009.0
Inhibition of human Thr160-phospho CDK2/CyclinA,Oc1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1138472,=,=,IC50,nM,2300.0,IC50,uM,2.3,Oc1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2009.0
Inhibition of human Thr160-phospho CDK2/CyclinA,c1ccc(Nc2nc(OCC3CCCCC3)c3[nH]cnc3n2)cc1,CHEMBL1138472,=,=,IC50,nM,1000.0,IC50,uM,1.0,c1ccc(Nc2nc(OCC3CCCCC3)c3[nH]cnc3n2)cc1,2009.0
Inhibition of CDK2/cyclinA,O[C@H]1CC[C@H](c2n[nH]cc2-c2ccnc(NC3CCCC3)n2)CC1,CHEMBL1154397,=,=,IC50,nM,590.0,IC50,uM,0.59,O[C@H]1CC[C@H](c2n[nH]cc2-c2ccnc(NC3CCCC3)n2)CC1,2009.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2ccnc(Nc3ccc(C#N)cc3)n2)n1C(C)C,CHEMBL1155842,<,<,IC50,nM,3.0,IC50,uM,0.003,Cc1ncc(-c2ccnc(Nc3ccc(C#N)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2/Cyclin E,CC(=O)N1CCN(c2ccc(Nc3nccc(-c4cnc(C)n4C(C)C)n3)cc2)CC1,CHEMBL1155842,<,<,IC50,nM,3.0,IC50,uM,0.003,CC(=O)N1CCN(c2ccc(Nc3nccc(-c4cnc(C)n4C(C)C)n3)cc2)CC1,2008.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)n2)n1C(C)C,CHEMBL1155842,<,<,IC50,nM,3.0,IC50,uM,0.003,Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2/Cyclin E,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1,CHEMBL1155842,<,<,IC50,nM,3.0,IC50,uM,0.003,COCCNS(=O)(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1,2008.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2ccnc(Nc3ccc(Cl)cc3)n2)n1C(C)C,CHEMBL1155842,<,<,IC50,nM,3.0,IC50,uM,0.003,Cc1ncc(-c2ccnc(Nc3ccc(Cl)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2ccnc(Nc3ccc(F)cc3)n2)n1C(C)C,CHEMBL1155842,=,=,IC50,nM,3.0,IC50,uM,0.003,Cc1ncc(-c2ccnc(Nc3ccc(F)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2/Cyclin E,COc1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1,CHEMBL1155842,=,=,IC50,nM,8.0,IC50,uM,0.008,COc1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1,2008.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2ccnc(Nc3ccc(N(C)C)cc3)n2)n1C(C)C,CHEMBL1155842,=,=,IC50,nM,24.0,IC50,uM,0.024,Cc1ncc(-c2ccnc(Nc3ccc(N(C)C)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2nc(Nc3ccc(N4CCC[C@H]4C(=O)N(C)C)cc3)ncc2F)n1C(C)C,CHEMBL1155842,=,=,IC50,nM,46.0,IC50,uM,0.046,Cc1ncc(-c2nc(Nc3ccc(N4CCC[C@H]4C(=O)N(C)C)cc3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2/Cyclin E,CC(=O)N[C@@H]1CCN(c2ccc(Nc3ncc(F)c(-c4cnc(C)n4C(C)C)n3)cc2)C1,CHEMBL1155842,>,>,IC50,nM,0.3,IC50,uM,0.0003,CC(=O)N[C@@H]1CCN(c2ccc(Nc3ncc(F)c(-c4cnc(C)n4C(C)C)n3)cc2)C1,2008.0
Inhibition of CDK2/Cyclin E,CC(=O)NC1CN(c2ccc(Nc3ncc(F)c(-c4cnc(C)n4C(C)C)n3)cc2)C1,CHEMBL1155842,=,=,IC50,nM,0.5,IC50,uM,0.0005,CC(=O)NC1CN(c2ccc(Nc3ncc(F)c(-c4cnc(C)n4C(C)C)n3)cc2)C1,2008.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2F)n1C(C)C,CHEMBL1155842,=,=,IC50,nM,8.0,IC50,uM,0.008,Cc1ncc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)n1C(C)C,CHEMBL1155842,=,=,IC50,nM,9.0,IC50,uM,0.009,Cc1ncc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2nc(Nc3ccc(N4CCN(C(=O)CO)CC4)cc3)ncc2F)n1C(C)C,CHEMBL1155842,=,=,IC50,nM,6.0,IC50,uM,0.006,Cc1ncc(-c2nc(Nc3ccc(N4CCN(C(=O)CO)CC4)cc3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(C(=O)CN(C)C)CC4)cc3)n2)n1C(C)C,CHEMBL1155842,=,=,IC50,nM,16.0,IC50,uM,0.016,Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(C(=O)CN(C)C)CC4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(C(=O)[C@H](C)O)CC4)cc3)n2)n1C(C)C,CHEMBL1155842,=,=,IC50,nM,17.0,IC50,uM,0.017,Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(C(=O)[C@H](C)O)CC4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(C(=O)CO)CC4)cc3)n2)n1C(C)C,CHEMBL1155842,=,=,IC50,nM,17.0,IC50,uM,0.017,Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(C(=O)CO)CC4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2/Cyclin E,COCCS(=O)(=O)N1CCN(c2ccc(Nc3nccc(-c4cnc(C)n4C(C)C)n3)cc2)CC1,CHEMBL1155842,<,<,IC50,nM,3.0,IC50,uM,0.003,COCCS(=O)(=O)N1CCN(c2ccc(Nc3nccc(-c4cnc(C)n4C(C)C)n3)cc2)CC1,2008.0
Inhibition of CDK2/Cyclin E,Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(S(=O)(=O)CCN(C)C)CC4)cc3)n2)n1C(C)C,CHEMBL1155842,=,=,IC50,nM,3.0,IC50,uM,0.003,Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(S(=O)(=O)CCN(C)C)CC4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,Cc1cc(CNc2ncc(Br)c(Nc3cc(C4CC4)[nH]n3)n2)on1,CHEMBL1155933,=,=,IC50,nM,110.0,IC50,uM,0.11,Cc1cc(CNc2ncc(Br)c(Nc3cc(C4CC4)[nH]n3)n2)on1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21.[Cl-],CHEMBL1155938,=,=,IC50,nM,500000.0,IC50,uM,500.0,O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21.[Cl-],2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,Cc1cccc(-c2ccccc2C(=O)N2CCc3c([nH]c4ccccc34)C2)c1,CHEMBL1155938,=,=,IC50,nM,386000.0,IC50,uM,386.0,Cc1cccc(-c2ccccc2C(=O)N2CCc3c([nH]c4ccccc34)C2)c1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(c1ccccc1-c1cccnc1)N1CCc2c([nH]c3ccccc23)C1,CHEMBL1155938,=,=,IC50,nM,312000.0,IC50,uM,312.0,O=C(c1ccccc1-c1cccnc1)N1CCc2c([nH]c3ccccc23)C1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(c1ccccc1-c1ccncc1)N1CCc2c([nH]c3ccccc23)C1,CHEMBL1155938,=,=,IC50,nM,354000.0,IC50,uM,354.0,O=C(c1ccccc1-c1ccncc1)N1CCc2c([nH]c3ccccc23)C1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(NCCc1c[nH]c2ccccc12)c1cccc(-c2cccnc2)c1,CHEMBL1155938,=,=,IC50,nM,150000.0,IC50,uM,150.0,O=C(NCCc1c[nH]c2ccccc12)c1cccc(-c2cccnc2)c1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,CN(CCc1c[nH]c2ccccc12)C(=O)c1ccc(-c2ccncc2)cc1,CHEMBL1155938,=,=,IC50,nM,92000.0,IC50,uM,92.0,CN(CCc1c[nH]c2ccccc12)C(=O)c1ccc(-c2ccncc2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,COc1ccccc1-c1ccc(C(=O)N2CCc3c([nH]c4ccccc34)C2)cc1,CHEMBL1155938,=,=,IC50,nM,321000.0,IC50,uM,321.0,COc1ccccc1-c1ccc(C(=O)N2CCc3c([nH]c4ccccc34)C2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,COc1cccc(-c2ccc(C(=O)N3CCc4c([nH]c5ccccc45)C3)cc2)c1,CHEMBL1155938,=,=,IC50,nM,424000.0,IC50,uM,424.0,COc1cccc(-c2ccc(C(=O)N3CCc4c([nH]c5ccccc45)C3)cc2)c1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,Cc1ccccc1-c1ccc(C(=O)N2CCc3c([nH]c4ccccc34)C2)cc1,CHEMBL1155938,=,=,IC50,nM,340000.0,IC50,uM,340.0,Cc1ccccc1-c1ccc(C(=O)N2CCc3c([nH]c4ccccc34)C2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,Cc1cccc(-c2ccc(C(=O)N3CCc4c([nH]c5ccccc45)C3)cc2)c1,CHEMBL1155938,=,=,IC50,nM,405000.0,IC50,uM,405.0,Cc1cccc(-c2ccc(C(=O)N3CCc4c([nH]c5ccccc45)C3)cc2)c1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,Cc1ccc(-c2ccc(C(=O)N3CCc4c([nH]c5ccccc45)C3)cc2)cc1,CHEMBL1155938,=,=,IC50,nM,736000.0,IC50,uM,736.0,Cc1ccc(-c2ccc(C(=O)N3CCc4c([nH]c5ccccc45)C3)cc2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(c1ccc(-c2ccccc2F)cc1)N1CCc2c([nH]c3ccccc23)C1,CHEMBL1155938,=,=,IC50,nM,310000.0,IC50,uM,310.0,O=C(c1ccc(-c2ccccc2F)cc1)N1CCc2c([nH]c3ccccc23)C1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(c1ccc(-c2cccc(F)c2)cc1)N1CCc2c([nH]c3ccccc23)C1,CHEMBL1155938,=,=,IC50,nM,296000.0,IC50,uM,296.0,O=C(c1ccc(-c2cccc(F)c2)cc1)N1CCc2c([nH]c3ccccc23)C1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(c1ccc(-c2ccc(F)cc2)cc1)N1CCc2c([nH]c3ccccc23)C1,CHEMBL1155938,=,=,IC50,nM,438000.0,IC50,uM,438.0,O=C(c1ccc(-c2ccc(F)cc2)cc1)N1CCc2c([nH]c3ccccc23)C1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,COc1ccccc1-c1cccc(C(=O)N2CCc3c([nH]c4ccccc34)C2)c1,CHEMBL1155938,=,=,IC50,nM,1109000.0,IC50,uM,1109.0,COc1ccccc1-c1cccc(C(=O)N2CCc3c([nH]c4ccccc34)C2)c1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,COc1cccc(-c2cccc(C(=O)N3CCc4c([nH]c5ccccc45)C3)c2)c1,CHEMBL1155938,=,=,IC50,nM,362000.0,IC50,uM,362.0,COc1cccc(-c2cccc(C(=O)N3CCc4c([nH]c5ccccc45)C3)c2)c1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,Cc1ccccc1-c1cccc(C(=O)N2CCc3c([nH]c4ccccc34)C2)c1,CHEMBL1155938,=,=,IC50,nM,665000.0,IC50,uM,665.0,Cc1ccccc1-c1cccc(C(=O)N2CCc3c([nH]c4ccccc34)C2)c1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,Cc1cccc(-c2cccc(C(=O)N3CCc4c([nH]c5ccccc45)C3)c2)c1,CHEMBL1155938,=,=,IC50,nM,465000.0,IC50,uM,465.0,Cc1cccc(-c2cccc(C(=O)N3CCc4c([nH]c5ccccc45)C3)c2)c1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,Cc1ccc(-c2cccc(C(=O)N3CCc4c([nH]c5ccccc45)C3)c2)cc1,CHEMBL1155938,=,=,IC50,nM,466000.0,IC50,uM,466.0,Cc1ccc(-c2cccc(C(=O)N3CCc4c([nH]c5ccccc45)C3)c2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(c1cccc(-c2ccccc2F)c1)N1CCc2c([nH]c3ccccc23)C1,CHEMBL1155938,=,=,IC50,nM,335000.0,IC50,uM,335.0,O=C(c1cccc(-c2ccccc2F)c1)N1CCc2c([nH]c3ccccc23)C1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(c1cccc(-c2cccc(F)c2)c1)N1CCc2c([nH]c3ccccc23)C1,CHEMBL1155938,=,=,IC50,nM,611000.0,IC50,uM,611.0,O=C(c1cccc(-c2cccc(F)c2)c1)N1CCc2c([nH]c3ccccc23)C1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(c1cccc(-c2ccc(F)cc2)c1)N1CCc2c([nH]c3ccccc23)C1,CHEMBL1155938,=,=,IC50,nM,318000.0,IC50,uM,318.0,O=C(c1cccc(-c2ccc(F)cc2)c1)N1CCc2c([nH]c3ccccc23)C1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(c1ccccc1-c1ccccc1F)N1CCc2c([nH]c3ccccc23)C1,CHEMBL1155938,=,=,IC50,nM,434000.0,IC50,uM,434.0,O=C(c1ccccc1-c1ccccc1F)N1CCc2c([nH]c3ccccc23)C1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(c1ccccc1-c1cccc(F)c1)N1CCc2c([nH]c3ccccc23)C1,CHEMBL1155938,=,=,IC50,nM,480000.0,IC50,uM,480.0,O=C(c1ccccc1-c1cccc(F)c1)N1CCc2c([nH]c3ccccc23)C1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(c1ccccc1-c1ccc(F)cc1)N1CCc2c([nH]c3ccccc23)C1,CHEMBL1155938,=,=,IC50,nM,357000.0,IC50,uM,357.0,O=C(c1ccccc1-c1ccc(F)cc1)N1CCc2c([nH]c3ccccc23)C1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,Cc1cccc(-c2ccccc2C(=O)NCCc2c[nH]c3ccccc23)c1,CHEMBL1155938,=,=,IC50,nM,406000.0,IC50,uM,406.0,Cc1cccc(-c2ccccc2C(=O)NCCc2c[nH]c3ccccc23)c1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(NCCc1c[nH]c2ccccc12)c1ccccc1-c1cccc(F)c1,CHEMBL1155938,=,=,IC50,nM,417000.0,IC50,uM,417.0,O=C(NCCc1c[nH]c2ccccc12)c1ccccc1-c1cccc(F)c1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,COc1ccccc1-c1ccccc1C(=O)NCCc1c[nH]c2ccccc12,CHEMBL1155938,=,=,IC50,nM,375000.0,IC50,uM,375.0,COc1ccccc1-c1ccccc1C(=O)NCCc1c[nH]c2ccccc12,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,COc1cccc(-c2ccccc2C(=O)NCCc2c[nH]c3ccccc23)c1,CHEMBL1155938,=,=,IC50,nM,926000.0,IC50,uM,926.0,COc1cccc(-c2ccccc2C(=O)NCCc2c[nH]c3ccccc23)c1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,COc1ccc(-c2ccccc2C(=O)NCCc2c[nH]c3ccccc23)cc1,CHEMBL1155938,=,=,IC50,nM,921000.0,IC50,uM,921.0,COc1ccc(-c2ccccc2C(=O)NCCc2c[nH]c3ccccc23)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,CC(C)(C)c1ccc(-c2ccccc2C(=O)NCCc2c[nH]c3ccccc23)cc1,CHEMBL1155938,=,=,IC50,nM,262000.0,IC50,uM,262.0,CC(C)(C)c1ccc(-c2ccccc2C(=O)NCCc2c[nH]c3ccccc23)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(NCCc1c[nH]c2ccccc12)c1ccccc1-c1ccc(F)cc1,CHEMBL1155938,=,=,IC50,nM,1216000.0,IC50,uM,1216.0,O=C(NCCc1c[nH]c2ccccc12)c1ccccc1-c1ccc(F)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(NCCc1c[nH]c2ccccc12)c1cccc(-c2ccccc2)c1,CHEMBL1155938,=,=,IC50,nM,1002000.0,IC50,uM,1002.0,O=C(NCCc1c[nH]c2ccccc12)c1cccc(-c2ccccc2)c1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,COc1ccc(-c2ccc(C(=O)NCCc3c[nH]c4ccccc34)cc2)cc1,CHEMBL1155938,=,=,IC50,nM,1085000.0,IC50,uM,1085.0,COc1ccc(-c2ccc(C(=O)NCCc3c[nH]c4ccccc34)cc2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,CC(C)(C)c1ccc(-c2ccc(C(=O)NCCc3c[nH]c4ccccc34)cc2)cc1,CHEMBL1155938,=,=,IC50,nM,790000.0,IC50,uM,790.0,CC(C)(C)c1ccc(-c2ccc(C(=O)NCCc3c[nH]c4ccccc34)cc2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,Cc1ccc(-c2ccc(C(=O)NCCc3c[nH]c4ccccc34)cc2)cc1,CHEMBL1155938,=,=,IC50,nM,816000.0,IC50,uM,816.0,Cc1ccc(-c2ccc(C(=O)NCCc3c[nH]c4ccccc34)cc2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(NCCc1c[nH]c2ccccc12)c1ccc(-c2ccc(F)cc2)cc1,CHEMBL1155938,=,=,IC50,nM,764000.0,IC50,uM,764.0,O=C(NCCc1c[nH]c2ccccc12)c1ccc(-c2ccc(F)cc2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,O=C(NCCc1c[nH]c2ccccc12)c1ccc(-c2ccccc2)cc1,CHEMBL1155938,=,=,IC50,nM,855000.0,IC50,uM,855.0,O=C(NCCc1c[nH]c2ccccc12)c1ccc(-c2ccccc2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,CN(CCc1c[nH]c2ccccc12)C(=O)c1ccc(-c2ccc(-c3ccccc3)cc2)cc1,CHEMBL1155938,=,=,IC50,nM,91000.0,IC50,uM,91.0,CN(CCc1c[nH]c2ccccc12)C(=O)c1ccc(-c2ccc(-c3ccccc3)cc2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,COc1ccc(-c2ccc(C(=O)N(C)CCc3c[nH]c4ccccc34)cc2)cc1,CHEMBL1155938,=,=,IC50,nM,289000.0,IC50,uM,289.0,COc1ccc(-c2ccc(C(=O)N(C)CCc3c[nH]c4ccccc34)cc2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,CN(CCc1c[nH]c2ccccc12)C(=O)c1ccc(-c2ccc(C(C)(C)C)cc2)cc1,CHEMBL1155938,=,=,IC50,nM,745000.0,IC50,uM,745.0,CN(CCc1c[nH]c2ccccc12)C(=O)c1ccc(-c2ccc(C(C)(C)C)cc2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,Cc1ccc(-c2ccc(C(=O)N(C)CCc3c[nH]c4ccccc34)cc2)cc1,CHEMBL1155938,=,=,IC50,nM,70000.0,IC50,uM,70.0,Cc1ccc(-c2ccc(C(=O)N(C)CCc3c[nH]c4ccccc34)cc2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,CN(CCc1c[nH]c2ccccc12)C(=O)c1ccc(-c2ccc(F)cc2)cc1,CHEMBL1155938,=,=,IC50,nM,875000.0,IC50,uM,875.0,CN(CCc1c[nH]c2ccccc12)C(=O)c1ccc(-c2ccc(F)cc2)cc1,2008.0
Inhibition of human CDK2/GST-cyclin A expressed in Sf9 cells assessed as histone phosphorylation,CN(CCc1c[nH]c2ccccc12)C(=O)c1ccc(-c2ccccc2)cc1,CHEMBL1155938,=,=,IC50,nM,521000.0,IC50,uM,521.0,CN(CCc1c[nH]c2ccccc12)C(=O)c1ccc(-c2ccccc2)cc1,2008.0
Inhibition of CDK2,CCCCOc1c(C(=O)c2ccccc2)cnc2[nH]ncc12,CHEMBL1155871,=,=,IC50,nM,110.0,IC50,uM,0.11,CCCCOc1c(C(=O)c2ccccc2)cnc2[nH]ncc12,2008.0
Inhibition of CDK2/CyclinA,CCN1C(=O)C(C)(C)c2cc3[nH]c4c(c3cc21)CCCc1c(C)n[nH]c1-4,CHEMBL1155876,=,=,IC50,nM,15000.0,IC50,uM,15.0,CCN1C(=O)C(C)(C)c2cc3[nH]c4c(c3cc21)CCCc1c(C)n[nH]c1-4,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL1156543,=,=,IC50,nM,370.0,IC50,uM,0.37,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,CHEMBL1156543,=,=,IC50,nM,47.0,IC50,uM,0.047,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(F)cccc1Cl,CHEMBL1156543,=,=,IC50,nM,110.0,IC50,uM,0.11,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(F)cccc1Cl,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,COc1cccc(F)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,CHEMBL1156543,=,=,IC50,nM,350.0,IC50,uM,0.35,COc1cccc(F)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(F)cc(F)cc1F,CHEMBL1156543,=,=,IC50,nM,750.0,IC50,uM,0.75,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(F)cc(F)cc1F,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,Cl.O=C(N[C@H]1CCCNC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,CHEMBL1156543,=,=,IC50,nM,44.0,IC50,uM,0.044,Cl.O=C(N[C@H]1CCCNC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,CHEMBL1156543,=,=,IC50,nM,140.0,IC50,uM,0.14,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,N[C@H]1CC[C@H](NC(=O)c2n[nH]cc2NC(=O)c2c(F)cccc2F)CC1,CHEMBL1156543,=,=,IC50,nM,38.0,IC50,uM,0.038,N[C@H]1CC[C@H](NC(=O)c2n[nH]cc2NC(=O)c2c(F)cccc2F)CC1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(N[C@H]1CC[C@H](O)CC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,CHEMBL1156543,=,=,IC50,nM,19.0,IC50,uM,0.019,O=C(N[C@H]1CC[C@H](O)CC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(NC1CCCCC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,CHEMBL1156543,=,=,IC50,nM,12.0,IC50,uM,0.012,O=C(NC1CCCCC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(NCC1CC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,CHEMBL1156543,=,=,IC50,nM,25.0,IC50,uM,0.025,O=C(NCC1CC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(Nc1ccc(F)cc1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,CHEMBL1156543,=,=,IC50,nM,3.0,IC50,uM,0.003,O=C(Nc1ccc(F)cc1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(Nc1c[nH]nc1C(=O)Nc1ccc(F)cc1)c1ccccc1,CHEMBL1156543,=,=,IC50,nM,140.0,IC50,uM,0.14,O=C(Nc1c[nH]nc1C(=O)Nc1ccc(F)cc1)c1ccccc1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(Nc1ccc(F)cc1)c1n[nH]cc1NC(=O)C1CCCCC1,CHEMBL1156543,=,=,IC50,nM,90.0,IC50,uM,0.09,O=C(Nc1ccc(F)cc1)c1n[nH]cc1NC(=O)C1CCCCC1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(Cc1ccccc1)Nc1c[nH]nc1C(=O)Nc1ccc(F)cc1,CHEMBL1156543,=,=,IC50,nM,1600.0,IC50,uM,1.6,O=C(Cc1ccccc1)Nc1c[nH]nc1C(=O)Nc1ccc(F)cc1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(CO)Nc1c[nH]nc1C(=O)Nc1ccc(F)cc1,CHEMBL1156543,=,=,IC50,nM,730.0,IC50,uM,0.73,O=C(CO)Nc1c[nH]nc1C(=O)Nc1ccc(F)cc1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,CC(=O)Nc1c[nH]nc1C(=O)Nc1ccc(F)cc1,CHEMBL1156543,=,=,IC50,nM,850.0,IC50,uM,0.85,CC(=O)Nc1c[nH]nc1C(=O)Nc1ccc(F)cc1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,Nc1c[nH]nc1C(=O)Nc1ccc(F)cc1,CHEMBL1156543,=,=,IC50,nM,85000.0,IC50,uM,85.0,Nc1c[nH]nc1C(=O)Nc1ccc(F)cc1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,c1ccc2[nH]c(-c3cc[nH]n3)nc2c1,CHEMBL1156543,=,=,IC50,nM,25000.0,IC50,uM,25.0,c1ccc2[nH]c(-c3cc[nH]n3)nc2c1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(Nc1ccccc1)c1cc[nH]n1,CHEMBL1156543,=,=,IC50,nM,97000.0,IC50,uM,97.0,O=C(Nc1ccccc1)c1cc[nH]n1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,NS(=O)(=O)c1ccc(NC(=O)c2n[nH]c3ccccc23)cc1,CHEMBL1156543,=,=,IC50,nM,660.0,IC50,uM,0.66,NS(=O)(=O)c1ccc(NC(=O)c2n[nH]c3ccccc23)cc1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,O=C(Nc1ccccc1)c1n[nH]c2ccccc12,CHEMBL1156543,=,=,IC50,nM,3000.0,IC50,uM,3.0,O=C(Nc1ccccc1)c1n[nH]c2ccccc12,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,CC(C)Nc1cc(N[C@H]2CC[C@H](N)CC2)nc2c(C#N)cnn12,CHEMBL1156543,=,=,IC50,nM,30.0,IC50,uM,0.03,CC(C)Nc1cc(N[C@H]2CC[C@H](N)CC2)nc2c(C#N)cnn12,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,CC(C)Nc1cc(Cl)nc2c(C#N)cnn12,CHEMBL1156543,=,=,IC50,nM,1500.0,IC50,uM,1.5,CC(C)Nc1cc(Cl)nc2c(C#N)cnn12,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,NS(=O)(=O)c1ccc(Nc2cncc(Cl)n2)cc1,CHEMBL1156543,=,=,IC50,nM,1900.0,IC50,uM,1.9,NS(=O)(=O)c1ccc(Nc2cncc(Cl)n2)cc1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,Clc1cncc(Nc2ccccc2)n1,CHEMBL1156543,=,=,IC50,nM,7000.0,IC50,uM,7.0,Clc1cncc(Nc2ccccc2)n1,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,N#Cc1cnn2cccnc12,CHEMBL1156543,=,=,IC50,nM,370.0,IC50,uM,0.37,N#Cc1cnn2cccnc12,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,NS(=O)(=O)c1cccc2c(O)cccc12,CHEMBL1156543,=,=,IC50,nM,120000.0,IC50,uM,120.0,NS(=O)(=O)c1cccc2c(O)cccc12,2008.0
Inhibition of CDK2/Cyclin A by radiometric assay,c1ccc2[nH]ncc2c1,CHEMBL1156543,=,=,IC50,nM,185000.0,IC50,uM,185.0,c1ccc2[nH]ncc2c1,2008.0
Inhibition of CDK2/Cyclin A at 1 mM by radiometric assay,N#Cc1cnn2cccnc12,CHEMBL1156543,=,=,Inhibition,%,54.0,INH,%,54.0,N#Cc1cnn2cccnc12,2008.0
Inhibition of CDK2/Cyclin A at 1 mM by radiometric assay,Nc1cncc(Cl)n1,CHEMBL1156543,=,=,Inhibition,%,64.0,INH,%,64.0,Nc1cncc(Cl)n1,2008.0
Inhibition of CDK2 in human HCT116 cells assessed as Rb(Thr321) phosphorylation,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,CHEMBL1156543,,,Activity,,,Activity,,,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,2008.0
Inhibition of CDK2 in human HCT116 cells assessed as NPM(Thr199) phosphorylation,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,CHEMBL1156543,,,Activity,,,Activity,,,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C,CHEMBL1151712,=,=,Activity,%,4.7,Activity,%,4.7,CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1,CHEMBL1151712,=,=,Activity,%,2.8,Activity,%,2.8,NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1,2008.0
Inhibition of human CDK2/Cyc2,N=C(N)SCCCN1C(=O)C2=C(C1=O)n1ccc3cccc(c31)C1Cc3ccccc3N21,CHEMBL1151764,=,=,IC50,nM,4300.0,IC50,uM,4.3,N=C(N)SCCCN1C(=O)C2=C(C1=O)n1ccc3cccc(c31)C1Cc3ccccc3N21,2008.0
Inhibition of human CDK2/CycA,CNC(=N)SCCCN1C(=O)C2=C(C1=O)n1ccc3cccc(c31)C1Cc3ccccc3N21,CHEMBL1151764,=,=,IC50,nM,5300.0,IC50,uM,5.3,CNC(=N)SCCCN1C(=O)C2=C(C1=O)n1ccc3cccc(c31)C1Cc3ccccc3N21,2008.0
Inhibition of human CDK2/CycA,CCNC(=N)SCCCN1C(=O)C2=C(C1=O)n1ccc3cccc(c31)C1Cc3ccccc3N21,CHEMBL1151764,=,=,IC50,nM,6800.0,IC50,uM,6.8,CCNC(=N)SCCCN1C(=O)C2=C(C1=O)n1ccc3cccc(c31)C1Cc3ccccc3N21,2008.0
Inhibition of human CDK2/CycA,O=C1C2=C(C(=O)N1CCCSC1=NCCN1)n1ccc3cccc(c31)C1Cc3ccccc3N21,CHEMBL1151764,=,=,IC50,nM,7700.0,IC50,uM,7.7,O=C1C2=C(C(=O)N1CCCSC1=NCCN1)n1ccc3cccc(c31)C1Cc3ccccc3N21,2008.0
Inhibition of human CDK2/CycA,N=C(Nc1ccccc1)SCCCN1C(=O)C2=C(C1=O)n1ccc3cccc(c31)C1Cc3ccccc3N21,CHEMBL1151764,=,=,IC50,nM,5100.0,IC50,uM,5.1,N=C(Nc1ccccc1)SCCCN1C(=O)C2=C(C1=O)n1ccc3cccc(c31)C1Cc3ccccc3N21,2008.0
Inhibition of human CDK2/CycA,N=C(N)SCCCn1c(=O)c2c(c1=O)n1c3ccccc3cc1c1cccc3ccn2c31,CHEMBL1151764,=,=,IC50,nM,3600.0,IC50,uM,3.6,N=C(N)SCCCn1c(=O)c2c(c1=O)n1c3ccccc3cc1c1cccc3ccn2c31,2008.0
Inhibition of human CDK2/CycA,CNC(=N)SCCCn1c(=O)c2c(c1=O)n1c3ccccc3cc1c1cccc3ccn2c31,CHEMBL1151764,=,=,IC50,nM,6300.0,IC50,uM,6.3,CNC(=N)SCCCn1c(=O)c2c(c1=O)n1c3ccccc3cc1c1cccc3ccn2c31,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,CHEMBL1152177,<,<,IC50,nM,6.0,IC50,uM,0.006,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(C(N)=O)cc3)n2)n1C(C)C,CHEMBL1152177,=,=,IC50,nM,3.0,IC50,uM,0.003,Cc1ncc(-c2ccnc(Nc3ccc(C(N)=O)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,CNC(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1,CHEMBL1152177,=,=,IC50,nM,3.0,IC50,uM,0.003,CNC(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)N(C)C)cc3)n2)n1C(C)C,CHEMBL1152177,=,=,IC50,nM,8.0,IC50,uM,0.008,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)N(C)C)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NC4CC4)cc3)n2)n1C(C)C,CHEMBL1152177,=,=,IC50,nM,17.0,IC50,uM,0.017,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NC4CC4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NCCO)cc3)n2)n1C(C)C,CHEMBL1152177,=,=,IC50,nM,2.0,IC50,uM,0.002,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NCCO)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,CCn1c(-c2ccnc(Nc3ccc(C(=O)NC)cc3)n2)cnc1C,CHEMBL1152177,=,=,IC50,nM,56.0,IC50,uM,0.056,CCn1c(-c2ccnc(Nc3ccc(C(=O)NC)cc3)n2)cnc1C,2008.0
Inhibition of CDK2,CNC(=O)c1ccc(Nc2nccc(-c3cnc(C)n3CC3CC3)n2)cc1,CHEMBL1152177,=,=,IC50,nM,42.0,IC50,uM,0.042,CNC(=O)c1ccc(Nc2nccc(-c3cnc(C)n3CC3CC3)n2)cc1,2008.0
Inhibition of CDK2,CNC(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C3CCCC3)n2)cc1,CHEMBL1152177,=,=,IC50,nM,2.0,IC50,uM,0.002,CNC(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C3CCCC3)n2)cc1,2008.0
Inhibition of CDK2,CNC(=O)c1ccc(Nc2nccc(-c3cnc(C4CC4)n3C(C)C)n2)cc1,CHEMBL1152177,=,=,IC50,nM,81.0,IC50,uM,0.081,CNC(=O)c1ccc(Nc2nccc(-c3cnc(C4CC4)n3C(C)C)n2)cc1,2008.0
Inhibition of CDK2,CNC(=O)c1ccc(Nc2nccc(-c3cnc(COC)n3C(C)C)n2)cc1,CHEMBL1152177,=,=,IC50,nM,62.0,IC50,uM,0.062,CNC(=O)c1ccc(Nc2nccc(-c3cnc(COC)n3C(C)C)n2)cc1,2008.0
Inhibition of CDK2,Cc1ncc(-c2nc(Nc3ccc(C(N)=O)cc3)ncc2F)n1C(C)C,CHEMBL1152177,<,<,IC50,nM,1.0,IC50,uM,0.001,Cc1ncc(-c2nc(Nc3ccc(C(N)=O)cc3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2,CNC(=O)c1ccc(Nc2ncc(F)c(-c3cnc(C)n3C(C)C)n2)cc1,CHEMBL1152177,=,=,IC50,nM,3.0,IC50,uM,0.003,CNC(=O)c1ccc(Nc2ncc(F)c(-c3cnc(C)n3C(C)C)n2)cc1,2008.0
Inhibition of CDK2,Cc1ncc(-c2nc(Nc3ccc(C(=O)N(C)C)cc3)ncc2F)n1C(C)C,CHEMBL1152177,=,=,IC50,nM,2.0,IC50,uM,0.002,Cc1ncc(-c2nc(Nc3ccc(C(=O)N(C)C)cc3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(C(N)=O)c(F)c3)n2)n1C(C)C,CHEMBL1152177,<,<,IC50,nM,1.0,IC50,uM,0.001,Cc1ncc(-c2ccnc(Nc3ccc(C(N)=O)c(F)c3)n2)n1C(C)C,2008.0
Inhibition of CDK2,CNC(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1F,CHEMBL1152177,<,<,IC50,nM,1.0,IC50,uM,0.001,CNC(=O)c1ccc(Nc2nccc(-c3cnc(C)n3C(C)C)n2)cc1F,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)N(C)C)c(F)c3)n2)n1C(C)C,CHEMBL1152177,=,=,IC50,nM,6.0,IC50,uM,0.006,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)N(C)C)c(F)c3)n2)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2nc(Nc3ccc(C(N)=O)c(F)c3)ncc2F)n1C(C)C,CHEMBL1152177,<,<,IC50,nM,1.0,IC50,uM,0.001,Cc1ncc(-c2nc(Nc3ccc(C(N)=O)c(F)c3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2,CNC(=O)c1ccc(Nc2ncc(F)c(-c3cnc(C)n3C(C)C)n2)cc1F,CHEMBL1152177,<,<,IC50,nM,1.0,IC50,uM,0.001,CNC(=O)c1ccc(Nc2ncc(F)c(-c3cnc(C)n3C(C)C)n2)cc1F,2008.0
Inhibition of CDK2,Cc1ncc(-c2nc(Nc3ccc(C(=O)N(C)C)c(F)c3)ncc2F)n1C(C)C,CHEMBL1152177,=,=,IC50,nM,2.0,IC50,uM,0.002,Cc1ncc(-c2nc(Nc3ccc(C(=O)N(C)C)c(F)c3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2,Cc1cc(Nc2ncc(F)c(-c3cnc(C)n3C(C)C)n2)ccc1C(=O)N(C)C,CHEMBL1152177,=,=,IC50,nM,9.0,IC50,uM,0.009,Cc1cc(Nc2ncc(F)c(-c3cnc(C)n3C(C)C)n2)ccc1C(=O)N(C)C,2008.0
Inhibition of CDK2,O=c1[nH]cnc2[nH]c(-c3ccnc(/C=C/c4ccc(CN5CCOCC5)cc4)c3)cc12,CHEMBL1152141,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=c1[nH]cnc2[nH]c(-c3ccnc(/C=C/c4ccc(CN5CCOCC5)cc4)c3)cc12,2008.0
Inhibition of CDK2,CN(C)CCOc1ccc(/C=C/c2cc(-c3cc4c(=O)[nH]cnc4[nH]3)ccn2)cc1,CHEMBL1152141,=,=,IC50,nM,8200.0,IC50,uM,8.2,CN(C)CCOc1ccc(/C=C/c2cc(-c3cc4c(=O)[nH]cnc4[nH]3)ccn2)cc1,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,CHEMBL1152195,=,=,IC50,nM,6.0,IC50,uM,0.006,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)N4CCN(C)CC4)cc3)n2)n1C(C)C,CHEMBL1152195,=,=,IC50,nM,9.0,IC50,uM,0.009,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)N4CCN(C)CC4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CCN(C)CC4)cc3)ncc2F)n1C(C)C,CHEMBL1152195,=,=,IC50,nM,18.0,IC50,uM,0.018,Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CCN(C)CC4)cc3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3)n2)n1C(C)C,CHEMBL1152195,=,=,IC50,nM,37.0,IC50,uM,0.037,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3)ncc2F)n1C(C)C,CHEMBL1152195,=,=,IC50,nM,36.0,IC50,uM,0.036,Cc1ncc(-c2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NC4CCN(C)CC4)c(F)c3)n2)n1C(C)C,CHEMBL1152195,=,=,IC50,nM,11.0,IC50,uM,0.011,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NC4CCN(C)CC4)c(F)c3)n2)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)c(F)c3)ncc2F)n1C(C)C,CHEMBL1152195,=,=,IC50,nM,1.0,IC50,uM,0.001,Cc1ncc(-c2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)c(F)c3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NCCN(C)C)c(F)c3)n2)n1C(C)C,CHEMBL1152195,=,=,IC50,nM,3.0,IC50,uM,0.003,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)NCCN(C)C)c(F)c3)n2)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2nc(Nc3ccc(C(=O)NCCN(C)C)c(F)c3)ncc2F)n1C(C)C,CHEMBL1152195,=,=,IC50,nM,2.0,IC50,uM,0.002,Cc1ncc(-c2nc(Nc3ccc(C(=O)NCCN(C)C)c(F)c3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CC[C@H](N(C)C)C4)cc3)ncc2F)n1C(C)C,CHEMBL1152195,=,=,IC50,nM,2.0,IC50,uM,0.002,Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CC[C@H](N(C)C)C4)cc3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CC[C@@H](N(C)C)C4)cc3)ncc2F)n1C(C)C,CHEMBL1152195,=,=,IC50,nM,6.0,IC50,uM,0.006,Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CC[C@@H](N(C)C)C4)cc3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2,Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CCCN(C)CC4)cc3)ncc2F)n1C(C)C,CHEMBL1152195,=,=,IC50,nM,2.0,IC50,uM,0.002,Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CCCN(C)CC4)cc3)ncc2F)n1C(C)C,2008.0
Inhibition of CDK2,CCCN(C)[C@H]1CCN(C(=O)c2ccc(Nc3nccc(-c4cnc(C)n4C(C)C)n3)cc2)C1,CHEMBL1152195,=,=,IC50,nM,4.0,IC50,uM,0.004,CCCN(C)[C@H]1CCN(C(=O)c2ccc(Nc3nccc(-c4cnc(C)n4C(C)C)n3)cc2)C1,2008.0
Inhibition of CDK2,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)N4CC[C@H](NC5CC5)C4)cc3)n2)n1C(C)C,CHEMBL1152195,<,<,IC50,nM,1.0,IC50,uM,0.001,Cc1ncc(-c2ccnc(Nc3ccc(C(=O)N4CC[C@H](NC5CC5)C4)cc3)n2)n1C(C)C,2008.0
Inhibition of CDK2,CN[C@H]1CCN(C(=O)c2ccc(Nc3nccc(-c4cnc(C)n4C(C)C)n3)cc2)C1,CHEMBL1152195,=,=,IC50,nM,2.0,IC50,uM,0.002,CN[C@H]1CCN(C(=O)c2ccc(Nc3nccc(-c4cnc(C)n4C(C)C)n3)cc2)C1,2008.0
Inhibition of CDK2,CN[C@H]1CCN(C(=O)c2ccc(Nc3ncc(F)c(-c4cnc(C)n4C(C)C)n3)cc2)C1,CHEMBL1152195,=,=,IC50,nM,2.0,IC50,uM,0.002,CN[C@H]1CCN(C(=O)c2ccc(Nc3ncc(F)c(-c4cnc(C)n4C(C)C)n3)cc2)C1,2008.0
Inhibition of CDK2/Cyclin A by fluorescence polarization assay,C[C@@H]1CNC[C@@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1,CHEMBL1152130,=,=,IC50,nM,200.0,IC50,uM,0.2,C[C@@H]1CNC[C@@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1,2008.0
Inhibition of CDK2/Cyclin A by fluorescence polarization assay,C[C@@H]1CNC[C@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1,CHEMBL1152130,=,=,IC50,nM,20.0,IC50,uM,0.02,C[C@@H]1CNC[C@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1,2008.0
Inhibition of CDK2/Cyclin A by fluorescence polarization assay,C[C@H]1CNC[C@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1,CHEMBL1152130,=,=,IC50,nM,5.0,IC50,uM,0.005,C[C@H]1CNC[C@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1,2008.0
Inhibition of CDK2/Cyclin A by fluorescence polarization assay,C[C@H]1CNC[C@@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1,CHEMBL1152130,=,=,IC50,nM,36.0,IC50,uM,0.036,C[C@H]1CNC[C@@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1,2008.0
Inhibition of CDK2/Cyclin A by fluorescence polarization assay,CC1CNCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1,CHEMBL1152130,=,=,IC50,nM,140.0,IC50,uM,0.14,CC1CNCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1,2008.0
Inhibition of CDK2/Cyclin A by fluorescence polarization assay,CC1CCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CN1,CHEMBL1152130,=,=,IC50,nM,14.0,IC50,uM,0.014,CC1CCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CN1,2008.0
Inhibition of CDK2/Cyclin A by fluorescence polarization assay,CC1NCCCC1C(=O)Nc1ncc(SCc2ncc(C(C)(C)C)o2)s1,CHEMBL1152130,=,=,IC50,nM,95.0,IC50,uM,0.095,CC1NCCCC1C(=O)Nc1ncc(SCc2ncc(C(C)(C)C)o2)s1,2008.0
Inhibition of CDK2/Cyclin A by fluorescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCCNC3)s2)o1,CHEMBL1152130,=,=,IC50,nM,20.0,IC50,uM,0.02,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCCNC3)s2)o1,2008.0
Inhibition of CDK2/Cyclin A by fluorescence polarization assay,CC(C)C1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1,CHEMBL1152130,=,=,IC50,nM,17.0,IC50,uM,0.017,CC(C)C1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1,2008.0
Inhibition of CDK2/Cyclin A by fluorescence polarization assay,CCC1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1,CHEMBL1152130,=,=,IC50,nM,3.0,IC50,uM,0.003,CCC1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1,2008.0
Inhibition of CDK2/Cyclin A by fluorescence polarization assay,CC1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1,CHEMBL1152130,=,=,IC50,nM,15.0,IC50,uM,0.015,CC1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1,2008.0
Inhibition of CDK2/Cyclin A by fluorescence polarization assay,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,CHEMBL1152130,=,=,IC50,nM,46.0,IC50,uM,0.046,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1,CHEMBL1151712,,,Activity,,,Activity,,,Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1,CHEMBL1151712,,,Activity,,,Activity,,,Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1,CHEMBL1151712,,,Activity,,,Activity,,,Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1,CHEMBL1151712,,,Activity,,,Activity,,,Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1,CHEMBL1151712,,,Activity,,,Activity,,,Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1,CHEMBL1151712,,,Activity,,,Activity,,,CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1,CHEMBL1151712,=,=,Activity,%,0.5,Activity,%,0.5,O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1,2008.0
Binding affinity to human CDK2 at 10 uM relative to control,c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1,CHEMBL1151712,,,Activity,,,Activity,,,c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1,2008.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CCc1cc2c(N/N=C\c3cccs3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,1.1,IC50,ug ml-1,1.1,CCc1cc2c(N/N=C\c3cccs3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,Cc1cc2c(N/N=C\c3cccs3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,1.7,IC50,ug ml-1,1.7,Cc1cc2c(N/N=C\c3cccs3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)c1cc2c(N/N=C\c3cccs3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,0.35,IC50,ug ml-1,0.35,CC(C)c1cc2c(N/N=C\c3cccs3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)(C)c1cc2c(N/N=C\c3cccs3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,0.56,IC50,ug ml-1,0.56,CC(C)(C)c1cc2c(N/N=C\c3cccs3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,C(=N\Nc1ncnc2sc(Cc3ccccc3)cc12)\c1cccs1,CHEMBL1149082,=,=,IC50,ug.mL-1,6.5,IC50,ug ml-1,6.5,C(=N\Nc1ncnc2sc(Cc3ccccc3)cc12)\c1cccs1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CCc1c(C)sc2ncnc(N/N=C\c3cccs3)c12,CHEMBL1149082,=,=,IC50,ug.mL-1,12.0,IC50,ug ml-1,12.0,CCc1c(C)sc2ncnc(N/N=C\c3cccs3)c12,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,C(=N\Nc1ncnc2sc3c(c12)CCCC3)\c1cccs1,CHEMBL1149082,>,>,IC50,ug.mL-1,20.0,IC50,ug ml-1,20.0,C(=N\Nc1ncnc2sc3c(c12)CCCC3)\c1cccs1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,Cc1csc2ncnc(N/N=C\c3cccs3)c12,CHEMBL1149082,>,>,IC50,ug.mL-1,20.0,IC50,ug ml-1,20.0,Cc1csc2ncnc(N/N=C\c3cccs3)c12,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CCc1cc2c(N/N=C\c3cccs3)nc(C)nc2s1,CHEMBL1149082,>,>,IC50,ug.mL-1,20.0,IC50,ug ml-1,20.0,CCc1cc2c(N/N=C\c3cccs3)nc(C)nc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CCc1cc2c(N/N=C\c3cccs3)nc(-c3ccccc3)nc2s1,CHEMBL1149082,>,>,IC50,ug.mL-1,20.0,IC50,ug ml-1,20.0,CCc1cc2c(N/N=C\c3cccs3)nc(-c3ccccc3)nc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,C/C(=N/Nc1ncnc2sc(C(C)C)cc12)c1cccs1,CHEMBL1149082,=,=,IC50,ug.mL-1,8.9,IC50,ug ml-1,8.9,C/C(=N/Nc1ncnc2sc(C(C)C)cc12)c1cccs1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)c1cc2c(-n3ccc(-c4cccs4)n3)ncnc2s1,CHEMBL1149082,>,>,IC50,ug.mL-1,20.0,IC50,ug ml-1,20.0,CC(C)c1cc2c(-n3ccc(-c4cccs4)n3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CCc1cc2c(N/N=C\C(C)(C)C)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,3.8,IC50,ug ml-1,3.8,CCc1cc2c(N/N=C\C(C)(C)C)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CCc1cc2c(N/N=C\C3CC3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,4.1,IC50,ug ml-1,4.1,CCc1cc2c(N/N=C\C3CC3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)c1cc2c(N/N=C\c3ccccn3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,3.1,IC50,ug ml-1,3.1,CC(C)c1cc2c(N/N=C\c3ccccn3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)c1cc2c(N/N=C\c3cccnc3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,0.7,IC50,ug ml-1,0.7,CC(C)c1cc2c(N/N=C\c3cccnc3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)c1cc2c(N/N=C\c3ccncc3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,0.33,IC50,ug ml-1,0.33,CC(C)c1cc2c(N/N=C\c3ccncc3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)c1cc2c(N/N=C\c3ccccc3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,0.88,IC50,ug ml-1,0.88,CC(C)c1cc2c(N/N=C\c3ccccc3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)c1cc2c(N/N=C\c3ccco3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,0.55,IC50,ug ml-1,0.55,CC(C)c1cc2c(N/N=C\c3ccco3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)(C)c1cc2c(N/N=C\c3ccccn3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,2.8,IC50,ug ml-1,2.8,CC(C)(C)c1cc2c(N/N=C\c3ccccn3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)(C)c1cc2c(N/N=C\c3cccnc3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,0.56,IC50,ug ml-1,0.56,CC(C)(C)c1cc2c(N/N=C\c3cccnc3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,Cc1ccc(/C=N\Nc2ncnc3sc(C(C)(C)C)cc23)nc1,CHEMBL1149082,=,=,IC50,ug.mL-1,12.0,IC50,ug ml-1,12.0,Cc1ccc(/C=N\Nc2ncnc3sc(C(C)(C)C)cc23)nc1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,Cc1cccc(/C=N\Nc2ncnc3sc(C(C)(C)C)cc23)n1,CHEMBL1149082,=,=,IC50,ug.mL-1,6.9,IC50,ug ml-1,6.9,Cc1cccc(/C=N\Nc2ncnc3sc(C(C)(C)C)cc23)n1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)(C)c1cc2c(N/N=C\c3cccc(CN)n3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,3.6,IC50,ug ml-1,3.6,CC(C)(C)c1cc2c(N/N=C\c3cccc(CN)n3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CNCc1cccc(/C=N\Nc2ncnc3sc(C(C)(C)C)cc23)n1,CHEMBL1149082,=,=,IC50,ug.mL-1,7.1,IC50,ug ml-1,7.1,CNCc1cccc(/C=N\Nc2ncnc3sc(C(C)(C)C)cc23)n1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CN(C)Cc1cccc(/C=N\Nc2ncnc3sc(C(C)(C)C)cc23)n1,CHEMBL1149082,=,=,IC50,ug.mL-1,1.4,IC50,ug ml-1,1.4,CN(C)Cc1cccc(/C=N\Nc2ncnc3sc(C(C)(C)C)cc23)n1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)(C)c1cc2c(N/N=C\c3cccc(CN4CCOCC4)n3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,5.5,IC50,ug ml-1,5.5,CC(C)(C)c1cc2c(N/N=C\c3cccc(CN4CCOCC4)n3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation by dose-response curve analysis,CC(C)(C)c1cc2c(N/N=C\c3cccc(CO)n3)ncnc2s1,CHEMBL1149082,=,=,IC50,ug.mL-1,2.1,IC50,ug ml-1,2.1,CC(C)(C)c1cc2c(N/N=C\c3cccc(CO)n3)ncnc2s1,2009.0
Inhibition of CDK2-mediated retinoblastoma protein phosphorylation up to 20 ug/mL by dose-response curve analysis,C(=N\Nc1ncnc2sc(Cc3ccccc3)cc12)\c1cccs1,CHEMBL1149082,,,Activity,,,Activity,,,C(=N\Nc1ncnc2sc(Cc3ccccc3)cc12)\c1cccs1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1cccc(Br)c1)c1nscc1NCc1ccc2ccccc2n1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1cccc(Br)c1)c1nscc1NCc1ccc2ccccc2n1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1cccc(Br)c1)c1nscc1NCc1cnoc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1cccc(Br)c1)c1nscc1NCc1cnoc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1ccnc2ccccc12,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1ccnc2ccccc12,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1cccc(Br)c1)c1nscc1NCc1ccnc2ccccc12,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1cccc(Br)c1)c1nscc1NCc1ccnc2ccccc12,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1cccc(Br)c1)c1nscc1NCCc1ccc2c(c1)OCO2,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1cccc(Br)c1)c1nscc1NCCc1ccc2c(c1)OCO2,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCCc1ccc2c(c1)OCO2,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCCc1ccc2c(c1)OCO2,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1ccc(F)c(F)c1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1ccc(F)c(F)c1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(NCc1ccc2c(c1)OCO2)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(NCc1ccc2c(c1)OCO2)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,Cc1ccc(NC(=O)c2nscc2NCc2ccncc2)c(F)c1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,Cc1ccc(NC(=O)c2nscc2NCc2ccncc2)c(F)c1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,Cc1cc(NC(=O)c2nscc2NCc2ccncc2)ccc1C(F)(F)F,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,Cc1cc(NC(=O)c2nscc2NCc2ccncc2)ccc1C(F)(F)F,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,Cc1ccc(NC(=O)c2nscc2NCc2ccncc2)cc1C(F)(F)F,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,Cc1ccc(NC(=O)c2nscc2NCc2ccncc2)cc1C(F)(F)F,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1ccc(Cl)c(Cl)c1)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1ccc(Cl)c(Cl)c1)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(NC1=CC2C=NNC2C=C1)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(NC1=CC2C=NNC2C=C1)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1ccc2ccccc2n1)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1ccc2ccccc2n1)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1ccccc1Br)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1ccccc1Br)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1ccc(Br)cc1)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1ccc(Br)cc1)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1cccc(Br)c1)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1cccc(Br)c1)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1ccc(Cl)cc1)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1ccc(Cl)cc1)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,CC(C)(C)c1ccc(NC(=O)c2nscc2NCc2ccncc2)cc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,CC(C)(C)c1ccc(NC(=O)c2nscc2NCc2ccncc2)cc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,CC(C)(C)c1cccc(NC(=O)c2nscc2NCc2ccncc2)c1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,CC(C)(C)c1cccc(NC(=O)c2nscc2NCc2ccncc2)c1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1ccc(OC(F)(F)F)cc1)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1ccc(OC(F)(F)F)cc1)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1cccc(OC(F)(F)F)c1)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1cccc(OC(F)(F)F)c1)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1ccc(C(F)(F)F)cc1)c1nscc1NCc1ccccn1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1ccc(C(F)(F)F)cc1)c1nscc1NCc1ccccn1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1ccc(C(F)(F)F)cc1)c1nscc1NCc1cccnc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1ccc(C(F)(F)F)cc1)c1nscc1NCc1cccnc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1ccc(C(F)(F)F)cc1)c1nscc1NCc1ccncc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1ccc(C(F)(F)F)cc1)c1nscc1NCc1ccncc1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1ccccn1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1ccccn1,2009.0
Inhibition of CDK2 at 10 uM by HTRF assay,O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1cccnc1,CHEMBL1136839,<,<,Inhibition,%,30.0,INH,%,30.0,O=C(Nc1cccc(C(F)(F)F)c1)c1nscc1NCc1cccnc1,2009.0
Inhibition of Cdk2,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,CHEMBL1152817,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,2003.0
Inhibition of CDK2/cyclin A,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,CHEMBL1152817,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,2003.0
Inhibition of CDK2,COc1ccc(-n2cnc3ccc(-c4nnc(SCc5cccc(C#N)c5)o4)cc32)cc1,CHEMBL1152750,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-n2cnc3ccc(-c4nnc(SCc5cccc(C#N)c5)o4)cc32)cc1,2009.0
Inhibition of CDK2/Cyclin A,Cl.N[C@@H](CCCN/C=C1\C(=O)Nc2ccc(Br)cc21)C(=O)O,CHEMBL1154450,=,=,IC50,nM,6600.0,IC50,uM,6.6,Cl.N[C@@H](CCCN/C=C1\C(=O)Nc2ccc(Br)cc21)C(=O)O,2008.0
Inhibition of CDK2/Cyclin A,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL1154450,=,=,IC50,nM,700.0,IC50,uM,0.7,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2008.0
Inhibition of human CDK2/Cyclin E by IMAP assay,C=CCc1c(C)nc2sc3c(N)ncnc3c2c1C,CHEMBL1154537,>,>,Ki,nM,5000.0,Ki,nM,5000.0,C=CCc1c(C)nc2sc3c(N)ncnc3c2c1C,2009.0
Inhibition of CDK2/cyclin A at 1 uM relative to control,CSc1cc(Oc2ccnc3[nH]c(=O)[nH]c23)ccc1NC(=O)Nc1cccc(C(F)(F)F)c1,CHEMBL1136991,=,=,Residual_activity,%,100.0,Residual_activity,%,100.0,CSc1cc(Oc2ccnc3[nH]c(=O)[nH]c23)ccc1NC(=O)Nc1cccc(C(F)(F)F)c1,2009.0
Inhibition of CDK2/cyclin A at 1 uM relative to control,O=C(Nc1cc(C(F)(F)F)ccc1F)Nc1ccc(Oc2ccnc3[nH]c(=O)[nH]c23)c2ccccc12,CHEMBL1136991,=,=,Residual_activity,%,100.0,Residual_activity,%,100.0,O=C(Nc1cc(C(F)(F)F)ccc1F)Nc1ccc(Oc2ccnc3[nH]c(=O)[nH]c23)c2ccccc12,2009.0
Inhibition of CDK2/cyclin A at 1 uM relative to control,CC(C)(C)c1cccc(NC(=O)Nc2ccc(Oc3ccnc4[nH]c(=O)[nH]c34)c3ccccc23)c1,CHEMBL1136991,=,=,Residual_activity,%,100.0,Residual_activity,%,100.0,CC(C)(C)c1cccc(NC(=O)Nc2ccc(Oc3ccnc4[nH]c(=O)[nH]c34)c3ccccc23)c1,2009.0
Inhibition of CDK2,O[C@H]1CC[C@H](Nc2ccc3nnc(-c4cccc(C(F)(F)F)c4)n3n2)CC1,CHEMBL1136908,=,=,Ki,nM,3100.0,Ki,nM,3100.0,O[C@H]1CC[C@H](Nc2ccc3nnc(-c4cccc(C(F)(F)F)c4)n3n2)CC1,2009.0
Inhibition of CDK2,FC(F)(F)c1cccc(-c2nnc3ccc(NC4CCNCC4)nn23)c1,CHEMBL1136908,>,>,Ki,nM,4000.0,Ki,nM,4000.0,FC(F)(F)c1cccc(-c2nnc3ccc(NC4CCNCC4)nn23)c1,2009.0
Inhibition of CDK2 at 10 uM,Cc1cccc(-c2nc(Nc3ccncc3)c3ccccc3n2)n1,CHEMBL1158406,=,=,Inhibition,%,2.0,INH,%,2.0,Cc1cccc(-c2nc(Nc3ccncc3)c3ccccc3n2)n1,2009.0
Inhibition of CDK2/Cyclin A,CN1CCN(c2cccc(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3C)CC4)c2)CC1,CHEMBL1151962,=,=,IC50,nM,1.0,IC50,uM,0.001,CN1CCN(c2cccc(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3C)CC4)c2)CC1,2009.0
Inhibition of CDK2/Cyclin A,Cn1nc(C(N)=O)c2c1-c1nc(Nc3ccccc3)ncc1CC2,CHEMBL1151962,=,=,IC50,nM,2.0,IC50,uM,0.002,Cn1nc(C(N)=O)c2c1-c1nc(Nc3ccccc3)ncc1CC2,2009.0
Inhibition of CDK2/Cyclin A,CN1CCN(c2ccc(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3C)CC4)cc2)CC1,CHEMBL1151962,=,=,IC50,nM,2.0,IC50,uM,0.002,CN1CCN(c2ccc(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3C)CC4)cc2)CC1,2009.0
Inhibition of CDK2/Cyclin A,Cn1nc(C(N)=O)c2c1-c1nc(Nc3ccc(N4CCOCC4)cc3)ncc1CC2,CHEMBL1151962,=,=,IC50,nM,14.0,IC50,uM,0.014,Cn1nc(C(N)=O)c2c1-c1nc(Nc3ccc(N4CCOCC4)cc3)ncc1CC2,2009.0
Inhibition of CDK2/Cyclin A,CN1CCN(c2ccc(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3C)C(C)(C)C4)cc2)CC1,CHEMBL1151962,=,=,IC50,nM,17.0,IC50,uM,0.017,CN1CCN(c2ccc(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3C)C(C)(C)C4)cc2)CC1,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1CCc1cnc(Nc3ccccc3)nc1-2,CHEMBL1151962,=,=,IC50,nM,19.0,IC50,uM,0.019,CNC(=O)c1nn(C)c2c1CCc1cnc(Nc3ccccc3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,Cn1nc(C(N)=O)c2c1-c1nc(Nc3ccccc3)ncc1CC2(C)C,CHEMBL1151962,=,=,IC50,nM,24.0,IC50,uM,0.024,Cn1nc(C(N)=O)c2c1-c1nc(Nc3ccccc3)ncc1CC2(C)C,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(OC4CCN(C)CC4)cc3)nc1-2,CHEMBL1151962,=,=,IC50,nM,29.0,IC50,uM,0.029,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(OC4CCN(C)CC4)cc3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(N4CCN(C)CC4)c3)nc1-2,CHEMBL1151962,=,=,IC50,nM,31.0,IC50,uM,0.031,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(N4CCN(C)CC4)c3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(CN(C)C)cc3)nc1-2,CHEMBL1151962,=,=,IC50,nM,35.0,IC50,uM,0.035,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(CN(C)C)cc3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(CN4CCOCC4)cc3)nc1-2,CHEMBL1151962,=,=,IC50,nM,36.0,IC50,uM,0.036,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(CN4CCOCC4)cc3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1CCc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,CHEMBL1151962,=,=,IC50,nM,45.0,IC50,uM,0.045,CNC(=O)c1nn(C)c2c1CCc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,CHEMBL1151962,=,=,IC50,nM,45.0,IC50,uM,0.045,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(OC4CCN(C)CC4)c3)nc1-2,CHEMBL1151962,=,=,IC50,nM,47.0,IC50,uM,0.047,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(OC4CCN(C)CC4)c3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(CN4CCN(C)CC4)cc3)nc1-2,CHEMBL1151962,=,=,IC50,nM,55.0,IC50,uM,0.055,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(CN4CCN(C)CC4)cc3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(CN4CCN(C)CC4)c3)nc1-2,CHEMBL1151962,=,=,IC50,nM,59.0,IC50,uM,0.059,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(CN4CCN(C)CC4)c3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N(C)C)cc3)nc1-2,CHEMBL1151962,=,=,IC50,nM,59.0,IC50,uM,0.059,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N(C)C)cc3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,Cn1nc(C(=O)NCCO)c2c1-c1nc(Nc3ccccc3)ncc1CC2,CHEMBL1151962,=,=,IC50,nM,74.0,IC50,uM,0.074,Cn1nc(C(=O)NCCO)c2c1-c1nc(Nc3ccccc3)ncc1CC2,2009.0
Inhibition of CDK2/Cyclin A,Cn1nc(C(=O)NC2CC2)c2c1-c1nc(Nc3ccccc3)ncc1CC2,CHEMBL1151962,=,=,IC50,nM,81.0,IC50,uM,0.081,Cn1nc(C(=O)NC2CC2)c2c1-c1nc(Nc3ccccc3)ncc1CC2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(CN(C)C)c3)nc1-2,CHEMBL1151962,=,=,IC50,nM,83.0,IC50,uM,0.083,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(CN(C)C)c3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCOCC4)cc3)nc1-2,CHEMBL1151962,=,=,IC50,nM,137.0,IC50,uM,0.137,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCOCC4)cc3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(CN4CCOCC4)c3)nc1-2,CHEMBL1151962,=,=,IC50,nM,160.0,IC50,uM,0.16,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(CN4CCOCC4)c3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(N(C)C)c3)nc1-2,CHEMBL1151962,=,=,IC50,nM,220.0,IC50,uM,0.22,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(N(C)C)c3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(N4CCOCC4)c3)nc1-2,CHEMBL1151962,=,=,IC50,nM,248.0,IC50,uM,0.248,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3cccc(N4CCOCC4)c3)nc1-2,2009.0
Inhibition of CDK2/Cyclin E,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,CHEMBL1151962,=,=,IC50,nM,363.0,IC50,uM,0.363,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,2009.0
Inhibition of CDK2/Cyclin A,Cn1nc(C(=O)Nc2ccccc2)c2c1-c1nc(Nc3ccccc3)ncc1CC2,CHEMBL1151962,=,=,IC50,nM,574.0,IC50,uM,0.574,Cn1nc(C(=O)Nc2ccccc2)c2c1-c1nc(Nc3ccccc3)ncc1CC2,2009.0
Inhibition of CDK2/Cyclin A,Cn1nc(C(=O)NCc2ccccc2)c2c1-c1nc(Nc3ccccc3)ncc1CC2,CHEMBL1151962,=,=,IC50,nM,1053.0,IC50,uM,1.053,Cn1nc(C(=O)NCc2ccccc2)c2c1-c1nc(Nc3ccccc3)ncc1CC2,2009.0
Inhibition of CDK2/Cyclin A,Cn1nc(C(=O)NC2CCCC2)c2c1-c1nc(Nc3ccccc3)ncc1CC2,CHEMBL1151962,=,=,IC50,nM,3900.0,IC50,uM,3.9,Cn1nc(C(=O)NC2CCCC2)c2c1-c1nc(Nc3ccccc3)ncc1CC2,2009.0
Inhibition of CDK2 in human A2780 cells assessed as reduction of hyperphosphorylated form of retinoblastoma protein at 3 uM relative to control,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,CHEMBL1151962,,,Activity,,,Activity,,,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,2009.0
Inhibition of CDK2 in human A2780 cells assessed as accumulation of hypophosphorylated form of retinoblastoma protein at 1 uM relative to control,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,CHEMBL1151962,,,Activity,,,Activity,,,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,2009.0
Inhibition of CDK2 in human A2780 cells assessed as accumulation of hypophosphorylated form of retinoblastoma protein at 3 uM relative to control,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,CHEMBL1151962,,,Activity,,,Activity,,,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,2009.0
Inhibition of CDK2 in human A2780 cells assessed as reduction of hyperphosphorylated form of retinoblastoma protein at 1 uM relative to control,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,CHEMBL1151962,,,Activity,,,Activity,,,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,2009.0
Inhibition of CDK2/cyclinA after 1 hr by mobility shift electrophoresis assay,COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1,CHEMBL1151963,>,>,IC50,nM,50000.0,IC50,uM,50.0,COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1,2009.0
Inhibition of recombinant CDK2/CycA,COc1cc(O)c2c(c1)C(=O)C1=C(C2=O)[C@H](O)[C@@H](O)[C@@](C)(O)[C@@H]1O,CHEMBL1151842,>,>,IC50,ug.mL-1,10.0,IC50,ug ml-1,10.0,COc1cc(O)c2c(c1)C(=O)C1=C(C2=O)[C@H](O)[C@@H](O)[C@@](C)(O)[C@@H]1O,2009.0
Inhibition of recombinant CDK2/CycA,COc1cc(O)c2c(c1)C(=O)c1cc(C)c(O)cc1C2=O,CHEMBL1151842,>,>,IC50,ug.mL-1,10.0,IC50,ug ml-1,10.0,COc1cc(O)c2c(c1)C(=O)c1cc(C)c(O)cc1C2=O,2009.0
Inhibition of recombinant CDK2/CycA,COc1cc(O)c2c(c1)C(=O)c1cc(C)c(O)c(O)c1C2=O,CHEMBL1151842,>,>,IC50,ug.mL-1,10.0,IC50,ug ml-1,10.0,COc1cc(O)c2c(c1)C(=O)c1cc(C)c(O)c(O)c1C2=O,2009.0
Inhibition of recombinant CDK2/CycA,COc1cc2c(c(O)c1-c1c(OC)cc(O)c3c1C(=O)C1=C(C3=O)[C@H](O)[C@@H](O)[C@@](C)(O)[C@@H]1O)C(=O)c1cc(O)c(C)cc1C2=O,CHEMBL1151842,>,>,IC50,ug.mL-1,10.0,IC50,ug ml-1,10.0,COc1cc2c(c(O)c1-c1c(OC)cc(O)c3c1C(=O)C1=C(C3=O)[C@H](O)[C@@H](O)[C@@](C)(O)[C@@H]1O)C(=O)c1cc(O)c(C)cc1C2=O,2009.0
Inhibition of CDK2/Cyclin A,CCSc1nn2c(COc3ccc(Cl)cc3)nnc2s1,CHEMBL1152892,=,=,IC50,nM,24000.0,IC50,uM,24.0,CCSc1nn2c(COc3ccc(Cl)cc3)nnc2s1,2009.0
Inhibition of CDK2/Cyclin A,CCSc1nn2c(Cc3ccccc3)nnc2s1,CHEMBL1152892,=,=,IC50,nM,24000.0,IC50,uM,24.0,CCSc1nn2c(Cc3ccccc3)nnc2s1,2009.0
Inhibition of CDK2/Cyclin A,S=c1[nH]c(=S)c2c(Cc3nn4c(Cc5ccccc5)nnc4s3)n[nH]c2[nH]1,CHEMBL1152892,=,=,IC50,nM,24000.0,IC50,uM,24.0,S=c1[nH]c(=S)c2c(Cc3nn4c(Cc5ccccc5)nnc4s3)n[nH]c2[nH]1,2009.0
Inhibition of CDK2/Cyclin A,Cc1nnc2sc(Cc3n[nH]c4[nH]c(=S)[nH]c(=S)c34)nn12,CHEMBL1152892,=,=,IC50,nM,24000.0,IC50,uM,24.0,Cc1nnc2sc(Cc3n[nH]c4[nH]c(=S)[nH]c(=S)c34)nn12,2009.0
Inhibition of CDK2/Cyclin A,Cc1nnc2sc(SSc3nn4c(C)nnc4s3)nn12,CHEMBL1152892,=,=,IC50,nM,23000.0,IC50,uM,23.0,Cc1nnc2sc(SSc3nn4c(C)nnc4s3)nn12,2009.0
Inhibition of CDK2/Cyclin A,Sc1nn2c(Cc3ccccc3)nnc2s1,CHEMBL1152892,=,=,IC50,nM,23000.0,IC50,uM,23.0,Sc1nn2c(Cc3ccccc3)nnc2s1,2009.0
Inhibition of CDK2/Cyclin A,Cc1nnc2sc(SCc3ccccc3)nn12,CHEMBL1152892,=,=,IC50,nM,16000.0,IC50,uM,16.0,Cc1nnc2sc(SCc3ccccc3)nn12,2009.0
Inhibition of CDK2/Cyclin A,NNc1nn2c(COc3ccc(Cl)cc3)nnc2s1,CHEMBL1152892,=,=,IC50,nM,15000.0,IC50,uM,15.0,NNc1nn2c(COc3ccc(Cl)cc3)nnc2s1,2009.0
Inhibition of CDK2/Cyclin A,c1ccc(Cc2nnc3sc(SSc4nn5c(Cc6ccccc6)nnc5s4)nn23)cc1,CHEMBL1152892,=,=,IC50,nM,15000.0,IC50,uM,15.0,c1ccc(Cc2nnc3sc(SSc4nn5c(Cc6ccccc6)nnc5s4)nn23)cc1,2009.0
Inhibition of CDK2/Cyclin A,Nc1nc(O)c(Cc2nn3c(Cc4ccccc4)nnc3s2)s1,CHEMBL1152892,=,=,IC50,nM,14000.0,IC50,uM,14.0,Nc1nc(O)c(Cc2nn3c(Cc4ccccc4)nnc3s2)s1,2009.0
Inhibition of CDK2/Cyclin A,Cc1nnc2sc(NN)nn12,CHEMBL1152892,=,=,IC50,nM,11000.0,IC50,uM,11.0,Cc1nnc2sc(NN)nn12,2009.0
Inhibition of CDK2/Cyclin A,CCSc1nn2c(C)nnc2s1,CHEMBL1152892,=,=,IC50,nM,11000.0,IC50,uM,11.0,CCSc1nn2c(C)nnc2s1,2009.0
Inhibition of CDK2/Cyclin A,Cc1nnc2sc(S)nn12,CHEMBL1152892,=,=,IC50,nM,6800.0,IC50,uM,6.8,Cc1nnc2sc(S)nn12,2009.0
Inhibition of CDK2/Cyclin A,Clc1ccc(OCc2nnc3sc(SSc4nn5c(COc6ccc(Cl)cc6)nnc5s4)nn23)cc1,CHEMBL1152892,=,=,IC50,nM,820.0,IC50,uM,0.82,Clc1ccc(OCc2nnc3sc(SSc4nn5c(COc6ccc(Cl)cc6)nnc5s4)nn23)cc1,2009.0
Inhibition of CDK2/Cyclin A,Cc1nnc2sc(-c3ccc(N)cc3)nn12,CHEMBL1152892,=,=,IC50,nM,570.0,IC50,uM,0.57,Cc1nnc2sc(-c3ccc(N)cc3)nn12,2009.0
Inhibition of CDK2/Cyclin A,Sc1nn2c(COc3ccc(Cl)cc3)nnc2s1,CHEMBL1152892,=,=,IC50,nM,400.0,IC50,uM,0.4,Sc1nn2c(COc3ccc(Cl)cc3)nnc2s1,2009.0
Inhibition of CDK2/Cyclin A,Nc1ccc(-c2nn3c(COc4ccc(Cl)cc4)nnc3s2)cc1,CHEMBL1152892,=,=,IC50,nM,330.0,IC50,uM,0.33,Nc1ccc(-c2nn3c(COc4ccc(Cl)cc4)nnc3s2)cc1,2009.0
Inhibition of CDK2/Cyclin A,Cc1nnc2sc(Cc3sc(N)nc3O)nn12,CHEMBL1152892,=,=,IC50,nM,250.0,IC50,uM,0.25,Cc1nnc2sc(Cc3sc(N)nc3O)nn12,2009.0
Inhibition of CDK2/Cyclin A,Nc1nc(O)c(Cc2nn3c(COc4ccc(Cl)cc4)nnc3s2)s1,CHEMBL1152892,=,=,IC50,nM,180.0,IC50,uM,0.18,Nc1nc(O)c(Cc2nn3c(COc4ccc(Cl)cc4)nnc3s2)s1,2009.0
Inhibition of CDK2/Cyclin A,S=c1[nH]c(=S)c2c(Cc3nn4c(COc5ccc(Cl)cc5)nnc4s3)n[nH]c2[nH]1,CHEMBL1152892,=,=,IC50,nM,37000.0,IC50,uM,37.0,S=c1[nH]c(=S)c2c(Cc3nn4c(COc5ccc(Cl)cc5)nnc4s3)n[nH]c2[nH]1,2009.0
Inhibition of CDK2/Cyclin A,Nc1ccc(-c2nn3c(Cc4ccccc4)nnc3s2)cc1,CHEMBL1152892,>,>,IC50,nM,28000.0,IC50,uM,28.0,Nc1ccc(-c2nn3c(Cc4ccccc4)nnc3s2)cc1,2009.0
Inhibition of CDK2/Cyclin A,c1ccc(CSc2nn3c(Cc4ccccc4)nnc3s2)cc1,CHEMBL1152892,>,>,IC50,nM,28000.0,IC50,uM,28.0,c1ccc(CSc2nn3c(Cc4ccccc4)nnc3s2)cc1,2009.0
Inhibition of CDK2/Cyclin A,Clc1ccc(OCc2nnc3sc(SCc4ccccc4)nn23)cc1,CHEMBL1152892,>,>,IC50,nM,28000.0,IC50,uM,28.0,Clc1ccc(OCc2nnc3sc(SCc4ccccc4)nn23)cc1,2009.0
Inhibition of CDK2/Cyclin A,NNc1nn2c(Cc3ccccc3)nnc2s1,CHEMBL1152892,>,>,IC50,nM,28000.0,IC50,uM,28.0,NNc1nn2c(Cc3ccccc3)nnc2s1,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,O=C(C(=O)N1CCc2ccccc21)c1c[nH]c2ccccc12,CHEMBL1153510,=,=,IC50,nM,760000.0,IC50,uM,760.0,O=C(C(=O)N1CCc2ccccc21)c1c[nH]c2ccccc12,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,O=C(C(=O)N1CCc2ccccc21)c1c[nH]c2ccc(F)cc12,CHEMBL1153510,=,=,IC50,nM,1160000.0,IC50,uM,1160.0,O=C(C(=O)N1CCc2ccccc21)c1c[nH]c2ccc(F)cc12,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,O=C(C(=O)N1CCc2ccccc21)c1c[nH]c2ccc(Cl)cc12,CHEMBL1153510,=,=,IC50,nM,985000.0,IC50,uM,985.0,O=C(C(=O)N1CCc2ccccc21)c1c[nH]c2ccc(Cl)cc12,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,Cc1ccc2[nH]cc(C(=O)C(=O)N3CCc4ccccc43)c2c1,CHEMBL1153510,=,=,IC50,nM,951000.0,IC50,uM,951.0,Cc1ccc2[nH]cc(C(=O)C(=O)N3CCc4ccccc43)c2c1,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,O=C(C(=O)N1CCc2cc(F)ccc21)c1c[nH]c2ccccc12,CHEMBL1153510,=,=,IC50,nM,790000.0,IC50,uM,790.0,O=C(C(=O)N1CCc2cc(F)ccc21)c1c[nH]c2ccccc12,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,O=C(C(=O)N1CCc2cc(Cl)ccc21)c1c[nH]c2ccccc12,CHEMBL1153510,=,=,IC50,nM,1030000.0,IC50,uM,1030.0,O=C(C(=O)N1CCc2cc(Cl)ccc21)c1c[nH]c2ccccc12,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,Cc1ccc2c(c1)CCN2C(=O)C(=O)c1c[nH]c2ccccc12,CHEMBL1153510,=,=,IC50,nM,910000.0,IC50,uM,910.0,Cc1ccc2c(c1)CCN2C(=O)C(=O)c1c[nH]c2ccccc12,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,O=C(C(=O)N1CCc2cc(F)ccc21)c1c[nH]c2ccc(F)cc12,CHEMBL1153510,=,=,IC50,nM,816000.0,IC50,uM,816.0,O=C(C(=O)N1CCc2cc(F)ccc21)c1c[nH]c2ccc(F)cc12,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,O=C(C(=O)N1CCc2cc(Cl)ccc21)c1c[nH]c2ccc(Cl)cc12,CHEMBL1153510,=,=,IC50,nM,915000.0,IC50,uM,915.0,O=C(C(=O)N1CCc2cc(Cl)ccc21)c1c[nH]c2ccc(Cl)cc12,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,Cc1ccc2c(c1)CCN2C(=O)C(=O)c1c[nH]c2ccc(C)cc12,CHEMBL1153510,=,=,IC50,nM,710000.0,IC50,uM,710.0,Cc1ccc2c(c1)CCN2C(=O)C(=O)c1c[nH]c2ccc(C)cc12,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,c1ccc2c(c1)ccn2CCc1c[nH]c2ccccc12,CHEMBL1153510,>,>,IC50,nM,500000.0,IC50,uM,500.0,c1ccc2c(c1)ccn2CCc1c[nH]c2ccccc12,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,Fc1ccc2[nH]cc(CCn3ccc4ccccc43)c2c1,CHEMBL1153510,=,=,IC50,nM,200000.0,IC50,uM,200.0,Fc1ccc2[nH]cc(CCn3ccc4ccccc43)c2c1,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,Clc1ccc2[nH]cc(CCn3ccc4ccccc43)c2c1,CHEMBL1153510,>,>,IC50,nM,500000.0,IC50,uM,500.0,Clc1ccc2[nH]cc(CCn3ccc4ccccc43)c2c1,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,Cc1ccc2[nH]cc(CCn3ccc4ccccc43)c2c1,CHEMBL1153510,=,=,IC50,nM,400000.0,IC50,uM,400.0,Cc1ccc2[nH]cc(CCn3ccc4ccccc43)c2c1,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,Fc1ccc2c(ccn2CCc2c[nH]c3ccccc23)c1,CHEMBL1153510,>,>,IC50,nM,500000.0,IC50,uM,500.0,Fc1ccc2c(ccn2CCc2c[nH]c3ccccc23)c1,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,Clc1ccc2c(ccn2CCc2c[nH]c3ccccc23)c1,CHEMBL1153510,=,=,IC50,nM,430000.0,IC50,uM,430.0,Clc1ccc2c(ccn2CCc2c[nH]c3ccccc23)c1,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,Cc1ccc2c(ccn2CCc2c[nH]c3ccccc23)c1,CHEMBL1153510,=,=,IC50,nM,500000.0,IC50,uM,500.0,Cc1ccc2c(ccn2CCc2c[nH]c3ccccc23)c1,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,Clc1ccc2c(ccn2CCc2c[nH]c3ccc(Cl)cc23)c1,CHEMBL1153510,=,=,IC50,nM,862000.0,IC50,uM,862.0,Clc1ccc2c(ccn2CCc2c[nH]c3ccc(Cl)cc23)c1,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,Cc1ccc2c(ccn2CCc2c[nH]c3ccc(C)cc23)c1,CHEMBL1153510,=,=,IC50,nM,960000.0,IC50,uM,960.0,Cc1ccc2c(ccn2CCc2c[nH]c3ccc(C)cc23)c1,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,c1ccc2c(c1)CCN2CCN1CCc2ccccc21,CHEMBL1153510,=,=,IC50,nM,1230000.0,IC50,uM,1230.0,c1ccc2c(c1)CCN2CCN1CCc2ccccc21,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,c1ccc2c(c1)CCN2CCCN1CCc2ccccc21,CHEMBL1153510,,,IC50,,,IC50,,,c1ccc2c(c1)CCN2CCCN1CCc2ccccc21,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,c1ccc2c(c1)CCN2CCCCN1CCc2ccccc21,CHEMBL1153510,,,IC50,,,IC50,,,c1ccc2c(c1)CCN2CCCCN1CCc2ccccc21,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,c1ccc2c(c1)CCN2CCCCCN1CCc2ccccc21,CHEMBL1153510,,,IC50,,,IC50,,,c1ccc2c(c1)CCN2CCCCCN1CCc2ccccc21,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,c1ccc2c(c1)CCN2CCCCCCN1CCc2ccccc21,CHEMBL1153510,,,IC50,,,IC50,,,c1ccc2c(c1)CCN2CCCCCCN1CCc2ccccc21,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,c1ccc2c(c1)ccn2CCn1ccc2ccccc21,CHEMBL1153510,=,=,IC50,nM,940000.0,IC50,uM,940.0,c1ccc2c(c1)ccn2CCn1ccc2ccccc21,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,c1ccc2c(c1)ccn2CCCn1ccc2ccccc21,CHEMBL1153510,=,=,IC50,nM,1070000.0,IC50,uM,1070.0,c1ccc2c(c1)ccn2CCCn1ccc2ccccc21,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,c1ccc2c(c1)ccn2CCCCn1ccc2ccccc21,CHEMBL1153510,=,=,IC50,nM,1026000.0,IC50,uM,1026.0,c1ccc2c(c1)ccn2CCCCn1ccc2ccccc21,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,c1ccc2c(c1)ccn2CCCCCn1ccc2ccccc21,CHEMBL1153510,=,=,IC50,nM,950000.0,IC50,uM,950.0,c1ccc2c(c1)ccn2CCCCCn1ccc2ccccc21,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,c1ccc2c(c1)ccn2CCCCCCn1ccc2ccccc21,CHEMBL1153510,=,=,IC50,nM,1210000.0,IC50,uM,1210.0,c1ccc2c(c1)ccn2CCCCCCn1ccc2ccccc21,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,Fc1ccc2c(ccn2CCc2c[nH]c3ccc(F)cc23)c1,CHEMBL1153510,=,=,IC50,nM,895000.0,IC50,uM,895.0,Fc1ccc2c(ccn2CCc2c[nH]c3ccc(F)cc23)c1,2009.0
Inhibition of human CDK2/ Cyclin A catalytic subunit expressed in Sf9 insect cells assessed as histone H1 phosphorylation-associated depletion in ATP level by luminescence assay,O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21.[Cl-],CHEMBL1153510,=,=,IC50,nM,500000.0,IC50,uM,500.0,O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21.[Cl-],2009.0
Inhibition of CDK2/cyclin A at 1 uM,C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F,CHEMBL1154027,<,<,Inhibition,%,50.0,INH,%,50.0,C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F,2009.0
Inhibition of CDK2/cyclin E at 1 uM,C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F,CHEMBL1154027,<,<,Inhibition,%,50.0,INH,%,50.0,C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F,2009.0
Inhibition of CDK2,Cc1ccc2c(c1)N(Cc1cc(F)cc3c1OCOC3)C(=O)/C2=N\O,CHEMBL1153595,>,>,Ki,nM,30000.0,Ki,uM,30.0,Cc1ccc2c(c1)N(Cc1cc(F)cc3c1OCOC3)C(=O)/C2=N\O,2009.0
Effect on wild type recombinant CDK2/cyclin E1 assessed as p27kip1 phosphorylation after 1 hr by immunoblot analysis,C#CCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,CHEMBL1153613,,,Activity,,,Activity,,,C#CCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,2009.0
Effect on wild type recombinant CDK2/cyclin E1 assessed as p27kip1 phosphorylation after 1 hr by immunoblot analysis,[N-]=[N+]=Nc1ccc(NP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)[C@H](O)[C@@H]2O)cc1,CHEMBL1153613,,,Activity,,,Activity,,,[N-]=[N+]=Nc1ccc(NP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)[C@H](O)[C@@H]2O)cc1,2009.0
Effect on wild type recombinant CDK2/cyclin E1 assessed as p27kip1 phosphorylation after 1 hr by immunoblot analysis,[N-]=[N+]=NCCOP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,CHEMBL1153613,,,Activity,,,Activity,,,[N-]=[N+]=NCCOP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,2009.0
Effect on wild type recombinant CDK2/cyclin E1 assessed as p27kip1 phosphorylation after 1 hr by immunoblot analysis,[N-]=[N+]=NCCOCCOCCOCCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,CHEMBL1153613,,,Activity,,,Activity,,,[N-]=[N+]=NCCOCCOCCOCCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,2009.0
Effect on wild type recombinant CDK2/cyclin E1 assessed as p27kip1 phosphorylation after 1 hr by immunoblot analysis,[N-]=[N+]=NCCCCCCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,CHEMBL1153613,,,Activity,,,Activity,,,[N-]=[N+]=NCCCCCCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,2009.0
Effect on wild type recombinant CDK2/cyclin E1 assessed as p27kip1 phosphorylation after 1 hr by immunoblot analysis,C=CCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,CHEMBL1153613,,,Activity,,,Activity,,,C=CCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,2009.0
Effect on wild type recombinant CDK2/cyclin E1 assessed as p27kip1 phosphorylation after 1 hr by immunoblot analysis,C#CCCCOP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,CHEMBL1153613,,,Activity,,,Activity,,,C#CCCCOP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,2009.0
Effect on wild type recombinant CDK2/cyclin E1 assessed as p27kip1 phosphorylation after 1 hr by immunoblot analysis,C#CCCCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,CHEMBL1153613,,,Activity,,,Activity,,,C#CCCCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,2009.0
Effect on wild type recombinant CDK2/cyclin E1 assessed as p27kip1 phosphorylation after 1 hr by immunoblot analysis,C#CCCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,CHEMBL1153613,,,Activity,,,Activity,,,C#CCCNP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,2009.0
Selectivity for CDK2 as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,CHEMBL1150977,=,=,Selectivity,,0.0588,Selectivity,,0.0588,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,2008.0
Selectivity for CDK2 as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1150977,=,=,Selectivity,,0.1696,Selectivity,,0.1696,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2008.0
Selectivity for CDK2 as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,CHEMBL1150977,=,=,Selectivity,,0.0833,Selectivity,,0.0833,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,2008.0
Selectivity for CDK2 as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL1150977,=,=,Selectivity,,0.0313,Selectivity,,0.0313,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2008.0
Percent residual CDK2-cyclinA activity in the presence of 10uM inhibitor,O=C(O)Cc1c2ccccc2n2c1[nH]c(=O)c1ccccc12,CHEMBL1150975,=,=,Activity,%,91.0,Activity,%,91.0,O=C(O)Cc1c2ccccc2n2c1[nH]c(=O)c1ccccc12,2003.0
Percent residual CDK2-cyclinA activity in the presence of 10uM inhibitor,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,CHEMBL1150975,=,=,Activity,%,18.0,Activity,%,18.0,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,2003.0
Percent residual CDK2-cyclinA activity in the presence of 10uM inhibitor,Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O,CHEMBL1150975,=,=,Activity,%,75.0,Activity,%,75.0,Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O,2003.0
Binding constant for full-length CDK2,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,2008.0
Binding constant for full-length CDK2,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,2008.0
Binding constant for full-length CDK2,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,CHEMBL1150977,=,=,Kd,nM,760.0,Kd,nM,760.0,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,2008.0
Binding constant for full-length CDK2,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,2008.0
Binding constant for full-length CDK2,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,2008.0
Binding constant for full-length CDK2,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,CHEMBL1150977,=,=,Kd,nM,69.0,Kd,nM,69.0,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,2008.0
Binding constant for full-length CDK2,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,2008.0
Binding constant for full-length CDK2,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,2008.0
Binding constant for full-length CDK2,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,2008.0
Binding constant for full-length CDK2,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,2008.0
Binding constant for full-length CDK2,COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,2008.0
Binding constant for full-length CDK2,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,2008.0
Binding constant for full-length CDK2,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,2008.0
Binding constant for full-length CDK2,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,2008.0
Binding constant for full-length CDK2,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1150977,=,=,Kd,nM,550.0,Kd,nM,550.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2008.0
Binding constant for full-length CDK2,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,2008.0
Binding constant for full-length CDK2,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,2008.0
Binding constant for full-length CDK2,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,2008.0
Binding constant for full-length CDK2,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,2008.0
Binding constant for full-length CDK2,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,CHEMBL1150977,=,=,Kd,nM,23.0,Kd,nM,23.0,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,2008.0
Binding constant for full-length CDK2,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,2008.0
Binding constant for full-length CDK2,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,2008.0
Binding constant for full-length CDK2,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,2008.0
Binding constant for full-length CDK2,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,2008.0
Binding constant for full-length CDK2,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2008.0
Binding constant for full-length CDK2,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2008.0
Binding constant for full-length CDK2,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,2008.0
Binding constant for full-length CDK2,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL1150977,=,=,Kd,nM,3400.0,Kd,nM,3400.0,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2008.0
Binding constant for full-length CDK2,Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,2008.0
Binding constant for full-length CDK2,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,2008.0
Binding constant for full-length CDK2,NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1,2008.0
Binding constant for full-length CDK2,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,2008.0
Binding constant for full-length CDK2,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1150977,=,=,Kd,nM,7.0,Kd,nM,7.0,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2008.0
Binding constant for full-length CDK2,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,2008.0
Binding constant for full-length CDK2,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,2008.0
Binding constant for full-length CDK2,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,2008.0
Binding constant for full-length CDK2,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,2008.0
Binding constant for full-length CDK2,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,CHEMBL1150977,>,>,Kd,nM,10000.0,Kd,uM,10.0,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,2008.0
Inhibition of CDK2 assessed as enzyme activity at 1 uM relative to untreated control,Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl,CHEMBL1155237,=,=,Activity,%,100.0,Activity,%,100.0,Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl,2009.0
Inhibition of C-terminal 6xHis-tagged CDK2 by [gamma-33-P]ATP based assay,Cc1ccc(-c2ccc3occ(-c4ccc([S@+](C)[O-])cc4)c3c2)o1,CHEMBL1154165,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Cc1ccc(-c2ccc3occ(-c4ccc([S@+](C)[O-])cc4)c3c2)o1,2009.0
Inhibition of C-terminal 6xHis-tagged CDK2 by [gamma-33-P]ATP based assay,CC[S@+]([O-])c1ccc(-c2coc3ccc(-c4ccc(C)o4)cc23)cc1,CHEMBL1154165,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CC[S@+]([O-])c1ccc(-c2coc3ccc(-c4ccc(C)o4)cc23)cc1,2009.0
Inhibition of CDK2 assessed as remaining enzyme activity at 3 uM relative to DMSO,COc1ccccc1-n1c(-c2ccccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12,CHEMBL1154183,=,=,Activity,%,97.0,Activity,%,97.0,COc1ccccc1-n1c(-c2ccccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12,2009.0
Inhibition of CDK2 assessed as remaining enzyme activity at 1 uM relative to DMSO,COc1ccccc1-n1c(-c2cc(O)ccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12,CHEMBL1154183,=,=,Activity,%,90.0,Activity,%,90.0,COc1ccccc1-n1c(-c2cc(O)ccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12,2009.0
Inhibition of CDK2,COc1cccc(Nc2ncc(C)c(-c3c[nH]c(C(=O)N[C@H](CO)c4cccc(Cl)c4)c3)n2)c1OC,CHEMBL1154622,>,>,Ki,nM,2500.0,Ki,nM,2500.0,COc1cccc(Nc2ncc(C)c(-c3c[nH]c(C(=O)N[C@H](CO)c4cccc(Cl)c4)c3)n2)c1OC,2009.0
Inhibition of CDK2,Cc1cnc(Nc2cccc3c2OCCO3)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,CHEMBL1154622,=,=,Ki,nM,138.0,Ki,nM,138.0,Cc1cnc(Nc2cccc3c2OCCO3)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2cccc3c2OC(F)(F)O3)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,CHEMBL1154622,=,=,Ki,nM,170.0,Ki,nM,170.0,Cc1cnc(Nc2cccc3c2OC(F)(F)O3)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2cccc3c2OCO3)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,CHEMBL1154622,=,=,Ki,nM,209.0,Ki,nM,209.0,Cc1cnc(Nc2cccc3c2OCO3)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2cccc3c2CCCC3)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,CHEMBL1154622,=,=,Ki,nM,250.0,Ki,nM,250.0,Cc1cnc(Nc2cccc3c2CCCC3)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2cccc3c2CCC3)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,CHEMBL1154622,=,=,Ki,nM,642.0,Ki,nM,642.0,Cc1cnc(Nc2cccc3c2CCC3)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,2009.0
Inhibition of CDK2,CCc1ccccc1Nc1ncc(C)c(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)n1,CHEMBL1154622,=,=,Ki,nM,450.0,Ki,nM,450.0,CCc1ccccc1Nc1ncc(C)c(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)n1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2ccc(Cl)cc2F)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,CHEMBL1154622,=,=,Ki,nM,316.0,Ki,nM,316.0,Cc1cnc(Nc2ccc(Cl)cc2F)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,CHEMBL1154622,=,=,Ki,nM,852.0,Ki,nM,852.0,Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,2009.0
Inhibition of CDK2,Cc1cc(Cl)ccc1Nc1ncc(C)c(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)n1,CHEMBL1154622,=,=,Ki,nM,76.0,Ki,nM,76.0,Cc1cc(Cl)ccc1Nc1ncc(C)c(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)n1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2cccc(F)c2C)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,CHEMBL1154622,=,=,Ki,nM,150.0,Ki,nM,150.0,Cc1cnc(Nc2cccc(F)c2C)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2cccc(C)c2C)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,CHEMBL1154622,=,=,Ki,nM,41.0,Ki,nM,41.0,Cc1cnc(Nc2cccc(C)c2C)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,2009.0
Inhibition of CDK2,Cc1cccc([C@@H](CO)NC(=O)c2cc(-c3nc(Nc4ccccc4)ncc3C)c[nH]2)c1,CHEMBL1154622,=,=,Ki,nM,69.0,Ki,nM,69.0,Cc1cccc([C@@H](CO)NC(=O)c2cc(-c3nc(Nc4ccccc4)ncc3C)c[nH]2)c1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2ccccc2)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,CHEMBL1154622,=,=,Ki,nM,290.0,Ki,nM,290.0,Cc1cnc(Nc2ccccc2)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2ccccc2)nc1-c1c[nH]c(C(=O)N[C@@H](CO)c2ccccc2)c1,CHEMBL1154622,=,=,Ki,nM,1100.0,Ki,nM,1100.0,Cc1cnc(Nc2ccccc2)nc1-c1c[nH]c(C(=O)N[C@@H](CO)c2ccccc2)c1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2ccccc2O)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2ccccc2)c1,CHEMBL1154622,<,<,Ki,nM,100.0,Ki,nM,100.0,Cc1cnc(Nc2ccccc2O)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2ccccc2)c1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2ccccc2C(F)(F)F)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2ccccc2)c1,CHEMBL1154622,>,>,Ki,nM,4000.0,Ki,nM,4000.0,Cc1cnc(Nc2ccccc2C(F)(F)F)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2ccccc2)c1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2ccccc2F)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2ccccc2)c1,CHEMBL1154622,=,=,Ki,nM,57.0,Ki,nM,57.0,Cc1cnc(Nc2ccccc2F)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2ccccc2)c1,2009.0
Inhibition of CDK2,CCc1ccccc1Nc1ncc(C)c(-c2c[nH]c(C(=O)N[C@H](CO)c3ccccc3)c2)n1,CHEMBL1154622,=,=,Ki,nM,210.0,Ki,nM,210.0,CCc1ccccc1Nc1ncc(C)c(-c2c[nH]c(C(=O)N[C@H](CO)c3ccccc3)c2)n1,2009.0
Inhibition of CDK2,Cc1ccccc1Nc1ncc(C)c(-c2c[nH]c(C(=O)N[C@H](CO)c3ccccc3)c2)n1,CHEMBL1154622,=,=,Ki,nM,140.0,Ki,nM,140.0,Cc1ccccc1Nc1ncc(C)c(-c2c[nH]c(C(=O)N[C@H](CO)c3ccccc3)c2)n1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2ccccc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2ccccc2)c1,CHEMBL1154622,=,=,Ki,nM,240.0,Ki,nM,240.0,Cc1cnc(Nc2ccccc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2ccccc2)c1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2ccccc2)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2ccccc2)c1,CHEMBL1154622,=,=,Ki,nM,16.0,Ki,nM,16.0,Cc1cnc(Nc2ccccc2)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2ccccc2)c1,2009.0
Inhibition of CDK2 at 10 uM,O=C1OC(/C=C/c2ccccc2)=N/C1=C\c1cccnc1,CHEMBL1154675,,,Inhibition,%,,INH,,,O=C1OC(/C=C/c2ccccc2)=N/C1=C\c1cccnc1,2009.0
Inhibition of CDK2,Cc1cnc(Nc2ccccc2)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(F)c2)c1,CHEMBL1154622,,,Ki,,,Ki,,,Cc1cnc(Nc2ccccc2)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(F)c2)c1,2009.0
Inhibition of CDK2,Cc1ccccc1Nc1ncc(C)c(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)n1,CHEMBL1154622,,,Ki,,,Ki,,,Cc1ccccc1Nc1ncc(C)c(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)n1,2009.0
Inhibition of CDK2 by HTRF assay,O=c1[nH]c(CN2CC[C@H](O)C2)nc2c1sc1ccc(-c3ccc(O)cc3)cc12,CHEMBL1154637,>,>,Ki,nM,1000.0,Ki,microM,1.0,O=c1[nH]c(CN2CC[C@H](O)C2)nc2c1sc1ccc(-c3ccc(O)cc3)cc12,2009.0
Inhibition of CDK2 by HTRF assay,O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12,CHEMBL1154637,>,>,Ki,nM,1000.0,Ki,microM,1.0,O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12,2009.0
Inhibition of CDK2,C=CC(=O)N1CCC[C@H]1C(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCCOC,CHEMBL1154692,>,>,IC50,nM,10000.0,IC50,microM,10.0,C=CC(=O)N1CCC[C@H]1C(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCCOC,2009.0
Inhibition of CDK2,C=CC(=O)N1CCC[C@H]1C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3F)ncnc2cc1OCCOC,CHEMBL1154692,>,>,IC50,nM,10000.0,IC50,microM,10.0,C=CC(=O)N1CCC[C@H]1C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3F)ncnc2cc1OCCOC,2009.0
Inhibition of CDK2,Cc1c(I)c(=O)n(C2CCCC2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12,CHEMBL1154741,>,>,IC50,nM,360.0,IC50,nM,360.0,Cc1c(I)c(=O)n(C2CCCC2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12,2010.0
Inhibition of CDK2 at 2 uM,c1ccc2c(c1)CC(Nc1nc(Nc3ccncc3)nc(N3CCNCC3)n1)C2,CHEMBL1154592,<,<,Inhibition,%,50.0,INH,%,50.0,c1ccc2c(c1)CC(Nc1nc(Nc3ccncc3)nc(N3CCNCC3)n1)C2,2009.0
Inhibition of CDK2,Cc1cc(Nc2cnc(C#N)c(N[C@@H](C)c3ncc(F)cn3)n2)n[nH]1,CHEMBL1156131,=,=,IC50,nM,50.0,IC50,uM,0.05,Cc1cc(Nc2cnc(C#N)c(N[C@@H](C)c3ncc(F)cn3)n2)n[nH]1,2009.0
Inhibition of CDK2,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)c(C#N)nc2C)n[nH]1,CHEMBL1156131,=,=,IC50,nM,410.0,IC50,uM,0.41,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)c(C#N)nc2C)n[nH]1,2009.0
Inhibition of CDK2,Cc1cc(Nc2nc(N[C@@H](C)c3ccc(F)cn3)c(C#N)nc2C)n[nH]1,CHEMBL1156131,=,=,IC50,nM,460.0,IC50,uM,0.46,Cc1cc(Nc2nc(N[C@@H](C)c3ccc(F)cn3)c(C#N)nc2C)n[nH]1,2009.0
Inhibition of CDK2,Cc1cc(Nc2cnc(C#N)c(N[C@@H](C)c3ccc(F)cn3)n2)n[nH]1,CHEMBL1156131,=,=,IC50,nM,30.0,IC50,uM,0.03,Cc1cc(Nc2cnc(C#N)c(N[C@@H](C)c3ccc(F)cn3)n2)n[nH]1,2009.0
Binding affinity to human CDK2 at 200 nM by cell-based competition binding assay relative to control in presence of DTT,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CSSC[C@@H](C(=O)NCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1152541,=,=,Activity,%,100.0,Activity,%,100.0,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CSSC[C@@H](C(=O)NCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009.0
Binding affinity to human CDK2 at 500 nM by cell-based competition binding assay relative to control in presence of DTT,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1152541,=,=,Activity,%,69.0,Activity,%,69.0,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009.0
Binding affinity to human CDK2 at 50 nM by cell-based competition binding assay relative to control in presence of DTT,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CNC(=O)C[C@@H](C(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1152541,=,=,Activity,%,100.0,Activity,%,100.0,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CNC(=O)C[C@@H](C(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009.0
Ratio of compound to staurosporine binding affinity to human CDK2 in presence of DTT,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1152541,=,=,Selectivity ratio,,50.0,Selectivity ratio,,50.0,CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009.0
Inhibition of CDK2 at 10 uM,CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21,CHEMBL1152632,=,=,Inhibition,%,4.0,INH,%,4.0,CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21,2009.0
Inhibition of CDK2 at 10 uM,O=C1Nc2ccccc2/C1=C1\C(=O)N(CCCc2ccccc2)c2ccccc21,CHEMBL1152632,=,=,Inhibition,%,0.0,INH,%,0.0,O=C1Nc2ccccc2/C1=C1\C(=O)N(CCCc2ccccc2)c2ccccc21,2009.0
Inhibition of CDK2,NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21,CHEMBL1153138,=,=,IC50,nM,140.0,IC50,uM,0.14,NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21,2010.0
Inhibition of CDK2,Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC[C@@H](N)C2)ccc2[nH]ccc12,CHEMBL1153090,=,=,IC50,nM,17000.0,IC50,nM,17000.0,Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC[C@@H](N)C2)ccc2[nH]ccc12,2009.0
Inhibition of CDK2,O=C(O)c1cc2c(c3c1c([N+](=O)[O-])cc1ccccc13)OCO2,CHEMBL1156890,>,>,IC50,nM,20000.0,IC50,uM,20.0,O=C(O)c1cc2c(c3c1c([N+](=O)[O-])cc1ccccc13)OCO2,2010.0
Inhibition of CDK2,COc1cccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,CHEMBL1156890,>,>,IC50,nM,20000.0,IC50,uM,20.0,COc1cccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,2010.0
Inhibition of CDK2,COc1cccc2c1c(OC)c([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,CHEMBL1156890,>,>,IC50,nM,20000.0,IC50,uM,20.0,COc1cccc2c1c(OC)c([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,2010.0
Inhibition of CDK2,COc1cc(OC)c2cc([N+](=O)[O-])c3c(C(=O)O)cc4c(c3c2c1)OCO4,CHEMBL1156890,>,>,IC50,nM,20000.0,IC50,uM,20.0,COc1cc(OC)c2cc([N+](=O)[O-])c3c(C(=O)O)cc4c(c3c2c1)OCO4,2010.0
Inhibition of CDK2,O=C(O)c1cc2c(c3c1c([N+](=O)[O-])cc1ccc(O)cc13)OCO2,CHEMBL1156890,=,=,IC50,nM,30000.0,IC50,uM,30.0,O=C(O)c1cc2c(c3c1c([N+](=O)[O-])cc1ccc(O)cc13)OCO2,2010.0
Inhibition of CDK2,COc1c(O)ccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,CHEMBL1156890,=,=,IC50,nM,25000.0,IC50,uM,25.0,COc1c(O)ccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,2010.0
Inhibition of CDK2,COc1cc(O)cc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,CHEMBL1156890,=,=,IC50,nM,25000.0,IC50,uM,25.0,COc1cc(O)cc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,2010.0
Inhibition of CDK2,O=C(O)c1cc2c(c3c1c([N+](=O)[O-])cc1c(O)cccc13)OCO2,CHEMBL1156890,=,=,IC50,nM,15000.0,IC50,uM,15.0,O=C(O)c1cc2c(c3c1c([N+](=O)[O-])cc1c(O)cccc13)OCO2,2010.0
Inhibition of CDK2,COc1ccc2cc([N+](=O)[O-])c3c(C(=O)O)cc4c(c3c2c1)OCO4,CHEMBL1156890,>,>,IC50,nM,20000.0,IC50,uM,20.0,COc1ccc2cc([N+](=O)[O-])c3c(C(=O)O)cc4c(c3c2c1)OCO4,2010.0
Inhibition of CDK2,O=C(O)c1cc(O)c(O)c2c1c([N+](=O)[O-])cc1ccccc12,CHEMBL1156890,=,=,IC50,nM,13400.0,IC50,uM,13.4,O=C(O)c1cc(O)c(O)c2c1c([N+](=O)[O-])cc1ccccc12,2010.0
Inhibition of CDK2,O=C(O)c1cc(O)c(O)c2c1c([N+](=O)[O-])c(Cl)c1ccccc12,CHEMBL1156890,=,=,IC50,nM,18000.0,IC50,uM,18.0,O=C(O)c1cc(O)c(O)c2c1c([N+](=O)[O-])c(Cl)c1ccccc12,2010.0
Inhibition of CDK2,COc1cccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc(O)c(O)c12,CHEMBL1156890,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc(O)c(O)c12,2010.0
Inhibition of CDK2,O=C(O)c1cc(O)c(O)c2c1c([N+](=O)[O-])cc1c(O)cccc12,CHEMBL1156890,=,=,IC50,nM,5700.0,IC50,uM,5.7,O=C(O)c1cc(O)c(O)c2c1c([N+](=O)[O-])cc1c(O)cccc12,2010.0
Inhibition of CDK2,COc1cccc2c1c(Cl)c([N+](=O)[O-])c1c(C(=O)O)cc(O)c(O)c12,CHEMBL1156890,=,=,IC50,nM,16500.0,IC50,uM,16.5,COc1cccc2c1c(Cl)c([N+](=O)[O-])c1c(C(=O)O)cc(O)c(O)c12,2010.0
Inhibition of CDK2,O=C1Nc2cc3ccccc3c3c4c(cc1c23)OCO4,CHEMBL1156890,=,=,IC50,nM,15000.0,IC50,uM,15.0,O=C1Nc2cc3ccccc3c3c4c(cc1c23)OCO4,2010.0
Inhibition of CDK2,COc1cccc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1,CHEMBL1156890,=,=,IC50,nM,1200.0,IC50,uM,1.2,COc1cccc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1,2010.0
Inhibition of CDK2,COc1ccc2c(cc3c4c(cc5c(c42)OCO5)C(=O)N3)c1OC,CHEMBL1156890,>,>,IC50,nM,15000.0,IC50,uM,15.0,COc1ccc2c(cc3c4c(cc5c(c42)OCO5)C(=O)N3)c1OC,2010.0
Inhibition of CDK2,COc1cc(OC)c2cc3c4c(cc5c(c4c2c1)OCO5)C(=O)N3,CHEMBL1156890,>,>,IC50,nM,15000.0,IC50,uM,15.0,COc1cc(OC)c2cc3c4c(cc5c(c4c2c1)OCO5)C(=O)N3,2010.0
Inhibition of CDK2,COc1c(O)ccc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1,CHEMBL1156890,=,=,IC50,nM,2900.0,IC50,uM,2.9,COc1c(O)ccc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1,2010.0
Inhibition of CDK2,COc1cc(O)cc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1,CHEMBL1156890,>,>,IC50,nM,35000.0,IC50,uM,35.0,COc1cc(O)cc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1,2010.0
Inhibition of CDK2,O=C1Nc2cc3c(O)cccc3c3c4c(cc1c23)OCO4,CHEMBL1156890,=,=,IC50,nM,35.0,IC50,uM,0.035,O=C1Nc2cc3c(O)cccc3c3c4c(cc1c23)OCO4,2010.0
Inhibition of CDK2,O=C1Nc2cc3c(O)c(O)ccc3c3c4c(cc1c23)OCO4,CHEMBL1156890,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1Nc2cc3c(O)c(O)ccc3c3c4c(cc1c23)OCO4,2010.0
Inhibition of CDK2,O=C1Nc2cc3c(O)cc(O)cc3c3c4c(cc1c23)OCO4,CHEMBL1156890,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C1Nc2cc3c(O)cc(O)cc3c3c4c(cc1c23)OCO4,2010.0
Inhibition of CDK2,O=C1Nc2cc3ccc(O)cc3c3c4c(cc1c23)OCO4,CHEMBL1156890,=,=,IC50,nM,2150.0,IC50,uM,2.15,O=C1Nc2cc3ccc(O)cc3c3c4c(cc1c23)OCO4,2010.0
Inhibition of CDK2,COc1cccc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1C,CHEMBL1156890,>,>,IC50,nM,35000.0,IC50,uM,35.0,COc1cccc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1C,2010.0
Inhibition of CDK2,CN1C(=O)c2cc3c(c4c2c1cc1c(O)cccc14)OCO3,CHEMBL1156890,>,>,IC50,nM,35000.0,IC50,uM,35.0,CN1C(=O)c2cc3c(c4c2c1cc1c(O)cccc14)OCO3,2010.0
Inhibition of CDK2,O=C1Nc2cc3ccccc3c3c(O)c(O)cc1c23,CHEMBL1156890,>,>,IC50,nM,35000.0,IC50,uM,35.0,O=C1Nc2cc3ccccc3c3c(O)c(O)cc1c23,2010.0
Inhibition of CDK2,O=C1Nc2c(Cl)c3ccccc3c3c(O)c(O)cc1c23,CHEMBL1156890,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C1Nc2c(Cl)c3ccccc3c3c(O)c(O)cc1c23,2010.0
Inhibition of CDK2,COc1cccc2c1cc1c3c(cc(O)c(O)c32)C(=O)N1,CHEMBL1156890,>,>,IC50,nM,35000.0,IC50,uM,35.0,COc1cccc2c1cc1c3c(cc(O)c(O)c32)C(=O)N1,2010.0
Inhibition of CDK2,O=C1Nc2cc3c(O)cccc3c3c(O)c(O)cc1c23,CHEMBL1156890,>,>,IC50,nM,35000.0,IC50,uM,35.0,O=C1Nc2cc3c(O)cccc3c3c(O)c(O)cc1c23,2010.0
Inhibition of CDK2,COc1cccc2c1c(Cl)c1c3c(cc(O)c(O)c32)C(=O)N1,CHEMBL1156890,=,=,IC50,nM,10000.0,IC50,uM,10.0,COc1cccc2c1c(Cl)c1c3c(cc(O)c(O)c32)C(=O)N1,2010.0
Inhibition of CDK2,COc1cc2c(cc1OC)-c1c3c(cc4c1[C@H](C2)N(C)CC4)OCO3,CHEMBL1156890,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1cc2c(cc1OC)-c1c3c(cc4c1[C@H](C2)N(C)CC4)OCO3,2010.0
Inhibition of CDK2,COc1ccc2c(c1OC)CC1c3c(cc4c(c3-2)OCO4)CCN1C,CHEMBL1156890,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc2c(c1OC)CC1c3c(cc4c(c3-2)OCO4)CCN1C,2010.0
Inhibition of CDK2,Br.CN1CCc2cc3c(c4c2[C@H]1Cc1ccccc1-4)OCO3,CHEMBL1156890,>,>,IC50,nM,50000.0,IC50,uM,50.0,Br.CN1CCc2cc3c(c4c2[C@H]1Cc1ccccc1-4)OCO3,2010.0
Inhibition of CDK2,COc1ccc2c(c1O)-c1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3,CHEMBL1156890,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc2c(c1O)-c1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3,2010.0
Inhibition of CDK2,COc1cc2c3c(c1O)-c1c(ccc(OC)c1OC)C[C@@H]3N(C)CC2,CHEMBL1156890,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1cc2c3c(c1O)-c1c(ccc(OC)c1OC)C[C@@H]3N(C)CC2,2010.0
Inhibition of CDK2,COc1ccc2c(c1O)-c1c(O)c(OC)cc3c1[C@H](C2)N(C)CC3,CHEMBL1156890,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc2c(c1O)-c1c(O)c(OC)cc3c1[C@H](C2)N(C)CC3,2010.0
Inhibition of CDK2,COC1=C[C@]23CCN(C)[C@H](Cc4ccc(OC)c(O)c42)C3=CC1=O,CHEMBL1156890,>,>,IC50,nM,50000.0,IC50,uM,50.0,COC1=C[C@]23CCN(C)[C@H](Cc4ccc(OC)c(O)c42)C3=CC1=O,2010.0
Inhibition of CDK2,COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O,CHEMBL1156890,>,>,IC50,nM,50000.0,IC50,uM,50.0,COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O,2010.0
Inhibition of CDK2,COc1cccc2c1C[C@@H]1c3c(cc4c(c3-2)OCO4)CCN1C,CHEMBL1156890,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1cccc2c1C[C@@H]1c3c(cc4c(c3-2)OCO4)CCN1C,2010.0
Inhibition of CDK2,COc1ccc2c(c1OC)CN1CCc3cc4c(cc3C1C2)OCO4,CHEMBL1156890,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc2c(c1OC)CN1CCc3cc4c(cc3C1C2)OCO4,2010.0
Inhibition of CDK2,COc1c(O)cc2c3c(cc4ccc(O)cc4c13)NC2=O,CHEMBL1156890,=,=,IC50,nM,140.0,IC50,uM,0.14,COc1c(O)cc2c3c(cc4ccc(O)cc4c13)NC2=O,2010.0
Inhibition of CDK2,COc1ccc2nc3[nH]nc(C)c3c(OC)c2c1,CHEMBL1156890,=,=,IC50,nM,20.0,IC50,uM,0.02,COc1ccc2nc3[nH]nc(C)c3c(OC)c2c1,2010.0
Inhibition of CDK2 at 50 uM,O=C(O)c1cc2c(c3c1c([N+](=O)[O-])cc1ccccc13)OCO2,CHEMBL1156890,,,Activity,,,Activity,,,O=C(O)c1cc2c(c3c1c([N+](=O)[O-])cc1ccccc13)OCO2,2010.0
Inhibition of CDK2 at 50 uM,COc1cccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,CHEMBL1156890,,,Activity,,,Activity,,,COc1cccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,2010.0
Inhibition of CDK2 at 50 uM,COc1cccc2c1c(OC)c([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,CHEMBL1156890,,,Activity,,,Activity,,,COc1cccc2c1c(OC)c([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,2010.0
Inhibition of CDK2 at 50 uM,COc1cc(OC)c2cc([N+](=O)[O-])c3c(C(=O)O)cc4c(c3c2c1)OCO4,CHEMBL1156890,,,Activity,,,Activity,,,COc1cc(OC)c2cc([N+](=O)[O-])c3c(C(=O)O)cc4c(c3c2c1)OCO4,2010.0
Inhibition of CDK2 at 50 uM,O=C(O)c1cc2c(c3c1c([N+](=O)[O-])cc1ccc(O)cc13)OCO2,CHEMBL1156890,,,Activity,,,Activity,,,O=C(O)c1cc2c(c3c1c([N+](=O)[O-])cc1ccc(O)cc13)OCO2,2010.0
Inhibition of CDK2 at 50 uM,COc1c(O)ccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,CHEMBL1156890,,,Activity,,,Activity,,,COc1c(O)ccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,2010.0
Inhibition of CDK2 at 50 uM,COc1cc(O)cc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,CHEMBL1156890,,,Activity,,,Activity,,,COc1cc(O)cc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc3c(c12)OCO3,2010.0
Inhibition of CDK2 at 50 uM,O=C(O)c1cc2c(c3c1c([N+](=O)[O-])cc1c(O)cccc13)OCO2,CHEMBL1156890,,,Activity,,,Activity,,,O=C(O)c1cc2c(c3c1c([N+](=O)[O-])cc1c(O)cccc13)OCO2,2010.0
Inhibition of CDK2 at 50 uM,COc1ccc2cc([N+](=O)[O-])c3c(C(=O)O)cc4c(c3c2c1)OCO4,CHEMBL1156890,,,Activity,,,Activity,,,COc1ccc2cc([N+](=O)[O-])c3c(C(=O)O)cc4c(c3c2c1)OCO4,2010.0
Inhibition of CDK2 at 50 uM,O=C(O)c1cc(O)c(O)c2c1c([N+](=O)[O-])cc1ccccc12,CHEMBL1156890,,,Activity,,,Activity,,,O=C(O)c1cc(O)c(O)c2c1c([N+](=O)[O-])cc1ccccc12,2010.0
Inhibition of CDK2 at 50 uM,O=C(O)c1cc(O)c(O)c2c1c([N+](=O)[O-])c(Cl)c1ccccc12,CHEMBL1156890,,,Activity,,,Activity,,,O=C(O)c1cc(O)c(O)c2c1c([N+](=O)[O-])c(Cl)c1ccccc12,2010.0
Inhibition of CDK2 at 50 uM,COc1cccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc(O)c(O)c12,CHEMBL1156890,,,Activity,,,Activity,,,COc1cccc2c1cc([N+](=O)[O-])c1c(C(=O)O)cc(O)c(O)c12,2010.0
Inhibition of CDK2 at 50 uM,O=C(O)c1cc(O)c(O)c2c1c([N+](=O)[O-])cc1c(O)cccc12,CHEMBL1156890,,,Activity,,,Activity,,,O=C(O)c1cc(O)c(O)c2c1c([N+](=O)[O-])cc1c(O)cccc12,2010.0
Inhibition of CDK2 at 50 uM,COc1cccc2c1c(Cl)c([N+](=O)[O-])c1c(C(=O)O)cc(O)c(O)c12,CHEMBL1156890,,,Activity,,,Activity,,,COc1cccc2c1c(Cl)c([N+](=O)[O-])c1c(C(=O)O)cc(O)c(O)c12,2010.0
Inhibition of CDK2 at 50 uM,O=C1Nc2cc3ccccc3c3c4c(cc1c23)OCO4,CHEMBL1156890,,,Activity,,,Activity,,,O=C1Nc2cc3ccccc3c3c4c(cc1c23)OCO4,2010.0
Inhibition of CDK2 at 50 uM,COc1cccc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1,CHEMBL1156890,,,Activity,,,Activity,,,COc1cccc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1,2010.0
Inhibition of CDK2 at 50 uM,COc1ccc2c(cc3c4c(cc5c(c42)OCO5)C(=O)N3)c1OC,CHEMBL1156890,,,Activity,,,Activity,,,COc1ccc2c(cc3c4c(cc5c(c42)OCO5)C(=O)N3)c1OC,2010.0
Inhibition of CDK2 at 50 uM,COc1cc(OC)c2cc3c4c(cc5c(c4c2c1)OCO5)C(=O)N3,CHEMBL1156890,,,Activity,,,Activity,,,COc1cc(OC)c2cc3c4c(cc5c(c4c2c1)OCO5)C(=O)N3,2010.0
Inhibition of CDK2 at 50 uM,COc1c(O)ccc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1,CHEMBL1156890,,,Activity,,,Activity,,,COc1c(O)ccc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1,2010.0
Inhibition of CDK2 at 50 uM,COc1cc(O)cc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1,CHEMBL1156890,,,Activity,,,Activity,,,COc1cc(O)cc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1,2010.0
Inhibition of CDK2 at 50 uM,O=C1Nc2cc3c(O)cccc3c3c4c(cc1c23)OCO4,CHEMBL1156890,,,Activity,,,Activity,,,O=C1Nc2cc3c(O)cccc3c3c4c(cc1c23)OCO4,2010.0
Inhibition of CDK2 at 50 uM,O=C1Nc2cc3c(O)c(O)ccc3c3c4c(cc1c23)OCO4,CHEMBL1156890,,,Activity,,,Activity,,,O=C1Nc2cc3c(O)c(O)ccc3c3c4c(cc1c23)OCO4,2010.0
Inhibition of CDK2 at 50 uM,O=C1Nc2cc3c(O)cc(O)cc3c3c4c(cc1c23)OCO4,CHEMBL1156890,,,Activity,,,Activity,,,O=C1Nc2cc3c(O)cc(O)cc3c3c4c(cc1c23)OCO4,2010.0
Inhibition of CDK2 at 50 uM,O=C1Nc2cc3ccc(O)cc3c3c4c(cc1c23)OCO4,CHEMBL1156890,,,Activity,,,Activity,,,O=C1Nc2cc3ccc(O)cc3c3c4c(cc1c23)OCO4,2010.0
Inhibition of CDK2 at 50 uM,COc1cccc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1C,CHEMBL1156890,,,Activity,,,Activity,,,COc1cccc2c1cc1c3c(cc4c(c32)OCO4)C(=O)N1C,2010.0
Inhibition of CDK2 at 50 uM,CN1C(=O)c2cc3c(c4c2c1cc1c(O)cccc14)OCO3,CHEMBL1156890,,,Activity,,,Activity,,,CN1C(=O)c2cc3c(c4c2c1cc1c(O)cccc14)OCO3,2010.0
Inhibition of CDK2 at 50 uM,O=C1Nc2cc3ccccc3c3c(O)c(O)cc1c23,CHEMBL1156890,,,Activity,,,Activity,,,O=C1Nc2cc3ccccc3c3c(O)c(O)cc1c23,2010.0
Inhibition of CDK2 at 50 uM,O=C1Nc2c(Cl)c3ccccc3c3c(O)c(O)cc1c23,CHEMBL1156890,,,Activity,,,Activity,,,O=C1Nc2c(Cl)c3ccccc3c3c(O)c(O)cc1c23,2010.0
Inhibition of CDK2 at 50 uM,COc1cccc2c1cc1c3c(cc(O)c(O)c32)C(=O)N1,CHEMBL1156890,,,Activity,,,Activity,,,COc1cccc2c1cc1c3c(cc(O)c(O)c32)C(=O)N1,2010.0
Inhibition of CDK2 at 50 uM,O=C1Nc2cc3c(O)cccc3c3c(O)c(O)cc1c23,CHEMBL1156890,,,Activity,,,Activity,,,O=C1Nc2cc3c(O)cccc3c3c(O)c(O)cc1c23,2010.0
Inhibition of CDK2 at 50 uM,COc1cccc2c1c(Cl)c1c3c(cc(O)c(O)c32)C(=O)N1,CHEMBL1156890,,,Activity,,,Activity,,,COc1cccc2c1c(Cl)c1c3c(cc(O)c(O)c32)C(=O)N1,2010.0
Inhibition of CDK2,COc1c(O)cc2c3c(cc4ccc(O)cc4c13)NC2=O,CHEMBL1156897,=,=,IC50,nM,140.0,IC50,nM,140.0,COc1c(O)cc2c3c(cc4ccc(O)cc4c13)NC2=O,2010.0
Inhibition of CDK2,O=C1Nc2cc3c(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cccc3c3c4c(cc1c23)OCO4,CHEMBL1156897,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C1Nc2cc3c(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cccc3c3c4c(cc1c23)OCO4,2010.0
Inhibition of recombinant CDK2 by IMAP assay,C[C@@H](Oc1ccc2ncccc2c1)c1c(Cl)ccc(F)c1Cl,CHEMBL1156877,>,>,IC50,nM,50000.0,IC50,uM,50.0,C[C@@H](Oc1ccc2ncccc2c1)c1c(Cl)ccc(F)c1Cl,2010.0
Inhibition of recombinant CDK2 by IMAP assay,C[C@@H](Oc1ccc2ncc(C3CC3C(N)=O)cc2c1)c1c(Cl)ccc(F)c1Cl,CHEMBL1156877,>,>,IC50,nM,50000.0,IC50,uM,50.0,C[C@@H](Oc1ccc2ncc(C3CC3C(N)=O)cc2c1)c1c(Cl)ccc(F)c1Cl,2010.0
Inhibition of recombinant CDK2 by IMAP assay,C[C@@H](Oc1ccc2ncc(/C=C/C(N)=O)cc2c1)c1c(Cl)ccc(F)c1Cl,CHEMBL1156877,>,>,IC50,nM,50000.0,IC50,uM,50.0,C[C@@H](Oc1ccc2ncc(/C=C/C(N)=O)cc2c1)c1c(Cl)ccc(F)c1Cl,2010.0
Inhibition of CDK2,Nc1nn(-c2cccc(-c3ccc4cc[nH]c4c3)c2)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL1159125,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1nn(-c2cccc(-c3ccc4cc[nH]c4c3)c2)cc1-c1ccc2c(c1)CCNC2=O,2010.0
Inhibition of CDK2 in human A2780 cells assessed as reduction in hyperphosphorylated pRb level at 1 to 3 uM after 24 hrs by immunoblot,CNC(=O)c1nn(C)c2c1CCc1cnc(NC3CCN(C(=O)C4CCN(S(C)(=O)=O)CC4)CC3)nc1-2,CHEMBL1157561,,,Activity,,,Activity,,,CNC(=O)c1nn(C)c2c1CCc1cnc(NC3CCN(C(=O)C4CCN(S(C)(=O)=O)CC4)CC3)nc1-2,2010.0
Inhibition of CDK2 at 3 to 6 uM relative to control,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC,CHEMBL1157712,>,>,Inhibition,%,50.0,INH,%,50.0,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC,2010.0
Inhibition of CDK2 at 3 uM relative to control,NC(=O)c1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1,CHEMBL1157712,>,>,Inhibition,%,50.0,INH,%,50.0,NC(=O)c1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1,2010.0
Inhibition of Cdk2 at 20 uM,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12,CHEMBL1155393,=,=,Inhibition,%,93.0,INH,%,93.0,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12,2010.0
Inhibition of Cdk2,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12,CHEMBL1155393,=,=,IC50,nM,2500.0,IC50,nM,2500.0,CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12,2010.0
Inhibition of Cdk2,CCCC(=O)Nc1n[nH]c2c(F)c(Cl)c(-c3ccccc3)cc12,CHEMBL1155393,=,=,IC50,nM,3160.0,IC50,nM,3160.0,CCCC(=O)Nc1n[nH]c2c(F)c(Cl)c(-c3ccccc3)cc12,2010.0
Inhibition of Cdk2,CCCC(=O)Nc1n[nH]c2c(Cl)c(Cl)c(-c3ccccc3)cc12,CHEMBL1155393,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CCCC(=O)Nc1n[nH]c2c(Cl)c(Cl)c(-c3ccccc3)cc12,2010.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4)s3)cc12,CHEMBL1154933,=,=,IC50,nM,72.0,IC50,nM,72.0,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4)s3)cc12,2010.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3nnc(NC[C@H](N)Cc4ccccc4)s3)cc12,CHEMBL1154933,,,IC50,,,IC50,,,Cc1n[nH]c2ccc(-c3nnc(NC[C@H](N)Cc4ccccc4)s3)cc12,2010.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4F)s3)cc12,CHEMBL1154933,=,=,IC50,nM,104.0,IC50,nM,104.0,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4F)s3)cc12,2010.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4Cl)s3)cc12,CHEMBL1154933,=,=,IC50,nM,57.0,IC50,nM,57.0,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4Cl)s3)cc12,2010.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4C(F)(F)F)s3)cc12,CHEMBL1154933,=,=,IC50,nM,198.0,IC50,nM,198.0,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4C(F)(F)F)s3)cc12,2010.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4cccc(F)c4)s3)cc12,CHEMBL1154933,,,IC50,,,IC50,,,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4cccc(F)c4)s3)cc12,2010.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4cccc(Cl)c4)s3)cc12,CHEMBL1154933,=,=,IC50,nM,17.0,IC50,nM,17.0,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4cccc(Cl)c4)s3)cc12,2010.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4cccc(C(F)(F)F)c4)s3)cc12,CHEMBL1154933,=,=,IC50,nM,35.0,IC50,nM,35.0,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4cccc(C(F)(F)F)c4)s3)cc12,2010.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(Cl)cc4)s3)cc12,CHEMBL1154933,=,=,IC50,nM,72.0,IC50,nM,72.0,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(Cl)cc4)s3)cc12,2010.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc12,CHEMBL1154933,=,=,IC50,nM,17.0,IC50,nM,17.0,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc12,2010.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(Cl)cc4Cl)s3)cc12,CHEMBL1154933,=,=,IC50,nM,70.0,IC50,nM,70.0,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(Cl)cc4Cl)s3)cc12,2010.0
Inhibition of CDK2,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(F)c(F)c4)s3)cc12,CHEMBL1154933,=,=,IC50,nM,19.0,IC50,nM,19.0,Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(F)c(F)c4)s3)cc12,2010.0
Inhibition of CDK2,CCc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4)s3)cc12,CHEMBL1154933,,,IC50,,,IC50,,,CCc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4)s3)cc12,2010.0
Inhibition of CDK2,N[C@H](CNc1nnc(-c2ccc3[nH]nc(C4CC4)c3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154933,=,=,IC50,nM,135.0,IC50,nM,135.0,N[C@H](CNc1nnc(-c2ccc3[nH]nc(C4CC4)c3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1nnc(-c2ccc3[nH]nc(-c4ccccc4)c3c2)s1)Cc1cccc(C(F)(F)F)c1,CHEMBL1154933,=,=,IC50,nM,79.0,IC50,nM,79.0,N[C@H](CNc1nnc(-c2ccc3[nH]nc(-c4ccccc4)c3c2)s1)Cc1cccc(C(F)(F)F)c1,2010.0
Inhibition of CDK2,N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1cccc(C(F)(F)F)c1,CHEMBL1154933,,,IC50,,,IC50,,,N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1cccc(C(F)(F)F)c1,2010.0
Inhibition of CDK2,N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(F)cc1,CHEMBL1154933,=,=,IC50,nM,74.0,IC50,nM,74.0,N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(Cl)cc1,CHEMBL1154933,=,=,IC50,nM,41.0,IC50,nM,41.0,N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(Cl)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154933,=,=,IC50,nM,24.0,IC50,nM,24.0,N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(Cl)cc1Cl,CHEMBL1154933,=,=,IC50,nM,323.0,IC50,nM,323.0,N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(Cl)cc1Cl,2010.0
Inhibition of CDK2,N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154933,=,=,IC50,nM,53.0,IC50,nM,53.0,N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,Cc1cc2cc(-c3nnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)ccc2cn1,CHEMBL1154933,=,=,IC50,nM,607.0,IC50,nM,607.0,Cc1cc2cc(-c3nnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)ccc2cn1,2010.0
Inhibition of CDK2,N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,=,=,IC50,nM,53.0,IC50,nM,53.0,N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1ncc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,=,=,IC50,nM,12.4,IC50,nM,12.4,N[C@H](CNc1ncc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1cnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,=,=,IC50,nM,1070.0,IC50,nM,1070.0,N[C@H](CNc1cnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1cc(-c2ccc3cnccc3c2)no1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,=,=,IC50,nM,93.0,IC50,nM,93.0,N[C@H](CNc1cc(-c2ccc3cnccc3c2)no1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CCc1cc(-c2ccc3cnccc3c2)no1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,=,=,IC50,nM,117.0,IC50,nM,117.0,N[C@H](CCc1cc(-c2ccc3cnccc3c2)no1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CCc1nc(-c2ccc3cnccc3c2)no1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,=,=,IC50,nM,4630.0,IC50,nM,4630.0,N[C@H](CCc1nc(-c2ccc3cnccc3c2)no1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1nnc(-c2ccc3cnccc3c2)o1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,=,=,IC50,nM,348.0,IC50,nM,348.0,N[C@H](CNc1nnc(-c2ccc3cnccc3c2)o1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,Nc1cc2cc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)ccc2cn1,CHEMBL1154944,=,=,IC50,nM,15.4,IC50,nM,15.4,Nc1cc2cc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)ccc2cn1,2010.0
Inhibition of CDK2,N[C@H](CNc1ncc(-c2ccc3cncnc3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,=,=,IC50,nM,136.0,IC50,nM,136.0,N[C@H](CNc1ncc(-c2ccc3cncnc3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1ncc(-c2ccc3nnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,>,>,IC50,nM,2000.0,IC50,nM,2000.0,N[C@H](CNc1ncc(-c2ccc3nnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1ncc(-c2ccc3cn[nH]c3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,>,>,IC50,nM,1000.0,IC50,nM,1000.0,N[C@H](CNc1ncc(-c2ccc3cn[nH]c3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,Cn1ncc2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc21,CHEMBL1154944,,,IC50,,,IC50,,,Cn1ncc2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc21,2010.0
Inhibition of CDK2,Cn1nc(N)c2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc21,CHEMBL1154944,>,>,IC50,nM,2000.0,IC50,nM,2000.0,Cn1nc(N)c2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc21,2010.0
Inhibition of CDK2,Nc1noc2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc12,CHEMBL1154944,>,>,IC50,nM,2000.0,IC50,nM,2000.0,Nc1noc2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc12,2010.0
Inhibition of CDK2,N[C@H](CNc1ncc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,,,IC50,,,IC50,,,N[C@H](CNc1ncc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1ncc(-c2ccc3nnn(N)c3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,=,=,IC50,nM,55.3,IC50,nM,55.3,N[C@H](CNc1ncc(-c2ccc3nnn(N)c3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1ncc(-c2ccc3c(c2)CC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,=,=,IC50,nM,185.0,IC50,nM,185.0,N[C@H](CNc1ncc(-c2ccc3c(c2)CC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1ncc(-c2ccc3[nH]c(=O)oc3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,=,=,IC50,nM,138.0,IC50,nM,138.0,N[C@H](CNc1ncc(-c2ccc3[nH]c(=O)oc3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1ncc(-c2ccc3[nH]c(=O)sc3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,=,=,IC50,nM,285.0,IC50,nM,285.0,N[C@H](CNc1ncc(-c2ccc3[nH]c(=O)sc3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,Cn1c(=O)[nH]c2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc21,CHEMBL1154944,=,=,IC50,nM,276.0,IC50,nM,276.0,Cn1c(=O)[nH]c2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc21,2010.0
Inhibition of CDK2,N[C@H](CNc1ncc(-c2ccc3c(c2)CCC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,>,>,IC50,nM,25000.0,IC50,nM,25000.0,N[C@H](CNc1ncc(-c2ccc3c(c2)CCC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1ncc(-c2ccc3cn[nH]c(=O)c3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,>,>,IC50,nM,1000.0,IC50,nM,1000.0,N[C@H](CNc1ncc(-c2ccc3cn[nH]c(=O)c3c2)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,NC(=O)c1ccc(-c2cnc(NC[C@@H](N)Cc3ccc(C(F)(F)F)cc3)s2)cc1,CHEMBL1154944,>,>,IC50,nM,10000.0,IC50,nM,10000.0,NC(=O)c1ccc(-c2cnc(NC[C@@H](N)Cc3ccc(C(F)(F)F)cc3)s2)cc1,2010.0
Inhibition of CDK2,N[C@H](CNc1ncc(-c2ccc3c(c2)CNC3=O)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1154944,>,>,IC50,nM,9000.0,IC50,nM,9000.0,N[C@H](CNc1ncc(-c2ccc3c(c2)CNC3=O)s1)Cc1ccc(C(F)(F)F)cc1,2010.0
Inhibition of CDK2,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccc(OC)c2)cc1,CHEMBL1154953,=,=,Ki,nM,95.0,Ki,nM,95.0,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccc(OC)c2)cc1,2010.0
Inhibition of CDK2,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccnc2)cc1,CHEMBL1154953,=,=,Ki,nM,62.0,Ki,nM,62.0,COc1ccc(C2=NNC(=O)/C2=N\Nc2cccnc2)cc1,2010.0
Inhibition of CDK2,COc1ccncc1C1=NNC(=O)/C1=N\Nc1ccccc1,CHEMBL1154953,=,=,Ki,nM,76.0,Ki,nM,76.0,COc1ccncc1C1=NNC(=O)/C1=N\Nc1ccccc1,2010.0
Inhibition of CDK2,Cn1cc(C2=C(c3cccc(NCC(O)CO)c3)C(=O)NC2=O)c2cc(F)ccc21,CHEMBL1154951,=,=,Kd,nM,150.0,Kd,uM,0.15,Cn1cc(C2=C(c3cccc(NCC(O)CO)c3)C(=O)NC2=O)c2cc(F)ccc21,2010.0
Inhibition of CDK2 at 5 uM,O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O,CHEMBL1154316,=,=,Inhibition,%,-1.0,INH,%,-1.0,O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O,2009.0
Inhibition of CDK2,CN1C[C@@H]2C[C@H]1CN2c1ccc(-c2ccnc3c(-c4cccc(O)c4)c(-c4ccncc4)nn23)cc1,CHEMBL1154392,=,=,IC50,nM,26400.0,IC50,uM,26.4,CN1C[C@@H]2C[C@H]1CN2c1ccc(-c2ccnc3c(-c4cccc(O)c4)c(-c4ccncc4)nn23)cc1,2009.0
Inhibition of CDK2,CN(C)Cc1ccc(-c2cnn3c(-c4cccc(NC(=O)c5cccc(C(F)(F)F)c5)c4)ccnc23)cc1,CHEMBL1153694,>,>,IC50,nM,2000.0,IC50,uM,2.0,CN(C)Cc1ccc(-c2cnn3c(-c4cccc(NC(=O)c5cccc(C(F)(F)F)c5)c4)ccnc23)cc1,2009.0
Inhibition of CDK2,COc1cc2c(cc1Cl)C(c1ccc(Cl)c(Cl)c1)=NCC2,CHEMBL1153754,<,>,IC50,nM,10000.0,pIC50,,5.0,COc1cc2c(cc1Cl)C(c1ccc(Cl)c(Cl)c1)=NCC2,2009.0
Inhibition of CDK2,COc1cc2c(cc1Cl)C(c1cccc(Cl)c1)=NCC2,CHEMBL1153754,<,>,IC50,nM,10000.0,pIC50,,5.0,COc1cc2c(cc1Cl)C(c1cccc(Cl)c1)=NCC2,2009.0
Inhibition of CDK2,Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(-c3ccc(C(=O)NCCO)cc3)ccnc21,CHEMBL1156283,=,=,IC50,nM,35.5,IC50,nM,35.5,Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(-c3ccc(C(=O)NCCO)cc3)ccnc21,2010.0
Inhibition of CDK2 at 10 uM,O=C(Nc1ccccc1)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12,CHEMBL1156291,<,<,Inhibition,%,50.0,INH,%,50.0,O=C(Nc1ccccc1)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12,2010.0
Inhibition of CDK2,O=C(Nc1cccc(-c2ccnc3cc(-c4ccncc4)nn23)c1)c1cccc(C(F)(F)F)c1,CHEMBL1156255,>,>,IC50,nM,50000.0,IC50,uM,50.0,O=C(Nc1cccc(-c2ccnc3cc(-c4ccncc4)nn23)c1)c1cccc(C(F)(F)F)c1,2009.0
Inhibition of CDK2,CP(C)(=O)c1ccc(Nc2nc(C3CCCC3)nc3c2ncn3CCc2cccc(O)c2)cc1,CHEMBL1156260,=,=,IC50,nM,20900.0,IC50,uM,20.9,CP(C)(=O)c1ccc(Nc2nc(C3CCCC3)nc3c2ncn3CCc2cccc(O)c2)cc1,2010.0
Inhibition of CDK2,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,CHEMBL1156260,=,=,IC50,nM,70.0,IC50,nM,70.0,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,2010.0
Inhibition of CDK2,CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1,CHEMBL1157009,>,>,IC50,nM,50000.0,IC50,uM,50.0,CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1,2009.0
Inhibition of CDK2,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1,CHEMBL1157009,>,>,IC50,nM,50000.0,IC50,uM,50.0,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1,2009.0
Inhibition of CDK2,COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1,CHEMBL1157898,,,Inhibition,%,,INH,,,COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1,2010.0
Inhibition of CDK2,COc1ccccc1/C=C1/C(=O)Nc2ccccc21,CHEMBL1157898,,,Inhibition,%,,INH,,,COc1ccccc1/C=C1/C(=O)Nc2ccccc21,2010.0
Inhibition of CDK2,O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1F,CHEMBL1157898,,,Inhibition,%,,INH,,,O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1F,2010.0
Inhibition of CDK2,O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1[N+](=O)[O-],CHEMBL1157898,,,Inhibition,%,,INH,,,O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1[N+](=O)[O-],2010.0
Inhibition of CDK2,O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1S(=O)(=O)O,CHEMBL1157898,,,Inhibition,%,,INH,,,O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1S(=O)(=O)O,2010.0
Inhibition of CDK2,O=C1Nc2ccc(Cl)cc2/C1=C\c1ccc2c(c1)OCO2,CHEMBL1157898,,,Inhibition,%,,INH,,,O=C1Nc2ccc(Cl)cc2/C1=C\c1ccc2c(c1)OCO2,2010.0
Inhibition of CDK2,O=C1Nc2ccc(Cl)cc2/C1=C\c1cc(F)cc(F)c1,CHEMBL1157898,,,Inhibition,%,,INH,,,O=C1Nc2ccc(Cl)cc2/C1=C\c1cc(F)cc(F)c1,2010.0
Inhibition of CDK2,NC(=O)Cc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc1,CHEMBL1157898,,,Inhibition,%,,INH,,,NC(=O)Cc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc1,2010.0
Inhibition of CDK2,COc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1OC,CHEMBL1157898,,,Inhibition,%,,INH,,,COc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1OC,2010.0
Inhibition of CDK2,COc1cc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc(OC)c1OC,CHEMBL1157898,,,Inhibition,%,,INH,,,COc1cc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc(OC)c1OC,2010.0
Inhibition of CDK2,COc1cc(OC)c(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1,CHEMBL1157898,<,<,Inhibition,%,20.0,INH,%,20.0,COc1cc(OC)c(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1,2010.0
Inhibition of CDK2,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,CHEMBL1157898,,,Inhibition,%,,INH,,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,2010.0
Inhibition of CDK2,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,CHEMBL1155519,=,=,Ki,nM,390.0,Ki,nM,390.0,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,2010.0
Inhibition of CDK2,Cc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)n2)s1,CHEMBL1155519,=,=,Ki,nM,3967.0,Ki,nM,3967.0,Cc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)n2)s1,2010.0
Inhibition of CDK2,CC(=O)N1CCN(c2ccc(Nc3nccc(-c4sc(C)nc4C)n3)cc2)CC1,CHEMBL1155519,=,=,Ki,nM,432.0,Ki,nM,432.0,CC(=O)N1CCN(c2ccc(Nc3nccc(-c4sc(C)nc4C)n3)cc2)CC1,2010.0
Inhibition of CDK2,CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1,CHEMBL1155519,=,=,Ki,nM,297.0,Ki,nM,297.0,CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1,2010.0
Inhibition of CDK2,CC(=O)N1CCN(c2ccc(Nc3nccc(-c4sc(N)nc4C)n3)cc2)CC1,CHEMBL1155519,=,=,Ki,nM,522.0,Ki,nM,522.0,CC(=O)N1CCN(c2ccc(Nc3nccc(-c4sc(N)nc4C)n3)cc2)CC1,2010.0
Inhibition of CDK2,CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)s1,CHEMBL1155519,=,=,Ki,nM,151.0,Ki,nM,151.0,CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)s1,2010.0
Inhibition of CDK2,CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)s1,CHEMBL1155519,=,=,Ki,nM,156.0,Ki,nM,156.0,CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)s1,2010.0
Inhibition of CDK2,Cc1nc(C)c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)s1,CHEMBL1155519,=,=,Ki,nM,1039.0,Ki,nM,1039.0,Cc1nc(C)c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)s1,2010.0
Inhibition of CDK2,CCNc1nc(C)c(-c2ccnc(Nc3ccc(CNC(C)=O)cc3)n2)s1,CHEMBL1155519,=,=,Ki,nM,32.0,Ki,nM,32.0,CCNc1nc(C)c(-c2ccnc(Nc3ccc(CNC(C)=O)cc3)n2)s1,2010.0
Inhibition of CDK2,CCNc1nc(C)c(-c2ccnc(Nc3cc(OC)c(OC)c(OC)c3)n2)s1,CHEMBL1155519,=,=,Ki,nM,463.0,Ki,nM,463.0,CCNc1nc(C)c(-c2ccnc(Nc3cc(OC)c(OC)c(OC)c3)n2)s1,2010.0
Inhibition of CDK2,CNc1nc(C)c(-c2ccnc(Nc3cc(OC)c(OC)c(OC)c3)n2)s1,CHEMBL1155519,=,=,Ki,nM,256.0,Ki,nM,256.0,CNc1nc(C)c(-c2ccnc(Nc3cc(OC)c(OC)c(OC)c3)n2)s1,2010.0
Inhibition of CDK2,COc1cc(Nc2nccc(-c3sc(C)nc3C)n2)cc(OC)c1OC,CHEMBL1155519,=,=,Ki,nM,239.0,Ki,nM,239.0,COc1cc(Nc2nccc(-c3sc(C)nc3C)n2)cc(OC)c1OC,2010.0
Inhibition of CDK2,Cc1nc(C)c(-c2ccnc(Nc3ccc(N)cc3)n2)s1,CHEMBL1155519,=,=,Ki,nM,168.0,Ki,nM,168.0,Cc1nc(C)c(-c2ccnc(Nc3ccc(N)cc3)n2)s1,2010.0
Inhibition of CDK2,CNc1ccc(Nc2nccc(-c3sc(C)nc3C)n2)cc1,CHEMBL1155519,=,=,Ki,nM,286.0,Ki,nM,286.0,CNc1ccc(Nc2nccc(-c3sc(C)nc3C)n2)cc1,2010.0
Inhibition of CDK2,Cc1nc(C)c(-c2ccnc(Nc3ccc(N(C)C)cc3)n2)s1,CHEMBL1155519,=,=,Ki,nM,251.0,Ki,nM,251.0,Cc1nc(C)c(-c2ccnc(Nc3ccc(N(C)C)cc3)n2)s1,2010.0
Inhibition of CDK2,Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,CHEMBL1155519,=,=,Ki,nM,2.0,Ki,nM,2.0,Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,2010.0
Inhibition of CDK2 at 1 uM,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1,2010.0
Inhibition of CDK2 at 1 uM,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1,2010.0
Inhibition of CDK2 at 1 uM,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1,2010.0
Inhibition of CDK2 at 1 uM,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1,2010.0
Inhibition of CDK2 at 1 uM,O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1,2010.0
Inhibition of CDK2 at 1 uM,O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1,2010.0
Inhibition of CDK2 at 1 uM,COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1,2010.0
Inhibition of CDK2 at 1 uM,O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1,2010.0
Inhibition of CDK2 at 1 uM,FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21,2010.0
Inhibition of CDK2 at 1 uM,CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1,CHEMBL1165965,<,<,Inhibition,%,50.0,INH,%,50.0,CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1,2010.0
Inhibition of CDK2,NC(=O)Cn1nc(C(N)=O)c2c1-c1nc(Nc3ccccc3)ncc1CC2,CHEMBL1177807,=,=,IC50,nM,10.0,IC50,nM,10.0,NC(=O)Cn1nc(C(N)=O)c2c1-c1nc(Nc3ccccc3)ncc1CC2,2010.0
Inhibition of CDK2,NC(=O)c1nn(CC2CCNCC2)c2c1CCc1cnc(Nc3ccccc3)nc1-2,CHEMBL1177807,=,=,IC50,nM,12.0,IC50,nM,12.0,NC(=O)c1nn(CC2CCNCC2)c2c1CCc1cnc(Nc3ccccc3)nc1-2,2010.0
Inhibition of CDK2,NCCCn1nc(C(N)=O)c2c1-c1nc(Nc3ccccc3)ncc1CC2,CHEMBL1177807,=,=,IC50,nM,1.0,IC50,nM,1.0,NCCCn1nc(C(N)=O)c2c1-c1nc(Nc3ccccc3)ncc1CC2,2010.0
Inhibition of CDK2,Cc1cc(CNC(=O)c2nn(C)c3c2CCc2cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc2-3)ccn1,CHEMBL1177807,=,=,IC50,nM,319.0,IC50,nM,319.0,Cc1cc(CNC(=O)c2nn(C)c3c2CCc2cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc2-3)ccn1,2010.0
Inhibition of CDK2,Cc1cc(CNC(=O)c2nn(CCCN)c3c2CCc2cnc(Nc4cccc(CC(=O)N(C)C)c4)nc2-3)ccn1,CHEMBL1177807,=,=,IC50,nM,500.0,IC50,nM,500.0,Cc1cc(CNC(=O)c2nn(CCCN)c3c2CCc2cnc(Nc4cccc(CC(=O)N(C)C)c4)nc2-3)ccn1,2010.0
Inhibition of CDK2 at 10 uM,CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1,CHEMBL1177794,=,=,Inhibition,%,10.0,INH,%,10.0,CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1,2010.0
Inhibition of CDK2 at 10 uM,CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1,CHEMBL1177794,=,=,Inhibition,%,13.0,INH,%,13.0,CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1,2010.0
Inhibition of recombinant CDK2 after 15 mins,CN(C)CCNC(=O)c1ccc(-c2cnc3ccc(NCc4ccc(Cl)c(Cl)c4)nn23)cc1,CHEMBL1221302,>,>,IC50,nM,100000.0,IC50,uM,100.0,CN(C)CCNC(=O)c1ccc(-c2cnc3ccc(NCc4ccc(Cl)c(Cl)c4)nn23)cc1,2010.0
Inhibition of recombinant CDK2 after 15 mins,O=C(NCCN1CCCC1)c1ccc(-c2cnc3ccc(NCc4ccc(Cl)c(Cl)c4)nn23)cc1,CHEMBL1221302,>,>,IC50,nM,100000.0,IC50,uM,100.0,O=C(NCCN1CCCC1)c1ccc(-c2cnc3ccc(NCc4ccc(Cl)c(Cl)c4)nn23)cc1,2010.0
Inhibition of recombinant CDK2 after 15 mins,O=C(NC[C@@H]1CCCN1)c1ccc(-c2cnc3ccc(NCc4ccc(Cl)c(Cl)c4)nn23)cc1,CHEMBL1221302,=,=,IC50,nM,95000.0,IC50,uM,95.0,O=C(NC[C@@H]1CCCN1)c1ccc(-c2cnc3ccc(NCc4ccc(Cl)c(Cl)c4)nn23)cc1,2010.0
Inhibition of recombinant CDK2 after 15 mins,O=C(NC[C@@H]1CCCN1)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1,CHEMBL1221302,>,>,IC50,nM,100000.0,IC50,uM,100.0,O=C(NC[C@@H]1CCCN1)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1,2010.0
Inhibition of recombinant CDK2 after 15 mins,O=C(NC[C@@H]1CCCN1)c1ccc(-c2cnc3ccc(NCc4cccc(Cl)c4)nn23)cc1,CHEMBL1221302,>,>,IC50,nM,100000.0,IC50,uM,100.0,O=C(NC[C@@H]1CCCN1)c1ccc(-c2cnc3ccc(NCc4cccc(Cl)c4)nn23)cc1,2010.0
Inhibition of recombinant CDK2 after 15 mins,CN(C)CCNC(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1,CHEMBL1221302,>,>,IC50,nM,100000.0,IC50,uM,100.0,CN(C)CCNC(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1,2010.0
Inhibition of recombinant CDK2 after 15 mins,CCN(CC)CCNC(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1,CHEMBL1221302,,,IC50,,,IC50,,,CCN(CC)CCNC(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1,2010.0
Inhibition of recombinant CDK2 after 15 mins,CC(CN(C)C)NC(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1,CHEMBL1221302,,,IC50,,,IC50,,,CC(CN(C)C)NC(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1,2010.0
Inhibition of CDK2-mediated p53 phosphorylation,O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1,CHEMBL1221185,,,Inhibition,%,,INH,,,O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1,2006.0
Induction of CDK2 in HEK293T cells transfected with FLAG-tagged p27 at 200 nM by autoradiography,CC(=O)O[C@@H](C)/C=C\C(=O)N[C@@H]1C[C@H](C)[C@H](C/C=C(C)/C=C/[C@H]2O[C@](C)(O)C[C@@]3(CO3)[C@@H]2O)O[C@@H]1C,CHEMBL1221204,,,Activity,,,Activity,,,CC(=O)O[C@@H](C)/C=C\C(=O)N[C@@H]1C[C@H](C)[C@H](C/C=C(C)/C=C/[C@H]2O[C@](C)(O)C[C@@]3(CO3)[C@@H]2O)O[C@@H]1C,2007.0
Induction of CDK2 in HEK293T cells transfected with FLAG-tagged truncated p27 at 200 nM by autoradiography,CC(=O)O[C@@H](C)/C=C\C(=O)N[C@@H]1C[C@H](C)[C@H](C/C=C(C)/C=C/[C@H]2O[C@](C)(O)C[C@@]3(CO3)[C@@H]2O)O[C@@H]1C,CHEMBL1221204,,,Activity,,,Activity,,,CC(=O)O[C@@H](C)/C=C\C(=O)N[C@@H]1C[C@H](C)[C@H](C/C=C(C)/C=C/[C@H]2O[C@](C)(O)C[C@@]3(CO3)[C@@H]2O)O[C@@H]1C,2007.0
Induction of CDK2 in HEK293T cells transfected with FLAG-tagged p27 at 20 nM by Western blot analysis,CC(=O)O[C@@H](C)/C=C\C(=O)N[C@@H]1C[C@H](C)[C@H](C/C=C(C)/C=C/[C@H]2O[C@](C)(O)C[C@@]3(CO3)[C@@H]2O)O[C@@H]1C,CHEMBL1221204,,,Activity,,,Activity,,,CC(=O)O[C@@H](C)/C=C\C(=O)N[C@@H]1C[C@H](C)[C@H](C/C=C(C)/C=C/[C@H]2O[C@](C)(O)C[C@@]3(CO3)[C@@H]2O)O[C@@H]1C,2007.0
Induction of CDK2 in HEK293T cells transfected with FLAG-tagged truncated p27 at 20 nM by Western blot analysis,CC(=O)O[C@@H](C)/C=C\C(=O)N[C@@H]1C[C@H](C)[C@H](C/C=C(C)/C=C/[C@H]2O[C@](C)(O)C[C@@]3(CO3)[C@@H]2O)O[C@@H]1C,CHEMBL1221204,,,Activity,,,Activity,,,CC(=O)O[C@@H](C)/C=C\C(=O)N[C@@H]1C[C@H](C)[C@H](C/C=C(C)/C=C/[C@H]2O[C@](C)(O)C[C@@]3(CO3)[C@@H]2O)O[C@@H]1C,2007.0
Induction of CDK2 in HEK293T cells transfected with FLAG-tagged p27 at 190 nM by Western blot analysis,CO[C@]1(C)C[C@@]2(CO2)[C@H](O)[C@@H](/C=C/C(C)=C/C[C@@H]2O[C@H](C)[C@H](NC(=O)/C=C\[C@H](C)OC(C)=O)C[C@@H]2C)O1,CHEMBL1221204,,,Activity,,,Activity,,,CO[C@]1(C)C[C@@]2(CO2)[C@H](O)[C@@H](/C=C/C(C)=C/C[C@@H]2O[C@H](C)[C@H](NC(=O)/C=C\[C@H](C)OC(C)=O)C[C@@H]2C)O1,2007.0
Induction of CDK2 in HEK293T cells transfected with FLAG-tagged truncated p27 at 190 nM by Western blot analysis,CO[C@]1(C)C[C@@]2(CO2)[C@H](O)[C@@H](/C=C/C(C)=C/C[C@@H]2O[C@H](C)[C@H](NC(=O)/C=C\[C@H](C)OC(C)=O)C[C@@H]2C)O1,CHEMBL1221204,,,Activity,,,Activity,,,CO[C@]1(C)C[C@@]2(CO2)[C@H](O)[C@@H](/C=C/C(C)=C/C[C@@H]2O[C@H](C)[C@H](NC(=O)/C=C\[C@H](C)OC(C)=O)C[C@@H]2C)O1,2007.0
Inhibition of cdk2,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1221210,=,=,IC50,nM,40.0,IC50,nM,40.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2008.0
Inhibition of cdk2,O=C1NCCc2[nH]c(-c3ccncc3)cc21,CHEMBL1221210,=,=,IC50,nM,240.0,IC50,nM,240.0,O=C1NCCc2[nH]c(-c3ccncc3)cc21,2008.0
Inhibition of CDK2 by HTRF assay,CNc1nccc(-c2cccnc2Oc2ccc(NC(=O)c3ccccc3Nc3ccccc3)cc2)n1,CHEMBL1240487,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CNc1nccc(-c2cccnc2Oc2ccc(NC(=O)c3ccccc3Nc3ccccc3)cc2)n1,2010.0
Inhibition of human CDK2,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,CHEMBL1240338,>,>,IC50,nM,10000.0,IC50,nmol/L,10000.0,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,2008.0
Binding affinity to CDK2,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,CHEMBL1240346,=,=,Kd,nM,20.0,Kd,nM,20.0,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,2009.0
Inhibition of CDK2,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,CHEMBL1240533,=,=,IC50,nM,7000.0,IC50,uM,7.0,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,2006.0
Inhibition of CDK2,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL1240533,=,=,IC50,nM,700.0,IC50,uM,0.7,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2006.0
Inhibition of CDK2,CCNc1cc(N[C@H]2CC[C@@H](O)CC2)nc(Nc2ccc3c(ccn3Cc3ccccc3)c2)n1,CHEMBL1240533,>,>,IC50,nM,50000.0,IC50,uM,50.0,CCNc1cc(N[C@H]2CC[C@@H](O)CC2)nc(Nc2ccc3c(ccn3Cc3ccccc3)c2)n1,2006.0
Inhibition of CDK2,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1240533,=,=,IC50,nM,170.0,IC50,uM,0.17,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2006.0
Inhibition of CDK2,CCCCOc1c(C(=O)c2c(F)cc(F)cc2F)c[nH]c2nncc1-2,CHEMBL1240533,=,=,IC50,nM,50.0,IC50,uM,0.05,CCCCOc1c(C(=O)c2c(F)cc(F)cc2F)c[nH]c2nncc1-2,2006.0
Inhibition of CDK2,COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2,CHEMBL1240533,=,=,IC50,nM,35.0,IC50,uM,0.035,COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2,2006.0
Inhibition of CDK2,O=C1C(c2c(O)[nH]c3ccc(S(=O)(=O)O)cc23)=Nc2ccccc21,CHEMBL1240533,=,=,IC50,nM,22.0,IC50,uM,0.022,O=C1C(c2c(O)[nH]c3ccc(S(=O)(=O)O)cc23)=Nc2ccccc21,2006.0
Inhibition of CDK2,O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1,CHEMBL1240533,=,=,IC50,nM,15.0,IC50,uM,0.015,O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1,2006.0
Inhibition of CDK2,O=C(Nc1cc(CN[C@H]2Cc3ccc(Cl)cc3C2)n[nH]1)Nc1cccc2c1[C@@H]1CCCN1C2=O,CHEMBL1240533,=,=,IC50,nM,78.0,IC50,uM,0.078,O=C(Nc1cc(CN[C@H]2Cc3ccc(Cl)cc3C2)n[nH]1)Nc1cccc2c1[C@@H]1CCCN1C2=O,2006.0
Inhibition of CDK2,O=C(Nc1ccccn1)Nc1cccc2c1[C@H]1CCCN1C2=O,CHEMBL1240533,=,=,IC50,nM,440.0,IC50,uM,0.44,O=C(Nc1ccccn1)Nc1cccc2c1[C@H]1CCCN1C2=O,2006.0
Inhibition of CDK2,COC(=O)[C@@]1(Cc2ccc(O)c(CC=C(C)C)c2)OC(=O)C(O)=C1c1ccc(O)cc1,CHEMBL1240533,=,=,IC50,nM,1500.0,IC50,uM,1.5,COC(=O)[C@@]1(Cc2ccc(O)c(CC=C(C)C)c2)OC(=O)C(O)=C1c1ccc(O)cc1,2006.0
Inhibition of CDK2,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(Oc4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1240533,=,=,IC50,nM,2110.0,IC50,uM,2.11,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(Oc4ccccc4Cl)oc23)[C@H](O)C1,2006.0
Inhibition of CDK2,NC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(=O)(=O)NCCOCCO)cc1)C(=O)N2,CHEMBL1240533,=,=,IC50,nM,4500.0,IC50,uM,4.5,NC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(=O)(=O)NCCOCCO)cc1)C(=O)N2,2006.0
Inhibition of CDK2,CC(C)(C)Nc1nc(C(F)(F)F)nc2ccc(Nc3ccccc3)cc12,CHEMBL1240533,=,=,IC50,nM,600.0,IC50,uM,0.6,CC(C)(C)Nc1nc(C(F)(F)F)nc2ccc(Nc3ccccc3)cc12,2006.0
Inhibition of CDK2,CC(C)(C)Nc1nc(C(F)(F)F)nc2ccc(-c3cccnc3)cc12,CHEMBL1240533,=,=,IC50,nM,1200.0,IC50,uM,1.2,CC(C)(C)Nc1nc(C(F)(F)F)nc2ccc(-c3cccnc3)cc12,2006.0
Inhibition of CDK2,c1ccc2c(c1)Cc1c-2n[nH]c1-c1ccncc1,CHEMBL1240533,=,=,IC50,nM,1300.0,IC50,uM,1.3,c1ccc2c(c1)Cc1c-2n[nH]c1-c1ccncc1,2006.0
Inhibition of CDK2,Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(OCC(O)CN(C)C)cc2)n1,CHEMBL1240533,=,=,IC50,nM,1.0,IC50,uM,0.001,Cc1nc2ccccn2c1-c1ccnc(Nc2ccc(OCC(O)CN(C)C)cc2)n1,2006.0
Inhibition of CDK2,Cc1ccc(F)c(Nc2nccc(-c3ccc(S(N)(=O)=O)cc3)n2)c1,CHEMBL1240533,=,=,IC50,nM,32.0,IC50,uM,0.032,Cc1ccc(F)c(Nc2nccc(-c3ccc(S(N)(=O)=O)cc3)n2)c1,2006.0
Inhibition of CDK2,CCCCOc1c(C(=O)c2c(F)cc(C)cc2F)ccc2[nH]ncc12,CHEMBL1240533,=,=,IC50,nM,6.0,IC50,uM,0.006,CCCCOc1c(C(=O)c2c(F)cc(C)cc2F)ccc2[nH]ncc12,2006.0
Inhibition of CDK2,Nc1nc(N)c(N=O)c(=O)[nH]1,CHEMBL1240533,=,=,IC50,nM,9.0,IC50,uM,0.009,Nc1nc(N)c(N=O)c(=O)[nH]1,2006.0
Inhibition of CDK2,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc(OCc2ccccc2)c1N=O,CHEMBL1240533,=,=,IC50,nM,2200.0,IC50,uM,2.2,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc(OCc2ccccc2)c1N=O,2006.0
Inhibition of CDK2,Nc1nc2ccc(C(=O)c3c(F)cccc3Cl)cc2n1Cc1c(F)cccc1F,CHEMBL1240533,=,=,IC50,nM,33.0,IC50,uM,0.033,Nc1nc2ccc(C(=O)c3c(F)cccc3Cl)cc2n1Cc1c(F)cccc1F,2006.0
Inhibition of CDK2,COc1ccc(-c2[nH]nc3c2C(=O)c2c(NC(=O)NNC(=O)c4ccc(O)cc4)cccc2-3)cc1,CHEMBL1240533,=,=,IC50,nM,9.0,IC50,uM,0.009,COc1ccc(-c2[nH]nc3c2C(=O)c2c(NC(=O)NNC(=O)c4ccc(O)cc4)cccc2-3)cc1,2006.0
Inhibition of CDK2,CN(C)CCNS(=O)(=O)c1ccc(Nc2cccc(-c3cnc4ccccn34)c2)cc1,CHEMBL1240533,=,=,IC50,nM,5.0,IC50,uM,0.005,CN(C)CCNS(=O)(=O)c1ccc(Nc2cccc(-c3cnc4ccccn34)c2)cc1,2006.0
Inhibition of CDK2,O=C(Cc1ccc2ccccc2c1)Nc1cc(C2CC2)n[nH]1,CHEMBL1240533,=,=,IC50,nM,37.0,IC50,uM,0.037,O=C(Cc1ccc2ccccc2c1)Nc1cc(C2CC2)n[nH]1,2006.0
Inhibition of CDK2,FC(F)(F)c1cnc(Nc2ccc3[nH]cnc3c2)nc1Nc1ccccc1Cl,CHEMBL1240533,=,=,IC50,nM,2.0,IC50,uM,0.002,FC(F)(F)c1cnc(Nc2ccc3[nH]cnc3c2)nc1Nc1ccccc1Cl,2006.0
Inhibition of CDK2 at 10 mM,COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1,CHEMBL1240296,=,=,IC50,nM,100000.0,IC50,uM,100.0,COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1,2004.0
Inhibition of wild type CDK2,CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21,CHEMBL1240301,=,=,IC50,nM,18000.0,IC50,uM,18.0,CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21,2005.0
Inhibition of CDK2 F80G mutant,CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21,CHEMBL1240301,=,=,IC50,nM,15.0,IC50,uM,0.015,CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21,2005.0
Inhibition of wild type CDK2,CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21,CHEMBL1240301,=,=,IC50,nM,29000.0,IC50,uM,29.0,CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21,2005.0
Inhibition of CDK2 F80G mutant,CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21,CHEMBL1240301,=,=,IC50,nM,5.0,IC50,uM,0.005,CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21,2005.0
Binding affinity to CDK2,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,CHEMBL1240346,>,>,Kd,nM,10000.0,Kd,uM,10.0,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,2009.0
Binding affinity to CDK2,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1240346,>,>,Kd,nM,10000.0,Kd,uM,10.0,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2009.0
Binding affinity to CDK2,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,CHEMBL1240346,>,>,Kd,nM,10000.0,Kd,uM,10.0,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,2009.0
Binding affinity to CDK2,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,CHEMBL1240346,>,>,Kd,nM,10000.0,Kd,uM,10.0,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,2009.0
Binding affinity to CDK2,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,CHEMBL1240346,>,>,Kd,nM,10000.0,Kd,uM,10.0,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,2009.0
Binding affinity to CDK2,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,CHEMBL1240346,>,>,Kd,nM,10000.0,Kd,uM,10.0,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,2009.0
Inhibition of CDK2 at 10 uM relative to control,CCNC(=O)NCc1ccccc1-c1cc(-c2cnc(NC(C)C)s2)nc(NCCN(C)C)n1,CHEMBL1255531,,,Inhibition,%,,INH,,,CCNC(=O)NCc1ccccc1-c1cc(-c2cnc(NC(C)C)s2)nc(NCCN(C)C)n1,2010.0
Inhibition of CDK2,Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc([C@@H](C)N3C[C@@H](C)O[C@@H](C)C3)ns2)n1,CHEMBL1268847,>,>,IC50,nM,10.0,IC50,nM,10.0,Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc([C@@H](C)N3C[C@@H](C)O[C@@H](C)C3)ns2)n1,2010.0
Inhibition of CDK2,COc1ccc(NC(=O)c2n[nH]c3ccccc23)cc1,CHEMBL1287686,=,=,IC50,nM,3000.0,IC50,uM,3.0,COc1ccc(NC(=O)c2n[nH]c3ccccc23)cc1,2010.0
Inhibition of CDK2,COc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1,CHEMBL1287686,=,=,IC50,nM,4000.0,IC50,uM,4.0,COc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,O=C(/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)NO,CHEMBL1629443,=,=,IC50,nM,440.0,IC50,uM,0.44,O=C(/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)NO,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,O=C(/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)s1)NO,CHEMBL1629443,=,=,IC50,nM,440.0,IC50,uM,0.44,O=C(/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)s1)NO,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,O=C(/C=C/c1cccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)c1)NO,CHEMBL1629443,=,=,IC50,nM,920.0,IC50,uM,0.92,O=C(/C=C/c1cccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)c1)NO,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,O=C(/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cc1)NO,CHEMBL1629443,=,=,IC50,nM,850.0,IC50,uM,0.85,O=C(/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cc1)NO,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,Nc1ccccc1NC(=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,CHEMBL1629443,=,=,IC50,nM,15000.0,IC50,uM,15.0,Nc1ccccc1NC(=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,Nc1ccccc1NC(=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)s1,CHEMBL1629443,=,=,IC50,nM,2100.0,IC50,uM,2.1,Nc1ccccc1NC(=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)s1,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,Nc1ccccc1NC(=O)/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,CHEMBL1629443,=,=,IC50,nM,1900.0,IC50,uM,1.9,Nc1ccccc1NC(=O)/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,Nc1ccccc1NC(=O)/C=C/c1cccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)c1,CHEMBL1629443,=,=,IC50,nM,850.0,IC50,uM,0.85,Nc1ccccc1NC(=O)/C=C/c1cccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)c1,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,Nc1ccccc1NC(=O)/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cc1,CHEMBL1629443,=,=,IC50,nM,1200.0,IC50,uM,1.2,Nc1ccccc1NC(=O)/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cc1,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,Nc1ccccc1NC(=O)CCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cc1,CHEMBL1629443,=,=,IC50,nM,1400.0,IC50,uM,1.4,Nc1ccccc1NC(=O)CCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cc1,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,O=C(NO)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,CHEMBL1629443,=,=,IC50,nM,460.0,IC50,uM,0.46,O=C(NO)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,O=C(NO)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)s1,CHEMBL1629443,=,=,IC50,nM,200.0,IC50,uM,0.2,O=C(NO)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)s1,2010.0
Inhibition of CDK2 by flash plate based radioactive enzyme assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,CHEMBL1629443,=,=,IC50,nM,11000.0,IC50,uM,11.0,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,O=C1NC(=O)/C(=C/c2ccc(OCc3ccccc3)c(OCc3ccccc3)c2)N1,CHEMBL1629446,,,Inhibition,%,,INH,,,O=C1NC(=O)/C(=C/c2ccc(OCc3ccccc3)c(OCc3ccccc3)c2)N1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1ccc2nc3c(=O)[nH]c(=O)nc-3n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2c1,CHEMBL1629446,,,Inhibition,%,,INH,,,COc1ccc2nc3c(=O)[nH]c(=O)nc-3n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2c1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COC(=O)C(=O)c1c(C(=O)OC)nc2n[nH]c(=N)n2c1-c1cccc([N+](=O)[O-])c1,CHEMBL1629446,,,Inhibition,%,,INH,,,COC(=O)C(=O)c1c(C(=O)OC)nc2n[nH]c(=N)n2c1-c1cccc([N+](=O)[O-])c1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,Oc1ccc(Nc2ncnc3[nH]cnc23)cc1CN(CCCl)CCCl,CHEMBL1629446,=,=,Inhibition,%,98.0,INH,%,98.0,Oc1ccc(Nc2ncnc3[nH]cnc23)cc1CN(CCCl)CCCl,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1ccc([C@H]2c3cc4c(cc3OC(O)(CO)[C@H]2C(=O)O)OCO4)c(OC)c1,CHEMBL1629446,,,Inhibition,%,,INH,,,COc1ccc([C@H]2c3cc4c(cc3OC(O)(CO)[C@H]2C(=O)O)OCO4)c(OC)c1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,CSc1nc(N[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(Cl)c(=O)[nH]1,CHEMBL1629446,,,Inhibition,%,,INH,,,CSc1nc(N[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(Cl)c(=O)[nH]1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COC(=O)c1cc(-c2ccc(N)cc2)c2c(=O)n(-c3ccccc3)[nH]c2c1,CHEMBL1629446,,,Inhibition,%,,INH,,,COC(=O)c1cc(-c2ccc(N)cc2)c2c(=O)n(-c3ccccc3)[nH]c2c1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1ccc(-c2c3c(nc4nc(SCCc5ccccc5)nc(N)c24)CCCC3)cc1OC,CHEMBL1629446,,,Inhibition,%,,INH,,,COc1ccc(-c2c3c(nc4nc(SCCc5ccccc5)nc(N)c24)CCCC3)cc1OC,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1nc(N[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(Cl)c(=O)[nH]1,CHEMBL1629446,,,Inhibition,%,,INH,,,COc1nc(N[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(Cl)c(=O)[nH]1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,CN1C=NC([N+](=O)[O-])C1NCCN1CCNC1=O,CHEMBL1629446,,,Inhibition,%,,INH,,,CN1C=NC([N+](=O)[O-])C1NCCN1CCNC1=O,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,Nc1n[nH]c(Sc2ncccc2[N+](=O)[O-])n1,CHEMBL1629446,,,Inhibition,%,,INH,,,Nc1n[nH]c(Sc2ncccc2[N+](=O)[O-])n1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,N=C(N)NCCC[C@H]1NC(=O)[C@@H](Cc2ccc(O)cc2)NC1=O,CHEMBL1629446,,,Inhibition,%,,INH,,,N=C(N)NCCC[C@H]1NC(=O)[C@@H](Cc2ccc(O)cc2)NC1=O,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1cc(/C=C2/NC(=O)NC2=O)cc(OC)c1OC,CHEMBL1629446,=,=,Inhibition,%,84.0,INH,%,84.0,COc1cc(/C=C2/NC(=O)NC2=O)cc(OC)c1OC,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1cc(/C=C2\CCNC2=O)ccc1Oc1ccccc1,CHEMBL1629446,,,Inhibition,%,,INH,,,COc1cc(/C=C2\CCNC2=O)ccc1Oc1ccccc1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1cc2c(cc1Cl)nc1c(=O)[nH]c(=O)nc-1n2CCN1CCCC1,CHEMBL1629446,,,Inhibition,%,,INH,,,COc1cc2c(cc1Cl)nc1c(=O)[nH]c(=O)nc-1n2CCN1CCCC1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,O=C(O)CCN(CCC(=O)O)c1ccc(/C=C2\SC(=S)NC2=O)cc1,CHEMBL1629446,=,=,Inhibition,%,27.0,INH,%,27.0,O=C(O)CCN(CCC(=O)O)c1ccc(/C=C2\SC(=S)NC2=O)cc1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1cc(-c2cc(-c3cc(C)cc(Cl)c3O)nc3ncnc(N)c23)ccc1O,CHEMBL1629446,=,=,Inhibition,%,91.0,INH,%,91.0,COc1cc(-c2cc(-c3cc(C)cc(Cl)c3O)nc3ncnc(N)c23)ccc1O,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1ccc(-c2c3c(nc4nc(SCC(=O)c5ccc(Br)cc5)nc(N)c24)CCCC3)cc1OC,CHEMBL1629446,,,Inhibition,%,,INH,,,COc1ccc(-c2c3c(nc4nc(SCC(=O)c5ccc(Br)cc5)nc(N)c24)CCCC3)cc1OC,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1ccc(/C=C2\SC(=O)NC2=O)cc1S(=O)(=O)O,CHEMBL1629446,,,Inhibition,%,,INH,,,COc1ccc(/C=C2\SC(=O)NC2=O)cc1S(=O)(=O)O,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,CNc1nnc(Sc2ncccc2[N+](=O)[O-])s1,CHEMBL1629446,,,Inhibition,%,,INH,,,CNc1nnc(Sc2ncccc2[N+](=O)[O-])s1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COC(=O)C(=O)c1c(C(=O)OC)nc2n[nH]c(=N)n2c1-c1ccc(O)c(OC)c1,CHEMBL1629446,,,Inhibition,%,,INH,,,COC(=O)C(=O)c1c(C(=O)OC)nc2n[nH]c(=N)n2c1-c1ccc(O)c(OC)c1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,O=C1NC(N2CCC[C@H](CO)C2)=N/C1=C\c1ccccc1,CHEMBL1629446,,,Inhibition,%,,INH,,,O=C1NC(N2CCC[C@H](CO)C2)=N/C1=C\c1ccccc1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1ccc(-c2cc(-c3ccc(F)cc3)[nH]c(=O)c2O)cc1,CHEMBL1629446,=,=,Inhibition,%,94.0,INH,%,94.0,COc1ccc(-c2cc(-c3ccc(F)cc3)[nH]c(=O)c2O)cc1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,Cc1ccc(Nc2nnc(-c3ccc([N+](=O)[O-])cc3)o2)cc1Cl,CHEMBL1629446,=,=,Inhibition,%,22.0,INH,%,22.0,Cc1ccc(Nc2nnc(-c3ccc([N+](=O)[O-])cc3)o2)cc1Cl,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,CHEMBL1629446,,,Inhibition,%,,INH,,,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1cc(/C=C2\NC(=O)NC2=O)ccc1OCC(=O)c1ccccc1,CHEMBL1629446,,,Inhibition,%,,INH,,,COc1cc(/C=C2\NC(=O)NC2=O)ccc1OCC(=O)c1ccccc1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1cc(/C=C2\NC(=O)NC2=O)ccc1OCC(=O)C1CCOCC1,CHEMBL1629446,,,Inhibition,%,,INH,,,COc1cc(/C=C2\NC(=O)NC2=O)ccc1OCC(=O)C1CCOCC1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,O=C1NC(=O)/C(=C/c2cccc3c2OCO3)N1,CHEMBL1629446,=,=,Inhibition,%,27.0,INH,%,27.0,O=C1NC(=O)/C(=C/c2cccc3c2OCO3)N1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,O=C1NC(=O)/C(=C/c2ccc3c(c2)CN(CCO)CO3)N1,CHEMBL1629446,,,Inhibition,%,,INH,,,O=C1NC(=O)/C(=C/c2ccc3c(c2)CN(CCO)CO3)N1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,COc1ccc(CCN2COc3c([C@@H](C)CCC=C(C)C)ccc(C)c3C2)cc1OC,CHEMBL1629446,,,Inhibition,%,,INH,,,COc1ccc(CCN2COc3c([C@@H](C)CCC=C(C)C)ccc(C)c3C2)cc1OC,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,CC(C)=CCC[C@H](C)c1ccc(C)c2c1OCN(CCCCCO)C2,CHEMBL1629446,,,Inhibition,%,,INH,,,CC(C)=CCC[C@H](C)c1ccc(C)c2c1OCN(CCCCCO)C2,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,O=C1NC(=O)/C(=C/c2ccc(N(CCO)CCO)cc2)N1,CHEMBL1629446,,,Inhibition,%,,INH,,,O=C1NC(=O)/C(=C/c2ccc(N(CCO)CCO)cc2)N1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,O=C1NC(=O)/C(=C/c2ccc(/C=C3/NC(=O)NC3=O)cc2)N1,CHEMBL1629446,,,Inhibition,%,,INH,,,O=C1NC(=O)/C(=C/c2ccc(/C=C3/NC(=O)NC3=O)cc2)N1,2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,CCCCOc1ccc(/C=C2\NC(=O)NC2=O)cc1[N+](=O)[O-],CHEMBL1629446,,,Inhibition,%,,INH,,,CCCCOc1ccc(/C=C2\NC(=O)NC2=O)cc1[N+](=O)[O-],2010.0
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,O[C@]12C=C(c3[nH]ccc4c5ccccc5nc3-4)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@H]12,CHEMBL1629446,,,Inhibition,%,,INH,,,O[C@]12C=C(c3[nH]ccc4c5ccccc5nc3-4)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@H]12,2010.0
Inhibition of CDK2 at 10 uM,CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1,CHEMBL1641460,=,=,Inhibition,%,10.0,INH,%,10.0,CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1,2011.0
Inhibition of CDK2 at 1 uM,CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1,CHEMBL1641460,=,=,Inhibition,%,10.0,INH,%,10.0,CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1,2011.0
Inhibition of CDK2,CCN(Cc1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1)C(C)(C)CO.Cl,CHEMBL1649074,>,>,IC50,nM,100.0,IC50,nM,100.0,CCN(Cc1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1)C(C)(C)CO.Cl,2011.0
Inhibition of CDK2,Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(CN3CCC(F)(F)C3)ns2)n1.Cl,CHEMBL1649074,>,>,IC50,nM,100.0,IC50,nM,100.0,Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(CN3CCC(F)(F)C3)ns2)n1.Cl,2011.0
Inhibition of CDK2,Cl.[2H]C([2H])(c1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1)N1CCC(F)(F)C1,CHEMBL1649074,>,>,IC50,nM,100.0,IC50,nM,100.0,Cl.[2H]C([2H])(c1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1)N1CCC(F)(F)C1,2011.0
Inhibition of CDK2A by Caliper mobility shift assay,COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O,CHEMBL1649097,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O,2011.0
Inhibition of CDK2A by Caliper mobility shift assay,COc1cc(O)c2c(c1)CCC[C@H](O)CC(=O)/C=C\C[C@H](C)OC2=O,CHEMBL1649097,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1cc(O)c2c(c1)CCC[C@H](O)CC(=O)/C=C\C[C@H](C)OC2=O,2011.0
Inhibition of CDK2,Nc1nccc(-c2ccc3c(N)n[nH]c3c2)n1,CHEMBL1687694,=,=,IC50,nM,280.0,IC50,uM,0.28,Nc1nccc(-c2ccc3c(N)n[nH]c3c2)n1,2010.0
Inhibition of Cdk2,C[C@H]1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccnc2ccccc12,CHEMBL1759913,,,Inhibition,%,,INH,,,C[C@H]1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccnc2ccccc12,2011.0
Inhibition of CDK2 in presence of 60 uM ATP,Nc1nc(Nc2cccnc2)sc1C(=O)c1ccccc1F,CHEMBL1759882,=,=,IC50,nM,25.0,IC50,nM,25.0,Nc1nc(Nc2cccnc2)sc1C(=O)c1ccccc1F,2011.0
Inhibition of CDK2,COc1cc(Nc2nccc(Nc3cnc4ccccc4c3)n2)cc(OC)c1OC,CHEMBL1759866,=,=,IC50,nM,711.0,IC50,uM,0.711,COc1cc(Nc2nccc(Nc3cnc4ccccc4c3)n2)cc(OC)c1OC,2011.0
Inhibition of CDK2,c1ccc2ncc(Nc3ccnc(Nc4ccc(OCCCN5CCCCC5)cc4)n3)cc2c1,CHEMBL1759866,=,=,IC50,nM,19500.0,IC50,uM,19.5,c1ccc2ncc(Nc3ccnc(Nc4ccc(OCCCN5CCCCC5)cc4)n3)cc2c1,2011.0
Inhibition of human CDK2,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1,CHEMBL1781916,,,Inhibition,%,,INH,,,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1,2009.0
Inhibition of CDK2,O=C(c1ccco1)N1N=C(c2cccnc2)CC1c1ccccc1O,CHEMBL1781905,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(c1ccco1)N1N=C(c2cccnc2)CC1c1ccccc1O,2010.0
Inhibition of CDK2,Cc1ccc(C(=O)NCCO)cc1-n1cnc(OCc2ccc(F)cc2F)c(Cl)c1=O,CHEMBL1795201,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccc(C(=O)NCCO)cc1-n1cnc(OCc2ccc(F)cc2F)c(Cl)c1=O,2011.0
Inhibition of CDK2 at 1 uM,COCCN1CCc2cc(Nc3ncc(Cl)c(N[C@@H]4CCCC[C@H]4NS(C)(=O)=O)n3)c(OC)cc2CC1,CHEMBL1795227,<,<,Inhibition,%,65.0,INH,%,65.0,COCCN1CCc2cc(Nc3ncc(Cl)c(N[C@@H]4CCCC[C@H]4NS(C)(=O)=O)n3)c(OC)cc2CC1,2011.0
Inhibition of CDK2 at 1 uM,COCCN1CCc2cc(Nc3ncc(Cl)c(N[C@@H]4CCCC[C@H]4N(C)S(C)(=O)=O)n3)c(OC)cc2CC1,CHEMBL1795227,<,<,Inhibition,%,65.0,INH,%,65.0,COCCN1CCc2cc(Nc3ncc(Cl)c(N[C@@H]4CCCC[C@H]4N(C)S(C)(=O)=O)n3)c(OC)cc2CC1,2011.0
Inhibition of CDK2 at 10 uM,O=c1c(Cl)c(OCc2ccc(F)cc2F)cc(CO)n1-c1c(F)cccc1F,CHEMBL1795280,<,<,Inhibition,%,50.0,INH,%,50.0,O=c1c(Cl)c(OCc2ccc(F)cc2F)cc(CO)n1-c1c(F)cccc1F,2011.0
Inhibition of CDK2 at 10 uM,Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cccc(C(N)=O)c1,CHEMBL1795280,<,<,Inhibition,%,50.0,INH,%,50.0,Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cccc(C(N)=O)c1,2011.0
Inhibition of Cdk2,CSc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C)ns2)n1,CHEMBL1799927,=,=,IC50,nM,2273.0,IC50,nM,2273.0,CSc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C)ns2)n1,2010.0
Binding affinity to human Cdk2,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,CHEMBL1799934,>,>,Kd,nM,10000.0,Kd,uM,10.0,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,2011.0
Inhibition of CDK2 in human HCT116 cells assessed as decrease in protein level at 30 to 40 umol/L after 24 hrs by immunoblotting analysis,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL1800061,,,Inhibition,%,,INH,,,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2010.0
Inhibition of CDK2-mediated phosphorylation of RB at Ser780 in human HCT116 cells after 4 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2-mediated phosphorylation of RB at Ser780 in human HCT116 cells after 24 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2-mediated phosphorylation of RB at Ser795 in human HCT116 cells after 4 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2-mediated phosphorylation of RB at Ser795 in human HCT116 cells after 24 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2-mediated phosphorylation of RB at Ser801 in human HCT116 cells after 4 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2-mediated phosphorylation of RB at Ser801 in human HCT116 cells after 24 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2-mediated phosphorylation of RB at Ser807/811 in human HCT116 cells after 4 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2-mediated phosphorylation of RB at Ser807/811 in human HCT116 cells after 24 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2-mediated phosphorylation of RB at Thr821 in human HCT116 cells after 4 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2-mediated phosphorylation of RB at Thr821 in human HCT116 cells after 24 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of phospho-CDK2-mediated phosphorylation of RB protein in human HCT116 cells after 4 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2-mediated phosphorylation of RB protein in human HCT116 cells after 4 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of phospho-CDK2-mediated phosphorylation of RNA pol3 in human HCT116 cells after 4 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2-mediated phosphorylation of RNA pol3 in human HCT116 cells after 4 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2 in human HCT116 cells assessed as decrease in protein level at 1 umol/L after 24 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2 phosphorylation at Thr170 in human HCT116 cells after 24 hrs by immunoblotting analysis,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL1800061,,,Inhibition,%,,INH,,,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2010.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nc(NC2CCCC2)cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)n1,CHEMBL1799991,=,=,IC50,nM,15.0,IC50,uM,0.015,Nc1nc(NC2CCCC2)cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nccc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)n1,CHEMBL1799991,=,=,IC50,nM,21.0,IC50,uM,0.021,Nc1nccc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Cc1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1,CHEMBL1799991,=,=,IC50,nM,42.0,IC50,uM,0.042,Cc1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCCC2)n1,CHEMBL1799991,=,=,IC50,nM,42.0,IC50,uM,0.042,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCCC2)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,CCc1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1,CHEMBL1799991,=,=,IC50,nM,50.0,IC50,uM,0.05,CCc1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCCCC2)n1,CHEMBL1799991,=,=,IC50,nM,52.0,IC50,uM,0.052,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCCCC2)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nc(NC2CCCCC2)cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)n1,CHEMBL1799991,=,=,IC50,nM,60.0,IC50,uM,0.06,Nc1nc(NC2CCCCC2)cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,CC(C)c1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1,CHEMBL1799991,=,=,IC50,nM,68.0,IC50,uM,0.068,CC(C)c1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCCCCC2)n1,CHEMBL1799991,=,=,IC50,nM,90.0,IC50,uM,0.09,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCCCCC2)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCNCC2)n1,CHEMBL1799991,=,=,IC50,nM,200.0,IC50,uM,0.2,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCNCC2)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,CN(C)c1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1,CHEMBL1799991,=,=,IC50,nM,250.0,IC50,uM,0.25,CN(C)c1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,CN1CCN(c2cc(-c3cc(N4C[C@H](O)[C@@H](O)C4)ccc3O)nc(N)n2)CC1,CHEMBL1799991,=,=,IC50,nM,300.0,IC50,uM,0.3,CN1CCN(c2cc(-c3cc(N4C[C@H](O)[C@@H](O)C4)ccc3O)nc(N)n2)CC1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCCNC2)n1,CHEMBL1799991,=,=,IC50,nM,360.0,IC50,uM,0.36,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CCCNC2)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,CCCCCCc1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1,CHEMBL1799991,=,=,IC50,nM,450.0,IC50,uM,0.45,CCCCCCc1cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)nc(N)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nc(NCCN2CCOCC2)cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)n1,CHEMBL1799991,=,=,IC50,nM,450.0,IC50,uM,0.45,Nc1nc(NCCN2CCOCC2)cc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nccc(-c2cc(N3CCOCC3)ccc2O)n1,CHEMBL1799991,=,=,IC50,nM,790.0,IC50,uM,0.79,Nc1nccc(-c2cc(N3CCOCC3)ccc2O)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(N2CCOCC2)n1,CHEMBL1799991,=,=,IC50,nM,940.0,IC50,uM,0.94,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(N2CCOCC2)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nccc(-c2cc(N3CCC(O)C3)ccc2O)n1,CHEMBL1799991,=,=,IC50,nM,2110.0,IC50,uM,2.11,Nc1nccc(-c2cc(N3CCC(O)C3)ccc2O)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nccc(-c2cc(N3CCC(O)CC3)ccc2O)n1,CHEMBL1799991,=,=,IC50,nM,3760.0,IC50,uM,3.76,Nc1nccc(-c2cc(N3CCC(O)CC3)ccc2O)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nccc(-c2cc(N3CCS(=O)(=O)CC3)ccc2O)n1,CHEMBL1799991,=,=,IC50,nM,3980.0,IC50,uM,3.98,Nc1nccc(-c2cc(N3CCS(=O)(=O)CC3)ccc2O)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nccc(-c2cc(N3CCCCC3)ccc2O)n1,CHEMBL1799991,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1nccc(-c2cc(N3CCCCC3)ccc2O)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,CCC1CCN(c2ccc(O)c(-c3ccnc(N)n3)c2)CC1,CHEMBL1799991,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCC1CCN(c2ccc(O)c(-c3ccnc(N)n3)c2)CC1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nccc(-c2cc(N3CCC(=O)CC3)ccc2O)n1,CHEMBL1799991,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1nccc(-c2cc(N3CCC(=O)CC3)ccc2O)n1,2011.0
Inhibition of CDK2 in presence of 100 uM ATP,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CC2)n1,CHEMBL1799991,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1nc(-c2cc(N3C[C@H](O)[C@@H](O)C3)ccc2O)cc(C2CC2)n1,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,O=c1[nH]cc(-c2ccc(N3CCOCC3)cc2)c2sc(-c3ccncc3)cc12,CHEMBL1806471,=,=,IC50,nM,15848.93,pIC50,,4.8,O=c1[nH]cc(-c2ccc(N3CCOCC3)cc2)c2sc(-c3ccncc3)cc12,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,Cc1cc(-c2cc3c(=O)[nH]cc(-c4cccc(NS(C)(=O)=O)c4)c3s2)ccn1,CHEMBL1806471,,,pIC50,,,pIC50,,,Cc1cc(-c2cc3c(=O)[nH]cc(-c4cccc(NS(C)(=O)=O)c4)c3s2)ccn1,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,CS(=O)(=O)Nc1cccc(-c2c[nH]c(=O)c3cc(-c4ccnc5[nH]ccc45)sc23)c1,CHEMBL1806471,=,=,IC50,nM,3162.28,pIC50,,5.5,CS(=O)(=O)Nc1cccc(-c2c[nH]c(=O)c3cc(-c4ccnc5[nH]ccc45)sc23)c1,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,O=c1[nH]cc(-c2ccc(N3CCOCC3)cc2)c2sc(-c3cn[nH]c3)cc12,CHEMBL1806471,=,=,IC50,nM,251.19,pIC50,,6.6,O=c1[nH]cc(-c2ccc(N3CCOCC3)cc2)c2sc(-c3cn[nH]c3)cc12,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,Cn1cc(-c2ccc(N3CCOCC3)cc2)c2sc(-c3ccncc3)cc2c1=O,CHEMBL1806471,<,>,IC50,nM,15848.93,pIC50,,4.8,Cn1cc(-c2ccc(N3CCOCC3)cc2)c2sc(-c3ccncc3)cc2c1=O,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,COc1ncc(-c2ccc(N3CCOCC3)cc2)c2sc(-c3ccncc3)cc12,CHEMBL1806471,<,>,IC50,nM,15848.93,pIC50,,4.8,COc1ncc(-c2ccc(N3CCOCC3)cc2)c2sc(-c3ccncc3)cc12,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,N#Cc1ccc(F)c(-c2c[nH]c(=O)c3cc(-c4ccncc4)sc23)c1,CHEMBL1806471,=,=,IC50,nM,199.53,pIC50,,6.7,N#Cc1ccc(F)c(-c2c[nH]c(=O)c3cc(-c4ccncc4)sc23)c1,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,O=c1[nH]cc(-c2ccc3c(c2)OCCO3)c2sc(-c3ccncc3)cc12,CHEMBL1806471,=,=,IC50,nM,1584.89,pIC50,,5.8,O=c1[nH]cc(-c2ccc3c(c2)OCCO3)c2sc(-c3ccncc3)cc12,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,N#CCc1cccc(-c2c[nH]c(=O)c3cc(-c4ccncc4)sc23)c1,CHEMBL1806471,=,=,IC50,nM,3981.07,pIC50,,5.4,N#CCc1cccc(-c2c[nH]c(=O)c3cc(-c4ccncc4)sc23)c1,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,O=c1[nH]cc(-c2cccc(Cl)n2)c2sc(-c3ccncc3)cc12,CHEMBL1806471,<,>,IC50,nM,15848.93,pIC50,,4.8,O=c1[nH]cc(-c2cccc(Cl)n2)c2sc(-c3ccncc3)cc12,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,N#Cc1cscc1-c1c[nH]c(=O)c2cc(-c3ccncc3)sc12,CHEMBL1806471,=,=,IC50,nM,158.49,pIC50,,6.8,N#Cc1cscc1-c1c[nH]c(=O)c2cc(-c3ccncc3)sc12,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,COCc1ccccc1-c1c[nH]c(=O)c2cc(-c3ccncc3)sc12,CHEMBL1806471,=,=,IC50,nM,5011.87,pIC50,,5.3,COCc1ccccc1-c1c[nH]c(=O)c2cc(-c3ccncc3)sc12,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,CCOc1ccc(-c2c[nH]c(=O)c3cc(-c4ccncc4)sc23)cn1,CHEMBL1806471,=,=,IC50,nM,6309.57,pIC50,,5.2,CCOc1ccc(-c2c[nH]c(=O)c3cc(-c4ccncc4)sc23)cn1,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,COc1cc(F)ccc1-c1c[nH]c(=O)c2cc(-c3ccncc3)sc12,CHEMBL1806471,=,=,IC50,nM,5011.87,pIC50,,5.3,COc1cc(F)ccc1-c1c[nH]c(=O)c2cc(-c3ccncc3)sc12,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,CN(C)C(=O)c1ccccc1-c1c[nH]c(=O)c2cc(-c3ccncc3)sc12,CHEMBL1806471,<,>,IC50,nM,15848.93,pIC50,,4.8,CN(C)C(=O)c1ccccc1-c1c[nH]c(=O)c2cc(-c3ccncc3)sc12,2011.0
Inhibition of recombinant CDK2 expressed in baculovirus using [gamma-32P]-ATP by 33-P leadseeker assay,O=c1[nH]cc(-c2cccc3cccnc23)c2sc(-c3ccncc3)cc12,CHEMBL1806471,=,=,IC50,nM,12589.25,pIC50,,4.9,O=c1[nH]cc(-c2cccc3cccnc23)c2sc(-c3ccncc3)cc12,2011.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,CHEMBL1806477,=,=,IC50,nM,1.0,IC50,uM,0.001,NS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1,2011.0
Inhibition of CDK2,CC(=O)N1CCN(c2ccc(Nc3nccc(-c4cnc5ccccn45)n3)cc2)CC1,CHEMBL1806477,=,=,IC50,nM,78.0,IC50,uM,0.078,CC(=O)N1CCN(c2ccc(Nc3nccc(-c4cnc5ccccn45)n3)cc2)CC1,2011.0
Inhibition of CDK2,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1nccc(-c2cnc3ccccn23)n1,CHEMBL1806477,>,>,IC50,nM,100000.0,IC50,uM,100.0,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1nccc(-c2cnc3ccccn23)n1,2011.0
Inhibition of CDK2,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(F)c(-c2cnc3ccccn23)n1,CHEMBL1806477,=,=,IC50,nM,2700.0,IC50,uM,2.7,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(F)c(-c2cnc3ccccn23)n1,2011.0
Inhibition of CDK2,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,CHEMBL1806477,=,=,IC50,nM,1100.0,IC50,uM,1.1,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,2011.0
Inhibition of CDK2,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Br)c(-c2cnc3ccccn23)n1,CHEMBL1806477,=,=,IC50,nM,1100.0,IC50,uM,1.1,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Br)c(-c2cnc3ccccn23)n1,2011.0
Inhibition of CDK2,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(C)c(-c2cnc3ccccn23)n1,CHEMBL1806477,=,=,IC50,nM,10000.0,IC50,uM,10.0,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(C)c(-c2cnc3ccccn23)n1,2011.0
Inhibition of CDK2,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(C(F)(F)F)c(-c2cnc3ccccn23)n1,CHEMBL1806477,=,=,IC50,nM,16000.0,IC50,uM,16.0,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(C(F)(F)F)c(-c2cnc3ccccn23)n1,2011.0
Inhibition of CDK2,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(OC)c(-c2cnc3ccccn23)n1,CHEMBL1806477,=,=,IC50,nM,53000.0,IC50,uM,53.0,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(OC)c(-c2cnc3ccccn23)n1,2011.0
Inhibition of CDK2,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(C#N)c(-c2cnc3ccccn23)n1,CHEMBL1806477,=,=,IC50,nM,27000.0,IC50,uM,27.0,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(C#N)c(-c2cnc3ccccn23)n1,2011.0
Inhibition of CDK2,Cc1ccc(C(=O)NC2CC2)cc1Nc1ncnn2cc(C(=O)c3ccccc3)c(C)c12,CHEMBL1806462,>,>,IC50,nM,25000.0,IC50,uM,25.0,Cc1ccc(C(=O)NC2CC2)cc1Nc1ncnn2cc(C(=O)c3ccccc3)c(C)c12,2011.0
Inhibition of CDK2,c1ccc2[nH]ncc2c1,CHEMBL1817560,=,=,IC50,nM,185000.0,IC50,uM,185.0,c1ccc2[nH]ncc2c1,2011.0
Activity of CDK2 kinase at 1 uM,CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1,CHEMBL1821651,=,=,Activity,%,87.0,Activity,%,87.0,CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1,2011.0
Inhibition of CDK2,N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1821694,=,=,IC50,nM,50.0,IC50,uM,0.05,N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1,2011.0
Inhibition of CDK2,N[C@H](CNc1nnc(-c2ccc3c(c2)CC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1821694,=,=,IC50,nM,190.0,IC50,uM,0.19,N[C@H](CNc1nnc(-c2ccc3c(c2)CC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1,2011.0
Inhibition of CDK2,N[C@H](CNC(=O)c1ccc2cnccc2c1)Cc1ccc(C(F)(F)F)cc1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,N[C@H](CNC(=O)c1ccc2cnccc2c1)Cc1ccc(C(F)(F)F)cc1,2011.0
Inhibition of CDK2,O=C(NC(c1ccccc1)C1CCNCC1)c1ccc2cnccc2c1,CHEMBL1821694,=,=,IC50,nM,19700.0,IC50,uM,19.7,O=C(NC(c1ccccc1)C1CCNCC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1ccc2ccccc2c1)C1CCNCC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1ccc2ccccc2c1)C1CCNCC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1nccs1)C1CCNCC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1nccs1)C1CCNCC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,COc1ccc(C(NC(=O)c2ccc3cnccc3c2)C2CCNCC2)cc1F,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,COc1ccc(C(NC(=O)c2ccc3cnccc3c2)C2CCNCC2)cc1F,2011.0
Inhibition of CDK2,O=C(NC(c1ccc(F)c(F)c1)C1CCNCC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1ccc(F)c(F)c1)C1CCNCC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1ccc(Cl)c(-c2ccccc2)c1)C1CCNCC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1ccc(Cl)c(-c2ccccc2)c1)C1CCNCC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,N#Cc1cc(C(NC(=O)c2ccc3cnccc3c2)C2CCNCC2)ccc1Cl,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,N#Cc1cc(C(NC(=O)c2ccc3cnccc3c2)C2CCNCC2)ccc1Cl,2011.0
Inhibition of CDK2,O=C(NC(c1cccc(Cl)c1)C1CCNCC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1cccc(Cl)c1)C1CCNCC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1ccc(Cl)cc1)C1CCNCC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1ccc(Cl)cc1)C1CCNCC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1ccc(Cl)c(F)c1)C1CCNCC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1ccc(Cl)c(F)c1)C1CCNCC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1cccc(Cl)c1Cl)C1CCNCC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1cccc(Cl)c1Cl)C1CCNCC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1cnc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1cnc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2cnc(F)cc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2cnc(F)cc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCCNC1)c1ccc2cnccc2c1,CHEMBL1821694,=,=,IC50,nM,21000.0,IC50,uM,21.0,O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCCNC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(N[C@@H](c1ccc(Cl)c(Cl)c1)C1CNC1)c1ccc2cnccc2c1,CHEMBL1821694,=,=,IC50,nM,680.0,IC50,uM,0.68,O=C(N[C@@H](c1ccc(Cl)c(Cl)c1)C1CNC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(N[C@H](c1ccc(Cl)c(Cl)c1)C1CNC1)c1ccc2cnccc2c1,CHEMBL1821694,=,=,IC50,nM,9800.0,IC50,uM,9.8,O=C(N[C@H](c1ccc(Cl)c(Cl)c1)C1CNC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCCCC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCCCC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1cncnc1)c1ccc(Cl)c(Cl)c1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1cncnc1)c1ccc(Cl)c(Cl)c1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(NC(c1ccncc1)c1ccc(Cl)c(Cl)c1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(NC(c1ccncc1)c1ccc(Cl)c(Cl)c1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,CC(C)CN1CCC([C@@H](NC(=O)c2ccc3cnccc3c2)c2ccc(Cl)c(Cl)c2)CC1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,CC(C)CN1CCC([C@@H](NC(=O)c2ccc3cnccc3c2)c2ccc(Cl)c(Cl)c2)CC1,2011.0
Inhibition of CDK2,O=C(N[C@@H](c1ccc(Cl)c(Cl)c1)C1CCN(Cc2ccccc2)CC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(N[C@@H](c1ccc(Cl)c(Cl)c1)C1CCN(Cc2ccccc2)CC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,O=C(N[C@@H](c1ccc(Cl)c(Cl)c1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1)c1ccc2cnccc2c1,CHEMBL1821694,>,>,IC50,nM,25000.0,IC50,uM,25.0,O=C(N[C@@H](c1ccc(Cl)c(Cl)c1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1)c1ccc2cnccc2c1,2011.0
Inhibition of CDK2,CN1CC([C@@H](NC(=O)c2ccc3cnccc3c2)c2ccc(Cl)c(Cl)c2)C1,CHEMBL1821694,=,=,IC50,nM,360.0,IC50,uM,0.36,CN1CC([C@@H](NC(=O)c2ccc3cnccc3c2)c2ccc(Cl)c(Cl)c2)C1,2011.0
Inhibition of human CDK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control,Nc1c(F)c(NCCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,CHEMBL1833925,<,<,Inhibition,%,35.0,INH,%,35.0,Nc1c(F)c(NCCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1,2011.0
Inhibition of human CDK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control,Nc1c(F)c(NCCNc2ccccn2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CCCC1,CHEMBL1833925,<,<,Inhibition,%,35.0,INH,%,35.0,Nc1c(F)c(NCCNc2ccccn2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CCCC1,2011.0
Inhibition of human CDK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control,C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,CHEMBL1833925,<,<,Inhibition,%,35.0,INH,%,35.0,C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,2011.0
Inhibition of human CDK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control,CC(C)[C@@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,CHEMBL1833925,<,<,Inhibition,%,35.0,INH,%,35.0,CC(C)[C@@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,2011.0
Inhibition of human CDK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control,Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCCC1)CO2,CHEMBL1833925,<,<,Inhibition,%,35.0,INH,%,35.0,Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCCC1)CO2,2011.0
Inhibition of recombinant CDK2,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O,CHEMBL1833940,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O,2011.0
Binding constant for CDK2 kinase domain,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,2011.0
Binding constant for CDK2 kinase domain,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,2011.0
Binding constant for CDK2 kinase domain,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,2011.0
Binding constant for CDK2 kinase domain,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,2011.0
Binding constant for CDK2 kinase domain,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,2011.0
Binding constant for CDK2 kinase domain,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,2011.0
Binding constant for CDK2 kinase domain,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,2011.0
Binding constant for CDK2 kinase domain,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,2011.0
Binding constant for CDK2 kinase domain,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,2011.0
Binding constant for CDK2 kinase domain,CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,2011.0
Binding constant for CDK2 kinase domain,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,2011.0
Binding constant for CDK2 kinase domain,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2011.0
Binding constant for CDK2 kinase domain,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,CHEMBL1908390,=,=,Kd,nM,5200.0,Kd,nM,5200.0,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,2011.0
Binding constant for CDK2 kinase domain,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,CHEMBL1908390,=,=,Kd,nM,1400.0,Kd,nM,1400.0,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,2011.0
Binding constant for CDK2 kinase domain,CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl,2011.0
Binding constant for CDK2 kinase domain,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2011.0
Binding constant for CDK2 kinase domain,Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,2011.0
Binding constant for CDK2 kinase domain,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,2011.0
Binding constant for CDK2 kinase domain,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,2011.0
Binding constant for CDK2 kinase domain,COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1,2011.0
Binding constant for CDK2 kinase domain,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,2011.0
Binding constant for CDK2 kinase domain,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,2011.0
Binding constant for CDK2 kinase domain,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,2011.0
Binding constant for CDK2 kinase domain,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,2011.0
Binding constant for CDK2 kinase domain,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,2011.0
Binding constant for CDK2 kinase domain,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,2011.0
Binding constant for CDK2 kinase domain,Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12,2011.0
Binding constant for CDK2 kinase domain,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,2011.0
Binding constant for CDK2 kinase domain,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL1908390,=,=,Kd,nM,550.0,Kd,nM,550.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2011.0
Binding constant for CDK2 kinase domain,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,2011.0
Binding constant for CDK2 kinase domain,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,2011.0
Binding constant for CDK2 kinase domain,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,2011.0
Binding constant for CDK2 kinase domain,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,2011.0
Binding constant for CDK2 kinase domain,Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1,2011.0
Binding constant for CDK2 kinase domain,OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1,2011.0
Binding constant for CDK2 kinase domain,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,CHEMBL1908390,=,=,Kd,nM,5000.0,Kd,nM,5000.0,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,2011.0
Binding constant for CDK2 kinase domain,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC,2011.0
Binding constant for CDK2 kinase domain,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,2011.0
Binding constant for CDK2 kinase domain,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,CHEMBL1908390,=,=,Kd,nM,69.0,Kd,nM,69.0,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,2011.0
Binding constant for CDK2 kinase domain,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2011.0
Binding constant for CDK2 kinase domain,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,2011.0
Binding constant for CDK2 kinase domain,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,2011.0
Binding constant for CDK2 kinase domain,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,2011.0
Binding constant for CDK2 kinase domain,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,2011.0
Binding constant for CDK2 kinase domain,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,2011.0
Binding constant for CDK2 kinase domain,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,CHEMBL1908390,=,=,Kd,nM,0.53,Kd,nM,0.53,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,2011.0
Binding constant for CDK2 kinase domain,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,2011.0
Binding constant for CDK2 kinase domain,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,CHEMBL1908390,=,=,Kd,nM,20.0,Kd,nM,20.0,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,2011.0
Binding constant for CDK2 kinase domain,CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12,2011.0
Binding constant for CDK2 kinase domain,COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C,2011.0
Binding constant for CDK2 kinase domain,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,2011.0
Binding constant for CDK2 kinase domain,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,2011.0
Binding constant for CDK2 kinase domain,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,2011.0
Binding constant for CDK2 kinase domain,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,2011.0
Binding constant for CDK2 kinase domain,Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,2011.0
Binding constant for CDK2 kinase domain,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,CHEMBL1908390,=,=,Kd,nM,450.0,Kd,nM,450.0,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,2011.0
Binding constant for CDK2 kinase domain,C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F,2011.0
Binding constant for CDK2 kinase domain,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,2011.0
Binding constant for CDK2 kinase domain,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,2011.0
Binding constant for CDK2 kinase domain,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,2011.0
Binding constant for CDK2 kinase domain,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21,2011.0
Binding constant for CDK2 kinase domain,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,2011.0
Binding constant for CDK2 kinase domain,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,CHEMBL1908390,=,=,Kd,nM,8700.0,Kd,nM,8700.0,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,2011.0
Binding constant for CDK2 kinase domain,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,CHEMBL1908390,=,=,Kd,nM,30.0,Kd,nM,30.0,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,2011.0
Binding constant for CDK2 kinase domain,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,2011.0
Binding constant for CDK2 kinase domain,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,2011.0
Binding constant for CDK2 kinase domain,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,2011.0
Binding constant for CDK2 kinase domain,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1908390,=,=,Kd,nM,7.0,Kd,nM,7.0,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2011.0
Binding constant for CDK2 kinase domain,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,2011.0
Binding constant for CDK2 kinase domain,O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl,2011.0
Binding constant for CDK2 kinase domain,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,2011.0
Binding constant for CDK2 kinase domain,CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1,CHEMBL1908390,>,>,Kd,nM,10000.0,Kd,nM,10000.0,CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1,2011.0
Inhibition of CDK2,Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1,CHEMBL1909564,=,=,Ki,nM,1300.0,Ki,uM,1.3,Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1,2011.0
Inhibition of CDK2,CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)[C@H](C)O,CHEMBL1921760,,,Inhibition,%,,INH,,,CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)[C@H](C)O,2011.0
Inhibition of CDK2,CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL1921760,,,Inhibition,%,,INH,,,CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2011.0
Inhibition of CDK2 at 10 uM,NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O,CHEMBL1926538,=,=,Inhibition,%,-2.0,INH,%,-2.0,NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O,2012.0
Inhibition of CDK2,Cc1cnc2nc1-c1cccc(c1)OCC/C=C/CN(C)Cc1cccc(c1)N2,CHEMBL1933054,=,=,IC50,nM,150.0,IC50,uM,0.15,Cc1cnc2nc1-c1cccc(c1)OCC/C=C/CN(C)Cc1cccc(c1)N2,2012.0
Inhibition of CDK2,CN1C/C=C/CCOc2cccc(c2)-c2nc(nc3[nH]cnc23)Nc2cccc(c2)C1,CHEMBL1933054,=,=,IC50,nM,4100.0,IC50,uM,4.1,CN1C/C=C/CCOc2cccc(c2)-c2nc(nc3[nH]cnc23)Nc2cccc(c2)C1,2012.0
Inhibition of CDK2,Oc1ccc(-c2nc(Nc3cccc(Cl)c3)nc3[nH]cnc23)cc1,CHEMBL1933054,=,=,IC50,nM,7000.0,IC50,uM,7.0,Oc1ccc(-c2nc(Nc3cccc(Cl)c3)nc3[nH]cnc23)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc(Nc3cccc(NC(=O)CN)c3)nc3[nH]cnc23)cc1OC,CHEMBL1933054,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2nc(Nc3cccc(NC(=O)CN)c3)nc3[nH]cnc23)cc1OC,2012.0
Inhibition of CDK2,CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br,CHEMBL1933054,=,=,IC50,nM,1500.0,IC50,uM,1.5,CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br,2012.0
Inhibition of Cdk2,O=C(c1cc2cc(F)ccc2[nH]1)N1C[C@]2(CCN(C3CCCNC3)C2)c2ccccc21,CHEMBL1933021,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C(c1cc2cc(F)ccc2[nH]1)N1C[C@]2(CCN(C3CCCNC3)C2)c2ccccc21,2012.0
Inhibition of Cdk2,O=C(c1cc2ccc(F)cc2[nH]1)N1C[C@]2(CCN(C3CCNC3)C2)c2ccccc21,CHEMBL1933021,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C(c1cc2ccc(F)cc2[nH]1)N1C[C@]2(CCN(C3CCNC3)C2)c2ccccc21,2012.0
Inhibition of Cdk2,C[C@@H]1CCC(N2CC[C@]3(CN(C(=O)c4cc5ccccc5[nH]4)c4ccccc43)C2)CN1,CHEMBL1933021,>,>,IC50,nM,30000.0,IC50,uM,30.0,C[C@@H]1CCC(N2CC[C@]3(CN(C(=O)c4cc5ccccc5[nH]4)c4ccccc43)C2)CN1,2012.0
Inhibition of Cdk2,C[C@@H]1CCC(N2CC[C@]3(CN(C(=O)c4cc5ccc(F)cc5[nH]4)c4ccccc43)C2)CN1,CHEMBL1933021,>,>,IC50,nM,30000.0,IC50,uM,30.0,C[C@@H]1CCC(N2CC[C@]3(CN(C(=O)c4cc5ccc(F)cc5[nH]4)c4ccccc43)C2)CN1,2012.0
Inhibition of human CDK2 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM,C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,CHEMBL1938230,<,<,Inhibition,%,35.0,INH,%,35.0,C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,2012.0
Inhibition of human CDK2 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM,C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23,CHEMBL1938230,<,<,Inhibition,%,35.0,INH,%,35.0,C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23,2012.0
Inhibition of human CDK2 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM,C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,CHEMBL1938230,<,<,Inhibition,%,35.0,INH,%,35.0,C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23,2012.0
Inhibition of human CDK2 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM,C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23,CHEMBL1938230,<,<,Inhibition,%,35.0,INH,%,35.0,C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23,2012.0
Inhibition of CDK2 using ATP as substrate,Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCNCC1)NC2=O,CHEMBL1944596,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCNCC1)NC2=O,2012.0
Inhibition of CDK2 in human HCT116 cells assessed as Rb phosphorylation at 40 nM after 24 hrs by Western blot analysis,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL1944548,,,Inhibition,%,,INH,,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,2012.0
Inhibition of CDK2 in human MV411 cells assessed as Rb phosphorylation after 24 hrs by Western blot analysis,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL1944548,=,=,IC50,nM,130.0,IC50,uM,0.13,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,2012.0
Inhibition of CDK2 in human MV411 cells assessed as Stat5 phosphorylation after 24 hrs by Western blot analysis,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL1944548,,,Inhibition,%,,INH,,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,2012.0
Inhibition of CDK2 in human MV411 cells assessed as FLT3 phosphorylation after 24 hrs by Western blot analysis,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL1944548,,,Inhibition,%,,INH,,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,2012.0
Inhibition of CDK2 in human HCT116 cells assessed as Rb phosphorylation at 200 nM after 24 hrs by Western blot analysis,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL1944548,,,Inhibition,%,,INH,,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,2012.0
Inhibition of CDK2 assessed as activity remaining at 10 uM,O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CC1CCOCC1,CHEMBL1944561,=,=,Activity,%,90.0,Activity,%,90.0,O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CC1CCOCC1,2011.0
Inhibition of CDK2 assessed as activity remaining at 10 uM,CC(C)(O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1,CHEMBL1944561,=,=,Activity,%,81.0,Activity,%,81.0,CC(C)(O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1,2011.0
Inhibition of CDK2 assessed as activity remaining at 10 uM,O=c1[nH]c2ncc(-c3ccc4[nH]cnc4c3)nc2n1CC1CCCCC1,CHEMBL1944561,=,=,Activity,%,81.0,Activity,%,81.0,O=c1[nH]c2ncc(-c3ccc4[nH]cnc4c3)nc2n1CC1CCCCC1,2011.0
Inhibition of CDK2,COc1ccc(C(=O)NC[C@@H](O)CO)cc1/C=C/c1ccc(Cl)cc1,CHEMBL1949587,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc(C(=O)NC[C@@H](O)CO)cc1/C=C/c1ccc(Cl)cc1,2012.0
Inhibition of CDK2,COc1ccc(C(=O)NC[C@H](O)CO)cc1/C=C/c1ccc(Cl)cc1,CHEMBL1949587,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1ccc(C(=O)NC[C@H](O)CO)cc1/C=C/c1ccc(Cl)cc1,2012.0
Binding affinity to human Cdk2 by fluorescence spectroscopy,O=S(=O)(O)c1cccc2cccc(Nc3ccccc3)c12,CHEMBL1949610,=,=,Kd,nM,37000.0,Kd,uM,37.0,O=S(=O)(O)c1cccc2cccc(Nc3ccccc3)c12,2011.0
Inhibition of CDK2,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1,CHEMBL1955730,=,=,IC50,nM,794.33,pIC50,,6.1,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1,CHEMBL1955730,=,=,IC50,nM,501.19,pIC50,,6.3,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1Cl,CHEMBL1955730,=,=,IC50,nM,501.19,pIC50,,6.3,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1Cl,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1F,CHEMBL1955730,=,=,IC50,nM,501.19,pIC50,,6.3,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1F,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)c(F)c1,CHEMBL1955730,=,=,IC50,nM,5011.87,pIC50,,5.3,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)c(F)c1,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)c(C)c1,CHEMBL1955730,<,>,IC50,nM,15848.93,pIC50,,4.8,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)c(C)c1,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1-c1ccncc1,CHEMBL1955730,<,>,IC50,nM,15848.93,pIC50,,4.8,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1-c1ccncc1,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1N1CCOCC1,CHEMBL1955730,<,>,IC50,nM,15848.93,pIC50,,4.8,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1N1CCOCC1,2012.0
Inhibition of CDK2 by AlphaLISA assay,O=C(NCc1ccncc1)c1ncoc1-c1ccc(Oc2ccccc2)c(Cl)c1,CHEMBL1955730,<,>,IC50,nM,15848.93,pIC50,,4.8,O=C(NCc1ccncc1)c1ncoc1-c1ccc(Oc2ccccc2)c(Cl)c1,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cn1,CHEMBL1955730,=,=,IC50,nM,5011.87,pIC50,,5.3,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cn1,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ncc(-c2ocnc2C(=O)NCc2ccncc2)cc1Cl,CHEMBL1955730,=,=,IC50,nM,5011.87,pIC50,,5.3,COc1ncc(-c2ocnc2C(=O)NCc2ccncc2)cc1Cl,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)nc1Cl,CHEMBL1955730,<,>,IC50,nM,15848.93,pIC50,,4.8,COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)nc1Cl,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1cnc(-c2ocnc2C(=O)NCc2ccncc2)cc1Cl,CHEMBL1955730,<,>,IC50,nM,15848.93,pIC50,,4.8,COc1cnc(-c2ocnc2C(=O)NCc2ccncc2)cc1Cl,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccnc(Cl)c2)cc1Cl,CHEMBL1955730,=,=,IC50,nM,630.96,pIC50,,6.2,COc1ccc(-c2ocnc2C(=O)NCc2ccnc(Cl)c2)cc1Cl,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccnc(C)c2)cc1Cl,CHEMBL1955730,=,=,IC50,nM,1258.93,pIC50,,5.9,COc1ccc(-c2ocnc2C(=O)NCc2ccnc(C)c2)cc1Cl,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1cc(CNC(=O)c2ncoc2-c2ccc(OC)c(Cl)c2)ccn1,CHEMBL1955730,=,=,IC50,nM,630.96,pIC50,,6.2,COc1cc(CNC(=O)c2ncoc2-c2ccc(OC)c(Cl)c2)ccn1,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccnc(C(F)(F)F)c2)cc1Cl,CHEMBL1955730,=,=,IC50,nM,1995.26,pIC50,,5.7,COc1ccc(-c2ocnc2C(=O)NCc2ccnc(C(F)(F)F)c2)cc1Cl,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccnnc2)cc1Cl,CHEMBL1955730,=,=,IC50,nM,501.19,pIC50,,6.3,COc1ccc(-c2ocnc2C(=O)NCc2ccnnc2)cc1Cl,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccnc(C)n2)cc1Cl,CHEMBL1955730,=,=,IC50,nM,3162.28,pIC50,,5.5,COc1ccc(-c2ocnc2C(=O)NCc2ccnc(C)n2)cc1Cl,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCCc2ccncc2)cc1Cl,CHEMBL1955730,=,=,IC50,nM,3162.28,pIC50,,5.5,COc1ccc(-c2ocnc2C(=O)NCCc2ccncc2)cc1Cl,2012.0
Inhibition of CDK2 by AlphaLISA assay,COc1ccc(-c2ocnc2C(=O)NCc2ccn3ccnc3c2)cc1Cl,CHEMBL1955730,=,=,IC50,nM,501.19,pIC50,,6.3,COc1ccc(-c2ocnc2C(=O)NCc2ccn3ccnc3c2)cc1Cl,2012.0
Inhibition of CDK2,CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21,CHEMBL1955726,=,=,IC50,nM,3500.0,IC50,nM,3500.0,CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21,2007.0
Inhibition of CDK2,CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21,CHEMBL1955726,=,=,IC50,nM,7000.0,IC50,nM,7000.0,CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21,2007.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCC4CCNCC4)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,=,=,IC50,nM,135.0,IC50,uM,0.135,COc1ccc(-c2nc3c(NCC4CCNCC4)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(OCC4CCNCC4)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,=,=,IC50,nM,133.0,IC50,uM,0.133,COc1ccc(-c2nc3c(OCC4CCNCC4)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCNC(C)=O)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,=,=,IC50,nM,370.0,IC50,uM,0.37,COc1ccc(-c2nc3c(NCCCNC(C)=O)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCNC(=O)C(C)C)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,>,>,IC50,nM,5280.0,IC50,uM,5.28,COc1ccc(-c2nc3c(NCCCNC(=O)C(C)C)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCNC(=O)C(C)(C)C)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2nc3c(NCCCNC(=O)C(C)(C)C)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCNC(=O)C4CC4)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,=,=,IC50,nM,1370.0,IC50,uM,1.37,COc1ccc(-c2nc3c(NCCCNC(=O)C4CC4)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCNC(=O)C4(CN)CC4)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,=,=,IC50,nM,70.0,IC50,uM,0.07,COc1ccc(-c2nc3c(NCCCNC(=O)C4(CN)CC4)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,>,>,IC50,nM,4910.0,IC50,uM,4.91,COc1ccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCN(C)C(=O)C4CCC4)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,=,=,IC50,nM,187.0,IC50,uM,0.187,COc1ccc(-c2nc3c(NCCCN(C)C(=O)C4CCC4)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCNC(=O)C4CC(O)C4)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,=,=,IC50,nM,345.0,IC50,uM,0.345,COc1ccc(-c2nc3c(NCCCNC(=O)C4CC(O)C4)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,=,=,IC50,nM,2790.0,IC50,uM,2.79,COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCNC(=O)c4ccccc4)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,=,=,IC50,nM,3970.0,IC50,uM,3.97,COc1ccc(-c2nc3c(NCCCNC(=O)c4ccccc4)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCNC(=O)c4cccnc4)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,,,IC50,,,IC50,,,COc1ccc(-c2nc3c(NCCCNC(=O)c4cccnc4)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCNC(=O)c4cccs4)c(Br)cnc3[nH]2)cc1,CHEMBL2010664,,,IC50,,,IC50,,,COc1ccc(-c2nc3c(NCCCNC(=O)c4cccs4)c(Br)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,Nc1cccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)c1,CHEMBL2010664,=,=,IC50,nM,155.0,IC50,uM,0.155,Nc1cccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)c1,2012.0
Inhibition of CDK2,O=C(NCCCNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12)C1CCC1,CHEMBL2010664,=,=,IC50,nM,518.0,IC50,uM,0.518,O=C(NCCCNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12)C1CCC1,2012.0
Inhibition of CDK2,NC(=O)c1cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc2c1NCCCNC(=O)C1CCC1,CHEMBL2010664,=,=,IC50,nM,9410.0,IC50,uM,9.41,NC(=O)c1cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc2c1NCCCNC(=O)C1CCC1,2012.0
Inhibition of CDK2,COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(C(N)=O)cnc3[nH]2)cc1,CHEMBL2010664,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(C(N)=O)cnc3[nH]2)cc1,2012.0
Inhibition of CDK2,COc1ccccc1-c1nc2c(NCC(O)CNC(=O)C3CCC3)c(Br)cnc2[nH]1,CHEMBL2010664,=,=,IC50,nM,4650.0,IC50,uM,4.65,COc1ccccc1-c1nc2c(NCC(O)CNC(=O)C3CCC3)c(Br)cnc2[nH]1,2012.0
Inhibition of CDK2,COc1ccc(F)cc1-c1nc2c(NCCCNC(=O)C3CCC3)c(Br)cnc2[nH]1,CHEMBL2010664,=,=,IC50,nM,6520.0,IC50,uM,6.52,COc1ccc(F)cc1-c1nc2c(NCCCNC(=O)C3CCC3)c(Br)cnc2[nH]1,2012.0
Inhibition of CDK2,COc1cc(F)ccc1-c1nc2c(NCCCNC(=O)C3CCC3)c(Br)cnc2[nH]1,CHEMBL2010664,=,=,IC50,nM,2020.0,IC50,uM,2.02,COc1cc(F)ccc1-c1nc2c(NCCCNC(=O)C3CCC3)c(Br)cnc2[nH]1,2012.0
Inhibition of CDK2 by filter binding assay,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,CHEMBL2021894,>,>,IC50,nM,5000.0,IC50,uM,5.0,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,2011.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,COc1ccc(-c2nc(Nc3cccc(C(=O)NC4CCNC4)c3)nc3[nH]cnc23)cc1OC,CHEMBL2021910,,,IC50,,,IC50,,,COc1ccc(-c2nc(Nc3cccc(C(=O)NC4CCNC4)c3)nc3[nH]cnc23)cc1OC,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,COc1ccc(-c2nc(Nc3cccc(NC(=O)C4CCNCC4)c3)nc3[nH]cnc23)cc1OC,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2nc(Nc3cccc(NC(=O)C4CCNCC4)c3)nc3[nH]cnc23)cc1OC,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,COc1ccc(-c2nc(Nc3cccc(C(=O)NC4CCNCC4)c3)nc3[nH]cnc23)cc1OC,CHEMBL2021910,,,IC50,,,IC50,,,COc1ccc(-c2nc(Nc3cccc(C(=O)NC4CCNCC4)c3)nc3[nH]cnc23)cc1OC,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,COc1ccc(-c2nc(Nc3cccc(NC(=O)N4CCCCC4)c3)nc3[nH]cnc23)cc1,CHEMBL2021910,,,IC50,,,IC50,,,COc1ccc(-c2nc(Nc3cccc(NC(=O)N4CCCCC4)c3)nc3[nH]cnc23)cc1,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,COc1ccc(-c2nc(Nc3cccc(NC(=O)NCCN4CCOCC4)c3)nc3[nH]cnc23)cc1,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2nc(Nc3cccc(NC(=O)NCCN4CCOCC4)c3)nc3[nH]cnc23)cc1,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,COc1ccc(-c2nc(Nc3cccc(NC(=O)NCCN4CCOCC4)c3)nc3[nH]cnc23)cc1OC,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2nc(Nc3cccc(NC(=O)NCCN4CCOCC4)c3)nc3[nH]cnc23)cc1OC,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,COc1ccc(-c2nc(Nc3cccc(NC(=O)NC4CCNC4)c3)nc3[nH]cnc23)cc1,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2nc(Nc3cccc(NC(=O)NC4CCNC4)c3)nc3[nH]cnc23)cc1,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,COc1ccc(-c2nc(Nc3cccc(NC(=O)NC4CCNC4)c3)nc3[nH]cnc23)cc1OC,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2nc(Nc3cccc(NC(=O)NC4CCNC4)c3)nc3[nH]cnc23)cc1OC,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,COc1cc(-c2nc(Nc3cccc(NC(=O)N4CCCC4)c3)nc3[nH]cnc23)ccc1N,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1cc(-c2nc(Nc3cccc(NC(=O)N4CCCC4)c3)nc3[nH]cnc23)ccc1N,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,O=C(Nc1cccc(Nc2nc(-c3ccc(F)nc3)c3nc[nH]c3n2)c1)N1CCCC1,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(Nc1cccc(Nc2nc(-c3ccc(F)nc3)c3nc[nH]c3n2)c1)N1CCCC1,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,O=C(Nc1cccc(Nc2nc(-c3ccncc3)c3nc[nH]c3n2)c1)N1CCCC1,CHEMBL2021910,,,IC50,,,IC50,,,O=C(Nc1cccc(Nc2nc(-c3ccncc3)c3nc[nH]c3n2)c1)N1CCCC1,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,O=C(Nc1cccc(Nc2nc(-c3ccc4c(c3)OCO4)c3nc[nH]c3n2)c1)N1CCCC1,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(Nc1cccc(Nc2nc(-c3ccc4c(c3)OCO4)c3nc[nH]c3n2)c1)N1CCCC1,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,COc1ccc(-c2nc(Nc3cccc(NC(=O)N4CCCC4)c3)nc3[nH]cnc23)cc1OC,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2nc(Nc3cccc(NC(=O)N4CCCC4)c3)nc3[nH]cnc23)cc1OC,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,COc1ccc(-c2nc(Nc3cccc(NC(=O)N4CCCC4)c3)nc3[nH]cnc23)cc1,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2nc(Nc3cccc(NC(=O)N4CCCC4)c3)nc3[nH]cnc23)cc1,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,CN1CCN(Cc2cccc(-c3nc(Nc4cccc(Cl)c4)nc4[nH]cnc34)c2)CC1,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN1CCN(Cc2cccc(-c3nc(Nc4cccc(Cl)c4)nc4[nH]cnc34)c2)CC1,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,Oc1ccc(-c2nc(Nc3cccc(Cl)c3)nc3[nH]cnc23)cc1,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,Oc1ccc(-c2nc(Nc3cccc(Cl)c3)nc3[nH]cnc23)cc1,2012.0
Inhibition of CDK2 using RbING as substrate after 2 hrs by luminescence assay,COc1ccc(-c2nc(Nc3cccc(Cl)c3)nc3[nH]cnc23)cc1OC,CHEMBL2021910,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2nc(Nc3cccc(Cl)c3)nc3[nH]cnc23)cc1OC,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,CN1C/C=C/COCC2CCCN(C2)c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL2034857,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN1C/C=C/COCC2CCCN(C2)c2ccnc(n2)Nc2cccc(c2)C1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,CN1C/C=C/CCn2ccc3ccc(cc32)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL2034857,=,=,IC50,nM,77.0,IC50,uM,0.077,CN1C/C=C/CCn2ccc3ccc(cc32)-c2ccnc(n2)Nc2cccc(c2)C1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,C1=C/Cn2ccc3ccc(cc32)-c2ccnc(n2)Nc2cccc(c2)COC/1,CHEMBL2034857,=,=,IC50,nM,83.0,IC50,uM,0.083,C1=C/Cn2ccc3ccc(cc32)-c2ccnc(n2)Nc2cccc(c2)COC/1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,CN1C/C=C/CCOc2cc(ccn2)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL2034857,=,=,IC50,nM,22.0,IC50,uM,0.022,CN1C/C=C/CCOc2cc(ccn2)-c2ccnc(n2)Nc2cccc(c2)C1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,CN1C/C=C/COCc2cncc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL2034857,=,=,IC50,nM,420.0,IC50,uM,0.42,CN1C/C=C/COCc2cncc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,C1=C/COCc2cncc(c2)-c2ccnc(n2)Nc2cccc(c2)COC/1,CHEMBL2034857,=,=,IC50,nM,200.0,IC50,uM,0.2,C1=C/COCc2cncc(c2)-c2ccnc(n2)Nc2cccc(c2)COC/1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,CN1C/C=C/COCc2ccc(o2)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL2034857,=,=,IC50,nM,320.0,IC50,uM,0.32,CN1C/C=C/COCc2ccc(o2)-c2ccnc(n2)Nc2cccc(c2)C1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,C1=C/COCc2ccc(o2)-c2ccnc(n2)Nc2cccc(c2)COC/1,CHEMBL2034857,=,=,IC50,nM,680.0,IC50,uM,0.68,C1=C/COCc2ccc(o2)-c2ccnc(n2)Nc2cccc(c2)COC/1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,C1=C/Cn2ccc3ccc(cc32)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)COC/1,CHEMBL2034857,=,=,IC50,nM,230.0,IC50,uM,0.23,C1=C/Cn2ccc3ccc(cc32)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)COC/1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,Cc1cnc2nc1-c1ccc3ccn(c3c1)C/C=C/COCc1cc(ccc1OCCN1CCCC1)N2,CHEMBL2034857,=,=,IC50,nM,2500.0,IC50,uM,2.5,Cc1cnc2nc1-c1ccc3ccn(c3c1)C/C=C/COCc1cc(ccc1OCCN1CCCC1)N2,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cncc(c2)COC/1,CHEMBL2034857,=,=,IC50,nM,3200.0,IC50,uM,3.2,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cncc(c2)COC/1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccnc(c2)OCC/1,CHEMBL2034857,=,=,IC50,nM,270.0,IC50,uM,0.27,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccnc(c2)OCC/1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,Cc1cnc2nc1-c1ccnc(c1)OCC/C=C/COCc1cc(ccc1OCCN1CCCC1)N2,CHEMBL2034857,=,=,IC50,nM,3900.0,IC50,uM,3.9,Cc1cnc2nc1-c1ccnc(c1)OCC/C=C/COCc1cc(ccc1OCCN1CCCC1)N2,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,CN1C/C=C/COCc2ccc(o2)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)C1,CHEMBL2034857,=,=,IC50,nM,1600.0,IC50,uM,1.6,CN1C/C=C/COCc2ccc(o2)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)C1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,CN1C/C=C/COCc2ccc(s2)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)C1,CHEMBL2034857,=,=,IC50,nM,710.0,IC50,uM,0.71,CN1C/C=C/COCc2ccc(s2)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)C1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,COCCOc1ccc2cc1CN(C)C/C=C/COCc1ccc(o1)-c1ccnc(n1)N2,CHEMBL2034857,=,=,IC50,nM,8600.0,IC50,uM,8.6,COCCOc1ccc2cc1CN(C)C/C=C/COCc1ccc(o1)-c1ccnc(n1)N2,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,COCCOc1ccc2cc1CN(C)C/C=C/COCc1ccc(s1)-c1ccnc(n1)N2,CHEMBL2034857,=,=,IC50,nM,330.0,IC50,uM,0.33,COCCOc1ccc2cc1CN(C)C/C=C/COCc1ccc(s1)-c1ccnc(n1)N2,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(s2)COC/1,CHEMBL2034857,=,=,IC50,nM,2900.0,IC50,uM,2.9,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(s2)COC/1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2csc(c2)COC/1,CHEMBL2034857,=,=,IC50,nM,6800.0,IC50,uM,6.8,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2csc(c2)COC/1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1,CHEMBL2034857,=,=,IC50,nM,7000.0,IC50,uM,7.0,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2coc(c2)COC/1,CHEMBL2034857,>,>,IC50,nM,10000.0,IC50,uM,10.0,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2coc(c2)COC/1,2012.0
Inhibition of recombinant CDK2 using RbING as substrate after 2 hrs by luminometric assay,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cc(co2)COC/1,CHEMBL2034857,>,>,IC50,nM,10000.0,IC50,uM,10.0,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cc(co2)COC/1,2012.0
Inhibition of CDK2 by caliper method,CC(Oc1cc(-c2cc(-c3ccc(CN(C)C)cc3)cnc2N)ccc1C(N)=O)c1ccccc1C(F)(F)F,CHEMBL2040736,=,=,IC50,nM,2740.0,IC50,uM,2.74,CC(Oc1cc(-c2cc(-c3ccc(CN(C)C)cc3)cnc2N)ccc1C(N)=O)c1ccccc1C(F)(F)F,2012.0
Inhibition of CDK2 by caliper method,C[C@@H](/C=C\C(F)(F)F)Oc1cc(-c2cc(-c3cc(CN(C)C)cs3)cnc2N)ccc1C(N)=O,CHEMBL2040736,=,=,IC50,nM,530.0,IC50,uM,0.53,C[C@@H](/C=C\C(F)(F)F)Oc1cc(-c2cc(-c3cc(CN(C)C)cs3)cnc2N)ccc1C(N)=O,2012.0
Inhibition of CDK2 by caliper method,C[C@H](/C=C\C(F)(F)F)Oc1cc(-c2cc(-c3cc(CN(C)C)cs3)cnc2N)ccc1C(N)=O,CHEMBL2040736,=,=,IC50,nM,4570.0,IC50,uM,4.57,C[C@H](/C=C\C(F)(F)F)Oc1cc(-c2cc(-c3cc(CN(C)C)cs3)cnc2N)ccc1C(N)=O,2012.0
Inhibition of CDK2 by caliper method,C[C@@H](Oc1cc(-c2cc(-c3cc(CN(C)C)cs3)cnc2N)ccc1C(N)=O)c1ccccc1C(F)(F)F,CHEMBL2040736,=,=,IC50,nM,26600.0,IC50,uM,26.6,C[C@@H](Oc1cc(-c2cc(-c3cc(CN(C)C)cs3)cnc2N)ccc1C(N)=O)c1ccccc1C(F)(F)F,2012.0
Inhibition of CDK2 at 10 uM,O=C(Nc1ccc(Oc2ccnc(-c3ncc(C(F)(F)F)[nH]3)c2)cc1)Nc1ccc(Cl)c(C(F)(F)F)c1,CHEMBL2046400,=,=,Inhibition,%,7.8,INH,%,7.8,O=C(Nc1ccc(Oc2ccnc(-c3ncc(C(F)(F)F)[nH]3)c2)cc1)Nc1ccc(Cl)c(C(F)(F)F)c1,2012.0
Inhibition of CDK2 at 1 uM,N[C@@H]1CCCN(c2c(Br)cccc2/C=C2\SC(=O)NC2=O)C1,CHEMBL2046384,,,Inhibition,%,,INH,,,N[C@@H]1CCCN(c2c(Br)cccc2/C=C2\SC(=O)NC2=O)C1,2012.0
Inhibition of CDK2,CC(C)C[C@H]1CN(c2ccc(C(F)(F)F)c(C(=O)c3cccnc3N)n2)CCN1,CHEMBL2046282,>,>,Ki,nM,4000.0,Ki,uM,4.0,CC(C)C[C@H]1CN(c2ccc(C(F)(F)F)c(C(=O)c3cccnc3N)n2)CCN1,2012.0
Inhibition of CDK2,CC(=O)Nc1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,CHEMBL2062503,=,=,IC50,nM,26000.0,IC50,uM,26.0,CC(=O)Nc1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,2012.0
Inhibition of CDK2,CC(=O)Nc1ccc2cnn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,CHEMBL2062503,>,>,IC50,nM,30000.0,IC50,uM,30.0,CC(=O)Nc1ccc2cnn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,2012.0
Inhibition of CDK2,CC(=O)Nc1cnc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,CHEMBL2062503,>,>,IC50,nM,30000.0,IC50,uM,30.0,CC(=O)Nc1cnc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,2012.0
Inhibition of CDK2,CC(=O)Nc1ccc2ccn(-c3cc(NCCCN(C)C)n4ncc(C#N)c4n3)c2c1,CHEMBL2062503,>,>,IC50,nM,30000.0,IC50,uM,30.0,CC(=O)Nc1ccc2ccn(-c3cc(NCCCN(C)C)n4ncc(C#N)c4n3)c2c1,2012.0
Inhibition of CDK2,CC(=O)N(C)c1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,CHEMBL2062503,>,>,IC50,nM,30000.0,IC50,uM,30.0,CC(=O)N(C)c1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,2012.0
Inhibition of CDK2,CC(=O)Nc1ccc2[nH]cc(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,CHEMBL2062503,=,=,IC50,nM,14000.0,IC50,uM,14.0,CC(=O)Nc1ccc2[nH]cc(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1,2012.0
Inhibition of CDK2,CC(=O)Nc1ccc2c(c1)c(-c1cc(NC3CC3)n3ncc(C#N)c3n1)cn2CCC(=O)O,CHEMBL2062503,>,>,IC50,nM,30000.0,IC50,uM,30.0,CC(=O)Nc1ccc2c(c1)c(-c1cc(NC3CC3)n3ncc(C#N)c3n1)cn2CCC(=O)O,2012.0
Inhibition of human recombinant CDK2 using ulight CFFKNIVTPRTPPPSQGK-amide as substrate assessed as residual activity at 1 uM after 30 mins by Cerep assay,N#Cc1ccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCO5)o3)cc2)cc1,CHEMBL2062370,>,>,Activity,%,80.0,Activity,%,80.0,N#Cc1ccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCO5)o3)cc2)cc1,2012.0
Inhibition of CDK2,CN(C)C[C@@H](NC(=O)c1ccc2[nH]nc(-c3nc4ccccc4[nH]3)c2c1)c1ccccc1,CHEMBL2062373,=,=,Ki,nM,3.4,Ki,uM,0.0034,CN(C)C[C@@H](NC(=O)c1ccc2[nH]nc(-c3nc4ccccc4[nH]3)c2c1)c1ccccc1,2012.0
Inhibition of CDK2 at 1 uM,CN1CCN(C(=O)N2Cc3c(NC(=O)c4cccc(Oc5ccccc5)c4)n[nH]c3C2(C)C)[C@@H](Cc2ccccc2)C1,CHEMBL2062373,=,=,Inhibition,%,20.0,INH,%,20.0,CN1CCN(C(=O)N2Cc3c(NC(=O)c4cccc(Oc5ccccc5)c4)n[nH]c3C2(C)C)[C@@H](Cc2ccccc2)C1,2012.0
Inhibition of CDK2,CN(C)C[C@@H](NC(=O)N1Cc2c(NC(=O)c3ccccc3)n[nH]c2C1(C)C)c1ccccc1,CHEMBL2062373,=,=,Ki,nM,1800.0,Ki,uM,1.8,CN(C)C[C@@H](NC(=O)N1Cc2c(NC(=O)c3ccccc3)n[nH]c2C1(C)C)c1ccccc1,2012.0
Inhibition of CDK2,CN(C)C[C@@H](OC(=O)N1Cc2c(NC(=O)c3ccccc3)n[nH]c2C1(C)C)c1ccccc1,CHEMBL2062373,=,=,Ki,nM,2000.0,Ki,uM,2.0,CN(C)C[C@@H](OC(=O)N1Cc2c(NC(=O)c3ccccc3)n[nH]c2C1(C)C)c1ccccc1,2012.0
Inhibition of CDK2,CN(C)C[C@@H](OC(=O)N1Cc2c(NC(=O)c3ccc(F)cc3)n[nH]c2C1(C)C)c1ccccc1,CHEMBL2062373,=,=,Ki,nM,1160.0,Ki,uM,1.16,CN(C)C[C@@H](OC(=O)N1Cc2c(NC(=O)c3ccc(F)cc3)n[nH]c2C1(C)C)c1ccccc1,2012.0
Inhibition of CDK2,CN(C)C[C@@H](OC(=O)N1Cc2c(NC(=O)C(C)(C)C)n[nH]c2C1(C)C)c1ccccc1,CHEMBL2062373,=,=,IC50,nM,450.0,IC50,nM,450.0,CN(C)C[C@@H](OC(=O)N1Cc2c(NC(=O)C(C)(C)C)n[nH]c2C1(C)C)c1ccccc1,2012.0
Inhibition of CDK2A at 10 uM,ClC(Cn1ncc2c(NCc3ccccc3)ncnc21)c1ccccc1,CHEMBL2069178,=,=,Inhibition,%,8.0,INH,%,8.0,ClC(Cn1ncc2c(NCc3ccccc3)ncnc21)c1ccccc1,2012.0
Inhibition of CDK2,Cn1c2ccccc2c2c3c(c4c5ccccc5n(CC(O)CO)c4c21)C(=O)NC3=O,CHEMBL2086254,<,<,IC50,nM,60.0,IC50,uM,0.06,Cn1c2ccccc2c2c3c(c4c5ccccc5n(CC(O)CO)c4c21)C(=O)NC3=O,2012.0
Inhibition of CDK2,Cn1cc(C2=C(c3cn(CC(O)CO)c4ccccc34)C(=O)NC2=O)c2ccccc21,CHEMBL2086254,=,=,IC50,nM,1610.0,IC50,uM,1.61,Cn1cc(C2=C(c3cn(CC(O)CO)c4ccccc34)C(=O)NC2=O)c2ccccc21,2012.0
Inhibition of CDK2,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(N)(=O)=O)c4)n3)ccn2)cc1,CHEMBL2157945,,,IC50,,,IC50,,,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(N)(=O)=O)c4)n3)ccn2)cc1,2012.0
Inhibition of CDK2,CN1CCN(c2cc(-c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccn2)CC1,CHEMBL2157945,,,IC50,,,IC50,,,CN1CCN(c2cc(-c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccn2)CC1,2012.0
Inhibition of CDK2,c1ccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)cc1,CHEMBL2157945,,,IC50,,,IC50,,,c1ccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)cc1,2012.0
Inhibition of CDK2,N#Cc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1,CHEMBL2157945,,,IC50,,,IC50,,,N#Cc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1,2012.0
Inhibition of CDK2,COc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1,CHEMBL2157945,,,IC50,,,IC50,,,COc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1,2012.0
Inhibition of CDK2,FC(F)(F)c1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1,CHEMBL2157945,,,IC50,,,IC50,,,FC(F)(F)c1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1,2012.0
Inhibition of CDK2,NS(=O)(=O)c1ccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)cc1,CHEMBL2157945,,,IC50,,,IC50,,,NS(=O)(=O)c1ccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)cc1,2012.0
Inhibition of CDK2,Clc1ccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)cc1,CHEMBL2157945,,,IC50,,,IC50,,,Clc1ccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)cc1,2012.0
Inhibition of CDK2,CCN(CC)c1cc(-c2ccnc(Nc3cccc(S(N)(=O)=O)c3)n2)ccn1,CHEMBL2157945,<,<,IC50,nM,5.2,IC50,uM,0.0052,CCN(CC)c1cc(-c2ccnc(Nc3cccc(S(N)(=O)=O)c3)n2)ccn1,2012.0
Inhibition of CDK2,OCCCNc1cc(-c2ccnc(Nc3cccc(Cl)c3)n2)ccn1,CHEMBL2157945,<,<,IC50,nM,5.2,IC50,uM,0.0052,OCCCNc1cc(-c2ccnc(Nc3cccc(Cl)c3)n2)ccn1,2012.0
Inhibition of CDK2,CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1Cl,CHEMBL2157945,=,=,IC50,nM,7100.0,IC50,uM,7.1,CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1Cl,2012.0
Inhibition of CDK2,CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1C,CHEMBL2157945,=,=,IC50,nM,3000.0,IC50,uM,3.0,CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1C,2012.0
Inhibition of CDK2,CCN(CC)S(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)c1,CHEMBL2157945,=,=,IC50,nM,560.0,IC50,uM,0.56,CCN(CC)S(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)c1,2012.0
Inhibition of CDK2,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(Cl)c(S(=O)(=O)N(C)C)c4)n3)ccn2)cc1,CHEMBL2157945,=,=,IC50,nM,520.0,IC50,uM,0.52,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(Cl)c(S(=O)(=O)N(C)C)c4)n3)ccn2)cc1,2012.0
Inhibition of CDK2,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(=O)(=O)N(C)C)c4)n3)ccn2)cc1,CHEMBL2157945,=,=,IC50,nM,460.0,IC50,uM,0.46,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(=O)(=O)N(C)C)c4)n3)ccn2)cc1,2012.0
Inhibition of CDK2,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(Cl)c(S(=O)(=O)NC)c4)n3)ccn2)cc1,CHEMBL2157945,=,=,IC50,nM,140.0,IC50,uM,0.14,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(Cl)c(S(=O)(=O)NC)c4)n3)ccn2)cc1,2012.0
Inhibition of CDK2,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(=O)(=O)NC)c4)n3)ccn2)cc1,CHEMBL2157945,=,=,IC50,nM,110.0,IC50,uM,0.11,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(=O)(=O)NC)c4)n3)ccn2)cc1,2012.0
Inhibition of CDK2,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4cccc(S(=O)(=O)NC)c4)n3)ccn2)cc1,CHEMBL2157945,=,=,IC50,nM,100.0,IC50,uM,0.1,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4cccc(S(=O)(=O)NC)c4)n3)ccn2)cc1,2012.0
Inhibition of CDK2,Cc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1,CHEMBL2157945,=,=,IC50,nM,46.0,IC50,uM,0.046,Cc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1,2012.0
Inhibition of CDK2,NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4C5CCC4COC5)c3)n2)c1,CHEMBL2157945,=,=,IC50,nM,31.0,IC50,uM,0.031,NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4C5CCC4COC5)c3)n2)c1,2012.0
Inhibition of CDK2,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccn2)cc1,CHEMBL2157945,=,=,IC50,nM,23.0,IC50,uM,0.023,CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccn2)cc1,2012.0
Inhibition of CDK2,NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4CC5CCC(C4)O5)c3)n2)c1,CHEMBL2157945,=,=,IC50,nM,21.0,IC50,uM,0.021,NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4CC5CCC(C4)O5)c3)n2)c1,2012.0
Inhibition of CDK2,NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1,CHEMBL2157945,=,=,IC50,nM,19.0,IC50,uM,0.019,NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1,2012.0
Inhibition of CDK2,NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4CCCCC4)c3)n2)c1,CHEMBL2157945,=,=,IC50,nM,16.0,IC50,uM,0.016,NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4CCCCC4)c3)n2)c1,2012.0
Inhibition of CDK2,Clc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1,CHEMBL2157945,=,=,IC50,nM,8.9,IC50,uM,0.0089,Clc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1,2012.0
Inhibition of CDK2,NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(NCCCO)c3)n2)c1,CHEMBL2157945,=,=,IC50,nM,6.7,IC50,uM,0.0067,NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(NCCCO)c3)n2)c1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,CCOc1ccc(Nc2c(C)c(N[C@@H]3CCCNC3)nc3ccnn23)cc1,CHEMBL2163300,>,>,IC50,nM,100000.0,IC50,uM,100.0,CCOc1ccc(Nc2c(C)c(N[C@@H]3CCCNC3)nc3ccnn23)cc1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,CCc1c(N[C@H]2CC[C@H](N)CC2)nc2ccnn2c1Nc1ccccc1Cl,CHEMBL2163300,>,>,IC50,nM,300000.0,IC50,uM,300.0,CCc1c(N[C@H]2CC[C@H](N)CC2)nc2ccnn2c1Nc1ccccc1Cl,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,Cc1c(N[C@H]2CC[C@H](N)CC2)nc2ccnn2c1Nc1ccccc1Cl,CHEMBL2163300,=,=,IC50,nM,6400.0,IC50,uM,6.4,Cc1c(N[C@H]2CC[C@H](N)CC2)nc2ccnn2c1Nc1ccccc1Cl,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,N[C@H]1CC[C@H](Nc2cc(Nc3ccccc3Cl)n3nccc3n2)CC1,CHEMBL2163300,=,=,IC50,nM,390.0,IC50,uM,0.39,N[C@H]1CC[C@H](Nc2cc(Nc3ccccc3Cl)n3nccc3n2)CC1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,Cc1nc2ccc(Nc3c(C)c(N[C@H]4CCCNC4)nc4ccnn34)cc2s1,CHEMBL2163300,=,=,IC50,nM,25000.0,IC50,uM,25.0,Cc1nc2ccc(Nc3c(C)c(N[C@H]4CCCNC4)nc4ccnn34)cc2s1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,Cc1c(N[C@H]2CCCNC2)nc2ccnn2c1Nc1ccc2c(cnn2C)c1,CHEMBL2163300,=,=,IC50,nM,27000.0,IC50,uM,27.0,Cc1c(N[C@H]2CCCNC2)nc2ccnn2c1Nc1ccc2c(cnn2C)c1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,CC(=O)c1ccc(-c2ccc(Nc3c(C)c(N[C@H]4CCCNC4)nc4ccnn34)cc2)s1,CHEMBL2163300,=,=,IC50,nM,21000.0,IC50,uM,21.0,CC(=O)c1ccc(-c2ccc(Nc3c(C)c(N[C@H]4CCCNC4)nc4ccnn34)cc2)s1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,Cc1c(N[C@H]2CCCNC2)nc2ccnn2c1Nc1ccc(C(=O)NC2CCCC2)cc1,CHEMBL2163300,=,=,IC50,nM,49000.0,IC50,uM,49.0,Cc1c(N[C@H]2CCCNC2)nc2ccnn2c1Nc1ccc(C(=O)NC2CCCC2)cc1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,Cc1c(N[C@H]2CCCNC2)nc2ccnn2c1Nc1ccc(OCCN2CCOCC2)cc1,CHEMBL2163300,=,=,IC50,nM,62000.0,IC50,uM,62.0,Cc1c(N[C@H]2CCCNC2)nc2ccnn2c1Nc1ccc(OCCN2CCOCC2)cc1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,COCCOc1ccc(Nc2c(C)c(N[C@H]3CCCNC3)nc3ccnn23)cc1,CHEMBL2163300,=,=,IC50,nM,22000.0,IC50,uM,22.0,COCCOc1ccc(Nc2c(C)c(N[C@H]3CCCNC3)nc3ccnn23)cc1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,CCOc1ccc(Nc2c(C)c(N[C@H]3CCCNC3)nc3ccnn23)cc1,CHEMBL2163300,=,=,IC50,nM,23000.0,IC50,uM,23.0,CCOc1ccc(Nc2c(C)c(N[C@H]3CCCNC3)nc3ccnn23)cc1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,CCc1c(NC2CCCNC2)nc2ccnn2c1Nc1ccc(F)c(Cl)c1,CHEMBL2163300,=,=,IC50,nM,24000.0,IC50,uM,24.0,CCc1c(NC2CCCNC2)nc2ccnn2c1Nc1ccc(F)c(Cl)c1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,Cc1c(NC2CCCNC2)nc2ccnn2c1Nc1ccc(F)c(Cl)c1,CHEMBL2163300,=,=,IC50,nM,33000.0,IC50,uM,33.0,Cc1c(NC2CCCNC2)nc2ccnn2c1Nc1ccc(F)c(Cl)c1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,Fc1ccc(Nc2cc(NC3CCCNC3)nc3ccnn23)cc1Cl,CHEMBL2163300,=,=,IC50,nM,700.0,IC50,uM,0.7,Fc1ccc(Nc2cc(NC3CCCNC3)nc3ccnn23)cc1Cl,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,N[C@H]1CC[C@H](Nc2nc3ccnn3c(Nc3ccc(F)c(Cl)c3)c2-c2ccccc2)CC1,CHEMBL2163300,=,=,IC50,nM,6000.0,IC50,uM,6.0,N[C@H]1CC[C@H](Nc2nc3ccnn3c(Nc3ccc(F)c(Cl)c3)c2-c2ccccc2)CC1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,CCCc1c(N[C@H]2CC[C@H](N)CC2)nc2ccnn2c1Nc1ccc(F)c(Cl)c1,CHEMBL2163300,=,=,IC50,nM,2100.0,IC50,uM,2.1,CCCc1c(N[C@H]2CC[C@H](N)CC2)nc2ccnn2c1Nc1ccc(F)c(Cl)c1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,CCc1c(N[C@H]2CC[C@H](N)CC2)nc2ccnn2c1Nc1ccc(F)c(Cl)c1,CHEMBL2163300,=,=,IC50,nM,3600.0,IC50,uM,3.6,CCc1c(N[C@H]2CC[C@H](N)CC2)nc2ccnn2c1Nc1ccc(F)c(Cl)c1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,Cc1c(N[C@H]2CC[C@H](N)CC2)nc2ccnn2c1Nc1ccc(F)c(Cl)c1,CHEMBL2163300,=,=,IC50,nM,11000.0,IC50,uM,11.0,Cc1c(N[C@H]2CC[C@H](N)CC2)nc2ccnn2c1Nc1ccc(F)c(Cl)c1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,N[C@H]1CC[C@H](Nc2cc(Nc3ccc(F)c(Cl)c3)n3ncc(Br)c3n2)CC1,CHEMBL2163300,=,=,IC50,nM,3.4,IC50,uM,0.0034,N[C@H]1CC[C@H](Nc2cc(Nc3ccc(F)c(Cl)c3)n3ncc(Br)c3n2)CC1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,N[C@H]1CC[C@H](Nc2cc(Nc3ccc(F)c(Cl)c3)n3ncc(Cl)c3n2)CC1,CHEMBL2163300,=,=,IC50,nM,3.0,IC50,uM,0.003,N[C@H]1CC[C@H](Nc2cc(Nc3ccc(F)c(Cl)c3)n3ncc(Cl)c3n2)CC1,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,N#Cc1cnn2c(Nc3ccc(F)c(Cl)c3)cc(N[C@H]3CC[C@H](N)CC3)nc12,CHEMBL2163300,=,=,IC50,nM,4.0,IC50,uM,0.004,N#Cc1cnn2c(Nc3ccc(F)c(Cl)c3)cc(N[C@H]3CC[C@H](N)CC3)nc12,2012.0
Inhibition of CDK2 after 60 mins using [33P]-gamma-ATP by liquid scintillation counter,N[C@H]1CC[C@H](Nc2cc(Nc3ccc(F)c(Cl)c3)n3nccc3n2)CC1,CHEMBL2163300,=,=,IC50,nM,55.0,IC50,uM,0.055,N[C@H]1CC[C@H](Nc2cc(Nc3ccc(F)c(Cl)c3)n3nccc3n2)CC1,2012.0
Inhibition of human CDK2,O=C(CBr)N(c1ccccc1)S(=O)(=O)c1cc(Cl)sc1Cl,CHEMBL2169756,>,>,IC50,nM,20000.0,IC50,uM,20.0,O=C(CBr)N(c1ccccc1)S(=O)(=O)c1cc(Cl)sc1Cl,2012.0
Inhibition of human recombinant CDK2 by radiometric kinase assay,CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccccc5)n(C5CCCC5)c4n3)cc2)CC1,CHEMBL2177100,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccccc5)n(C5CCCC5)c4n3)cc2)CC1,2012.0
Binding affinity to CDK2 at 1 uM,Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1,CHEMBL2203208,<,<,Activity,%,50.0,Activity,%,50.0,Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1,2012.0
Inhibition of CDK2 assessed as residual activity at 10 uM relative to control,O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1,CHEMBL2203081,=,=,Activity,%,53.0,Activity,%,53.0,O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1,2012.0
Inhibition of CDK2,CN(c1ccc(F)c(NC(=O)c2cccc(OC(C)(C)C#N)c2Cl)c1)c1ccc2nc(NC(=O)C3CC3)sc2n1,CHEMBL2203033,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CN(c1ccc(F)c(NC(=O)c2cccc(OC(C)(C)C#N)c2Cl)c1)c1ccc2nc(NC(=O)C3CC3)sc2n1,2012.0
Inhibition of CDK2,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,CHEMBL2203257,<,>,IC50,nM,10000.0,pIC50,,5.0,CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1,2012.0
Inhibition of CDK2,O=S1(=O)NCCCNc2nc(ncc2Br)Nc2cccc1c2,CHEMBL2203227,=,=,IC50,nM,140.0,IC50,nM,140.0,O=S1(=O)NCCCNc2nc(ncc2Br)Nc2cccc1c2,2011.0
Inhibition of CDK2,C[C@@H]1C[C@H]2CN1CCn1nc3c(cccc3c1O)-c1nc3c(cccc3nc1O)O2,CHEMBL2203227,=,=,IC50,nM,3.4,IC50,nM,3.4,C[C@@H]1C[C@H]2CN1CCn1nc3c(cccc3c1O)-c1nc3c(cccc3nc1O)O2,2011.0
Inhibition of CDK2,N#CCNc1nc(Nc2ccccc2)ncc1Br,CHEMBL2203227,=,=,IC50,nM,100.0,IC50,nM,100.0,N#CCNc1nc(Nc2ccccc2)ncc1Br,2011.0
Inhibition of CDK2,Cn1cc(Nc2ncc(C3CC3)c(NCCCNC(=O)C3CCC3)n2)cn1,CHEMBL2203069,=,=,IC50,nM,110.0,IC50,uM,0.11,Cn1cc(Nc2ncc(C3CC3)c(NCCCNC(=O)C3CCC3)n2)cn1,2012.0
Inhibition of CDK2,O=C(NCCCNc1nc(Nc2ccc(N3CCOCC3)cc2)ncc1C1CC1)C1CCC1,CHEMBL2203069,=,=,IC50,nM,630.0,IC50,uM,0.63,O=C(NCCCNc1nc(Nc2ccc(N3CCOCC3)cc2)ncc1C1CC1)C1CCC1,2012.0
Inhibition of CDK2,COc1cc(Br)c(C[C@H](C(=O)[O-])[N+](C)(C)C)c(Br)c1,CHEMBL2203016,>,>,IC50,ug.mL-1,50.0,IC50,ug ml-1,50.0,COc1cc(Br)c(C[C@H](C(=O)[O-])[N+](C)(C)C)c(Br)c1,2012.0
Inhibition of CDK2,C[N+](C)(C)[C@H](Cc1cc(Br)c(O)c(I)c1)C(=O)[O-],CHEMBL2203016,>,>,IC50,ug.mL-1,50.0,IC50,ug ml-1,50.0,C[N+](C)(C)[C@H](Cc1cc(Br)c(O)c(I)c1)C(=O)[O-],2012.0
Inhibition of CDK2,COc1c(Br)cc(C[C@H](C(=O)[O-])[N+](C)(C)C)cc1I,CHEMBL2203016,>,>,IC50,ug.mL-1,50.0,IC50,ug ml-1,50.0,COc1c(Br)cc(C[C@H](C(=O)[O-])[N+](C)(C)C)cc1I,2012.0
Inhibition of CDK2,C[N+](C)(C)[C@H](Cc1cc(I)c(O)c(I)c1)C(=O)[O-],CHEMBL2203016,>,>,IC50,ug.mL-1,50.0,IC50,ug ml-1,50.0,C[N+](C)(C)[C@H](Cc1cc(I)c(O)c(I)c1)C(=O)[O-],2012.0
Inhibition of CDK2,COc1c(I)cc(C[C@H](C(=O)[O-])[N+](C)(C)C)cc1I,CHEMBL2203016,>,>,IC50,ug.mL-1,50.0,IC50,ug ml-1,50.0,COc1c(I)cc(C[C@H](C(=O)[O-])[N+](C)(C)C)cc1I,2012.0
Inhibition of CDK2,C[N+](C)(C)[C@H](CCOc1c(Br)cc(Br)cc1I)C(=O)[O-],CHEMBL2203016,>,>,IC50,ug.mL-1,50.0,IC50,ug ml-1,50.0,C[N+](C)(C)[C@H](CCOc1c(Br)cc(Br)cc1I)C(=O)[O-],2012.0
Inhibition of CDK2,C[N+](C)(C)[C@H](CCOc1c(Cl)cc(Br)cc1Cl)C(=O)[O-],CHEMBL2203016,>,>,IC50,ug.mL-1,50.0,IC50,ug ml-1,50.0,C[N+](C)(C)[C@H](CCOc1c(Cl)cc(Br)cc1Cl)C(=O)[O-],2012.0
Inhibition of CDK2,C[N+](C)(C)[C@H](CCOc1ccc(Br)cc1Br)C(=O)[O-],CHEMBL2203016,>,>,IC50,ug.mL-1,50.0,IC50,ug ml-1,50.0,C[N+](C)(C)[C@H](CCOc1ccc(Br)cc1Br)C(=O)[O-],2012.0
Inhibition of CDK2,C[N+](C)(C)[C@H](CCOc1c(Br)cc(Br)cc1Br)C(=O)[O-],CHEMBL2203016,>,>,IC50,ug.mL-1,50.0,IC50,ug ml-1,50.0,C[N+](C)(C)[C@H](CCOc1c(Br)cc(Br)cc1Br)C(=O)[O-],2012.0
Inhibition of CDK2,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL2203016,=,=,IC50,ug.mL-1,11.76,IC50,ug ml-1,11.76,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2012.0
Inhibition of CDK2 (unknown origin),CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,CHEMBL3046684,=,=,IC50,nM,30.0,IC50,uM,0.03,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,2010.0
Inhibition of CDK2 (unknown origin),CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL3046684,=,=,IC50,nM,0.1,IC50,uM,0.0001,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2010.0
Destabilization of CDK2 in Homo sapiens (human) IMR32 cells by immunoblot analysis,COc1c(-c2cc(-c3ccccc3)n(-c3ccccc3F)n2)ccc2occc12,CHEMBL3046914,,,Activity,,,Activity,,,COc1c(-c2cc(-c3ccccc3)n(-c3ccccc3F)n2)ccc2occc12,2012.0
Destabilization of CDK2 in Homo sapiens (human) IMR32 cells by immunoblot analysis,COc1c(-c2cc(-c3ccccc3)n(-c3cccc(F)c3)n2)ccc2occc12,CHEMBL3046914,,,Activity,,,Activity,,,COc1c(-c2cc(-c3ccccc3)n(-c3cccc(F)c3)n2)ccc2occc12,2012.0
Destabilization of CDK2 in Homo sapiens (human) IMR32 cells by immunoblot analysis,COc1c(-c2cc(-c3ccccc3)on2)ccc2occc12,CHEMBL3046914,,,Activity,,,Activity,,,COc1c(-c2cc(-c3ccccc3)on2)ccc2occc12,2012.0
Destabilization of CDK2 in Homo sapiens (human) HeLa cells by immunoblot analysis,COc1c(-c2cc(-c3ccccc3)n(-c3ccccc3F)n2)ccc2occc12,CHEMBL3046914,,,Activity,,,Activity,,,COc1c(-c2cc(-c3ccccc3)n(-c3ccccc3F)n2)ccc2occc12,2012.0
Destabilization of CDK2 in Homo sapiens (human) HeLa cells by immunoblot analysis,COc1c(-c2cc(-c3ccccc3)n(-c3cccc(F)c3)n2)ccc2occc12,CHEMBL3046914,,,Activity,,,Activity,,,COc1c(-c2cc(-c3ccccc3)n(-c3cccc(F)c3)n2)ccc2occc12,2012.0
Destabilization of CDK2 in Homo sapiens (human) HeLa cells by immunoblot analysis,COc1c(-c2cc(-c3ccccc3)on2)ccc2occc12,CHEMBL3046914,,,Activity,,,Activity,,,COc1c(-c2cc(-c3ccccc3)on2)ccc2occc12,2012.0
Destabilization of CDK2 in Homo sapiens (human) Jurkat cells by immunoblot analysis,COc1c(-c2cc(-c3ccccc3)n(-c3ccccc3F)n2)ccc2occc12,CHEMBL3046914,,,Activity,,,Activity,,,COc1c(-c2cc(-c3ccccc3)n(-c3ccccc3F)n2)ccc2occc12,2012.0
Destabilization of CDK2 in Homo sapiens (human) Jurkat cells by immunoblot analysis,COc1c(-c2cc(-c3ccccc3)n(-c3cccc(F)c3)n2)ccc2occc12,CHEMBL3046914,,,Activity,,,Activity,,,COc1c(-c2cc(-c3ccccc3)n(-c3cccc(F)c3)n2)ccc2occc12,2012.0
Destabilization of CDK2 in Homo sapiens (human) Jurkat cells by immunoblot analysis,COc1c(-c2cc(-c3ccccc3)on2)ccc2occc12,CHEMBL3046914,,,Activity,,,Activity,,,COc1c(-c2cc(-c3ccccc3)on2)ccc2occc12,2012.0
Inhibition of human CDK2 after 30 mins by scintillation counting analysis,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL2311463,=,=,Ki,nM,190.0,Ki,nM,190.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2013.0
Inhibition of human CDK2 after 30 mins by scintillation counting analysis,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,CHEMBL2311463,=,=,Ki,nM,38.0,Ki,nM,38.0,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,2013.0
Inhibition of human CDK2 after 30 mins by scintillation counting analysis,CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4)oc23)[C@@H]1CO.Cl,CHEMBL2311463,<,<,Ki,nM,100.0,Ki,nM,100.0,CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4)oc23)[C@@H]1CO.Cl,2013.0
Inhibition of CDK2 (unknown origin) at 1 uM,CC(C)(C)[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1,CHEMBL2321829,=,=,Inhibition,%,44.0,INH,%,44.0,CC(C)(C)[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1,2013.0
Inhibition of CDK2 (unknown origin) at 1 uM,C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1,CHEMBL2321829,=,=,Inhibition,%,65.0,INH,%,65.0,C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1,2013.0
Inhibition of CDK2 (unknown origin) at 1 uM,C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C#N,CHEMBL2321829,=,=,Inhibition,%,81.0,INH,%,81.0,C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C#N,2013.0
Inhibition of CDK2 (unknown origin) at 1 uM,C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C,CHEMBL2321829,=,=,Inhibition,%,84.0,INH,%,84.0,C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C,2013.0
Inhibition of CDK2 (unknown origin) at 10 uM,C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1,CHEMBL2321829,=,=,Inhibition,%,96.0,INH,%,96.0,C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1,2013.0
Inhibition of CDK2 (unknown origin) at 10 uM,C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)O,CHEMBL2321829,=,=,Inhibition,%,95.0,INH,%,95.0,C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)O,2013.0
Inhibition of CDK2 (unknown origin) at 10 uM,CC(C)NC(=O)c1c[nH]c2ncc(C3CC3)nc12,CHEMBL2321829,=,=,Inhibition,%,92.0,INH,%,92.0,CC(C)NC(=O)c1c[nH]c2ncc(C3CC3)nc12,2013.0
Inhibition of CDK2 (unknown origin),COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2,CHEMBL2321712,=,=,IC50,nM,1330.0,IC50,uM,1.33,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2,2013.0
Inhibition of CDK2 (unknown origin),Cc1[nH]nc2c1N=C(c1ccccc1Cl)c1cc(N)ccc1N2,CHEMBL2321712,=,=,IC50,nM,88.0,IC50,uM,0.088,Cc1[nH]nc2c1N=C(c1ccccc1Cl)c1cc(N)ccc1N2,2013.0
Inhibition of CDK2 kinase (unknown origin) using [33P]-ATP at 10 uM after 20 to 40 mins by scintillation counting analysis,O=C(Nc1ccc(Cl)cc1)Nc1ccc2c(c1)C(Nc1ccc(Cl)cc1Cl)=NS2(=O)=O,CHEMBL2331514,=,=,Inhibition,%,-53.0,INH,%,-53.0,O=C(Nc1ccc(Cl)cc1)Nc1ccc2c(c1)C(Nc1ccc(Cl)cc1Cl)=NS2(=O)=O,2013.0
Inhibition of CDK2 (unknown origin),O=C(Nc1ccc(Oc2ncnc3[nH]ncc23)cc1)Nc1ccc(Cl)c(C(F)(F)F)c1,CHEMBL2331331,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(Nc1ccc(Oc2ncnc3[nH]ncc23)cc1)Nc1ccc(Cl)c(C(F)(F)F)c1,2013.0
Inhibition of CDK2 (unknown origin) at 1 uM,Cc1ccc(-c2ccc3ncc4c(c3n2)n(C2CCN(C(=O)[C@H](C)O)CC2)c(=O)n4C)cn1,CHEMBL2331555,=,=,Inhibition,%,0.5,INH,%,0.5,Cc1ccc(-c2ccc3ncc4c(c3n2)n(C2CCN(C(=O)[C@H](C)O)CC2)c(=O)n4C)cn1,2013.0
Inhibition of CDK2 (unknown origin) at 1 uM relative to control,CCNC(=O)Nc1nc2ccc(-c3ccccc3OC)cc2s1,CHEMBL2346496,=,=,Inhibition,%,100.0,INH,%,100.0,CCNC(=O)Nc1nc2ccc(-c3ccccc3OC)cc2s1,2013.0
Inhibition of CDK2 (unknown origin) at 1 uM relative to control,CN(C)CCC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,CHEMBL2346524,=,=,Inhibition,%,-4.0,INH,%,-4.0,CN(C)CCC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,2013.0
Inhibition of CDK2 (unknown origin),N#Cc1ccc2ccn(-c3cc(N)ncn3)c2n1,CHEMBL2346586,>,>,IC50,nM,83000.0,IC50,uM,83.0,N#Cc1ccc2ccn(-c3cc(N)ncn3)c2n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2cc(-c3cccnc3Cl)c3cnc(Cl)cc32)n1,CHEMBL2346586,>,>,IC50,nM,83000.0,IC50,uM,83.0,Nc1nccc(-n2cc(-c3cccnc3Cl)c3cnc(Cl)cc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2cc(-c3cccnc3Cl)c3cnccc32)n1,CHEMBL2346586,=,=,IC50,nM,310.0,IC50,uM,0.31,Nc1nccc(-n2cc(-c3cccnc3Cl)c3cnccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2cc(-c3ccc(Cl)cc3)c3cnccc32)n1,CHEMBL2346586,=,=,IC50,nM,60.0,IC50,uM,0.06,Nc1nccc(-n2cc(-c3ccc(Cl)cc3)c3cnccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2cc(-c3cccc(Cl)c3)c3cnccc32)n1,CHEMBL2346586,>,>,IC50,nM,83000.0,IC50,uM,83.0,Nc1nccc(-n2cc(-c3cccc(Cl)c3)c3cnccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2cc(-c3ccccc3Cl)c3cnccc32)n1,CHEMBL2346586,=,=,IC50,nM,110.0,IC50,uM,0.11,Nc1nccc(-n2cc(-c3ccccc3Cl)c3cnccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2cc(C3=CCOCC3)c3cnccc32)n1,CHEMBL2346586,=,=,IC50,nM,160.0,IC50,uM,0.16,Nc1nccc(-n2cc(C3=CCOCC3)c3cnccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2cc(-c3ccoc3)c3cnccc32)n1,CHEMBL2346586,=,=,IC50,nM,100.0,IC50,uM,0.1,Nc1nccc(-n2cc(-c3ccoc3)c3cnccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2cc(-c3cc[nH]n3)c3cnccc32)n1,CHEMBL2346586,=,=,IC50,nM,550.0,IC50,uM,0.55,Nc1nccc(-n2cc(-c3cc[nH]n3)c3cnccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2cc(-c3ccncc3)c3cnccc32)n1,CHEMBL2346586,=,=,IC50,nM,160.0,IC50,uM,0.16,Nc1nccc(-n2cc(-c3ccncc3)c3cnccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2cc(-c3cccnc3)c3cnccc32)n1,CHEMBL2346586,=,=,IC50,nM,1100.0,IC50,uM,1.1,Nc1nccc(-n2cc(-c3cccnc3)c3cnccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2cc(-c3ccccc3)c3cnccc32)n1,CHEMBL2346586,=,=,IC50,nM,310.0,IC50,uM,0.31,Nc1nccc(-n2cc(-c3ccccc3)c3cnccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),N#Cc1cnc2ccn(-c3ccnc(N)n3)c2c1,CHEMBL2346586,>,>,IC50,nM,83000.0,IC50,uM,83.0,N#Cc1cnc2ccn(-c3ccnc(N)n3)c2c1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2ccc3cnc(Cl)cc32)n1,CHEMBL2346586,=,=,IC50,nM,38000.0,IC50,uM,38.0,Nc1nccc(-n2ccc3cnc(Cl)cc32)n1,2013.0
Inhibition of CDK2 (unknown origin),N#Cc1cc2c(ccn2-c2ccnc(N)n2)cn1,CHEMBL2346586,>,>,IC50,nM,44000.0,IC50,uM,44.0,N#Cc1cc2c(ccn2-c2ccnc(N)n2)cn1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2ccc3ncccc32)n1,CHEMBL2346586,=,=,IC50,nM,21000.0,IC50,uM,21.0,Nc1nccc(-n2ccc3ncccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2ccc3cnccc32)n1,CHEMBL2346586,=,=,IC50,nM,3700.0,IC50,uM,3.7,Nc1nccc(-n2ccc3cnccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2ccc3ccncc32)n1,CHEMBL2346586,=,=,IC50,nM,45100.0,IC50,uM,45.1,Nc1nccc(-n2ccc3ccncc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2ccc3cccnc32)n1,CHEMBL2346586,=,=,IC50,nM,42000.0,IC50,uM,42.0,Nc1nccc(-n2ccc3cccnc32)n1,2013.0
Inhibition of CDK2 (unknown origin),N#Cc1ccc2c(ccn2-c2ccnc(N)n2)c1,CHEMBL2346586,>,>,IC50,nM,29100.0,IC50,uM,29.1,N#Cc1ccc2c(ccn2-c2ccnc(N)n2)c1,2013.0
Inhibition of CDK2 (unknown origin),C#Cc1ccc2ccn(-c3ccnc(N)n3)c2c1,CHEMBL2346586,=,=,IC50,nM,10000.0,IC50,uM,10.0,C#Cc1ccc2ccn(-c3ccnc(N)n3)c2c1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2ccc3ccc(O)cc32)n1,CHEMBL2346586,=,=,IC50,nM,5000.0,IC50,uM,5.0,Nc1nccc(-n2ccc3ccc(O)cc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2ccc3ccc(C(F)(F)F)cc32)n1,CHEMBL2346586,=,=,IC50,nM,17000.0,IC50,uM,17.0,Nc1nccc(-n2ccc3ccc(C(F)(F)F)cc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2ccc3ccc([N+](=O)[O-])cc32)n1,CHEMBL2346586,>,>,IC50,nM,30600.0,IC50,uM,30.6,Nc1nccc(-n2ccc3ccc([N+](=O)[O-])cc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2ccc3ccc(Br)cc32)n1,CHEMBL2346586,=,=,IC50,nM,8200.0,IC50,uM,8.2,Nc1nccc(-n2ccc3ccc(Br)cc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2ccc3ccc(Cl)cc32)n1,CHEMBL2346586,=,=,IC50,nM,3700.0,IC50,uM,3.7,Nc1nccc(-n2ccc3ccc(Cl)cc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2ccc3ccc(F)cc32)n1,CHEMBL2346586,=,=,IC50,nM,34000.0,IC50,uM,34.0,Nc1nccc(-n2ccc3ccc(F)cc32)n1,2013.0
Inhibition of CDK2 (unknown origin),Nc1nccc(-n2ccc3ccccc32)n1,CHEMBL2346586,=,=,IC50,nM,28500.0,IC50,uM,28.5,Nc1nccc(-n2ccc3ccccc32)n1,2013.0
Inhibition of CDK2 (unknown origin),N#Cc1ccc2ccn(-c3ccncn3)c2c1,CHEMBL2346586,>,>,IC50,nM,83000.0,IC50,uM,83.0,N#Cc1ccc2ccn(-c3ccncn3)c2c1,2013.0
Inhibition of CDK2 (unknown origin),N#Cc1ccc2ccn(-c3nccc(N)n3)c2c1,CHEMBL2346586,>,>,IC50,nM,29000.0,IC50,uM,29.0,N#Cc1ccc2ccn(-c3nccc(N)n3)c2c1,2013.0
Inhibition of CDK2 (unknown origin),N#Cc1ccc2ccn(-c3cc(N)ncn3)c2c1,CHEMBL2346586,>,>,IC50,nM,83000.0,IC50,uM,83.0,N#Cc1ccc2ccn(-c3cc(N)ncn3)c2c1,2013.0
Inhibition of CDK2 (unknown origin),N#Cc1ccc2ccn(-c3ccnc(N)c3)c2c1,CHEMBL2346586,=,=,IC50,nM,39000.0,IC50,uM,39.0,N#Cc1ccc2ccn(-c3ccnc(N)c3)c2c1,2013.0
Inhibition of CDK2 (unknown origin),N#Cc1ccc2ccn(-c3cccc(N)n3)c2c1,CHEMBL2346586,=,=,IC50,nM,45000.0,IC50,uM,45.0,N#Cc1ccc2ccn(-c3cccc(N)n3)c2c1,2013.0
Inhibition of CDK2 (unknown origin),CNc1nccc(-n2ccc3ccc(C#N)cc32)n1,CHEMBL2346586,=,=,IC50,nM,2700.0,IC50,uM,2.7,CNc1nccc(-n2ccc3ccc(C#N)cc32)n1,2013.0
Inhibition of CDK2 (unknown origin),N#Cc1ccc2ccn(-c3ccnc(N)n3)c2c1,CHEMBL2346586,=,=,IC50,nM,16500.0,IC50,uM,16.5,N#Cc1ccc2ccn(-c3ccnc(N)n3)c2c1,2013.0
Inhibition of CDK2-mediated Rb phosphorylation at Ser 807/811 in human NCI-H929 cells at 0.005 uM after 24 hrs by immunoblotting analysis,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,CHEMBL2375244,,,Inhibition,%,,INH,,,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,2013.0
Inhibition of CDK2-mediated Rb phosphorylation at Ser 807/811 in human NCI-H929 cells at 1.5 uM after 24 hrs by immunoblotting analysis,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)sc1C(=O)c1ccccc1[N+](=O)[O-],CHEMBL2375244,,,Inhibition,%,,INH,,,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)sc1C(=O)c1ccccc1[N+](=O)[O-],2013.0
Inhibition of CDK2-mediated Rb phosphorylation at Ser 807/811 in human A673 cells at 0.05 uM after 24 hrs by immunoblotting analysis,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,CHEMBL2375244,,,Inhibition,%,,INH,,,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,2013.0
Inhibition of CDK2-mediated Rb phosphorylation at Ser 807/811 in human A673 cells at 0.25 uM after 24 hrs by immunoblotting analysis,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)sc1C(=O)c1ccccc1[N+](=O)[O-],CHEMBL2375244,,,Inhibition,%,,INH,,,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)sc1C(=O)c1ccccc1[N+](=O)[O-],2013.0
Inhibition of CDK2 (unknown origin) at 10 uM relative to control,C[C@@H](NC(=O)c1c[nH]c2ncc(-c3ncn4cc(F)cc(F)c34)nc12)C(=O)N1CC(C#N)C1,CHEMBL2375236,=,=,Inhibition,%,36.0,INH,%,36.0,C[C@@H](NC(=O)c1c[nH]c2ncc(-c3ncn4cc(F)cc(F)c34)nc12)C(=O)N1CC(C#N)C1,2013.0
Inhibition of CDK2 (unknown origin) at 10 uM relative to control,Cn1nc(-c2cnc3[nH]cc(C(=O)N[C@@H](C(=O)N4CC(C#N)C4)C4CC4)c3n2)c2ccc(Cl)cc21,CHEMBL2375236,=,=,Inhibition,%,32.0,INH,%,32.0,Cn1nc(-c2cnc3[nH]cc(C(=O)N[C@@H](C(=O)N4CC(C#N)C4)C4CC4)c3n2)c2ccc(Cl)cc21,2013.0
Inhibition of CDK2 (unknown origin) at 10 uM relative to control,CC[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1,CHEMBL2375236,=,=,Inhibition,%,23.0,INH,%,23.0,CC[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1,2013.0
Inhibition of CDK2 (unknown origin) at 10 uM relative to control,C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)cc(F)c34)nc12)C(=O)N1CC(C#N)C1,CHEMBL2375236,=,=,Inhibition,%,5.0,INH,%,5.0,C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)cc(F)c34)nc12)C(=O)N1CC(C#N)C1,2013.0
Inhibition of CDK2 (unknown origin) at 10 uM relative to control,C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1,CHEMBL2375236,=,=,Inhibition,%,-4.0,INH,%,-4.0,C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1,2013.0
Inhibition of CDK2 (unknown origin) at 10 uM relative to control,C[C@@H](NC(=O)c1c[nH]c2ncc(-c3cn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1,CHEMBL2375236,=,=,Inhibition,%,55.0,INH,%,55.0,C[C@@H](NC(=O)c1c[nH]c2ncc(-c3cn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1,2013.0
Inhibition of human CDK2,COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2,CHEMBL2380296,>,>,IC50,nM,30000.0,IC50,nM,30000.0,COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2,2013.0
Inhibition of CDK2 (unknown origin) after 60 mins,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,CHEMBL2401692,=,=,IC50,nM,3970.0,IC50,uM,3.97,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,2013.0
Inhibition of CDK2 in human G361 cells sensitized with nocodazole assessed as NPM phosphorylation at Thr199 at 640 nM after 8 hrs by immunoblotting analysis,NC1CCC(Nc2nc(NCc3ccc(-c4ccccc4O)nc3)c3ncn(C4CCCC4)c3n2)CC1,CHEMBL2401709,,,Inhibition,%,,INH,,,NC1CCC(Nc2nc(NCc3ccc(-c4ccccc4O)nc3)c3ncn(C4CCCC4)c3n2)CC1,2013.0
Inhibition of CDK2 in human G361 cells sensitized with nocodazole assessed as NPM phosphorylation at Thr199 at 640 nM after 4 hrs by immunoblotting analysis,NC1CCC(Nc2nc(NCc3ccc(-c4ccccc4O)nc3)c3ncn(C4CCCC4)c3n2)CC1,CHEMBL2401709,,,Inhibition,%,,INH,,,NC1CCC(Nc2nc(NCc3ccc(-c4ccccc4O)nc3)c3ncn(C4CCCC4)c3n2)CC1,2013.0
Inhibition of CDK2 (unknown origin),CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1C,CHEMBL2406966,=,=,IC50,nM,7200.0,IC50,uM,7.2,CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1C,2013.0
Inhibition of CDK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis,O=C(NC1(Cc2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,CHEMBL2417377,<,<,Inhibition,%,35.0,INH,%,35.0,O=C(NC1(Cc2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,2013.0
Inhibition of CDK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis,O=C(NC1(c2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,CHEMBL2417377,<,<,Inhibition,%,35.0,INH,%,35.0,O=C(NC1(c2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,2013.0
Inhibition of CDK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis,O=C(NC1(c2ccccc2)CCC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,CHEMBL2417377,<,<,Inhibition,%,35.0,INH,%,35.0,O=C(NC1(c2ccccc2)CCC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,2013.0
Inhibition of CDK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis,O=C(NC1(c2ccccc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,CHEMBL2417377,<,<,Inhibition,%,35.0,INH,%,35.0,O=C(NC1(c2ccccc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,2013.0
Inhibition of CDK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis,CC(C)(NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1,CHEMBL2417377,<,<,Inhibition,%,35.0,INH,%,35.0,CC(C)(NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1,2013.0
Inhibition of CDK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis,CCC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1,CHEMBL2417377,<,<,Inhibition,%,35.0,INH,%,35.0,CCC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1,2013.0
Inhibition of CDK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis,O=C(N[C@H](CO)c1ccccc1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,CHEMBL2417377,<,<,Inhibition,%,35.0,INH,%,35.0,O=C(N[C@H](CO)c1ccccc1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,2013.0
Inhibition of CDK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis,CC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1,CHEMBL2417377,<,<,Inhibition,%,35.0,INH,%,35.0,CC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1,2013.0
Inhibition of CDK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis,C[C@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1,CHEMBL2417377,<,<,Inhibition,%,35.0,INH,%,35.0,C[C@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1,2013.0
Inhibition of CDK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis,C[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1,CHEMBL2417377,<,<,Inhibition,%,35.0,INH,%,35.0,C[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1,2013.0
Inhibition of CDK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis,NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,CHEMBL2417377,<,<,Inhibition,%,35.0,INH,%,35.0,NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,2013.0
Inhibition of CDK2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis,O=C(O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,CHEMBL2417377,=,=,Inhibition,%,59.1,INH,%,59.1,O=C(O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1,2013.0
Inhibition of CDK2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control,c1ccc(CC2CCC3(CCN(c4ncnc5[nH]cnc45)CC3)NC2)cc1,CHEMBL2417369,=,=,Inhibition,%,15.0,INH,%,15.0,c1ccc(CC2CCC3(CCN(c4ncnc5[nH]cnc45)CC3)NC2)cc1,2013.0
Inhibition of CDK2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control,c1ccc(CC2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1,CHEMBL2417369,=,=,Inhibition,%,21.0,INH,%,21.0,c1ccc(CC2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1,2013.0
Inhibition of CDK2 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control,c1ccc(C2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1,CHEMBL2417369,=,=,Inhibition,%,19.0,INH,%,19.0,c1ccc(C2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1,2013.0
Inhibition of CDK2 (unknown origin) at 100 nM,Cn1cc(-c2cnc3[nH]cc(-c4cnn(Cc5ccccc5)c4)c3c2)cn1,CHEMBL2417505,=,=,Inhibition,%,41.0,INH,%,41.0,Cn1cc(-c2cnc3[nH]cc(-c4cnn(Cc5ccccc5)c4)c3c2)cn1,2013.0
Competitive binding affinity to CDK2 (unknown origin) at 10 uM in presence of ATP relative to control,O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1,CHEMBL2424622,=,=,Inhibition,%,100.0,INH,%,100.0,O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1,2013.0
Competitive binding affinity to CDK2 (unknown origin) at 10 uM in presence of ATP relative to control,O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1,CHEMBL2424622,=,=,Inhibition,%,90.0,INH,%,90.0,O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL2424530,=,=,IC50,nM,500.0,IC50,uM,0.5,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,CHEMBL2424530,=,=,IC50,nM,7000.0,IC50,uM,7.0,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,COc1ccc(-c2nn(-c3ccccc3)cc2C(=O)NC(=S)Nc2ccc(Cl)cc2)cc1,CHEMBL2424530,=,=,IC50,nM,30.0,IC50,uM,0.03,COc1ccc(-c2nn(-c3ccccc3)cc2C(=O)NC(=S)Nc2ccc(Cl)cc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,COc1ccc(-c2nn(-c3ccccc3)cc2C(=O)NC(=S)Nc2ccc(F)cc2)cc1,CHEMBL2424530,=,=,IC50,nM,32.0,IC50,uM,0.032,COc1ccc(-c2nn(-c3ccccc3)cc2C(=O)NC(=S)Nc2ccc(F)cc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(OC)cc2)cc1,CHEMBL2424530,=,=,IC50,nM,25.0,IC50,uM,0.025,COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(OC)cc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,COc1ccc(-c2nn(-c3ccccc3)cc2C(=O)NC(=S)Nc2ccc(C)cc2)cc1,CHEMBL2424530,=,=,IC50,nM,29.0,IC50,uM,0.029,COc1ccc(-c2nn(-c3ccccc3)cc2C(=O)NC(=S)Nc2ccc(C)cc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,O=C(NC(=S)Nc1ccc(Cl)cc1)c1cn(-c2ccccc2)nc1-c1ccc(F)cc1,CHEMBL2424530,=,=,IC50,nM,44.0,IC50,uM,0.044,O=C(NC(=S)Nc1ccc(Cl)cc1)c1cn(-c2ccccc2)nc1-c1ccc(F)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,O=C(NC(=S)Nc1ccc(F)cc1)c1cn(-c2ccccc2)nc1-c1ccc(F)cc1,CHEMBL2424530,=,=,IC50,nM,49.0,IC50,uM,0.049,O=C(NC(=S)Nc1ccc(F)cc1)c1cn(-c2ccccc2)nc1-c1ccc(F)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)cc1,CHEMBL2424530,=,=,IC50,nM,36.0,IC50,uM,0.036,COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,Cc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)cc1,CHEMBL2424530,=,=,IC50,nM,43.0,IC50,uM,0.043,Cc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(F)cc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,O=C(NC(=S)Nc1ccc(Cl)cc1)c1cn(-c2ccccc2)nc1-c1ccc(Cl)cc1,CHEMBL2424530,=,=,IC50,nM,58.0,IC50,uM,0.058,O=C(NC(=S)Nc1ccc(Cl)cc1)c1cn(-c2ccccc2)nc1-c1ccc(Cl)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,O=C(NC(=S)Nc1ccc(F)cc1)c1cn(-c2ccccc2)nc1-c1ccc(Cl)cc1,CHEMBL2424530,=,=,IC50,nM,59.0,IC50,uM,0.059,O=C(NC(=S)Nc1ccc(F)cc1)c1cn(-c2ccccc2)nc1-c1ccc(Cl)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(Cl)cc2)cc1,CHEMBL2424530,=,=,IC50,nM,37.0,IC50,uM,0.037,COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(Cl)cc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,Cc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(Cl)cc2)cc1,CHEMBL2424530,=,=,IC50,nM,42.0,IC50,uM,0.042,Cc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(Cl)cc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,Cc1ccc(-c2nn(-c3ccccc3)cc2C(=O)NC(=S)Nc2ccc(Cl)cc2)cc1,CHEMBL2424530,=,=,IC50,nM,63.0,IC50,uM,0.063,Cc1ccc(-c2nn(-c3ccccc3)cc2C(=O)NC(=S)Nc2ccc(Cl)cc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,Cc1ccc(-c2nn(-c3ccccc3)cc2C(=O)NC(=S)Nc2ccc(F)cc2)cc1,CHEMBL2424530,=,=,IC50,nM,41.0,IC50,uM,0.041,Cc1ccc(-c2nn(-c3ccccc3)cc2C(=O)NC(=S)Nc2ccc(F)cc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(C)cc2)cc1,CHEMBL2424530,=,=,IC50,nM,47.0,IC50,uM,0.047,COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(C)cc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,Cc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(C)cc2)cc1,CHEMBL2424530,=,=,IC50,nM,52.0,IC50,uM,0.052,Cc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccc(C)cc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,O=C(NC(=S)Nc1ccc(Cl)cc1)c1cn(-c2ccccc2)nc1-c1ccccc1,CHEMBL2424530,=,=,IC50,nM,71.0,IC50,uM,0.071,O=C(NC(=S)Nc1ccc(Cl)cc1)c1cn(-c2ccccc2)nc1-c1ccccc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,O=C(NC(=S)Nc1ccc(F)cc1)c1cn(-c2ccccc2)nc1-c1ccccc1,CHEMBL2424530,=,=,IC50,nM,75.0,IC50,uM,0.075,O=C(NC(=S)Nc1ccc(F)cc1)c1cn(-c2ccccc2)nc1-c1ccccc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccccc2)cc1,CHEMBL2424530,=,=,IC50,nM,56.0,IC50,uM,0.056,COc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccccc2)cc1,2013.0
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP,Cc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccccc2)cc1,CHEMBL2424530,=,=,IC50,nM,69.0,IC50,uM,0.069,Cc1ccc(NC(=S)NC(=O)c2cn(-c3ccccc3)nc2-c2ccccc2)cc1,2013.0
Competitive binding affinity to CDK2 (unknown origin) at 10 uM in presence of ATP relative to control,O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1,CHEMBL2424622,=,=,Inhibition,%,94.0,INH,%,94.0,O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1,2013.0
Competitive binding affinity to CDK2 (unknown origin) at 10 uM in presence of ATP relative to control,O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1,CHEMBL2424622,=,=,Inhibition,%,94.0,INH,%,94.0,O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1,2013.0
Inhibition of human CDK2 assessed as residual activity at 1 uM relative to control,CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12,CHEMBL2429821,=,=,Activity,%,9.0,Activity,%,9.0,CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12,2013.0
Inhibition of human CDK2 assessed as residual activity at 10 uM relative to control,CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12,CHEMBL2429821,=,=,Activity,%,5.0,Activity,%,5.0,CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12,2013.0
Inhibition of human CDK2 assessed as residual activity at 25 uM relative to control,COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1,CHEMBL2429821,=,=,Activity,%,83.0,Activity,%,83.0,COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1,2013.0
Inhibition of human CDK2 assessed as residual activity at 10 uM relative to control,NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1,CHEMBL2429821,=,=,Activity,%,113.0,Activity,%,113.0,NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1,2013.0
Inhibition of human CDK2 assessed as residual activity at 1 uM relative to control,CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1,CHEMBL2429821,=,=,Activity,%,92.2,Activity,%,92.2,CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1,2013.0
Inhibition of human CDK2 assessed as residual activity at 10 uM relative to control,CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1,CHEMBL2429821,=,=,Activity,%,103.84,Activity,%,103.84,CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1,2013.0
Inhibition of human CDK2 assessed as residual activity at 1 uM relative to control,CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1,CHEMBL2429821,=,=,Activity,%,76.71,Activity,%,76.71,CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1,2013.0
Inhibition of human CDK2 assessed as residual activity at 10 uM relative to control,CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1,CHEMBL2429821,=,=,Activity,%,40.33,Activity,%,40.33,CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1,2013.0
Inhibition of wild type human CDK2 by high throughput ATP-[33P] radiolabeled assay,CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1,CHEMBL2434948,=,=,IC50,nM,1180.0,IC50,nM,1180.0,CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1,2013.0
Inhibition of wild type human CDK2 by high throughput ATP-[33P] radiolabeled assay,CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5cnc6[nH]ccc6c5)c4c3)cc2)CC1,CHEMBL2434948,=,=,IC50,nM,720.0,IC50,nM,720.0,CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5cnc6[nH]ccc6c5)c4c3)cc2)CC1,2013.0
Inhibition of CDK2 (unknown origin),Cc1nnc(-c2cccc(-c3cnn4ccc(NCCN)nc34)c2)o1,CHEMBL2440090,=,=,IC50,nM,580.0,IC50,nM,580.0,Cc1nnc(-c2cccc(-c3cnn4ccc(NCCN)nc34)c2)o1,2013.0
Inhibition of CDK2 (unknown origin),c1cncc(CNc2ccn3ncc(-c4ccc5ccccc5c4)c3n2)c1,CHEMBL2440090,>,>,IC50,nM,50000.0,IC50,nM,50000.0,c1cncc(CNc2ccn3ncc(-c4ccc5ccccc5c4)c3n2)c1,2013.0
Inhibition of CDK2 (unknown origin) at 0.1 uM relative to control,CN(C)Cc1ccc([C@H]2C[C@@H]2C(=O)Nc2nc3ccc(-c4cn[nH]c4)cc3s2)cc1,CHEMBL3085719,>,>,Inhibition,%,50.0,INH,%,50.0,CN(C)Cc1ccc([C@H]2C[C@@H]2C(=O)Nc2nc3ccc(-c4cn[nH]c4)cc3s2)cc1,2013.0
Inhibition of CDK-2 (unknown origin) after 90 mins by TR-FRET/IMAP fluorescence polarization assay,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3cc(Cl)c(OC(=O)N(C)C)cc3oc2=O)c1,CHEMBL3085763,>,>,IC50,nM,50000.0,IC50,uM,50.0,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3cc(Cl)c(OC(=O)N(C)C)cc3oc2=O)c1,2013.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,CN(C)C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,CN(C)C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,CCC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,CCC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,C[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,C[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,O=C(N[C@@H](Cc1ccc(O)cc1)C(=O)O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,O=C(N[C@@H](Cc1ccc(O)cc1)C(=O)O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,O=C(NCCc1ccc(O)cc1)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,O=C(NCCc1ccc(O)cc1)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1cccc(O)c1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1cccc(O)c1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)NS(C)(=O)=O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)NS(C)(=O)=O)c2cc(-c3cccs3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(N)=O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(N)=O)c2cc(-c3cccs3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(CO)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(CO)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,CCCCCCc1ccc2nc(C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)OC)cc(C(=O)O)c2c1,CHEMBL3098110,,,Inhibition,%,,INH,,,CCCCCCc1ccc2nc(C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)OC)cc(C(=O)O)c2c1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(CCc3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(CCc3ccc(Cl)cc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(N3CCOCC3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(N3CCOCC3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cc(Cl)cc(Cl)c3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cc(Cl)cc(Cl)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccc(Cl)cc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3Cl)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3Cl)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-mediated Rb phosphorylation by cell-based assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,CN(C)C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN(C)C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,CCC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,C[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,C[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,O=C(N[C@@H](Cc1ccc(O)cc1)C(=O)O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(N[C@@H](Cc1ccc(O)cc1)C(=O)O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,O=C(NCCc1ccc(O)cc1)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(NCCc1ccc(O)cc1)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1cccc(O)c1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1cccc(O)c1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)NS(C)(=O)=O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)NS(C)(=O)=O)c2cc(-c3cccs3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(N)=O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(N)=O)c2cc(-c3cccs3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(CO)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(CO)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,CCCCCCc1ccc2nc(C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)OC)cc(C(=O)O)c2c1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCCCCCc1ccc2nc(C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)OC)cc(C(=O)O)c2c1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(CCc3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(CCc3ccc(Cl)cc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(N3CCOCC3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(N3CCOCC3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cc(Cl)cc(Cl)c3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cc(Cl)cc(Cl)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccc(Cl)cc3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3Cl)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3Cl)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin)-cyclin A interaction preincubated for 30 mins at room temperature followed by incubation at 40 degC for 30 mins by SDS-PAGE analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,2014.0
Inhibition of active state of CDK2 (unknown origin) at 1 uM,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1,CHEMBL3098110,,,Inhibition,%,,INH,,,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1,2014.0
Binding affinity to human CDK2 by isothermal titration calorimetric analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(CCc3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,55.0,Kd,uM,0.055,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(CCc3ccc(Cl)cc3)ccc2n1,2014.0
Binding affinity to human CDK2 by isothermal titration calorimetric analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,50.0,Kd,uM,0.05,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Binding affinity to human CDK2 by isothermal titration calorimetric analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,300.0,Kd,uM,0.3,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1,2014.0
Binding affinity to human CDK2 by isothermal titration calorimetric analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,1000.0,Kd,uM,1.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,25.0,Kd,uM,0.025,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,240.0,Kd,uM,0.24,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,CN(C)C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,350.0,Kd,uM,0.35,CN(C)C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,300.0,Kd,uM,0.3,CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,CCC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,400.0,Kd,uM,0.4,CCC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,C[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,4000.0,Kd,uM,4.0,C[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,O=C(N[C@@H](Cc1ccc(O)cc1)C(=O)O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,Kd,nM,10000.0,Kd,uM,10.0,O=C(N[C@@H](Cc1ccc(O)cc1)C(=O)O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,O=C(NCCc1ccc(O)cc1)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,>,>,Kd,nM,40000.0,Kd,uM,40.0,O=C(NCCc1ccc(O)cc1)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1cccc(O)c1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,Kd,nM,40000.0,Kd,uM,40.0,COC(=O)[C@H](Cc1cccc(O)c1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,Kd,nM,40000.0,Kd,uM,40.0,COC(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,4000.0,Kd,uM,4.0,COC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)NS(C)(=O)=O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,>,>,Kd,nM,40000.0,Kd,uM,40.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)NS(C)(=O)=O)c2cc(-c3cccs3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(N)=O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,>,>,Kd,nM,40000.0,Kd,uM,40.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(N)=O)c2cc(-c3cccs3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(CO)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,Kd,nM,40000.0,Kd,uM,40.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(CO)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,CCCCCCc1ccc2nc(C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)OC)cc(C(=O)O)c2c1,CHEMBL3098110,=,=,Kd,nM,76.0,Kd,uM,0.076,CCCCCCc1ccc2nc(C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)OC)cc(C(=O)O)c2c1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,5.0,Kd,uM,0.005,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(CCc3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,48.0,Kd,uM,0.048,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(CCc3ccc(Cl)cc3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,40.0,Kd,uM,0.04,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(N3CCOCC3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,2400.0,Kd,uM,2.4,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(N3CCOCC3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,12000.0,Kd,uM,12.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cc(Cl)cc(Cl)c3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,320.0,Kd,uM,0.32,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cc(Cl)cc(Cl)c3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,900.0,Kd,uM,0.9,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccc(Cl)cc3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3Cl)ccc2n1,CHEMBL3098110,=,=,Kd,nM,800.0,Kd,uM,0.8,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3Cl)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,300.0,Kd,uM,0.3,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1,2014.0
Binding affinity to CDK2 (unknown origin) at 20 to 80 degC by circular dichroism analysis,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,=,=,Kd,nM,1100.0,Kd,uM,1.1,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,<,<,Ki,nM,100.0,Ki,uM,0.1,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,100.0,Ki,uM,0.1,COC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,CN(C)C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,160.0,Ki,uM,0.16,CN(C)C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,100.0,Ki,uM,0.1,CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,CCC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,300.0,Ki,uM,0.3,CCC[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,C[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,2500.0,Ki,uM,2.5,C[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,O=C(N[C@@H](Cc1ccc(O)cc1)C(=O)O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,12000.0,Ki,uM,12.0,O=C(N[C@@H](Cc1ccc(O)cc1)C(=O)O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,O=C(NCCc1ccc(O)cc1)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,>,>,Ki,nM,40000.0,Ki,uM,40.0,O=C(NCCc1ccc(O)cc1)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1cccc(O)c1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,Ki,nM,40000.0,Ki,uM,40.0,COC(=O)[C@H](Cc1cccc(O)c1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,Ki,nM,40000.0,Ki,uM,40.0,COC(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,2500.0,Ki,uM,2.5,COC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)NS(C)(=O)=O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,>,>,Ki,nM,40000.0,Ki,uM,40.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)NS(C)(=O)=O)c2cc(-c3cccs3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(N)=O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,>,>,Ki,nM,40000.0,Ki,uM,40.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(N)=O)c2cc(-c3cccs3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(CO)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,>,>,Ki,nM,40000.0,Ki,uM,40.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(CO)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,CCCCCCc1ccc2nc(C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)OC)cc(C(=O)O)c2c1,CHEMBL3098110,<,<,Ki,nM,100.0,Ki,uM,0.1,CCCCCCc1ccc2nc(C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)OC)cc(C(=O)O)c2c1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,<,<,Ki,nM,100.0,Ki,uM,0.1,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(/C=C/c3ccc(Cl)cc3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(CCc3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,<,<,Ki,nM,100.0,Ki,uM,0.1,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(CCc3ccc(Cl)cc3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,CHEMBL3098110,<,<,Ki,nM,100.0,Ki,uM,0.1,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(C(F)(F)F)c3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(N3CCOCC3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,2800.0,Ki,uM,2.8,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(N3CCOCC3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,10000.0,Ki,uM,10.0,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cc(Cl)cc(Cl)c3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,200.0,Ki,uM,0.2,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cc(Cl)cc(Cl)c3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccc(Cl)cc3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,900.0,Ki,uM,0.9,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccc(Cl)cc3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3Cl)ccc2n1,CHEMBL3098110,=,=,Ki,nM,700.0,Ki,uM,0.7,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3ccccc3Cl)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,140.0,Ki,uM,0.14,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1,2014.0
Displacement of B-Alexa-Fluor647 from CDK2 (unknown origin) by fluorescence polarization assay,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,CHEMBL3098110,=,=,Ki,nM,900.0,Ki,uM,0.9,COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccs3)ccc2n1,2014.0
Inhibition of CDK2 (unknown origin) at 1 uM after 1 hr,CC1(C)OC(=O)N([C@H]2CC[C@H](c3cnc(N)c(-c4ncccn4)c3)CC2)[C@H]1c1ccccc1,CHEMBL3098003,,,Inhibition,%,,INH,,,CC1(C)OC(=O)N([C@H]2CC[C@H](c3cnc(N)c(-c4ncccn4)c3)CC2)[C@H]1c1ccccc1,2013.0
Inhibition of CDK2 (unknown origin) at 1 uM after 1 hr,CC1(C)OC(=O)N(c2ccc(-c3cnc(N)c(-c4ncccn4)c3)cc2)[C@H]1c1ccccc1,CHEMBL3098003,,,Inhibition,%,,INH,,,CC1(C)OC(=O)N(c2ccc(-c3cnc(N)c(-c4ncccn4)c3)cc2)[C@H]1c1ccccc1,2013.0
Inhibition of human recombinant CDK2 using ATP/Ulight-CFFKNIVTPRTPPPSQGK-amide as substrate after 30 mins by LANCE assay,Cc1nn(-c2ccc(Cl)cc2Cl)c2c1c1c(c3cccn32)C(=O)NC1=O,CHEMBL3108740,=,=,IC50,nM,2800.0,IC50,uM,2.8,Cc1nn(-c2ccc(Cl)cc2Cl)c2c1c1c(c3cccn32)C(=O)NC1=O,2013.0
Inhibition of His-6-tagged CDK2 (unknown origin) expressed in baculovirus-infected insect cells using histone H1 as substrate after 1 hr by by liquid scintillation counting in presence of [gamma-33P]ATP,COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2,CHEMBL3112420,=,=,IC50,nM,22.0,IC50,uM,0.022,COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2,2014.0
Inhibition of human CDK2 at 10 uM,C[C@@H]1NC(c2ccc(Br)cc2)=Nc2nc3ccccn3c2C1=O,CHEMBL3124806,,,Inhibition,%,,INH,,,C[C@@H]1NC(c2ccc(Br)cc2)=Nc2nc3ccccn3c2C1=O,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)cc1,CHEMBL3124838,>,>,IC50,nM,4910.0,IC50,uM,4.91,COc1ccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(=O)NCC(C)C)cs4)cnc3[nH]2)cc1,CHEMBL3124838,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(=O)NCC(C)C)cs4)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(C(N)=S)cnc3[nH]2)cc1,CHEMBL3124838,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(C(N)=S)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3c(OCCCNC(=O)C4CCCC4)c(-c4csc(C(=O)O)c4)cnc3[nH]2)cc1,CHEMBL3124838,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2nc3c(OCCCNC(=O)C4CCCC4)c(-c4csc(C(=O)O)c4)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3c(OCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1,CHEMBL3124838,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2nc3c(OCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1,CHEMBL3124838,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1,CHEMBL3124838,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC,CHEMBL3124838,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1,CHEMBL3124838,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),CCC(C)CNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1,CHEMBL3124838,>,>,IC50,nM,30000.0,IC50,uM,30.0,CCC(C)CNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)CO)c4)cnc3[nH]2)cc1,CHEMBL3124838,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)CO)c4)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COCCNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1,CHEMBL3124838,>,>,IC50,nM,30000.0,IC50,uM,30.0,COCCNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(=O)O)cs4)cnc3[nH]2)cc1,CHEMBL3124838,=,=,IC50,nM,13600.0,IC50,uM,13.6,COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(=O)O)cs4)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3cc(-c4csc(C(C)=O)c4)cnc3[nH]2)cc1,CHEMBL3124838,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(-c2nc3cc(-c4csc(C(C)=O)c4)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1,CHEMBL3124838,=,=,IC50,nM,2790.0,IC50,uM,2.79,COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(N)=O)cs4)cnc3[nH]2)cc1,CHEMBL3124838,=,=,IC50,nM,1450.0,IC50,uM,1.45,COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(N)=O)cs4)cnc3[nH]2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2nc3cc(-c4csc(C(N)=O)c4)cnc3[nH]2)cc1,CHEMBL3124838,=,=,IC50,nM,984.0,IC50,uM,0.984,COc1ccc(-c2nc3cc(-c4csc(C(N)=O)c4)cnc3[nH]2)cc1,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 1000 uM after 90 mins by microfluidic peptide phosphorylation assay,c1cnc2[nH]ccc2c1,CHEMBL3132769,=,=,Inhibition,%,45.5,INH,%,45.5,c1cnc2[nH]ccc2c1,2014.0
Inhibition of CDK2 (unknown origin),COc1cc(Nc2nccc(-c3ccc(Cl)cc3)n2)cc(OC)c1OC,CHEMBL3132747,=,=,IC50,nM,18782.0,IC50,uM,18.782,COc1cc(Nc2nccc(-c3ccc(Cl)cc3)n2)cc(OC)c1OC,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.1 uM after 90 mins by microfluidic peptide phosphorylation assay,C[C@H](CN(C)C)Oc1nc(Nc2cc3cccc(Cl)c3cn2)cnc1C#N,CHEMBL3132769,=,=,Inhibition,%,1.5,INH,%,1.5,C[C@H](CN(C)C)Oc1nc(Nc2cc3cccc(Cl)c3cn2)cnc1C#N,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.35 uM after 90 mins by microfluidic peptide phosphorylation assay,COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CCNCC1,CHEMBL3132769,=,=,Inhibition,%,6.0,INH,%,6.0,COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CCNCC1,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 9 uM after 90 mins by microfluidic peptide phosphorylation assay,NCC1CN(c2ncnc3[nH]c4cnccc4c23)CCO1,CHEMBL3132769,=,=,Inhibition,%,26.5,INH,%,26.5,NCC1CN(c2ncnc3[nH]c4cnccc4c23)CCO1,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 90 uM after 90 mins by microfluidic peptide phosphorylation assay,NCC1CN(c2ncnc3[nH]cnc23)CCO1,CHEMBL3132769,=,=,Inhibition,%,53.0,INH,%,53.0,NCC1CN(c2ncnc3[nH]cnc23)CCO1,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 420 uM after 90 mins by microfluidic peptide phosphorylation assay,c1nc(N2CCOCC2)c2nc[nH]c2n1,CHEMBL3132769,=,=,Inhibition,%,75.0,INH,%,75.0,c1nc(N2CCOCC2)c2nc[nH]c2n1,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.02 uM after 90 mins by microfluidic peptide phosphorylation assay,NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,CHEMBL3132769,=,=,Inhibition,%,6.0,INH,%,6.0,NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.06 uM after 90 mins by microfluidic peptide phosphorylation assay,NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,CHEMBL3132769,=,=,Inhibition,%,1.0,INH,%,1.0,NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 2 uM after 90 mins by microfluidic peptide phosphorylation assay,NC1CCN(c2ncnc3[nH]ccc23)CC1,CHEMBL3132769,=,=,Inhibition,%,0.0,INH,%,0.0,NC1CCN(c2ncnc3[nH]ccc23)CC1,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 8 uM after 90 mins by microfluidic peptide phosphorylation assay,NCC1CCN(c2ncnc3[nH]ccc23)CC1,CHEMBL3132769,=,=,Inhibition,%,7.0,INH,%,7.0,NCC1CCN(c2ncnc3[nH]ccc23)CC1,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.2 uM after 90 mins by microfluidic peptide phosphorylation assay,Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1,CHEMBL3132769,=,=,Inhibition,%,7.5,INH,%,7.5,Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 95 uM after 90 mins by microfluidic peptide phosphorylation assay,NCCc1ccc(-c2ncnc3[nH]cnc23)cc1,CHEMBL3132769,=,=,Inhibition,%,39.5,INH,%,39.5,NCCc1ccc(-c2ncnc3[nH]cnc23)cc1,2014.0
Inhibition of human full length CDK2 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 70 uM after 90 mins by microfluidic peptide phosphorylation assay,CNCc1ccc(-c2ncnc3[nH]cnc23)cc1,CHEMBL3132769,=,=,Inhibition,%,34.0,INH,%,34.0,CNCc1ccc(-c2ncnc3[nH]cnc23)cc1,2014.0
Inhibition of recombinant CDK2 (unknown origin) using poly-Glu-Tyr peptide as substrate,Nc1ccccc1NC(=O)c1ccc(COc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)cc1,CHEMBL3217617,=,=,IC50,nM,22000.0,IC50,uM,22.0,Nc1ccccc1NC(=O)c1ccc(COc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)cc1,2012.0
Inhibition of recombinant CDK2 (unknown origin) using poly-Glu-Tyr peptide as substrate,C#Cc1cccc(Nc2ncnc3ccc(OCc4ccc(C(=O)Nc5ccccc5N)cc4)cc23)c1,CHEMBL3217617,=,=,IC50,nM,13000.0,IC50,uM,13.0,C#Cc1cccc(Nc2ncnc3ccc(OCc4ccc(C(=O)Nc5ccccc5N)cc4)cc23)c1,2012.0
Inhibition of recombinant CDK2 (unknown origin) using poly-Glu-Tyr peptide as substrate,C#Cc1cccc(Nc2ncnc3ccc(S(=O)(=O)n4ccc(/C=C/C(=O)Nc5ccccc5N)c4)cc23)c1,CHEMBL3217617,=,=,IC50,nM,17000.0,IC50,uM,17.0,C#Cc1cccc(Nc2ncnc3ccc(S(=O)(=O)n4ccc(/C=C/C(=O)Nc5ccccc5N)c4)cc23)c1,2012.0
Inhibition of recombinant CDK2 (unknown origin) using poly-Glu-Tyr peptide as substrate,C#Cc1cccc(Nc2ncnc3ccc(S(=O)(=O)n4ccc(/C=C/C(=O)NO)c4)cc23)c1,CHEMBL3217617,>,>,IC50,nM,100000.0,IC50,uM,100.0,C#Cc1cccc(Nc2ncnc3ccc(S(=O)(=O)n4ccc(/C=C/C(=O)NO)c4)cc23)c1,2012.0
Inhibition of recombinant CDK2 (unknown origin) using poly-Glu-Tyr peptide as substrate,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,CHEMBL3217617,>,>,IC50,nM,100000.0,IC50,uM,100.0,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,2012.0
Inhibition of CDK2 (unknown origin) at 10 uM,CC1(C)C(=O)Nc2cc3nccc(Oc4ccc(NC(=O)Nc5ccc(F)c(C(F)(F)F)c5)cc4Cl)c3cc21,CHEMBL3217507,=,=,Inhibition,%,7.8,INH,%,7.8,CC1(C)C(=O)Nc2cc3nccc(Oc4ccc(NC(=O)Nc5ccc(F)c(C(F)(F)F)c5)cc4Cl)c3cc21,2013.0
Inhibition of CDK2 (unknown origin) at 1 uM relative to control,CCOC(=O)c1sc(-c2ccncc2)nc1O,CHEMBL3259739,=,=,Inhibition,%,100.0,INH,%,100.0,CCOC(=O)c1sc(-c2ccncc2)nc1O,2014.0
Inhibition of CDK2 (unknown origin) at 1 uM relative to control,NC(=O)c1sc(-c2ccnc(N)n2)nc1-c1ccc(Cl)cc1Cl,CHEMBL3259739,=,=,Inhibition,%,100.0,INH,%,100.0,NC(=O)c1sc(-c2ccnc(N)n2)nc1-c1ccc(Cl)cc1Cl,2014.0
Inhibition of CDK2 (unknown origin) at 1 uM relative to control,COc1ccc(-c2nc(-c3ccnc(N)n3)sc2C(N)=O)c(Cl)c1,CHEMBL3259739,=,=,Inhibition,%,84.0,INH,%,84.0,COc1ccc(-c2nc(-c3ccnc(N)n3)sc2C(N)=O)c(Cl)c1,2014.0
Inhibition of CDK2 (unknown origin),O=C(CC1CNC(=O)c2cc(-c3cn[nH]c3)cn21)NCc1cccc(F)c1,CHEMBL3297733,=,=,IC50,nM,60.0,IC50,uM,0.06,O=C(CC1CNC(=O)c2cc(-c3cn[nH]c3)cn21)NCc1cccc(F)c1,2013.0
Inhibition of CDK2 (unknown origin) at 0.1 uM,O=S(=O)(c1ccccc1)c1cc(Nc2cc(C3CCCC3)[nH]n2)nc(N[C@H]2CC[C@H](O)CC2)c1,CHEMBL3352735,=,=,Inhibition,%,70.0,INH,%,70.0,O=S(=O)(c1ccccc1)c1cc(Nc2cc(C3CCCC3)[nH]n2)nc(N[C@H]2CC[C@H](O)CC2)c1,2014.0
Inhibition of CDK2 (unknown origin) in presence of 1 mM ATP,CN(Cc1ccccc1)C(=O)c1ccc(S(=O)(=O)Nc2ccccc2)cc1,CHEMBL3351882,>,>,IC50,nM,100000.0,IC50,uM,100.0,CN(Cc1ccccc1)C(=O)c1ccc(S(=O)(=O)Nc2ccccc2)cc1,2015.0
Inhibition of Cdk2 (unknown origin),O=C(N[C@H](CO)c1ccc(F)c(Cl)c1)N1CCc2cnc(NC3CCOCC3)nc2C1,CHEMBL3297705,=,=,IC50,nM,16.0,IC50,nM,16.0,O=C(N[C@H](CO)c1ccc(F)c(Cl)c1)N1CCc2cnc(NC3CCOCC3)nc2C1,2014.0
Inhibition of Cdk2 (unknown origin),O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1,CHEMBL3297705,=,=,IC50,nM,10.0,IC50,nM,10.0,O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1,2014.0
Inhibition of Cdk2 (unknown origin),O=C(N[C@H](CO)c1ccc(Cl)c(Cl)c1)N1CCc2cnc(NC3CCOCC3)nc2C1,CHEMBL3297705,=,=,IC50,nM,11.0,IC50,nM,11.0,O=C(N[C@H](CO)c1ccc(Cl)c(Cl)c1)N1CCc2cnc(NC3CCOCC3)nc2C1,2014.0
Inhibition of Cdk2 (unknown origin),C[C@@H](NC(=O)N1CCc2cnc(NC3CCOCC3)nc2C1)c1ccc2cc[nH]c2c1,CHEMBL3297705,=,=,IC50,nM,69.0,IC50,nM,69.0,C[C@@H](NC(=O)N1CCc2cnc(NC3CCOCC3)nc2C1)c1ccc2cc[nH]c2c1,2014.0
Inhibition of Cdk2 (unknown origin),C[C@@H](NC(=O)N1CCc2cnc(NC3CCOCC3)nc2C1)c1ccc(Cl)c(F)c1,CHEMBL3297705,=,=,IC50,nM,13.0,IC50,nM,13.0,C[C@@H](NC(=O)N1CCc2cnc(NC3CCOCC3)nc2C1)c1ccc(Cl)c(F)c1,2014.0
Inhibition of Cdk2 (unknown origin),CC[C@@H](NC(=O)N1CCc2cnc(NC3CCOCC3)nc2C1)c1ccc(C#N)c(Cl)c1,CHEMBL3297705,=,=,IC50,nM,2.0,IC50,nM,2.0,CC[C@@H](NC(=O)N1CCc2cnc(NC3CCOCC3)nc2C1)c1ccc(C#N)c(Cl)c1,2014.0
Inhibition of Cdk2 (unknown origin),C[C@@H](NC(=O)N1CCc2cnc(N[C@H]3CCO[C@@H](CO)C3)nc2C1)c1ccc(Cl)c(Cl)c1,CHEMBL3297705,=,=,IC50,nM,2.0,IC50,nM,2.0,C[C@@H](NC(=O)N1CCc2cnc(N[C@H]3CCO[C@@H](CO)C3)nc2C1)c1ccc(Cl)c(Cl)c1,2014.0
Inhibition of Cdk2 (unknown origin),C[C@@H](CO)Nc1ncc2c(n1)CN(C(=O)N[C@H](C)c1ccc(Cl)c(Cl)c1)CC2,CHEMBL3297705,=,=,IC50,nM,104.0,IC50,nM,104.0,C[C@@H](CO)Nc1ncc2c(n1)CN(C(=O)N[C@H](C)c1ccc(Cl)c(Cl)c1)CC2,2014.0
Inhibition of Cdk2 (unknown origin),CC[C@@H](NC(=O)N1CCc2cnc(N[C@@H](C)CO)nc2C1)c1ccc(F)c(F)c1,CHEMBL3297705,=,=,IC50,nM,13.0,IC50,nM,13.0,CC[C@@H](NC(=O)N1CCc2cnc(N[C@@H](C)CO)nc2C1)c1ccc(F)c(F)c1,2014.0
Inhibition of Cdk2 (unknown origin),CC[C@@H](NC(=O)N1CCc2cnc(N[C@@H](C)CO)nc2C1)c1ccc(Cl)c(Cl)c1,CHEMBL3297705,=,=,IC50,nM,12.0,IC50,nM,12.0,CC[C@@H](NC(=O)N1CCc2cnc(N[C@@H](C)CO)nc2C1)c1ccc(Cl)c(Cl)c1,2014.0
Inhibition of Cdk2 (unknown origin),C[C@@H](CO)Nc1ncc2c(n1)CN(C(=O)N[C@H](C)c1ccc(C(F)(F)F)c(F)c1)CC2,CHEMBL3297705,=,=,IC50,nM,821.0,IC50,nM,821.0,C[C@@H](CO)Nc1ncc2c(n1)CN(C(=O)N[C@H](C)c1ccc(C(F)(F)F)c(F)c1)CC2,2014.0
Inhibition of Cdk2 (unknown origin),CC[C@@H](NC(=O)N1CCc2cnc(N[C@@H](C)CO)nc2C1)c1ccc(OC)c(Cl)c1,CHEMBL3297705,=,=,IC50,nM,71.0,IC50,nM,71.0,CC[C@@H](NC(=O)N1CCc2cnc(N[C@@H](C)CO)nc2C1)c1ccc(OC)c(Cl)c1,2014.0
Inhibition of Cdk2 (unknown origin),Cc1cc(Nc2ncc3c(n2)CN(C(=O)N[C@H](C)c2ccc(Cl)c(Cl)c2)CC3)ccn1,CHEMBL3297705,=,=,IC50,nM,9.0,IC50,nM,9.0,Cc1cc(Nc2ncc3c(n2)CN(C(=O)N[C@H](C)c2ccc(Cl)c(Cl)c2)CC3)ccn1,2014.0
Inhibition of Cdk2 (unknown origin),C[C@@H](NC(=O)N1CCc2cnc(Nc3cnn(C)c3)nc2C1)c1ccc(Cl)c(Cl)c1,CHEMBL3297705,=,=,IC50,nM,4.0,IC50,nM,4.0,C[C@@H](NC(=O)N1CCc2cnc(Nc3cnn(C)c3)nc2C1)c1ccc(Cl)c(Cl)c1,2014.0
Inhibition of Cdk2 (unknown origin),C[C@@H](NC(=O)N1CCc2cnc(Nc3ccnn3C)nc2C1)c1ccc(Cl)c(Cl)c1,CHEMBL3297705,=,=,IC50,nM,23.0,IC50,nM,23.0,C[C@@H](NC(=O)N1CCc2cnc(Nc3ccnn3C)nc2C1)c1ccc(Cl)c(Cl)c1,2014.0
Inhibition of CDK2 (unknown origin),Clc1ccc(-c2ccc(-c3nccn3-c3ccc(N4CCNCC4)cc3)o2)cc1,CHEMBL3351352,>,>,IC50,nM,30000.0,IC50,uM,30.0,Clc1ccc(-c2ccc(-c3nccn3-c3ccc(N4CCNCC4)cc3)o2)cc1,2014.0
Inhibition of human recombinant CDK2 using Ulight-CFFKNIVTPRTPPPSQGK-amide substrate assessed as remaining enzyme activity at 1 uM after 30 mins relative to control,O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Br)c(O)c(Br)c1,CHEMBL3352815,=,=,Activity,%,95.0,Activity,%,95.0,O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Br)c(O)c(Br)c1,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1O,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1O,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)nc(C)nc2cc1O,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)nc(C)nc2cc1O,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCO,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCO,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCC(=O)O,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCC(=O)O,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCC(N)=O,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCC(N)=O,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)nc(N)nc2cc1O,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)nc(N)nc2cc1O,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)nc(NCCc3ccccn3)nc2cc1O,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)nc(NCCc3ccccn3)nc2cc1O,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)ccc1O,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)ccc1O,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,O=C(Nc1ccc(NC(=O)c2ccccn2)cc1)c1ccc(O)c([N+](=O)[O-])c1,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C(Nc1ccc(NC(=O)c2ccccn2)cc1)c1ccc(O)c([N+](=O)[O-])c1,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)ccc1O,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)ccc1O,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)c(N)cc1O,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)c(N)cc1O,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)ccc1OCC(=O)O,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)ccc1OCC(=O)O,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)cc(-c2c[nH]c(=O)[nH]c2=O)c1,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)cc(-c2c[nH]c(=O)[nH]c2=O)c1,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,O=C(Nc1ccc(NC(=O)c2ccccn2)cc1)c1cccc(-c2c[nH]c(=O)[nH]c2=O)c1,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C(Nc1ccc(NC(=O)c2ccccn2)cc1)c1cccc(-c2c[nH]c(=O)[nH]c2=O)c1,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1ccc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)cc1-c1c[nH]c(=O)[nH]c1=O,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)cc1-c1c[nH]c(=O)[nH]c1=O,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)cc(N2CCC(=O)NC2=O)c1,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)cc(N2CCC(=O)NC2=O)c1,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,COc1cc(C(=O)Nc2ccc(NC(=O)C3CCCCN3)cc2)cc(-c2c[nH]c(=O)[nH]c2=O)c1,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc(C(=O)Nc2ccc(NC(=O)C3CCCCN3)cc2)cc(-c2c[nH]c(=O)[nH]c2=O)c1,2014.0
Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay,CCNC(=O)Nc1ccc(NC(=O)c2cc(OC)cc(-c3c[nH]c(=O)[nH]c3=O)c2)cc1,CHEMBL3351874,>,>,IC50,nM,30000.0,IC50,uM,30.0,CCNC(=O)Nc1ccc(NC(=O)c2cc(OC)cc(-c3c[nH]c(=O)[nH]c3=O)c2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2cccc3nc(NC(=O)C4CC4)nn23)cc1,CHEMBL3351789,>,>,IC50,nM,10000.0,IC50,nM,10000.0,COc1ccc(-c2cccc3nc(NC(=O)C4CC4)nn23)cc1,2014.0
Inhibition of CDK2 (unknown origin),CC(=O)c1ccc(N2CCN(C(=O)CN3CC[C@@H](C(=O)Nc4ccc(O)c(Cl)c4)C3)CC2)cc1,CHEMBL3351461,>,>,IC50,nM,50000.0,IC50,uM,50.0,CC(=O)c1ccc(N2CCN(C(=O)CN3CC[C@@H](C(=O)Nc4ccc(O)c(Cl)c4)C3)CC2)cc1,2014.0
Inhibition of CDK2 (unknown origin),COC1CCN(c2nccc(Nc3cc(NC(=O)c4c(Cl)cccc4Cl)ccn3)n2)CC1,CHEMBL3351701,=,=,IC50,nM,503.0,IC50,nM,503.0,COC1CCN(c2nccc(Nc3cc(NC(=O)c4c(Cl)cccc4Cl)ccn3)n2)CC1,2014.0
Inhibition of CDK2 (unknown origin),COC1CCN(c2nccc(Nc3cc4[nH]c(-c5cn[nH]c5)nc4cn3)n2)CC1,CHEMBL3351701,=,=,IC50,nM,90.0,IC50,nM,90.0,COC1CCN(c2nccc(Nc3cc4[nH]c(-c5cn[nH]c5)nc4cn3)n2)CC1,2014.0
Inhibition of CDK2 (unknown origin),COC1CCN(c2nccc(Nc3cc4[nH]c(-c5cn[nH]c5)cc4cn3)n2)CC1,CHEMBL3351701,=,=,IC50,nM,5.0,IC50,nM,5.0,COC1CCN(c2nccc(Nc3cc4[nH]c(-c5cn[nH]c5)cc4cn3)n2)CC1,2014.0
Inhibition of CDK2 (unknown origin),COC1CCN(c2nccc(Nc3cc4c(cn3)cc(-c3cn[nH]c3)n4C(C)C)n2)CC1,CHEMBL3351701,=,=,IC50,nM,10.0,IC50,nM,10.0,COC1CCN(c2nccc(Nc3cc4c(cn3)cc(-c3cn[nH]c3)n4C(C)C)n2)CC1,2014.0
Inhibition of CDK2 (unknown origin),COC1CCN(c2nccc(Nc3cc4c(ccn4C(C)C)cn3)n2)CC1,CHEMBL3351701,=,=,IC50,nM,80.0,IC50,nM,80.0,COC1CCN(c2nccc(Nc3cc4c(ccn4C(C)C)cn3)n2)CC1,2014.0
Inhibition of CDK2 (unknown origin),COC1CCN(c2nccc(Nc3cc4c(ccn4C4CCCC4)cn3)n2)CC1,CHEMBL3351701,=,=,IC50,nM,93.0,IC50,nM,93.0,COC1CCN(c2nccc(Nc3cc4c(ccn4C4CCCC4)cn3)n2)CC1,2014.0
Inhibition of CDK2 (unknown origin),COC1CCN(c2nccc(Nc3cc4c(cn3)ncn4C(C)C)n2)CC1,CHEMBL3351701,=,=,IC50,nM,2220.0,IC50,nM,2220.0,COC1CCN(c2nccc(Nc3cc4c(cn3)ncn4C(C)C)n2)CC1,2014.0
Inhibition of CDK2 (unknown origin),COC1CCN(c2nccc(Nc3cc4c(cn3)c(N)nn4C(C)C)n2)CC1,CHEMBL3351701,=,=,IC50,nM,530.0,IC50,nM,530.0,COC1CCN(c2nccc(Nc3cc4c(cn3)c(N)nn4C(C)C)n2)CC1,2014.0
Inhibition of CDK2 (unknown origin),COC1CCN(c2nccc(Nc3cc4c(C(C)C)n[nH]c4cn3)n2)CC1,CHEMBL3351701,=,=,IC50,nM,476.0,IC50,nM,476.0,COC1CCN(c2nccc(Nc3cc4c(C(C)C)n[nH]c4cn3)n2)CC1,2014.0
Inhibition of CDK2 (unknown origin) assessed as residual enzyme activity at 10 uM,CO[C@H]1CC[C@H](NC(=O)c2n[nH]cc2NC(=O)c2ccccc2)CC1,CHEMBL3352013,=,=,Activity,%,1.0,Activity,%,1.0,CO[C@H]1CC[C@H](NC(=O)c2n[nH]cc2NC(=O)c2ccccc2)CC1,2014.0
Inhibition of CDK2 (unknown origin) assessed as residual enzyme activity at 10 uM,COc1cccc(OC)c1C(=O)Nc1c[nH]nc1C(=O)N[C@H]1CC[C@H](OC)CC1,CHEMBL3352013,=,=,Activity,%,9.0,Activity,%,9.0,COc1cccc(OC)c1C(=O)Nc1c[nH]nc1C(=O)N[C@H]1CC[C@H](OC)CC1,2014.0
Inhibition of CDK2 (unknown origin) assessed as residual enzyme activity at 10 uM,CO[C@H]1CC[C@H](NC(=O)c2n[nH]cc2NC(=O)c2ccc(-c3ccccc3)o2)CC1,CHEMBL3352013,=,=,Activity,%,1.0,Activity,%,1.0,CO[C@H]1CC[C@H](NC(=O)c2n[nH]cc2NC(=O)c2ccc(-c3ccccc3)o2)CC1,2014.0
Inhibition of CDK2 (unknown origin) assessed as residual enzyme activity at 10 uM,COc1cccc(OC)c1C(=O)Nc1c[nH]nc1C(=O)NCc1ccccc1,CHEMBL3352013,=,=,Activity,%,38.0,Activity,%,38.0,COc1cccc(OC)c1C(=O)Nc1c[nH]nc1C(=O)NCc1ccccc1,2014.0
Inhibition of CDK2 (unknown origin) at 1 uM,Nc1ncc(-c2ccc3[nH]nc(-c4cnc5ccccc5c4)c3c2)s1,CHEMBL3393014,>,>,Inhibition,%,90.0,INH,%,90.0,Nc1ncc(-c2ccc3[nH]nc(-c4cnc5ccccc5c4)c3c2)s1,2015.0
Inhibition of CDK2 (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay,CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2C2CCCCC2)ccn1,CHEMBL3393036,<,<,Inhibition,%,50.0,INH,%,50.0,CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2C2CCCCC2)ccn1,2015.0
Inhibition of CDK2 (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay,COC(Cn1c(SC2CCC(C(=O)O)CC2O)nc(-c2ccc(F)cc2)c1-c1ccnc(NC(C)=O)c1)OC,CHEMBL3393036,<,<,Inhibition,%,50.0,INH,%,50.0,COC(Cn1c(SC2CCC(C(=O)O)CC2O)nc(-c2ccc(F)cc2)c1-c1ccnc(NC(C)=O)c1)OC,2015.0
Inhibition of CDK2 (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay,CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2C2CC2)ccn1,CHEMBL3393036,<,<,Inhibition,%,50.0,INH,%,50.0,CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2C2CC2)ccn1,2015.0
Inhibition of CDK2 (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay,CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2CC2CCCO2)ccn1,CHEMBL3393036,<,<,Inhibition,%,50.0,INH,%,50.0,CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2CC2CCCO2)ccn1,2015.0
Inhibition of CDK2 (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay,CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(Sc3cccc(I)n3)n2C2CCCCC2)ccn1,CHEMBL3393036,<,<,Inhibition,%,50.0,INH,%,50.0,CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(Sc3cccc(I)n3)n2C2CCCCC2)ccn1,2015.0
Inhibition of CDK2 (unknown origin) at 1 ug/ml relative to control,CN(C(=O)c1ccccc1)c1ccc2[nH]c(-c3n[nH]c4ccccc34)cc2n1,CHEMBL3399927,=,=,Inhibition,%,28.23,INH,%,28.23,CN(C(=O)c1ccccc1)c1ccc2[nH]c(-c3n[nH]c4ccccc34)cc2n1,2015.0
Inhibition of CDK2 (unknown origin) at 1 ug/ml relative to control,CN(C(=O)c1ccc(Cl)cc1)c1ccc2[nH]c(-c3n[nH]c4ccccc34)cc2n1,CHEMBL3399927,=,=,Inhibition,%,35.47,INH,%,35.47,CN(C(=O)c1ccc(Cl)cc1)c1ccc2[nH]c(-c3n[nH]c4ccccc34)cc2n1,2015.0
Inhibition of CDK2 (unknown origin) at 1 ug/ml relative to control,CN(C(=O)Nc1ccccc1)c1ccc2[nH]c(-c3n[nH]c4ccccc34)cc2n1,CHEMBL3399927,=,=,Inhibition,%,13.77,INH,%,13.77,CN(C(=O)Nc1ccccc1)c1ccc2[nH]c(-c3n[nH]c4ccccc34)cc2n1,2015.0
Inhibition of CDK2 (unknown origin),Fc1cnc2[nH]cc(-c3ncc(F)c(N[C@H]4C5CCC(CC5)[C@@H]4c4nnn[nH]4)n3)c2c1,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,Fc1cnc2[nH]cc(-c3ncc(F)c(N[C@H]4C5CCC(CC5)[C@@H]4c4nnn[nH]4)n3)c2c1,2015.0
Inhibition of CDK2 (unknown origin),O=P(O)(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,O=P(O)(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015.0
Inhibition of CDK2 (unknown origin),O=P(O)(O)CC[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,O=P(O)(O)CC[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015.0
Inhibition of CDK2 (unknown origin),O=c1[nH]c(=O)n(C[C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)o1,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,O=c1[nH]c(=O)n(C[C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)o1,2015.0
Inhibition of CDK2 (unknown origin),Oc1cc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)no1,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,Oc1cc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)no1,2015.0
Inhibition of CDK2 (unknown origin),CC(=O)NS(=O)(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,CC(=O)NS(=O)(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015.0
Inhibition of CDK2 (unknown origin),Oc1cc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)on1,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,Oc1cc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)on1,2015.0
Inhibition of CDK2 (unknown origin),O=c1nc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)[nH]o1,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,O=c1nc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)[nH]o1,2015.0
Inhibition of CDK2 (unknown origin),NS(=O)(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,NS(=O)(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015.0
Inhibition of CDK2 (unknown origin),OCC(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,OCC(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015.0
Inhibition of CDK2 (unknown origin),Oc1cc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)[nH]n1,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,Oc1cc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)[nH]n1,2015.0
Inhibition of CDK2 (unknown origin),CNC(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,CNC(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015.0
Inhibition of CDK2 (unknown origin),CC(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,=,=,Ki,nM,1200.0,Ki,uM,1.2,CC(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015.0
Inhibition of CDK2 (unknown origin),Cc1noc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)n1,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,Cc1noc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)n1,2015.0
Inhibition of CDK2 (unknown origin),Cc1nnc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)o1,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,Cc1nnc([C@H]2C3CCC(CC3)[C@@H]2Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)o1,2015.0
Inhibition of CDK2 (unknown origin),CS(=O)(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,CHEMBL3399966,>,>,Ki,nM,4000.0,Ki,uM,4.0,CS(=O)(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,COc1cc(N2CCN(C)CC2)ccc1Nc1cc(-c2c[nH]c3cnccc23)ncn1,CHEMBL3421608,=,=,IC50,nM,12295.0,IC50,uM,12.295,COc1cc(N2CCN(C)CC2)ccc1Nc1cc(-c2c[nH]c3cnccc23)ncn1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,CN1CCN(c2ccc(Nc3cc(-c4c[nH]c5cnccc45)ncn3)cc2)CC1,CHEMBL3421608,=,=,IC50,nM,577.0,IC50,uM,0.577,CN1CCN(c2ccc(Nc3cc(-c4c[nH]c5cnccc45)ncn3)cc2)CC1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,CN1CCN(c2ccc(Nc3cc(-c4c[nH]c5ccccc45)ncn3)cc2)CC1,CHEMBL3421608,=,=,IC50,nM,33215.0,IC50,uM,33.215,CN1CCN(c2ccc(Nc3cc(-c4c[nH]c5ccccc45)ncn3)cc2)CC1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1cc(-c2c[nH]c3cnccc23)ncn1,CHEMBL3421608,=,=,IC50,nM,14060.0,IC50,uM,14.06,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1cc(-c2c[nH]c3cnccc23)ncn1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1cc(-c2cn(C)c3cnccc23)ncn1,CHEMBL3421608,=,=,IC50,nM,14789.0,IC50,uM,14.789,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1cc(-c2cn(C)c3cnccc23)ncn1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1nccc(-c2c[nH]c3cnccc23)n1,CHEMBL3421608,=,=,IC50,nM,1995.0,IC50,uM,1.995,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1nccc(-c2c[nH]c3cnccc23)n1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2c[nH]c3cnccc23)n1,CHEMBL3421608,=,=,IC50,nM,1819.0,IC50,uM,1.819,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2c[nH]c3cnccc23)n1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2cn(C)c3cnccc23)n1,CHEMBL3421608,=,=,IC50,nM,4473.0,IC50,uM,4.473,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2cn(C)c3cnccc23)n1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2c[nH]c3cnc(C)cc23)n1,CHEMBL3421608,=,=,IC50,nM,10476.0,IC50,uM,10.476,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2c[nH]c3cnc(C)cc23)n1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2c[nH]c3c(C)nccc23)n1,CHEMBL3421608,=,=,IC50,nM,17368.0,IC50,uM,17.368,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2c[nH]c3c(C)nccc23)n1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2cn(C)c3c(C)nccc23)n1,CHEMBL3421608,=,=,IC50,nM,13713.0,IC50,uM,13.713,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2cn(C)c3c(C)nccc23)n1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,CN1CCN(c2ccc(Nc3ncc(Cl)c(-c4c[nH]c5cnccc45)n3)cc2)CC1,CHEMBL3421608,=,=,IC50,nM,20.0,IC50,uM,0.02,CN1CCN(c2ccc(Nc3ncc(Cl)c(-c4c[nH]c5cnccc45)n3)cc2)CC1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,O=C(NC1CCCC1)c1ccc(-c2nccc(-c3c[nH]c4cnccc34)n2)cc1,CHEMBL3421608,=,=,IC50,nM,45885.0,IC50,uM,45.885,O=C(NC1CCCC1)c1ccc(-c2nccc(-c3c[nH]c4cnccc34)n2)cc1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,CS(=O)(=O)c1ccc(-c2nccc(-c3c[nH]c4cnccc34)n2)cc1,CHEMBL3421608,=,=,IC50,nM,16884.0,IC50,uM,16.884,CS(=O)(=O)c1ccc(-c2nccc(-c3c[nH]c4cnccc34)n2)cc1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,Cn1cc(-c2ccnc(-c3ccc(S(C)(=O)=O)cc3)n2)c2ccncc21,CHEMBL3421608,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cn1cc(-c2ccnc(-c3ccc(S(C)(=O)=O)cc3)n2)c2ccncc21,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,Cc1nccc2c(-c3ccnc(-c4ccc(S(C)(=O)=O)cc4)n3)c[nH]c12,CHEMBL3421608,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1nccc2c(-c3ccnc(-c4ccc(S(C)(=O)=O)cc4)n3)c[nH]c12,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,C(=C/c1nccc(-c2c[nH]c3cnccc23)n1)\c1ccccc1,CHEMBL3421608,=,=,IC50,nM,5176.0,IC50,uM,5.176,C(=C/c1nccc(-c2c[nH]c3cnccc23)n1)\c1ccccc1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,Cc1nccc(-c2c[nH]c3cnccc23)n1,CHEMBL3421608,=,=,IC50,nM,38379.0,IC50,uM,38.379,Cc1nccc(-c2c[nH]c3cnccc23)n1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,Cc1nccc(-c2cn(Cc3ccccc3)c3cnccc23)n1,CHEMBL3421608,=,=,IC50,nM,56703.0,IC50,uM,56.703,Cc1nccc(-c2cn(Cc3ccccc3)c3cnccc23)n1,2015.0
Inhibition of human recombinant full length C-terminal His6-tagged CDK2 expressed in baculovirus infected Sf21 insect cells using fluorescence substrate after 60 mins by caliper off-chip incubation mobility shift assay,c1cc2c(-c3ccnc4[nH]ccc34)c[nH]c2cn1,CHEMBL3421608,=,=,IC50,nM,314.0,IC50,uM,0.314,c1cc2c(-c3ccnc4[nH]ccc34)c[nH]c2cn1,2015.0
Binding affinity to N-terminal His-tagged CDK2 (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as melting temperature by thermal shift assay (Rvb = 41.5 degC),O=C(O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1,CHEMBL3425453,=,=,Tm,degrees C,47.7,Tm,degrees C,47.7,O=C(O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1,2015.0
Inhibition of human CDK2,CCn1nc(C#Cc2cc(C(=O)Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)ccc2C)c2c(N)ncnc21,CHEMBL3425429,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCn1nc(C#Cc2cc(C(=O)Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)ccc2C)c2c(N)ncnc21,2015.0
Binding affinity to N-terminal His-tagged CDK2 (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as melting temperature by thermal shift assay (Rvb = 41.5 degC),O=C(O)[C@H]1CSC(c2ccc3cc(O)ccc3n2)=N1,CHEMBL3425453,=,=,Tm,degrees C,43.4,Tm,degrees C,43.4,O=C(O)[C@H]1CSC(c2ccc3cc(O)ccc3n2)=N1,2015.0
Binding affinity to N-terminal His-tagged CDK2 (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as melting temperature by thermal shift assay (Rvb = 41.5 degC),O=C(O)[C@H]1CSC(c2ccc3cccc(O)c3n2)=N1,CHEMBL3425453,=,=,Tm,degrees C,43.9,Tm,degrees C,43.9,O=C(O)[C@H]1CSC(c2ccc3cccc(O)c3n2)=N1,2015.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.9,Thermal melting change,degrees C,0.9,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.6,Thermal melting change,degrees C,-0.6,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.1,Thermal melting change,degrees C,0.1,CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1,CHEMBL1145498,=,=,Thermal melting change,degrees C,3.0,Thermal melting change,degrees C,3.0,Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.9,Thermal melting change,degrees C,0.9,Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.7,Thermal melting change,degrees C,-0.7,NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.4,Thermal melting change,degrees C,0.4,O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C(O)Cc1ccc(O)c([N+](=O)[O-])c1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.1,Thermal melting change,degrees C,1.1,O=C(O)Cc1ccc(O)c([N+](=O)[O-])c1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,5.9,Thermal melting change,degrees C,5.9,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,5.2,Thermal melting change,degrees C,5.2,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.2,Thermal melting change,degrees C,0.2,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1,CHEMBL1145498,=,=,Thermal melting change,degrees C,6.3,Thermal melting change,degrees C,6.3,N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2,CHEMBL1145498,=,=,Thermal melting change,degrees C,6.6,Thermal melting change,degrees C,6.6,N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\O,CHEMBL1145498,=,=,Thermal melting change,degrees C,9.1,Thermal melting change,degrees C,9.1,O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F,CHEMBL1145498,=,=,Thermal melting change,degrees C,15.9,Thermal melting change,degrees C,15.9,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cn1cc(/C=C2/C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.3,Thermal melting change,degrees C,1.3,Cn1cc(/C=C2/C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.0,Thermal melting change,degrees C,0.0,,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CCOc1ccc(/C=C2/SC(=O)N(CCN)C2=O)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.1,Thermal melting change,degrees C,-0.1,CCOc1ccc(/C=C2/SC(=O)N(CCN)C2=O)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=c1c(-c2ccc(F)cc2)c(-c2ccncc2)[nH]n1-c1ccc(Cl)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.2,Thermal melting change,degrees C,0.2,O=c1c(-c2ccc(F)cc2)c(-c2ccncc2)[nH]n1-c1ccc(Cl)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.5,Thermal melting change,degrees C,-0.5,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.8,Thermal melting change,degrees C,-0.8,Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1nccc(-c2c(-c3ccc(F)cc3)ncn2[C@H]2CC[C@H](O)CC2)n1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.6,Thermal melting change,degrees C,-0.6,COc1nccc(-c2c(-c3ccc(F)cc3)ncn2[C@H]2CC[C@H](O)CC2)n1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.9,Thermal melting change,degrees C,0.9,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.8,Thermal melting change,degrees C,-0.8,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.4,Thermal melting change,degrees C,-0.4,CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.5,Thermal melting change,degrees C,-0.5,COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.4,Thermal melting change,degrees C,-0.4,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cl.NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.1,Thermal melting change,degrees C,0.1,Cl.NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)c(C)c1C(=O)N1CCN(C)CC1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.4,Thermal melting change,degrees C,-0.4,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)c(C)c1C(=O)N1CCN(C)CC1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.1,Thermal melting change,degrees C,0.1,Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.0,Thermal melting change,degrees C,0.0,COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,,CHEMBL1145498,=,=,Thermal melting change,degrees C,2.9,Thermal melting change,degrees C,2.9,,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-1.5,Thermal melting change,degrees C,-1.5,O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CN(c1cccnc1)c1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cn1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.5,Thermal melting change,degrees C,-0.5,CN(c1cccnc1)c1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cn1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12,CHEMBL1145498,=,=,Thermal melting change,degrees C,10.6,Thermal melting change,degrees C,10.6,CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.2,Thermal melting change,degrees C,0.2,Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,CHEMBL1145498,=,=,Thermal melting change,degrees C,6.1,Thermal melting change,degrees C,6.1,Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.0,Thermal melting change,degrees C,0.0,O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.3,Thermal melting change,degrees C,-0.3,,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1,CHEMBL1145498,=,=,Thermal melting change,degrees C,3.3,Thermal melting change,degrees C,3.3,CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.6,Thermal melting change,degrees C,-0.6,COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CN1CCc2[nH]c(=S)c(C#N)c(-c3cccs3)c2C1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.0,Thermal melting change,degrees C,0.0,CN1CCc2[nH]c(=S)c(C#N)c(-c3cccs3)c2C1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(O)c1c(F)cccc1F,CHEMBL1145498,=,=,Thermal melting change,degrees C,8.2,Thermal melting change,degrees C,8.2,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(O)c1c(F)cccc1F,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.2,Thermal melting change,degrees C,0.2,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.5,Thermal melting change,degrees C,-0.5,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CN1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.1,Thermal melting change,degrees C,0.1,CN1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.0,Thermal melting change,degrees C,0.0,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.8,Thermal melting change,degrees C,1.8,O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Brc1c(Br)c(Br)c2[nH]nnc2c1Br,CHEMBL1145498,=,=,Thermal melting change,degrees C,2.2,Thermal melting change,degrees C,2.2,Brc1c(Br)c(Br)c2[nH]nnc2c1Br,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Nc1cc2ncnc(Nc3cccc(Br)c3)c2cc1N,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.4,Thermal melting change,degrees C,1.4,Nc1cc2ncnc(Nc3cccc(Br)c3)c2cc1N,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.4,Thermal melting change,degrees C,0.4,CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,NC1=N/C(=C2/CCNC(=O)c3[nH]ccc32)C(=O)N1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.7,Thermal melting change,degrees C,0.7,NC1=N/C(=C2/CCNC(=O)c3[nH]ccc32)C(=O)N1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1cc(C[C@H]2C(=O)OC[C@@H]2Cc2ccc(OC)c(OC)c2)ccc1O,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.6,Thermal melting change,degrees C,0.6,COc1cc(C[C@H]2C(=O)OC[C@@H]2Cc2ccc(OC)c(OC)c2)ccc1O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1C=C2C(=Nc3c2c2c(c4c3=NC3=C4CCC=C3)C=NC=2)CC1,CHEMBL1145498,=,=,Thermal melting change,degrees C,4.0,Thermal melting change,degrees C,4.0,O=C1C=C2C(=Nc3c2c2c(c4c3=NC3=C4CCC=C3)C=NC=2)CC1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC.[Cl-],CHEMBL1145498,=,=,Thermal melting change,degrees C,0.2,Thermal melting change,degrees C,0.2,COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC.[Cl-],2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.1,Thermal melting change,degrees C,0.1,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,C[S+]([O-])c1ccc(CSc2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.5,Thermal melting change,degrees C,0.5,C[S+]([O-])c1ccc(CSc2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,CHEMBL1145498,=,=,Thermal melting change,degrees C,2.3,Thermal melting change,degrees C,2.3,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.7,Thermal melting change,degrees C,0.7,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.4,Thermal melting change,degrees C,0.4,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(C)c1cc(/C=C(\C#N)C(=O)NCCCc2ccccc2)cc(C(C)C)c1O,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.2,Thermal melting change,degrees C,1.2,CC(C)c1cc(/C=C(\C#N)C(=O)NCCCc2ccccc2)cc(C(C)C)c1O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cc1cc2ncc(-c3ccccc3)nc2cc1C,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.3,Thermal melting change,degrees C,0.3,Cc1cc2ncc(-c3ccccc3)nc2cc1C,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.4,Thermal melting change,degrees C,1.4,,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.1,Thermal melting change,degrees C,0.1,CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.7,Thermal melting change,degrees C,0.7,CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Nc1ncnc2c1c(I)cn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,CHEMBL1145498,=,=,Thermal melting change,degrees C,2.9,Thermal melting change,degrees C,2.9,Nc1ncnc2c1c(I)cn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C(O)c1cc(NCc2cc(O)ccc2O)ccc1O,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.4,Thermal melting change,degrees C,0.4,O=C(O)c1cc(NCc2cc(O)ccc2O)ccc1O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,OC[C@H]1O[C@@H](n2cnc3cc(Cl)c(Cl)cc32)[C@H](O)[C@@H]1O,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.3,Thermal melting change,degrees C,0.3,OC[C@H]1O[C@@H](n2cnc3cc(Cl)c(Cl)cc32)[C@H](O)[C@@H]1O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C(O)c1cc(N(Cc2ccccc2O)Cc2cc(O)ccc2O)ccc1O,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.3,Thermal melting change,degrees C,1.3,O=C(O)c1cc(N(Cc2ccccc2O)Cc2cc(O)ccc2O)ccc1O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1Nc2ccc(I)cc2/C1=C\c1cc(Br)c(O)c(Br)c1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.2,Thermal melting change,degrees C,1.2,O=C1Nc2ccc(I)cc2/C1=C\c1cc(Br)c(O)c(Br)c1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.9,Thermal melting change,degrees C,0.9,CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CN(C)c1ncnc2nc[nH]c12,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.3,Thermal melting change,degrees C,0.3,CN(C)c1ncnc2nc[nH]c12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cc1ccc2c(c1)C(=O)c1cc(O)cc(O)c1C2=O,CHEMBL1145498,=,=,Thermal melting change,degrees C,3.2,Thermal melting change,degrees C,3.2,Cc1ccc2c(c1)C(=O)c1cc(O)cc(O)c1C2=O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=c1ccc2ccc(O)c(O)c2o1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.7,Thermal melting change,degrees C,0.7,O=c1ccc2ccc(O)c(O)c2o1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1cc(O)c2c(c1)oc(=O)c1c3cc(O)c(O)cc3oc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,-4.5,Thermal melting change,degrees C,-4.5,COc1cc(O)c2c(c1)oc(=O)c1c3cc(O)c(O)cc3oc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12,CHEMBL1145498,=,=,Thermal melting change,degrees C,4.7,Thermal melting change,degrees C,4.7,CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.2,Thermal melting change,degrees C,0.2,O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1,CHEMBL1145498,=,=,Thermal melting change,degrees C,3.6,Thermal melting change,degrees C,3.6,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1,CHEMBL1145498,=,=,Thermal melting change,degrees C,4.4,Thermal melting change,degrees C,4.4,O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,N#CC(C#N)=Cc1ccc(O)c(O)c1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.1,Thermal melting change,degrees C,1.1,N#CC(C#N)=Cc1ccc(O)c(O)c1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.9,Thermal melting change,degrees C,0.9,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1ccccc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.1,Thermal melting change,degrees C,1.1,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1ccccc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CCOc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2)c1O,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.8,Thermal melting change,degrees C,0.8,CCOc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2)c1O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.0,Thermal melting change,degrees C,1.0,C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O,CHEMBL1145498,=,=,Thermal melting change,degrees C,4.1,Thermal melting change,degrees C,4.1,O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.5,Thermal melting change,degrees C,0.5,C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1c2ccccc2-c2n[nH]c3cccc1c23,CHEMBL1145498,=,=,Thermal melting change,degrees C,2.6,Thermal melting change,degrees C,2.6,O=C1c2ccccc2-c2n[nH]c3cccc1c23,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,,CHEMBL1145498,=,=,Thermal melting change,degrees C,6.1,Thermal melting change,degrees C,6.1,,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccccc2)c2ccc(F)cc2)CC1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.2,Thermal melting change,degrees C,1.2,Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccccc2)c2ccc(F)cc2)CC1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.6,Thermal melting change,degrees C,1.6,Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.7,Thermal melting change,degrees C,0.7,Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C,CHEMBL1145498,=,=,Thermal melting change,degrees C,-3.4,Thermal melting change,degrees C,-3.4,CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CN(C)c1ccc(CC2C(=O)Nc3ccccc32)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.0,Thermal melting change,degrees C,1.0,CN(C)c1ccc(CC2C(=O)Nc3ccccc32)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCC(Br)C2,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.1,Thermal melting change,degrees C,0.1,O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCC(Br)C2,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CCOC(=O)c1cnc2oc3ccc(O)cc3c2c1-c1ccccc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.0,Thermal melting change,degrees C,1.0,CCOC(=O)c1cnc2oc3ccc(O)cc3c2c1-c1ccccc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21.[Cl-],CHEMBL1145498,=,=,Thermal melting change,degrees C,0.0,Thermal melting change,degrees C,0.0,O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21.[Cl-],2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.5,Thermal melting change,degrees C,0.5,COC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.3,Thermal melting change,degrees C,0.3,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1Nc2ccccc2/C1=C/c1cnc[nH]1,CHEMBL1145498,=,=,Thermal melting change,degrees C,6.6,Thermal melting change,degrees C,6.6,O=C1Nc2ccccc2/C1=C/c1cnc[nH]1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=S(=O)(c1cccc2c(Cl)cccc12)N1CCCNCC1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.8,Thermal melting change,degrees C,0.8,O=S(=O)(c1cccc2c(Cl)cccc12)N1CCCNCC1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.9,Thermal melting change,degrees C,1.9,COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,NC1=NC(=O)/C(=C2\CCNC(=O)c3[nH]c(Br)cc32)N1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.5,Thermal melting change,degrees C,1.5,NC1=NC(=O)/C(=C2\CCNC(=O)c3[nH]c(Br)cc32)N1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12,CHEMBL1145498,=,=,Thermal melting change,degrees C,6.6,Thermal melting change,degrees C,6.6,O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COC(=O)[C@]1(O)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1145498,=,=,Thermal melting change,degrees C,10.3,Thermal melting change,degrees C,10.3,COC(=O)[C@]1(O)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.0,Thermal melting change,degrees C,0.0,COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cl.NCCNS(=O)(=O)c1cccc2c(Cl)cccc12,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.1,Thermal melting change,degrees C,0.1,Cl.NCCNS(=O)(=O)c1cccc2c(Cl)cccc12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cc1cc(C=C2C(=O)C=CC2=O)cc(C)c1O,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.0,Thermal melting change,degrees C,1.0,Cc1cc(C=C2C(=O)C=CC2=O)cc(C)c1O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(C)(C)c1cc(C=C2C(=O)C=CC2=O)cc(C(C)(C)C)c1O,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.2,Thermal melting change,degrees C,1.2,CC(C)(C)c1cc(C=C2C(=O)C=CC2=O)cc(C(C)(C)C)c1O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.2,Thermal melting change,degrees C,1.2,CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(C)N(CCO)c1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,CHEMBL1145498,=,=,Thermal melting change,degrees C,4.5,Thermal melting change,degrees C,4.5,CC(C)N(CCO)c1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,N=C(N)NCCNS(=O)(=O)c1cccc2cnccc12,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.3,Thermal melting change,degrees C,0.3,N=C(N)NCCNS(=O)(=O)c1cccc2cnccc12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CNC(=O)c1cc(Oc2ccc(Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-3.5,Thermal melting change,degrees C,-3.5,CNC(=O)c1cc(Oc2ccc(Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.8,Thermal melting change,degrees C,0.8,COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CCn1cnc2c(N)nc(N(c3cccc(Cl)c3)[C@@H]3CCCC[C@@H]3N)nc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,4.7,Thermal melting change,degrees C,4.7,CCn1cnc2c(N)nc(N(c3cccc(Cl)c3)[C@@H]3CCCC[C@@H]3N)nc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.6,Thermal melting change,degrees C,1.6,CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.4,Thermal melting change,degrees C,0.4,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(C)n1cnc2c(NCc3ccccc3O)nc(NCCCO)nc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.2,Thermal melting change,degrees C,1.2,CC(C)n1cnc2c(NCc3ccccc3O)nc(NCCCO)nc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.6,Thermal melting change,degrees C,1.6,COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.5,Thermal melting change,degrees C,-0.5,O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cc1ccc(NC(=O)c2cccc(N(C)C)c2)cc1NC(=O)c1ccc(O)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.3,Thermal melting change,degrees C,0.3,Cc1ccc(NC(=O)c2cccc(N(C)C)c2)cc1NC(=O)c1ccc(O)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.4,Thermal melting change,degrees C,0.4,Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,C[C@@H]1C[C@H]2O[C@@H]2/C=C\C=C\C(=O)Cc2c(Cl)c(O)cc(O)c2C(=O)O1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.5,Thermal melting change,degrees C,0.5,C[C@@H]1C[C@H]2O[C@@H]2/C=C\C=C\C(=O)Cc2c(Cl)c(O)cc(O)c2C(=O)O1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2,CHEMBL1145498,=,=,Thermal melting change,degrees C,2.3,Thermal melting change,degrees C,2.3,CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.5,Thermal melting change,degrees C,0.5,O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.5,Thermal melting change,degrees C,1.5,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C(O)/C=C/c1cc(CO)ccc1CO,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.9,Thermal melting change,degrees C,0.9,O=C(O)/C=C/c1cc(CO)ccc1CO,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1cccc(-c2cc(=O)c3ccccc3o2)c1N,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.3,Thermal melting change,degrees C,0.3,COc1cccc(-c2cc(=O)c3ccccc3o2)c1N,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1CC(=O)c2[nH]c3c4[nH]c5c(c4c4cn(Br)cc4c3c2C1)CCC=C5,CHEMBL1145498,=,=,Thermal melting change,degrees C,3.6,Thermal melting change,degrees C,3.6,O=C1CC(=O)c2[nH]c3c4[nH]c5c(c4c4cn(Br)cc4c3c2C1)CCC=C5,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Oc1cc(O)cc(/C=C/c2ccc(O)c(O)c2)c1,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.2,Thermal melting change,degrees C,1.2,Oc1cc(O)cc(/C=C/c2ccc(O)c(O)c2)c1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,N#C/C(=C(/N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.4,Thermal melting change,degrees C,0.4,N#C/C(=C(/N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1Nc2ccc(I)cc2/C1=C1/Nc2ccccc2/C1=N\O,CHEMBL1145498,=,=,Thermal melting change,degrees C,6.8,Thermal melting change,degrees C,6.8,O=C1Nc2ccc(I)cc2/C1=C1/Nc2ccccc2/C1=N\O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1Nc2ccc(S(=O)(=O)O)cc2/C1=C1/Nc2ccccc2/C1=N\O,CHEMBL1145498,=,=,Thermal melting change,degrees C,8.1,Thermal melting change,degrees C,8.1,O=C1Nc2ccc(S(=O)(=O)O)cc2/C1=C1/Nc2ccccc2/C1=N\O,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,-1.1,Thermal melting change,degrees C,-1.1,O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.3,Thermal melting change,degrees C,-0.3,Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1Nc2ccccc2/C1=C\c1ccc[nH]1,CHEMBL1145498,=,=,Thermal melting change,degrees C,3.4,Thermal melting change,degrees C,3.4,O=C1Nc2ccccc2/C1=C\c1ccc[nH]1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,CHEMBL1145498,=,=,Thermal melting change,degrees C,5.3,Thermal melting change,degrees C,5.3,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(=O)O/N=C1C(=C2/C(=O)Nc3cc(Br)ccc32)/Nc2ccccc2/1,CHEMBL1145498,=,=,Thermal melting change,degrees C,3.2,Thermal melting change,degrees C,3.2,CC(=O)O/N=C1C(=C2/C(=O)Nc3cc(Br)ccc32)/Nc2ccccc2/1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.7,Thermal melting change,degrees C,1.7,CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CC(=O)O.Cn1cc(C2=C(c3cn(CCCN)c4ccccc34)C(=O)NC2=O)c2ccccc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,3.0,Thermal melting change,degrees C,3.0,CC(=O)O.Cn1cc(C2=C(c3cn(CCCN)c4ccccc34)C(=O)NC2=O)c2ccccc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.5,Thermal melting change,degrees C,1.5,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.5,Thermal melting change,degrees C,0.5,COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2,CHEMBL1145498,=,=,Thermal melting change,degrees C,6.1,Thermal melting change,degrees C,6.1,COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.9,Thermal melting change,degrees C,0.9,O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Nc1n[nH]c2nc3ccccc3nc12,CHEMBL1145498,=,=,Thermal melting change,degrees C,1.3,Thermal melting change,degrees C,1.3,Nc1n[nH]c2nc3ccccc3nc12,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CS(=O)(=O)O.Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,8.4,Thermal melting change,degrees C,8.4,CS(=O)(=O)O.Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Cl.Cn1cc(C2=C(c3ccc4cc5n(c4c3)CCC(CN)C5)C(=O)NC2=O)c2ccccc21,CHEMBL1145498,=,=,Thermal melting change,degrees C,2.4,Thermal melting change,degrees C,2.4,Cl.Cn1cc(C2=C(c3ccc4cc5n(c4c3)CCC(CN)C5)C(=O)NC2=O)c2ccccc21,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CN(C)CC1CCn2c(c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc32)C1,CHEMBL1145498,=,=,Thermal melting change,degrees C,2.5,Thermal melting change,degrees C,2.5,CN(C)CC1CCn2c(c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc32)C1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,CN[C@@H]1CC2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL1145498,=,=,Thermal melting change,degrees C,13.8,Thermal melting change,degrees C,13.8,CN[C@@H]1CC2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.7,Thermal melting change,degrees C,0.7,c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,COc1cc2ncnc(Nc3cccc(O)c3)c2cc1OC,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.3,Thermal melting change,degrees C,0.3,COc1cc2ncnc(Nc3cccc(O)c3)c2cc1OC,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.4,Thermal melting change,degrees C,0.4,Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.1,Thermal melting change,degrees C,-0.1,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,O=c1sn(Cc2ccccc2)c(=S)n1Cc1ccccc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.3,Thermal melting change,degrees C,0.3,O=c1sn(Cc2ccccc2)c(=S)n1Cc1ccccc1,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,C=CNC#N,CHEMBL1145498,=,=,Thermal melting change,degrees C,-0.2,Thermal melting change,degrees C,-0.2,C=CNC#N,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,N#CC(=C(/N)Sc1ccccc1N)/C(C#N)=C(/N)Sc1ccccc1N,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.7,Thermal melting change,degrees C,0.7,N#CC(=C(/N)Sc1ccccc1N)/C(C#N)=C(/N)Sc1ccccc1N,2007.0
Delta TM value showing the stabilisation of CDK2 produced by compound binding,NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1,CHEMBL1145498,=,=,Thermal melting change,degrees C,0.6,Thermal melting change,degrees C,0.6,NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1,2007.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1nc2ccccc2c2[nH]c3ccccc3c12,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)c1nc2ccccc2c2[nH]c3ccccc3c12,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,CC(C)(C)c1ccc2[nH]c3c4ccccc4nc(C(=O)O)c3c2c1,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(C)(C)c1ccc2[nH]c3c4ccccc4nc(C(=O)O)c3c2c1,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1nc2ccccc2c2[nH]c3ccc(C(F)(F)F)cc3c12,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)c1nc2ccccc2c2[nH]c3ccc(C(F)(F)F)cc3c12,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1nc2ccccc2c2[nH]c3ccc([N+](=O)[O-])cc3c12,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)c1nc2ccccc2c2[nH]c3ccc([N+](=O)[O-])cc3c12,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,Cc1ccc2[nH]c3c4ccccc4nc(C(=O)O)c3c2c1,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccc2[nH]c3c4ccccc4nc(C(=O)O)c3c2c1,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1ccc2[nH]c3c4ccccc4nc(C(=O)O)c3c2c1,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)c1ccc2[nH]c3c4ccccc4nc(C(=O)O)c3c2c1,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1nc2ccc(I)cc2c2[nH]c3ccc(Cl)cc3c12,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)c1nc2ccc(I)cc2c2[nH]c3ccc(Cl)cc3c12,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1nc2ccccc2c2[nH]c3c(Cl)cccc3c12,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)c1nc2ccccc2c2[nH]c3c(Cl)cccc3c12,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1nc2ccccc2c2[nH]c3c(Br)cccc3c12,CHEMBL3588821,>,>,IC50,nM,100000.0,IC50,uM,100.0,O=C(O)c1nc2ccccc2c2[nH]c3c(Br)cccc3c12,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1nc2ccccc2c2[nH]c3c(I)cccc3c12,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)c1nc2ccccc2c2[nH]c3c(I)cccc3c12,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,COc1cccc2c1[nH]c1c3ccccc3nc(C(=O)O)c21,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1cccc2c1[nH]c1c3ccccc3nc(C(=O)O)c21,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,COc1ccc2c(c1)nc(C(=O)O)c1c3cccc(F)c3[nH]c21,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc2c(c1)nc(C(=O)O)c1c3cccc(F)c3[nH]c21,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,COc1ccc2c(c1)nc(C(=O)O)c1c3cccc(Cl)c3[nH]c21,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc2c(c1)nc(C(=O)O)c1c3cccc(Cl)c3[nH]c21,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,COc1ccc2c(c1)nc(C(=O)O)c1c3cccc(Br)c3[nH]c21,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc2c(c1)nc(C(=O)O)c1c3cccc(Br)c3[nH]c21,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,COc1ccc2c(c1)nc(C(=O)O)c1c3cccc(I)c3[nH]c21,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc2c(c1)nc(C(=O)O)c1c3cccc(I)c3[nH]c21,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1nc2ccc(I)cc2c2[nH]c3c(F)cccc3c12,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)c1nc2ccc(I)cc2c2[nH]c3c(F)cccc3c12,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1nc2ccc(I)cc2c2[nH]c3c(Cl)cccc3c12,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)c1nc2ccc(I)cc2c2[nH]c3c(Cl)cccc3c12,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1nc2ccc(I)cc2c2[nH]c3c(Br)cccc3c12,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)c1nc2ccc(I)cc2c2[nH]c3c(Br)cccc3c12,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,COc1ccc2nc(C(=O)O)c3c4cccc(Cl)c4[nH]c3c2c1,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc2nc(C(=O)O)c3c4cccc(Cl)c4[nH]c3c2c1,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,COc1cccc(-c2ccc3nc(C(=O)O)c4c5cccc(Cl)c5[nH]c4c3c2)c1,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1cccc(-c2ccc3nc(C(=O)O)c4c5cccc(Cl)c5[nH]c4c3c2)c1,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,COc1ccc(-c2ccc3nc(C(=O)O)c4c5cccc(Cl)c5[nH]c4c3c2)cc1,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1ccc(-c2ccc3nc(C(=O)O)c4c5cccc(Cl)c5[nH]c4c3c2)cc1,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1nc2ccsc2c2[nH]c3c(Cl)cccc3c12,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)c1nc2ccsc2c2[nH]c3c(Cl)cccc3c12,2015.0
Inhibition of human recombinant CDK2 using [gamma-33P]ATP as substrate after 30 mins by scintillation counting analysis,O=C(O)c1nc2cccnc2c2[nH]c3c(Br)cccc3c12,CHEMBL3588821,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)c1nc2cccnc2c2[nH]c3c(Br)cccc3c12,2015.0
Inhibition of CDK2 (unknown origin) at 0.5 uM relative to control,Nc1nccc(-c2c[nH]c3ccccc23)n1,CHEMBL3596148,=,=,Inhibition,%,0.0,INH,%,0.0,Nc1nccc(-c2c[nH]c3ccccc23)n1,2015.0
Inhibition of CDK2 (unknown origin) at 0.5 uM relative to control,Nc1nccc(-c2cn(C(=O)N3CCOCC3)c3ccc(Br)cc23)n1,CHEMBL3596148,=,=,Inhibition,%,0.0,INH,%,0.0,Nc1nccc(-c2cn(C(=O)N3CCOCC3)c3ccc(Br)cc23)n1,2015.0
Inhibition of CDK2 (unknown origin) at 0.5 uM relative to control,Cc1noc(C)c1Cn1cc(-c2ccnc(N)n2)c2ccccc21,CHEMBL3596148,=,=,Inhibition,%,0.0,INH,%,0.0,Cc1noc(C)c1Cn1cc(-c2ccnc(N)n2)c2ccccc21,2015.0
Inhibition of CDK2 (unknown origin) using GST-fused pRb (792 to 928) as substrate preincubated for 2 mins followed by [gamma-32P]-ATP addition measured after 15 mins by beta plate counting analysis,O=c1c(Br)cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1C1CCCC1,CHEMBL3603804,=,=,IC50,nM,43.0,IC50,nM,43.0,O=c1c(Br)cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1C1CCCC1,2015.0
Inhibition of CDK2 (unknown origin) using GST-fused pRb (792 to 928) as substrate preincubated for 2 mins followed by [gamma-32P]-ATP addition measured after 15 mins by beta plate counting analysis,Cc1c(Br)c(=O)n(C2CCCC2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12,CHEMBL3603804,=,=,IC50,nM,439.0,IC50,nM,439.0,Cc1c(Br)c(=O)n(C2CCCC2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12,2015.0
Inhibition of CDK2 (unknown origin) using GST-fused pRb (792 to 928) as substrate preincubated for 2 mins followed by [gamma-32P]-ATP addition measured after 15 mins by beta plate counting analysis,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n(C2CCCC2)c1=O,CHEMBL3603804,=,=,IC50,nM,230.0,IC50,nM,230.0,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n(C2CCCC2)c1=O,2015.0
Inhibition of CDK2 (unknown origin) expressed in baculovirus infected insect cells using GST-fused pRb (792 to 928) as substrate preincubated for 2 mins followed by [gamma-32P]-ATP addition measured after 15 mins by beta plate counting analysis,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,CHEMBL3603804,>,>,IC50,nM,5000.0,IC50,uM,5.0,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL3611967,=,=,Inhibition,%,-100.0,INH,%,-100.0,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,Cc1ccc(NC(=O)/C(C#N)=C\Nc2ccc(S(=O)(=O)Nc3cc(C)on3)cc2)cc1,CHEMBL3611967,=,=,Inhibition,%,0.0,INH,%,0.0,Cc1ccc(NC(=O)/C(C#N)=C\Nc2ccc(S(=O)(=O)Nc3cc(C)on3)cc2)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,Cc1cc(NS(=O)(=O)c2ccc(N/C=C(/C#N)C(=O)Nc3ccc(Cl)cc3)cc2)no1,CHEMBL3611967,=,=,Inhibition,%,-4.0,INH,%,-4.0,Cc1cc(NS(=O)(=O)c2ccc(N/C=C(/C#N)C(=O)Nc3ccc(Cl)cc3)cc2)no1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,Cc1cc(NS(=O)(=O)c2ccc(N/C=C(/C#N)C(=O)Nc3ccc(Br)cc3)cc2)no1,CHEMBL3611967,=,=,Inhibition,%,-12.0,INH,%,-12.0,Cc1cc(NS(=O)(=O)c2ccc(N/C=C(/C#N)C(=O)Nc3ccc(Br)cc3)cc2)no1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,Cc1ccc(Nc2c(C(N)=O)cnc3ccc(S(=O)(=O)Nc4cc(C)on4)cc23)cc1,CHEMBL3611967,=,=,Inhibition,%,-11.0,INH,%,-11.0,Cc1ccc(Nc2c(C(N)=O)cnc3ccc(S(=O)(=O)Nc4cc(C)on4)cc23)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,Cc1cc(NS(=O)(=O)c2ccc3ncc(C(N)=O)c(Nc4ccc(Cl)cc4)c3c2)no1,CHEMBL3611967,=,=,Inhibition,%,-10.0,INH,%,-10.0,Cc1cc(NS(=O)(=O)c2ccc3ncc(C(N)=O)c(Nc4ccc(Cl)cc4)c3c2)no1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,Cc1cc(NS(=O)(=O)c2ccc3ncc(C(N)=O)c(Nc4ccc(Br)cc4)c3c2)no1,CHEMBL3611967,=,=,Inhibition,%,-1.0,INH,%,-1.0,Cc1cc(NS(=O)(=O)c2ccc3ncc(C(N)=O)c(Nc4ccc(Br)cc4)c3c2)no1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,Cc1ccc(Nc2c(C(N)=O)cnc3ccc(C(=O)/C=C/c4ccc(N(C)C)cc4)cc23)cc1,CHEMBL3611967,=,=,Inhibition,%,-5.0,INH,%,-5.0,Cc1ccc(Nc2c(C(N)=O)cnc3ccc(C(=O)/C=C/c4ccc(N(C)C)cc4)cc23)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,CN(C)c1ccc(/C=C/C(=O)c2ccc3ncc(C(N)=O)c(Nc4ccc(Cl)cc4)c3c2)cc1,CHEMBL3611967,=,=,Inhibition,%,-1.0,INH,%,-1.0,CN(C)c1ccc(/C=C/C(=O)c2ccc3ncc(C(N)=O)c(Nc4ccc(Cl)cc4)c3c2)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,CN(C)c1ccc(/C=C/C(=O)c2ccc3ncc(C(N)=O)c(Nc4ccc(Br)cc4)c3c2)cc1,CHEMBL3611967,=,=,Inhibition,%,-8.0,INH,%,-8.0,CN(C)c1ccc(/C=C/C(=O)c2ccc3ncc(C(N)=O)c(Nc4ccc(Br)cc4)c3c2)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,Cc1ccc(Nc2c(C(N)=O)cnc3ccc(C(=O)/C=C/c4ccc(Cl)cc4)cc23)cc1,CHEMBL3611967,=,=,Inhibition,%,-7.0,INH,%,-7.0,Cc1ccc(Nc2c(C(N)=O)cnc3ccc(C(=O)/C=C/c4ccc(Cl)cc4)cc23)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,NC(=O)c1cnc2ccc(C(=O)/C=C/c3ccc(Cl)cc3)cc2c1Nc1ccc(Cl)cc1,CHEMBL3611967,=,=,Inhibition,%,-12.0,INH,%,-12.0,NC(=O)c1cnc2ccc(C(=O)/C=C/c3ccc(Cl)cc3)cc2c1Nc1ccc(Cl)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,NC(=O)c1cnc2ccc(C(=O)/C=C/c3ccc(Cl)cc3)cc2c1Nc1ccc(Br)cc1,CHEMBL3611967,=,=,Inhibition,%,-3.0,INH,%,-3.0,NC(=O)c1cnc2ccc(C(=O)/C=C/c3ccc(Cl)cc3)cc2c1Nc1ccc(Br)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,Cc1ccc(Nc2c(C(N)=O)cnc3ccc(-c4csc(N)n4)cc23)cc1,CHEMBL3611967,=,=,Inhibition,%,-2.0,INH,%,-2.0,Cc1ccc(Nc2c(C(N)=O)cnc3ccc(-c4csc(N)n4)cc23)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,NC(=O)c1cnc2ccc(-c3csc(N)n3)cc2c1Nc1ccc(Cl)cc1,CHEMBL3611967,=,=,Inhibition,%,-7.0,INH,%,-7.0,NC(=O)c1cnc2ccc(-c3csc(N)n3)cc2c1Nc1ccc(Cl)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,NC(=O)c1cnc2ccc(-c3csc(N)n3)cc2c1Nc1ccc(Br)cc1,CHEMBL3611967,=,=,Inhibition,%,-9.0,INH,%,-9.0,NC(=O)c1cnc2ccc(-c3csc(N)n3)cc2c1Nc1ccc(Br)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,Cc1ccc(Nc2c(C(N)=O)cnc3ccc(-c4csc(NC(=S)Nc5ccccc5)n4)cc23)cc1,CHEMBL3611967,=,=,Inhibition,%,0.0,INH,%,0.0,Cc1ccc(Nc2c(C(N)=O)cnc3ccc(-c4csc(NC(=S)Nc5ccccc5)n4)cc23)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,NC(=O)c1cnc2ccc(-c3csc(NC(=S)Nc4ccccc4)n3)cc2c1Nc1ccc(Cl)cc1,CHEMBL3611967,=,=,Inhibition,%,-1.0,INH,%,-1.0,NC(=O)c1cnc2ccc(-c3csc(NC(=S)Nc4ccccc4)n3)cc2c1Nc1ccc(Cl)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,NC(=O)c1cnc2ccc(-c3csc(NC(=S)Nc4ccccc4)n3)cc2c1Nc1ccc(Br)cc1,CHEMBL3611967,,,Inhibition,%,,INH,,,NC(=O)c1cnc2ccc(-c3csc(NC(=S)Nc4ccccc4)n3)cc2c1Nc1ccc(Br)cc1,2015.0
Binding affinity to human CDK2 Y180A mutant expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation by ADP-Glo Max assay,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,CHEMBL3616388,=,=,IC50,nM,151400.0,IC50,uM,151.4,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,2015.0
Binding affinity to human CDK2 R150A mutant expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation by ADP-Glo Max assay,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,CHEMBL3616388,=,=,IC50,nM,884700.0,IC50,uM,884.7,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring 2.5 mM HHASPRK phosphorylation by ADP-Glo Max assay in presence of 75 uM ATP,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,CHEMBL3616388,=,=,IC50,nM,69800.0,IC50,uM,69.8,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring 1.25 mM HHASPRK phosphorylation by ADP-Glo Max assay in presence of 75 uM ATP,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,CHEMBL3616388,=,=,IC50,nM,58150.0,IC50,uM,58.15,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring 250 uM HHASPRK phosphorylation by ADP-Glo Max assay in presence of 750 uM ATP,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,CHEMBL3616388,=,=,IC50,nM,55110.0,IC50,uM,55.11,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring 250 uM HHASPRK phosphorylation by ADP-Glo Max assay in presence of 375 uM ATP,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,CHEMBL3616388,=,=,IC50,nM,78330.0,IC50,uM,78.33,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring 250 uM HHASPRK phosphorylation by ADP-Glo Max assay in presence of 75 uM ATP,CCOc1cc(C(=O)Nc2ccc(S(=O)(=O)Nc3nc(C)cc(C)n3)cc2)cc(OCC)c1OCC,CHEMBL3616388,=,=,IC50,nM,105100.0,IC50,uM,105.1,CCOc1cc(C(=O)Nc2ccc(S(=O)(=O)Nc3nc(C)cc(C)n3)cc2)cc(OCC)c1OCC,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring 250 uM HHASPRK phosphorylation by ADP-Glo Max assay in presence of 75 uM ATP,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,CHEMBL3616388,=,=,IC50,nM,52120.0,IC50,uM,52.12,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,CCOc1cc(C(=O)Nc2ccc(S(=O)(=O)Nc3nc(C)cc(C)n3)cc2)cc(OCC)c1OCC,CHEMBL3616388,=,=,Inhibition,%,62.26,INH,%,62.26,CCOc1cc(C(=O)Nc2ccc(S(=O)(=O)Nc3nc(C)cc(C)n3)cc2)cc(OCC)c1OCC,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,Cc1ccccc1C(=O)N(Cc1ccc(C(F)(F)F)cc1)c1ccc(CC(=O)NCc2ccc(F)cc2)cc1,CHEMBL3616388,=,=,Inhibition,%,37.53,INH,%,37.53,Cc1ccccc1C(=O)N(Cc1ccc(C(F)(F)F)cc1)c1ccc(CC(=O)NCc2ccc(F)cc2)cc1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,CCN(C(=O)CCNC(=O)Cn1cnc2ccccc2c1=O)c1cccc(C(F)(F)F)c1,CHEMBL3616388,=,=,Inhibition,%,8.39,INH,%,8.39,CCN(C(=O)CCNC(=O)Cn1cnc2ccccc2c1=O)c1cccc(C(F)(F)F)c1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,CN1C(=O)c2cccc3c(S(=O)(=O)NCCC(=O)O)ccc1c23,CHEMBL3616388,=,=,Inhibition,%,5.54,INH,%,5.54,CN1C(=O)c2cccc3c(S(=O)(=O)NCCC(=O)O)ccc1c23,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,Cc1[nH]c2ccccc2c1/C=N/c1ccccc1C(=O)O,CHEMBL3616388,<,<,Inhibition,%,5.0,INH,%,5.0,Cc1[nH]c2ccccc2c1/C=N/c1ccccc1C(=O)O,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,O=C(CSc1nc2ccc(NC(=O)CSCC(=O)Nc3ccc4ccccc4c3)cc2s1)NCCOc1ccccc1,CHEMBL3616388,<,<,Inhibition,%,5.0,INH,%,5.0,O=C(CSc1nc2ccc(NC(=O)CSCC(=O)Nc3ccc4ccccc4c3)cc2s1)NCCOc1ccccc1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,COc1ccccc1OCCOc1ccccc1/C=c1\sc2n(c1=O)C(c1ccccc1)C(C(=O)Nc1ccccc1)=C(C)N=2,CHEMBL3616388,<,<,Inhibition,%,5.0,INH,%,5.0,COc1ccccc1OCCOc1ccccc1/C=c1\sc2n(c1=O)C(c1ccccc1)C(C(=O)Nc1ccccc1)=C(C)N=2,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=O)CCCCC(=O)Nc3ccc(S(=O)(=O)Nc4nc(C)cc(C)n4)cc3)cc2)n1,CHEMBL3616388,=,=,Inhibition,%,38.02,INH,%,38.02,Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=O)CCCCC(=O)Nc3ccc(S(=O)(=O)Nc4nc(C)cc(C)n4)cc3)cc2)n1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,CHEMBL3616388,=,=,Inhibition,%,65.48,INH,%,65.48,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,C/C(Cc1ccccc1)=N\Nc1nnc2c(n1)[nH]c1ccccc12,CHEMBL3616388,=,=,Inhibition,%,35.17,INH,%,35.17,C/C(Cc1ccccc1)=N\Nc1nnc2c(n1)[nH]c1ccccc12,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,OC(CN1CCN(CC(O)Cn2c3ccc(Br)cc3c3cc(Br)cc(Br)c32)CC1)Cn1c2ccccc2c2ccccc21,CHEMBL3616388,=,=,Inhibition,%,31.03,INH,%,31.03,OC(CN1CCN(CC(O)Cn2c3ccc(Br)cc3c3cc(Br)cc(Br)c32)CC1)Cn1c2ccccc2c2ccccc21,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,Cn1c(=O)[nH]c(=O)c2c1nc(N/N=C1/C(=O)Nc3ccccc31)n2CC(O)COc1ccccc1,CHEMBL3616388,<,<,Inhibition,%,5.0,INH,%,5.0,Cn1c(=O)[nH]c(=O)c2c1nc(N/N=C1/C(=O)Nc3ccccc31)n2CC(O)COc1ccccc1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,Cc1ccc(S(=O)(=O)Nc2ccc(C(=O)N3N=C(c4c(-c5ccccc5)c5cc(Br)ccc5[nH]c4=O)CC3c3ccccc3)cc2)cc1,CHEMBL3616388,<,<,Inhibition,%,5.0,INH,%,5.0,Cc1ccc(S(=O)(=O)Nc2ccc(C(=O)N3N=C(c4c(-c5ccccc5)c5cc(Br)ccc5[nH]c4=O)CC3c3ccccc3)cc2)cc1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,CC(=O)C1=C(O)C(=O)N(CO)C1c1ccccc1,CHEMBL3616388,<,<,Inhibition,%,5.0,INH,%,5.0,CC(=O)C1=C(O)C(=O)N(CO)C1c1ccccc1,2015.0
Binding affinity to N-terminal His-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with cyclin A3 by measuring HHASPRK phosphorylation at 100 uM by ADP-Glo Max assay relative to control,CCOC(=O)C(Cc1ccc(OC)c([N+](=O)[O-])c1)NC(=O)CCC(=O)Nc1ccc(S(N)(=O)=O)cc1,CHEMBL3616388,<,<,Inhibition,%,5.0,INH,%,5.0,CCOC(=O)C(Cc1ccc(OC)c([N+](=O)[O-])c1)NC(=O)CCC(=O)Nc1ccc(S(N)(=O)=O)cc1,2015.0
Binding affinity to GST-tagged recombinant human CDK2 (1 to 298 amino acid residues) expressed in Escherichia coli BL21 assessed as inhibition of interaction with His-tagged cyclin A3 preincubated overnight with GST-tagged protein followed by His-tagged cyclin A3 addition by GST pull down assay,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,CHEMBL3616388,,,Activity,,,Activity,,,CSc1ccc(/C=N/c2cc([N+](=O)[O-])ccc2O)cc1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM,COc1ccc(-c2cnccc2-c2cnc(NC(=O)C(C)C)s2)c(C(F)(F)F)c1,CHEMBL3621108,>,>,Inhibition,%,90.0,INH,%,90.0,COc1ccc(-c2cnccc2-c2cnc(NC(=O)C(C)C)s2)c(C(F)(F)F)c1,2015.0
Inhibition of CDK2 (unknown origin),CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4ccccc4F)c23)CC1,CHEMBL3621099,=,=,IC50,nM,610.0,IC50,nM,610.0,CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4ccccc4F)c23)CC1,2015.0
Inhibition of CDK2 (unknown origin),CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c23)c1C,CHEMBL3621099,=,=,IC50,nM,2700.0,IC50,nM,2700.0,CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c23)c1C,2015.0
Inhibition of CDK2 (unknown origin),CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4cccc(NC(=O)c5ccc(N(C)C)cc5)c4F)c23)CC1,CHEMBL3621099,>,>,IC50,nM,50000.0,IC50,nM,50000.0,CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4cccc(NC(=O)c5ccc(N(C)C)cc5)c4F)c23)CC1,2015.0
Inhibition of human recombinant CDK2,CN(C)CCCNC(=O)c1csc2nc(-c3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)cn12,CHEMBL3621115,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN(C)CCCNC(=O)c1csc2nc(-c3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)cn12,2015.0
Inhibition of CDK2 (unknown origin) assessed as remaining activity at 10 uM by high-throughput assay relative to control,O=C1c2ccccc2-c2c1oc1ccccc1c2=O,CHEMBL3627674,=,=,Activity,%,82.0,Activity,%,82.0,O=C1c2ccccc2-c2c1oc1ccccc1c2=O,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay,CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1,CHEMBL3627608,=,=,Inhibition,%,67.35,INH,%,67.35,CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay,CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1,CHEMBL3627608,=,=,Inhibition,%,75.74,INH,%,75.74,CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1,2015.0
Inhibition of CDK2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay,COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC,CHEMBL3627608,=,=,Inhibition,%,7.06,INH,%,7.06,COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC,2015.0
Inhibition of CDK2 phosphorylation in human Hep2 cells at 100 uM after 24 hrs by Western blot analysis relative to control,Cc1[nH]c2c(c1C1(C)NC3=C(C(=O)CC(c4ccccc4)C3)C1=O)C(=O)CC(c1ccccc1)C2,CHEMBL3632525,,,Inhibition,%,,INH,,,Cc1[nH]c2c(c1C1(C)NC3=C(C(=O)CC(c4ccccc4)C3)C1=O)C(=O)CC(c1ccccc1)C2,2015.0
Inhibition of CDK2 phosphorylation in HEK293T cells at 100 uM after 24 hrs by Western blot analysis relative to control,Cc1[nH]c2c(c1C1(C)NC3=C(C(=O)CC(c4ccccc4)C3)C1=O)C(=O)CC(c1ccccc1)C2,CHEMBL3632525,,,Inhibition,%,,INH,,,Cc1[nH]c2c(c1C1(C)NC3=C(C(=O)CC(c4ccccc4)C3)C1=O)C(=O)CC(c1ccccc1)C2,2015.0
Binding affinity to CDK2 allosteric site (unknown origin),Cc1[nH]c2c(c1C1(C)NC3=C(C(=O)CC(c4ccccc4)C3)C1=O)C(=O)CC(c1ccccc1)C2,CHEMBL3632525,>,>,IC50,nM,91000.0,IC50,uM,91.0,Cc1[nH]c2c(c1C1(C)NC3=C(C(=O)CC(c4ccccc4)C3)C1=O)C(=O)CC(c1ccccc1)C2,2015.0
Binding affinity to CDK2 allosteric site (unknown origin),O=S(=O)(O)c1cccc2cccc(Nc3ccccc3)c12,CHEMBL3632525,=,=,IC50,nM,91000.0,IC50,uM,91.0,O=S(=O)(O)c1cccc2cccc(Nc3ccccc3)c12,2015.0
Inhibition of CDK2 (unknown origin) after 120 mins by HotSpot assay,CC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2c1,CHEMBL3632549,,,IC50,,,IC50,,,CC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2c1,2015.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,3.0,IC50,nM,3.0,C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2ncccc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,770.0,IC50,nM,770.0,CC[C@H](Nc1nc(NCc2ncccc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CC(C)Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,16.0,IC50,nM,16.0,CC(C)Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@@H](COC)[C@H](C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,9.0,IC50,nM,9.0,CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@@H](COC)[C@H](C)O)n2)cc1,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",Cc1cc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O,CHEMBL3638817,=,=,IC50,nM,7.0,IC50,nM,7.0,Cc1cc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CC(C)(O)CSc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,8.0,IC50,nM,8.0,CC(C)(O)CSc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCOC(=O)N=S(=O)(CC)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,42.0,IC50,nM,42.0,CCOC(=O)N=S(=O)(CC)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,5.0,IC50,nM,5.0,CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,4.0,IC50,nM,4.0,CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1,2013.0
"Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.",CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)[C@H](C)O,CHEMBL3639056,=,=,IC50,nM,90.0,IC50,nM,90.0,CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)[C@H](C)O,2014.0
"Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.",CCC(O)[C@@H](CC)Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1,CHEMBL3639056,=,=,IC50,nM,220.0,IC50,nM,220.0,CCC(O)[C@@H](CC)Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1,2014.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@@H](C)C(C)(C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,24.0,IC50,nM,24.0,CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@@H](C)C(C)(C)O)n2)cc1,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@H](CO)Nc1nc(Nc2ccc(S(=O)(CC3CC3)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br,CHEMBL3638817,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@H](CO)Nc1nc(Nc2ccc(S(=O)(CC3CC3)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2ccc(C)nc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,520.0,IC50,nM,520.0,CC[C@H](Nc1nc(NCc2ccc(C)nc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,90.0,IC50,nM,90.0,CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,10.0,IC50,nM,10.0,C[C@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](COC)[C@@H](C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,9.0,IC50,nM,9.0,CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](COC)[C@@H](C)O)n2)cc1,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2ccncc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,40.0,IC50,nM,40.0,CC[C@H](Nc1nc(NCc2ccncc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCOC(=O)N=S(=O)(CC)c1ccc(Nc2ncc(Br)c(O[C@H](C)[C@H](C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,19.0,IC50,nM,19.0,CCOC(=O)N=S(=O)(CC)c1ccc(Nc2ncc(Br)c(O[C@H](C)[C@H](C)O)n2)cc1,2013.0
"Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.",CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(C)C,CHEMBL3639056,=,=,IC50,nM,690.0,IC50,nM,690.0,CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(C)C,2014.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCOC(=O)N=S(=O)(CC)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,11.0,IC50,nM,11.0,CCOC(=O)N=S(=O)(CC)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2cccc(F)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,120.0,IC50,nM,120.0,CC[C@H](Nc1nc(NCc2cccc(F)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,7.0,IC50,nM,7.0,C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](COC)[C@H](C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,7.0,IC50,nM,7.0,CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](COC)[C@H](C)O)n2)cc1,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@@H](Nc1nc(Nc2ccc(S(=O)(=NS(=O)(=O)CC[Si](C)(C)C)C3CCCC3)cc2)ncc1Br)C(C)(C)O,CHEMBL3638817,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@@H](Nc1nc(Nc2ccc(S(=O)(=NS(=O)(=O)CC[Si](C)(C)C)C3CCCC3)cc2)ncc1Br)C(C)(C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,9.0,IC50,nM,9.0,CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@@H](Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)(C)O,CHEMBL3638817,=,=,IC50,nM,6.0,IC50,nM,6.0,C[C@@H](Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)(C)O,2013.0
"Kinase Screen Assay: KINOMEscan (Ambit Biosciences, San Diego, Calif.), a high-throughput method for screening small molecular agents against a large panel of human kinases, was utilized for compound 2. The technology is a competition binding assay that profiled the selectivity of compound 2 against 350 kinases, each fused to a proprietary tag. The quantity of each kinase bound to an immobilized, active site-directed ligand was measured in the presence and absence of compound 2.",Cc1nc(Nc2nc3ccc(-c4cccc(C(=O)Nc5cccc(C(F)(F)F)c5)c4)nc3s2)cc(N2CCNCC2)n1,CHEMBL3639044,=,=,Kd,nM,840.0,Kd,nM,840.0,Cc1nc(Nc2nc3ccc(-c4cccc(C(=O)Nc5cccc(C(F)(F)F)c5)c4)nc3s2)cc(N2CCNCC2)n1,2014.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1C,CHEMBL3638817,=,=,IC50,nM,78.0,IC50,nM,78.0,CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1C,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",COc1cc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O,CHEMBL3638817,=,=,IC50,nM,2.0,IC50,nM,2.0,COc1cc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O,2013.0
"In Vitro Kinase Inhibition Assay: In vitro kinase assay analysis may be performed using standard techniques described in the art. These techniques are also used by commercial services providers in order to offer in vitro kinase activity assay services, e.g. the assays offered by Millipore Inc. (worldwide website www(dot)millipore.com), ProQinase GmbH (worldwide website www(dot)proqinase.de) and others. All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50ul reaction volume. The reaction mixture was pipetted in four steps in the following order: 20ul of assay buffer (standard buffer),5ul of ATP solution (in H2O, 5 ul of test compound (in 10% DMSO), 10ul of substrate/10ul of enzyme solution (premixed)The assay for all enzymes contained 60 mM HEPES-NaOH (pH 7.5), 3 mM MgCl2, 3 mM MnCl2, 3uM Na-Orthovanadate, 1.2 mM DTT, 50 ug/ml PEG2000, 1 uM [33P]-ATP (approx. 5x1005 cpm per well).",COc1cc(F)ccc1-c1ccnc(NC(=O)C2CCC(NC(C)=O)C2)c1,CHEMBL3638701,=,=,IC50,nM,913.0,IC50,nM,913.0,COc1cc(F)ccc1-c1ccnc(NC(=O)C2CCC(NC(C)=O)C2)c1,2015.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",COc1cc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)ccc1S(C)(=N)=O,CHEMBL3638817,=,=,IC50,nM,3.0,IC50,nM,3.0,COc1cc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)ccc1S(C)(=N)=O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CN=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,7.0,IC50,nM,7.0,CN=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@@H](Nc1nc(Nc2ccc(S(=O)(CC=O)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br)C(C)(C)O,CHEMBL3638817,=,=,IC50,nM,49.0,IC50,nM,49.0,C[C@@H](Nc1nc(Nc2ccc(S(=O)(CC=O)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br)C(C)(C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@@H](COC)[C@H](C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,28.0,IC50,nM,28.0,CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@@H](COC)[C@H](C)O)n2)cc1,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,20.0,IC50,nM,20.0,CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",COc1cc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O,CHEMBL3638817,=,=,IC50,nM,6.0,IC50,nM,6.0,COc1cc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCC(C)Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,33.0,IC50,nM,33.0,CCC(C)Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CC(O)CSc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,41.0,IC50,nM,41.0,CC(O)CSc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC(C)n1cnc2c(NCc3cccnc3)nc(NC[C@@H](C)O)nc21,CHEMBL3638727,=,=,IC50,nM,290.0,IC50,nM,290.0,CC(C)n1cnc2c(NCc3cccnc3)nc(NC[C@@H](C)O)nc21,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCC(Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)(C)O,CHEMBL3638817,=,=,IC50,nM,27.0,IC50,nM,27.0,CCC(Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)(C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@@H](Nc1nc(Nc2ccc(S(=N)(=O)C3CCCC3)cc2)ncc1Br)C(C)(C)O,CHEMBL3638817,=,=,IC50,nM,25.0,IC50,nM,25.0,C[C@@H](Nc1nc(Nc2ccc(S(=N)(=O)C3CCCC3)cc2)ncc1Br)C(C)(C)O,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2ccc(C(F)(F)F)nc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,40.0,IC50,nM,40.0,CC[C@H](Nc1nc(NCc2ccc(C(F)(F)F)nc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",COC[C@@H](Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)[C@@H](C)O,CHEMBL3638817,=,=,IC50,nM,4.0,IC50,nM,4.0,COC[C@@H](Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)[C@@H](C)O,2013.0
"Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.",CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3639056,=,=,IC50,nM,30.0,IC50,nM,30.0,CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2014.0
"Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.",CCC(O)[C@H](CC)Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1,CHEMBL3639056,=,=,IC50,nM,110.0,IC50,nM,110.0,CCC(O)[C@H](CC)Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1,2014.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@@H](C)[C@H](C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,4.0,IC50,nM,4.0,CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@@H](C)[C@H](C)O)n2)cc1,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",Cc1cc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)ccc1S(C)(=N)=O,CHEMBL3638817,=,=,IC50,nM,4.0,IC50,nM,4.0,Cc1cc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)ccc1S(C)(=N)=O,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2cccc(Cl)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,100.0,IC50,nM,100.0,CC[C@H](Nc1nc(NCc2cccc(Cl)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NC2CCC2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,160.0,IC50,nM,160.0,CC[C@H](Nc1nc(NC2CCC2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.",CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(C)(C)C,CHEMBL3639056,=,=,IC50,nM,1000.0,IC50,nM,1000.0,CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(C)(C)C,2014.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2cc(C)nc(C)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,50.0,IC50,nM,50.0,CC[C@H](Nc1nc(NCc2cc(C)nc(C)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.",CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(C)C,CHEMBL3639056,=,=,IC50,nM,1100.0,IC50,nM,1100.0,CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(C)C,2014.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CN=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1OC,CHEMBL3638817,=,=,IC50,nM,6.0,IC50,nM,6.0,CN=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1OC,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",COc1cc(Nc2ncc(Br)c(O[C@H](C)[C@H](C)O)n2)ccc1S(C)(=N)=O,CHEMBL3638817,=,=,IC50,nM,8.0,IC50,nM,8.0,COc1cc(Nc2ncc(Br)c(O[C@H](C)[C@H](C)O)n2)ccc1S(C)(=N)=O,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NC2CC2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,50.0,IC50,nM,50.0,CC[C@H](Nc1nc(NC2CC2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.",CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(C)(C)O,CHEMBL3639056,=,=,IC50,nM,70.0,IC50,nM,70.0,CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(C)(C)O,2014.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@H](Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br)C(C)(C)O,CHEMBL3638817,=,=,IC50,nM,4.0,IC50,nM,4.0,C[C@H](Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br)C(C)(C)O,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2ccc(C)nc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,3250.0,IC50,nM,3250.0,CC[C@H](Nc1nc(NCc2ccc(C)nc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.",CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(C)(C)C,CHEMBL3639056,=,=,IC50,nM,390.0,IC50,nM,390.0,CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(C)(C)C,2014.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC(C)n1cnc2c(NCc3cccnc3)nc(NCC(O)C(F)(F)F)nc21,CHEMBL3638727,=,=,IC50,nM,570.0,IC50,nM,570.0,CC(C)n1cnc2c(NCc3cccnc3)nc(NCC(O)C(F)(F)F)nc21,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(O[C@H](C)[C@H](C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,14.0,IC50,nM,14.0,CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(O[C@H](C)[C@H](C)O)n2)cc1,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCC(CO)Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,16.0,IC50,nM,16.0,CCC(CO)Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",Cc1cc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O,CHEMBL3638817,=,=,IC50,nM,4.0,IC50,nM,4.0,Cc1cc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,12.0,IC50,nM,12.0,CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)cc1,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,27.0,IC50,nM,27.0,CCS(=N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,20.0,IC50,nM,20.0,C[C@@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",COc1cc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)ccc1S(C)(=N)=O,CHEMBL3638817,=,=,IC50,nM,4.0,IC50,nM,4.0,COc1cc(Nc2ncc(Br)c(N[C@H](C)[C@H](C)O)n2)ccc1S(C)(=N)=O,2013.0
"In Vitro Kinase Inhibition Assay: In vitro kinase assay analysis may be performed using standard techniques described in the art. These techniques are also used by commercial services providers in order to offer in vitro kinase activity assay services, e.g. the assays offered by Millipore Inc. (worldwide website www(dot)millipore.com), ProQinase GmbH (worldwide website www(dot)proqinase.de) and others. All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50ul reaction volume. The reaction mixture was pipetted in four steps in the following order: 20ul of assay buffer (standard buffer),5ul of ATP solution (in H2O, 5 ul of test compound (in 10% DMSO), 10ul of substrate/10ul of enzyme solution (premixed)The assay for all enzymes contained 60 mM HEPES-NaOH (pH 7.5), 3 mM MgCl2, 3 mM MnCl2, 3uM Na-Orthovanadate, 1.2 mM DTT, 50 ug/ml PEG2000, 1 uM [33P]-ATP (approx. 5x1005 cpm per well).",COc1cc(F)ccc1-c1ccnc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)c1,CHEMBL3638701,=,=,IC50,nM,168.0,IC50,nM,168.0,COc1cc(F)ccc1-c1ccnc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)c1,2015.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2cccc(F)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,20.0,IC50,nM,20.0,CC[C@H](Nc1nc(NCc2cccc(F)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CC(O)C(C)Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,8.0,IC50,nM,8.0,CC(O)C(C)Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@H](CO)Nc1nc(Nc2ccc(S(C)(=O)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,390.0,IC50,nM,390.0,C[C@H](CO)Nc1nc(Nc2ccc(S(C)(=O)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCOC(=O)N=S(=O)(CC)c1ccc(Nc2ncc(Br)c(N[C@@H](COC)[C@H](C)O)n2)cc1,CHEMBL3638817,=,=,IC50,nM,51.0,IC50,nM,51.0,CCOC(=O)N=S(=O)(CC)c1ccc(Nc2ncc(Br)c(N[C@@H](COC)[C@H](C)O)n2)cc1,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",COc1cc(Nc2ncc(Br)c(N[C@H](C)[C@@H](C)O)n2)ccc1S(C)(=N)=O,CHEMBL3638817,=,=,IC50,nM,4.0,IC50,nM,4.0,COc1cc(Nc2ncc(Br)c(N[C@H](C)[C@@H](C)O)n2)ccc1S(C)(=N)=O,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2cccc(Cl)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,10.0,IC50,nM,10.0,CC[C@H](Nc1nc(NCc2cccc(Cl)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@@H](Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br)C(C)(C)O,CHEMBL3638817,=,=,IC50,nM,4.0,IC50,nM,4.0,C[C@@H](Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br)C(C)(C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,6.0,IC50,nM,6.0,C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=O)(CC=O)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,130.0,IC50,nM,130.0,C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=O)(CC=O)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",COC[C@H](Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)[C@H](C)O,CHEMBL3638817,=,=,IC50,nM,6.0,IC50,nM,6.0,COC[C@H](Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)[C@H](C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@@H](Nc1nc(Nc2ccc(S(=N)(=O)CC3CC3)cc2)ncc1Br)C(C)(C)O,CHEMBL3638817,=,=,IC50,nM,4.0,IC50,nM,4.0,C[C@@H](Nc1nc(Nc2ccc(S(=N)(=O)CC3CC3)cc2)ncc1Br)C(C)(C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(CCO)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,54.0,IC50,nM,54.0,C[C@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(CCO)=NS(=O)(=O)CC[Si](C)(C)C)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",Cc1cc(Nc2ncc(Br)c(N[C@@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O,CHEMBL3638817,=,=,IC50,nM,7.0,IC50,nM,7.0,Cc1cc(Nc2ncc(Br)c(N[C@@H](C)C(C)(C)O)n2)ccc1S(C)(=N)=O,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCC2CC2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,40.0,IC50,nM,40.0,CC[C@H](Nc1nc(NCC2CC2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CC(Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)(C)O,CHEMBL3638817,=,=,IC50,nM,11.0,IC50,nM,11.0,CC(Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)(C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CC(C)(O)CSc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,8.0,IC50,nM,8.0,CC(C)(O)CSc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CCC(Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(F)(F)F,CHEMBL3638727,=,=,IC50,nM,90.0,IC50,nM,90.0,CCC(Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(F)(F)F,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CN=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@@H](C)O)n2)cc1OC,CHEMBL3638817,=,=,IC50,nM,4.0,IC50,nM,4.0,CN=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)[C@@H](C)O)n2)cc1OC,2013.0
"Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.",CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(C)(C)O,CHEMBL3639056,=,=,IC50,nM,200.0,IC50,nM,200.0,CC[C@@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(C)(C)O,2014.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CC(CO)Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,4.0,IC50,nM,4.0,CC(CO)Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1C,CHEMBL3638817,=,=,IC50,nM,48.0,IC50,nM,48.0,CCOC(=O)N=S(C)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)C(C)(C)O)n2)cc1C,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C=S(N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)CO)n2)cc1,CHEMBL3638817,<,<,IC50,nM,10.0,IC50,nM,10.0,C=S(N)(=O)c1ccc(Nc2ncc(Br)c(N[C@H](C)CO)n2)cc1,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(CC3CC3)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,830.0,IC50,nM,830.0,CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(CC3CC3)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@H](Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)(C)O,CHEMBL3638817,=,=,IC50,nM,2.0,IC50,nM,2.0,C[C@H](Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)(C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@@H](Nc1nc(Nc2ccc(S(=N)(=O)C3CC3)cc2)ncc1Br)C(C)(C)O,CHEMBL3638817,=,=,IC50,nM,8.0,IC50,nM,8.0,C[C@@H](Nc1nc(Nc2ccc(S(=N)(=O)C3CC3)cc2)ncc1Br)C(C)(C)O,2013.0
"Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.",CC[C@H](Nc1nc(NCc2cccc(C)n2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL3638727,=,=,IC50,nM,50.0,IC50,nM,50.0,CC[C@H](Nc1nc(NCc2cccc(C)n2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCC(Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)O,CHEMBL3638817,=,=,IC50,nM,18.0,IC50,nM,18.0,CCC(Sc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br)C(C)O,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,2.0,IC50,nM,2.0,C[C@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(C)(=N)=O)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CCOc1nc(Nc2ccc(S(=N)(=O)CC)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,63.0,IC50,nM,63.0,CCOc1nc(Nc2ccc(S(=N)(=O)CC)cc2)ncc1Br,2013.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",C[C@@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br,CHEMBL3638817,=,=,IC50,nM,3.0,IC50,nM,3.0,C[C@@H](O)[C@@H](C)Nc1nc(Nc2ccc(S(=N)(=O)CCO)cc2)ncc1Br,2013.0
Inhibition of CDK2 (unknown origin),O=C(O)C1CN(Cc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2)C1,CHEMBL3739276,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)C1CN(Cc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2)C1,2015.0
Binding affinity to N-terminal His-tagged human CDK2 expressed in Escherichia coli BL21-AI by STD-NMR analysis,c1ccc(CNc2ncnc3[nH]cnc23)cc1,CHEMBL3751749,,,Activity,,,Activity,,,c1ccc(CNc2ncnc3[nH]cnc23)cc1,2015.0
Binding affinity to N-terminal His-tagged human CDK2 expressed in Escherichia coli BL21-AI by STD-NMR analysis,N=C(N)NCCNS(=O)(=O)c1cccc2cnccc12,CHEMBL3751749,,,Activity,,,Activity,,,N=C(N)NCCNS(=O)(=O)c1cccc2cnccc12,2015.0
Binding affinity to N-terminal His-tagged human CDK2 expressed in Escherichia coli BL21-AI by STD-NMR analysis,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,CHEMBL3751749,,,Activity,,,Activity,,,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,2015.0
Binding affinity to N-terminal His-tagged human CDK2 expressed in Escherichia coli BL21-AI by STD-NMR analysis,CNc1ncnc2ccc([N+](=O)[O-])cc12,CHEMBL3751749,,,Activity,,,Activity,,,CNc1ncnc2ccc([N+](=O)[O-])cc12,2015.0
Binding affinity to N-terminal His-tagged human CDK2 expressed in Escherichia coli BL21-AI by STD-NMR analysis,Cc1ccc(Cn2cc(-n3c(-c4ccc(Cn5nc(C)c(Cl)c5C)o4)n[nH]c3=S)cn2)cc1,CHEMBL3751749,,,Activity,,,Activity,,,Cc1ccc(Cn2cc(-n3c(-c4ccc(Cn5nc(C)c(Cl)c5C)o4)n[nH]c3=S)cn2)cc1,2015.0
Binding affinity to N-terminal His-tagged human CDK2 expressed in Escherichia coli BL21-AI by STD-NMR analysis,Cc1ccc(Cn2cc(-n3c(-c4ccc(Cn5cc(Cl)cn5)cc4)n[nH]c3=S)cn2)cc1,CHEMBL3751749,,,Activity,,,Activity,,,Cc1ccc(Cn2cc(-n3c(-c4ccc(Cn5cc(Cl)cn5)cc4)n[nH]c3=S)cn2)cc1,2015.0
Binding affinity to N-terminal His-tagged human CDK2 expressed in Escherichia coli BL21-AI by STD-NMR analysis,Cc1ccc(Cn2cc(-n3c(-c4ccc(Cn5nc(C)cc5C)o4)n[nH]c3=S)cn2)cc1,CHEMBL3751749,,,Activity,,,Activity,,,Cc1ccc(Cn2cc(-n3c(-c4ccc(Cn5nc(C)cc5C)o4)n[nH]c3=S)cn2)cc1,2015.0
Binding affinity to N-terminal His-tagged human CDK2 expressed in Escherichia coli BL21-AI by STD-NMR analysis,Cc1ccc(Cn2nccc2-n2c(-c3cc(C)n(C)n3)n[nH]c2=S)cc1,CHEMBL3751749,,,Activity,,,Activity,,,Cc1ccc(Cn2nccc2-n2c(-c3cc(C)n(C)n3)n[nH]c2=S)cc1,2015.0
Binding affinity to N-terminal His-tagged human CDK2 expressed in Escherichia coli BL21-AI by STD-NMR analysis,Cc1ccc(Cn2cc(-n3c(-c4ccc(Cn5cccn5)cc4)n[nH]c3=S)cn2)cc1,CHEMBL3751749,,,Activity,,,Activity,,,Cc1ccc(Cn2cc(-n3c(-c4ccc(Cn5cccn5)cc4)n[nH]c3=S)cn2)cc1,2015.0
Binding affinity to N-terminal His-tagged human CDK2 expressed in Escherichia coli BL21-AI by STD-NMR analysis,CC(C)=CCNc1ncnc2[nH]cnc12,CHEMBL3751749,,,Activity,,,Activity,,,CC(C)=CCNc1ncnc2[nH]cnc12,2015.0
Binding affinity to human CDK2 by isothermal titration calorimetric analysis,Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,CHEMBL3751749,=,=,Kd,nM,184000.0,Kd,uM,184.0,Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,2015.0
Binding affinity to human CDK2 by isothermal titration calorimetric analysis,c1ccc(CNc2ncnc3[nH]cnc23)cc1,CHEMBL3751749,=,=,Kd,nM,62000.0,Kd,uM,62.0,c1ccc(CNc2ncnc3[nH]cnc23)cc1,2015.0
Binding affinity to human CDK2 by isothermal titration calorimetric analysis,N=C(N)NCCNS(=O)(=O)c1cccc2cnccc12,CHEMBL3751749,=,=,Kd,nM,286000.0,Kd,uM,286.0,N=C(N)NCCNS(=O)(=O)c1cccc2cnccc12,2015.0
Binding affinity to human CDK2 by isothermal titration calorimetric analysis,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,CHEMBL3751749,=,=,Kd,nM,460000.0,Kd,uM,460.0,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,2015.0
Binding affinity to human CDK2 by isothermal titration calorimetric analysis,CNc1ncnc2ccc([N+](=O)[O-])cc12,CHEMBL3751749,=,=,Kd,nM,208000.0,Kd,uM,208.0,CNc1ncnc2ccc([N+](=O)[O-])cc12,2015.0
Binding affinity to human CDK2 by isothermal titration calorimetric analysis,CC(C)=CCNc1ncnc2[nH]cnc12,CHEMBL3751749,=,=,Kd,nM,35000.0,Kd,uM,35.0,CC(C)=CCNc1ncnc2[nH]cnc12,2015.0
Inhibition of human recombinant CDK2 assessed as residual activity at 10 uM after 1 hr by qPCR analysis relative to control,Cc1c(Cl)cccc1NC(=O)c1sc2nc3c(cc2c1N)C(=O)CC3,CHEMBL3769377,=,=,Activity,%,100.0,Activity,%,100.0,Cc1c(Cl)cccc1NC(=O)c1sc2nc3c(cc2c1N)C(=O)CC3,2015.0
Inhibition of CDK2 in human G361 cells assessed as reduction in phosphorylation of RNA polymerase 2 at C-terminus at 15 uM incubated for 0.5 to 24 hrs by immunoblotting analysis,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(N[C@H]3CC[C@H](N)CC3)nc12,CHEMBL3774312,,,Inhibition,%,,INH,,,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(N[C@H]3CC[C@H](N)CC3)nc12,2016.0
Inhibition of CDK2 in human G361 cells assessed as reduction in phosphorylation of RNA polymerase 2 at C-terminus at 0.75 uM incubated for 0.5 to 24 hrs by immunoblotting analysis,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(NCC(C)(C)O)nc12,CHEMBL3774312,,,Inhibition,%,,INH,,,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(NCC(C)(C)O)nc12,2016.0
Inhibition of CDK2 in human G361 cells assessed as reduction in phosphorylation of RNA polymerase 2 at C-terminus at 1 uM incubated for 0.5 to 24 hrs by immunoblotting analysis,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(N3CCOCC3)nc12,CHEMBL3774312,,,Inhibition,%,,INH,,,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(N3CCOCC3)nc12,2016.0
Inhibition of CDK2 in human G361 cells assessed as reduction in phosphorylation of RNA polymerase 2 at C-terminus at 1 uM incubated for 0.5 to 24 hrs by immunoblotting analysis,CC(O)CNc1nc(NCc2ccc(-c3ccccn3)cc2)c2[nH]nc(C(C)C)c2n1,CHEMBL3774312,,,Inhibition,%,,INH,,,CC(O)CNc1nc(NCc2ccc(-c3ccccn3)cc2)c2[nH]nc(C(C)C)c2n1,2016.0
Inhibition of CDK2 in human G361 cells assessed as reduction in phosphorylation of RNA polymerase 2 at C-terminus at 2.4 to 24 uM incubated for 24 hrs by immunoblotting analysis,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2[nH]nc(C(C)C)c2n1,CHEMBL3774312,,,Inhibition,%,,INH,,,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2[nH]nc(C(C)C)c2n1,2016.0
Inhibition of CDK2 in human G361 cells assessed as reduction in phosphorylation of RNA polymerase 2 at C-terminus at 0.25 to 2.5 uM incubated for 24 hrs by immunoblotting analysis,CC[C@H](CO)Nc1nc(NCc2ccc(-c3ccccn3)cc2)c2ncn(C(C)C)c2n1,CHEMBL3774312,,,Inhibition,%,,INH,,,CC[C@H](CO)Nc1nc(NCc2ccc(-c3ccccn3)cc2)c2ncn(C(C)C)c2n1,2016.0
Inhibition of CDK2 in human G361 cells assessed as reduction in phosphorylation of RNA polymerase 2 at C-terminus at 1.5 to 15 uM incubated for 24 hrs by immunoblotting analysis,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(N[C@H]3CC[C@H](N)CC3)nc12,CHEMBL3774312,,,Inhibition,%,,INH,,,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(N[C@H]3CC[C@H](N)CC3)nc12,2016.0
Inhibition of CDK2 in human G361 cells assessed as reduction in phosphorylation of RNA polymerase 2 at C-terminus at 0.075 to 0.75 uM incubated for 24 hrs by immunoblotting analysis,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(NCC(C)(C)O)nc12,CHEMBL3774312,,,Inhibition,%,,INH,,,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(NCC(C)(C)O)nc12,2016.0
Inhibition of CDK2 in human G361 cells assessed as reduction in phosphorylation of RNA polymerase 2 at C-terminus at 0.1 to 1 uM incubated for 24 hrs by immunoblotting analysis,CC(O)CNc1nc(NCc2ccc(-c3ccccn3)cc2)c2[nH]nc(C(C)C)c2n1,CHEMBL3774312,,,Inhibition,%,,INH,,,CC(O)CNc1nc(NCc2ccc(-c3ccccn3)cc2)c2[nH]nc(C(C)C)c2n1,2016.0
Inhibition of partial length human CDK2 expressed in bacterial system at 1 uM,Cc1cnc(N)nc1OCC(C)(C)CO,CHEMBL3779767,,,Inhibition,%,,INH,,,Cc1cnc(N)nc1OCC(C)(C)CO,2016.0
Inhibition of CDK2A (unknown origin) in presence of [gamma33P]ATP,Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,CHEMBL3785066,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,2016.0
Inhibition of CDK2A (unknown origin) in presence of [gamma33P]ATP,Nc1ncnc2c1c(-c1cccc(OC[C@@H]3CCCO3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,CHEMBL3785066,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1ncnc2c1c(-c1cccc(OC[C@@H]3CCCO3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,2016.0
Inhibition of CDK2A (unknown origin) in presence of [gamma33P]ATP,Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,CHEMBL3785066,=,=,IC50,nM,410.0,IC50,uM,0.41,Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,2016.0
Inhibition of CDK2A (unknown origin) in presence of [gamma33P]ATP,Nc1ncnc2c1c(-c1cccc(OCC34CCC(CC3)O4)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,CHEMBL3785066,>,>,IC50,nM,10000.0,IC50,uM,10.0,Nc1ncnc2c1c(-c1cccc(OCC34CCC(CC3)O4)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,2016.0
Inhibition of CDK2A (unknown origin) in presence of [gamma33P]ATP,CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cccc(OC[C@@H]5CCCO5)c4F)c4c(N)ncnc43)C2)CC1,CHEMBL3785066,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cccc(OC[C@@H]5CCCO5)c4F)c4c(N)ncnc43)C2)CC1,2016.0
Inhibition of CDK2A (unknown origin) in presence of [gamma33P]ATP,CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cc(OC[C@@H]5CCCO5)ccc4F)c4c(N)ncnc43)C2)CC1,CHEMBL3785066,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cc(OC[C@@H]5CCCO5)ccc4F)c4c(N)ncnc43)C2)CC1,2016.0
Inhibition of CDK2 (unknown origin),Nc1ncccc1-c1nc2ccccc2[nH]1,CHEMBL3797138,=,=,IC50,nM,25000.0,IC50,uM,25.0,Nc1ncccc1-c1nc2ccccc2[nH]1,2016.0
Inhibition of CDK2 (unknown origin),Nc1ncc(-c2ccccc2)cc1-c1nc2ccccc2[nH]1,CHEMBL3797138,=,=,IC50,nM,1300.0,IC50,uM,1.3,Nc1ncc(-c2ccccc2)cc1-c1nc2ccccc2[nH]1,2016.0
Inhibition of CDK2 (unknown origin),CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4ccccc4[nH]3)c2)c1,CHEMBL3797138,=,=,IC50,nM,5700.0,IC50,uM,5.7,CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4ccccc4[nH]3)c2)c1,2016.0
Inhibition of CDK2 (unknown origin),CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4cccc(N5CCNCC5)c4[nH]3)c2)c1,CHEMBL3797138,=,=,IC50,nM,4000.0,IC50,uM,4.0,CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4cccc(N5CCNCC5)c4[nH]3)c2)c1,2016.0
Inhibition of CDK2 (unknown origin),CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4cccc(N5CCNCC5)c4[nH]3)n2)c1,CHEMBL3797138,=,=,IC50,nM,11000.0,IC50,uM,11.0,CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4cccc(N5CCNCC5)c4[nH]3)n2)c1,2016.0
Inhibition of CDK2 (unknown origin),CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4cccc(N5CCNCC5)c4n3C)n2)c1,CHEMBL3797138,=,=,IC50,nM,1400.0,IC50,uM,1.4,CN(C)C(=O)c1cccc(-c2cnc(N)c(-c3nc4cccc(N5CCNCC5)c4n3C)n2)c1,2016.0
Inhibition of CDK2 (unknown origin),C[C@H]1CN(c2cccc3nc(-c4nc(-c5cccc(C(=O)N(C)C)c5)cnc4N)n(C)c23)CCN1,CHEMBL3797138,=,=,IC50,nM,3400.0,IC50,uM,3.4,C[C@H]1CN(c2cccc3nc(-c4nc(-c5cccc(C(=O)N(C)C)c5)cnc4N)n(C)c23)CCN1,2016.0
Inhibition of CDK2 (unknown origin),C[C@H]1CN(c2cccc3nc(-c4nc(-c5cc(C(=O)N(C)C)ccn5)cnc4N)n(C)c23)CCN1,CHEMBL3797138,>,>,IC50,nM,25000.0,IC50,uM,25.0,C[C@H]1CN(c2cccc3nc(-c4nc(-c5cc(C(=O)N(C)C)ccn5)cnc4N)n(C)c23)CCN1,2016.0
Inhibition of full length wild type human CDK2 expressed in bacterial system assessed as enzyme activity at 1 uM relative to control,CN(C)S(=O)(=O)Nc1ccc(F)c(Nc2ncccc2-c2ncnc3[nH]cnc23)c1F,CHEMBL3797029,=,=,Activity,%,99.0,Activity,%,99.0,CN(C)S(=O)(=O)Nc1ccc(F)c(Nc2ncccc2-c2ncnc3[nH]cnc23)c1F,2016.0
Inhibition of full length human CDK2 expressed in bacterial system assessed as enzyme activity at 10 uM by KINOMEScan assay,O=C1C2=C(C(=O)c3c(O)ccc(O)c31)[C@@H](O)[C@@H](O)[C@@H](O)C2,CHEMBL3808372,=,=,Activity,%,92.0,Activity,%,92.0,O=C1C2=C(C(=O)c3c(O)ccc(O)c31)[C@@H](O)[C@@H](O)[C@@H](O)C2,2016.0
Inhibition of CDK2 (unknown origin),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL3813619,=,=,IC50,nM,170.0,IC50,uM,0.17,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2016.0
Inhibition of CDK2 (unknown origin) incubated for 1 hr by spectrophotometric analysis,CN1C(=O)COc2c1cnc1ccc(Sc3nnc4c(F)cc(-c5cnn(C)c5)cn34)cc21,CHEMBL3817824,>,>,IC50,nM,30000.0,IC50,nM,30000.0,CN1C(=O)COc2c1cnc1ccc(Sc3nnc4c(F)cc(-c5cnn(C)c5)cn34)cc21,2016.0
Inhibition of CDK2 (unknown origin) incubated for 1 hr by spectrophotometric analysis,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL3817824,=,=,IC50,nM,2.6,IC50,nM,2.6,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2016.0
Inhibition of CDK-2 (unknown origin) at 10 uM,COc1cccc(Nc2nccc(Nc3ccc4[nH]ncc4c3)n2)c1,CHEMBL3817755,=,=,Inhibition,%,76.0,INH,%,76.0,COc1cccc(Nc2nccc(Nc3ccc4[nH]ncc4c3)n2)c1,2016.0
Inhibition of CDK-2 (unknown origin) at 10 uM,COc1ccc(Nc2nccc(Nc3ccc4[nH]ncc4c3)n2)cc1,CHEMBL3817755,=,=,Inhibition,%,71.0,INH,%,71.0,COc1ccc(Nc2nccc(Nc3ccc4[nH]ncc4c3)n2)cc1,2016.0
Inhibition of human recombinant full-length CDK2 expressed in Escherichia coli at 1 uM after 30 mins,O=C(Nc1cc(Nc2c(Cl)cnc3c2OCO3)ccn1)C1CC1,CHEMBL3817795,<,<,Inhibition,%,80.0,INH,%,80.0,O=C(Nc1cc(Nc2c(Cl)cnc3c2OCO3)ccn1)C1CC1,2016.0
Inhibition of CDK2 (unknown origin),COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,CHEMBL3822394,=,=,IC50,nM,1030.0,IC50,uM,1.03,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,2016.0
Inhibition of CDK2 (unknown origin),CC(=O)N1CCC(n2cc(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)cn2)CC1,CHEMBL3822394,=,=,IC50,nM,25.0,IC50,uM,0.025,CC(=O)N1CCC(n2cc(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)cn2)CC1,2016.0
Inhibition of CDK2 (unknown origin),COc1nn(C2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,CHEMBL3822394,=,=,IC50,nM,494.0,IC50,uM,0.494,COc1nn(C2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,2016.0
Inhibition of CDK2 (unknown origin),CC(=O)N1CCC(n2cc(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)c(C)n2)CC1,CHEMBL3822394,=,=,IC50,nM,135.0,IC50,uM,0.135,CC(=O)N1CCC(n2cc(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)c(C)n2)CC1,2016.0
Inhibition of CDK2 (unknown origin),Cc1nn(C2CCNCC2)cc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,CHEMBL3822394,=,=,IC50,nM,392.0,IC50,uM,0.392,Cc1nn(C2CCNCC2)cc1Nc1ncc(Cl)c(-c2cnc3ccccn23)n1,2016.0
Inhibition of CDK2 (unknown origin),CC(=O)N1CCC(n2ncc(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)c2C)CC1,CHEMBL3822394,=,=,IC50,nM,232.0,IC50,uM,0.232,CC(=O)N1CCC(n2ncc(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)c2C)CC1,2016.0
Inhibition of CDK2 (unknown origin),Cc1c(Nc2ncc(Cl)c(-c3cnc4ccccn34)n2)cnn1C1CCNCC1,CHEMBL3822394,=,=,IC50,nM,392.0,IC50,uM,0.392,Cc1c(Nc2ncc(Cl)c(-c3cnc4ccccn34)n2)cnn1C1CCNCC1,2016.0
Inhibition of CDK2 (unknown origin),CC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)c2C)CC1,CHEMBL3822394,=,=,IC50,nM,1680.0,IC50,uM,1.68,CC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)c2C)CC1,2016.0
Inhibition of CDK2 (unknown origin),COc1nn(C2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,CHEMBL3822394,=,=,IC50,nM,361.0,IC50,uM,0.361,COc1nn(C2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,2016.0
Inhibition of CDK2 (unknown origin),CC(=O)N1CCC(n2cc(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c(C)n2)CC1,CHEMBL3822394,=,=,IC50,nM,63.0,IC50,uM,0.063,CC(=O)N1CCC(n2cc(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c(C)n2)CC1,2016.0
Inhibition of CDK2 (unknown origin),CC(=O)N1CCC(n2ncc(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1,CHEMBL3822394,=,=,IC50,nM,254.0,IC50,uM,0.254,CC(=O)N1CCC(n2ncc(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1,2016.0
Inhibition of CDK2 (unknown origin),Cc1nn(C2CCNCC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,CHEMBL3822394,=,=,IC50,nM,1520.0,IC50,uM,1.52,Cc1nn(C2CCNCC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,2016.0
Inhibition of CDK2 (unknown origin),CC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1,CHEMBL3822394,=,=,IC50,nM,1380.0,IC50,uM,1.38,CC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1,2016.0
Inhibition of CDK2 (unknown origin),CCOc1nn(C2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,CHEMBL3822394,=,=,IC50,nM,545.0,IC50,uM,0.545,CCOc1nn(C2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,2016.0
Inhibition of CDK2 (unknown origin),CCc1nn(C2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,CHEMBL3822394,=,=,IC50,nM,113.0,IC50,uM,0.113,CCc1nn(C2CCN(C(C)=O)CC2)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,2016.0
Inhibition of CDK2 (unknown origin),CCc1c(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)cnn1C1CCN(C(C)=O)CC1,CHEMBL3822394,=,=,IC50,nM,832.0,IC50,uM,0.832,CCc1c(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)cnn1C1CCN(C(C)=O)CC1,2016.0
Inhibition of CDK2 (unknown origin),Cc1nn(C2CCN(C(=O)[C@@H](C)O)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,CHEMBL3822394,=,=,IC50,nM,700.0,IC50,uM,0.7,Cc1nn(C2CCN(C(=O)[C@@H](C)O)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,2016.0
Binding affinity to full length human CDK2 (1 to 298 residues) expressed in bacterial expression system by KINOMEscan competition assay,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/c1cnc2ccc(Br)cn12,CHEMBL3856187,=,=,Kd,nM,540.0,Kd,nM,540.0,Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/c1cnc2ccc(Br)cn12,2016.0
Binding affinity to full length human CDK2 (1 to 298 residues) expressed in bacterial expression system by KINOMEscan competition assay,COc1ccccc1-c1cc(Nc2ccc(F)c(NS(C)(=O)=O)c2)ncn1,CHEMBL3856187,>,>,Ki,nM,1000.0,Ki,nM,1000.0,COc1ccccc1-c1cc(Nc2ccc(F)c(NS(C)(=O)=O)c2)ncn1,2016.0
Inhibition of recombinant CDK2 (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotinylated Histone H1 as substrate after 1 hr in presence of 33P-ATP by liquid scintillation counting analysis,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,CHEMBL3856187,=,=,IC50,nM,1.0,IC50,nmol/L,1.0,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,2016.0
Inhibition of CDK2 (unknown origin),CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL3856187,=,=,IC50,nM,3.0,IC50,nM,3.0,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,2016.0
Inhibition of CDK2 (unknown origin),Cc1c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)sc(=O)n1C,CHEMBL3856187,=,=,Ki,nM,149.0,Ki,nM,149.0,Cc1c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)sc(=O)n1C,2016.0
Inhibition of CDK2 (unknown origin),Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,CHEMBL3856187,=,=,Ki,nM,2.0,Ki,nM,2.0,Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,2016.0
Inhibition of GST-tagged human recombinant CDK2 assessed as residual activity at 2 uM using Ser/Thr12 peptide as substrate by Z' LYTE assay relative to control,O=C1N/C(=N/c2ccccc2)S/C1=C\c1ccc(O)cc1,CHEMBL3856225,=,=,Activity,%,69.63,Activity,%,69.63,O=C1N/C(=N/c2ccccc2)S/C1=C\c1ccc(O)cc1,2016.0
Inhibition of GST-tagged human recombinant CDK2 assessed as residual activity at 2 uM using Ser/Thr12 peptide as substrate by Z' LYTE assay relative to control,O=C1N/C(=N/c2ccccc2)S/C1=C\c1ccc(F)cc1,CHEMBL3856225,=,=,Activity,%,68.93,Activity,%,68.93,O=C1N/C(=N/c2ccccc2)S/C1=C\c1ccc(F)cc1,2016.0
Inhibition of GST-tagged human recombinant CDK2 assessed as residual activity at 2 uM using Ser/Thr12 peptide as substrate by Z' LYTE assay relative to control,O=C1N/C(=N/Cc2ccccc2)S/C1=C\c1ccc(Cl)c([N+](=O)[O-])c1,CHEMBL3856225,=,=,Activity,%,68.4,Activity,%,68.4,O=C1N/C(=N/Cc2ccccc2)S/C1=C\c1ccc(Cl)c([N+](=O)[O-])c1,2016.0
Inhibition of GST-tagged human recombinant CDK2 assessed as residual activity at 2 uM using Ser/Thr12 peptide as substrate by Z' LYTE assay relative to control,O=C1N=C(NCc2ccccc2)S/C1=C\c1ccc(O)cc1,CHEMBL3856225,=,=,Activity,%,63.23,Activity,%,63.23,O=C1N=C(NCc2ccccc2)S/C1=C\c1ccc(O)cc1,2016.0
Inhibition of GST-tagged human recombinant CDK2 assessed as residual activity at 2 uM using Ser/Thr12 peptide as substrate by Z' LYTE assay relative to control,COc1ccc(/C=C2\S/C(=N\Cc3ccccc3)NC2=O)cc1[N+](=O)[O-],CHEMBL3856225,=,=,Activity,%,73.01,Activity,%,73.01,COc1ccc(/C=C2\S/C(=N\Cc3ccccc3)NC2=O)cc1[N+](=O)[O-],2016.0
Inhibition of GST-tagged human recombinant CDK2 assessed as residual activity at 2 uM using Ser/Thr12 peptide as substrate by Z' LYTE assay relative to control,CCOc1cc(/C=C2\S/C(=N\Cc3ccccc3)NC2=O)ccc1O,CHEMBL3856225,=,=,Activity,%,39.1,Activity,%,39.1,CCOc1cc(/C=C2\S/C(=N\Cc3ccccc3)NC2=O)ccc1O,2016.0
Inhibition of GST-tagged human recombinant CDK2 assessed as residual activity at 2 uM using Ser/Thr12 peptide as substrate by Z' LYTE assay relative to control,COc1ccc(/C=C2\S/C(=N\Cc3ccccc3)NC2=O)cc1OC,CHEMBL3856225,=,=,Activity,%,53.83,Activity,%,53.83,COc1ccc(/C=C2\S/C(=N\Cc3ccccc3)NC2=O)cc1OC,2016.0
Inhibition of CDK2 (unknown origin),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1,CHEMBL3865806,=,=,IC50,nM,60.0,IC50,nM,60.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1,2016.0
Inhibition of CDK2 (unknown origin) at 1 uM,O=C(O)/C=C\C(=O)Nc1cccc(-c2n[nH]c3ccc(NS(=O)(=O)c4ccccc4)cc23)c1,CHEMBL3871274,=,=,Inhibition,%,17.0,INH,%,17.0,O=C(O)/C=C\C(=O)Nc1cccc(-c2n[nH]c3ccc(NS(=O)(=O)c4ccccc4)cc23)c1,2016.0
Inhibition of CDK2 (unknown origin),CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21,CHEMBL3875183,=,=,IC50,nM,605.0,IC50,nM,605.0,CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21,2017.0
Inhibition of CDK2 (unknown origin),CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,CHEMBL3875233,=,=,IC50,nM,1.0,IC50,nM,1.0,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,2017.0
"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",CS(=N)(=O)c1ccc(Nc2ncc(Br)c(Nc3ccccc3)n2)cc1,CHEMBL3638817,=,=,IC50,nM,33.0,IC50,nM,33.0,CS(=N)(=O)c1ccc(Nc2ncc(Br)c(Nc3ccccc3)n2)cc1,2013.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)C3CC3)cc2)ncc1C(F)(F)F,CHEMBL3639233,=,=,IC50,nM,6.0,IC50,nM,6.0,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)C3CC3)cc2)ncc1C(F)(F)F,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F,CHEMBL3639233,=,=,IC50,nM,4.0,IC50,nM,4.0,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C[C@@H](Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F)C(C)(C)O,CHEMBL3639233,=,=,IC50,nM,8.0,IC50,nM,8.0,C[C@@H](Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F)C(C)(C)O,2014.0
"HTS Assay: The GSK3beta primary screen was conducted in assay ready 1536 plates (Aurora 29847) that contain 2.5 mL/well of 10 mM compound. Human GSK3beta as a GST fusion expressed in baculoviral system was purchased from BPS Bioscience (San Diego, Calif.). The GSK3beta peptide substrate was from American Peptide (Sunnyvale, Calif.; Cat 311153). 1 L/well of CABPE (22.5 nM GSK3beta , 8 uM peptide in AB buffer (12.5 mM DTT, 0.25 mg/mL BSA, 0.5 unit/mL Heparin)), 0.5 L/well of 125 uM of ATP, and 1 L/well of positive control 50 uM of GW8510 (positive control) or AB (DMSO only neutral control) in respective wells according to plate design using BioRAPTR (Beckman, Brea, Calif.). Reactions were incubated at room temperature for 60 minutes. 2.5 uL/well of ADP-Glo (Promega, V9103) was added with BioRAPTR, and incubated at room temperature for 40 minutes followed by addition of 5 uL/well of ADP-Glo detection reagent (Promega, V9103) with Combi nL (Thermo, Waltham, Mass.).",Cc1nccc(-c2ccc(C(=O)N3CCOCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1,CHEMBL3639177,=,=,IC50,nM,1500.0,IC50,nM,1500.0,Cc1nccc(-c2ccc(C(=O)N3CCOCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1,2015.0
"HTS Assay: The GSK3beta primary screen was conducted in assay ready 1536 plates (Aurora 29847) that contain 2.5 mL/well of 10 mM compound. Human GSK3beta as a GST fusion expressed in baculoviral system was purchased from BPS Bioscience (San Diego, Calif.). The GSK3beta peptide substrate was from American Peptide (Sunnyvale, Calif.; Cat 311153). 1 L/well of CABPE (22.5 nM GSK3beta , 8 uM peptide in AB buffer (12.5 mM DTT, 0.25 mg/mL BSA, 0.5 unit/mL Heparin)), 0.5 L/well of 125 uM of ATP, and 1 L/well of positive control 50 uM of GW8510 (positive control) or AB (DMSO only neutral control) in respective wells according to plate design using BioRAPTR (Beckman, Brea, Calif.). Reactions were incubated at room temperature for 60 minutes. 2.5 uL/well of ADP-Glo (Promega, V9103) was added with BioRAPTR, and incubated at room temperature for 40 minutes followed by addition of 5 uL/well of ADP-Glo detection reagent (Promega, V9103) with Combi nL (Thermo, Waltham, Mass.).",Cc1nccc(-c2ccc(C(=O)N(C)C)c(Cl)c2)c1C#Cc1ccc(N)nc1,CHEMBL3639177,=,=,IC50,nM,3900.0,IC50,nM,3900.0,Cc1nccc(-c2ccc(C(=O)N(C)C)c(Cl)c2)c1C#Cc1ccc(N)nc1,2015.0
"HTS Assay: The GSK3beta primary screen was conducted in assay ready 1536 plates (Aurora 29847) that contain 2.5 mL/well of 10 mM compound. Human GSK3beta as a GST fusion expressed in baculoviral system was purchased from BPS Bioscience (San Diego, Calif.). The GSK3beta peptide substrate was from American Peptide (Sunnyvale, Calif.; Cat 311153). 1 L/well of CABPE (22.5 nM GSK3beta , 8 uM peptide in AB buffer (12.5 mM DTT, 0.25 mg/mL BSA, 0.5 unit/mL Heparin)), 0.5 L/well of 125 uM of ATP, and 1 L/well of positive control 50 uM of GW8510 (positive control) or AB (DMSO only neutral control) in respective wells according to plate design using BioRAPTR (Beckman, Brea, Calif.). Reactions were incubated at room temperature for 60 minutes. 2.5 uL/well of ADP-Glo (Promega, V9103) was added with BioRAPTR, and incubated at room temperature for 40 minutes followed by addition of 5 uL/well of ADP-Glo detection reagent (Promega, V9103) with Combi nL (Thermo, Waltham, Mass.).",Cc1nccc(-c2ccc(C(=O)N3CCOCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1,CHEMBL3639177,=,=,IC50,nM,2200.0,IC50,nM,2200.0,Cc1nccc(-c2ccc(C(=O)N3CCOCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1,2015.0
"HTS Assay: The GSK3beta primary screen was conducted in assay ready 1536 plates (Aurora 29847) that contain 2.5 mL/well of 10 mM compound. Human GSK3beta as a GST fusion expressed in baculoviral system was purchased from BPS Bioscience (San Diego, Calif.). The GSK3beta peptide substrate was from American Peptide (Sunnyvale, Calif.; Cat 311153). 1 L/well of CABPE (22.5 nM GSK3beta , 8 uM peptide in AB buffer (12.5 mM DTT, 0.25 mg/mL BSA, 0.5 unit/mL Heparin)), 0.5 L/well of 125 uM of ATP, and 1 L/well of positive control 50 uM of GW8510 (positive control) or AB (DMSO only neutral control) in respective wells according to plate design using BioRAPTR (Beckman, Brea, Calif.). Reactions were incubated at room temperature for 60 minutes. 2.5 uL/well of ADP-Glo (Promega, V9103) was added with BioRAPTR, and incubated at room temperature for 40 minutes followed by addition of 5 uL/well of ADP-Glo detection reagent (Promega, V9103) with Combi nL (Thermo, Waltham, Mass.).",Cc1nccc(-c2ccc(C(=O)N(C)C)c(Cl)c2)c1C#Cc1ccc(N)nc1,CHEMBL3639177,=,=,IC50,nM,4400.0,IC50,nM,4400.0,Cc1nccc(-c2ccc(C(=O)N(C)C)c(Cl)c2)c1C#Cc1ccc(N)nc1,2015.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",Brc1cnn2c(NCc3ccncc3)cc(-c3ccccc3)nc12,CHEMBL3639187,=,=,IC50,nM,20.0,IC50,nM,20.0,Brc1cnn2c(NCc3ccncc3)cc(-c3ccccc3)nc12,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",Brc1cnn2c(NCc3ccncc3)cc(-c3ccccc3)nc12,CHEMBL3639187,=,=,IC50,nM,29.0,IC50,nM,29.0,Brc1cnn2c(NCc3ccncc3)cc(-c3ccccc3)nc12,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",Fc1ccccc1-c1cc(NCc2ccncc2)n2ncc(Br)c2n1,CHEMBL3639187,=,=,IC50,nM,32.0,IC50,nM,32.0,Fc1ccccc1-c1cc(NCc2ccncc2)n2ncc(Br)c2n1,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",Fc1ccccc1-c1cc(NCc2ccncc2)n2ncc(Br)c2n1,CHEMBL3639187,=,=,IC50,nM,24.0,IC50,nM,24.0,Fc1ccccc1-c1cc(NCc2ccncc2)n2ncc(Br)c2n1,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",Fc1ccccc1-c1cc(NCc2cccnc2)n2ncc(Br)c2n1,CHEMBL3639187,=,=,IC50,nM,11.0,IC50,nM,11.0,Fc1ccccc1-c1cc(NCc2cccnc2)n2ncc(Br)c2n1,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",Fc1ccccc1-c1cc(NCc2cccnc2)n2ncc(Cl)c2n1,CHEMBL3639187,=,=,IC50,nM,21.0,IC50,nM,21.0,Fc1ccccc1-c1cc(NCc2cccnc2)n2ncc(Cl)c2n1,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",Clc1ccccc1-c1cc(NCc2cccnc2)n2ncc(Br)c2n1,CHEMBL3639187,=,=,IC50,nM,3.0,IC50,nM,3.0,Clc1ccccc1-c1cc(NCc2cccnc2)n2ncc(Br)c2n1,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",Fc1ccccc1-c1cc(NCc2ccncc2)n2ncc(Cl)c2n1,CHEMBL3639187,=,=,IC50,nM,64.0,IC50,nM,64.0,Fc1ccccc1-c1cc(NCc2ccncc2)n2ncc(Cl)c2n1,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",Fc1ccccc1-c1cc(NCc2ccncc2)n2ncc(Cl)c2n1,CHEMBL3639187,=,=,IC50,nM,29.0,IC50,nM,29.0,Fc1ccccc1-c1cc(NCc2ccncc2)n2ncc(Cl)c2n1,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",Clc1ccccc1-c1cc(NCc2ccncc2)n2ncc(Br)c2n1,CHEMBL3639187,=,=,IC50,nM,10.0,IC50,nM,10.0,Clc1ccccc1-c1cc(NCc2ccncc2)n2ncc(Br)c2n1,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",Clc1ccccc1-c1cc(NCc2ccncc2)n2ncc(Br)c2n1,CHEMBL3639187,=,=,IC50,nM,6.0,IC50,nM,6.0,Clc1ccccc1-c1cc(NCc2ccncc2)n2ncc(Br)c2n1,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",CC(C)c1cc(NCc2ccncc2)n2ncc(Br)c2n1,CHEMBL3639187,=,=,IC50,nM,42.0,IC50,nM,42.0,CC(C)c1cc(NCc2ccncc2)n2ncc(Br)c2n1,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",CC(C)(C)c1cc(NCc2ccncc2)n2ncc(Br)c2n1,CHEMBL3639187,=,=,IC50,nM,170.0,IC50,nM,170.0,CC(C)(C)c1cc(NCc2ccncc2)n2ncc(Br)c2n1,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",N#Cc1cnn2c(NCc3ccncc3)cc(-c3ccccc3)nc12,CHEMBL3639187,=,=,IC50,nM,620.0,IC50,nM,620.0,N#Cc1cnn2c(NCc3ccncc3)cc(-c3ccccc3)nc12,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",CN1CCN(c2cc(NCc3cccnc3)n3nccc3n2)CC1,CHEMBL3639187,=,=,IC50,nM,5600.0,IC50,nM,5600.0,CN1CCN(c2cc(NCc3cccnc3)n3nccc3n2)CC1,2013.0
"In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).",CN1CCN(c2cc(NCc3cccnc3)n3ncc(Br)c3n2)CC1,CHEMBL3639187,=,=,IC50,nM,140.0,IC50,nM,140.0,CN1CCN(c2cc(NCc3cccnc3)n3ncc(Br)c3n2)CC1,2013.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)C3CC3)cc2)ncc1C(F)(F)F,CHEMBL3639233,=,=,IC50,nM,16.0,IC50,nM,16.0,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)C3CC3)cc2)ncc1C(F)(F)F,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F,CHEMBL3639233,=,=,IC50,nM,8.0,IC50,nM,8.0,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C[C@@H](Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F)C(C)(C)O,CHEMBL3639233,=,=,IC50,nM,12.0,IC50,nM,12.0,C[C@@H](Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F)C(C)(C)O,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C[C@@H](Oc1nc(Nc2ccc(S(=O)(=O)C3CC3)cc2)ncc1C(F)(F)F)C(C)(C)O,CHEMBL3639233,=,=,IC50,nM,21.0,IC50,nM,21.0,C[C@@H](Oc1nc(Nc2ccc(S(=O)(=O)C3CC3)cc2)ncc1C(F)(F)F)C(C)(C)O,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)c3ccccc3)cc2)ncc1C(F)(F)F,CHEMBL3639233,=,=,IC50,nM,36.0,IC50,nM,36.0,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)c3ccccc3)cc2)ncc1C(F)(F)F,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)C(F)F)cc2)ncc1C(F)(F)F,CHEMBL3639233,=,=,IC50,nM,12.0,IC50,nM,12.0,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)C(F)F)cc2)ncc1C(F)(F)F,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)C3CCCC3)cc2)ncc1C(F)(F)F,CHEMBL3639233,=,=,IC50,nM,21.0,IC50,nM,21.0,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)C3CCCC3)cc2)ncc1C(F)(F)F,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C=CCS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(O[C@H](C)C(C)(C)O)n2)cc1,CHEMBL3639233,=,=,IC50,nM,11.0,IC50,nM,11.0,C=CCS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(O[C@H](C)C(C)(C)O)n2)cc1,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",CC(C)S(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(O[C@H](C)[C@@H](C)O)n2)cc1,CHEMBL3639233,=,=,IC50,nM,6.0,IC50,nM,6.0,CC(C)S(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(O[C@H](C)[C@@H](C)O)n2)cc1,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C#CCS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(O[C@H](C)C(C)(C)O)n2)cc1,CHEMBL3639233,=,=,IC50,nM,43.0,IC50,nM,43.0,C#CCS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(O[C@H](C)C(C)(C)O)n2)cc1,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)CCO)cc2)ncc1C(F)(F)F,CHEMBL3639233,=,=,IC50,nM,3.0,IC50,nM,3.0,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=O)(=O)CCO)cc2)ncc1C(F)(F)F,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",COC[C@@H](C)Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F,CHEMBL3639233,=,=,IC50,nM,12.0,IC50,nM,12.0,COC[C@@H](C)Oc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C#CCOc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F,CHEMBL3639233,=,=,IC50,nM,25.0,IC50,nM,25.0,C#CCOc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",CS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(OCCC(F)(F)F)n2)cc1,CHEMBL3639233,=,=,IC50,nM,94.0,IC50,nM,94.0,CS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(OCCC(F)(F)F)n2)cc1,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",C=CCOc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F,CHEMBL3639233,=,=,IC50,nM,49.0,IC50,nM,49.0,C=CCOc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F,2014.0
"Kinase Assay: CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 uM) in assay buffer [50 mM Tris/HCl pH 8.0; 10 mM MgCl2; 0.1 mM Na ortho-vanadate; 1.0 mM dithiothreitol; 0.5 uM adenosine trisphosphate (ATP); 10 ug/measuring point histone IIIS; 0.2 uCi/measuring point 33P-gamma ATP; 0.05% NP40; 1.25% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C. The amount of incorporated 33P (substrate phosphorylation) was determined.",CS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(OC3CCCCC3)n2)cc1,CHEMBL3639233,=,=,IC50,nM,480.0,IC50,nM,480.0,CS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(OC3CCCCC3)n2)cc1,2014.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccccn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccccn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CCN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CCN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCF)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCF)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",COCCN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,COCCN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC(C)OCCN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC(C)OCCN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCOCCO)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCOCCO)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",C[C@@H](O)CN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,C[C@@H](O)CN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC(C)(C)O)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC(C)(C)O)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCCO)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCCO)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC(O)CO)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC(O)CO)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C[C@@H](O)CO)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C[C@@H](O)CO)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C[C@H](O)CO)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C[C@H](O)CO)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C5CCCC5)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C5CCCC5)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC(C)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC(CO)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC(CO)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",COC(=O)C(C)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,COC(=O)C(C)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC(C(=O)O)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC(C(=O)O)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC5CCCCC5)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC5CCCCC5)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC(C)CN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC(C)CN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CCC(C)CN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CCC(C)CN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)CC5CCCCC5)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)CC5CCCCC5)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC(C)CCCN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC(C)CCCN1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC(F)(F)F)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC(F)(F)F)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC(N)=O)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC(N)=O)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC#N)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CC#N)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCC#N)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCC#N)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC(=O)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC(=O)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)C5CC5)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)C5CC5)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)C5CCCCC5)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)C5CCCCC5)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)CC5CCCCC5)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)CC5CCCCC5)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)CCC5CCCC5)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)CCC5CCCC5)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)CN)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)CN)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)CC(=O)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)CC(=O)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)N5CCCC5)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)N5CCCC5)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)N5CCCCC5)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)N5CCCCC5)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)N5CCOCC5)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)N5CCOCC5)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",C[C@@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1C(=O)OC(C)(C)C,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1C(=O)OC(C)(C)C,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",C[C@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1C(=O)OC(C)(C)C,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,C[C@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1C(=O)OC(C)(C)C,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",C[C@@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",C[C@@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1CCO,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1CCO,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",C[C@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,C[C@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",C[C@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1CCO,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,C[C@H]1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1CCO,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNC(C)(C)C4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNC(C)(C)C4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC(C)N1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC1CN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC(C)N1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNC(=O)C4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNC(=O)C4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCCNCC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,=,=,IC50,nM,8000.0,IC50,nM,8000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCCNCC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC(N)C4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC(N)C4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC[C@H](O)C4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC[C@H](O)C4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC(O)C4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CC(O)C4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N(C)CCN)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N(C)CCN)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N(C)CCO)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N(C)CCO)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CC(O)C4)cn3)nc2n1C1CCCC1,CHEMBL3638874,=,=,IC50,nM,14000.0,IC50,nM,14000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CC(O)C4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCN(S(C)(=O)=O)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCN(S(C)(=O)=O)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCNCC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN1CCN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN1CCN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC1CN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC1CN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",C[C@H]1CN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,C[C@H]1CN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CCN1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCN(C)C(=O)C4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCN(C)C(=O)C4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC(=O)N1CCN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC(=O)N1CCN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC(C)N1CCN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC(C)N1CCN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCN(C(=O)CN)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCN(C(=O)CN)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CC5CCC(C4)N5)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CC5CCC(C4)N5)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",C[C@@H]1CN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)C[C@H](C)N1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,C[C@@H]1CN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)C[C@H](C)N1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCC(O)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCC(O)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",COCCN1CCN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,COCCN1CCN(Cc2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCN(CCO)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(CN4CCN(CCO)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",C[C@H](CO)NCc1ccc(Nc2ncc3cc(C(=O)N(C)C)n(C4CCCC4)c3n2)nc1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,C[C@H](CO)NCc1ccc(Nc2ncc3cc(C(=O)N(C)C)n(C4CCCC4)c3n2)nc1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)NC4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)NC4CCNCC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N(C)C4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N(C)C4CCNCC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCNCC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCC(N(C)C)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCC(N(C)C)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCC(O)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N4CCC(O)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N(C)CCN)cn3)nc2n1C1CCCC1,CHEMBL3638874,=,=,IC50,nM,4700.0,IC50,nM,4700.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(C(=O)N(C)CCN)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC(N(C)C)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC(N(C)C)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC(O)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC(O)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC(CCO)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,=,=,IC50,nM,2900.0,IC50,nM,2900.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCC(CCO)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(C4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(C4CCNCC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC(C)N1CCC(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC(C)N1CCC(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(C4CCN(CCO)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(C4CCN(CCO)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)nn3)nc2n1C1CCCC1,CHEMBL3638874,=,=,IC50,nM,20000.0,IC50,nM,20000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)nn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)nn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)nn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC(C)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nn2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nn2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCO)CC4)nn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCO)CC4)nn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3cnc(N4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3cnc(N4CCNCC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3cnc(N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3cnc(N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccccn3)nc2n1C1CCC(C)(O)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccccn3)nc2n1C1CCC(C)(O)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C1CCN(c2ccc(Nc3ncc4cc(C#N)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,=,=,IC50,nM,8300.0,IC50,nM,8300.0,CN(C)C1CCN(c2ccc(Nc3ncc4cc(C#N)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CNC(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CNC(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CNC(=O)c1cc2cnc(Nc3ccc(N4CCN(C(C)C)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CNC(=O)c1cc2cnc(Nc3ccc(N4CCN(C(C)C)CC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",c1ncc(-c2cc3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n2C2CCCC2)o1,CHEMBL3638874,=,=,IC50,nM,3500.0,IC50,nM,3500.0,c1ncc(-c2cc3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n2C2CCCC2)o1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",c1ncc(-c2cc3cnc(Nc4ccc(CN5CCNCC5)cn4)nc3n2C2CCCC2)o1,CHEMBL3638874,=,=,IC50,nM,2800.0,IC50,nM,2800.0,c1ncc(-c2cc3cnc(Nc4ccc(CN5CCNCC5)cn4)nc3n2C2CCCC2)o1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4=O)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4=O)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCOCC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCOCC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,=,=,IC50,nM,76000.0,IC50,nM,76000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CC(C)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)nc2)CC1,2015.0
"IMAP-FPT (Molecular Devices Trade Mark Technology) Endpoint Assay: The assay was run under the conditions identical to that for CDK1/cyclin B except 0.25 nM CDK1/cyclin B was replaced with 0.3 nM CDK2/cyclin A. A 384-well microtiter IMAP-FPT (Molecular Devices Trade Mark Technology) endpoint assay was used for CDK1/cyclin B kinase activity measurements. The same assay was used for IC50 determination of small molecule inhibitors. In general, the kinase reactions were carried out in 20 μL volumes in the reaction solution, which is composed of 2 μL compound (in 20% DMSO), 8 μL CDK1/cyclin B in the 1× Reaction Buffer (Molecular Devices, Cat. No. R8139), 10 μL substrate mixture of Tamra Histone-H1 peptide (Molecular Devices, Cat. No. R7384) and ATP (Amersham Pharmacia, Cat. No. 27-2056-01) in the 1× Reaction Buffer with 1 mM DTT freshly added. The final reaction mixture contains compound (inhibitor) with the concentration varying from 0.005-10 μM, 2% DMSO, 0.25 nM CDK1/cyclin B, 100 nM Tamra Histone-H1 peptide, and 20 μM ATP.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1,CHEMBL3638874,>,>,IC50,nM,15000.0,IC50,nM,15000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(CCO)CC4)cn3)nc2n1C1CCCC1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,780.0,IC50,nM,780.0,CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,1100.0,IC50,nM,1100.0,COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1,CHEMBL3886246,=,=,IC50,nM,1100.0,IC50,nM,1100.0,CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1,CHEMBL3886246,=,=,IC50,nM,850.0,IC50,nM,850.0,CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3cccc4c3OCCC4)n2)c1,CHEMBL3886246,=,=,IC50,nM,330.0,IC50,nM,330.0,CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3cccc4c3OCCC4)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3cccc4c3OCCC4)n2)c1,CHEMBL3886246,=,=,IC50,nM,270.0,IC50,nM,270.0,CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3cccc4c3OCCC4)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CS(=O)(Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1)=NC#N,CHEMBL3886246,=,=,IC50,nM,20000.0,IC50,nM,20000.0,CS(=O)(Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1)=NC#N,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CNC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,430.0,IC50,nM,430.0,CNC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCOC(=O)N=S(C)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,560.0,IC50,nM,560.0,CCOC(=O)N=S(C)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,220.0,IC50,nM,220.0,COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,470.0,IC50,nM,470.0,COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,540.0,IC50,nM,540.0,COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1,CHEMBL3886246,=,=,IC50,nM,280.0,IC50,nM,280.0,CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1,CHEMBL3886246,=,=,IC50,nM,480.0,IC50,nM,480.0,CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,320.0,IC50,nM,320.0,COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,310.0,IC50,nM,310.0,COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=O)=NC#N)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,240.0,IC50,nM,240.0,COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=O)=NC#N)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=O)=NC#N)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,330.0,IC50,nM,330.0,COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=O)=NC#N)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=O)=NC#N)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,570.0,IC50,nM,570.0,COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=O)=NC#N)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCS(=O)(Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1)=NC#N,CHEMBL3886246,=,=,IC50,nM,170.0,IC50,nM,170.0,CCS(=O)(Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1)=NC#N,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,380.0,IC50,nM,380.0,CCS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,410.0,IC50,nM,410.0,CCS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,350.0,IC50,nM,350.0,CCS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=O)=NC#N)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,73.0,IC50,nM,73.0,COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=O)=NC#N)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,170.0,IC50,nM,170.0,COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,210.0,IC50,nM,210.0,COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,180.0,IC50,nM,180.0,COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=O)=NC#N)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,120.0,IC50,nM,120.0,COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=O)=NC#N)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,86.0,IC50,nM,86.0,COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,110.0,IC50,nM,110.0,COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,120.0,IC50,nM,120.0,COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(CS(C)(=O)=NC#N)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,130.0,IC50,nM,130.0,COc1cc(CS(C)(=O)=NC#N)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(CS(C)(=N)=O)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,150.0,IC50,nM,150.0,COc1cc(CS(C)(=N)=O)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(CS(C)(=N)=O)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,210.0,IC50,nM,210.0,COc1cc(CS(C)(=N)=O)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(CS(C)(=N)=O)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,190.0,IC50,nM,190.0,COc1cc(CS(C)(=N)=O)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=O)=NC#N)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,290.0,IC50,nM,290.0,CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=O)=NC#N)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,510.0,IC50,nM,510.0,CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,260.0,IC50,nM,260.0,CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,240.0,IC50,nM,240.0,CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=O)=NC#N)cc(C(F)(F)F)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,200.0,IC50,nM,200.0,COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=O)=NC#N)cc(C(F)(F)F)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=N)=O)cc(C(F)(F)F)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,180.0,IC50,nM,180.0,COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=N)=O)cc(C(F)(F)F)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCS(=O)(Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1)=NC#N,CHEMBL3886246,=,=,IC50,nM,160.0,IC50,nM,160.0,CCS(=O)(Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1)=NC#N,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCS(=N)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,290.0,IC50,nM,290.0,CCS(=N)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCS(=N)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,220.0,IC50,nM,220.0,CCS(=N)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCS(=N)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,250.0,IC50,nM,250.0,CCS(=N)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=O)=NC#N)cc(C(F)(F)C(F)(F)F)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,630.0,IC50,nM,630.0,COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=O)=NC#N)cc(C(F)(F)C(F)(F)F)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=N)=O)cc(C(F)(F)C(F)(F)F)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,230.0,IC50,nM,230.0,COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=N)=O)cc(C(F)(F)C(F)(F)F)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cccc(CS(=O)(=NC#N)C3CC3)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,220.0,IC50,nM,220.0,COc1cc(F)ccc1-c1nc(Nc2cccc(CS(=O)(=NC#N)C3CC3)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cccc(CS(=N)(=O)C3CC3)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,410.0,IC50,nM,410.0,COc1cc(F)ccc1-c1nc(Nc2cccc(CS(=N)(=O)C3CC3)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=O)(=NC#N)C3CC3)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,250.0,IC50,nM,250.0,COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=O)(=NC#N)C3CC3)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=N)(=O)C3CC3)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,410.0,IC50,nM,410.0,COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=N)(=O)C3CC3)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=N)(=O)C3CC3)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,580.0,IC50,nM,580.0,COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=N)(=O)C3CC3)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=N)(=O)C3CC3)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,380.0,IC50,nM,380.0,COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=N)(=O)C3CC3)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3cccc4c3OCC4)n2)c1,CHEMBL3886246,=,=,IC50,nM,350.0,IC50,nM,350.0,CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3cccc4c3OCC4)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccc(F)cc3)n2)c1,CHEMBL3886246,=,=,IC50,nM,770.0,IC50,nM,770.0,CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccc(F)cc3)n2)c1,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(Cl)cc(CS(C)(=O)=NC#N)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,160.0,IC50,nM,160.0,COc1cc(F)ccc1-c1nc(Nc2cc(Cl)cc(CS(C)(=O)=NC#N)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(Cl)cc(CS(C)(=N)=O)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,180.0,IC50,nM,180.0,COc1cc(F)ccc1-c1nc(Nc2cc(Cl)cc(CS(C)(=N)=O)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COc1cc(F)ccc1-c1nc(Nc2cc(C)cc(CS(C)(=O)=NC#N)c2)ncc1F,CHEMBL3886246,=,=,IC50,nM,220.0,IC50,nM,220.0,COc1cc(F)ccc1-c1nc(Nc2cc(C)cc(CS(C)(=O)=NC#N)c2)ncc1F,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",,CHEMBL3886246,=,=,IC50,nM,320.0,IC50,nM,320.0,,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",,CHEMBL3886246,=,=,IC50,nM,290.0,IC50,nM,290.0,,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",,CHEMBL3886246,=,=,IC50,nM,170.0,IC50,nM,170.0,,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",,CHEMBL3886246,=,=,IC50,nM,200.0,IC50,nM,200.0,,2015.0
"CDK2/CycE Kinase Assay: Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany)For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.",COCCOC(=O)N=S(C)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,CHEMBL3886246,=,=,IC50,nM,330.0,IC50,nM,330.0,COCCOC(=O)N=S(C)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1,2015.0
"LanthaScreen TR-FRET Assay: Compound 1 was also assayed to determine the IC50 values for three different kinases (PCTAIRE1, DYRK1a, and CDK2) in comparison to Gsk3beta. The assay was conducted with the same method described below in the second assay. Activity on human GSK-3beta was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266). In a first screening assay, compounds were tested in duplicate at a concentration of 10 Î¼M.Human recombinant enzyme GSK-3beta was incubated for 90 minutes at 22° C. in the presence of compounds or vehicle in a reaction buffer containing ATP plus 100 nM unphosphorylated specific substrate peptide (Ulight-CFFKNIVTPRTPPPSQGK-amide). Substrate phosphorylation was measured by LANCE technology (PerkinElmer, Conn., USA). The results, reported in the following Table 4, are expressed as a percent of inhibition of control specific activity obtained in the presence of the test compounds (as % inhibition at 10 um).",COc1ccc2[nH]nc(C(=O)NCC3CCN(CCc4ccc(O)cc4)CC3)c2c1,CHEMBL3886303,=,=,IC50,nM,36000.0,IC50,nM,36000.0,COc1ccc2[nH]nc(C(=O)NCC3CCN(CCc4ccc(O)cc4)CC3)c2c1,2015.0
"Mobility Shift Assay: Agents: 1-fold kinase buffer without MnCl2: 50 mM HEPES, pH 7.5, 0.0015% Brij-35, 10 mM MgCl2, 2 mM DTT. 1-fold kinase buffer with MnCl2: 50 mM HEPES, pH 7.5, 0.0015% Brij-35, 10 mM MgCl2, 10 mM MnCl2, 2 mM DTT. Termination solution: 100 mM HEPES, pH 7.5, 0.0015% Brij-35, 0.2% Coating Reagent#3, 50 mM EDTA. 2.5-fold kinase solution: The kinase was added to the 1-fold kinase buffer to form a 2.5-fold kinase solution. 2.5-fold substrate solution: FAM fluorescence-labelled polypeptide and ATP were added to the 1-fold kinase buffer to form a 2.5-fold substrate solution. Compounds: The final test concentration of the compound was 10 μM at maximum. Firstly, a 50-fold concentration (i.e. 500 μM) was prepared with 100% DMSO. The compound was diluted with 100% DMSO by 5 folds at 5 concentrations (successively 500 μM, 100 μM, 20 μM, 4 μM, and 0.8 μM). After diluting with 1-fold kinase buffer by 10 folds, 5 μl of the samples were transferred to a 384-well reaction plate. Two negative control wells and two positive control wells were set at each line respectively. Replication was made in a 96-well plate in five concentrations of 5-fold compound. 10% DMSO was added to the positive control well, and 5 μl of EDTA (250 mM) was added to the negative control well. Procedure: To the 384-well reaction plate was added 5-fold compound dissolved in 10% DMSO at 5 μl/well. To the 384-well reaction plate was added 2.5-fold kinase solution at 10 Î¼l/well. The plate was incubated at room temperature for 10 mins. To the 384-well reaction plate was added 2.5-fold substrate solution at 10 μl/well. The plate was incubated at 28° C. for a certain period. 25 μl termination solution was added to terminate the reaction.",Nc1ccc(-c2ccc3ncc4c(=O)[nH]c(=O)n(-c5cccc(C(F)(F)F)c5)c4c3n2)cn1,CHEMBL3886794,>,>,IC50,nM,10000.0,IC50,nM,10000.0,Nc1ccc(-c2ccc3ncc4c(=O)[nH]c(=O)n(-c5cccc(C(F)(F)F)c5)c4c3n2)cn1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,6350.0,IC50,nM,6350.0,C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CC1CC1,CHEMBL3886995,=,=,IC50,nM,3040.0,IC50,nM,3040.0,C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CC1CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,CHEMBL3886995,=,=,IC50,nM,1920.0,IC50,nM,1920.0,C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1(C)C,CHEMBL3886995,=,=,IC50,nM,3480.0,IC50,nM,3480.0,CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1(C)C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)C1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,CHEMBL3886995,=,=,IC50,nM,695.0,IC50,nM,695.0,CC(C)C1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCN(C5CCC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,628.0,IC50,nM,628.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCN(C5CCC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CCC(C)(C)C,CHEMBL3886995,=,=,IC50,nM,2580.0,IC50,nM,2580.0,CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CCC(C)(C)C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1(C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CC1CC1,CHEMBL3886995,=,=,IC50,nM,1520.0,IC50,nM,1520.0,CC1(C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CC1CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1(C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,CHEMBL3886995,=,=,IC50,nM,2120.0,IC50,nM,2120.0,CC1(C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C[C@@H](C)O,CHEMBL3886995,=,=,IC50,nM,5110.0,IC50,nM,5110.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C[C@@H](C)O,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1CCN(C2CCN(c3ccc(Nc4ncc5cc6n(c5n4)C4(CCCCC4)CNC6=O)nc3)CC2)C1,CHEMBL3886995,=,=,IC50,nM,1070.0,IC50,nM,1070.0,CC1CCN(C2CCN(c3ccc(Nc4ncc5cc6n(c5n4)C4(CCCCC4)CNC6=O)nc3)CC2)C1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H]1C,CHEMBL3886995,=,=,IC50,nM,4530.0,IC50,nM,4530.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CCC(C)(C)C,CHEMBL3886995,=,=,IC50,nM,2280.0,IC50,nM,2280.0,C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CCC(C)(C)C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCCCC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,1500.0,IC50,nM,1500.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCCCC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN(C)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,41410.0,IC50,nM,41410.0,CN(C)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H](C)N1,CHEMBL3886995,=,=,IC50,nM,3560.0,IC50,nM,3560.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H](C)N1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCNCC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,1080.0,IC50,nM,1080.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCNCC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C,CHEMBL3886995,=,=,IC50,nM,1920.0,IC50,nM,1920.0,C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1250.0,IC50,nM,1250.0,C[C@@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1660.0,IC50,nM,1660.0,CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,1460.0,IC50,nM,1460.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,CHEMBL3886995,=,=,IC50,nM,3500.0,IC50,nM,3500.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CC(C)(C)O,CHEMBL3886995,=,=,IC50,nM,3970.0,IC50,nM,3970.0,CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CC(C)(C)O,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCC(C(F)(F)F)CC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,11600.0,IC50,nM,11600.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCC(C(F)(F)F)CC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(C(=O)N4CCNCC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,124.0,IC50,nM,124.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(C(=O)N4CCNCC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H](O)CN1[C@H](C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,CHEMBL3886995,=,=,IC50,nM,3710.0,IC50,nM,3710.0,C[C@H](O)CN1[C@H](C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,CHEMBL3886995,=,=,IC50,nM,6100.0,IC50,nM,6100.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1(C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C1CC1,CHEMBL3886995,=,=,IC50,nM,1680.0,IC50,nM,1680.0,CC1(C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C1CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1250.0,IC50,nM,1250.0,CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H](C)N1C,CHEMBL3886995,=,=,IC50,nM,9620.0,IC50,nM,9620.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H](C)N1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(Cc2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1660.0,IC50,nM,1660.0,CC(C)N1CCN(Cc2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCN1[C@H](C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,CHEMBL3886995,=,=,IC50,nM,4620.0,IC50,nM,4620.0,CCN1[C@H](C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,3580.0,IC50,nM,3580.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCN(CC5CC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,1280.0,IC50,nM,1280.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCN(CC5CC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(C(=O)c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,367.0,IC50,nM,367.0,CC(C)N1CCN(C(=O)c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCN(CC)C1CCN(C(=O)c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C1,CHEMBL3886995,=,=,IC50,nM,288.0,IC50,nM,288.0,CCN(CC)C1CCN(C(=O)c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,CHEMBL3886995,=,=,IC50,nM,1760.0,IC50,nM,1760.0,C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(C(=O)N4CCN(C5CCC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,202.0,IC50,nM,202.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(C(=O)N4CCN(C5CCC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H](C)N1C[C@@H](C)O,CHEMBL3886995,=,=,IC50,nM,3390.0,IC50,nM,3390.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H](C)N1C[C@@H](C)O,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C,CHEMBL3886995,=,=,IC50,nM,4700.0,IC50,nM,4700.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC(C)N1CC1CC1,CHEMBL3886995,=,=,IC50,nM,3980.0,IC50,nM,3980.0,CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC(C)N1CC1CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1C,CHEMBL3886995,=,=,IC50,nM,3600.0,IC50,nM,3600.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C1,CHEMBL3886995,=,=,IC50,nM,3060.0,IC50,nM,3060.0,CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCN(CC)C1CCN(C2CCN(c3ccc(Nc4ncc5cc6n(c5n4)C4(CCCCC4)CNC6=O)nc3)CC2)C1,CHEMBL3886995,=,=,IC50,nM,1580.0,IC50,nM,1580.0,CCN(CC)C1CCN(C2CCN(c3ccc(Nc4ncc5cc6n(c5n4)C4(CCCCC4)CNC6=O)nc3)CC2)C1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN(C)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nn2)CC1,CHEMBL3886995,=,=,IC50,nM,1460.0,IC50,nM,1460.0,CN(C)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nn2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nn2)CC1,CHEMBL3886995,=,=,IC50,nM,1260.0,IC50,nM,1260.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nn2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C1,CHEMBL3886995,=,=,IC50,nM,3960.0,IC50,nM,3960.0,CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@@H]1C,CHEMBL3886995,=,=,IC50,nM,2630.0,IC50,nM,2630.0,C[C@@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,1350.0,IC50,nM,1350.0,O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@H]1C,CHEMBL3886995,=,=,IC50,nM,7300.0,IC50,nM,7300.0,C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN(C)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,6900.0,IC50,nM,6900.0,CN(C)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,9960.0,IC50,nM,9960.0,CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCC(C)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,6010.0,IC50,nM,6010.0,CCC(C)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN1CCN(C(=O)c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,187.0,IC50,nM,187.0,CN1CCN(C(=O)c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)(C)CCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1(C)C,CHEMBL3886995,=,=,IC50,nM,2170.0,IC50,nM,2170.0,CC(C)(C)CCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1(C)C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@H](C)N1,CHEMBL3886995,=,=,IC50,nM,9350.0,IC50,nM,9350.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@H](C)N1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)(O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,2950.0,IC50,nM,2950.0,CC(C)(O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCC(C)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,4540.0,IC50,nM,4540.0,CCC(C)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1C,CHEMBL3886995,=,=,IC50,nM,7610.0,IC50,nM,7610.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCCCC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,2840.0,IC50,nM,2840.0,O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCCCC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,3770.0,IC50,nM,3770.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCC(C)CN1[C@H](C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@@H]1C,CHEMBL3886995,=,=,IC50,nM,5200.0,IC50,nM,5200.0,CCC(C)CN1[C@H](C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)(C)CCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,291.0,IC50,nM,291.0,CC(C)(C)CCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1620.0,IC50,nM,1620.0,CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCOCCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1890.0,IC50,nM,1890.0,CCOCCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CCN1CC1CC1,CHEMBL3886995,=,=,IC50,nM,2930.0,IC50,nM,2930.0,CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CCN1CC1CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(C(=O)N4CCN(CC5CC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,393.0,IC50,nM,393.0,O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(C(=O)N4CCN(CC5CC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC(C)N1CCC(C)(C)C,CHEMBL3886995,=,=,IC50,nM,16500.0,IC50,nM,16500.0,CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC(C)N1CCC(C)(C)C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(N4CCNCC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,11100.0,IC50,nM,11100.0,O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(N4CCNCC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nn2)CC1,CHEMBL3886995,=,=,IC50,nM,4500.0,IC50,nM,4500.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nn2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(N4CCOCC4)nn3)nc12,CHEMBL3886995,=,=,IC50,nM,2280.0,IC50,nM,2280.0,O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(N4CCOCC4)nn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN(C)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nn2)CC1,CHEMBL3886995,=,=,IC50,nM,3030.0,IC50,nM,3030.0,CN(C)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nn2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)[C@H]1CNC(=O)c2cc3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n21,CHEMBL3886995,=,=,IC50,nM,16460.0,IC50,nM,16460.0,CC(C)[C@H]1CNC(=O)c2cc3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n21,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCC(C)[C@@H]1CNC(=O)c2cc3cnc(Nc4ccc(N5CCN(C)CC5)cn4)nc3n21,CHEMBL3886995,=,=,IC50,nM,4380.0,IC50,nM,4380.0,CCC(C)[C@@H]1CNC(=O)c2cc3cnc(Nc4ccc(N5CCN(C)CC5)cn4)nc3n21,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)C[C@@H]1CNC(=O)c2cc3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n21,CHEMBL3886995,=,=,IC50,nM,2500.0,IC50,nM,2500.0,CC(C)C[C@@H]1CNC(=O)c2cc3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n21,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)C[C@@H]1CNC(=O)c2cc3cnc(Nc4ccc(N5CCN(C)CC5)cn4)nc3n21,CHEMBL3886995,=,=,IC50,nM,6620.0,IC50,nM,6620.0,CC(C)C[C@@H]1CNC(=O)c2cc3cnc(Nc4ccc(N5CCN(C)CC5)cn4)nc3n21,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,3160.0,IC50,nM,3160.0,C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CC1CC1,CHEMBL3886995,=,=,IC50,nM,1890.0,IC50,nM,1890.0,C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CC1CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,CHEMBL3886995,=,=,IC50,nM,616.0,IC50,nM,616.0,C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1(C)C,CHEMBL3886995,=,=,IC50,nM,1500.0,IC50,nM,1500.0,CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1(C)C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)C1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,CHEMBL3886995,=,=,IC50,nM,204.0,IC50,nM,204.0,CC(C)C1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCN(C5CCC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,190.0,IC50,nM,190.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCN(C5CCC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CCC(C)(C)C,CHEMBL3886995,=,=,IC50,nM,646.0,IC50,nM,646.0,CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CCC(C)(C)C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1(C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CC1CC1,CHEMBL3886995,=,=,IC50,nM,377.0,IC50,nM,377.0,CC1(C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CC1CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1(C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,CHEMBL3886995,=,=,IC50,nM,1130.0,IC50,nM,1130.0,CC1(C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C[C@@H](C)O,CHEMBL3886995,=,=,IC50,nM,4340.0,IC50,nM,4340.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C[C@@H](C)O,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1CCN(C2CCN(c3ccc(Nc4ncc5cc6n(c5n4)C4(CCCCC4)CNC6=O)nc3)CC2)C1,CHEMBL3886995,=,=,IC50,nM,738.0,IC50,nM,738.0,CC1CCN(C2CCN(c3ccc(Nc4ncc5cc6n(c5n4)C4(CCCCC4)CNC6=O)nc3)CC2)C1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H]1C,CHEMBL3886995,=,=,IC50,nM,1490.0,IC50,nM,1490.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CCC(C)(C)C,CHEMBL3886995,=,=,IC50,nM,1410.0,IC50,nM,1410.0,C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CCC(C)(C)C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN(C)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,3150.0,IC50,nM,3150.0,CN(C)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H](C)N1,CHEMBL3886995,=,=,IC50,nM,1010.0,IC50,nM,1010.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H](C)N1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCNCC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,3030.0,IC50,nM,3030.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCNCC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C,CHEMBL3886995,=,=,IC50,nM,1360.0,IC50,nM,1360.0,C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,342.0,IC50,nM,342.0,C[C@@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1670.0,IC50,nM,1670.0,CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,857.0,IC50,nM,857.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,CHEMBL3886995,=,=,IC50,nM,2130.0,IC50,nM,2130.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CC(C)(C)O,CHEMBL3886995,=,=,IC50,nM,539.0,IC50,nM,539.0,CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1CC(C)(C)O,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCC(C(F)(F)F)CC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,1840.0,IC50,nM,1840.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCC(C(F)(F)F)CC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(C(=O)N4CCNCC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,61.0,IC50,nM,61.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(C(=O)N4CCNCC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H](O)CN1[C@H](C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,CHEMBL3886995,=,=,IC50,nM,647.0,IC50,nM,647.0,C[C@H](O)CN1[C@H](C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,CHEMBL3886995,=,=,IC50,nM,4630.0,IC50,nM,4630.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1(C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C1CC1,CHEMBL3886995,=,=,IC50,nM,502.0,IC50,nM,502.0,CC1(C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C1CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,755.0,IC50,nM,755.0,CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H](C)N1C,CHEMBL3886995,=,=,IC50,nM,8360.0,IC50,nM,8360.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H](C)N1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(Cc2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1110.0,IC50,nM,1110.0,CC(C)N1CCN(Cc2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCN1[C@H](C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,CHEMBL3886995,=,=,IC50,nM,1400.0,IC50,nM,1400.0,CCN1[C@H](C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1510.0,IC50,nM,1510.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCN(CC5CC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,265.0,IC50,nM,265.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCN(CC5CC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(C(=O)c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,239.0,IC50,nM,239.0,CC(C)N1CCN(C(=O)c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,CHEMBL3886995,=,=,IC50,nM,915.0,IC50,nM,915.0,C[C@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(C(=O)N4CCN(C5CCC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,108.0,IC50,nM,108.0,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(C(=O)N4CCN(C5CCC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H](C)N1C[C@@H](C)O,CHEMBL3886995,=,=,IC50,nM,597.0,IC50,nM,597.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C[C@H](C)N1C[C@@H](C)O,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C,CHEMBL3886995,=,=,IC50,nM,1560.0,IC50,nM,1560.0,C[C@@H]1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CCN1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC(C)N1CC1CC1,CHEMBL3886995,=,=,IC50,nM,570.0,IC50,nM,570.0,CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC(C)N1CC1CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1C,CHEMBL3886995,=,=,IC50,nM,3090.0,IC50,nM,3090.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C1,CHEMBL3886995,=,=,IC50,nM,2570.0,IC50,nM,2570.0,CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)C1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCN(CC)C1CCN(C2CCN(c3ccc(Nc4ncc5cc6n(c5n4)C4(CCCCC4)CNC6=O)nc3)CC2)C1,CHEMBL3886995,=,=,IC50,nM,693.0,IC50,nM,693.0,CCN(CC)C1CCN(C2CCN(c3ccc(Nc4ncc5cc6n(c5n4)C4(CCCCC4)CNC6=O)nc3)CC2)C1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN(C)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nn2)CC1,CHEMBL3886995,=,=,IC50,nM,1390.0,IC50,nM,1390.0,CN(C)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nn2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nn2)CC1,CHEMBL3886995,=,=,IC50,nM,596.0,IC50,nM,596.0,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nn2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@@H]1C,CHEMBL3886995,=,=,IC50,nM,789.0,IC50,nM,789.0,C[C@@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@H]1C,CHEMBL3886995,=,=,IC50,nM,6290.0,IC50,nM,6290.0,C[C@H](O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCC(C)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,2130.0,IC50,nM,2130.0,CCC(C)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN1CCN(C(=O)c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,85.0,IC50,nM,85.0,CN1CCN(C(=O)c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)(C)CCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1(C)C,CHEMBL3886995,=,=,IC50,nM,457.0,IC50,nM,457.0,CC(C)(C)CCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1(C)C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)(O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,943.0,IC50,nM,943.0,CC(C)(O)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCC(C)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1370.0,IC50,nM,1370.0,CCC(C)CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCC(C)CN1[C@H](C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@@H]1C,CHEMBL3886995,=,=,IC50,nM,2830.0,IC50,nM,2830.0,CCC(C)CN1[C@H](C)CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)C[C@@H]1C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)(C)CCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,87.3,IC50,nM,87.3,CC(C)(C)CCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,4530.0,IC50,nM,4530.0,CCN(CC)C1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CCOCCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,990.0,IC50,nM,990.0,CCOCCN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CCN1CC1CC1,CHEMBL3886995,=,=,IC50,nM,1010.0,IC50,nM,1010.0,CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CCN1CC1CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(C(=O)N4CCN(CC5CC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,203.0,IC50,nM,203.0,O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(C(=O)N4CCN(CC5CC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC(C)N1CCC(C)(C)C,CHEMBL3886995,=,=,IC50,nM,2640.0,IC50,nM,2640.0,CC1CN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCC3)CNC5=O)nc2)CC(C)N1CCC(C)(C)C,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(N4CCOCC4)nn3)nc12,CHEMBL3886995,=,=,IC50,nM,1880.0,IC50,nM,1880.0,O=C1NCC2(CCCC2)n2c1cc1cnc(Nc3ccc(N4CCOCC4)nn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,CHEMBL3886995,=,=,IC50,nM,10.0,IC50,nM,10.0,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1.66,IC50,nM,1.66,CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCNCC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,1.08,IC50,nM,1.08,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCNCC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,3.58,IC50,nM,3.58,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,1.46,IC50,nM,1.46,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1.67,IC50,nM,1.67,CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCNCC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,3.03,IC50,nM,3.03,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCNCC4)cn3)nc12,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,CHEMBL3886995,=,=,IC50,nM,1.51,IC50,nM,1.51,CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,2016.0
"Caliper Assay: Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs. The assays were performed using microfluidic kinase detection technology (Caliper Assay Platform). The compounds were tested in 12-point dose-response format in singlicate at Km for ATP. Phosphoacceptor substrate peptide concentration used was 1 μM for all assays and Staurosporine was used as the reference compound for all assays. Specifics of each assay are as described below:CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 μM; Incubation time: 3 hr.CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 μM; Incubation time: 1 hr.CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 μM; Incubation time: 10 hr.CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 μM; Incubation time: 3 hr.",O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cn3)nc12,CHEMBL3886995,=,=,IC50,nM,0.857,IC50,nM,0.857,O=C1NCC2(CCCCC2)n2c1cc1cnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cn3)nc12,2016.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,CHEMBL3991601,=,=,Kd,nM,4232.0,Kd apparent,nM,4232.0,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL3991601,=,=,Kd,nM,243.0,Kd apparent,nM,243.0,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,CHEMBL3991601,=,=,Kd,nM,19.0,Kd apparent,nM,19.0,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,CHEMBL3991601,=,=,Kd,nM,169.0,Kd apparent,nM,169.0,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,CHEMBL3991601,=,=,Kd,nM,10487.0,Kd apparent,nM,10487.0,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12,CHEMBL3991601,=,=,Kd,nM,1775.0,Kd apparent,nM,1775.0,CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,CHEMBL3991601,=,=,Kd,nM,721.0,Kd apparent,nM,721.0,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O,CHEMBL3991601,=,=,Kd,nM,1073.0,Kd apparent,nM,1073.0,CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,CHEMBL3991601,=,=,Kd,nM,128.0,Kd apparent,nM,128.0,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,CHEMBL3991601,=,=,Kd,nM,5.0,Kd apparent,nM,5.0,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1,CHEMBL3991601,=,=,Kd,nM,91.0,Kd apparent,nM,91.0,CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1,CHEMBL3991601,=,=,Kd,nM,199.0,Kd apparent,nM,199.0,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12,CHEMBL3991601,=,=,Kd,nM,1688.0,Kd apparent,nM,1688.0,O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,CHEMBL3991601,=,=,Kd,nM,2113.0,Kd apparent,nM,2113.0,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1,CHEMBL3991601,=,=,Kd,nM,1656.0,Kd apparent,nM,1656.0,CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,CHEMBL3991601,=,=,Kd,nM,739.0,Kd apparent,nM,739.0,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1,CHEMBL3991601,=,=,Kd,nM,72.0,Kd apparent,nM,72.0,COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2nc[nH]c3nccc2-3)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2nc[nH]c3nccc2-3)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL3991601,=,=,Kd,nM,1337.0,Kd apparent,nM,1337.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1nc(Nc2n[nH]c3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1nc(Nc2n[nH]c3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL3991601,=,=,Kd,nM,101.0,Kd apparent,nM,101.0,COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@@H]1CN(Cc2ccc(F)cc2)[C@@H](C)CN1C(=O)c1cc2c(C(=O)C(=O)N(C)C)cn(C)c2cc1Cl,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@@H]1CN(Cc2ccc(F)cc2)[C@@H](C)CN1C(=O)c1cc2c(C(=O)C(=O)N(C)C)cn(C)c2cc1Cl,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,CHEMBL3991601,=,=,Kd,nM,330.0,Kd apparent,nM,330.0,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,CHEMBL3991601,=,=,Kd,nM,98.0,Kd apparent,nM,98.0,CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=c1[nH]ccc2cc(OC3CCNCC3)ccc12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=c1[nH]ccc2cc(OC3CCNCC3)ccc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,CHEMBL3991601,=,=,Kd,nM,205.0,Kd apparent,nM,205.0,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,CHEMBL3991601,=,=,Kd,nM,90.0,Kd apparent,nM,90.0,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(Nc1cccc(Cl)c1)Nc1ncc(CCNc2ncnc3ccsc23)s1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(Nc1cccc(Cl)c1)Nc1ncc(CCNc2ncnc3ccsc23)s1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,2017.0
"Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.",COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,CHEMBL3991601,>,>,Kd,nM,30000.0,Kd apparent,nM,30000.0,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,2017.0
Inhibition of full length human CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by KINOMEscan assay relative to control,CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)c(C)c2)ncn1,CHEMBL3994581,=,=,Activity,%,48.0,Activity,%,48.0,CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)c(C)c2)ncn1,2017.0
Inhibition of CDK2 (unknown origin),CN(C)CCn1cc(-c2ccn3c(-c4ccc(C(N)=O)c(OCc5cccc(F)c5)c4)cnc3c2)cn1,CHEMBL4002599,=,=,IC50,nM,370.0,IC50,nM,370.0,CN(C)CCn1cc(-c2ccn3c(-c4ccc(C(N)=O)c(OCc5cccc(F)c5)c4)cnc3c2)cn1,2017.0
Inhibition of CDK2 (unknown origin),COc1cc2ncccc2cc1NC(=O)c1csc2cncnc12,CHEMBL4002626,>,>,IC50,nM,50000.0,IC50,uM,50.0,COc1cc2ncccc2cc1NC(=O)c1csc2cncnc12,2017.0
Inhibition of CDK2 (unknown origin) at 1 uM,CN(C)Cc1ccc2ccc(Cl)c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c2c1,CHEMBL4002641,>,>,Inhibition,%,50.0,INH,%,50.0,CN(C)Cc1ccc2ccc(Cl)c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c2c1,2017.0
Inhibition of CDK2 (unknown origin),CN(C)Cc1ccc2ccc(Cl)c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c2c1,CHEMBL4002641,=,=,IC50,nM,220.0,IC50,nM,220.0,CN(C)Cc1ccc2ccc(Cl)c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c2c1,2017.0
Inhibition of CDK2 (unknown origin),Nc1nc(OCC2CCCCC2)c2nc[nH]c2n1,CHEMBL4004788,=,=,IC50,nM,17000.0,IC50,uM,17.0,Nc1nc(OCC2CCCCC2)c2nc[nH]c2n1,2017.0
Inhibition of CDK2 (unknown origin),NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL4004788,=,=,IC50,nM,5.0,IC50,uM,0.005,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2017.0
Inhibition of CDK2 (unknown origin),COc1nc(N)nc2nc[nH]c12,CHEMBL4004788,>,>,IC50,nM,100000.0,IC50,uM,100.0,COc1nc(N)nc2nc[nH]c12,2017.0
Inhibition of CDK2 (unknown origin),CCC(C)Oc1nc(N)nc2[nH]cnc12,CHEMBL4004788,=,=,IC50,nM,49000.0,IC50,uM,49.0,CCC(C)Oc1nc(N)nc2[nH]cnc12,2017.0
Inhibition of CDK2 (unknown origin),CC[C@@H](C)Oc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc(N)c1C=O,CHEMBL4004788,=,=,IC50,nM,0.8,IC50,nM,0.8,CC[C@@H](C)Oc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc(N)c1C=O,2017.0
Inhibition of CDK2 (unknown origin) after 60 mins by TR-FRET assay,CC1(C)OCC(=O)Nc2cc(Nc3nc(NCC(F)(F)F)c4occc4n3)ccc21,CHEMBL4007384,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC1(C)OCC(=O)Nc2cc(Nc3nc(NCC(F)(F)F)c4occc4n3)ccc21,2016.0
Inhibition of human CDK2 at 0.1 uM relative to control,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)[C@H]1CCCN1.Cl,CHEMBL4007390,=,=,Inhibition,%,8.0,INH,%,8.0,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)[C@H]1CCCN1.Cl,2017.0
Inhibition of CDK2 (unknown origin),COCCn1cc(NC(=O)c2csc(-c3nncn3C(C)C)n2)cn1,CHEMBL4007491,=,=,IC50,nM,1000.0,pIC50,,6.0,COCCn1cc(NC(=O)c2csc(-c3nncn3C(C)C)n2)cn1,2017.0
Inhibition of CDK2 (unknown origin),CC(C)(C)c1ccc(C(=O)Nc2cn3cc(-n4ccnc4)ccc3n2)cc1,CHEMBL4007491,=,=,IC50,nM,154.88,pIC50,,6.81,CC(C)(C)c1ccc(C(=O)Nc2cn3cc(-n4ccnc4)ccc3n2)cc1,2017.0
Inhibition of human CDK2,COc1ccc(-c2cnc3scc(NC(=O)C4CCCCC4)c3c2)cc1OC,CHEMBL4014275,,,IC50,,,IC50,,,COc1ccc(-c2cnc3scc(NC(=O)C4CCCCC4)c3c2)cc1OC,2017.0
Inhibition of human CDK2 at 10 uM relative to control,CCOc1cc(/C=C2\Oc3ccc(OC)cc3C2=O)ccc1O,CHEMBL4014275,<,<,Inhibition,%,50.0,INH,%,50.0,CCOc1cc(/C=C2\Oc3ccc(OC)cc3C2=O)ccc1O,2017.0
Inhibition of human CDK2 at 10 uM relative to control,COc1ccc2c(c1)C(=O)/C(=C/c1ccc(O)c(O)c1)O2,CHEMBL4014275,<,<,Inhibition,%,50.0,INH,%,50.0,COc1ccc2c(c1)C(=O)/C(=C/c1ccc(O)c(O)c1)O2,2017.0
Inhibition of human CDK2 at 10 uM relative to control,O=C1/C(=C/c2ccc(O)c(O)c2)Oc2cc(O)ccc21,CHEMBL4014275,<,<,Inhibition,%,50.0,INH,%,50.0,O=C1/C(=C/c2ccc(O)c(O)c2)Oc2cc(O)ccc21,2017.0
Inhibition of CDK2 (unknown origin) at 48 uM,Cc1ccc(CNc2nc(N)nc3[nH]c4cc(C)c(O)cc4c23)cc1,CHEMBL4020756,,,Inhibition,%,,INH,,,Cc1ccc(CNc2nc(N)nc3[nH]c4cc(C)c(O)cc4c23)cc1,2017.0
Inhibition of wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control,C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1,CHEMBL4024706,=,=,Activity,%,99.0,Activity,%,99.0,C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1,2017.0
Inhibition of CDK2 Lysine 2 labelling site (unknown origin) at 10 uM,c1cc(-c2c[nH]c3cnccc23)ccn1,CHEMBL4033637,=,=,Inhibition,%,-6.6,INH,%,-6.6,c1cc(-c2c[nH]c3cnccc23)ccn1,2017.0
Inhibition of CDK2 Lysine 1 labelling site (unknown origin) at 10 uM,c1cc(-c2c[nH]c3cnccc23)ccn1,CHEMBL4033637,=,=,Inhibition,%,-2.3,INH,%,-2.3,c1cc(-c2c[nH]c3cnccc23)ccn1,2017.0
Inhibition of wild-type human full length CDK2 (M1 to L298 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control,COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl,CHEMBL4043093,=,=,Activity,%,100.0,Activity,%,100.0,COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl,2017.0
Inhibition of CDK2 labeling at conserved Lys1 (LTGEVVALKK) in human PBMC at 1 uM,CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1,CHEMBL4043168,=,=,Inhibition,%,11.3,INH,%,11.3,CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1,2017.0
Inhibition of CDK2 labeling at conserved Lys2 (DLKPQNLLINTEGAIK) in human PBMC at 1 uM,CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1,CHEMBL4043168,=,=,Inhibition,%,16.8,INH,%,16.8,CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1,2017.0
Inhibition of CDK2 labeling at conserved Lys1 (LTGEVVALKK) in human PBMC at 0.1 uM,CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1,CHEMBL4043168,=,=,Inhibition,%,23.4,INH,%,23.4,CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1,2017.0
Inhibition of CDK2 labeling at conserved Lys2 (DLKPQNLLINTEGAIK) in human PBMC at 0.1 uM,CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1,CHEMBL4043168,=,=,Inhibition,%,19.2,INH,%,19.2,CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1,2017.0
Inhibition of CDK2 (unknown origin) at 1 uM relative to control,Cc1c(-c2ccncc2)c[nH]c1C(N)=O,CHEMBL4043169,<,<,Inhibition,%,20.0,INH,%,20.0,Cc1c(-c2ccncc2)c[nH]c1C(N)=O,2017.0
Inhibition of CDK2 (unknown origin) at 70 nM relative to control,Cc1cc(Nc2nccc3nc(-c4c(Cl)cc(C#N)cc4Cl)[nH]c23)ncn1,CHEMBL4043190,>,>,Inhibition,%,50.0,INH,%,50.0,Cc1cc(Nc2nccc3nc(-c4c(Cl)cc(C#N)cc4Cl)[nH]c23)ncn1,2017.0
Inhibition of CDK2 (unknown origin),Cc1cc(Nc2nccc3nc(-c4c(Cl)cc(C#N)cc4Cl)[nH]c23)ncn1,CHEMBL4043190,=,=,Ki,nM,89.0,Ki,nM,89.0,Cc1cc(Nc2nccc3nc(-c4c(Cl)cc(C#N)cc4Cl)[nH]c23)ncn1,2017.0
Inhibition of CDK2 (unknown origin) at 1 uM relative to control,N[C@H]1C[C@H](Oc2ccc3ncc(-c4ccc5cnccc5c4)n3n2)C1,CHEMBL4043290,=,=,Inhibition,%,17.0,INH,%,17.0,N[C@H]1C[C@H](Oc2ccc3ncc(-c4ccc5cnccc5c4)n3n2)C1,2018.0
Inhibition of wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N,CHEMBL4052645,=,=,Activity,%,100.0,Activity,%,100.0,CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N,2017.0
Inhibition of wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control,COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,CHEMBL4052645,=,=,Activity,%,88.0,Activity,%,88.0,COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,2017.0
Inhibition of CDK2 (unknown origin) at 0.45 uM relative to control,Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1,CHEMBL4052759,=,=,Inhibition,%,6.0,INH,%,6.0,Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1,2017.0
Inhibition of CDK2 (unknown origin) at 0.49 uM relative to control,Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1,CHEMBL4052759,=,=,Inhibition,%,1.3,INH,%,1.3,Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1,2017.0
Inhibition of CDK2 (unknown origin) at 0.078 uM relative to control,COC(=O)Nc1noc2cc(-c3c(-c4ccccn4)n[nH]c3C)ccc12,CHEMBL4052759,=,=,Inhibition,%,-4.3,INH,%,-4.3,COC(=O)Nc1noc2cc(-c3c(-c4ccccn4)n[nH]c3C)ccc12,2017.0
Inhibition of CDK2 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DLKPQNLLINTEGAIK probe by mass-spectrometric analysis relative to control,C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl,CHEMBL4118021,=,=,Inhibition,%,18.7,INH,%,18.7,C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl,2017.0
Inhibition of CDK2 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DLKPQNLLINTEGAIK probe by mass-spectrometric analysis relative to control,C=CC(=O)Nc1ccccc1Oc1nc(Nc2cnn(CCOC)c2)ncc1Cl,CHEMBL4118021,=,=,Inhibition,%,33.1,INH,%,33.1,C=CC(=O)Nc1ccccc1Oc1nc(Nc2cnn(CCOC)c2)ncc1Cl,2017.0
Inhibition of CDK2 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DLKPQNLLINTEGAIK probe by mass-spectrometric analysis relative to control,COc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O,CHEMBL4118021,=,=,Inhibition,%,30.0,INH,%,30.0,COc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O,2017.0
Binding affinity to CDK2 (unknown origin) by surface plasmon resonance analysis,C=C1CCC[C@H]2[C@]3(C)CC4=C(O[C@]3(C)CC[C@]12C)C(=O)C=C(NC)C4=O,CHEMBL4118028,=,=,Kd,nM,4800.0,Kd,uM,4.8,C=C1CCC[C@H]2[C@]3(C)CC4=C(O[C@]3(C)CC[C@]12C)C(=O)C=C(NC)C4=O,2017.0
Inhibition of CDK2 (unknown origin) at 0.45 uM relative to control,Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1,CHEMBL4118098,=,=,Inhibition,%,6.0,INH,%,6.0,Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1,2017.0
Inhibition of CDK2 (unknown origin) at 0.19 uM relative to control,Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1,CHEMBL4118098,=,=,Inhibition,%,-1.7,INH,%,-1.7,Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1,2017.0
Inhibition of CDK2 (unknown origin) at 0.164 uM relative to control,COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12,CHEMBL4118098,=,=,Inhibition,%,9.0,INH,%,9.0,COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12,2017.0
Inhibition of CDK2 in human MDA-MB-468 cells assessed as decrease in CDK2 phosphorylation at Thr180 residues at 15 uM after 12 to 26 hrs by Western blot analysis,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,CHEMBL4118232,,,Inhibition,%,,INH,,,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,2018.0
Inhibition of CDK2 in human MDA-MB-468 cells assessed as decrease in cyclin E phosphorylation at Thr62 residues at 15 uM after 12 to 26 hrs by Western blot analysis,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,CHEMBL4118232,,,Inhibition,%,,INH,,,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,2018.0
Inhibition of CDK2 in human MDA-MB-468 cells assessed as increase in bax expression level at 15 uM measured up to 36 hrs by Western blot analysis,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,CHEMBL4118232,,,Inhibition,%,,INH,,,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,2018.0
Inhibition of CDK2 in human MDA-MB-468 cells assessed as increase in bim expression level at 15 uM measured up to 36 hrs by Western blot analysis,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,CHEMBL4118232,,,Inhibition,%,,INH,,,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,2018.0
Inhibition of CDK2 in human MDA-MB-468 cells assessed as decrease in caspase 3 expression level at 15 uM measured up to 36 hrs by Western blot analysis,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,CHEMBL4118232,,,Inhibition,%,,INH,,,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,2018.0
Inhibition of CDK2 in human MDA-MB-468 cells assessed as increase in cleaved caspase 3 expression level at 15 uM measured up to 36 hrs by Western blot analysis,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,CHEMBL4118232,,,Inhibition,%,,INH,,,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,2018.0
Inhibition of CDK2 in human MDA-MB-468 cells assessed as increase in cleaved PARP expression level at 15 uM measured up to 36 hrs by Western blot analysis,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,CHEMBL4118232,,,Inhibition,%,,INH,,,COc1ccc(C(=O)NC2CCN(c3nccc(Nc4ccc(F)cc4)n3)CC2)cc1,2018.0
Inhibition of CDK2 (unknown origin) expressed in baculovirus infected Sf9 insect cells using histone H1 as substrate after 1 hr by liquid scintillation counting analysis,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,CHEMBL4118232,=,=,IC50,nM,1.0,IC50,nM,1.0,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,2018.0
Inhibition of CDK2 (unknown origin) at 0.004 uM by CDKN2A antibody-based spectrophotometry,N=c1[nH]c(=O)[nH]c2c1cnn2-c1ccc(S(N)(=O)=O)cc1,CHEMBL4130351,=,=,Inhibition,%,12.59,INH,%,12.591523,N=c1[nH]c(=O)[nH]c2c1cnn2-c1ccc(S(N)(=O)=O)cc1,2017.0
Inhibition of CDK2 (unknown origin) at 0.02 uM by CDKN2A antibody-based spectrophotometry,N=c1[nH]c(=O)[nH]c2c1cnn2-c1ccc(S(N)(=O)=O)cc1,CHEMBL4130351,=,=,Inhibition,%,39.03,INH,%,39.032691,N=c1[nH]c(=O)[nH]c2c1cnn2-c1ccc(S(N)(=O)=O)cc1,2017.0
Inhibition of CDK2 (unknown origin) at 0.1 uM by CDKN2A antibody-based spectrophotometry,N=c1[nH]c(=O)[nH]c2c1cnn2-c1ccc(S(N)(=O)=O)cc1,CHEMBL4130351,=,=,Inhibition,%,53.13,INH,%,53.129834,N=c1[nH]c(=O)[nH]c2c1cnn2-c1ccc(S(N)(=O)=O)cc1,2017.0
Inhibition of CDK2 (unknown origin) at 0.4 uM by CDKN2A antibody-based spectrophotometry,N=c1[nH]c(=O)[nH]c2c1cnn2-c1ccc(S(N)(=O)=O)cc1,CHEMBL4130351,=,=,Inhibition,%,68.8,INH,%,68.79842,N=c1[nH]c(=O)[nH]c2c1cnn2-c1ccc(S(N)(=O)=O)cc1,2017.0
Inhibition of CDK2 (unknown origin) at 0.5 uM by CDKN2A antibody-based spectrophotometry,N=c1[nH]c(=O)[nH]c2c1cnn2-c1ccc(S(N)(=O)=O)cc1,CHEMBL4130351,=,=,Inhibition,%,81.81,INH,%,81.808807,N=c1[nH]c(=O)[nH]c2c1cnn2-c1ccc(S(N)(=O)=O)cc1,2017.0
Inhibition of CDK2 (unknown origin) by CDKN2A antibody-based spectrophotometry,N=c1[nH]c(=O)[nH]c2c1cnn2-c1ccc(S(N)(=O)=O)cc1,CHEMBL4130351,=,=,IC50,nM,190.0,IC50,uM,0.19,N=c1[nH]c(=O)[nH]c2c1cnn2-c1ccc(S(N)(=O)=O)cc1,2017.0
Inhibition of human full length CDK2 expressed in bacterial expression system at 1 uM,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,CHEMBL4145685,,,Inhibition,%,,INH,,,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,2018.0
Inhibition of human full length CDK2 expressed in bacterial expression system at 1 uM,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,CHEMBL4145685,,,Inhibition,%,,INH,,,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,2018.0
Inhibition of human full length CDK2 expressed in bacterial expression system at 1 uM,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1,CHEMBL4145685,,,Inhibition,%,,INH,,,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1,2018.0
Inhibition of human full length CDK2 expressed in bacterial expression system at 1 uM,O=C(N[C@H]1CC[C@H](O)CC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,CHEMBL4145685,,,Inhibition,%,,INH,,,O=C(N[C@H]1CC[C@H](O)CC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,2018.0
Inhibition of human full length CDK3 expressed in bacterial expression system at 1 uM,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,CHEMBL4145685,,,Inhibition,%,,INH,,,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,2018.0
Inhibition of human full length CDK3 expressed in bacterial expression system at 1 uM,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,CHEMBL4145685,,,Inhibition,%,,INH,,,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,2018.0
Inhibition of human full length CDK3 expressed in bacterial expression system at 1 uM,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1,CHEMBL4145685,,,Inhibition,%,,INH,,,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1,2018.0
Inhibition of human full length CDK3 expressed in bacterial expression system at 1 uM,O=C(N[C@H]1CC[C@H](O)CC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,CHEMBL4145685,,,Inhibition,%,,INH,,,O=C(N[C@H]1CC[C@H](O)CC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,2018.0
Inhibition of DNA-tagged CDK2 (unknown origin) expressed in HEK293 cells at 10 uM after 1 hr by real-time fluorescent quantitative PCR analysis,Fc1ccc(Nc2nc(N3CCOCC3)c3nc[nH]c3n2)cc1,CHEMBL4152229,=,=,Inhibition,%,73.0,INH,%,73.0,Fc1ccc(Nc2nc(N3CCOCC3)c3nc[nH]c3n2)cc1,2018.0
Inhibition of CDK2 (unknown origin) by Hotspot assay,CN1CCN(Cc2ccc(NC(=O)c3n[nH]cc3Nc3ncnc4sccc34)cc2)CC1,CHEMBL4152300,=,=,IC50,nM,9.1,IC50,nM,9.1,CN1CCN(Cc2ccc(NC(=O)c3n[nH]cc3Nc3ncnc4sccc34)cc2)CC1,2018.0
Inhibition of CDK2 (unknown origin) by Hotspot assay,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(CN3CCOCC3)cc2)c2cc(C(C)C)sc2n1,CHEMBL4152300,=,=,IC50,nM,25.4,IC50,nM,25.4,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(CN3CCOCC3)cc2)c2cc(C(C)C)sc2n1,2018.0
Inhibition of CDK2 (unknown origin) by Hotspot assay,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(CN3CCN(C)CC3)cc2)c2cc(C(C)C)sc2n1,CHEMBL4152300,=,=,IC50,nM,21.5,IC50,nM,21.5,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(CN3CCN(C)CC3)cc2)c2cc(C(C)C)sc2n1,2018.0
Inhibition of CDK2 (unknown origin) by Hotspot assay,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCNCC3)cc2)c2ccsc2n1,CHEMBL4152300,=,=,IC50,nM,81.54,IC50,nM,81.54,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCNCC3)cc2)c2ccsc2n1,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,CN1CCN(Cc2ccc(NC(=O)c3nn(C)cc3Nc3ncnc4[nH]ccc34)cc2)CC1,CHEMBL4152300,=,=,Activity,%,98.55,Activity,%,98.55,CN1CCN(Cc2ccc(NC(=O)c3nn(C)cc3Nc3ncnc4[nH]ccc34)cc2)CC1,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,Cc1[nH]nc(C(=O)Nc2ccc(CN3CCN(C)CC3)cc2)c1Nc1ncnc2[nH]ccc12,CHEMBL4152300,=,=,Activity,%,99.9,Activity,%,99.9,Cc1[nH]nc(C(=O)Nc2ccc(CN3CCN(C)CC3)cc2)c1Nc1ncnc2[nH]ccc12,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,Cc1[nH]nc(C(=O)Nc2ccc(CN3CCN(C)CC3)cc2)c1Nc1ncnc2sccc12,CHEMBL4152300,=,=,Activity,%,99.65,Activity,%,99.65,Cc1[nH]nc(C(=O)Nc2ccc(CN3CCN(C)CC3)cc2)c1Nc1ncnc2sccc12,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(CN3CCN(C)CC3)cc2)c2ccsc2n1,CHEMBL4152300,=,=,Activity,%,51.1,Activity,%,51.1,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(CN3CCN(C)CC3)cc2)c2ccsc2n1,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(CN3CCOCC3)cc2)c2ccsc2n1,CHEMBL4152300,=,=,Activity,%,51.96,Activity,%,51.96,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(CN3CCOCC3)cc2)c2ccsc2n1,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,CN1CCN(Cc2ccc(NC(=O)c3n[nH]cc3Nc3nc(C4CC4)nc4sccc34)cc2)CC1,CHEMBL4152300,=,=,Activity,%,89.75,Activity,%,89.75,CN1CCN(Cc2ccc(NC(=O)c3n[nH]cc3Nc3nc(C4CC4)nc4sccc34)cc2)CC1,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,O=C(Nc1ccc(CN2CCOCC2)cc1)c1n[nH]cc1Nc1nc(C2CC2)nc2sccc12,CHEMBL4152300,=,=,Activity,%,81.41,Activity,%,81.41,O=C(Nc1ccc(CN2CCOCC2)cc1)c1n[nH]cc1Nc1nc(C2CC2)nc2sccc12,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCN(C)CC3)cc2)c2ccsc2n1,CHEMBL4152300,=,=,Activity,%,71.23,Activity,%,71.23,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCN(C)CC3)cc2)c2ccsc2n1,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCOCC3)cc2)c2ccsc2n1,CHEMBL4152300,=,=,Activity,%,78.81,Activity,%,78.81,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCOCC3)cc2)c2ccsc2n1,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,O=C(Nc1ccc(N2CCNCC2)cc1)c1n[nH]cc1Nc1nc(Cl)nc2sccc12,CHEMBL4152300,=,=,Activity,%,56.82,Activity,%,56.82,O=C(Nc1ccc(N2CCNCC2)cc1)c1n[nH]cc1Nc1nc(Cl)nc2sccc12,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,O=C(Nc1ccc(N2CCNCC2)cc1)c1n[nH]cc1Nc1nc(C2CC2)nc2sccc12,CHEMBL4152300,=,=,Activity,%,97.44,Activity,%,97.44,O=C(Nc1ccc(N2CCNCC2)cc1)c1n[nH]cc1Nc1nc(C2CC2)nc2sccc12,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,CCc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCNCC3)cc2)c2ccsc2n1,CHEMBL4152300,=,=,Activity,%,86.59,Activity,%,86.59,CCc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCNCC3)cc2)c2ccsc2n1,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,CC(C)c1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCNCC3)cc2)c2ccsc2n1,CHEMBL4152300,=,=,Activity,%,100.89,Activity,%,100.89,CC(C)c1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCNCC3)cc2)c2ccsc2n1,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,CC(C)(C)c1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCNCC3)cc2)c2ccsc2n1,CHEMBL4152300,=,=,Activity,%,100.32,Activity,%,100.32,CC(C)(C)c1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCNCC3)cc2)c2ccsc2n1,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,Cc1nc2c(c(Nc3c[nH]nc3C(=O)Nc3ccc(N4CCNCC4)cc3)n1)CCC2,CHEMBL4152300,=,=,Activity,%,86.3,Activity,%,86.3,Cc1nc2c(c(Nc3c[nH]nc3C(=O)Nc3ccc(N4CCNCC4)cc3)n1)CCC2,2018.0
Inhibition of CDK2 (unknown origin) assessed as residual activity at 0.123 uM by Hotspot assay relative to control,Cc1nc2c(c(Nc3c[nH]nc3C(=O)Nc3ccc(N4CCNCC4)cc3)n1)CCCC2,CHEMBL4152300,=,=,Activity,%,79.38,Activity,%,79.38,Cc1nc2c(c(Nc3c[nH]nc3C(=O)Nc3ccc(N4CCNCC4)cc3)n1)CCCC2,2018.0
Inhibition of CDK2 (unknown origin) at 0.123 uM by Hotspot assay relative to control,CN1CCN(Cc2ccc(NC(=O)c3n[nH]cc3Nc3ncnc4sccc34)cc2)CC1,CHEMBL4152300,>,>,Inhibition,%,80.0,INH,%,80.0,CN1CCN(Cc2ccc(NC(=O)c3n[nH]cc3Nc3ncnc4sccc34)cc2)CC1,2018.0
Inhibition of CDK2 (unknown origin) at 0.123 uM by Hotspot assay relative to control,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(CN3CCOCC3)cc2)c2cc(C(C)C)sc2n1,CHEMBL4152300,>,>,Inhibition,%,80.0,INH,%,80.0,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(CN3CCOCC3)cc2)c2cc(C(C)C)sc2n1,2018.0
Inhibition of CDK2 (unknown origin) at 0.123 uM by Hotspot assay relative to control,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(CN3CCN(C)CC3)cc2)c2cc(C(C)C)sc2n1,CHEMBL4152300,>,>,Inhibition,%,80.0,INH,%,80.0,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(CN3CCN(C)CC3)cc2)c2cc(C(C)C)sc2n1,2018.0
Inhibition of CDK2 (unknown origin) at 0.123 uM by Hotspot assay relative to control,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCNCC3)cc2)c2ccsc2n1,CHEMBL4152300,>,>,Inhibition,%,80.0,INH,%,80.0,Cc1nc(Nc2c[nH]nc2C(=O)Nc2ccc(N3CCNCC3)cc2)c2ccsc2n1,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control,Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1,CHEMBL4152344,=,=,Activity,%,98.0,Activity,%,98.0,Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1,2018.0
Inhibition of human CDK2 at 10 uM by ADP-Glo kinase assay,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,CHEMBL4177722,=,=,Inhibition,%,58.0,INH,%,58.0,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,2018.0
Inhibition of human CDK2 at 10 uM by ADP-Glo kinase assay,Cc1nc(N)c2ccn(C3CCN(C(=O)c4ccc(S(=O)(=O)F)cc4)CC3)c2n1,CHEMBL4177722,=,=,Inhibition,%,10.0,INH,%,10.0,Cc1nc(N)c2ccn(C3CCN(C(=O)c4ccc(S(=O)(=O)F)cc4)CC3)c2n1,2018.0
Inhibition of human CDK2 at 10 uM by ADP-Glo kinase assay,Nc1ncnc2c1ccn2C1CCN(C(=O)c2ccc(S(=O)(=O)F)cc2)CC1,CHEMBL4177722,=,=,Inhibition,%,0.0,INH,%,0.0,Nc1ncnc2c1ccn2C1CCN(C(=O)c2ccc(S(=O)(=O)F)cc2)CC1,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control,CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,CHEMBL4184148,=,=,Activity,%,97.0,Activity,%,97.0,CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,2017.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control,C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,CHEMBL4184148,=,=,Activity,%,100.0,Activity,%,100.0,C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,2017.0
Inhibition of wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control,Fc1cc(F)cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1,CHEMBL4184198,=,=,Activity,%,97.0,Activity,%,97.0,Fc1cc(F)cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1,2018.0
Inhibition of CDK2 (unknown origin),CN1CCN(CCCCOc2c(OCc3ccc(C#N)cc3)cc(O)c3c(=O)cc(-c4ccccc4)oc23)CC1,CHEMBL4190366,=,=,IC50,nM,6700.0,IC50,uM,6.7,CN1CCN(CCCCOc2c(OCc3ccc(C#N)cc3)cc(O)c3c(=O)cc(-c4ccccc4)oc23)CC1,2017.0
Inhibition of recombinant human CDK2 at 1 uM using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay relative to control,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cc3OC)n2)c1,CHEMBL4219138,=,=,Inhibition,%,2.9,INH,%,2.9,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cc3OC)n2)c1,2018.0
Inhibition of recombinant human CDK2 at 1 uM using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay relative to control,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4219138,=,=,Inhibition,%,5.1,INH,%,5.1,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,2018.0
Inhibition of recombinant human CDK2 at 1 uM using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay relative to control,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,CHEMBL4219138,=,=,Inhibition,%,1.2,INH,%,1.2,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,2018.0
Inhibition of CDK2 (unknown origin),CCN(CCO)Cc1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1,CHEMBL4219148,>,>,IC50,nM,500.0,IC50,nM,500.0,CCN(CCO)Cc1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1,2018.0
Inhibition of CDK2 (unknown origin),Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(Cc3ccccn3)ns2)n1,CHEMBL4219148,>,>,IC50,nM,500.0,IC50,nM,500.0,Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(Cc3ccccn3)ns2)n1,2018.0
Inhibition of CDK2 (unknown origin),Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C(NC(C)(C)C)c3ccccn3)ns2)n1,CHEMBL4219148,>,>,IC50,nM,1000.0,IC50,uM,1.0,Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C(NC(C)(C)C)c3ccccn3)ns2)n1,2018.0
Inhibition of CDK2 (unknown origin),CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1,CHEMBL4219163,=,=,IC50,nM,3800.0,IC50,uM,3.8,CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1,2018.0
Inhibition of CDK2 (unknown origin) at 1 uM,CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1,CHEMBL4219163,>,>,Inhibition,%,70.0,INH,%,70.0,CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1,2018.0
Inhibition of CDK2 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control,CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21,CHEMBL4229333,=,=,Inhibition,%,3.0,INH,%,3.0,CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21,2018.0
Inhibition of CDK2 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control,CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21,CHEMBL4229333,=,=,Inhibition,%,1.0,INH,%,1.0,CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CHEMBL4229344,=,=,Activity,%,95.0,Activity,%,95.0,Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1,2018.0
Inhibition of full length human CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual activity at 5 uM by KINOMEscan assay relative to control,CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12,CHEMBL4229410,=,=,Activity,%,97.0,Activity,%,97.0,CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12,2018.0
Binding affinity to full length human CDK2 (M1 to L298 residues) expressed in bacterial expression system by KINOMEscan assay,CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12,CHEMBL4229410,>=,>=,Kd,nM,5000.0,Kd,uM,5.0,CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12,2018.0
Inhibition of CDK2 (unknown origin),O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1,CHEMBL4229420,>,>,IC50,nM,3300.0,IC50,nM,3300.0,O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1,2018.0
Inhibition of CDK2 (unknown origin),O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1,CHEMBL4229420,>,>,IC50,nM,5000.0,IC50,nM,5000.0,O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1,2018.0
Inhibition of wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control,CCNc1cc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2C(F)(F)F)ccn1,CHEMBL4251622,=,=,Activity,%,98.0,Activity,%,98.0,CCNc1cc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2C(F)(F)F)ccn1,2018.0
Binding affinity to CDK2 (unknown origin) assessed as remaining unbound target protein level at 10 uM relative to control,COc1cc2c(=O)n(CCCN(C)C)c3c4cc[nH]c4ncc3c2cc1OC,CHEMBL4257589,=,=,Activity,%,100.0,Activity,%,100.0,COc1cc2c(=O)n(CCCN(C)C)c3c4cc[nH]c4ncc3c2cc1OC,2018.0
Inhibition of CDK2 (unknown origin) at 1 uM relative to control,NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1,CHEMBL4261595,=,=,Inhibition,%,2.0,INH,%,2.0,NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control,COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1,CHEMBL4261600,=,=,Activity,%,100.0,Activity,%,100.0,COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as fraction of unbound kinase to substrate at 0.1 uM after 1 hr by KinomeScan assay,O=C(Nc1ccc(Oc2c(Br)cnc3[nH]cnc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,CHEMBL4261615,=,=,Activity,%,0.0,Activity,%,0.0,O=C(Nc1ccc(Oc2c(Br)cnc3[nH]cnc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as fraction of unbound kinase to substrate at 0.1 uM after 1 hr by KinomeScan assay,O=C(Nc1ccc(Oc2ccnc3[nH]cnc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,CHEMBL4261615,=,=,Activity,%,0.0,Activity,%,0.0,O=C(Nc1ccc(Oc2ccnc3[nH]cnc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as fraction of unbound kinase to substrate at 0.1 uM after 1 hr by KinomeScan assay,CC(C)c1nc2c(Oc3ccc(NC(=O)c4cccn(-c5ccc(F)cc5)c4=O)cc3F)ccnc2[nH]1,CHEMBL4261615,=,=,Activity,%,41.0,Activity,%,41.0,CC(C)c1nc2c(Oc3ccc(NC(=O)c4cccn(-c5ccc(F)cc5)c4=O)cc3F)ccnc2[nH]1,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as fraction of unbound kinase to substrate at 0.1 uM after 1 hr by KinomeScan assay,Cc1cnc2[nH]cnc2c1Oc1ccc(NC(=O)c2cccn(-c3ccc(F)cc3)c2=O)cc1F,CHEMBL4261615,=,=,Activity,%,0.0,Activity,%,0.0,Cc1cnc2[nH]cnc2c1Oc1ccc(NC(=O)c2cccn(-c3ccc(F)cc3)c2=O)cc1F,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as fraction of unbound kinase to substrate at 1 uM after 1 hr by KinomeScan assay,O=C(Nc1ccc(Oc2c(Br)cnc3[nH]cnc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,CHEMBL4261615,=,=,Activity,%,0.0,Activity,%,0.0,O=C(Nc1ccc(Oc2c(Br)cnc3[nH]cnc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as fraction of unbound kinase to substrate at 1 uM after 1 hr by KinomeScan assay,O=C(Nc1ccc(Oc2ccnc3[nH]cnc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,CHEMBL4261615,=,=,Activity,%,0.0,Activity,%,0.0,O=C(Nc1ccc(Oc2ccnc3[nH]cnc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as fraction of unbound kinase to substrate at 1 uM after 1 hr by KinomeScan assay,CC(C)c1nc2c(Oc3ccc(NC(=O)c4cccn(-c5ccc(F)cc5)c4=O)cc3F)ccnc2[nH]1,CHEMBL4261615,=,=,Activity,%,95.5,Activity,%,95.5,CC(C)c1nc2c(Oc3ccc(NC(=O)c4cccn(-c5ccc(F)cc5)c4=O)cc3F)ccnc2[nH]1,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as fraction of unbound kinase to substrate at 1 uM after 1 hr by KinomeScan assay,Cc1cnc2[nH]cnc2c1Oc1ccc(NC(=O)c2cccn(-c3ccc(F)cc3)c2=O)cc1F,CHEMBL4261615,=,=,Activity,%,0.0,Activity,%,0.0,Cc1cnc2[nH]cnc2c1Oc1ccc(NC(=O)c2cccn(-c3ccc(F)cc3)c2=O)cc1F,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as fraction of unbound kinase to substrate at 10 uM after 1 hr by KinomeScan assay,O=C(Nc1ccc(Oc2c(Br)cnc3[nH]cnc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,CHEMBL4261615,=,=,Activity,%,32.0,Activity,%,32.0,O=C(Nc1ccc(Oc2c(Br)cnc3[nH]cnc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as fraction of unbound kinase to substrate at 10 uM after 1 hr by KinomeScan assay,O=C(Nc1ccc(Oc2ccnc3[nH]cnc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,CHEMBL4261615,=,=,Activity,%,48.0,Activity,%,48.0,O=C(Nc1ccc(Oc2ccnc3[nH]cnc23)c(F)c1)c1cccn(-c2ccc(F)cc2)c1=O,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as fraction of unbound kinase to substrate at 10 uM after 1 hr by KinomeScan assay,CC(C)c1nc2c(Oc3ccc(NC(=O)c4cccn(-c5ccc(F)cc5)c4=O)cc3F)ccnc2[nH]1,CHEMBL4261615,=,=,Activity,%,99.7,Activity,%,99.7,CC(C)c1nc2c(Oc3ccc(NC(=O)c4cccn(-c5ccc(F)cc5)c4=O)cc3F)ccnc2[nH]1,2018.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as fraction of unbound kinase to substrate at 10 uM after 1 hr by KinomeScan assay,Cc1cnc2[nH]cnc2c1Oc1ccc(NC(=O)c2cccn(-c3ccc(F)cc3)c2=O)cc1F,CHEMBL4261615,=,=,Activity,%,3.0,Activity,%,3.0,Cc1cnc2[nH]cnc2c1Oc1ccc(NC(=O)c2cccn(-c3ccc(F)cc3)c2=O)cc1F,2018.0
Inhibition of CDK2 (unknown origin),CSc1ncc2c(n1)CCc1cnc(Nc3ccc(C(=O)N(C)CCN(C)C)cc3)nc1-2,CHEMBL4265909,=,=,IC50,nM,90.0,IC50,uM,0.09,CSc1ncc2c(n1)CCc1cnc(Nc3ccc(C(=O)N(C)CCN(C)C)cc3)nc1-2,2018.0
Inhibition of CDK2 (unknown origin),CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL4270504,=,=,IC50,nM,700.0,IC50,uM,0.7,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2017.0
Inhibition of CDK2 (unknown origin),CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,CHEMBL4270504,=,=,IC50,nM,45.0,IC50,nM,45.0,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,2017.0
Inhibition of CDK2 (unknown origin),CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,CHEMBL4270504,=,=,IC50,nM,48.0,IC50,nM,48.0,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,2017.0
Inhibition of CDK2 (unknown origin),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL4270504,=,=,IC50,nM,170.0,IC50,nM,170.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2017.0
Inhibition of CDK2 (unknown origin),O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,CHEMBL4270504,=,=,IC50,nM,47.0,IC50,nM,47.0,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,2017.0
Inhibition of CDK2 (unknown origin),C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc([S@](=N)(=O)C3CC3)cc2)ncc1C(F)(F)F,CHEMBL4270504,=,=,IC50,nM,9.0,IC50,nM,9.0,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc([S@](=N)(=O)C3CC3)cc2)ncc1C(F)(F)F,2017.0
Inhibition of recombinant CDK2 (unknown origin) expressed in Sf9 cells using histone H1 derived biotinylated peptide and 33P-ATP incubated for 1 hr by liquid scintillation counting method,Cc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@@H]3CCO)nc12,CHEMBL4270504,=,=,IC50,nM,1.0,IC50,nM,1.0,Cc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@@H]3CCO)nc12,2017.0
Inhibition of wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system at 1 uM by Kinomescan method,O=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl,CHEMBL4304739,,,Inhibition,%,,INH,,,O=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl,2019.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control,CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl,CHEMBL4304811,=,=,Activity,%,92.0,Activity,%,92.0,CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl,2019.0
Inhibition of CDK2 (unknown origin),CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL4308846,=,=,IC50,nM,400.0,IC50,uM,0.4,CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2018.0
Inhibition of CDK2 (unknown origin),O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,CHEMBL4308846,=,=,IC50,nM,10.0,IC50,nM,10.0,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,2018.0
Inhibition of CDK2 (unknown origin) incubated for 40 mins by ADP-glo assay,CC(C)C/C=N/c1c(C#N)c2n(c1C(=O)Nc1ccc(Br)cc1)CCC2,CHEMBL4312005,=,=,IC50,nM,1270.0,IC50,uM,1.27,CC(C)C/C=N/c1c(C#N)c2n(c1C(=O)Nc1ccc(Br)cc1)CCC2,2020.0
Inhibition of CDK2 (unknown origin) incubated for 40 mins by ADP-glo assay,CC/C=N/c1c(C#N)c2n(c1C(=O)Nc1ccccc1)CCC2,CHEMBL4312005,=,=,IC50,nM,580.0,IC50,uM,0.58,CC/C=N/c1c(C#N)c2n(c1C(=O)Nc1ccccc1)CCC2,2020.0
Inhibition of CDK2 (unknown origin) incubated for 40 mins by ADP-glo assay,CCC1SCC(=O)N1c1c(C#N)c2n(c1C(=O)Nc1ccccc1)CCC2,CHEMBL4312005,=,=,IC50,nM,630.0,IC50,uM,0.63,CCC1SCC(=O)N1c1c(C#N)c2n(c1C(=O)Nc1ccccc1)CCC2,2020.0
Inhibition of CDK2 (unknown origin) incubated for 40 mins by ADP-glo assay,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CHEMBL4312005,>,>,IC50,nM,100000.0,IC50,uM,100.0,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL4321871,=,=,IC50,nM,5.012,pIC50,,8.3,c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,CHEMBL4321871,<,>,IC50,nM,19952.62,pIC50,,4.7,FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,CHEMBL4321871,=,=,IC50,nM,1.995,pIC50,,8.7,COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1,CHEMBL4321871,=,=,IC50,nM,199.53,pIC50,,6.7,COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1,CHEMBL4321871,=,=,IC50,nM,15.85,pIC50,,7.8,COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,Cc1cc(C)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,CHEMBL4321871,=,=,IC50,nM,3.162,pIC50,,8.5,Cc1cc(C)cc(Nc2nccc(-c3cnn4ncccc34)n2)c1,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,Fc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1F,CHEMBL4321871,=,=,IC50,nM,1.995,pIC50,,8.7,Fc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1F,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,Fc1ccc(Nc2nccc(-c3c(C4CC4)nn4ncccc34)n2)cc1F,CHEMBL4321871,<,>,IC50,nM,19952.62,pIC50,,4.7,Fc1ccc(Nc2nccc(-c3c(C4CC4)nn4ncccc34)n2)cc1F,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1,CHEMBL4321871,=,=,IC50,nM,6.31,pIC50,,8.2,c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1,CHEMBL4321871,<,>,IC50,nM,19952.62,pIC50,,4.7,FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,CHEMBL4321871,<,>,IC50,nM,19952.62,pIC50,,4.7,COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,CC(C)(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL4321871,=,=,IC50,nM,158.49,pIC50,,6.8,CC(C)(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2020.0
Inhibition of human CDK2 using biotinylated-aminohexyl-Ala-Ala-Ala-Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser(PO3)-Tyr-Arg-amide as substrate after 40 mins in presence of [gamma-32P]ATP by scintillation proximity assay,Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1,CHEMBL4321871,<,>,IC50,nM,19952.62,pIC50,,4.7,Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1,2020.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N,CHEMBL4330132,=,=,Activity,%,66.0,Activity,%,66.0,CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N,2019.0
Binding affinity to wild-type CDK2 (unknown origin) expressed in baculovirus infected Sf9 insect cells by isothermal titration calorimetric method,CN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4ccnc(N)n4)cc3)cc2C(F)(F)F)CC1,CHEMBL4346652,=,=,Kd,nM,52.7,Kd,nM,52.7,CN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4ccnc(N)n4)cc3)cc2C(F)(F)F)CC1,2019.0
Inhibition of CDK2 (unknown origin),Cc1nc(C)c(-c2ccnc(Nc3cccc([N+](=O)[O-])c3)n2)s1,CHEMBL4346652,=,=,Ki,nM,110.0,Ki,nM,110.0,Cc1nc(C)c(-c2ccnc(Nc3cccc([N+](=O)[O-])c3)n2)s1,2019.0
Inhibition of CDK2 (unknown origin),NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1,CHEMBL4346652,=,=,IC50,nM,60.0,IC50,nM,60.0,NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1,2019.0
Inhibition of CDK2 (unknown origin),Cc1cc(C)c(CNc2nc(N[C@@H](C)[C@@H](C)O)nc3c2ncn3C(C)C)cn1,CHEMBL4346652,=,=,IC50,nM,5.0,IC50,nM,5.0,Cc1cc(C)c(CNc2nc(N[C@@H](C)[C@@H](C)O)nc3c2ncn3C(C)C)cn1,2019.0
Inhibition of CDK2 (unknown origin),Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,CHEMBL4346652,=,=,Ki,nM,396.0,Ki,nM,396.0,Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1,2019.0
Inhibition of CDK2 (unknown origin),Cc1nc(C)c(-c2ccnc(N)n2)s1,CHEMBL4346652,=,=,Ki,nM,396.0,Ki,nM,396.0,Cc1nc(C)c(-c2ccnc(N)n2)s1,2019.0
Inhibition of CDK2 (unknown origin),COc1cc[nH]c1/C=C1\C(=O)Nc2ccc(F)c(C#C[C@@H](O)[C@@H](N)[C@@H](C)O)c21,CHEMBL4346652,=,=,IC50,nM,3.0,IC50,nM,3.0,COc1cc[nH]c1/C=C1\C(=O)Nc2ccc(F)c(C#C[C@@H](O)[C@@H](N)[C@@H](C)O)c21,2019.0
Inhibition of CDK2 (unknown origin),O=C1Nc2ccccc2/C1=C1/Nc2ccccc2C1=O,CHEMBL4346652,=,=,IC50,nM,2200.0,IC50,nM,2200.0,O=C1Nc2ccccc2/C1=C1/Nc2ccccc2C1=O,2019.0
Inhibition of recombinant CDK2 (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotinylated-histone H1 as substrate incubated for 1 hr in presence of cyclin by [33P]-ATP-based liquid scintillation counting method,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,CHEMBL4346652,=,=,IC50,nM,1.0,IC50,nM,1.0,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,2019.0
Binding affinity to CDK2 (unknown origin),C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL4346652,=,=,Kd,nM,1310.0,Kd,uM,1.31,C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2019.0
Inhibition of CDK2 (unknown origin),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL4346699,=,=,IC50,nM,170.0,IC50,nM,170.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2019.0
Inhibition of CDK2 (unknown origin),CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL4346699,=,=,IC50,nM,220.0,IC50,nM,220.0,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2019.0
Inhibition of CDK2 (unknown origin),CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,CHEMBL4346699,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,2019.0
Inhibition of CDK2 (unknown origin),CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL4346699,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,2019.0
Inhibition of CDK2 (unknown origin),CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,CHEMBL4346699,>,>,IC50,nM,500.0,IC50,nM,500.0,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,2019.0
Inhibition of recombinant CDK2 (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotinylated peptide as substrate after 1 hr in presence of [33P]ATP by TopCount scintillation counting method,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,CHEMBL4346699,=,=,IC50,nM,1.0,IC50,nM,1.0,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,2019.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl,CHEMBL4354843,=,=,Activity,%,100.0,Activity,%,100.0,C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl,2020.0
Inhibition of wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control,O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1,CHEMBL4364269,=,=,Activity,%,100.0,Activity,%,100.0,O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1,2019.0
Inhibition of CDK2 (unknown origin),CNc1ncc2c(-c3ccc(N4CCNCC4)cc3)nn(CC3CCC(N)CC3)c2n1,CHEMBL4368903,=,=,IC50,nM,114.0,IC50,uM,0.114,CNc1ncc2c(-c3ccc(N4CCNCC4)cc3)nn(CC3CCC(N)CC3)c2n1,2019.0
Inhibition of human CDK2 by kinobeads-based assay,C[C@H]1CN(c2n[nH]c3nc(N[C@H]4CC[C@H](NS(=O)(=O)CCC(F)(F)F)CC4)ncc23)CCO1,CHEMBL4368903,,,Inhibition,%,,INH,,,C[C@H]1CN(c2n[nH]c3nc(N[C@H]4CC[C@H](NS(=O)(=O)CCC(F)(F)F)CC4)ncc23)CCO1,2019.0
Inhibition of human CDK2 by kinobeads-based assay,COc1ccccc1-c1n[nH]c2nc(N[C@H]3CC[C@H](NS(=O)(=O)CCC(F)(F)F)CC3)nc(OC)c12,CHEMBL4368903,,,Inhibition,%,,INH,,,COc1ccccc1-c1n[nH]c2nc(N[C@H]3CC[C@H](NS(=O)(=O)CCC(F)(F)F)CC3)nc(OC)c12,2019.0
Inhibition of human CDK2 by kinobeads-based assay,COc1nc(N[C@H]2CC[C@H](NS(=O)(=O)CCC(C)C)CC2)nc2[nH]nc(N3CCOC[C@H]3C)c12,CHEMBL4368903,,,Inhibition,%,,INH,,,COc1nc(N[C@H]2CC[C@H](NS(=O)(=O)CCC(C)C)CC2)nc2[nH]nc(N3CCOC[C@H]3C)c12,2019.0
Inhibition of CDK2 (unknown origin),COc1c(O)cc(O)c2c(=O)cc(-c3ccccc3)oc12,CHEMBL4368927,=,=,IC50,nM,1460.0,IC50,uM,1.46,COc1c(O)cc(O)c2c(=O)cc(-c3ccccc3)oc12,2019.0
Inhibition of CDK2 (unknown origin),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL4368927,=,=,Ki,nM,40.0,Ki,nM,40.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2019.0
Inhibition of CDK2 (unknown origin) at 0.1 uM relative to control,COCCC#Cc1c(Cl)c2c(Cl)cc(C(N)=O)nc2n1[C@H]1CCCNC1,CHEMBL4371067,=,=,Inhibition,%,26.0,INH,%,26.0,COCCC#Cc1c(Cl)c2c(Cl)cc(C(N)=O)nc2n1[C@H]1CCCNC1,2019.0
Inhibition of CDK2 (unknown origin) at 1 uM relative to control,COCCC#Cc1c(Cl)c2c(Cl)cc(C(N)=O)nc2n1[C@H]1CCCNC1,CHEMBL4371067,=,=,Inhibition,%,71.0,INH,%,71.0,COCCC#Cc1c(Cl)c2c(Cl)cc(C(N)=O)nc2n1[C@H]1CCCNC1,2019.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system measured after 1 hr by kinomescan method,O=C(Nc1ccc2cc(C(=O)Nc3nccs3)ccc2c1)c1ccc(Cl)c(Cl)c1,CHEMBL4373706,=,=,Kd,nM,8020.0,Kd,uM,8.02,O=C(Nc1ccc2cc(C(=O)Nc3nccs3)ccc2c1)c1ccc(Cl)c(Cl)c1,2019.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,=,=,Activity,%,83.0,Activity,%,83.0,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C,2017.0
Inhibition of CDK2 in human Mino cells assessed as decrease in phosphorylation of RNA polymerase 2 C-terminal domain at Ser 2 residue at 12.5 nM by immunoblotting analysis,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(SCCN)nc12,CHEMBL4385606,,,Inhibition,%,,INH,,,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(SCCN)nc12,2019.0
Inhibition of CDK2 in human Mino cells assessed as decrease in phosphorylation of RNA polymerase 2 C-terminal domain at Ser 5 residue at 12.5 nM by immunoblotting analysis,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(SCCN)nc12,CHEMBL4385606,,,Inhibition,%,,INH,,,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(SCCN)nc12,2019.0
Inhibition of CDK2 in human Mino cells assessed as decrease in phosphorylation of Rb at Ser 608 residue at 12.5 nM by immunoblotting analysis,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(SCCN)nc12,CHEMBL4385606,,,Inhibition,%,,INH,,,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(SCCN)nc12,2019.0
Inhibition of CDK2 in human Mino cells assessed as decrease in phosphorylation of Rb at Ser 780 residue at 12.5 nM by immunoblotting analysis,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(SCCN)nc12,CHEMBL4385606,,,Inhibition,%,,INH,,,CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(SCCN)nc12,2019.0
Inhibition of wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control,O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1,CHEMBL4387741,=,=,Inhibition,%,67.0,INH,%,67.0,O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1,2019.0
Inhibition of wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control,O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1,CHEMBL4387741,=,=,Inhibition,%,99.0,INH,%,99.0,O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1,2019.0
Binding affinity to wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control,O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O,CHEMBL4390652,=,=,Activity,%,74.0,Activity,%,74.0,O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O,2019.0
Binding affinity to full-length human CDK2 expressed in Escherichia coli BL21 (DE3) pLysS cells by isothermal titration calorimetry,Nc1nc(-c2cccc(CC(=O)O)c2)c2nc[nH]c2n1,CHEMBL4390671,,,Activity,,,Activity,,,Nc1nc(-c2cccc(CC(=O)O)c2)c2nc[nH]c2n1,2019.0
Binding affinity to full-length human CDK2 expressed in Escherichia coli BL21 (DE3) pLysS cells at 1 to 5 mM by isothermal titration calorimetry,Nc1nc(Oc2cccc(CC(=O)O)c2)c2nc[nH]c2n1,CHEMBL4390671,,,Activity,,,Activity,,,Nc1nc(Oc2cccc(CC(=O)O)c2)c2nc[nH]c2n1,2019.0
Binding affinity to full-length human CDK2 expressed in Escherichia coli BL21 (DE3) pLysS cells at 1 to 5 mM by isothermal titration calorimetry,Nc1cccc(N)n1,CHEMBL4390671,,,Activity,,,Activity,,,Nc1cccc(N)n1,2019.0
Binding affinity to full-length human CDK2 expressed in Escherichia coli BL21 (DE3) pLysS cells at 5 mM by isothermal titration calorimetry,NS(=O)(=O)c1ccc(Br)cc1,CHEMBL4390671,,,Activity,,,Activity,,,NS(=O)(=O)c1ccc(Br)cc1,2019.0
Binding affinity to full-length human CDK2 expressed in Escherichia coli BL21 (DE3) pLysS cells by isothermal titration calorimetry,Nc1nc(I)c2nc[nH]c2n1,CHEMBL4390671,=,=,Kd,nM,350000.0,Kd,uM,350.0,Nc1nc(I)c2nc[nH]c2n1,2019.0
Binding affinity to full-length human CDK2 expressed in Escherichia coli BL21 (DE3) pLysS cells by isothermal titration calorimetry,Nc1nc(-c2cccc(CC(=O)O)c2)c2nc[nH]c2n1,CHEMBL4390671,=,=,Kd,nM,50000.0,Kd,uM,50.0,Nc1nc(-c2cccc(CC(=O)O)c2)c2nc[nH]c2n1,2019.0
Binding affinity to full-length human CDK2 expressed in Escherichia coli BL21 (DE3) pLysS cells at 5 mM by isothermal titration calorimetry,Brc1cn[nH]c1,CHEMBL4390671,,,Activity,,,Activity,,,Brc1cn[nH]c1,2019.0
Inhibition of CDK2 (unknown origin) using biotin-labelled STK substrate-1 as substrate incubated for 60 mins by HTRF assay,CC(=O)O.CNc1nc(Nc2cnc(C#N)c(O[C@@H]3CCCNC3)c2)ncc1-c1cnn(C)c1,CHEMBL4393675,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)O.CNc1nc(Nc2cnc(C#N)c(O[C@@H]3CCCNC3)c2)ncc1-c1cnn(C)c1,2019.0
Inhibition of CDK2 (unknown origin) using biotin-labelled STK substrate-1 as substrate incubated for 60 mins by HTRF assay,COc1cccc(OCCCN)c1-c1cc(Nc2cnc(C#N)cn2)n[nH]1,CHEMBL4393675,>,>,IC50,nM,10000.0,IC50,uM,10.0,COc1cccc(OCCCN)c1-c1cc(Nc2cnc(C#N)cn2)n[nH]1,2019.0
Inhibition of human recombinant CDK2 at 1 uM using Ulight-CFFKNIVTPRTPPPSQGK-amide as substrate incubated for 30 mins in presence of ATP by LANCE assay relative to control,CCc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,CHEMBL4393708,=,=,Inhibition,%,11.15,INH,%,11.15,CCc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,2019.0
Inhibition of CDK2 (unknown origin) at 100 nM by [gamma-33P]ATP-based radiometric or Alphascreen assay relative to control,Cc1cc(-n2cc(C(=O)N3CCO[C@@H](C)C3)c3ccc(O[C@@H](C)c4ccc(F)cn4)nc32)n[nH]1,CHEMBL4396868,=,=,Inhibition,%,5.0,INH,%,5.0,Cc1cc(-n2cc(C(=O)N3CCO[C@@H](C)C3)c3ccc(O[C@@H](C)c4ccc(F)cn4)nc32)n[nH]1,2019.0
Inhibition of CDK2 (unknown origin),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL4402527,=,=,IC50,nM,170.0,IC50,nM,170.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2019.0
Inhibition of CDK2 (unknown origin),CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL4402527,=,=,IC50,nM,90.0,IC50,nM,90.0,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2019.0
Inhibition of CDK2 (unknown origin),CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,CHEMBL4402527,=,=,IC50,nM,48.0,IC50,nM,48.0,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,2019.0
Inhibition of CDK2 (unknown origin),CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,CHEMBL4402527,=,=,IC50,nM,1.0,IC50,nM,1.0,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,2019.0
Inhibition of CDK2 (unknown origin),CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12,CHEMBL4402527,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12,2019.0
Inhibition of CDK2 (unknown origin),CC(C)c1cnn2c(NCc3ccccc3N(C)C)nc(OC3CCN(C)CC3)nc12,CHEMBL4402527,=,=,IC50,nM,3900.0,IC50,nM,3900.0,CC(C)c1cnn2c(NCc3ccccc3N(C)C)nc(OC3CCN(C)CC3)nc12,2019.0
Inhibition of CDK2 (unknown origin),CC(C)c1cnn2c(NCc3ccccc3-n3cccn3)nc(OC3CCCNC3)nc12,CHEMBL4402527,=,=,IC50,nM,6.4,IC50,nM,6.4,CC(C)c1cnn2c(NCc3ccccc3-n3cccn3)nc(OC3CCCNC3)nc12,2019.0
Inhibition of CDK2 (unknown origin),CC(C)c1cnn2c(NCc3cccc4[nH]ncc34)nc(OC3CCCNC3)nc12,CHEMBL4402527,<,<,IC50,nM,50.0,IC50,nM,50.0,CC(C)c1cnn2c(NCc3cccc4[nH]ncc34)nc(OC3CCCNC3)nc12,2019.0
Inhibition of CDK2 (unknown origin),CC(C)c1cnn2c(NCc3cccc4c3cnn4C)nc(OC3CCCNC3)nc12,CHEMBL4402527,<,<,IC50,nM,50.0,IC50,nM,50.0,CC(C)c1cnn2c(NCc3cccc4c3cnn4C)nc(OC3CCCNC3)nc12,2019.0
Inhibition of CDK2 (unknown origin),Clc1cnc(N[C@H]2CCCNC2)nc1-c1c[nH]c2ccccc12,CHEMBL4402527,>,>,IC50,nM,200.0,IC50,nM,200.0,Clc1cnc(N[C@H]2CCCNC2)nc1-c1c[nH]c2ccccc12,2019.0
Inhibition of CDK2 (unknown origin),Clc1cnc(N[C@@H]2CCCNC2)nc1-c1c[nH]c2ccccc12,CHEMBL4402527,>,>,IC50,nM,200.0,IC50,nM,200.0,Clc1cnc(N[C@@H]2CCCNC2)nc1-c1c[nH]c2ccccc12,2019.0
Inhibition of CDK2 (unknown origin) after 4 hrs,FC(F)(F)c1cnc(N[C@H]2CCCNC2)nc1-c1n[nH]c2ccccc12,CHEMBL4402527,>,>,IC50,nM,200.0,IC50,nM,200.0,FC(F)(F)c1cnc(N[C@H]2CCCNC2)nc1-c1n[nH]c2ccccc12,2019.0
Inhibition of CDK2 (unknown origin),CN(C)C/C=C/C(=O)Nc1cccc(C(=O)Nc2cccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)c2)c1,CHEMBL4402527,=,=,IC50,nM,96.9,IC50,nM,96.9,CN(C)C/C=C/C(=O)Nc1cccc(C(=O)Nc2cccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)c2)c1,2019.0
Inhibition of wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system assessed as enzyme remaining activity at 1000 nM by Kinomescan method relative to control,O=C(Nc1cccc(Br)c1)Nc1cc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2)ccc1F,CHEMBL4406794,=,=,Activity,%,93.0,Activity,%,93.0,O=C(Nc1cccc(Br)c1)Nc1cc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2)ccc1F,2019.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2n[nH]c3c2C(=O)c2c(C=O)cccc2-3)cc1,CHEMBL4406795,=,=,IC50,nM,57.0,IC50,nM,57.0,COc1ccc(-c2n[nH]c3c2C(=O)c2c(C=O)cccc2-3)cc1,2019.0
Inhibition of CDK2 (unknown origin),COc1ccc(-c2[nH]nc3c2C(=O)c2c(NC(=O)CN4CCN(C(=N)N)CC4)cccc2-3)cc1,CHEMBL4406795,=,=,IC50,nM,13.0,IC50,nM,13.0,COc1ccc(-c2[nH]nc3c2C(=O)c2c(NC(=O)CN4CCN(C(=N)N)CC4)cccc2-3)cc1,2019.0
Inhibition of CDK2 (unknown origin),NC(=O)Nc1cccc2c1C(=O)c1c(-c3csc(Cl)c3)n[nH]c1-2,CHEMBL4406795,=,=,IC50,nM,46.0,IC50,nM,46.0,NC(=O)Nc1cccc2c1C(=O)c1c(-c3csc(Cl)c3)n[nH]c1-2,2019.0
Inhibition of CDK2 (unknown origin),O=C(Nc1cccc2c1C(=O)c1c(-c3ccc(C(=O)N4CCNCC4)s3)n[nH]c1-2)NN1CCOCC1,CHEMBL4406795,=,=,IC50,nM,8.0,IC50,nM,8.0,O=C(Nc1cccc2c1C(=O)c1c(-c3ccc(C(=O)N4CCNCC4)s3)n[nH]c1-2)NN1CCOCC1,2019.0
Binding affinity to CDK2 (unknown origin),C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL4406837,=,=,Kd,nM,1300.0,Kd,uM,1.3,C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2019.0
Binding affinity to CDK2 (unknown origin) assessed as inactivation constant,C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL4406837,=,=,Kinact,10'3/M/s,5.0,Kinact,10'3/M/s,5.0,C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2019.0
Binding affinity to CDK2 (unknown origin) assessed as dissociation rate constant,C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL4406837,=,=,K,/s,0.07,K,/s,0.07,C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2019.0
Binding affinity to CDK2 (unknown origin) assessed as association rate constant,C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL4406837,=,=,K,10'6/M/s,0.55,K,10'6/M/s,0.55,C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2019.0
Competitive reversible inhibition of CDK2 (unknown origin),CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12,CHEMBL4406837,=,=,IC50,nM,620.0,IC50,nM,620.0,CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12,2019.0
Inhibition of CDK2 (unknown origin),O=C1Nc2ccc([N+](=O)[O-])cc2/C1=C1/Nc2ccc(O)cc2/C1=N\O,CHEMBL4406837,=,=,IC50,nM,2.0,IC50,nM,2.0,O=C1Nc2ccc([N+](=O)[O-])cc2/C1=C1/Nc2ccc(O)cc2/C1=N\O,2019.0
Inhibition of CDK2 (unknown origin) relative to control,C=CC(=O)N1CCN(C(=O)OC(C)(C)C)c2ccccc21,CHEMBL4406837,=,=,Inhibition,%,83.0,INH,%,83.0,C=CC(=O)N1CCN(C(=O)OC(C)(C)C)c2ccccc21,2019.0
Inhibition of CDK2 (unknown origin) relative to control,C=CC(=O)N1CCN(C(=O)OC)c2ccccc21,CHEMBL4406837,=,=,Inhibition,%,5.0,INH,%,5.0,C=CC(=O)N1CCN(C(=O)OC)c2ccccc21,2019.0
Competitive reversible inhibition of CDK2 (unknown origin),CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12,CHEMBL4406837,=,=,IC50,nM,900.0,IC50,nM,900.0,CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12,2019.0
Competitive reversible inhibition of CDK2 (unknown origin),CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,CHEMBL4406837,=,=,IC50,nM,3.0,IC50,nM,3.0,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12,2019.0
Inhibition of CDK2 (unknown origin) at 5 uM after 3 hrs by kinase-glo luminescent assay relative to control,CC(C)n1cnc2c(NCc3cccc(C(F)(F)F)c3)ncnc21,CHEMBL4422662,>,>,Inhibition,%,30.0,INH,%,30.0,CC(C)n1cnc2c(NCc3cccc(C(F)(F)F)c3)ncnc21,2019.0
Inhibition of CDK2 (unknown origin) after 3 hrs by kinase-glo luminescent assay relative to control,CC(C)n1cnc2c(NCc3cccc(C(F)(F)F)c3)ncnc21,CHEMBL4422662,=,=,IC50,nM,13000.0,IC50,uM,13.0,CC(C)n1cnc2c(NCc3cccc(C(F)(F)F)c3)ncnc21,2019.0
Inhibition of CDK2 (unknown origin) after 3 hrs by kinase-glo luminescent assay relative to control,CC(C1CC1)n1cnc2c(NCc3cccc(C(F)(F)F)c3)nc(NCCN(C)C)nc21,CHEMBL4422662,=,=,IC50,nM,37000.0,IC50,uM,37.0,CC(C1CC1)n1cnc2c(NCc3cccc(C(F)(F)F)c3)nc(NCCN(C)C)nc21,2019.0
Inhibition of CDK2 (unknown origin) after 3 hrs by kinase-glo luminescent assay relative to control,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL4422662,=,=,IC50,nM,400.0,IC50,uM,0.4,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2019.0
Inhibition of CDK2 (unknown origin) assessed as remaining enzyme activity at 1 uM,CC(=O)c1ccc(-c2c[nH]c3ncc(/C=C/C(=O)NCCc4ccccn4)cc23)cc1,CHEMBL4428132,=,=,Activity,%,85.0,Activity,%,85.0,CC(=O)c1ccc(-c2c[nH]c3ncc(/C=C/C(=O)NCCc4ccccn4)cc23)cc1,2016.0
Inhibition of CDK2 (unknown origin) assessed as remaining enzyme activity at 1 uM,COc1ccc(-c2c[nH]c3ncc(/C=C/C(=O)NCc4ccncc4)cc23)cc1,CHEMBL4428132,=,=,Activity,%,97.0,Activity,%,97.0,COc1ccc(-c2c[nH]c3ncc(/C=C/C(=O)NCc4ccncc4)cc23)cc1,2016.0
Inhibition of full-length recombinant human His-tagged CDK2 expressed in baculovirus expression system by Z'-LYTE assay,O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1,CHEMBL4477252,=,=,IC50,nM,12.0,IC50,nM,12.0,O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1,2016.0
Inhibition of full-length recombinant human His-tagged CDK2 expressed in baculovirus expression system by Z'-LYTE assay,Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1,CHEMBL4477252,<,<,IC50,nM,10.0,IC50,nM,10.0,Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1,2016.0
Inhibition of full-length recombinant human His-tagged CDK2 expressed in baculovirus expression system by Z'-LYTE assay,Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1,CHEMBL4477252,=,=,IC50,nM,2.2,IC50,nM,2.2,Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1,2016.0
Inhibition of full-length recombinant human His-tagged CDK2 expressed in baculovirus expression system by Z'-LYTE assay,Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12,CHEMBL4477252,=,=,IC50,nM,51.0,IC50,nM,51.0,Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12,2016.0
Inhibition of CDK2 (unknown origin),CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12,CHEMBL4610077,=,=,IC50,nM,880.0,IC50,nM,880.0,CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12,2020.0
Inhibition of CDK2 (unknown origin),CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@@H](O)CO)nc12,CHEMBL4610077,=,=,IC50,nM,3.0,IC50,nM,3.0,CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@@H](O)CO)nc12,2020.0
Inhibition of CDK2 (unknown origin),CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12,CHEMBL4610077,=,=,IC50,nM,620.0,IC50,nM,620.0,CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12,2020.0
Inhibition of CDK2 (unknown origin),Cc1cc(NC2CCN(C(=O)O[C@H]3CCN(C(=O)/C=C/CN(C)C)C3)CC2)n2ncc(C(C)C)c2n1,CHEMBL4610077,>,>,IC50,nM,8000.0,IC50,uM,8.0,Cc1cc(NC2CCN(C(=O)O[C@H]3CCN(C(=O)/C=C/CN(C)C)C3)CC2)n2ncc(C(C)C)c2n1,2020.0
Inhibition of CDK2 (unknown origin),CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N[C@@]2(C)CCC[C@@H](Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)nc1,CHEMBL4610077,=,=,IC50,nM,2117.0,IC50,nM,2117.0,CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N[C@@]2(C)CCC[C@@H](Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)nc1,2020.0
Inhibition of CDK2 (unknown origin),CN(C)C/C=C/C(=O)Nc1cccc(C(=O)Nc2cccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)c2)c1,CHEMBL4610077,=,=,IC50,nM,222.0,IC50,nM,222.0,CN(C)C/C=C/C(=O)Nc1cccc(C(=O)Nc2cccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)c2)c1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)cc1,CHEMBL4610077,=,=,IC50,nM,1300.0,IC50,nM,1300.0,C=CC(=O)Nc1ccc(C(=O)Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)Nc2cccc(Nc3n[nH]c4c3CN(C(=O)N[C@H](CN(C)C)c3ccccc3)C4(C)C)c2)cc1,CHEMBL4610077,=,=,IC50,nM,1140.0,IC50,nM,1140.0,C=CC(=O)Nc1ccc(C(=O)Nc2cccc(Nc3n[nH]c4c3CN(C(=O)N[C@H](CN(C)C)c3ccccc3)C4(C)C)c2)cc1,2020.0
Inhibition of CDK2 (unknown origin),CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,CHEMBL4613207,>,>,IC50,nM,50000.0,IC50,uM,50.0,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,2019.0
Inhibition of CDK2 (unknown origin),CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,CHEMBL4613207,>,>,IC50,nM,500.0,IC50,nM,500.0,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,2019.0
Inhibition of CDK2 (unknown origin),O=S1(=O)NCCCNc2nc(ncc2Br)Nc2cccc1c2,CHEMBL4613207,=,=,IC50,nM,140.0,IC50,nM,140.0,O=S1(=O)NCCCNc2nc(ncc2Br)Nc2cccc1c2,2019.0
Inhibition of CDK2 (unknown origin) in presence of high ATP,CCn1cnc2c(NCc3nc4ccc(F)c(F)c4[nH]3)nc(N3CCCC[C@H]3CCO)nc21,CHEMBL4613207,=,=,IC50,nM,321.0,IC50,nM,321.0,CCn1cnc2c(NCc3nc4ccc(F)c(F)c4[nH]3)nc(N3CCCC[C@H]3CCO)nc21,2019.0
Binding affinity to CDK2 (unknown origin),O=S(=O)(O)c1cccc2cccc(Nc3ccccc3)c12,CHEMBL4613207,=,=,Kd,nM,37000.0,Kd,uM,37.0,O=S(=O)(O)c1cccc2cccc(Nc3ccccc3)c12,2019.0
Inhibition of CDK2 (unknown origin),NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL4613207,=,=,IC50,nM,250.0,IC50,nM,250.0,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2019.0
Inhibition of CDK2 (unknown origin),COc1cc(/C=C2\Oc3cc4occc4c(OC)c3C2=O)ccc1OCC(=O)Nc1ccccc1,CHEMBL4613211,=,=,IC50,nM,1110.0,IC50,uM,1.11,COc1cc(/C=C2\Oc3cc4occc4c(OC)c3C2=O)ccc1OCC(=O)Nc1ccccc1,2019.0
Inhibition of CDK2 (unknown origin),C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,CHEMBL4613211,=,=,IC50,nM,1140.0,IC50,uM,1.14,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,2019.0
Inhibition of CDK2 (unknown origin) at 1 uM by PanQinase assay relative to control,c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,CHEMBL4619818,=,=,Inhibition,%,98.0,INH,%,98.0,c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1,2020.0
Inhibition of CDK2 (unknown origin) at 1 uM by PanQinase assay relative to control,CN(c1ccccc1)c1nccc(-c2cnn3ncccc23)n1,CHEMBL4619818,=,=,Inhibition,%,33.0,INH,%,33.0,CN(c1ccccc1)c1nccc(-c2cnn3ncccc23)n1,2020.0
Inhibition of recombinant human full length CDK2 (1 to 298 residues) expressed in bacterial expression system at 1 uM by DiscoverX competition binding assay relative to control,Cc1cccc(N(C)c2nccc(-c3cnn4ncccc34)n2)c1,CHEMBL4619818,=,=,Inhibition,%,12.0,INH,%,12.0,Cc1cccc(N(C)c2nccc(-c3cnn4ncccc34)n2)c1,2020.0
Inhibition of CDK2 (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(-n2c(C)ccc2CN2CCN(C)CC2)cc1)c1ccccc1,CHEMBL4622841,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(-n2c(C)ccc2CN2CCN(C)CC2)cc1)c1ccccc1,2020.0
Inhibition of CDK2 (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,CHEMBL4622841,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,2020.0
Inhibition of CDK2 (unknown origin) at 1 uM using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(-n2c(C)ccc2CN2CCN(C)CC2)cc1)c1ccccc1,CHEMBL4622841,,,Inhibition,%,,INH,,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(-n2c(C)ccc2CN2CCN(C)CC2)cc1)c1ccccc1,2020.0
Inhibition of CDK2 (unknown origin) at 500 nM relative to control,Cc1cc(Nc2cc(N3CCN(CCCN(C)C)CC3)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,CHEMBL4665632,=,=,Inhibition,%,7.0,INH,%,7.0,Cc1cc(Nc2cc(N3CCN(CCCN(C)C)CC3)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,2019.0
Inhibition of human CDK2 expressed in sf9 insect cells,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL4665831,=,=,IC50,nM,400.0,IC50,uM,0.4,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2020.0
Inhibition of human CDK2 expressed in sf9 insect cells,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4)oc23)[C@H](O)C1,CHEMBL4665831,=,=,IC50,nM,2400.0,IC50,uM,2.4,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4)oc23)[C@H](O)C1,2020.0
Inhibition of CDK2 (unknown origin) at 0.1 uM in presence of ATP at Km concentration by TR-FRET assay relative to control,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CCC(O)CC3)co2)ccn1,CHEMBL4665913,=,=,Inhibition,%,44.0,INH,%,44.0,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CCC(O)CC3)co2)ccn1,2020.0
Inhibition of CDK2 (unknown origin) at 0.1 uM in presence of ATP at Km concentration by TR-FRET assay relative to control,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CCC(F)CC3)co2)ccn1,CHEMBL4665913,=,=,Inhibition,%,20.0,INH,%,20.0,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CCC(F)CC3)co2)ccn1,2020.0
Inhibition of CDK2 (unknown origin) at 0.1 uM in presence of ATP at Km concentration by TR-FRET assay relative to control,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@@H](O)C3)co2)ccn1,CHEMBL4665913,=,=,Inhibition,%,0.0,INH,%,0.0,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@@H](O)C3)co2)ccn1,2020.0
Inhibition of CDK2 (unknown origin) at 0.1 uM in presence of ATP at Km concentration by TR-FRET assay relative to control,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@H](O)C3)co2)ccn1,CHEMBL4665913,=,=,Inhibition,%,9.0,INH,%,9.0,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@H](O)C3)co2)ccn1,2020.0
Inhibition of CDK2 (unknown origin) at 1 uM in presence of ATP at Km concentration by TR-FRET assay relative to control,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CCC(O)CC3)co2)ccn1,CHEMBL4665913,=,=,Inhibition,%,81.0,INH,%,81.0,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CCC(O)CC3)co2)ccn1,2020.0
Inhibition of CDK2 (unknown origin) at 1 uM in presence of ATP at Km concentration by TR-FRET assay relative to control,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CCC(F)CC3)co2)ccn1,CHEMBL4665913,=,=,Inhibition,%,69.0,INH,%,69.0,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CCC(F)CC3)co2)ccn1,2020.0
Inhibition of CDK2 (unknown origin) at 1 uM in presence of ATP at Km concentration by TR-FRET assay relative to control,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@@H](O)C3)co2)ccn1,CHEMBL4665913,=,=,Inhibition,%,10.0,INH,%,10.0,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@@H](O)C3)co2)ccn1,2020.0
Inhibition of CDK2 (unknown origin) at 1 uM in presence of ATP at Km concentration by TR-FRET assay relative to control,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@H](O)C3)co2)ccn1,CHEMBL4665913,=,=,Inhibition,%,15.0,INH,%,15.0,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@H](O)C3)co2)ccn1,2020.0
Inhibition of human CDK2 (2 to 298 residues) at 10 uM incubated for 5 mins in presence of [gamma33P]ATP by scintillation counting analysis relative to control,O=C(Cc1ccc(F)c(F)c1)N1CCC(Nc2ncc3c(N4CCOCC4)n[nH]c3n2)CC1,CHEMBL4673188,>,>,Inhibition,%,40.0,INH,%,40.0,O=C(Cc1ccc(F)c(F)c1)N1CCC(Nc2ncc3c(N4CCOCC4)n[nH]c3n2)CC1,2020.0
Inhibition of CDK2 in human A375 cells at 1 uM measured after 12 hr by DAPI staining based immunofluorescence analysis,Nc1ccccc1NC(=O)c1ccc(CNC(=O)c2n[nH]cc2NC(=O)c2c(Cl)cccc2Cl)cc1,CHEMBL4680185,,,Inhibition,%,,INH,,,Nc1ccccc1NC(=O)c1ccc(CNC(=O)c2n[nH]cc2NC(=O)c2c(Cl)cccc2Cl)cc1,2020.0
Inhibition of CDK2 in human A375 cells at 1 uM measured after 12 hr by DAPI staining based immunofluorescence analysis,Nc1ccccc1NC(=O)Cc1ccc(NC(=O)c2n[nH]cc2NC(=O)c2c(Cl)cccc2Cl)cc1,CHEMBL4680185,,,Inhibition,%,,INH,,,Nc1ccccc1NC(=O)Cc1ccc(NC(=O)c2n[nH]cc2NC(=O)c2c(Cl)cccc2Cl)cc1,2020.0
Inhibition of CDK2 (unknown origin),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL4699469,=,=,IC50,nM,70.0,IC50,nM,70.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2020.0
Inhibition of CDK2 (unknown origin),C[C@H](CO)Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)ncc1Br,CHEMBL4699469,=,=,IC50,nM,4.0,IC50,nM,4.0,C[C@H](CO)Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)ncc1Br,2020.0
Inhibition of CDK2 (unknown origin),C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=N)(=O)C3CC3)cc2)ncc1C(F)(F)F,CHEMBL4699469,=,=,IC50,nM,9.0,IC50,nM,9.0,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=N)(=O)C3CC3)cc2)ncc1C(F)(F)F,2020.0
Inhibition of CDK2 (unknown origin),COc1cc(F)ccc1-c1cc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)ncc1Cl,CHEMBL4699469,=,=,IC50,nM,2460.0,IC50,uM,2.46,COc1cc(F)ccc1-c1cc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)ncc1Cl,2020.0
Inhibition of CDK2 (unknown origin),COc1cc(F)ccc1-c1ncnc(Nc2cccc(CS(C)(=N)=O)c2)n1,CHEMBL4699469,=,=,IC50,nM,470.0,IC50,nM,470.0,COc1cc(F)ccc1-c1ncnc(Nc2cccc(CS(C)(=N)=O)c2)n1,2020.0
Inhibition of CDK2 (unknown origin),CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL4699469,=,=,IC50,nM,100.0,IC50,nM,100.0,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2020.0
Inhibition of CDK2 (unknown origin),CC[C@H](Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,CHEMBL4699469,=,=,IC50,nM,5.0,IC50,nM,5.0,CC[C@H](Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1)[C@@H](C)O,2020.0
Inhibition of CDK2 (unknown origin),CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,CHEMBL4699469,=,=,IC50,nM,1.0,IC50,nM,1.0,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,2020.0
Inhibition of CDK2 (unknown origin),O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,CHEMBL4699469,=,=,IC50,nM,47.0,IC50,nM,47.0,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,2020.0
Inhibition of human CDK2,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,CHEMBL4699469,=,=,IC50,nM,5.0,IC50,nM,5.0,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,2020.0
Inhibition of CDK2 in human MCF7 cells assessed as reduction in Rb phosphorylation at T821 residue incubated for 6 hrs by immunoblot analysis,CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1,CHEMBL4699469,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1,2020.0
Inhibition of CDK2 (unknown origin) using Ulight-labeled substrate by TR-FRET LANCE method,COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(O)CO)CC3)cc12,CHEMBL4699469,>,>,IC50,nM,1360.0,IC50,uM,1.36,COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(O)CO)CC3)cc12,2020.0
Inhibition of CDK2 (unknown origin) using Ulight-labeled substrate by TR-FRET LANCE method,COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)cc12,CHEMBL4699469,>,>,IC50,nM,320.0,IC50,uM,0.32,COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)cc12,2020.0
Inhibition of CDK2 (unknown origin) at 20 uM relative to control,CCCSc1nc2c(nnn2CCNC(=S)Nc2cccc3ccccc23)c(=O)[nH]1,CHEMBL4706492,<,<,Inhibition,%,10.0,INH,%,10.0,CCCSc1nc2c(nnn2CCNC(=S)Nc2cccc3ccccc23)c(=O)[nH]1,2020.0
Inhibition of CDK2 (unknown origin) at 300 nM relative to control,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OCC1CC1,CHEMBL4706588,=,=,Inhibition,%,3.8,INH,%,3.8,CNC(=O)c1sc(-c2ccnc(NC(=O)CNCCNc3c4c(nc5ccccc35)CCCC4)c2)nc1OCC1CC1,2020.0
Inhibition of CDK2 (unknown origin),Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3c(C)[nH]nc3n2)c(OC(C)C)cc1C1CCN(C)CC1,CHEMBL4715698,=,=,IC50,nM,920.0,IC50,uM,0.92,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3c(C)[nH]nc3n2)c(OC(C)C)cc1C1CCN(C)CC1,2016.0
Inhibition of CDK2 (unknown origin),CC(C)n1cnnc1-c1cccc(N2Cc3ccccc3C2=O)n1,CHEMBL4725315,=,=,IC50,nM,63.1,pIC50,,7.2,CC(C)n1cnnc1-c1cccc(N2Cc3ccccc3C2=O)n1,2020.0
Inhibition of CDK2 (unknown origin),CC(C)n1cnnc1-c1cccc(NC(=O)C2CCCCO2)n1,CHEMBL4725315,=,=,IC50,nM,3162.28,pIC50,,5.5,CC(C)n1cnnc1-c1cccc(NC(=O)C2CCCCO2)n1,2020.0
Inhibition of human CDK2 at 1 uM by kinome scan method relative to control,CC(C)N1c2cc(Nc3nccc(-c4cncc5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C,CHEMBL4725348,=,=,Inhibition,%,90.0,INH,%,90.0,CC(C)N1c2cc(Nc3nccc(-c4cncc5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C,2020.0
Inhibition of human CDK2 by kinome scan method,CC(C)N1c2cc(Nc3nccc(-c4cncc5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C,CHEMBL4725348,=,=,IC50,nM,168.9,IC50,nM,168.9,CC(C)N1c2cc(Nc3nccc(-c4cncc5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C,2020.0
Inhibition of wild-type human full length CDK2 (M1 to L298 residues) expressed in bacterial expression system at 1 uM by Kinomescan method,COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12,CHEMBL4725356,,,Inhibition,%,,INH,,,COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCOCC3)s2)c1,CHEMBL4739712,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCOCC3)s2)c1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCN(C)CC3)s2)c1,CHEMBL4739712,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCN(C)CC3)s2)c1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCN(CC)CC3)s2)c1,CHEMBL4739712,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCN(CC)CC3)s2)c1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCN(C(=O)OC(C)(C)C)CC3)s2)c1,CHEMBL4739712,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCN(C(=O)OC(C)(C)C)CC3)s2)c1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCC(N(C)C)CC3)s2)c1,CHEMBL4739712,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCC(N(C)C)CC3)s2)c1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)NC1CCC(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)CC1,CHEMBL4739712,=,=,IC50,nM,185.0,IC50,nM,185.0,C=CC(=O)NC1CCC(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)CC1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)NC1CCN(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)CC1,CHEMBL4739712,=,=,IC50,nM,174.0,IC50,nM,174.0,C=CC(=O)NC1CCN(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)CC1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)c(OC)c1,CHEMBL4739712,=,=,IC50,nM,126.0,IC50,nM,126.0,C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)c(OC)c1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(O[C@@H]2CCC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,=,=,IC50,nM,334.0,IC50,nM,334.0,C=CC(=O)Nc1ccc(O[C@@H]2CCC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(CNc4cc(C(F)(F)F)c(Cl)cn4)s3)C2)cc1,CHEMBL4739712,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(CNc4cc(C(F)(F)F)c(Cl)cn4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(/C=C/c4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,=,=,IC50,nM,22.9,IC50,nM,22.9,C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(/C=C/c4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(CCc4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,>,>,IC50,nM,10000.0,IC50,nM,10000.0,C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(CCc4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(COCc4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(COCc4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(CNCc4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,=,=,IC50,nM,3170.0,IC50,nM,3170.0,C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(CNCc4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(S(=O)(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,=,=,IC50,nM,264.0,IC50,nM,264.0,C=CC(=O)Nc1ccc(S(=O)(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc([S+]([O-])N2CCCC(Nc3ncc(SCc4cccnc4)s3)C2)cc1,CHEMBL4739712,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C=CC(=O)Nc1ccc([S+]([O-])N2CCCC(Nc3ncc(SCc4cccnc4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4ccccn4)s3)C2)cc1,CHEMBL4739712,>,>,IC50,nM,370.0,IC50,nM,370.0,C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4ccccn4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4cnc(C(F)(F)F)nc4)s3)C2)cc1,CHEMBL4739712,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4cnc(C(F)(F)F)nc4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)N1CCc2cc(S(=O)(=O)N3CCCC(Nc4ncc(SCc5ncc(C(C)(C)C)o5)s4)C3)ccc21,CHEMBL4739712,=,=,IC50,nM,124.0,IC50,nM,124.0,C=CC(=O)N1CCc2cc(S(=O)(=O)N3CCCC(Nc4ncc(SCc5ncc(C(C)(C)C)o5)s4)C3)ccc21,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(O[C@@H]2CCC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)c(C(F)(F)F)c1,CHEMBL4739712,=,=,IC50,nM,251.0,IC50,nM,251.0,C=CC(=O)Nc1ccc(O[C@@H]2CCC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)c(C(F)(F)F)c1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CCC[C@@H](Nc3ncc(SCC4CCOCC4)s3)C2)cc1,CHEMBL4739712,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C=CC(=O)Nc1ccc(C(=O)N2CCC[C@@H](Nc3ncc(SCC4CCOCC4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CCC[C@@H](Nc3ncc(SCc4cncnc4)s3)C2)cc1,CHEMBL4739712,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C=CC(=O)Nc1ccc(C(=O)N2CCC[C@@H](Nc3ncc(SCc4cncnc4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N2CC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,=,=,IC50,nM,11.9,IC50,nM,11.9,CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N2CC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),CN(C)C/C=C/C(=O)N1CCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CC1,CHEMBL4739712,=,=,IC50,nM,11.5,IC50,nM,11.5,CN(C)C/C=C/C(=O)N1CCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CC1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)N1CCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CC1,CHEMBL4739712,=,=,IC50,nM,10.8,IC50,nM,10.8,C=CC(=O)N1CCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CC1,2020.0
Inhibition of CDK2 (unknown origin),CN(C)CC/C=C/C(=O)Nc1ccc(C(=O)N2CCCC(C(=O)Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,=,=,IC50,nM,23.3,IC50,nM,23.3,CN(C)CC/C=C/C(=O)Nc1ccc(C(=O)N2CCCC(C(=O)Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CCCC(C(=O)Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,=,=,IC50,nM,11.0,IC50,nM,11.0,C=CC(=O)Nc1ccc(C(=O)N2CCCC(C(=O)Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1cccc(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)c1,CHEMBL4739712,=,=,IC50,nM,58.8,IC50,nM,58.8,C=CC(=O)Nc1cccc(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)c1,2020.0
Inhibition of CDK2 (unknown origin),CN(C)C/C=C/C(=O)Nc1cccc(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)c1,CHEMBL4739712,=,=,IC50,nM,29.0,IC50,nM,29.0,CN(C)C/C=C/C(=O)Nc1cccc(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)c1,2020.0
Inhibition of CDK2 (unknown origin),CN(C)C/C=C/C(=O)Nc1ccc(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)cc1,CHEMBL4739712,=,=,IC50,nM,7.8,IC50,nM,7.8,CN(C)C/C=C/C(=O)Nc1ccc(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1cccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)c1,CHEMBL4739712,=,=,IC50,nM,312.0,IC50,nM,312.0,C=CC(=O)Nc1cccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)c1,2020.0
Inhibition of CDK2 (unknown origin),CN(C)C/C=C/C(=O)Nc1cccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)c1,CHEMBL4739712,=,=,IC50,nM,286.0,IC50,nM,286.0,CN(C)C/C=C/C(=O)Nc1cccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)c1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)Nc2cccc(C(=O)Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)c2)cc1,CHEMBL4739712,=,=,IC50,nM,162.0,IC50,nM,162.0,C=CC(=O)Nc1ccc(C(=O)Nc2cccc(C(=O)Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)c2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,=,=,IC50,nM,108.0,IC50,nM,108.0,C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,=,=,IC50,nM,92.3,IC50,nM,92.3,CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),CN(C)C/C=C/C(=O)Nc1ccc(S(=O)(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,=,=,IC50,nM,689.0,IC50,nM,689.0,CN(C)C/C=C/C(=O)Nc1ccc(S(=O)(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of CDK2 (unknown origin),C=CC(=O)Nc1ccc(C(=O)N2CC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,CHEMBL4739712,=,=,IC50,nM,9.86,IC50,nM,9.86,C=CC(=O)Nc1ccc(C(=O)N2CC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,2020.0
Inhibition of human CDK2 at 1 uM by Selectscreen kinase assay,COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)c(F)c3)nc12,CHEMBL4765248,=,=,Inhibition,%,97.0,INH,%,97.0,COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)c(F)c3)nc12,2020.0
Inhibition of human CDK2 at 100 nM in presence of ATP relative to control,Cl.O=C1Nc2ccc(F)cc2/C1=C1/Nc2ccccc2/C1=N\OCCN1CCNCC1,CHEMBL4765285,=,=,Inhibition,%,43.0,INH,%,43.0,Cl.O=C1Nc2ccc(F)cc2/C1=C1/Nc2ccccc2/C1=N\OCCN1CCNCC1,2020.0
Inhibition of CDK2 in human A-375 cells at 1 uM incubated for 12 hrs by DAPI and immunofluorescence staining based confocal microscopic analysis,Cc1ccc(Nc2nc(Cl)nc3c2ncn3Cc2ccc(C(=O)Nc3ccccc3N)cc2)cc1,CHEMBL4765302,,,Inhibition,%,,INH,,,Cc1ccc(Nc2nc(Cl)nc3c2ncn3Cc2ccc(C(=O)Nc3ccccc3N)cc2)cc1,2020.0
Inhibition of CDK2 in human NCI-H929 cells by mass spectroscopic analysis,Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,% inhibition,uM,33.3,% inhibition,uM,33.3,Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O,2020.0
Inhibition of CDK2 in human NCI-H929 cells by mass spectroscopic analysis,CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1,CHEMBL4804281,=,=,% inhibition,uM,27.6,% inhibition,uM,27.6,CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1,2020.0
Inhibition of CDK2 in human NCI-H929 cells by mass spectroscopic analysis,COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1,CHEMBL4804281,=,=,% inhibition,uM,17.3,% inhibition,uM,17.3,COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1,2020.0
Inhibition of CDK2 in human NCI-H929 cells by mass spectroscopic analysis,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,% inhibition,uM,35.0,% inhibition,uM,35.0,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O,2020.0
Inhibition of CDK2 in human NCI-H929 cells by mass spectroscopic analysis,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,% inhibition,uM,21.6,% inhibition,uM,21.6,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O,2020.0
Inhibition of CDK2 in human NCI-H929 cells by mass spectroscopic analysis,Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,% inhibition,uM,68.5,% inhibition,uM,68.5,Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O,2020.0
Inhibition of CDK2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control,Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,Inhibition,%,0.0,INH,%,0.0,Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O,2020.0
Inhibition of CDK2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control,CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1,CHEMBL4804281,=,=,Inhibition,%,0.0,INH,%,0.0,CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1,2020.0
Inhibition of CDK2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control,COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1,CHEMBL4804281,=,=,Inhibition,%,0.0,INH,%,0.0,COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1,2020.0
Inhibition of CDK2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,Inhibition,%,35.0,INH,%,35.0,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O,2020.0
Inhibition of CDK2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,Inhibition,%,0.0,INH,%,0.0,Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O,2020.0
Inhibition of CDK2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control,Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O,CHEMBL4804281,=,=,Inhibition,%,50.0,INH,%,50.0,Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O,2020.0
Inhibition of human CDK2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control,CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1,CHEMBL4804282,=,=,Activity,%,95.0,Activity,%,95.0,CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1,2020.0
Inhibition of human CDK2 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control,COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F,CHEMBL4804283,=,=,Activity,%,91.0,Activity,%,91.0,COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F,2020.0
Inhibition of DNA-tagged human CDK2 assessed as percent of control at 50000 nM by qPCR analysis relative to control,CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21,CHEMBL4804284,=,=,Activity,%,100.0,Activity,%,100.0,CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21,2020.0
Inhibition of CDK2 (unknown origin) at 10 uM relative to control,Cn1cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)cn1,CHEMBL4804285,=,=,Inhibition,%,6.0,INH,%,6.0,Cn1cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)cn1,2019.0
Inhibition of CDK2 (unknown origin) at 10 uM relative to control,Fc1cccc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1,CHEMBL4804285,=,=,Inhibition,%,1.0,INH,%,1.0,Fc1cccc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1,2019.0
Inhibition of CDK2 (unknown origin) at 10 uM relative to control,Cc1cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)no1,CHEMBL4804285,=,=,Inhibition,%,3.0,INH,%,3.0,Cc1cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)no1,2019.0
Inhibition of human CDK2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control,CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1,CHEMBL4804286,=,=,Activity,%,100.0,Activity,%,100.0,CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1,2020.0
Inhibition of human CDK2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control,CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1,CHEMBL4804286,=,=,Activity,%,99.0,Activity,%,99.0,CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1,2020.0
Inhibition of CDK2 (unknown origin),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL5230096,=,=,IC50,nM,20.0,IC50,nM,20.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2020.0
Inhibition of CDK2 (unknown origin),O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,CHEMBL5230096,=,=,IC50,nM,10.0,IC50,nM,10.0,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,2020.0
Inhibition of CDK2 (unknown origin),Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,CHEMBL5230096,=,=,IC50,nM,6.0,IC50,nM,6.0,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,2020.0
Inhibition of CDK2 (unknown origin),CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,CHEMBL5230096,=,=,IC50,nM,45.0,IC50,nM,45.0,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,2020.0
Inhibition of CDK2 (unknown origin),COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,CHEMBL5230096,=,=,Ki,nM,3.0,Ki,nM,3.0,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,2020.0
Inhibition of CDK2 (unknown origin),CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL5230096,=,=,IC50,nM,700.0,IC50,uM,0.7,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2020.0
Inhibition of CDK2 (unknown origin),CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,CHEMBL5230096,=,=,IC50,nM,1.0,IC50,nM,1.0,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,2020.0
Inhibition of CDK2 (unknown origin),CC(C)(C)c1coc(CSc2cnc(NC(=O)C3CCNCC3)s2)n1,CHEMBL5230096,=,=,IC50,nM,48.0,IC50,nM,48.0,CC(C)(C)c1coc(CSc2cnc(NC(=O)C3CCNCC3)s2)n1,2020.0
Inhibition of CDK2 (unknown origin),CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,CHEMBL5230096,=,=,IC50,nM,8.0,IC50,nM,8.0,CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,2020.0
Inhibition of CDK2 (unknown origin),C[C@@H](CO)Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1,CHEMBL5230096,=,=,IC50,nM,160.0,IC50,uM,0.16,C[C@@H](CO)Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1,2020.0
Inhibition of CDK2 (unknown origin),C[C@@H](CO)Nc1nc(N)c(/[N+]([O-])=N/C#N)c(OCC2CCCCC2)n1,CHEMBL5230096,=,=,IC50,nM,300.0,IC50,uM,0.3,C[C@@H](CO)Nc1nc(N)c(/[N+]([O-])=N/C#N)c(OCC2CCCCC2)n1,2020.0
Inhibition of CDK2 (unknown origin),O=C(CCCn1cc(CNC2CCCCC2)c(-c2ccccc2)n1)NO,CHEMBL5230096,=,=,IC50,nM,4630.0,IC50,uM,4.63,O=C(CCCn1cc(CNC2CCCCC2)c(-c2ccccc2)n1)NO,2020.0
Inhibition of CDK2 (unknown origin),O=C(CCCn1cc(CNC2CC2)c(-c2ccccc2)n1)NO,CHEMBL5230096,=,=,IC50,nM,3700.0,IC50,uM,3.7,O=C(CCCn1cc(CNC2CC2)c(-c2ccccc2)n1)NO,2020.0
Inhibition of CDK2 (unknown origin),O=C1CC(=O)N(c2ccc(F)cc2)C(=S)N1C(=O)c1ccccc1,CHEMBL5230096,=,=,IC50,nM,4500.0,IC50,uM,4.5,O=C1CC(=O)N(c2ccc(F)cc2)C(=S)N1C(=O)c1ccccc1,2020.0
Inhibition of CDK2 (unknown origin),O=C(c1ccccc1)N1C(=O)C(C2C(=O)N(C(=O)c3ccccc3)C(=S)N(c3ccc(F)cc3)C2=O)C(=O)N(c2ccc(F)cc2)C1=S,CHEMBL5230096,=,=,IC50,nM,5200.0,IC50,uM,5.2,O=C(c1ccccc1)N1C(=O)C(C2C(=O)N(C(=O)c3ccccc3)C(=S)N(c3ccc(F)cc3)C2=O)C(=O)N(c2ccc(F)cc2)C1=S,2020.0
Inhibition of human CDK2 using TMB as substrate preincubated for 210 mins followed by substrate addition and measured after 15 to 25 mins by spectrophotometric analysis,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CHEMBL5230096,=,=,IC50,nM,430.0,IC50,uM,0.43,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,2020.0
Inhibition of human CDK2 using TMB as substrate preincubated for 210 mins followed by substrate addition and measured after 15 to 25 mins by spectrophotometric analysis,Cc1ccc(S(=O)(=O)Nc2ccc(-c3ccnc(Nc4ccc(S(=O)(=O)Nc5nccc(C)n5)cc4)c3C#N)cc2)cc1,CHEMBL5230096,=,=,IC50,nM,1790.0,IC50,uM,1.79,Cc1ccc(S(=O)(=O)Nc2ccc(-c3ccnc(Nc4ccc(S(=O)(=O)Nc5nccc(C)n5)cc4)c3C#N)cc2)cc1,2020.0
Inhibition of human CDK2 using TMB as substrate preincubated for 210 mins followed by substrate addition and measured after 15 to 25 mins by spectrophotometric analysis,Cc1ccc(S(=O)(=O)Nc2ccc(-c3ccnc(Nc4ccc(S(=O)(=O)Nc5cc(C)no5)cc4)c3C#N)cc2)cc1,CHEMBL5230096,=,=,IC50,nM,2530.0,IC50,uM,2.53,Cc1ccc(S(=O)(=O)Nc2ccc(-c3ccnc(Nc4ccc(S(=O)(=O)Nc5cc(C)no5)cc4)c3C#N)cc2)cc1,2020.0
Inhibition of human CDK2 using TMB as substrate preincubated for 210 mins followed by substrate addition and measured after 15 to 25 mins by spectrophotometric analysis,COc1ccccc1/C=C/C(=C(C#N)C#N)c1ccc(NS(=O)(=O)c2ccc(C)cc2)cc1,CHEMBL5230096,=,=,IC50,nM,2920.0,IC50,uM,2.92,COc1ccccc1/C=C/C(=C(C#N)C#N)c1ccc(NS(=O)(=O)c2ccc(C)cc2)cc1,2020.0
Inhibition of CDK2 (unknown origin) incubated for 10 min using histone H1 as substrate in presence of gamma32P-ATP by radioactive assay,Nc1c([N+](=O)[O-])cnc(NC2CCCCC2)c1[N+](=O)[O-],CHEMBL5230096,=,=,IC50,nM,1800.0,IC50,uM,1.8,Nc1c([N+](=O)[O-])cnc(NC2CCCCC2)c1[N+](=O)[O-],2020.0
Inhibition of CDK2 (unknown origin),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1n1ccc2cnc3[nH]ccc3c21,CHEMBL5244205,>,>,IC50,nM,1000.0,IC50,nM,1000.0,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1n1ccc2cnc3[nH]ccc3c21,2017.0
Inhibition of CDK2 (unknown origin) at 1000 nM relative to control,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1n1ccc2cnc3[nH]cc(C#N)c3c21,CHEMBL5244205,=,=,Inhibition,%,91.0,INH,%,91.0,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1n1ccc2cnc3[nH]cc(C#N)c3c21,2017.0
Inhibition of CDK2 (unknown origin),Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,CHEMBL5244251,=,=,IC50,nM,2.0,IC50,nM,2.0,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,2020.0
Inhibition of CDK2 (unknown origin),CN(C)CCCNC(=O)Cc1cccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)c1,CHEMBL5252509,=,=,IC50,nM,1000.0,IC50,uM,1.0,CN(C)CCCNC(=O)Cc1cccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)c1,2018.0
Inhibition of CDK2 (unknown origin) by Ambit kinase assay,COc1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,CHEMBL5252511,>,>,IC50,nM,2000.0,IC50,uM,2.0,COc1ccncc1NC(=O)c1ccnc(NC(=O)C2CC2)c1,2016.0
Inhibition of CDK2 (unknown origin) by Ambit kinase assay,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(NC(=O)C2CC2)c1,CHEMBL5252511,>,>,IC50,nM,2000.0,IC50,uM,2.0,O=C(Nc1cnccc1-c1ccccc1)c1ccnc(NC(=O)C2CC2)c1,2016.0
Inhibition of CDK2 (unknown origin) by Ambit kinase assay,O=C(Nc1cnccc1-c1ccc(F)cc1)c1ccnc(NC(=O)C2CC2)c1,CHEMBL5252511,>,>,IC50,nM,2000.0,IC50,uM,2.0,O=C(Nc1cnccc1-c1ccc(F)cc1)c1ccnc(NC(=O)C2CC2)c1,2016.0
Inhibition of CDK2 (unknown origin) by Ambit kinase assay,O=C(Nc1cnccc1-c1ccc(Cl)cc1)c1ccnc(NC(=O)C2CC2)c1,CHEMBL5252511,>,>,IC50,nM,2000.0,IC50,uM,2.0,O=C(Nc1cnccc1-c1ccc(Cl)cc1)c1ccnc(NC(=O)C2CC2)c1,2016.0
Inhibition of human CDK2,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,CHEMBL5252519,=,=,IC50,nM,5.0,IC50,uM,0.005,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1,2016.0
Inhibition of human CDK2 g-Arg-Pro-Met-Ser-Pro-Lys-LysLys-Ala-CONH2 peptide as substrate incubated for 30 to 60 mins by scintillation counter analysis,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCOCCO)cc1,CHEMBL5252532,=,=,IC50,nM,12.0,IC50,nM,12.0,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)NCCOCCO)cc1,2016.0
Inhibition of recombinant human CDK2 in presence of ATP by FlashPlate assays,COc1cc[nH]c1/C=C1\C(=O)Nc2ccc([N+](=O)[O-])cc21,CHEMBL5252532,=,=,IC50,nM,39000.0,IC50,uM,39.0,COc1cc[nH]c1/C=C1\C(=O)Nc2ccc([N+](=O)[O-])cc21,2016.0
Inhibition of CDK2 (unknown origin) in presence of ATP,COc1cc[nH]c1/C=C1\C(=O)Nc2ccc(F)c(C#C[C@@H](O)[C@@H](N)[C@@H](C)O)c21,CHEMBL5252532,=,=,IC50,nM,3.0,IC50,nM,3.0,COc1cc[nH]c1/C=C1\C(=O)Nc2ccc(F)c(C#C[C@@H](O)[C@@H](N)[C@@H](C)O)c21,2016.0
Inhibition of CDK2 (unknown origin) in presence of ATP,COc1cc[nH]c1/C=C1\C(=O)Nc2ccc(F)c(C#C[C@@H]3CCCN3)c21,CHEMBL5252532,=,=,IC50,nM,2.0,IC50,nM,2.0,COc1cc[nH]c1/C=C1\C(=O)Nc2ccc(F)c(C#C[C@@H]3CCCN3)c21,2016.0
Inhibition of CDK2 (unknown origin),CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,CHEMBL5252533,=,=,IC50,nM,1.0,IC50,nM,1.0,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,2016.0
Inhibition of CDK2 (unknown origin),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,CHEMBL5252533,=,=,IC50,nM,170.0,IC50,nM,170.0,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,2016.0
